aspirin has been researched along with Myocardial Infarction in 3457 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A meta-analysis of randomized clinical trials of fibrinolysis was performed, examining the interaction between aspirin and fibrinolysis in treating patients with acute myocardial infarction." | 10.16 | Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. ( Basinski, A; Naylor, CD, 1991) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 9.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 9.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| "Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)." | 9.51 | CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 9.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 9.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 9.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 9.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 9.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 9.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Aspirin is promptly administered to patients presenting with acute coronary syndromes." | 9.22 | Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. ( Ayele, GM; Brener, SJ; Lansky, AJ; Mehran, R; Stone, GW, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 9.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 9.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 9.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 9.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| "Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary intervention with stenting remains uncertain." | 9.20 | Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. ( Bach, RG; Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Zettler, ME, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 9.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 9.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "In ST-elevation myocardial infarction (STEMI) patients, residual platelet reactivity soon after a loading dose (LD) of prasugrel or ticagrelor is higher than that reported for healthy volunteers or subjects with stable coronary artery disease; and the majority of primary percutaneous coronary intervention (PPCI) procedures with bivalirudin monotherapy are performed without proper platelet inhibition." | 9.19 | Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. ( Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2014) |
| "To detect residual platelet aggregation following the switch from generic (GC) to brand clopidogrel (BC) in male patients after ST-elevated myocardial infarction (STEMI)." | 9.19 | Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction. ( Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV, 2014) |
| " In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension." | 9.17 | Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013) |
| "Patients with a recently diagnosed ST-elevation myocardial infarction (STEMI) and implanted coronary drug-eluting stent (DES) who need urgent surgery are at increased risk of surgical bleeding unless aspirin and clopidogrel are discontinued beforehand." | 9.17 | Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. ( Liu, XH; Qu, Y; Shen, H; Xia, JG, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 9.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 9.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)." | 9.16 | Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "This study sought to examine the relationship between the aspirin dose prescribed at hospital discharge and long-term outcomes after ST-segment elevation myocardial infarction in patients treated with primary percutaneous coronary intervention (PCI)." | 9.16 | Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t ( Baber, U; Claessen, BE; Dangas, GD; Dudek, D; Fahy, M; Grines, CL; Guagliumi, G; Kornowski, R; Lansky, AJ; Mehran, R; Parise, H; Stone, GW; Weisz, G; Witzenbichler, B; Wöhrle, J; Xu, K; Yu, J, 2012) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 9.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Large randomized clinical trials have shown the efficacy of aspirin, ACE (angiotensin converting enzyme) inhibitors and statins as secondary prevention measures in patients after an acute coronary syndrome with and without ST elevations." | 9.15 | Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Senges, J; Zahn, R; Zeymer, U, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 9.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 9.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "The impact of thienopyridine administration prior to primary stenting in acute myocardial infarction (AMI) has not been well studied." | 9.14 | Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. ( Cox, DA; Dangas, GD; Fahy, M; Garcia, E; Griffin, JJ; Grines, CL; Guagliumi, G; Iyengar, S; Lansky, AJ; Mehran, R; Rabbani, LE; Stant, J; Stone, GW; Stuckey, T; Tcheng, JE; Turco, M, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 9.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Inhibition of platelet thromboxane A(2) (TXA(2)) by aspirin is critical in patients with acute myocardial infarction (AMI), but some patients have persistent platelet TXA(2) production within 48 hours of the onset of AMI." | 9.14 | Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. ( Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Valles, J, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 9.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "Currently 162-325 mg aspirin is recommended for the treatment of acute coronary syndrome." | 9.14 | Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. ( Derhaschnig, U; Frossard, M; Fuchs, I; Jilma, B; Riedmüller, E; Spiel, AO, 2010) |
| "In subgroup analyses useful to formulate hypotheses from a large randomized trial in apparently healthy men, aspirin nonadherence or NSAID use explained the lack of clinical benefit of aspirin on first myocardial infarction that has been attributed to "aspirin resistance." | 9.14 | Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". ( Gurbel, PA; Hebert, PR; Hennekens, CH; Schneider, WR; Tantry, US, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "Using combined data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction patients), we compared the association between initial aspirin dose of 162 versus 325 mg and 24-hour and 7-day mortality, as well as rates of in-hospital moderate/severe bleeding." | 9.13 | Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. ( Armstrong, PW; Berger, JS; Califf, RM; Granger, CB; Harrington, RA; Ohman, EM; Peterson, ED; Simes, RJ; Stebbins, A; Van de Werf, F; White, HD, 2008) |
| " Whether the addition of intravenous tirofiban during this procedure produces further benefit has not been clarified in ST segment elevation myocardial infarction (STEMI) patients." | 9.13 | Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. ( Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 9.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 9.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Clinical guidelines recommend extended treatment with dual antiplatelet therapy (DAPT) with ticagrelor 60 mg (twice daily) beyond 12 months in high-risk patients with a history of myocardial infarction (MI) who have previously tolerated DAPT and are not at heightened bleeding risk." | 9.12 | Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. ( Ariza-Solé, A; Bonaca, M; Giannitsis, E; Hedberg, J; Hewitt, C; Jernberg, T; Lambrelli, D; Lesén, E; Maggioni, AP; Simeone, JC; Storey, RF; Ten Berg, J, 2021) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 9.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "To test the effectiveness of an intervention, delivered face-to-face by local firefighters, designed to increase utilization of 911 and self-administration of aspirin for seniors experiencing chest pain." | 9.12 | A community intervention by firefighters to increase 911 calls and aspirin use for chest pain. ( Cagle, A; Diehr, P; Eisenberg, M; Meischke, H; Rowe, S, 2006) |
| "To study the prevalence and importance of aspirin resistance in patients with an evolving acute myocardial infarction (AMI) by use of the Platelet Function Analyzer-100." | 9.12 | Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 9.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 9.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention." | 9.11 | Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 9.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "Antithrombotic treatment with warfarin and/or aspirin is widely used in preventing recurrence of thrombotic events after an acute myocardial infarction (AMI)." | 9.11 | Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. ( Arnesen, H; Hurlen, M; Seljeflot, I, 2004) |
| "To examine efficacy of clopidogrel before thrombolytic therapy (TLT) in patients with acute myocardial infarction (AMI)." | 9.11 | [First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation]. ( Akinina, SA; Petrik, ES; Sereshcheva, AKh; Shalaev, SV; Vorob'eva, NM, 2004) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 9.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| " One hundred ninety patients with a history of myocardial infarction were evaluated using arachidonic acid-stimulated light aggregometry at 3 different time points: while receiving their usual daily aspirin, after not receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 325 mg." | 9.11 | Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. ( Barber, K; DeFranco, A; Ghosheh, K; Reeves, MJ; Schwartz, DE; Schwartz, KA, 2005) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 9.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events." | 9.11 | Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. ( Braunwald, E; Cannon, CP; Gibson, CM; Lewis, BS; López-Sendón, JL; McCabe, CH; Montalescot, G; Murphy, SA; Sabatine, MS; Theroux, P, 2005) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 9.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 9.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding." | 9.10 | Warfarin, aspirin, or both after myocardial infarction. ( Abdelnoor, M; Arnesen, H; Erikssen, J; Hurlen, M; Smith, P, 2002) |
| "The purpose of the present study was to study the concept of aspirin resistance or non-responsiveness by investigating the response to long-term aspirin therapy in patients with a former acute myocardial infarction (AMI)." | 9.10 | Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. ( Andersen, K; Arnesen, H; Hurlen, M; Seljeflot, I, 2002) |
| "To examine the development of age-related cataract in a trial of beta carotene supplementation in men." | 9.10 | A randomized trial of beta carotene and age-related cataract in US physicians. ( Buring, JE; Christen, WG; Gaziano, JM; Glynn, RJ; Hennekens, CH; Manson, JE; Sperduto, RD, 2003) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 9.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "The anticoagulant, warfarin, and the antiplatelet agent, aspirin, have been shown to have similar benefits after myocardial infarction." | 9.10 | Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. ( Doggrell, SA, 2003) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 9.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "There is clear evidence from numerous randomized trials and their meta-analyses that aspirin reduces risks of first myocardial infarction (MI)." | 9.10 | Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. ( Buring, JE; Chan, KA; Gaziano, JM; Glynn, RJ; Hennekens, CH; Kurth, T; Walker, AM, 2003) |
| " We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction." | 9.10 | Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. ( Bylock, A; Emanuelsson, H; Goodvin, A; Nyström, P; Wallentin, L; Weaver, WD; Wilcox, RG, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "The aim of this study was to assess the influence of aspirin on selected inflammatory markers in patients recovering from acute myocardial infarction (AMI)." | 9.10 | Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. ( Arnesen, H; Eikvar, L; Hurlen, M; Seljeflot, I; Solheim, S, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 9.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "Both aspirin and warfarin when used alone are effective in the secondary prevention of vascular events and death after acute myocardial infarction." | 9.10 | Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. ( Brophy, MT; Ezekowitz, MD; Fiore, LD; Lu, D; Peduzzi, P; Sacco, J, 2002) |
| "To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms." | 9.10 | Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002) |
| "We examined the association of baseline plasma fibrinogen with future risk of myocardial infarction (MI) in the Physicians' Health Study." | 9.09 | A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. ( Hennekens, CH; Ma, J; Ridker, PM; Stampfer, MJ, 1999) |
| "Aspirin therapy confers conclusive net benefits in the acute phase of evolving myocardial infarction, but no clear evidence of benefit from the long-term use of aspirin after acute myocardial infarction (AMI) has been shown in any single study." | 9.09 | Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. ( Hattori, R; Ishikawa, K; Masuda, Y; Miyazaki, S; Motomiya, T; Ogawa, H; Saito, M; Tamura, Y; Tanaka, H; Yamaguchi, T; Yasue, H, 1999) |
| "Forty-three patients presenting with unstable angina or myocardial infarction were randomised double blind to warfarin [target international normalised ratio (INR), 2." | 9.09 | Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. ( Stewart, RA; Williams, MJ, 1999) |
| " We compared the safety and efficacy of two different antiplatelet drugs, aspirin (asa) and picotamide (pico)--a dual antithromboxane agent--in combination with low-intensity oral anticoagulation with warfarin or acenocoumarol in acute myocardial infarction (AMI)." | 9.09 | Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial. ( Corsini, G; Milani, M; Vetrano, A, 1999) |
| "In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation." | 9.09 | Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999) |
| "In an observational study we wanted to investigate whether ongoing use of aspirin in a cohort of 753 patients with acute myocardial infarction was able to (1) reduce infarct size as assessed by peak creatine kinase and lactate dehydrogenase, (2) increase the number of non-Q-wave myocardial infarctions, and (3) to what extent thrombolytic treatment at admission could modify these outcomes." | 9.09 | Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms. ( Abdelnoor, M; Landmark, K, 1999) |
| "Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction." | 9.09 | Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 9.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood." | 9.09 | Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000) |
| "We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA)." | 9.09 | Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting ( Baigent, C; Braunwald, E; Chen, ZM; Collins, R; Flather, M; Franzosi, MG; Kjekshus, J; Køber, L; Latini, R; Liu, LS; Maggioni, AP; Peto, R; Pfeffer, M; Pizzetti, F; Santoro, E; Sleight, P; Swedberg, K; Tavazzi, L; Tognoni, G; Wang, W; Yusuf, S, 2000) |
| "The efficacy and safety of warfarin, aspirin, and the two combined are compared in a long-term, randomized, open, multicentre study involving 3606 patients after acute myocardial infarction (1202 in each treatment group)." | 9.09 | Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. ( Arnesen, H; Hurlen, M; Smith, P, 2000) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "The effects of clopidogrel 75 mg or aspirin 100 (300) mg on platelet aggregation and activation by flow cytometry after stimulation with various agonists were determined in 30 patients with a past history of myocardial infarction." | 9.09 | Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. ( Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA, 2000) |
| "Assessing combined anti-platelet therapy in suspected acute myocardial infarction Aspirin has been shown to be effective in the emergency treatment of acute myocardial infarction." | 9.09 | Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ ( , 2000) |
| "The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)." | 9.09 | Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 9.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 9.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 9.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 9.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 9.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 9.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To assess effects of intravenous streptokinase, one month of oral aspirin, or both, on long term survival after suspected acute myocardial infarction." | 9.08 | ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ( Appleby, P; Baigent, C; Collins, R; Parish, S; Peto, R; Sleight, P, 1998) |
| "During 1 year of follow-up, we compared the mortality after acute myocardial infarction (AMI) prior to and after the introduction of a more widespread use of thrombolytic agents and aspirin." | 9.08 | One-year mortality after acute myocardial infarction prior to and after the implementation of a widespread use of thrombolysis and aspirin. Experiences from the community of Göteborg, Sweden. ( Dellborg, M; Hartford, M; Herlitz, J; Källström, G; Karlson, BW; Karlsson, T, 1998) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 9.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "There are conflicting reports on the interaction of aspirin with angiotensin-converting enzyme inhibitors in heart failure and systemic hypertension." | 9.08 | Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. ( Anthonio, RL; Crijns, HJ; de Kam, PJ; Kingma, JH; Oosterga, M; van Gilst, WH, 1998) |
| "In a follow-up analysis of 296 confirmed cases of myocardial infarction and 296 controls, we evaluated the association between lipoprotein (a) level and cardiovascular risk for those with and without hyperlipidemia as well as for those randomly allocated aspirin treatment and placebo." | 9.08 | Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. ( Ariyo, A; Hennekens, CH; Ridker, PM; Stampfer, MJ, 1998) |
| "The Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial compared the efficacy and safety of intravenous hirudin with heparin as adjunctive therapy to thrombolysis and aspirin in patients with acute myocardial infarction." | 9.07 | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. ( Antman, EM, 1994) |
| "The aim of this trial was to compare the efficacy of combination antithrombotic therapy with a prostacyclin-sparing aspirin plus anticoagulation versus conventional aspirin plus anticoagulation, when added to antianginal therapy, in patients with unstable angina or non-Q wave myocardial infarction already being treated with aspirin." | 9.07 | Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Cohen, M; Fox, KA; Fuster, V; Kronmal, R; Parry, G; Wieczorek, I; Xiong, J, 1994) |
| "This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 9.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
| "The Thrombolysis in Myocardial Infarction (TIMI) 5 trial was a randomized, dose-ranging, pilot trial of hirudin versus heparin, given with front-loaded tissue-type plasminogen activator and aspirin to 246 patients with acute myocardial infarction." | 9.07 | A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. ( Anderson, JL; Becker, RC; Cannon, CP; Gibson, RS; Haugland, JM; Henry, TD; Kleiman, NS; McCabe, CH; Mueller, HS; Schweiger, MJ, 1994) |
| "Forty two patients with acute myocardial infarction (AMI) were randomly distributed to the following groups: (1) the non-aspirin-treated group; (2) the daily-aspirin-treated group (aspirin, 300mg, once everyday); (3) the intermittent-aspirin-treated group (aspirin, 300mg, once every three days)." | 9.07 | [Improvement of prostacyclin-thromboxane A2 balance in patients with acute myocardial infarction by intermittent aspirin]. ( Luo, Y, 1993) |
| "This study documents that heparin prevents myocardial infarction better than aspirin during the acute phase of unstable angina." | 9.07 | Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. ( de Guise, P; Juneau, M; McCans, J; Qiu, S; Théroux, P; Waters, D, 1993) |
| "To assess the appropriate dose of aspirin in the treatment of patients with acute myocardial infarction (AMI), 60 cases of AMI were randomized into 2 groups, 30 cases each; one with conventional therapy, another with conventional therapy combined with daily oral aspirin 100mg." | 9.07 | [The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction]. ( Jin, L; Xu, SH; Yan, XW, 1993) |
| "A total of 907 patients with acute myocardial infarction were randomized between aspirin and ridogrel given in addition to streptokinase (1." | 9.07 | Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspir ( , 1994) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 9.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 9.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| "Patients admitted for suspected acute myocardial infarction within 6 hours (mean 3 hours 42 minutes) after onset of symptoms were randomised to double-blind treatment with low-dose oral aspirin or placebo." | 9.07 | Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction. ( Følling, M; Pedersen, D; Rodt, SA; Rønnevik, PK; von der Lippe, G, 1991) |
| "The influence of prophylactic low-dose aspirin on the clinical characteristics of subsequent nonfatal myocardial infarction was examined in the Physicians' Health Study, a randomized, double-blind placebo-controlled trial of alternate-day aspirin (325 mg) among 22,071 US male physicians." | 9.07 | Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. ( Buring, JE; Goldhaber, SZ; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "Data from 4524 patients in a randomized, controlled trial of aspirin were analyzed to determine if aspirin reduced the risk for hospitalization for gallstone disease." | 9.07 | One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease. ( Abbey, D; Kurata, JH; Marks, J, 1991) |
| "To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)." | 9.07 | Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991) |
| "In this study, 796 men with unstable coronary artery disease (that is, unstable angina or non-Q wave myocardial infarction) were randomized to double-blind placebo-controlled treatment with aspirin (75 mg/day)." | 9.07 | Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in ( Wallentin, LC, 1991) |
| "796 men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction [MI] ), were randomised to double-blind placebo-controlled treatment with oral aspirin 75 mg/day and/or 5 days of intermittent intravenous heparin." | 9.06 | Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. ( , 1990) |
| "We report the results of the Heparin-Aspirin Reperfusion Trial, a collaborative study comparing early intravenous heparin with oral aspirin as adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is used for coronary thrombolysis during acute myocardial infarction." | 9.06 | A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. ( Chaitman, BR; Hamilton, WP; Hsia, J; Kleiman, N; Roberts, R; Ross, AM, 1990) |
| "Aspirin is commonly accepted as a risk factor for gastric ulcer; however, there is little published evidence linking aspirin consumption to duodenal ulcer." | 9.06 | The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. ( Abbey, DE; Kurata, JH, 1990) |
| "Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear." | 9.06 | Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a randomized double-masked trial of the efficacy of aspirin in the secondary prevention of coronary heart disease." | 9.06 | Recruitment experience in the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1987) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 9.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 postmyocardial infarction (MI) patients, are compared and combined." | 9.05 | Aspirin in coronary heart disease. Comparison of six clinical trials. ( Canner, PL, 1983) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period." | 9.05 | A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980) |
| "Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose." | 9.05 | A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982) |
| "We studied the efficacy of aspirin and indomethacin therapy in relieving the discomfort of postmyocardial infarction pericarditis (PMIP) in two studies: (1) a retrospective evaluation of patients with symptomatic PMIP during a 5-year period and (2) a prospective, randomized, single-blind comparison of aspirin and indomethacin in similar patients." | 9.05 | Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. ( Alpert, JS; Berman, J; Haffajee, CI, 1981) |
| "Three randomized controlled trials of aspirin and secondary mortality have been conducted in patients who had had a myocardial infarction." | 9.05 | Aspirin and secondary mortality after myocardial infarction. ( Elwood, PC; Sweetnam, PM, 1980) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 9.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 9.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "45 mg kg-1 day-1) aspirin treatment have been evaluated in 15 patients after a recent (less than 17 days) acute myocardial infarction." | 9.05 | Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. ( Bernini, W; De Caterina, R; Donato, L; Filabozzi, P; Gazzetti, P; Giannessi, D; L'Abbate, A; Michelassi, C; Patrignani, P; Patrono, C, 1985) |
| "This study explores the effects on some hematological parameters of a low-dose aspirin regimen (50 mg/day) versus a conventional aspirin treatment with reported antithrombotic efficacy (324 mg/day), in patients with acute myocardial infarction." | 9.05 | Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. ( Battaglia, D; Bernini, W; Boem, A; De Caterina, R; Dell'Amico, F; Giannessi, D; L'Abbate, A; Michelassi, C; Patrignani, P; Patrono, C, 1985) |
| "The Aspirin Myocaridal Infarction Study is a randomized, double-blind clinical trial designed to study the potential value of aspirin in the reduction of mortality in patients who have had a prior myocardial infarction." | 9.04 | An intervention study-the aspirin myocardial infarction study. ( , 1977) |
| "Both the Coronary Drug Project (CDP) and the Aspirin Myocardial Infarction Study (AMIS) were successfully able to recruit adequate members of postmyocardial infarction patients to long-term multicenter clinical trials in the secondary prevention of coronary heart disease." | 9.04 | Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1979) |
| "A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner." | 9.04 | A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 9.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 8.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 8.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| "A short cut review was carried out to establish whether, in patients with suspected acute coronary syndromes presenting to the emergency department, what form of aspirin has the most rapid onset of action." | 8.91 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction? ( Hogg, K; Morris, N; Rigg, K, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors." | 8.90 | Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF, 2014) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 8.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 8.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " For the composite of non-fatal stroke, non-fatal myocardial infarction and vascular death, aspirin was associated with a 13% reduction in risk (risk ratio, RR: 0." | 8.87 | Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. ( Dinneen, SF; Eikelboom, JW; McGrath, E; O'Conghaile, A; O'Donnell, MJ; Oczkowski, C, 2011) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 8.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 8.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "There is considerable variation in the effect of aspirin therapy reducing the risk of myocardial infarction (MI)." | 8.84 | The influence of gender on the effects of aspirin in preventing myocardial infarction. ( Gan, WQ; Sin, DD; Yerman, T, 2007) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 8.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved for the reduction of atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI)." | 8.83 | Clopidogrel bisulfate: in ST-segment elevation myocardial infarction. ( Dickie, JS; Scott, LJ, 2006) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 8.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| "To review data concerning combined aspirin/warfarin versus aspirin alone for secondary prevention after myocardial infarction (MI)." | 8.82 | Aspirin and warfarin versus aspirin monotherapy after myocardial infarction. ( Gleason, BL; Jeddy, AS, 2003) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 8.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 8.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| "There is uncertainty about the role of intravenous unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with ST-elevation myocardial infarction (STEMI) treated with aspirin and thrombolysis." | 8.82 | Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. ( Eikelboom, JW; Mehta, SR; Menown, IB; Quinlan, DJ; Turpie, AG; Yusuf, S, 2005) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 8.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 8.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 8.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| "Although there is firm consensus that aspirin reduces the incidences (and severity) of reinfarction if given to patients after a myocardial infarction or in patients with unstable angina, there is disagreement about the optimum dose that should be used." | 8.79 | The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? ( Förster, W; Parratt, JR, 1997) |
| "This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies." | 8.79 | Is aspirin underused in myocardial infarction? ( Agustí, A; Arnau, JM, 1997) |
| "The roles of heparin and warfarin in reducing morbidity and mortality after acute myocardial infarction (AMI) are reviewed." | 8.78 | Heparin and warfarin therapy after acute myocardial infarction. ( Sproat, TT; Yedinak, KC, 1993) |
| " Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery." | 8.78 | [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992) |
| "The use of aspirin and thrombolytic agents in the management of acute myocardial infarction is now accepted as standard clinical practice, but not all patients with heart attack are suitable for such therapy." | 8.78 | Aspirin and thrombolytic therapy in the management of acute myocardial infarction. ( Hockings, B, 1990) |
| "In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina." | 8.77 | Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 8.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 8.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| "In AMI patients with a history of acute ischemic stroke, the risks of cardiovascular events were comparable between ticagrelor plus aspirin and clopidogrel plus aspirin." | 8.31 | Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Wang, CC; Wu, CH, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function." | 8.12 | The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. ( Li, F; Peng, R, 2022) |
| " This study set out to evaluate the prevalence of low platelet reactivity in patients with acute myocardial infarction treated with ticagrelor and aspirin." | 8.12 | Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. ( Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP, 2022) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 8.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| "Genotype-guided aspirin use for colorectal cancer chemoprevention may offer a cost-effective approach for the future management of average-risk individuals." | 8.02 | Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? ( Au, TH; Biltaji, E; Brixner, DI; Li, CI; Ose, J; Rivers, Z; Stenehjem, DD; Ulrich, CM; Walker, B, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 7.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 7.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| " This study sought to identify the predictors of aspirin nonadherence in adults with prior myocardial infarction (MI)." | 7.96 | Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction. ( Bhasin, V; Mehta, A; Parikh, PB; Skopicki, HA, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 7.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 7.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 7.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| "To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI) in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD." | 7.96 | Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. ( Bodtger, U; Capuano, A; Gislason, G; Jensen, MT; Lamberts, M; Lange, P; Nicolaisen, SK; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "We assessed the effects of ticagrelor, aspirin and prasugrel, started 7days after myocardial ischemia-reperfusion injury on remodeling, inflammation and fibrosis in the rat." | 7.91 | Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. ( Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y, 2019) |
| "Influence of pre-existing treatment with aspirin and/or statins prior to a first acute coronary syndrome (ACS) on clinical presentation, infarct size and inflammation markers." | 7.91 | Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. ( Denegri, A; Lüscher, TF; Mach, F; Matter, CM; Muller, O; Obeid, S; Räber, L; Shahin, M; Weidmann, L; Yousif, N, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 7.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| "Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)." | 7.88 | Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 7.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 7.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| " The risk and benefit of aspirin are not known in thrombocytopenic cancer patients experiencing acute myocardial infarction (AMI)." | 7.85 | Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. ( Feher, A; Gupta, D; Kampaktsis, PN; Parameswaran, R; Stein, EM; Steingart, R, 2017) |
| "The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid." | 7.85 | Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 7.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 7.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 7.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 7.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| " The aim of the current study was to compare these two point-of-care platelet function tests and to analyze the consistency between the two tests for evaluating on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI)." | 7.83 | Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. ( Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH, 2016) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 7.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)." | 7.81 | Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 7.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| "The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage." | 7.81 | Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015) |
| "Ticagrelor was daily administered throughout pregnancy to a 37-year-old pregnant woman until 36 weeks of gestation." | 7.81 | Use of ticagrelor in human pregnancy, the first experience. ( Jacquemyn, Y; Mannaerts, D; Muys, J; Verbruggen, M, 2015) |
| "Abstract The optimal dose of aspirin for patients presenting with acute myocardial infarction (AMI) while receiving chronic aspirin therapy has not been clearly established." | 7.80 | The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. ( Bonastre, J; Latorre, AM; Madrid, I; Moscardo, A; Ruano, M; Santos, MT; Valles, J, 2014) |
| "Aspirin and statins are established therapies for acute myocardial infarction (MI), but their benefits in patients with chronic heart failure (HF) remain elusive." | 7.80 | Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. ( Bland, JM; Cleland, JG; Crouch, S; Doherty, P; Gale, CP; Hall, AS; Køber, L; Lewinter, C; LeWinter, MM, 2014) |
| "The benefit of aspirin in primary prevention of myocardial infarction and the associated gastro-intestinal bleeding risks have not been well established in the elderly population with diabetes." | 7.80 | Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. ( Grégoire, JP; Moisan, J; Poirier, P; Sirois, C, 2014) |
| "Accumulated data suggest that low-dose aspirin after myocardial infarction (MI) may offer similar efficacy to higher dose aspirin with reduced risk of bleeding." | 7.80 | Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). ( Alexander, KP; Das, SR; de Lemos, JA; Desai, N; Enriquez, JR; Hall, HM; McGuire, DK; Peng, SA; Roe, MT; Wiviott, SD, 2014) |
| " The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)." | 7.80 | Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014) |
| "Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources." | 7.80 | Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study. ( Desai, NR; Gao, Y; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Zhang, H, 2014) |
| " We examined whether plasma L5 levels are elevated in patients with ST-segment elevation myocardial infarction (STEMI) and whether aspirin provides epigenetic protection of human coronary artery ECs (HCAECs) exposed to L5." | 7.79 | Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. ( Chang, FH; Chang, PY; Chang, SF; Chen, CH; Chen, YJ; Huang, WH; Lee, YT; Lu, J; Lu, SC; Yang, TC, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 7.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "High on-treatment platelet reactivity (HTPR) despite clopidogrel therapy is associated with adverse cardiac events after acute myocardial infarction (AMI)." | 7.78 | Clopidogrel response up to six months after acute myocardial infarction. ( Assali, A; Battler, A; Codner, P; Greenberg, G; Hasdai, D; Iakobishvili, Z; Kornowski, R; Lev, EI; Rechavia, E; Vaduganathan, M, 2012) |
| " We wanted to explore long-term variability of multiple electrode aggregometry (MEA) measurements and the agreement between MEA and light transmission aggregometry (LTA) in patients with non-ST elevation myocardial infarction (NSTEMI) treated with aspirin and clopidogrel." | 7.78 | Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. ( Andreassen, T; Bendz, B; Brosstad, F; Erikssen, G; Kunszt, G; Liestøl, K; Meen, O; Schjelderup, NM; Wettergreen, M, 2012) |
| "One of the foundations of the modern treatment of myocardial infarction (MI) is a combination antiplatelet therapy consisting of acetylsalicylic acid (ASA) and clopidogrel." | 7.78 | [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. ( Akhmetov, II; Arkhipova, AA; Galiavi, RA; Galiavich, AS; Minnetdinov, RSh; Valeeva, DD, 2012) |
| "Aspirin treatment is essential in patients with acute myocardial infarction (AMI) to block platelet thromboxane (TXA)₂ synthesis." | 7.77 | Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction. ( Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Vallés, J, 2011) |
| " From July 2002 through June 2008, compliance with 3 in-hospital acute myocardial infarction quality-of-care measures (administration of aspirin and β blockers on arrival, timely reperfusion) and mortality were assessed in consecutive patients eligible for ≥1 of the measures at 8 hospitals (n = 6,826)." | 7.77 | Changes over six years in administration of aspirin and beta blockers on arrival and timely reperfusion and in in-hospital and 30-day postadmission mortality in patients with acute myocardial infarction. ( Ballard, DJ; Filardo, G; Nicewander, D, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 7.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 7.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "To evaluate the risk of myocardial infarction and death from coronary heart disease after discontinuation of low dose aspirin in primary care patients with a history of cardiovascular events." | 7.77 | Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. ( Cea-Soriano, L; Johansson, S; Martín-Merino, E; Rodríguez, LA, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| " The influence of the CYP2C19 LOF alleles (*2 and *3) on clopidogrel response and clinical outcomes in East Asians with acute myocardial infarction (AMI) has not been reported." | 7.77 | Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. ( Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Koh, JS; Kwak, CH; Kwon, TJ; Park, Y; Tantry, US, 2011) |
| "To investigate the effect of aspirin on the platelets of survivors of myocardial infarction we correlated plasma salicylate level with platelet reactivity in ten patients and ten normal controls." | 7.76 | Plasma salicylate level and aspirin resistance in survivors of myocardial infarction. ( Ahmed, N; Davies, GJ; Meek, J, 2010) |
| "Chronic use of aspirin and statins has been associated with reduced risk of subsequent myocardial infarction (MI)." | 7.76 | Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. ( Arcieri, R; Commisso, C; Lanzillo, C; Lioy, E; Penco, M; Pendenza, G; Quarto, M; Romagnoli, E; Sciahbasi, A; Summaria, F, 2010) |
| "Chronic aspirin therapy is recommended by the American College of Cardiology/American Heart Association (ACC/AHA) following acute myocardial infarction (AMI) and by the Society of Thoracic Surgeons(STS) following coronary artery bypass graft (CABG)." | 7.76 | Intervention to increase the proportion of acute myocardial infarction or coronary artery bypass graft patients receiving an order for aspirin at hospital discharge. ( Brackbill, ML; Call, JT; Kline, VT; Sytsma, CS, 2010) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 7.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "We report a case of myocardial infarction associated with the use of sumatriptan and review the literature regarding similar cases." | 7.75 | Acute myocardial infarction with sumatriptan: a case report and review of the literature. ( Chalaupka, FD, 2009) |
| "In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 7.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 7.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| " This study was designed to determine the relation between responses to aspirin and clopidogrel as assessed by a point-of-care assay (Verify Now, Accumetrics, San Diego, California) and periprocedural myocardial infarction (PMI) in patients undergoing elective PCI for stable angina." | 7.74 | Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Hamilos, M; Sarma, J; Sarno, G; Vanderheyden, M; Wijns, W; Wyffels, E, 2008) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| " A patient suffering from coronary artery disease and taking metoprolol and aspirin was stung by wasps and developed cutaneous allergic signs including rash, urticaria and orbital oedema." | 7.74 | Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration. ( Ioannidis, TI; Karpeta, MZ; Kounis, GN; Kounis, NG; Mazarakis, A; Notaras, SP; Rallis, DG; Tsintoni, AC, 2007) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 7.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 7.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "Heterogeneity in response to aspirin (ASA) treatment, or "aspirin resistance," could be of importance in patients with ST-segment elevation myocardial infarction (STEMI)." | 7.74 | Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. ( Aznar, J; Breña, S; Fuset, MP; Moscardo, A; Perez, F; Piñon, M; Ruano, M; Santos, MT; Valles, J, 2007) |
| "Continuous aspirin treatment (120 mg/kg/d) reduces the expression of proinflammatory cytokines after myocardial infarction, but does not affect post-infarct cardiac remodeling and cardiac function." | 7.74 | High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction. ( Adamek, A; Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Hu, K; Wagner, H, 2007) |
| "(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry." | 7.74 | [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007) |
| "Aspirin reduces mortality for men and women with coronary heart disease (CHD)." | 7.74 | Gender differences in aspirin use among adults with coronary heart disease in the United States. ( Cannon, CP; McWilliams, JM; Opotowsky, AR, 2007) |
| "To determine whether patients with documented myocardial infarction (MI) while on aspirin therapy (cases) were more likely to be aspirin resistant than were patients with coronary artery disease (CAD) who had no history of MI (controls) and to assess clinical predictors of aspirin resistance in patients with stable CAD." | 7.74 | Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. ( Colby, E; Dorsch, MP; Dunn, SP; Lee, JS; Lynch, DR; Montague, D; Rodgers, JE; Schwartz, T; Smyth, SS, 2007) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 7.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 7.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 7.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 7.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "193 patients with their first non-Q-wave myocardial infarction (NQMI) were examined with the aim of studying the functional features of NQMI and estimate the influence of pre-hospital treatment with propranalol (PP), heparin and aspirin." | 7.73 | [Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease]. ( Baltabaev, TB; Beĭshenkulov, MT; Kudaĭbergenova, NT, 2005) |
| "The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding." | 7.73 | Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. ( Bertram, M; Liew, D; Nelson, MR; Vos, T, 2005) |
| "To determine whether specific limitations in electronic database studies may lead to biased estimates of the association between prescription, non-selective non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and myocardial infarction (MI) METHODS: Using our case-control study of NANSAIDs and first, non-fatal MI, we determined the odds ratio (OR) for prescription NANSAIDs and MI." | 7.73 | Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI). ( Berlin, JA; Hennessy, S; Ilkhanoff, L; Kimmel, SE; Lewis, JD, 2005) |
| "To determine whether patients taking aspirin for secondary prevention of myocardial infarction are at increased risk of recurrent disease when they take concomitant ibuprofen." | 7.73 | Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. ( Baron, M; Hudson, M; Pilote, L; Rahme, E, 2005) |
| " During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section." | 7.73 | [Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005) |
| "We sought to assess the association between prior aspirin use and mortality, all-cause readmission, and condition-specific readmission at one month and six months in a national sample of Medicare beneficiaries hospitalized with a confirmed myocardial infarction (MI)." | 7.73 | Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction. ( Curtis, JP; Foody, JM; Krumholz, HM; Masoudi, FA; Portnay, EL; Rathore, SS; Wang, Y, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 7.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| "To compare the effects of an aspirin-clopidogrel combination with those of the specific glycoprotein IIb/IIIa inhibitor tirofiban on myocardial no-reflow, nitric oxide concentration and activity of nitric oxide synthase (NOS) isoforms in a mini-swine model of acute myocardial infarction and reperfusion." | 7.73 | Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. ( Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL, 2006) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 7.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 7.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 7.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
| " Cardiac lesions induced by isoproterenol (ISO) are characterized by myocardial necrosis and exudative infiltration." | 7.72 | Effect of D-003 on isoproterenol-induced myocardial necrosis in rats. ( Arruzazabala, ML; Carbajal, D; González, J; Más, R; Mendoza, S; Molina, V; Noa, M, 2003) |
| "Experimental evidence raises the possibility that acetaminophen use could reduce the risk of myocardial infarction (MI)." | 7.72 | A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men. ( Palmer, JR; Rao, RS; Rosenberg, L, 2003) |
| "This study was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) are associated with lower odds of myocardial infarction (MI) and if NANSAIDs, particularly ibuprofen, interfere with aspirin's cardioprotective effect." | 7.72 | The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2004) |
| "There does not seem to be an increased risk of myocardial infarction among patients simultaneously consuming aspirin and ibuprofen compared with aspirin alone." | 7.72 | Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. ( Goldberg, KC; Patel, TN, 2004) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI)." | 7.72 | Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study. ( Frilling, B; Gieseler, U; Gitt, AK; Glunz, HG; Jagodzinski, E; Schiele, R; Schneider, S; Senges, J; Zahn, R, 2004) |
| "We examined the effect of aspirin use at the time of admission and discharge from a large-scale, prospective multicenter trial of patients who had been treated with primary percutaneous coronary intervention in acute myocardial infarction." | 7.72 | Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. ( Carroll, JD; Cox, DA; Fahy, M; Garcia, E; Griffin, JJ; Grines, CL; Kandzari, DE; Lansky, AJ; Mehran, R; Stone, GW; Stuckey, T; Tcheng, JE; Turco, M, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy." | 7.71 | Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002) |
| "The purpose of this study was to examine 2 decade-long trends in the use of aspirin and associated outcomes in patients hospitalized with acute myocardial infarction." | 7.71 | Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective. ( Goldberg, RJ; Gore, JM; Jackson, EA; Lessard, D; Sivasubramian, R; Spencer, FA; Yarzebski, J, 2002) |
| "Clinical trials have shown the efficacy of aspirin for acute myocardial infarction (AMI)." | 7.71 | Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies. ( Asbeck, F; Baumgärtel, B; Frilling, B; Gieseler, U; Gitt, AK; Glunz, HG; Schiele, R; Schneider, S; Senges, J; Zahn, R, 2001) |
| "Aspirin and angiotensin-converting enzyme (ACE) inhibitors are recommended for secondary prevention after acute myocardial infarction (AMI), but several studies have suggested that the combination of these medications may produce a negative interaction." | 7.71 | Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. ( Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001) |
| "Aspirin's role in the management of suspected myocardial infarction has been well established." | 7.71 | A study of the use of aspirin by general practitioners in suspected myocardial infarction. ( O'Shea, EB, 2001) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 7.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "Aspirin has been shown to be beneficial after a myocardial infarction and for other acute coronary syndromes." | 7.71 | Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? ( Elwood, P; Smith, A; Woollard, M, 2001) |
| "Unlike thrombolytic agents, there are conflicting data regarding the time-dependent effect of aspirin treatment on outcome in acute myocardial infarction (AMI)." | 7.71 | Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. ( Barbash, IM; Behar, S; Boyko, V; Freimark, D; Hod, H; Leor, J; Matetzky, S, 2002) |
| "Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction." | 7.71 | Clopidogrel--a myocardial infarction CURE? ( Bradley, C, 2001) |
| "Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low." | 7.71 | Underuse of aspirin in a referral population with documented coronary artery disease. ( Califf, RM; Chen, A; DeLong, ER; Hammill, BG; Kramer, JM; LaPointe, NA; McCants, CB; Muhlbaier, LH; Ostbye, T, 2002) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 7.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 7.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "The aim of this study was to investigate the influence of prehospital administration of aspirin and heparin on the initial patency of the infarct-related artery (IRA) in patients with acute myocardial infarction (MI)." | 7.71 | Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. ( Dambrink, JH; de Boer, MJ; Ernst, N; Hoorntje, JC; Nibbering, E; Suryapranata, H; van 't Hof, AW; Verheugt, FW; Zijlstra, F, 2002) |
| "To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home." | 7.70 | Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998) |
| "Regular aspirin is beneficial after myocardial infarction (MI)." | 7.70 | Aspirin after myocardial infarction: the importance of over-the-counter use. ( Hopper, S; Pierce, M, 1998) |
| "There are conflicting views on how hospital mortality with respect to acute myocardial infarction (AMI) has changed since the introduction of thrombolytics and aspirin." | 7.70 | Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? European Secondary Prevention Study Group. ( Abdelnoor, M; Reikvam, A; Sivertssen, E, 1998) |
| "Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI)." | 7.70 | Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. ( Bahr, RD; Gurbel, PA; Lowry, DR; O'Connor, CM; Serebruany, VL, 1998) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 7.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| " One hundred two (15%) took aspirin for their chest pain before the arrival of EMS personnel." | 7.70 | Prevalence of aspirin use among patients calling 9-1-1 for chest pain. ( Eisenberg, MS; Jaffy, MB; Meischke, H, 1998) |
| " The aim of our study was to assess the effectiveness of intervention, aimed at changing prescribing behaviour of general practitioners (GPs) with regard to early low dose aspirin in patients with suspected acute myocardial infarction (MI)." | 7.70 | Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial infarction. ( Adhikari, AA; de Silva, HJ; Gunatilake, SB; Gunawardhana, P; Seneviratne, SL, 1998) |
| "For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death." | 7.70 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999) |
| "In April 1996, we surveyed 539 patients who had suffered a myocardial infarction in 1995 to determine whether the prescription and use of aspirin after myocardial infarction differs by patient age, sex, and type of health insurance." | 7.70 | Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? ( Hill, JW; Roglieri, JL; Warburton, SW, 1998) |
| "The objective of this study was to investigate how the introduction of thrombolytics and aspirin has affected hospital mortality (case fatality) among patients with acute myocardial infarction." | 7.70 | Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: results from a new analytical approach. European Secondary Prevention Study Group. ( Aursnes, I; Reikvam, A, 1999) |
| "SYMPHONY (Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes) was a randomized, double-blind, aspirin-controlled trial with 2 concentration regimens of sibrafiban, an oral peptidomimetic GP IIb/IIIa antagonist, for long-term treatment instead of aspirin in patients after an ACS." | 7.70 | Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) ( Newby, LK, 1999) |
| "We describe the mortality during the subsequent 5 years after development of acute myocardial infarction prior to and after the introduction of a more widespread use of thrombolytic agents and aspirin in the community of Göteborg." | 7.70 | Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin. ( Abrahamsson, P; Dellborg, M; Herlitz, J; Karlson, BW; Karlsson, T; Lindqvist, J, 1999) |
| "The purpose of our study was to determine the frequency of aspirin administration among patients with acute myocardial infarction (MI) as dictated by physicians practicing in the United States." | 7.70 | Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. ( Becker, RC; Burns, M; French, W; Gore, JM; Lambrew, C; Rogers, WJ, 2000) |
| "The objective of this work was to examine the association of hospital and physician volume with use of aspirin and reperfusion therapy in the management of acute myocardial infarction (AMI) in eligible patients." | 7.70 | Association of physician and hospital volume with use of aspirin and reperfusion therapy in acute myocardial infarction. ( Palmer, RH; Soumerai, SB; Willison, DJ, 2000) |
| "Although aspirin is an effective, inexpensive, and safe treatment of acute myocardial infarction, the frequency of use of aspirin in actual medical practice is not known." | 7.69 | Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Kresowik, TF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1995) |
| "The aim of this study was to determine changes in treatment of myocardial infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, to assess the role of aspirin and antiaggregant therapy." | 7.69 | [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Richard, JL; Ruidavets, JB, 1995) |
| " The mechanism of the benefits of aspirin on survival after acute myocardial infarction is unknown." | 7.69 | Aspirin enhances the benefits of late reperfusion on infarct shape. A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction. ( Alhaddad, IA; Brown, EJ; Mir, R; Siddiqui, F; Tkaczevski, L, 1995) |
| "To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival." | 7.69 | Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996) |
| "In March 1994 a study in the British Medical Journal indicated a low rate of administration of aspirin and opiates by general practitioners in cases of suspected myocardial infarction." | 7.69 | The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction. ( Robertson, S; Strachan, DA, 1995) |
| "We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 7.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
| "We assessed whether audit might reduce the time taken to give thrombolysis and aspirin in patients with acute myocardial infarction (N = 116)." | 7.69 | Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. ( Currie, P; Gray, SM; Shaw, TR; Starkey, IR, 1994) |
| "Early low dose aspirin therapy is beneficial in myocardial infarction (MI)." | 7.69 | Use of early aspirin in suspected acute myocardial infarction by General Practitioners in Sri Lanka. ( de Silva, HJ; Gunatilake, SB; Seneviratne, SL, 1997) |
| "To assess the frequency and timing of aspirin administration in emergency department patients with possible myocardial infarction." | 7.69 | Emergency department use of aspirin in patients with possible acute myocardial infarction. ( Cannistra, L; Conte, FJ; Forman, DE; Garber, C; Leavitt, J; Miller, G; Noris, M; Parisi, AF; Saketkhou, BB; Sharma, SC; Tilkemeier, P, 1997) |
| "We present a series of fifteen patients treated with low dose aspirin for secondary prevention of ischemic heart disease who had upper GI bleeding and were admitted to our hospital because of unstable angina or myocardial infarction." | 7.69 | Aspirin for prevention of myocardial infarction. A double-edged sword. ( Amital, H; Bar-Dayan, Y; Levy, Y; Shoenfeld, Y, 1997) |
| "Platelet functional parameters (platelet aggregation, blood circulating reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a daily dose of 320 mg in relation to the outcome of the disease: Group 1, stabilization and Group 2, evolving myocardial infarction." | 7.68 | [Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system]. ( Shalaev, SV, 1992) |
| "2 mg/100 g body wt orally for 30 days) on myocardial infarction induced by isoproterenol (200 mg/kg body wt, subcutaneously for 2 days) has been studied in rats using activities of creatine kinase, aspartate amino transaminase, alanine amino transaminase and lactate dehydrogenase and levels of lipid peroxides as standard markers." | 7.68 | Effect of aspirin on isoproterenol induced myocardial infarction--a pilot study. ( Devi, CS; Geetha, A; Manjula, TS, 1992) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 7.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 7.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "We determined if the thromboxane A2 antagonist SQ 30,741 can reduce ultimate myocardial infarct size and reperfusion injury." | 7.67 | Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve. ( Grover, GJ; Schumacher, WA, 1989) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 7.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| "To assess whether aspirin reduces the risk of a first myocardial infarction (MI) in young women, we evaluated data from a case-control study among women less than 50 years of age without a prior MI: 48 of 551 cases of MI and 67 of 896 hospital controls had taken aspirin regularly for at least 12 weeks immediately before admission." | 7.66 | Aspirin and myocardial infarction in young women. ( Kaufman, DW; Miettinen, OS; Rosenberg, L; Shapiro, S; Slone, D; Stolley, PD, 1982) |
| " suggest that the myocardial infarction induced by isoproterenol in the rat may be determined by phenomenons of intracoronaric platelets aggregation." | 7.66 | [The role of the platelets in myocardial infarction induced by isoproterenol in the rat (author's transl)]. ( Cacciapuoti, AA; Genovese, A; Giuffrida, G; Mazza, F; Polverino, W, 1979) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 7.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| "The results of two large independent studies involving a combined total of 776 patients treated in hospital with a discharge diagnosis of acute myocardial infarction and 13,898 patients with other discharge diagnoses showed a negative association between regular aspirin intake and non-fatal myocardial infarction." | 7.65 | Regular aspirin intake and acute myocardial infarction. ( , 1974) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 6.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high." | 6.71 | Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. ( Chen, YP; Chen, ZM; Collins, R; Jiang, LX; Liu, LS; Pan, HC; Peto, R; Xie, JX, 2005) |
| "Fibrinogen was significantly lower after rt-PA versus TNK-tPA (3 h: 163 +/- 27 versus 380 +/- 54 mg/dl; p < 0." | 6.70 | Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. ( Ehlers, R; Helber, U; Hoffmeister, HM; Kazmaier, S; Letsch, R; Szabo, S; Walter, T, 2002) |
| " Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers." | 6.69 | Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study. ( Altmann, E; Cuffie-Jackson, CA; Molhoek, PG; Neuhaus, KL; Ronner, E; Simoons, ML; van der Wieken, LR; van Kesteren, HA; Zijnen, P, 2000) |
| "Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease." | 6.68 | Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997) |
| " At 24 hours, 202 patients were randomized to continue intravenous heparin therapy (n = 99) in full dosage or to discontinue heparin therapy and begin an oral antiplatelet regimen of aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)." | 6.67 | A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. ( Aylward, PE; Federman, J; Giles, RW; Harris, PJ; Hodge, RL; Nelson, GI; Thompson, PL; Thomson, A; Tonkin, AM; Walsh, WF, 1991) |
| "Aspirin intake was associated with a mean reduction in the incidence of infarction of 44." | 6.67 | Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. ( Buring, JE; Hennekens, CH; Manson, JE; Muller, JE; Ridker, PM, 1990) |
| "Aspirin was associated with fewer non-fatal reinfarctions (3." | 6.66 | Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study. ( , 1987) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 6.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 6.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 6.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| "In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 6.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 6.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| " The risk of bleeding during anticoagulant therapy has been evaluated in 10 recent studies of warfarin treatment for the prevention of arterial thromboembolism." | 6.17 | [Bleeding complications in oral anticoagulant treatment]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1995) |
| "A meta-analysis of randomized clinical trials of fibrinolysis was performed, examining the interaction between aspirin and fibrinolysis in treating patients with acute myocardial infarction." | 6.16 | Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. ( Basinski, A; Naylor, CD, 1991) |
| " On the basis of present information it is evident that, in addition to heparin, all patients suffering from suspected acute myocardial infarction should receive immediate low dose aspirin which should be continued for one to six months." | 6.16 | Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies. ( McGregor, M; Silberberg, JS, 1989) |
| " Conditions characterized by a reduction in platelet survival and where dipyridamole has been used include heart valve replacement, arterial grafting, cerebrovascular disorders, and disorders of peripheral circulation." | 6.15 | Dipyridamole: a critical evaluation. ( Alexander, MR; Rivey, MP; Taylor, JW, 1984) |
| "Large-scale clinical trials of the use of aspirin in post-myocardial infarction patients were based on the assumption that inhibition of platelet activity would reduce thromboembolism associated with atherosclerosis, and that thromboembolism is a major cause of the clinical complications of atherosclerosis." | 6.15 | Aspirin in the treatment of cardiovascular disease: a review. ( Kinlough-Rathbone, RL; Mustard, JF; Packham, MA, 1983) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 5.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| "In Chinese patients with negative cardiac troponin undergoing drug-eluting stent implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was driven mainly by a reduction in bleeding events without an increase in ischemic events." | 5.69 | Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. ( Chen, M; Cheng, K; Ge, J; Huang, J; Lan, J; Li, G; Qian, J; Wang, X; Wang, Y; Wei, G; Wu, H; Xu, L; Zhang, C; Zhang, H; Zhao, X, 2023) |
| "5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type." | 5.69 | Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M, 2023) |
| "In this prospective, open-label, multi-centre, 2 × 2 factorial, randomized, controlled study, 1,800 patients with diabetes mellitus and multi-vessel disease (inclusion criteria similar to FREEDOM trial) with indication for coronary revascularization will be randomly assigned to Supraflex Cruz or Xience stents and also to ticagrelor- or prasugrel- based antiplatelet strategies." | 5.69 | Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2. ( Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK, 2023) |
| "In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded." | 5.69 | Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. ( Benziger, CP; Effron, MB; Farrehi, PM; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Knowlton, KU; Marquis-Gravel, G; Muñoz, D; Pepine, CJ; Polonsky, TS; Re, RN; Roe, MT; Rothman, RL; Sleem, A; Stebbins, A; Whittle, J; Wruck, LM, 2023) |
| "The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy." | 5.69 | Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. ( Ahn, HS; Cha, KS; Choi, HH; Han, JK; Hur, SH; Hwang, D; Jo, SH; Kang, J; Kim, HS; Koo, BK; Lee, NH; Park, KW; Ryu, JK; Shin, ES; Suh, IW; Woo, SI; Yang, HM; Yang, S, 2023) |
| "We compared 482 STEMI patients who received aspirin, ticagrelor, and UFH loading in a non-PCI capable spoke hospital before transfer (NPHT) versus 227 prehospital triage setting (PTS) STEMI patients who received in-ambulance aspirin, followed by ticagrelor and UFH in the hub catheterization laboratory." | 5.62 | The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention. ( Bérubé, S; Couture, ÉL; d'Entremont, MA; Desgagnés, N; Huynh, T; Karzon, A; Laferrière, C; Lepage, S; Nguyen, M; Verreault-Julien, L, 2021) |
| "This post hoc subanalysis of the open-label, all-comers, randomised GLOBAL LEADERS trial, which compared 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) with 12-month aspirin monotherapy following 12-month DAPT, only included patients who, at 12 months, were free from ischaemic and bleeding events and were adherent to their assigned antiplatelet therapy." | 5.51 | Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. ( Gao, C; Garg, S; Hamm, C; Hara, H; Kawashima, H; Ono, M; Onuma, Y; Piek, JJ; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Wang, R; Windecker, S; Wykrzykowska, JJ, 2022) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| " Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD." | 5.51 | Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov ( Dumbleton, J; Fitzmaurice, D; Fraser, SD; Fuat, A; Gallagher, H; Griffith, KE; Hawkey, CJ; Henderson, RA; Lord, J; Lown, M; Maishman, T; Moore, MV; Roderick, PJ; Stevens, P; Stevenson, D; Taal, MW; Whitehead, A, 2022) |
| "In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. ( Angiolillo, DJ; Baber, U; Beerkens, FJ; Briguori, C; Cao, D; Claessen, B; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Huber, K; Kastrati, A; Kornowski, R; Krucoff, MW; Kunadian, V; Marx, S; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Steg, PG; Weisz, G; Zhang, Z, 2022) |
| "Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)." | 5.51 | CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022) |
| "A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting-enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary prevention of cardiovascular death and complications after myocardial infarction." | 5.51 | Polypill Strategy in Secondary Cardiovascular Prevention. ( Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D, 2022) |
| "In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events." | 5.51 | A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. ( Alexander, JH; Bhatt, DL; Budaj, A; Campo, G; Coppolecchia, R; Eikelboom, J; Ferreiro, JL; Hermanides, RS; James, SK; Jones, WS; Keller, L; Kirsch, B; Merkely, B; Mundl, H; Rao, SV; Shibasaki, T, 2022) |
| "The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)." | 5.51 | Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M, 2022) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 5.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| "Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent." | 5.41 | Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Cheema, AN; Eckstein, J; Lam, A; Liu, S, 2023) |
| "Considering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2." | 5.41 | Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ( Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 5.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| " Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis." | 5.41 | Personalised antiplatelet therapies for coronary artery disease: what the future holds. ( Angiolillo, DJ; Capodanno, D, 2023) |
| "Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD)." | 5.41 | P2Y ( Arnesen, H; Bhatt, DL; Calabrò, P; Cao, D; Chiarito, M; Franzone, A; Gragnano, F; Kang, J; Kastrati, A; Kim, HS; McFadden, EP; Mehran, R; Park, KW; Pettersen, AR; Pirondini, L; Pocock, S; Schunkert, H; Seljeflot, I; Steg, PG; Valgimigli, M; von Scheidt, M; Windecker, S; Woodward, M; Zhao, Q; Zhu, Y, 2023) |
| "Dual antiplatelet therapy with aspirin and P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) has been shown to be associated with better outcomes." | 5.41 | Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis. ( Aguiar, C; Albuquerque, F; Almeida, M; Ferreira, J; Gomes, DA; Mendes, M; Presume, J; Uva, MS, 2023) |
| "Myocardial infarction was significantly lower when adding clopidogrel or ticagrelor 90 mg to aspirin than those in the aspirin alone group." | 5.41 | Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. ( Liu, C; Ma, L, 2023) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months." | 5.41 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021) |
| "The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy." | 5.41 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. ( Ahmad, FS; Alikhaani, JD; Anderson, RD; Antman, EM; Bell, DS; Benziger, CP; Berdan, LG; Bradley, SM; Brown, LS; Campbell, JR; Carton, TW; Crenshaw, DL; Curtis, LH; Davidson, DR; DeWalt, DA; Edgley, K; Effron, MB; Farrehi, P; Fintel, DJ; Fonarow, GC; Ford, DE; Girotra, S; Goldberg, YH; Gregoire, KC; Gupta, K; Hammill, BG; Handberg, EM; Harrington, RA; Harris, DF; Haynes, K; Hernandez, AF; Hess, R; Jain, SK; Jones, WS; Kaushal, R; Kho, AN; Knowlton, KU; Kraschnewski, JL; Kripalani, S; Manning, BR; Marcus, GM; Marquis-Gravel, G; Masoudi, FA; McClay, JC; McCormick, TE; McTigue, KM; Merritt, JG; Modrow, MF; Mulder, H; Muñoz, D; Nauman, E; Paranjape, A; Pencina, MJ; Pepine, CJ; Polonsky, TS; Qualls, LG; Re, RN; Riley, D; Robertson, HR; Roe, MT; Roger, VL; Rothman, RL; Sharlow, AG; Shenkman, EA; VanWormer, JJ; Waitman, LR; Whittle, J; Wruck, LM; Zemon, DN; Zhou, L, 2021) |
| "Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068)." | 5.41 | Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. ( Aboyans, V; Berkowitz, SD; Bhatt, DL; Bosch, JJ; Connolly, SJ; Dagenais, GR; Dyal, L; Eikelboom, JW; Fox, KAA; Leong, DP; Muehlhofer, E; Probstfield, JL; Widimsky, P; Winkelmann, BR; Yusuf, S, 2021) |
| "Aspirin (150 mg/d) was administered every morning since 12 hours after CABG." | 5.40 | Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation. ( Mazur, P; Plicner, D; Sadowski, J; Stąpor, R; Undas, A; Ziętkiewicz, M, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 5.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 5.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| " This case shows that, in such particular conditions, a change in dipyridamole dosage can induce a myocardial infarction even if its blood level remains in the therapeutic range." | 5.36 | [Myocardial infarction after voluntary intoxication by drug interaction between dipyridamole and aspirin]. ( Amat, G; Brahic, H; Eschalier, A; Eschalier, R; Marcaggi, X; Ravan, R, 2010) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " After 3 months, the patient is free from adverse events." | 5.35 | Drug-eluting stents in a patient with favism: is the aspirin administration safe? ( Capoluongo, E; Di Russo, C; Ferraiuolo, G; Giardina, B; Loschiavo, P; Minucci, A; Rigattieri, S; Silvestri, P, 2008) |
| "The authors previously reported that perioperative aspirin and/or clonidine does not prevent a composite of death or myocardial infarction 30 days after noncardiac surgery." | 5.34 | One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery. ( Amir, M; Balasubramanian, K; Berwanger, O; Biccard, BM; Chan, MTV; Conen, D; Devereaux, PJ; Fleischmann, E; Forget, P; Gilron, I; Graham, M; Guyatt, G; Kumar, PA; Kurz, A; Lamy, A; Landoni, G; Leslie, K; Malaga, G; Manach, YL; Meyhoff, CS; Mrkobrada, M; Paniagua, P; Parlow, JL; Pettit, S; Popova, E; Sessler, DI; Sigamani, A; Srinathan, S; Torres, D; Turan, A; Villar, JC; Wang, CY; Whitlock, R; Xavier, D; Yusuf, S, 2020) |
| "The present results are similar to those observed in clinical trials where administration of low-dose aspirin plus prasugrel was associated with a low rate of major bleeding and CV events." | 5.34 | Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. ( Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 5.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "The risk of stroke is reduced with primary PTCA (OR = 0." | 5.33 | Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. ( Massel, D, 2005) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 5.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Using the ESRD database and the Cooperative Cardiovascular Project (CCP) database, we identified AMI patients who were receiving either peritoneal dialysis or hemodialysis before admission." | 5.32 | Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. ( Berger, AK; Duval, S; Krumholz, HM, 2003) |
| "Bradykinin is a potent endothelium-dependent vasodilator in the coronary vascular bed." | 5.32 | Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. ( Akula, A; Veeravalli, KK, 2004) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 5.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| " Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1." | 5.31 | Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. ( García Rodríguez, LA; Patrono, C; Varas, C, 2000) |
| "In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin." | 5.30 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes. ( Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D, 2019) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 5.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI." | 5.30 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. ( Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavík, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B, 2019) |
| "Long-term ticagrelor monotherapy following 1-month DAPT can favorably balance ischemic and bleeding risks in patients with multivessel PCI." | 5.30 | Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. ( Carrie, D; Chang, CC; Chichareon, P; Chowdhary, S; de Winter, RJ; Eitel, I; Garg, S; Hamm, C; Kogame, N; Magro, M; Modolo, R; Ong, P; Onuma, Y; Ottesen, MM; Serruys, PW; Steg, PG; Stoll, HP; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ; Zweiker, R, 2019) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus." | 5.30 | Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. ( Andersson, M; Bhatt, DL; Fox, K; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Mehta, SR; Ridderstråle, W; Simon, T; Steg, PG, 2019) |
| "5%), an independent adjudication process of reported and unreported potential endpoints, using standardised CEC procedures, in order to assess whether 23-month ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT is non-inferior to a standard regimen of DAPT for 12 months followed by aspirin monotherapy for the primary efficacy endpoint of death, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularisation and superior for the primary safety endpoint of type 3 or 5 bleeding according to the Bleeding Academic Research Consortium criteria." | 5.30 | Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). ( Aminian, A; Benit, E; Bolognese, L; Bryniarski, K; Buszman, P; Dominici, M; Ferrario, M; Franzone, A; Garg, S; Hamm, C; Heg, D; Huber, K; Janssens, L; Juni, P; Leonardi, S; Liebetrau, C; McFadden, E; Naber, C; Petrov, I; Piccolo, R; Prokopczuk, J; Serruys, P; Slagboom, T; Steg, G; Tumscitz, C; Valgimigli, M; van Geuns, RJ; Vranckx, P; Vrolix, M; Windecker, S; Zurakowski, A, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding." | 5.30 | Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019) |
| "SOCRATES compared ticagrelor and aspirin in 13,199 patients with acute minor stroke or high-risk transient ischemic attack." | 5.30 | Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2019) |
| " The dosage of aspirin decreased from 500 mg or more per day in 1986 to a daily dose of approximately 250 mg in 1989." | 5.29 | [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Ruidavets, JB, 1994) |
| "When myocardial infarction is due to coronary embolism from endocarditic valves standard thrombolysis regimes should be avoided." | 5.29 | Acute coronary embolism complicating aortic valve endocarditis treated with streptokinase and aspirin. A case report. ( Connolly, DL; Crowley, JJ; Dardas, PS; Kenny, A; Petch, MC, 1994) |
| "Aspirin treatment is found to counteract the effect of isoproterenol on lipid and lipid peroxide formation and associated enzyme changes in heart mitochondria." | 5.29 | Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats. ( Devi, CS; Manjula, TS, 1993) |
| "Aspirin treated rats showed lower mortality rate and smaller changes in the myocardium on histopathological examination when compared to corresponding animals given isoproterenol alone." | 5.28 | Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation. ( Menon, VP; Muraleedharan, D; Sushama Kumari, S; Varghese, A, 1990) |
| "TRA2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (vorapaxar) and PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticagrelor) were blinded, randomized placebo-controlled trials of antiplatelet therapy for the prevention of ischemic events in stable patients with symptomatic atherosclerosis." | 5.27 | Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cavallari, I; Cohen, M; Creager, MA; Goodrich, EL; Morrow, DA; Olin, J; Piazza, G; Sabatine, MS; Scirica, BS; Steg, PG; Storey, RF, 2018) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 5.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| " The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)." | 5.27 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 5.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| " Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months." | 5.27 | Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la ( Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 5.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
| "To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Chelmow, D; Coker, TR; Davidson, KW; Davis, EM; Donahue, KE; Jaén, CR; Krist, AH; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Tseng, CW; Wong, JB, 2022) |
| "Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine." | 5.22 | Causes of late mortality with dual antiplatelet therapy after coronary stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Elmariah, S; Kereiakes, DJ; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Wiviott, SD; Yeh, RW, 2016) |
| "Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month versus DAPT with either ticagrelor (acute coronary syndrome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA ≤100 mg for 24 months." | 5.22 | Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. ( Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S, 2016) |
| "Aspirin is promptly administered to patients presenting with acute coronary syndromes." | 5.22 | Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. ( Ayele, GM; Brener, SJ; Lansky, AJ; Mehran, R; Stone, GW, 2016) |
| "In EES-treated subjects, significant reductions in stent thrombosis and MI and an increase in bleeding were observed with continued thienopyridine beyond 1 year compared with aspirin alone." | 5.22 | Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. ( Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW, 2016) |
| "The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI)." | 5.22 | Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. ( Asanin, M; Čolić, M; Krljanac, G; Kruzliak, P; Lasica, R; Marinkovic, J; Mrdovic, I; Savic, L; Stanković, S, 2016) |
| "We analyzed data from the randomized TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes) trial of aspirin plus prasugrel or clopidogrel following ACS." | 5.22 | Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. ( Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| " The prediction rule assigned 1 point each for myocardial infarction at presentation, prior myocardial infarction or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; -1 point for age 65 to younger than 75 years; and -2 points for age 75 years or older." | 5.22 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. ( Apruzzese, PK; Camenzind, E; Cohen, DJ; Cutlip, DE; Gershlick, AH; Kereiakes, DJ; Massaro, JM; Mauri, L; Normand, SL; Rinaldi, MJ; Secemsky, EA; Song, Y; Spertus, JA; Steg, PG; Wijns, W; Yeh, RW, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " Patients randomized to continued thienopyridine and aspirin after 12 months had lower ischemic risk but higher bleeding risk than those treated with placebo and aspirin." | 5.22 | DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. ( Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Steg, PG; Wiviott, SD; Yeh, RW, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 5.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate." | 5.22 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 5.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| "Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI)." | 5.20 | Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. ( Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J, 2015) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 5.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| " Between 12 and 30 months, continued thienopyridine reduced stent thrombosis compared with placebo in patients with and without MI at presentation (MI group, 0." | 5.20 | Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. ( Cohen, DJ; Cutlip, DE; Gershlick, AH; Iancu, AC; Jacobs, A; Kereiakes, DJ; Massaro, JM; Mauri, L; Rinaldi, MJ; Steg, PG; Tanguay, JF; Windecker, S; Wiviott, SD; Yeh, RW, 2015) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 5.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| "Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary intervention with stenting remains uncertain." | 5.20 | Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. ( Bach, RG; Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Zettler, ME, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 5.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 5.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described." | 5.19 | Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014) |
| "Administration of aspirin before surgery and throughout the early postsurgical period had no significant effect on the rate of a composite of death or nonfatal myocardial infarction but increased the risk of major bleeding." | 5.19 | Aspirin in patients undergoing noncardiac surgery. ( Alonso-Coello, P; Amir, M; Baigent, C; Berwanger, O; Biccard, BM; Botto, F; Chan, MT; Chow, C; Chrolavicius, S; Cook, D; Devereaux, PJ; Eikelboom, J; Fleischmann, E; Forget, P; Gao, P; Garg, AX; Graham, M; Guyatt, G; Kearon, C; Kumar, PA; Kurz, A; Lamy, A; Le Manach, Y; Leslie, K; Lurati Buse, G; Malaga, G; Meyhoff, CS; Mizera, R; Mrkobrada, M; Paniagua, P; Parlow, JL; Pasin, L; Pettit, S; Pogue, J; Robinson, A; Rodseth, RN; Sessler, DI; Sigamani, A; Srinathan, S; Tiboni, M; Torres, D; VanHelder, T; Villar, JC; Wang, CY; Whitlock, R; Xavier, D; Yusuf, S, 2014) |
| "In ST-elevation myocardial infarction (STEMI) patients, residual platelet reactivity soon after a loading dose (LD) of prasugrel or ticagrelor is higher than that reported for healthy volunteers or subjects with stable coronary artery disease; and the majority of primary percutaneous coronary intervention (PPCI) procedures with bivalirudin monotherapy are performed without proper platelet inhibition." | 5.19 | Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. ( Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "To detect residual platelet aggregation following the switch from generic (GC) to brand clopidogrel (BC) in male patients after ST-elevated myocardial infarction (STEMI)." | 5.19 | Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction. ( Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV, 2014) |
| "Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors." | 5.19 | Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014) |
| "Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
| "MI is an early complication of pneumonia and is associated with in vivo platelet activation and serum TxB2 overproduction; aspirin 100 mg/day seems insufficient to inhibit thromboxane biosynthesis." | 5.19 | Platelet activation is associated with myocardial infarction in patients with pneumonia. ( Bertazzoni, G; Bucci, T; Calabrese, CM; Calvieri, C; Cangemi, R; Casciaro, M; Falcone, M; Farcomeni, A; Grieco, S; Palange, P; Pignatelli, P; Rossi, E; Taliani, G; Violi, F, 2014) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| " In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension." | 5.17 | Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013) |
| "The results indicate that tirofiban and warfarin combined with aspirin and clopidogrel could reduce the rates of MACCE and bleeding, and it could prevent non-acute stent thrombosis safely and effectively after percutaneous coronary intervention with DES." | 5.17 | [Prevention of non-acute stent thrombosis after drug-eluting stent implantation]. ( Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY, 2013) |
| "Patients with a recently diagnosed ST-elevation myocardial infarction (STEMI) and implanted coronary drug-eluting stent (DES) who need urgent surgery are at increased risk of surgical bleeding unless aspirin and clopidogrel are discontinued beforehand." | 5.17 | Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. ( Liu, XH; Qu, Y; Shen, H; Xia, JG, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably stroke and myocardial infarction." | 5.17 | Association of COX-2 rs20417 with aspirin resistance. ( Al-Hazzani, A; Alshatwi, AA; Jyothy, A; Kaul, S; Munshi, A; Sharma, V, 2013) |
| "Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke." | 5.17 | Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. ( FitzGerald, GA; Fries, S; Grant, GR; Grosser, T; Kapoor, SC; Lawson, JA, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 5.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "In the setting of ST-segment elevation myocardial infarction (STEMI), patients at high risk of systemic emboli who undergo primary percutaneous coronary intervention (PCI) using stents might require triple antithrombotic therapy (a combination of aspirin, thienopyridine, and vitamin K antagonist [VKA])." | 5.16 | Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZO ( Dangas, GD; Mehran, R; Nikolsky, E; Parise, H; Pocock, SJ; Stone, GW; Xu, K; Yu, J, 2012) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 5.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "Thrombolysis, as reperfusion therapy for ST segment elevation myocardial infarction (STEMI), induces a pro-thrombotic status with enhanced platelet activity; this study aims to evaluate P2Y12 platelet reactivity and response to clopidogrel in the post-thrombolysis scenario." | 5.16 | P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. ( Alonso-Rodríguez, D; Bangueses, R; Cuellas, C; de Miguel, A; de Prado, AP; Diego, A; Fernandez-Vazquez, F; Martín, J; Samaniego, B; Vega, B, 2012) |
| "This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)." | 5.16 | Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "This study sought to examine the relationship between the aspirin dose prescribed at hospital discharge and long-term outcomes after ST-segment elevation myocardial infarction in patients treated with primary percutaneous coronary intervention (PCI)." | 5.16 | Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t ( Baber, U; Claessen, BE; Dangas, GD; Dudek, D; Fahy, M; Grines, CL; Guagliumi, G; Kornowski, R; Lansky, AJ; Mehran, R; Parise, H; Stone, GW; Weisz, G; Witzenbichler, B; Wöhrle, J; Xu, K; Yu, J, 2012) |
| "Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes." | 5.15 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 5.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Large randomized clinical trials have shown the efficacy of aspirin, ACE (angiotensin converting enzyme) inhibitors and statins as secondary prevention measures in patients after an acute coronary syndrome with and without ST elevations." | 5.15 | Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Senges, J; Zahn, R; Zeymer, U, 2011) |
| " The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin." | 5.15 | Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 5.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "In 111 patients with acute ST segment elevation myocardial infarction (STEMI), duplo measurements of iron (Fe)-induced platelet aggregation (FIPA) were performed after clopidogrel, acetylsalicylic acid and/or tirofiban treatment." | 5.14 | Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction. ( Ottervanger, JP; Remijn, JA; Slingerland, RJ; Smit, JJ; van 't Hof, AW; van Oeveren, W; Zijlstra, F, 2009) |
| "Patients with thrombolysis in myocardial infarction (TIMI) 3 flow <48 hours after fibrinolysis for ST-elevation myocardial infarction were randomized to aspirin plus coumarin, with prolonged heparinization until the target international normalized ratio (2-3) was reached, or aspirin with standard heparinization." | 5.14 | Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. ( Aengevaeren, WR; Brouwer, MA; Kievit, PC; van den Bergh, PJ; Veen, G; Verheugt, FW, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 5.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "The impact of thienopyridine administration prior to primary stenting in acute myocardial infarction (AMI) has not been well studied." | 5.14 | Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. ( Cox, DA; Dangas, GD; Fahy, M; Garcia, E; Griffin, JJ; Grines, CL; Guagliumi, G; Iyengar, S; Lansky, AJ; Mehran, R; Rabbani, LE; Stant, J; Stone, GW; Stuckey, T; Tcheng, JE; Turco, M, 2009) |
| "We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease." | 5.14 | Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 5.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Inhibition of platelet thromboxane A(2) (TXA(2)) by aspirin is critical in patients with acute myocardial infarction (AMI), but some patients have persistent platelet TXA(2) production within 48 hours of the onset of AMI." | 5.14 | Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. ( Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Valles, J, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 5.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "Currently 162-325 mg aspirin is recommended for the treatment of acute coronary syndrome." | 5.14 | Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. ( Derhaschnig, U; Frossard, M; Fuchs, I; Jilma, B; Riedmüller, E; Spiel, AO, 2010) |
| "In subgroup analyses useful to formulate hypotheses from a large randomized trial in apparently healthy men, aspirin nonadherence or NSAID use explained the lack of clinical benefit of aspirin on first myocardial infarction that has been attributed to "aspirin resistance." | 5.14 | Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". ( Gurbel, PA; Hebert, PR; Hennekens, CH; Schneider, WR; Tantry, US, 2010) |
| "Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease." | 5.14 | Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. ( Jannati, M; Khalili, A; Kojuri, J; Mahboodi, A; Mahmoody, Y; Zangbar Sabegh, B, 2010) |
| "In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)." | 5.14 | Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "Prespecified two-centre substudy of the prospective, international, multicentre, placebo controlled Ongoing Tirofiban in Myocardial Infarction Evaluation trial 2 (On-TIME-2 trial)." | 5.14 | Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. ( Dill, T; Hamm, C; Heestermans, T; Ottervanger, JP; Slingerland, R; Smit, JJ; ten Berg, J; van 't Hof, AW; van Werkum, JW, 2010) |
| "Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse 1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse outcome." | 5.14 | Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr ( Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Fileti, L; Furgieri, A; Meliga, E; Russo, F; Valgimigli, M, 2010) |
| "To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel." | 5.13 | Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. ( Angiolillo, DJ; Campo, G; Colangelo, S; de Cesare, N; Ferrari, F; Ferrari, R; Furgieri, A; Hamon, M; Kubbajeh, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "Using combined data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction patients), we compared the association between initial aspirin dose of 162 versus 325 mg and 24-hour and 7-day mortality, as well as rates of in-hospital moderate/severe bleeding." | 5.13 | Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. ( Armstrong, PW; Berger, JS; Califf, RM; Granger, CB; Harrington, RA; Ohman, EM; Peterson, ED; Simes, RJ; Stebbins, A; Van de Werf, F; White, HD, 2008) |
| "We extended the follow-up of 2473 patients from the Dutch TIA Trial (recruitment March 1986 to March 1989, all treated with aspirin; CIAO) and 186 Dutch participants of the European Atrial Fibrillation Trial (recruitment June 1988 to May 1992, 26% on anticoagulants during the trial; CIAF)." | 5.13 | Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event. ( Algra, A; Gorter, JW; Kappelle, LJ; Koudstaal, PJ; van Gijn, J; van Wijk, I, 2008) |
| "In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28) study, 3,491 patients underwent angiography a median of 3." | 5.13 | Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. ( Buros, JL; Cannon, CP; Gibson, CM; Josephson, ME; Lord, E; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS; Shui, A; Zimetbaum, PJ, 2008) |
| " Whether the addition of intravenous tirofiban during this procedure produces further benefit has not been clarified in ST segment elevation myocardial infarction (STEMI) patients." | 5.13 | Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. ( Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 5.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 5.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| "Clinical guidelines recommend extended treatment with dual antiplatelet therapy (DAPT) with ticagrelor 60 mg (twice daily) beyond 12 months in high-risk patients with a history of myocardial infarction (MI) who have previously tolerated DAPT and are not at heightened bleeding risk." | 5.12 | Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. ( Ariza-Solé, A; Bonaca, M; Giannitsis, E; Hedberg, J; Hewitt, C; Jernberg, T; Lambrelli, D; Lesén, E; Maggioni, AP; Simeone, JC; Storey, RF; Ten Berg, J, 2021) |
| "Warfarin, aspirin, and the combination of these, have all proven to be efficacious in preventing future events after myocardial infarction." | 5.12 | Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. ( Arnesen, H; Eikvar, L; Hurlen, M; Seljeflot, I, 2006) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 5.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation." | 5.12 | Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. ( Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006) |
| "To test the effectiveness of an intervention, delivered face-to-face by local firefighters, designed to increase utilization of 911 and self-administration of aspirin for seniors experiencing chest pain." | 5.12 | A community intervention by firefighters to increase 911 calls and aspirin use for chest pain. ( Cagle, A; Diehr, P; Eisenberg, M; Meischke, H; Rowe, S, 2006) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "To study the prevalence and importance of aspirin resistance in patients with an evolving acute myocardial infarction (AMI) by use of the Platelet Function Analyzer-100." | 5.12 | Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "15,222 patients with ST-elevation acute myocardial infarction and normal intraventricular conduction were randomly assigned streptokinase and aspirin plus bivalirudin or unfractionated heparin in the HERO-2 trial; randomisation did not alter 30-day mortality." | 5.12 | Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. ( French, JK; Gao, W; Raffel, OC; Stewart, RA; White, HD; Wong, CK, 2006) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 5.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease." | 5.12 | The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006) |
| "Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding." | 5.12 | Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. ( Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW, 2007) |
| "Oral anticoagulants are better than aspirin for secondary prevention after myocardial infarction and after cerebral ischaemia in combination with non-rheumatic atrial fibrillation." | 5.12 | Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2007) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 5.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "Impaired antiplatelet response to clopidogrel but not to aspirin may contribute to smaller anti-inflammatory response in patients with ST-elevation myocardial infarction." | 5.12 | Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. ( Bobilewicz, D; Filipiak, KJ; Grabowski, M; Huczek, Z; Imiela, T; Malek, LA; Opolski, G; Spiewak, M; Szpotanska, M, 2007) |
| " The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7." | 5.12 | Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007) |
| "To assess the efficacy and safety of a treatment with clopidogrel when associated or not to the treatment with tirofiban and aspirin for high-risk non-ST segment elevation myocardial infarction (non-STEMI), without early angioplasty." | 5.12 | [Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism]. ( Blancas Gómez-Casero, R; Chana García, M; González Manzanares, JL; López Matamala, B; Martín Delgado, C; Martínez Díaz, C; Nevado Losada, E; Serrano Castañeda, J; Yáñez Parareda, E, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "We evaluated whether the use of glycoprotein IIb/IIIa receptor inhibitors, in addition to heparin and aspirin, imparts an incremental benefit in a subgroup of patients with acute coronary syndromes (ACS) who had congestive heart failure (CHF) symptoms at presentation." | 5.11 | Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. ( Harrington, RA; Hochman, JS; Houghtaling, PL; Jaber, WA; Marso, SP; Menon, V; Prior, DL; Simoons, ML; Srichai, MB, 2004) |
| "The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention." | 5.11 | Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 5.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| " Platelet-leukocyte conjugate formation (induced by thrombin receptor activating peptide (TRAP)) and platelet aggregation (induced by ADP and arachidonic acid) were assessed in 30 patients with unstable angina or non-ST elevation myocardial infarction." | 5.11 | Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. ( Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP, 2004) |
| "The Heart Attack Survival Kit (HASK) project is a prospective, randomized trial, testing the effectiveness of an intervention delivered door-to-door by firefighters to increase use of 911 and ingestion of aspirin for symptoms of acute myocardial infarction (AMI) among seniors in King County, Washington." | 5.11 | Evaluation of a public education program delivered by firefighters on early recognition of a heart attack. ( Cagle, A; Diehr, P; Eisenberg, M; Meischke, H; Rowe, S, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "Antithrombotic treatment with warfarin and/or aspirin is widely used in preventing recurrence of thrombotic events after an acute myocardial infarction (AMI)." | 5.11 | Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. ( Arnesen, H; Hurlen, M; Seljeflot, I, 2004) |
| "To examine efficacy of clopidogrel before thrombolytic therapy (TLT) in patients with acute myocardial infarction (AMI)." | 5.11 | [First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation]. ( Akinina, SA; Petrik, ES; Sereshcheva, AKh; Shalaev, SV; Vorob'eva, NM, 2004) |
| "We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials." | 5.11 | Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. ( Bhapkar, MV; Califf, RM; Graffagnino, C; Kassem-Moussa, H; Mahaffey, KW; Newby, LK; Sila, CA; Simes, RJ; Tasissa, G; White, HD, 2004) |
| "Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke." | 5.11 | A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. ( Buring, JE; Cook, NR; Gaziano, JM; Gordon, D; Hennekens, CH; Lee, IM; Manson, JE; Ridker, PM, 2005) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 5.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| " One hundred ninety patients with a history of myocardial infarction were evaluated using arachidonic acid-stimulated light aggregometry at 3 different time points: while receiving their usual daily aspirin, after not receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 325 mg." | 5.11 | Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. ( Barber, K; DeFranco, A; Ghosheh, K; Reeves, MJ; Schwartz, DE; Schwartz, KA, 2005) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 5.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized trial of 2,116 patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 mg before PCI and 75 mg daily for one year afterward compared with placebo load and placebo days 29 to 365 in reducing the combined risk of death, myocardial infarction, and stroke." | 5.11 | Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria ( Beinart, SC; Bouin, O; Caro, J; Chen, R; Gabriel, S; Jackson, J; Kolm, P; Mahoney, EM; Steinhubl, S; Topol, E; Veledar, E; Weintraub, WS; Zhang, Z, 2005) |
| "To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events." | 5.11 | Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. ( Braunwald, E; Cannon, CP; Gibson, CM; Lewis, BS; López-Sendón, JL; McCabe, CH; Montalescot, G; Murphy, SA; Sabatine, MS; Theroux, P, 2005) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 5.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "Antiplatelet treatment with aspirin and oral anticoagulants reduces recurrence of ischaemic events after myocardial infarction." | 5.10 | Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. ( Deckers, JW; Grobbee, DE; Jonker, JJ; van Es, RF; Verheugt, FW, 2002) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 5.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding." | 5.10 | Warfarin, aspirin, or both after myocardial infarction. ( Abdelnoor, M; Arnesen, H; Erikssen, J; Hurlen, M; Smith, P, 2002) |
| "The purpose of the present study was to study the concept of aspirin resistance or non-responsiveness by investigating the response to long-term aspirin therapy in patients with a former acute myocardial infarction (AMI)." | 5.10 | Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. ( Andersen, K; Arnesen, H; Hurlen, M; Seljeflot, I, 2002) |
| "To examine the development of age-related cataract in a trial of beta carotene supplementation in men." | 5.10 | A randomized trial of beta carotene and age-related cataract in US physicians. ( Buring, JE; Christen, WG; Gaziano, JM; Glynn, RJ; Hennekens, CH; Manson, JE; Sperduto, RD, 2003) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 5.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "The anticoagulant, warfarin, and the antiplatelet agent, aspirin, have been shown to have similar benefits after myocardial infarction." | 5.10 | Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. ( Doggrell, SA, 2003) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 5.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "There is clear evidence from numerous randomized trials and their meta-analyses that aspirin reduces risks of first myocardial infarction (MI)." | 5.10 | Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. ( Buring, JE; Chan, KA; Gaziano, JM; Glynn, RJ; Hennekens, CH; Kurth, T; Walker, AM, 2003) |
| " The purpose of the study was to evaluate the effects of tirofiban on clinical stabilization parameters in patients with unstable angina (UA) and non-Q-wave myocardial infarction (MI)." | 5.10 | Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. ( Cakmak, M; Cam, N; Okmen, E; Tartan, Z, 2003) |
| " We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction." | 5.10 | Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. ( Bylock, A; Emanuelsson, H; Goodvin, A; Nyström, P; Wallentin, L; Weaver, WD; Wilcox, RG, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "The aim of this study was to assess the influence of aspirin on selected inflammatory markers in patients recovering from acute myocardial infarction (AMI)." | 5.10 | Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. ( Arnesen, H; Eikvar, L; Hurlen, M; Seljeflot, I; Solheim, S, 2003) |
| "The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6." | 5.10 | Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). ( Berger, PB; Bhatt, DL; Chan, AW; DiBattiste, PM; Moliterno, DJ; Sapp, SK; Stone, GW; Topol, EJ; Wolski, K; Yakubov, SL, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 5.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "Both aspirin and warfarin when used alone are effective in the secondary prevention of vascular events and death after acute myocardial infarction." | 5.10 | Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. ( Brophy, MT; Ezekowitz, MD; Fiore, LD; Lu, D; Peduzzi, P; Sacco, J, 2002) |
| "To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms." | 5.10 | Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002) |
| "To assess the impact of fee-for-service (FFS) versus HMO medical insurance coverage on receipt of aspirin, beta-blockers, and calcium channel blockers at the time of hospital discharge following an acute myocardial infarction." | 5.09 | Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance. ( Goldberg, RJ; Gore, JM; Gurwitz, JH; McCormick, D; Savageau, J; Yarzebski, J, 1999) |
| "We examined the association of baseline plasma fibrinogen with future risk of myocardial infarction (MI) in the Physicians' Health Study." | 5.09 | A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. ( Hennekens, CH; Ma, J; Ridker, PM; Stampfer, MJ, 1999) |
| "Aspirin therapy confers conclusive net benefits in the acute phase of evolving myocardial infarction, but no clear evidence of benefit from the long-term use of aspirin after acute myocardial infarction (AMI) has been shown in any single study." | 5.09 | Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. ( Hattori, R; Ishikawa, K; Masuda, Y; Miyazaki, S; Motomiya, T; Ogawa, H; Saito, M; Tamura, Y; Tanaka, H; Yamaguchi, T; Yasue, H, 1999) |
| " the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events." | 5.09 | The Hypertension Optimal Treatment study and the importance of lowering blood pressure. ( Hansson, L, 1999) |
| "Forty-three patients presenting with unstable angina or myocardial infarction were randomised double blind to warfarin [target international normalised ratio (INR), 2." | 5.09 | Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. ( Stewart, RA; Williams, MJ, 1999) |
| " We compared the safety and efficacy of two different antiplatelet drugs, aspirin (asa) and picotamide (pico)--a dual antithromboxane agent--in combination with low-intensity oral anticoagulation with warfarin or acenocoumarol in acute myocardial infarction (AMI)." | 5.09 | Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial. ( Corsini, G; Milani, M; Vetrano, A, 1999) |
| "In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation." | 5.09 | Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999) |
| "In an observational study we wanted to investigate whether ongoing use of aspirin in a cohort of 753 patients with acute myocardial infarction was able to (1) reduce infarct size as assessed by peak creatine kinase and lactate dehydrogenase, (2) increase the number of non-Q-wave myocardial infarctions, and (3) to what extent thrombolytic treatment at admission could modify these outcomes." | 5.09 | Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms. ( Abdelnoor, M; Landmark, K, 1999) |
| "Large clinical trials such as the second International Study of Infarct Survival routinely gave patients with myocardial infarction a chewed aspirin, yet there are no data to show whether chewing of aspirin is better, or worse, than swallowing a whole tablet." | 5.09 | Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. ( Cryer, B; Feldman, M, 1999) |
| "Despite use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction (MI) or refractory angina in the hospital." | 5.09 | Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. ( Yusuf, S, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction." | 5.09 | Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. ( Eto, K; Isshiki, T; Kondo, K; Ochiai, M; Oshima, A; Sato, T; Takeshita, S; Yokoyama, N, 1999) |
| " In the Physicians Health Study, the magnitude of reduction in the risk of myocardial infarction with aspirin therapy was related to baseline CRP levels, raising the possibility that the protective effect of aspirin may be due to antiinflammatory properties in addition to its antiplatelet effect." | 5.09 | Effect of short-term aspirin use on C-reactive protein. ( Feng, D; Lipinska, I; McKenna, C; Murillo, J; Tofler, GH; Tracy, RP, 2000) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 5.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "Although antiplatelet therapy with a specific inhibitor of phosphodiesterase-3 cilostazol improves stent patency compared with use of aspirin (ASA) alone, the specific role of cilostazol on platelet aggregation in patients with acute myocardial infarction (AMI) is less well understood." | 5.09 | Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. ( Ikeda, Y; Isaka, N; Ito, M; Kitai, T; Makino, K; Nakano, T; Nishikawa, M; Okinaka, T; Shiku, H; Tanigawa, T; Ueda, Y, 2000) |
| "We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA)." | 5.09 | Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting ( Baigent, C; Braunwald, E; Chen, ZM; Collins, R; Flather, M; Franzosi, MG; Kjekshus, J; Køber, L; Latini, R; Liu, LS; Maggioni, AP; Peto, R; Pfeffer, M; Pizzetti, F; Santoro, E; Sleight, P; Swedberg, K; Tavazzi, L; Tognoni, G; Wang, W; Yusuf, S, 2000) |
| "The efficacy and safety of warfarin, aspirin, and the two combined are compared in a long-term, randomized, open, multicentre study involving 3606 patients after acute myocardial infarction (1202 in each treatment group)." | 5.09 | Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. ( Arnesen, H; Hurlen, M; Smith, P, 2000) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "The effects of clopidogrel 75 mg or aspirin 100 (300) mg on platelet aggregation and activation by flow cytometry after stimulation with various agonists were determined in 30 patients with a past history of myocardial infarction." | 5.09 | Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. ( Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA, 2000) |
| "Assessing combined anti-platelet therapy in suspected acute myocardial infarction Aspirin has been shown to be effective in the emergency treatment of acute myocardial infarction." | 5.09 | Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ ( , 2000) |
| "The long-term risk of myocardial infarction (MI) or death remains high in patients with unstable angina, despite the use of aspirin." | 5.09 | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. ( , 2001) |
| "The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)." | 5.09 | Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 5.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 5.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| " At 5 hospitals, 39 patients with unstable angina or non-Q wave myocardial infarction, who were receiving aspirin and heparin, were administered intravenous AR-C69931MX with stepped dose increments over 3 h to a plateau of either 2 microg/kg/min for 21 h (Part 1; n = 12) or up to 69 h (Part 2; n = 13) or 4 microg/kg/min for up to 69 h (Part 3: n = 14)." | 5.09 | Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ( Oldroyd, KG; Storey, RF; Wilcox, RG, 2001) |
| "Patients with acute myocardial infarction aged < 80 years who were admitted to our institution within 3 hr of onset of symptoms were immediately treated with oral aspirin 330 mg and intravenous heparin 5,000 IU and were randomized to receive an intravenous bolus of mt-PA (monteplase) 15,000 IU/kg (thrombolytic group, n = 25) or no mt-PA (control group, n = 21), followed by angiography with PTCA if indicated." | 5.09 | [Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction]. ( Imai, H; Kondo, J; Kosokabe, T; Mukawa, H; Sone, T; Tsuboi, H; Uesugi, M, 2001) |
| "The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b." | 5.09 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). ( Bertrand-Hardy, JM; Darius, H; Diener, HC; Humphreys, M, 2001) |
| "In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events." | 5.09 | Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. ( Braunwald, E; Cannon, CP; DeLucca, PT; Demopoulos, LA; DiBattiste, PM; Frey, MJ; Gibson, CM; Lakkis, N; Neumann, FJ; Robertson, DH; Vicari, R; Weintraub, WS, 2001) |
| "In a double-blind randomized trial, 135 patients with unstable angina or non-ST-segment elevation myocardial infarction, with prior CABG, and who were poor candidates for a revascularization procedure received therapy with aspirin and placebo+warfarin, warfarin and placebo+aspirin, or aspirin and warfarin for 12 months." | 5.09 | Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. ( Bogaty, P; Huynh, T; Nasmith, J; Solymoss, S; Théroux, P, 2001) |
| "We randomized 277 patients with acute myocardial infarction to standard intravenous unfractionated heparin (UFH) or intravenous vasoflux 1, 4, 8, or 16 mg/kg as a bolus followed by 1, 4, 8, or 16 mg/kg per hour infusion, on top of streptokinase and aspirin, until angiography at 90 minutes." | 5.09 | Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). ( Anderson, HV; Gibson, M; Hirsh, J; Molhoek, PG; Peters, RJ; Spickler, W; Théroux, P; Weaver, WD; Weitz, JI; White, H, 2001) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 5.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "Angiographic patency of the culprit coronary artery lesion was assessed 90 and 120 minutes after the initiation of streptokinase and aspirin and again after 4 +/- 2 days in 68 patients with acute myocardial infarction." | 5.08 | Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. ( Bonan, R; Lespérance, J; Pérez-Villa, F; Shabani, F; Théroux, P; Waters, D, 1995) |
| "This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction." | 5.08 | Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. ( Brown, MA; Cross, DB; French, JK; Hamer, AW; Ormiston, JA; White, HD; Williams, BF, 1995) |
| "The authors examined the bleeding complications in 75 patients who received acenocoumarol and acetylsalicylic acid combined therapy." | 5.08 | [Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina]. ( Farkas, A; Sámóczi, M; Sipos, E; Tarján, J, 1995) |
| "To evaluate the efficacy and safety of hirudin, a direct thrombin inhibitor, in patients with acute myocardial infarction, a dose-finding, angiography study was carried out." | 5.08 | Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results. ( Bosma, AH; Hertzberger, DP; Kingma, JH; Laarman, GJ; Lok, DJ; Luz, CM; Molhoek, GP; Takens, LH; Van den Bos, AA; Zijnen, P, 1995) |
| "1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 5.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)." | 5.08 | Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 5.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non-Q-wave myocardial infarction." | 5.08 | Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) ( Buchwald, A; Hillis, SE; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 5.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To assess effects of intravenous streptokinase, one month of oral aspirin, or both, on long term survival after suspected acute myocardial infarction." | 5.08 | ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ( Appleby, P; Baigent, C; Collins, R; Parish, S; Peto, R; Sleight, P, 1998) |
| "During 1 year of follow-up, we compared the mortality after acute myocardial infarction (AMI) prior to and after the introduction of a more widespread use of thrombolytic agents and aspirin." | 5.08 | One-year mortality after acute myocardial infarction prior to and after the implementation of a widespread use of thrombolysis and aspirin. Experiences from the community of Göteborg, Sweden. ( Dellborg, M; Hartford, M; Herlitz, J; Källström, G; Karlson, BW; Karlsson, T, 1998) |
| "To evaluate a guideline-implementation intervention of clinician education by local opinion leaders and performance feedback to (1) increase use of lifesaving drugs (aspirin and thrombolytics in eligible elderly patients, beta-blockers in all eligible patients) for acute myocardial infarction (AMI), and (2) decrease use of a potentially harmful therapy (prophylactic lidocaine)." | 5.08 | Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. ( Asinger, R; Borbas, C; Gao, X; Gobel, F; Guadagnoli, E; Gurwitz, JH; Hauptman, PJ; McLaughlin, B; McLaughlin, TJ; Morris, N; Soumerai, SB; Willison, DJ, 1998) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 5.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "There are conflicting reports on the interaction of aspirin with angiotensin-converting enzyme inhibitors in heart failure and systemic hypertension." | 5.08 | Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. ( Anthonio, RL; Crijns, HJ; de Kam, PJ; Kingma, JH; Oosterga, M; van Gilst, WH, 1998) |
| "Forty-eight patients who presented within 12 h of acute myocardial infarction with ST segment elevation were assigned randomly to groups to receive aspirin (200 mg orally) and high-dose standard heparin 300 U/kg as an intravenous bolus (n = 25), or aspirin and placebo bolus (n = 23)." | 5.08 | Confirmation that heparin is an alternative means of promoting early reperfusion. ( Azevedo Júnior, A; Braga, JC; Brito, JC; Esteves, FP; Esteves, JP; Godinho, AG; Latado, AL; Rabelo Júnior, A; Rocha, MS; Silva, PR; Souza, VP; Teixeira, MS, 1998) |
| "In a follow-up analysis of 296 confirmed cases of myocardial infarction and 296 controls, we evaluated the association between lipoprotein (a) level and cardiovascular risk for those with and without hyperlipidemia as well as for those randomly allocated aspirin treatment and placebo." | 5.08 | Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. ( Ariyo, A; Hennekens, CH; Ridker, PM; Stampfer, MJ, 1998) |
| "Patients with heart disease are frequently maintained on a regimen of aspirin because of its ability to decrease thrombotic complications and reduce the prevalence of unstable angina and myocardial infarction." | 5.07 | Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. ( Guiraudon, GM; Lux, J; McKenzie, FN; Menkis, AH; Murkin, JM; Novick, RJ; Shannon, NA, 1994) |
| "In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks." | 5.07 | Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Fuster, V; McBride, R; Parry, G; Wieczorek, I; Xiong, J, 1993) |
| "The Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial compared the efficacy and safety of intravenous hirudin with heparin as adjunctive therapy to thrombolysis and aspirin in patients with acute myocardial infarction." | 5.07 | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. ( Antman, EM, 1994) |
| "To address this issue, 382 patients with acute myocardial infarction were randomized to receive in a double-blind fashion (along with intravenous heparin and aspirin) APSAC, front-loaded rt-PA or a combination of both agents." | 5.07 | Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. ( Cannon, CP; Diver, DJ; Greene, RM; Herson, S; Kirshenbaum, JM; Leya, F; Magorien, RD; McCabe, CH; Sequeira, RF; Shah, PK, 1994) |
| "The aim of this trial was to compare the efficacy of combination antithrombotic therapy with a prostacyclin-sparing aspirin plus anticoagulation versus conventional aspirin plus anticoagulation, when added to antianginal therapy, in patients with unstable angina or non-Q wave myocardial infarction already being treated with aspirin." | 5.07 | Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Cohen, M; Fox, KA; Fuster, V; Kronmal, R; Parry, G; Wieczorek, I; Xiong, J, 1994) |
| "This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 5.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
| "The Thrombolysis in Myocardial Infarction (TIMI) 5 trial was a randomized, dose-ranging, pilot trial of hirudin versus heparin, given with front-loaded tissue-type plasminogen activator and aspirin to 246 patients with acute myocardial infarction." | 5.07 | A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. ( Anderson, JL; Becker, RC; Cannon, CP; Gibson, RS; Haugland, JM; Henry, TD; Kleiman, NS; McCabe, CH; Mueller, HS; Schweiger, MJ, 1994) |
| "Forty two patients with acute myocardial infarction (AMI) were randomly distributed to the following groups: (1) the non-aspirin-treated group; (2) the daily-aspirin-treated group (aspirin, 300mg, once everyday); (3) the intermittent-aspirin-treated group (aspirin, 300mg, once every three days)." | 5.07 | [Improvement of prostacyclin-thromboxane A2 balance in patients with acute myocardial infarction by intermittent aspirin]. ( Luo, Y, 1993) |
| "In the present study, the authors evaluate the haemodynamic effects of continuous captopril therapy during one-year after a first anterior myocardial infarction (MI)." | 5.07 | [The evaluation of the hemodynamic effects of captopril one year after a myocardial infarct]. ( Luís, AS; Mourão, L; Neves, JL; Santos, AL; Santos, JM, 1994) |
| "This study documents that heparin prevents myocardial infarction better than aspirin during the acute phase of unstable angina." | 5.07 | Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. ( de Guise, P; Juneau, M; McCans, J; Qiu, S; Théroux, P; Waters, D, 1993) |
| "To assess the appropriate dose of aspirin in the treatment of patients with acute myocardial infarction (AMI), 60 cases of AMI were randomized into 2 groups, 30 cases each; one with conventional therapy, another with conventional therapy combined with daily oral aspirin 100mg." | 5.07 | [The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction]. ( Jin, L; Xu, SH; Yan, XW, 1993) |
| "The purpose of this study was to compare combination antithrombotic therapy with aspirin plus anticoagulation versus aspirin alone, when added to conventional antianginal therapy in patients with unstable rest angina or non-Q-wave myocardial infarction who were nonprior aspirin users." | 5.07 | Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Keller, C; Parry, G; Strain, J; Wieczorek, I; Xiong, J, 1994) |
| "A total of 907 patients with acute myocardial infarction were randomized between aspirin and ridogrel given in addition to streptokinase (1." | 5.07 | Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspir ( , 1994) |
| "Combination therapy with dipyridamole and aspirin reduces not only the risk of cerebrovascular ischemic events but also the risk of myocardial infarction." | 5.07 | Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. ( Laakso, M; Lowenthal, A; Riekkinen, PJ; Sivenius, J; Smets, P, 1993) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 5.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 5.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| "We analyzed the use of aspirin before and after myocardial infarction and that of calcium antagonists after myocardial infarction in 2231 survivors of myocardial infarction enrolled in the Survival and Ventricular Enlargement (SAVE) study over a three-year period (from January 1987 through January 1990)." | 5.07 | Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. ( Braunwald, E; Hamm, P; Lamas, GA; Pfeffer, MA; Rouleau, JL; Wertheimer, J, 1992) |
| " To test this hypothesis we evaluated the 11-dehydro-thromboxane B2 (11-d-TXB2) level, as an index of platelet activation, in 20 healthy subjects and in 30 patients with acute myocardial infarction (AMI)." | 5.07 | Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. ( Albanese, S; Bianchi, C; Ciabattoni, G; Coppola, E; Lanza, GA; Natale, A; Rebuzzi, AG, 1992) |
| "We report the management of the 831 patients from 18 hospitals which constituted the Irish component of the 17,183 subjects enrolled in the ISIS-2 trial which studied the effects of streptokinase infusion and aspirin therapy given to patients presenting within 24 hours of the onset of suspected acute myocardial infarction." | 5.07 | Medical management of acute myocardial infarction in Ireland: information from the Second International Study of Infarct Survival (ISIS-2). ( Horgan, JH; MacGowan, GA; O'Callaghan, D, 1991) |
| "Patients admitted for suspected acute myocardial infarction within 6 hours (mean 3 hours 42 minutes) after onset of symptoms were randomised to double-blind treatment with low-dose oral aspirin or placebo." | 5.07 | Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction. ( Følling, M; Pedersen, D; Rodt, SA; Rønnevik, PK; von der Lippe, G, 1991) |
| "The prostaglandin-thromboxane system, platelet hemostasis and central hemodynamics were evaluated in 51 patients with heart failure-complicated acute myocardial infarction during aspirin, roxicam and basic (nitrates + cardiac glycosides + diuretics) therapies." | 5.07 | [Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure]. ( Khosseĭn Shakhavat, AF; Shelest, AN; Shushliapin, OI, 1991) |
| "The influence of prophylactic low-dose aspirin on the clinical characteristics of subsequent nonfatal myocardial infarction was examined in the Physicians' Health Study, a randomized, double-blind placebo-controlled trial of alternate-day aspirin (325 mg) among 22,071 US male physicians." | 5.07 | Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. ( Buring, JE; Goldhaber, SZ; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "Data from 4524 patients in a randomized, controlled trial of aspirin were analyzed to determine if aspirin reduced the risk for hospitalization for gallstone disease." | 5.07 | One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease. ( Abbey, D; Kurata, JH; Marks, J, 1991) |
| "Regional ventricular wall motion analysis utilizing three different methods was performed on predischarge left ventriculograms from 291 of 367 patients enrolled in a randomized trial of single chain recombinant tissue-type plasminogen activator (rt-PA), aspirin and heparin with and without immediate angioplasty in patients with acute myocardial infarction." | 5.07 | Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group. ( Arnold, AE; de Bono, DP; Lubsen, J; Rutsch, W; Serruys, PW; Simoons, ML; Tijssen, JG; Verstraete, M, 1991) |
| "To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)." | 5.07 | Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991) |
| "In this study, 796 men with unstable coronary artery disease (that is, unstable angina or non-Q wave myocardial infarction) were randomized to double-blind placebo-controlled treatment with aspirin (75 mg/day)." | 5.07 | Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in ( Wallentin, LC, 1991) |
| "To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina." | 5.07 | Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. ( Buring, JE; Gaziano, JM; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "796 men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction [MI] ), were randomised to double-blind placebo-controlled treatment with oral aspirin 75 mg/day and/or 5 days of intermittent intravenous heparin." | 5.06 | Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. ( , 1990) |
| "We report the results of the Heparin-Aspirin Reperfusion Trial, a collaborative study comparing early intravenous heparin with oral aspirin as adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is used for coronary thrombolysis during acute myocardial infarction." | 5.06 | A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. ( Chaitman, BR; Hamilton, WP; Hsia, J; Kleiman, N; Roberts, R; Ross, AM, 1990) |
| "Aspirin is commonly accepted as a risk factor for gastric ulcer; however, there is little published evidence linking aspirin consumption to duodenal ulcer." | 5.06 | The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. ( Abbey, DE; Kurata, JH, 1990) |
| "Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear." | 5.06 | Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990) |
| "The aim of this study was to determine whether intravenous streptokinase administered with or without oral aspirin to patients with evolving myocardial infarction reduces the inducibility of ventricular tachycardia at electrophysiologic study and thus the risk of sudden death in infarct survivors." | 5.06 | Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. ( Bourke, JP; Richards, DA; Uther, JB; Young, AA, 1990) |
| "In the Persantine-Aspirin Reinfarction Study, Part II (PARIS II), 3,128 persons who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously, were randomized into two groups: dipyridamole (Persantine) plus aspirin (n = 1,563) and placebo (n = 1,565)." | 5.06 | Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. ( Klimt, CR; Knatterud, GL; Meier, P; Stamler, J, 1986) |
| "We tested the usefulness of aspirin (325 mg twice daily), heparin (1000 units per hour by intravenous infusion), and a combination of the two in the early management of acute unstable angina pectoris in a double-blind, randomized, placebo-controlled trial involving 479 patients." | 5.06 | Aspirin, heparin, or both to treat acute unstable angina. ( deGuise, P; Joly, P; Juneau, M; Latour, JG; Lévy, G; McCans, J; Ouimet, H; Pelletier, E; Stasiak, J; Théroux, P, 1988) |
| "A six year randomised trial was conducted among 5139 apparently healthy male doctors to see whether 500 mg aspirin daily would reduce the incidence of and mortality from stroke, myocardial infarction, or other vascular conditions." | 5.06 | Randomised trial of prophylactic daily aspirin in British male doctors. ( Collins, R; Gray, R; Hafner, B; Hennekens, C; Jamrozik, K; Norton, S; Peto, R; Thompson, E; Warlow, C; Wheatley, K, 1988) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a randomized double-masked trial of the efficacy of aspirin in the secondary prevention of coronary heart disease." | 5.06 | Recruitment experience in the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1987) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| " Although the disease technically is self-limiting, treatment with IV immunoglobulin (IVIG) and high-dose aspirin is necessary to prevent cardiac complications, such as coronary artery aneurysm, pericarditis, or myocarditis." | 5.05 | Kawasaki disease: Shedding light on a mysterious diagnosis. ( Galuppo, J; Kowker, A; Nicholas, J; Rolfs, J; Schmidt, E, 2020) |
| " In patients with previous myocardial infarction completing at least 1 year of DAPT, continuing DAPT with a reduced dose of ticagrelor 60 mg BID is a regimen to be considered for these patients; in general ACS patients, a reduced dose of 60 mg BID of ticagrelor after the first year of DAPT should be considered; and in the post-percutaneous coronary intervention patients, DAPT beyond 1 year should be considered after careful evaluation of the patient's thrombotic and bleeding risks." | 5.05 | Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. ( Dobesh, PP; Finks, SW; Trujillo, TC, 2020) |
| "Aspirin was associated with a slight decrease in AMI and ischemic stroke in absolute terms, with no differences in cardiovascular mortality." | 5.05 | Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. ( Lobo, M; Masson, G; Masson, W; Molinero, G, 2020) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 5.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 postmyocardial infarction (MI) patients, are compared and combined." | 5.05 | Aspirin in coronary heart disease. Comparison of six clinical trials. ( Canner, PL, 1983) |
| " Critical study of trials of long-term secondary prevention of myocardial infarction carried out between 1967 and 1982 have failed to yield any definitive conclusion as to the value of oral anticoagulants, aspirin, sulfinpyrazone or dipyridamole." | 5.05 | [Long-term antithrombotic treatment in coronary disease]. ( Hodara, M; Samama, M, 1983) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period." | 5.05 | A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980) |
| "The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously." | 5.05 | The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group. ( , 1980) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| "The long-term prognostic implications of the electrocardiographic location of a myocardial infarction and the subsequent retention or disappearance of diagnostic Q waves were examined in patients enrolled in the Aspirin Myocardial Infarction Study (AMIS)." | 5.05 | Prognostic implications of diagnostic Q waves after myocardial infarction. ( Bren, GB; Hutchinson, RG; Richardson, DW; Rios, JC; Ross, AM; Wasserman, AG, 1982) |
| "Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose." | 5.05 | A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982) |
| "In postmyocardial infarction patients longterm aspirin treatment with 1." | 5.05 | Does chronic aspirin treatment increase blood pressure in man? ( Kaufmann, W; Oster, P; Walter, E, 1981) |
| "We studied the efficacy of aspirin and indomethacin therapy in relieving the discomfort of postmyocardial infarction pericarditis (PMIP) in two studies: (1) a retrospective evaluation of patients with symptomatic PMIP during a 5-year period and (2) a prospective, randomized, single-blind comparison of aspirin and indomethacin in similar patients." | 5.05 | Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. ( Alpert, JS; Berman, J; Haffajee, CI, 1981) |
| "The Persantine-Aspirin Reinfarction Study (PARIS) was a randomized, controlled, double-blind study of dipyridamole (Persantine) and aspirin in secondary prevention of coronary heart disease." | 5.05 | Persantine-aspirin reinfarction study. Design, methods and baseline results. By the persantine-aspirin reinfarction study research group. ( , 1980) |
| "The Anturane Reinfarction Trial evaluated the effect of sulfinpyrazone (Anturane) (200 mg four times a day) vs placebo on cardiac mortality rates among patients recently recovered from an acute myocardial infarction." | 5.05 | The anturane reinfarction trial. ( Sherry, S, 1980) |
| "Three randomized controlled trials of aspirin and secondary mortality have been conducted in patients who had had a myocardial infarction." | 5.05 | Aspirin and secondary mortality after myocardial infarction. ( Elwood, PC; Sweetnam, PM, 1980) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 5.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 5.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "A randomized, double-blind clinical trial in 1266 men with unstable angina showed that 324 mg of aspirin daily for 12 weeks reduced the incidence of myocardial infarction by 51% (p = ." | 5.05 | Unstable angina: status of aspirin and other forms of therapy. ( Lewis, HD, 1985) |
| "Aspirin, sulfinpyrazone and the combination of aspirin/dipyridamole, which inhibit some aspects of platelet function, have been evaluated in large-scale clinical trials in secondary prevention of myocardial infarction." | 5.05 | Secondary prevention of myocardial infarction. ( Davies, JA, 1985) |
| " centers, 231 male diabetic patients who had either a recent amputation for gangrene (N = 207) or active gangrene (N = 24) were randomly assigned to a group which received aspirin (325 mg t." | 5.05 | V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. ( Abraira, C; Anderson, JW; Bingham, SF; Colwell, JA; Kwaan, HC, 1985) |
| "45 mg kg-1 day-1) aspirin treatment have been evaluated in 15 patients after a recent (less than 17 days) acute myocardial infarction." | 5.05 | Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. ( Bernini, W; De Caterina, R; Donato, L; Filabozzi, P; Gazzetti, P; Giannessi, D; L'Abbate, A; Michelassi, C; Patrignani, P; Patrono, C, 1985) |
| "This study explores the effects on some hematological parameters of a low-dose aspirin regimen (50 mg/day) versus a conventional aspirin treatment with reported antithrombotic efficacy (324 mg/day), in patients with acute myocardial infarction." | 5.05 | Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. ( Battaglia, D; Bernini, W; Boem, A; De Caterina, R; Dell'Amico, F; Giannessi, D; L'Abbate, A; Michelassi, C; Patrignani, P; Patrono, C, 1985) |
| "The Aspirin Myocaridal Infarction Study is a randomized, double-blind clinical trial designed to study the potential value of aspirin in the reduction of mortality in patients who have had a prior myocardial infarction." | 5.04 | An intervention study-the aspirin myocardial infarction study. ( , 1977) |
| "Both the Coronary Drug Project (CDP) and the Aspirin Myocardial Infarction Study (AMIS) were successfully able to recruit adequate members of postmyocardial infarction patients to long-term multicenter clinical trials in the secondary prevention of coronary heart disease." | 5.04 | Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1979) |
| "A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner." | 5.04 | A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979) |
| "1529 men with a history of myocardial infarction (MI) and previously treated with either dextrothyroxine or estrogen therapy in the Coronary Drug Project were selected for a study on the administration of aspirin on a daily basis." | 5.04 | Aspirin in coronary heart disease. The Coronary Drug Project Research Group. ( , 1976) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 5.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| "Across trials of cardiovascular and cerebrovascular disease, extended-duration clopidogrel on a background of aspirin has no overall effect on mortality or cancer but does reduce rates of myocardial infarction and stroke and increase rates of bleeding." | 4.98 | Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( Benavente, OR; Bhatt, DL; Connolly, SJ; Doros, G; Elmariah, S; Hsieh, WH; Liu, Y; Mauri, L; Steinhubl, SR; Yeh, RW; Yusuf, S, 2018) |
| " This report describes a case of Kounis-Zavras syndrome in the setting of aspirin-induced asthma also known as Samter-Beer triad combining nasal polyps, asthma, and aspirin allergy leading to vasospasm and myocardial infarction." | 4.98 | Kounis syndrome induced by oral intake of aspirin: case report and literature review. ( Cherti, M; Dakka, T; Doghmi, N; Hangouche, AJE; Lamliki, O; Oukerraj, L; Zarzur, J, 2018) |
| "Aspirin use in PVD might not be associated with improved cardiovascular outcomes or worse bleeding outcomes." | 4.95 | Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017) |
| "Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer." | 4.95 | Aspirin for Primary Prevention. ( Owens, DK; Richman, IB, 2017) |
| "The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI)." | 4.95 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. ( Kimura, T; Morimoto, T; Natsuaki, M; Shiomi, H; Toyota, T, 2017) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 4.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| " The question addressed was whether continuation of administration of preoperative aspirin until the day of coronary artery bypass grafting (CABG) could minimize postoperative mortality, prevalence of postoperative myocardial infarction (MI) with or without influence on postoperative bleeding, packed red blood cell (PRBC) transfusion and reoperation for bleeding." | 4.95 | What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting? ( Aboul-Hassan, SS; Cichon, R; Marczak, J; Stankowski, T, 2017) |
| "The net clinical benefit of aspirin in primary prevention is uncertain as the reduction in occlusive events needs to be balanced against the increase in gastro-intestinal and cerebral bleedings." | 4.93 | Aspirin use for primary prevention in elderly patients. ( Terrosu, P, 2016) |
| " We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction." | 4.91 | Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. ( Bainey, KR; Ferguson, C; Sharma, A, 2015) |
| "DAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)." | 4.91 | Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. ( Abo-Salem, E; Alsidawi, S; Effat, M; Helmy, T; Jamali, H, 2015) |
| "Among adults undergoing non-cardiac surgery who are at risk of a myocardial infarction, a long-standing question has been whether these patients should receive aspirin throughout the perioperative period." | 4.91 | Role of aspirin for prevention and treatment of perioperative cardiovascular events. ( Devereaux, PJ; Duceppe, E; Mrkobrada, M; Thomas, S, 2015) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 4.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| " We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patients after myocardial infarction." | 4.91 | Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. ( Julian, DG; Pocock, SJ; Rossello, X, 2015) |
| "A short cut review was carried out to establish whether, in patients with suspected acute coronary syndromes presenting to the emergency department, what form of aspirin has the most rapid onset of action." | 4.91 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction? ( Hogg, K; Morris, N; Rigg, K, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| "Current guidelines for the management of patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) recommend the administration of dual antiplatelet therapy with aspirin and an ADP receptor blocker "as early as possible" before angiography (upstream), though this suggestion is not based on the results of randomized clinical trials designed to investigate pre-hospital rather than in-hospital drug administration." | 4.90 | [Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention]. ( Bramucci, E; Ferlini, M; Mafrici, A; Marzegalli, M; Piccaluga, E; Sponzilli, C; Visconti, LO, 2014) |
| "PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors." | 4.90 | Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| " Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1." | 4.88 | Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. ( Benavente, OR; Hart, RG; Palacio, S; Pearce, LA, 2012) |
| "The meta-analysis results consistently indicate that, in individuals at low risk for cardiovascular disease, aspirin reduces the risk of MI at the cost of an increase in major bleeding and produces a modest nominally significant reduction in total mortality." | 4.88 | The aspirin controversy in primary prevention. ( Eikelboom, JW; Raju, NC, 2012) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 4.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| " Zofenopril proved to be very effective in patients with coronary artery disease and myocardial infarction, thanks to its unique effective mechanism of action for improving blood pressure control, left ventricular function and myocardial ischemia burden, as well as angiotensin-converting enzyme inhibition." | 4.88 | Long-term clinical experience with zofenopril. ( Bacchelli, S; Borghi, C; Degli Esposti, D, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 4.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " For the composite of non-fatal stroke, non-fatal myocardial infarction and vascular death, aspirin was associated with a 13% reduction in risk (risk ratio, RR: 0." | 4.87 | Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. ( Dinneen, SF; Eikelboom, JW; McGrath, E; O'Conghaile, A; O'Donnell, MJ; Oczkowski, C, 2011) |
| "Aspirin prevents deaths, myocardial infarction, and ischemic stroke, and increases hemorrhagic stroke and major bleeding when used in the primary prevention of cardiovascular disease." | 4.87 | Effect of aspirin on mortality in the primary prevention of cardiovascular disease. ( Eikelboom, J; Hirsh, J; O'Donnell, M; Raju, N; Sobieraj-Teague, M, 2011) |
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 4.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "Patients should be placed on the following medications: antiplatelet agents, (meta-analysis for aspirin, multiple randomized controlled trials [RCTs] for aspirin plus clopidogrel); a statin; atorvastatin has the best evidence (a single RCT); a beta-blocker (meta-analysis); renin-angiotensin-aldosterone system blockers, whether or not the ejection fraction is diminished after myocardial infarction (MI) (SOR: A, meta-analysis for angiotensin-converting enzyme [ACE] inhibitor; B, single RCT for ACE inhibitor plus aldosterone blocker)." | 4.86 | Clinical Inquiries: Which drugs should post-MI patients routinely receive? ( Holman, JR; Jamieson, B; Lin, V, 2010) |
| "In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
| "Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality." | 4.86 | Aspirin for the prevention of cardiovascular morbidity. ( Haider, B; Kaluski, E; Klapholz, M; Maher, J; Sanchez-Ross, M; Waller, AH, 2010) |
| "In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
| "Dual antiplatelet therapy with a thienopyridine (ticlopidine or clopidogrel) and aspirin is used to reduce the risk of late stent thrombosis and complications (myocardial infarction [MI] and death) after placement of a drug-eluting stent (DES)." | 4.86 | Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. ( Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| "Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management." | 4.85 | A new generation of antiplatelet agents. ( Harrington, RA; Sellers, MB; Tricoci, P, 2009) |
| "Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions." | 4.85 | Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009) |
| " The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1." | 4.85 | Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. ( Aggarwal, NR; Albuquerque, FN; Calvin, AD; Elamin, MB; Erwin, PJ; Fernandez-Balsells, MM; Geske, JB; Lampropulos, JF; Montori, VM; Murad, MH; Shi, Q; Smith, SA, 2009) |
| " Based on this concept, we have performed several large-scale clinical trials to provide EBM, including the Japanese Antiplatelets Myocardial Infarction Study [JAMIS; clinical improvement in acute myocardial infarction (AMI) patients with antiplatelet therapy], the Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI; comparison of the effects of beta-blockers and calcium antagonists on cardiovascular events in post-AMI patients), a multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors in patients with AMI (MUSASHI; effects of statin therapy on cardiovascular events in patients with AMI), and the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD trial; efficacy of low-dose aspirin therapy for primary prevention of atherosclerotic events in type 2 diabetic patients)." | 4.85 | Clinical evidence for Japanese population based on prospective studies--linking clinical trials and clinical practice. ( Kojima, S; Ogawa, H, 2009) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 4.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention." | 4.85 | Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009) |
| " I have selected 4 translations in the field of vascular neurology in which I have been involved in different respects: (1) the translation of results from men to women, taking the example of aspirin which, in primary prevention, decreases the risk of myocardial infarction in men and the risk of cerebral infarction in women, the reason for this sex difference being so far unknown; (2) the 'inverse translational research', from bedside to bench, taking the example of the disease we have identified--CADASIL--and showing how the study of one patient and his family led to the identification of a gene, Notch3, so far unknown in humans and to the discovery of its key role in the physiology of vascular smooth muscle cells; (3) the translation from individual case reports to multidisciplinary trials taking the example of hemicraniectomy in malignant cerebral infarction and emphasizing the interest in such rare and severe conditions of pooling and reporting the results of randomized clinical trials before the results of individual trials, and (4) the translation from research to practice, emphasizing not the well-known 'evidence to practice gap' but the slippery slope of 'lack of evidence to overpractice', taking the example of patent foramen ovale closure in migraine." | 4.84 | Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008. ( Bousser, MG, 2008) |
| " The clinical benefits of combined pravastatin-acetylsalicylic acid in the management of coronary patients have been demonstrated by a meta-analysis of five randomized clinical trials for secondary prevention; compared with pravastatin alone, the pravastatin-acetylsalicylic acid combination reduced the risk of fatal or non fatal myocardial infarction by 26%, the risk of ischemic stroke by 31%, and the risk of cardiovascular events at 5 years by 13%." | 4.84 | [Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. ( Hennekens, C, 2007) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "There is considerable variation in the effect of aspirin therapy reducing the risk of myocardial infarction (MI)." | 4.84 | The influence of gender on the effects of aspirin in preventing myocardial infarction. ( Gan, WQ; Sin, DD; Yerman, T, 2007) |
| "In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death." | 4.84 | Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. ( Hennekens, CH, 2007) |
| " Irrespective of International normalized ratio (INR), A+W did not significantly affect the risk of major adverse events (MAE: all cause death, non-fatal myocardial infarction, and non-fatal thrombo-embolic stroke) when compared with aspirin alone [OR 0." | 4.83 | Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. ( Andreotti, F; Biondi-Zoccai, GG; Crea, F; Testa, L, 2006) |
| " Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality." | 4.83 | Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. ( Avanzini, F; Berger, JS; Brown, DL; Pangrazzi, I; Roncaglioni, MC; Tognoni, G, 2006) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 4.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved for the reduction of atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI)." | 4.83 | Clopidogrel bisulfate: in ST-segment elevation myocardial infarction. ( Dickie, JS; Scott, LJ, 2006) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 4.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| "Among the 55 580 randomized participants (11 466 women), aspirin was associated with a statistically significant 32% reduction in the risk of a first MI and a significant 15% reduction in the risk of all important vascular events, but had no significant effects on nonfatal stroke or vascular death." | 4.82 | An update on aspirin in the primary prevention of cardiovascular disease. ( Eidelman, RS; Hebert, PR; Hennekens, CH; Weisman, SM, 2003) |
| "To review data concerning combined aspirin/warfarin versus aspirin alone for secondary prevention after myocardial infarction (MI)." | 4.82 | Aspirin and warfarin versus aspirin monotherapy after myocardial infarction. ( Gleason, BL; Jeddy, AS, 2003) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 4.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| " The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)." | 4.82 | Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004) |
| "The results of the VIGOR study that demonstrated an increase in risk of myocardial infarction with rofecoxib, can probably be explained by an anti-thrombotic effect of naproxene, the high dose of rofecoxib used, the type of patients included or the fact that aspirin had been contraindicated." | 4.82 | [Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors]. ( Deray, G, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Aspirin is the standard treatment for secondary prevention of stroke and other vascular events." | 4.82 | Triflusal for preventing serious vascular events in people at high risk. ( Alvarez-Sabin, J; Costa, J; Ferro, JM; Matias-Guiu, J; Torres, F, 2005) |
| " In patients with NSTEMI/UA, beta-blockers, nitrates and calcium antagonists will improve chest pain, and invasive management of ACS is indicated in < 48 h, if risk factors are present." | 4.82 | [Acute chest pain]. ( Perings, C; Trappe, HJ, 2005) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 4.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| "There is uncertainty about the role of intravenous unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with ST-elevation myocardial infarction (STEMI) treated with aspirin and thrombolysis." | 4.82 | Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. ( Eikelboom, JW; Mehta, SR; Menown, IB; Quinlan, DJ; Turpie, AG; Yusuf, S, 2005) |
| "The use of low doses of aspirin on a daily basis has increased greatly in the past 20 years, based on observations that it can significantly reduce the risk of heart attacks and strokes." | 4.81 | Potential cardioprotective actions of no-releasing aspirin. ( Fiorucci, S; Ignarro, LJ; Wallace, JL, 2002) |
| "Results from a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) study suggest that angiotensin-converting-enzyme (ACE) inhibitors may be less effective in patients receiving aspirin." | 4.81 | Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. ( Collins, R; Hall, A; Kober, L; Latini, R; Pfeffer, M; Pogue, J; Teo, KK; Torp-Pedersen, C; Yusuf, S, 2002) |
| "Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial infarction (MI), acute occlusive stroke, as well as in primary prevention." | 4.81 | Update on aspirin in the treatment and prevention of cardiovascular disease. ( Hennekens, CH, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 4.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| " Beta-blockers, nitrates, and calcium-channel blockers are useful for antiischemic therapy in patients with acute coronary syndromes." | 4.81 | [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. ( Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T, 2001) |
| " Patients receiving anti-GP IIb-IIIa therapy have a lower risk of death or myocardial infarction than those receiving the classic anti-agregant, aspirin, alone." | 4.81 | [GPIIb-IIIa inhibitors]. ( Nurden, P, 2001) |
| " coronary angioplasty (PTCA) with or without stent implantation), and in unstable angina/non-ST-segment elevation myocardial infarction, the risk of acute vessel occlusion by thrombosis is high in spite of treatment with aspirin and heparin." | 4.81 | Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. ( Bosch, X; Marrugat, J, 2001) |
| "Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation." | 4.81 | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. ( , 2002) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial." | 4.81 | [Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002) |
| "Data regarding possible mechanisms of aspirin (ASA) resistance in patients with recurrent myocardial infarction (MI) or vascular ischemia are limited." | 4.81 | Possible mechanisms of aspirin resistance. ( Cambria-Kiely, JA; Gandhi, PJ, 2002) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| " Strategies used for plaque stabilisation resulting in a reduction in cardiovascular mortality and morbidity are: smoking cessation; aspirin (acetylsalicylic acid); blood pressure control; lipid lowering agents when low density lipoprotein cholesterol is elevated despite dietary therapy; coronary bypass surgery in patients with left main stem disease or triple vessel coronary disease and diminished left ventricular function; and use of estrogen in postmenopausal women." | 4.80 | Choosing the most appropriate treatment for stable angina. Safety considerations. ( Asirvatham, S; Sebastian, C; Thadani, U, 1998) |
| "The Hypertension Optimal Treatment (HOT) study was designed to answer two questions: whether low-dose aspirin (75 mg/day) is effective in the primary prevention of myocardial infarction, without an increase in cerebral haemorrhage in hypertensive patients whose blood pressure is well controlled, and whether there are additional benefits with a progressive reduction of diastolic blood pressure from 90 mmHg to below 80 mmHg." | 4.80 | Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success. ( Chalmers, J, 1998) |
| "Aspirin and oral anticoagulants are effective treatments in the secondary prevention after myocardial infarction." | 4.80 | [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct]. ( Biancoli, S; Ceré, E; Di Pasquale, G; Lombardi, A; Ottani, F; Sassone, B, 1998) |
| "Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke." | 4.80 | Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. ( He, J; Klag, MJ; Vu, B; Whelton, PK, 1998) |
| "The effects of low-dose aspirin on cardiovascular disease have been tested in randomized trials in 3 types of populations: (1) patients with a history of cardiovascular disease; (2) patients with evolving acute myocardial infarction (MI), and (3) apparently healthy subjects." | 4.80 | Update on aspirin in the treatment and prevention of cardiovascular disease. ( Hennekens, CH, 1999) |
| "Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)." | 4.80 | Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999) |
| "Aspirin, a potent platelet inhibitor, is widely used in patients with cardiovascular diseases." | 4.80 | [Aspirin and prevention of cardiovascular risk]. ( Gabriel Steg, P; Karila-Cohen, D, 2000) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| " For primary prevention, aspirin showed no effect in a British study, but reduced the incidence of myocardial infarction by 44% per year in an American trial concerning men and by 32% concerning women." | 4.79 | [Blood thinning in heart patients]. ( Meier, B, 1995) |
| "Adjunctive therapy for acute myocardial infarction should include aspirin, beta-adrenergic blocking agents, and, in most patients, consideration of the use of angiotensin-converting enzyme inhibitors, especially if left ventricular function is reduced." | 4.79 | Adjunctive therapy in the management of patients with acute myocardial infarction. ( Reeder, GS, 1995) |
| " Smoking cessation, increased physical activity and lipid lowering are key lifestyle objectives, while beta blockade and aspirin should be routinely prescribed for all patients following acute myocardial infarction, unless there are specific contraindications." | 4.79 | What do we really know about secondary prevention after myocardial infarction? ( Wielgosz, AT, 1995) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| "Physicians should consider oxygen, morphine, nitrates, beta blockers, and aspirin as the foundation of early adjunctive treatment of acute myocardial infarction." | 4.79 | Adjunctive medical therapy for acute myocardial infarction. ( Forker, AD; Mancuso, GM; Vacek, JL, 1994) |
| "Aspirin given as a platelet antiaggregant has been shown to be effective for secondary prevention both in cardiology (myocardial infarction, uncontrolled angina pectoris, coronary bypass, etc." | 4.79 | [From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention]. ( Chollet, F, 1994) |
| "In the medical literature reports are accumulating a number of case reports suggesting the potential efficacy and safety of the combination of low-dose aspirin and warfarin to improve the efficacy of antithrombotic therapy in several clinical conditions, ranging from unstable angina to myocardial infarction." | 4.79 | [The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?]. ( Casazza, F; Cimminiello, C; Soncini, M, 1995) |
| " The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction." | 4.79 | Advances in antithrombotic therapy: novel agents. ( Hirsh, J; Turpie, AG; Weitz, JI, 1995) |
| "A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease." | 4.79 | Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? ( Patrono, C; Roth, GJ, 1996) |
| "Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 4.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 4.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| "Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely." | 4.79 | Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. ( Appleby, P; Baigent, C; Collins, R; Flather, M; Godwin, J; MacMahon, S; Mortensen, S; Peto, R; Remvig, L; Yusuf, S, 1996) |
| "Although there is firm consensus that aspirin reduces the incidences (and severity) of reinfarction if given to patients after a myocardial infarction or in patients with unstable angina, there is disagreement about the optimum dose that should be used." | 4.79 | The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? ( Förster, W; Parratt, JR, 1997) |
| "Is there any good reason to give intravenous nitroglycerin during evolving acute myocardial infarction? How about a beta blocker? Should an ACE inhibitor be started routinely within the first 24 hours of infarction? When is aspirin useful for suspected acute myocardial infarction? Is it safe in patients with contraindications to thrombolytic therapy? In this article, Dr Rapaport answers these and many more questions by summarizing findings of important studies and describing conclusions he has come to on the basis of his own clinical experience." | 4.79 | Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long? ( Rapaport, E, 1997) |
| "The clinical benefit of aspirin in coronary insufficiency has been validated in the acute phase of myocardial infarction and in secondary prevention with a reduction of the risk of recurrent infarction of the order of 30%." | 4.79 | [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice]. ( Garnier, LF, 1997) |
| "This article reviews the relevant published literature in order to assess whether aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug-utilisation studies." | 4.79 | Is aspirin underused in myocardial infarction? ( Agustí, A; Arnau, JM, 1997) |
| "Thrombolytic treatment and aspirin will save about 50 in 1000 patients treated for acute myocardial infarction, but with a risk of cerebral or other serious bleeding in two to three in every 1000." | 4.78 | Thrombolysis: state of the art. ( Sleight, P, 1993) |
| "The roles of heparin and warfarin in reducing morbidity and mortality after acute myocardial infarction (AMI) are reviewed." | 4.78 | Heparin and warfarin therapy after acute myocardial infarction. ( Sproat, TT; Yedinak, KC, 1993) |
| " Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery." | 4.78 | [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992) |
| "A wide array of clinical trials over the past two decades has established that aspirin is indicated to prevent myocardial infarction in patients with clinically evident coronary artery disease, and to prevent stroke in patients with a history of stroke or TIAs." | 4.78 | Prophylactic aspirin and the elderly population. ( Dalen, JE; Goldberg, RJ, 1992) |
| " Aspirin in doses of approximately 300 mg/day may be recommended for the primary prevention of myocardial infarction (MI), but only in those patients with a moderate to high risk of cardiovascular disease." | 4.78 | Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. ( Verstraete, M, 1991) |
| "The clinical benefit of aspirin in the acute phase of myocardial infarction is dramatically suggested by the results of the ISIS-2 trial." | 4.78 | Antiaggregating therapy in acute myocardial infarction. ( Cimminiello, C; Fiorista, F; Marzegalli, M; Uberti, T, 1991) |
| "The formation of the proischemic and prothrombotic thromboxane A2 (TXA2) and of its functional antagonist prostacyclin is increased in patients with unstable angina and myocardial infarction." | 4.78 | Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. ( Hornberger, W; Patscheke, H; Zehender, H, 1990) |
| "The use of aspirin and thrombolytic agents in the management of acute myocardial infarction is now accepted as standard clinical practice, but not all patients with heart attack are suitable for such therapy." | 4.78 | Aspirin and thrombolytic therapy in the management of acute myocardial infarction. ( Hockings, B, 1990) |
| " In such patients, aspirin diminishes by about half the incidence of myocardial infarction and death." | 4.77 | Polypharmacologic interactions in the management of thrombosis. ( Born, GV, 1989) |
| " Secondary prevention strategies include smoking cessation; the control of hyperlipidemia, obesity and diabetes; the management of hypertension and stress; exercise; the use of drugs such as beta blockers and aspirin, and increased attention to general health." | 4.77 | Secondary prevention in elderly survivors of heart attacks. ( Davenport, J; Whittaker, K, 1988) |
| "In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina." | 4.77 | Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987) |
| "In parallel with experimental research into methods for salvage of ischemic myocardium after acute myocardial infarction (AMI) over the last decade, there has been a growing interest in prostaglandins (PG) and their inhibition by aspirin-like drugs or nonsteroidal anti-inflammatory drugs (NSAID)." | 4.76 | Prostaglandin inhibition and myocardial infarct size. ( Becker, LC; Jugdutt, BI, 1981) |
| "Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay regimen for acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI)." | 4.31 | Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention. ( Abramowitz, J; Ben-Dor, I; Bernardo, NL; Case, BC; Deksissa, T; Hashim, H; Rogers, T; Satler, LF; Shea, C; Sutton, JA; Torguson, R; Waksman, R; Zhang, C, 2023) |
| " The system has been applied in: (1) the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial and (2) the New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial." | 4.31 | A hybrid automated event adjudication system for clinical trials. ( Bangdiwala, SI; Belanger, J; Bosch, J; Connolly, S; Dagenais, GR; Dyal, L; Eikelboom, J; Marsden, T; Renters, M; Swaminathan, B; Tang, C; Yuan, F, 2023) |
| "Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel." | 4.31 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou ( Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S, 2023) |
| "Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets." | 4.31 | Immature platelets and cardiovascular events in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Pedersen, OB, 2023) |
| "Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily." | 4.31 | Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. ( Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 4.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| " We report the case of a patient with acute myocardial infarction treated with ticagrelor and aspirin as oral antithrombotic therapy after primary percutaneous coronary intervention (PCI), manifesting in a significant bradyarrhythmic episode that required a switch of antiplatelet therapy." | 4.31 | Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report. ( Bertelli, A; Berteotti, M; Cesarini, D; Gori, AM; Marcucci, R; Muraca, I; Sorrentino, A; Valenti, R, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 4.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| "In AMI patients with a history of acute ischemic stroke, the risks of cardiovascular events were comparable between ticagrelor plus aspirin and clopidogrel plus aspirin." | 4.31 | Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Wang, CC; Wu, CH, 2023) |
| " At 25 min of ischemia, animals received intravenous aspirin (20 mg/kg) or vehicle." | 4.31 | Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat. ( Birnbaum, Y; Ye, R; Ye, Y, 2023) |
| "Low-dose acetylsalicylic acid (aspirin) prevents stroke and myocardial infarction in patients with cardiovascular disease (CVD), but whether it should be used for primary CVD prevention in older Chinese adults remains unclear." | 4.12 | The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. ( Sun, R; Sun, X; Zhang, L, 2022) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function." | 4.12 | The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. ( Li, F; Peng, R, 2022) |
| " This study set out to evaluate the prevalence of low platelet reactivity in patients with acute myocardial infarction treated with ticagrelor and aspirin." | 4.12 | Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. ( Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP, 2022) |
| "Fatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors." | 4.12 | Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. ( Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022) |
| "Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events." | 4.12 | Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. ( Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R, 2022) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 4.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "Genotype-guided aspirin use for colorectal cancer chemoprevention may offer a cost-effective approach for the future management of average-risk individuals." | 4.02 | Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? ( Au, TH; Biltaji, E; Brixner, DI; Li, CI; Ose, J; Rivers, Z; Stenehjem, DD; Ulrich, CM; Walker, B, 2021) |
| "The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction." | 4.02 | Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. ( Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 3.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 3.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| "In patients undergoing either MAG or SAG in the TiCAB trial, ticagrelor monotherapy compared with aspirin did not affect the rate of cardiovascular death, non-fatal MI, stroke or repeat revascularization, or the rate of bleeding, at 1 year after CABG." | 3.96 | Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. ( Böning, A; Kastrati, A; Laufer, G; Misfeld, M; Nowak, B; Sandner, SE; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Wiedemann, D, 2020) |
| " This study sought to identify the predictors of aspirin nonadherence in adults with prior myocardial infarction (MI)." | 3.96 | Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction. ( Bhasin, V; Mehta, A; Parikh, PB; Skopicki, HA, 2020) |
| "Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding." | 3.96 | Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). ( Al Rifai, M; Blaha, MJ; Blumenthal, RS; Budoff, M; Cainzos-Achirica, M; Dardari, Z; Duprez, DA; Dzaye, O; Greenland, P; Hong, J; McEvoy, JW; Miedema, MD; Mortensen, MB; Nasir, K; Yeboah, J, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 3.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 3.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS)." | 3.96 | Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. ( Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP, 2020) |
| " In the GLOBAL LEADERS study, time-to-first-event analysis did not show superiority of ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention to conventional 12-month DAPT followed by aspirin monotherapy in the reduction of the primary composite end point of all-cause mortality or new Q-wave myocardial infarction." | 3.96 | Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. ( Angioi, M; Barbato, E; Chichareon, P; Fontos, G; Gao, C; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Kogame, N; Leandro, S; Modolo, R; Niethammer, M; Ono, M; Onuma, Y; Ribeiro, VG; Serruys, PW; Sharif, F; Steg, PG; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; van Klaveren, D; Verbeeck, J; Wang, R; Windecker, S, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 3.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| "To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI) in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD." | 3.96 | Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. ( Bodtger, U; Capuano, A; Gislason, G; Jensen, MT; Lamberts, M; Lange, P; Nicolaisen, SK; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "We assessed the effects of ticagrelor, aspirin and prasugrel, started 7days after myocardial ischemia-reperfusion injury on remodeling, inflammation and fibrosis in the rat." | 3.91 | Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. ( Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y, 2019) |
| "Influence of pre-existing treatment with aspirin and/or statins prior to a first acute coronary syndrome (ACS) on clinical presentation, infarct size and inflammation markers." | 3.91 | Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. ( Denegri, A; Lüscher, TF; Mach, F; Matter, CM; Muller, O; Obeid, S; Räber, L; Shahin, M; Weidmann, L; Yousif, N, 2019) |
| "We conducted a prospective cohort study on patients enrolled in the Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial which was started in 2002." | 3.91 | One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. ( Doi, N; Jinnouchi, H; Masuda, I; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2019) |
| "In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD)." | 3.91 | External applicability of the COMPASS trial: the Western Denmark Heart Registry. ( Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M, 2019) |
| "For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding." | 3.91 | Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. ( Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D, 2019) |
| "We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project." | 3.91 | Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 3.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| " A well-known meta-analysis for six major multicentre trials to assess the efficacy of a given dose of aspirin in post-myocardial infarction patients is reanalysed." | 3.88 | Bayesian meta-analysis: The role of the between-sample heterogeneity. ( Moreno, E; Negrín, MA; Vázquez-Polo, FJ, 2018) |
| "To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI)." | 3.88 | Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. ( Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018) |
| "Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)." | 3.88 | Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018) |
| " HPR was defined as on-clopidogrel P2Y12 platelet reaction units >208 as measured by the VerifyNow assay; target vessel failure (TVF) was defined as the composite of all-cause death, myocardial infarction, or ischemia-driven target vessel revascularization." | 3.88 | Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. ( Généreux, P; Kirtane, AJ; Maehara, A; McAndrew, T; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B, 2018) |
| "To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions." | 3.88 | Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. ( Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E, 2018) |
| "Among 1469 patients with incident ST-elevation myocardial infarction (STEMI, 14%) or non-STEMI (86%), 390 patients were prescribed DAPT, 549 aspirin only, and 530 clopidogrel only." | 3.88 | Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. ( Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 3.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI." | 3.88 | Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. ( Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018) |
| "The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES." | 3.85 | Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 3.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Stent fracture (SF) and peri-stent contrast staining (PSS) after sirolimus-eluting stent (SES) implantation are considered to be related to very late stent thrombosis (VLST)." | 3.85 | Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation. ( Amano, H; Fuku, Y; Goto, T; Habara, S; Kadota, K; Kubo, S; Otsuru, S; Tada, T; Tanaka, H, 2017) |
| "The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR." | 3.85 | Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017) |
| "Dual anti-platelet treatment with clopidogrel and aspirin is indicated for most patients after myocardial infarction." | 3.85 | Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. ( Christiansen, CB; Gislason, G; Hansen, ML; Juul, N; Karasoy, D; Lamberts, M; Olesen, JB; Sorensen, R; Torp-Pedersen, C, 2017) |
| "In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding." | 3.85 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| " The risk and benefit of aspirin are not known in thrombocytopenic cancer patients experiencing acute myocardial infarction (AMI)." | 3.85 | Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. ( Feher, A; Gupta, D; Kampaktsis, PN; Parameswaran, R; Stein, EM; Steingart, R, 2017) |
| "The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid." | 3.85 | Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 3.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| " Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months." | 3.85 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 3.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| " Compared to patients treated with aspirin+clopidogrel, patients treated with aspirin+prasugrel had fewer BARC 3 or 5 bleedings (two [0." | 3.83 | Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). ( Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J, 2016) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 3.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| "Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period." | 3.83 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016) |
| " Vorapaxar, a novel platelet thrombin receptor (PAR-1/4) blocker, is currently approved for post-myocardial infarction and peripheral artery disease indications on top of clopidogrel or/and aspirin." | 3.83 | Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. ( Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL, 2016) |
| " We compared the incidence of fatal pulmonary embolism in patients undergoing elective primary total hip arthroplasty (THA) between those receiving aspirin, warfarin and low molecular weight heparin (LMWH) for the chemical component of a multi-modal thromboprophylaxis regime." | 3.83 | Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study. ( Bayley, E; Bhamber, NS; Brown, S; Howard, PW, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 3.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| " The aim of the current study was to compare these two point-of-care platelet function tests and to analyze the consistency between the two tests for evaluating on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI)." | 3.83 | Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. ( Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH, 2016) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 3.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)." | 3.81 | Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015) |
| "Preoperatively continued aspirin use was not associated with increased risk of intra- and post-operative blood loss, blood transfusion requirements and composite outcome of in-hospital death, stroke and reoperation for bleeding in off-pump CABG." | 3.81 | Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients. ( Pan, S; Song, Y; Sun, H; Wu, H; Xiao, F; Xu, J, 2015) |
| "Aspirin is a cornerstone in management of coronary artery disease (CAD)." | 3.81 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015) |
| "We describe a case of a 67-year-old man who required emergency surgery for acute intracranial bleeding after having received a loading dose of aspirin and ticagrelor for an acute ST-elevation myocardial infarction." | 3.81 | Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor. ( Bonhomme, F; Cartier Faessler, V; Fontana, P; Maillard, J, 2015) |
| "The objective of this study is to investigate the interaction of Panax quinquefolius saponin (PQS) and dual antiplatelets (aspirin and clopidogrel) on antiplatelet activity and vascular endothelial function in rats with acute myocardial infarction (AMI)." | 3.81 | Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction. ( Liu, J; Liu, Y; Shang, Q; Shi, D; Wang, B; Zhang, L; Zhang, Q, 2015) |
| "The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage." | 3.81 | Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015) |
| "Ticagrelor was daily administered throughout pregnancy to a 37-year-old pregnant woman until 36 weeks of gestation." | 3.81 | Use of ticagrelor in human pregnancy, the first experience. ( Jacquemyn, Y; Mannaerts, D; Muys, J; Verbruggen, M, 2015) |
| "The aim of this study was a) To identify predictors of the use of aspirin in the pre-hospital setting in acute myocardial infarction (AMI) and b) To analyze whether the use of any of the recommended medications was associated with outcome." | 3.81 | Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction. ( Axelsson, C; Bremer, A; Claesson, A; Herlitz, J; Jimenez-Herrera, M; Karlsson, T; Ravn-Fischer, A; Strandmark, R, 2015) |
| " Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting." | 3.81 | Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004) |
| "Abstract The optimal dose of aspirin for patients presenting with acute myocardial infarction (AMI) while receiving chronic aspirin therapy has not been clearly established." | 3.80 | The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. ( Bonastre, J; Latorre, AM; Madrid, I; Moscardo, A; Ruano, M; Santos, MT; Valles, J, 2014) |
| " The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months." | 3.80 | Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014) |
| " This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI." | 3.80 | Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014) |
| " Optimal use of 4 oral drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors) in all eligible patients with AMI or unfractionated heparin in non-ST-segment-elevation myocardial infarction was a highly cost-effective strategy (incremental cost-effectiveness ratios approximately US $3100 or less)." | 3.80 | Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. ( Coxson, PG; Goldman, L; Gu, D; He, J; Heidenreich, PA; Liu, J; Moran, AE; Wang, M; Zhao, D, 2014) |
| "This article refers to 'Impact of aspirin and statins on longterm survival in patients with acute myocardial infarction complicated by heart failure: an analysis in 1746 patients' by C." | 3.80 | Evidence-based co-medication in heart failure: necessary or bystander? ( Verheugt, FW, 2014) |
| "Aspirin and statins are established therapies for acute myocardial infarction (MI), but their benefits in patients with chronic heart failure (HF) remain elusive." | 3.80 | Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. ( Bland, JM; Cleland, JG; Crouch, S; Doherty, P; Gale, CP; Hall, AS; Køber, L; Lewinter, C; LeWinter, MM, 2014) |
| "Current guidelines recommend that patients with peripheral arterial disease (PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin-converting enzyme (ACE) inhibitors." | 3.80 | Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Bang, H; Chen, DC; Laird, JR; McCoach, CE; Singh, S; Westin, GG; Yeo, KK, 2014) |
| "The benefit of aspirin in primary prevention of myocardial infarction and the associated gastro-intestinal bleeding risks have not been well established in the elderly population with diabetes." | 3.80 | Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. ( Grégoire, JP; Moisan, J; Poirier, P; Sirois, C, 2014) |
| "Accumulated data suggest that low-dose aspirin after myocardial infarction (MI) may offer similar efficacy to higher dose aspirin with reduced risk of bleeding." | 3.80 | Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). ( Alexander, KP; Das, SR; de Lemos, JA; Desai, N; Enriquez, JR; Hall, HM; McGuire, DK; Peng, SA; Roe, MT; Wiviott, SD, 2014) |
| " The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)." | 3.80 | Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014) |
| "Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources." | 3.80 | Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study. ( Desai, NR; Gao, Y; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Zhang, H, 2014) |
| "Four years ago, Michelle Holmes, Wendy Chen and collegues reported a significant negative correlation between aspirin use and breast cancer (Holmes et al." | 3.80 | "Frankly, my dear, I don't give a damn". ( Evans, RG, 2014) |
| "A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis." | 3.79 | Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013) |
| " We examined whether plasma L5 levels are elevated in patients with ST-segment elevation myocardial infarction (STEMI) and whether aspirin provides epigenetic protection of human coronary artery ECs (HCAECs) exposed to L5." | 3.79 | Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. ( Chang, FH; Chang, PY; Chang, SF; Chen, CH; Chen, YJ; Huang, WH; Lee, YT; Lu, J; Lu, SC; Yang, TC, 2013) |
| " In addition, patients in the 6 am to 2 pm subgroup were more likely older, white race, and male, with higher rates of home aspirin use and lower rates of obesity." | 3.79 | Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. ( Antman, EM; Cannon, CP; Foody, JM; Giugliano, RP; Li, S; Mogabgab, O; Sabatine, MS; Wang, TY; Wiviott, SD, 2013) |
| "We included 177 stable coronary artery disease patients on aspirin monotherapy." | 3.79 | Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. ( Ajjan, R; Grove, EL; Hess, K; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 3.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "In Non-ST elevation myocardial infarction (NSTEMI) patients (n = 132) undergoing percutaneous coronary intervention (PCI) on dual antiplatelet therapy blood samples were collected within 24 h from 600 mg clopidogrel loading dose." | 3.79 | Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. ( Abbate, R; Becatti, M; Fiorillo, C; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Pignatelli, P; Violi, F, 2013) |
| "The American College of Cardiology and the American Heart Association recommend early aspirin administration to patients with symptoms of acute coronary syndrome (ACS)/acute myocardial infarction (AMI)." | 3.79 | Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin diagnostic and instruction tool. ( Barron, T; Clawson, J; Gummett, J; Olola, CH; Patterson, B; Robinson, D; Scott, G; Shiner, R; Wrigley, F, 2013) |
| " QIs for acute myocardial infarction were defined by an expert consensus group as appropriate prescription at discharge of aspirin, clopidogrel, β-blocker, statin, and an angiotensin-converting enzyme inhibitor in patients with left ventricular ejection fraction <0." | 3.79 | Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment. ( Capuano, F; Derumeaux, G; Desplanques-Leperre, A; Gardel, C; Grenier, C; Loirat, P; Schiele, F; Thebaut, JF, 2013) |
| " These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis." | 3.79 | Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Creager, MA, 1998) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel." | 3.78 | Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. ( Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S, 2012) |
| " We present a case of postoperative simultaneous left anterior descending and right coronary stent thrombosis that followed cessation of long-term aspirin therapy in a patient with stable coronary artery disease." | 3.78 | Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal. ( Abdelmalak, HD; Camporesi, EM; Karlnoski, R; Mangar, D; Omar, HR, 2012) |
| "Using a single group, pretest/posttest design, 50 migraineurs without prior history of stroke or MI were prospectively treated for 14 to 21 consecutive days with 325 mg generic enteric-coated aspirin, after undergoing a 14-day aspirin washout." | 3.78 | Aspirin's effect on platelet inhibition in migraineurs. ( Fuller, CJ; Jesurum, JT; Lucas, SM; Murinova, N; Truva, CM, 2012) |
| "Current guidelines recommend the use of dual antiplatelet therapy (DAT) (aspirin+clopidogrel) for patients after acute myocardial infarction (MI)." | 3.78 | Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. ( Couffinhal, T; Lafitte, M; Latry, P; Martin-Latry, K; Peter, C, 2012) |
| "High on-treatment platelet reactivity (HTPR) despite clopidogrel therapy is associated with adverse cardiac events after acute myocardial infarction (AMI)." | 3.78 | Clopidogrel response up to six months after acute myocardial infarction. ( Assali, A; Battler, A; Codner, P; Greenberg, G; Hasdai, D; Iakobishvili, Z; Kornowski, R; Lev, EI; Rechavia, E; Vaduganathan, M, 2012) |
| "The early administration of the anti-platelet agent clopidogrel in patients with acute coronary syndromes with or without ST-segment elevation has a beneficial effect on mortality and major adverse cardiac events." | 3.78 | Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus. ( Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months." | 3.78 | Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. ( Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M, 2012) |
| " We wanted to explore long-term variability of multiple electrode aggregometry (MEA) measurements and the agreement between MEA and light transmission aggregometry (LTA) in patients with non-ST elevation myocardial infarction (NSTEMI) treated with aspirin and clopidogrel." | 3.78 | Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. ( Andreassen, T; Bendz, B; Brosstad, F; Erikssen, G; Kunszt, G; Liestøl, K; Meen, O; Schjelderup, NM; Wettergreen, M, 2012) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "One of the foundations of the modern treatment of myocardial infarction (MI) is a combination antiplatelet therapy consisting of acetylsalicylic acid (ASA) and clopidogrel." | 3.78 | [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. ( Akhmetov, II; Arkhipova, AA; Galiavi, RA; Galiavich, AS; Minnetdinov, RSh; Valeeva, DD, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "For the treatment of acute myocardial infarction, heparin has been a topic of continuing debate for the past four decades." | 3.78 | Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction. ( Metz, BK; Topol, EJ, 1996) |
| "In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch." | 3.77 | Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. ( Alden, PB; Goldman, JA; Graber, JN; Rizvi, AZ; Rosenbaum, A; Sullivan, TM; Tretinyak, AS, 2011) |
| "Aspirin treatment is essential in patients with acute myocardial infarction (AMI) to block platelet thromboxane (TXA)₂ synthesis." | 3.77 | Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction. ( Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Vallés, J, 2011) |
| "Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding." | 3.77 | Cost-utility of aspirin and proton pump inhibitors for primary prevention. ( Earnshaw, SR; Fendrick, AM; McDade, C; Pignone, M; Scheiman, J, 2011) |
| " From July 2002 through June 2008, compliance with 3 in-hospital acute myocardial infarction quality-of-care measures (administration of aspirin and β blockers on arrival, timely reperfusion) and mortality were assessed in consecutive patients eligible for ≥1 of the measures at 8 hospitals (n = 6,826)." | 3.77 | Changes over six years in administration of aspirin and beta blockers on arrival and timely reperfusion and in in-hospital and 30-day postadmission mortality in patients with acute myocardial infarction. ( Ballard, DJ; Filardo, G; Nicewander, D, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 3.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 3.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "To evaluate the risk of myocardial infarction and death from coronary heart disease after discontinuation of low dose aspirin in primary care patients with a history of cardiovascular events." | 3.77 | Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. ( Cea-Soriano, L; Johansson, S; Martín-Merino, E; Rodríguez, LA, 2011) |
| "Pre-hospitalization medication such as aspirin and nitrates has been shown to affect the mode of presentation in acute coronary syndrome (ACS)." | 3.77 | Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry. ( Hoshida, S; Iwasaka, J; Iwasaka, T; Kijima, Y; Lim, YJ; Yuasa, F, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| " The influence of the CYP2C19 LOF alleles (*2 and *3) on clopidogrel response and clinical outcomes in East Asians with acute myocardial infarction (AMI) has not been reported." | 3.77 | Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. ( Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Koh, JS; Kwak, CH; Kwon, TJ; Park, Y; Tantry, US, 2011) |
| "To assess the long-term cost effectiveness of treatment for 1 month, and for 1 year with clopidogrel in addition to standard therapy (including aspirin) compared with standard therapy alone, in patients diagnosed with ST elevation acute myocardial infarction (STEMI) in the UK." | 3.76 | A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. ( Bakhai, A; Brennan, A; Holmes, MW; Karnon, J; Williams, R, 2010) |
| "To investigate the effect of aspirin on the platelets of survivors of myocardial infarction we correlated plasma salicylate level with platelet reactivity in ten patients and ten normal controls." | 3.76 | Plasma salicylate level and aspirin resistance in survivors of myocardial infarction. ( Ahmed, N; Davies, GJ; Meek, J, 2010) |
| "Chronic use of aspirin and statins has been associated with reduced risk of subsequent myocardial infarction (MI)." | 3.76 | Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. ( Arcieri, R; Commisso, C; Lanzillo, C; Lioy, E; Penco, M; Pendenza, G; Quarto, M; Romagnoli, E; Sciahbasi, A; Summaria, F, 2010) |
| "This study assesses the costs and effects of combination treatment with clopidogrel and aspirin in comparison to aspirin alone in patients with an ST-segment elevation myocardial infarction (STEMI) in a Dutch setting." | 3.76 | Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. ( de Charro, F; Heeg, B; Thurston, SJ; van Hout, B, 2010) |
| " Reported compliance with AMI performance measures was analyzed using data from the United States Department of Health and Human Services Hospital Compare Web site from 2007, including aspirin administration, beta-blocker administration, angiotensin-converting enzyme or angiotensin receptor blocking agents, and smoking cessation counseling." | 3.76 | Hospitals with percutaneous coronary intervention capability have greater adherence to established myocardial infarction guidelines. ( Chiang, J; Kao, J; Patel, V; Schopfer, D, 2010) |
| "Feedback reports and quality improvement improved prehospital ECG performance for patients with acute coronary syndrome and ST-elevation myocardial infarction and increased aspirin administration without prehospital transport delays." | 3.76 | Improving use of prehospital 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction. ( Beshansky, JR; Daudelin, DH; Goetz, JD; Kwong, M; Lane, WM; Porcaro, WA; Restuccia, MC; Ruthazer, R; Sayah, AJ; Selker, HP, 2010) |
| " Thrombolysis in myocardial infarction (TIMI) 3 flow predicted a good outcome, whereas recurrent ischemia in hospital, prior aspirin therapy and discharge creatinine predicted a poor outcome; age alone was not an adverse prognostic factor." | 3.76 | Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction. ( Attia, J; Baker, F; Collins, N; Hatton, R; Hiew, C; McElduff, P; Narasimhan, S; O'Connor, S; Williams, T, 2010) |
| "Chronic aspirin therapy is recommended by the American College of Cardiology/American Heart Association (ACC/AHA) following acute myocardial infarction (AMI) and by the Society of Thoracic Surgeons(STS) following coronary artery bypass graft (CABG)." | 3.76 | Intervention to increase the proportion of acute myocardial infarction or coronary artery bypass graft patients receiving an order for aspirin at hospital discharge. ( Brackbill, ML; Call, JT; Kline, VT; Sytsma, CS, 2010) |
| "The USPSTF recommends aspirin for the prevention of stroke and heart attack for those at risk, and screening for major depression and childhood obesity." | 3.76 | USPSTF recommendations you may have missed amid the breast cancer controversy. ( Campos-Outcalt, D, 2010) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)." | 3.75 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009) |
| " We replicated the observation of the Atherosclerosis Risk in Communities Study and observed an interaction of rs20417 with aspirin use on myocardial infarction risk (p for interaction=0." | 3.75 | Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. ( Bis, JC; Heckbert, SR; Lemaitre, RN; Lumley, TS; Marciante, K; Psaty, BM; Rice, K; Smith, NL; Wiggins, KL, 2009) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 3.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Encourage men age 45 to 79 years to use aspirin when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage." | 3.75 | Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. ( , 2009) |
| "We report a case of myocardial infarction associated with the use of sumatriptan and review the literature regarding similar cases." | 3.75 | Acute myocardial infarction with sumatriptan: a case report and review of the literature. ( Chalaupka, FD, 2009) |
| "In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 3.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 3.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| " This study was designed to determine the relation between responses to aspirin and clopidogrel as assessed by a point-of-care assay (Verify Now, Accumetrics, San Diego, California) and periprocedural myocardial infarction (PMI) in patients undergoing elective PCI for stable angina." | 3.74 | Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Hamilos, M; Sarma, J; Sarno, G; Vanderheyden, M; Wijns, W; Wyffels, E, 2008) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| "A standard four-drug regimen of aspirin, a beta-blocker, a lipid-lowering agent, and an angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker improves outcomes in survivors of myocardial infarction (MI), but adherence to this regimen is often poor." | 3.74 | Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare? ( Goldman, L; Moran, A, 2008) |
| "The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period." | 3.74 | Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding." | 3.74 | Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| " A patient suffering from coronary artery disease and taking metoprolol and aspirin was stung by wasps and developed cutaneous allergic signs including rash, urticaria and orbital oedema." | 3.74 | Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration. ( Ioannidis, TI; Karpeta, MZ; Kounis, GN; Kounis, NG; Mazarakis, A; Notaras, SP; Rallis, DG; Tsintoni, AC, 2007) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 3.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 3.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "Previously we studied 298 patients admitted to hospital with symptoms suggestive of an acute myocardial infarction (MI) despite treatment with aspirin, and 70 patients (23." | 3.74 | Variation and importance of aspirin resistance in patients with known cardiovascular disease. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Kristensen, SR; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "Heterogeneity in response to aspirin (ASA) treatment, or "aspirin resistance," could be of importance in patients with ST-segment elevation myocardial infarction (STEMI)." | 3.74 | Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. ( Aznar, J; Breña, S; Fuset, MP; Moscardo, A; Perez, F; Piñon, M; Ruano, M; Santos, MT; Valles, J, 2007) |
| "High post-treatment platelet reactivity (HPPR=adenosine diphosphate [ADP] 10 microM-induced platelet aggregation >70%) identifies low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for non-ST elevation acute coronary syndromes (NSTE-ACS)." | 3.74 | High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J, 2007) |
| "Adherence to guidelines for treating acute myocardial infarction, including aspirin, Beta blockers, and reperfusion via thrombolytics or PTCA." | 3.74 | Do orders limiting aggressive treatment impact care for acute myocardial infarction? ( Dobalian, A; Levy, C; Radcliff, TA, 2007) |
| "Continuous aspirin treatment (120 mg/kg/d) reduces the expression of proinflammatory cytokines after myocardial infarction, but does not affect post-infarct cardiac remodeling and cardiac function." | 3.74 | High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction. ( Adamek, A; Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Hu, K; Wagner, H, 2007) |
| "(i) to determine the proportion of "low-responders" or "resistants" patients during coronary syndrome (ii) to identify determinants of interindividual variability response to clopidogrel (iii) to compare aggregometry and VASP phosphorylation measured by flow cytometry." | 3.74 | [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. ( Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C, 2007) |
| "Aspirin reduces mortality for men and women with coronary heart disease (CHD)." | 3.74 | Gender differences in aspirin use among adults with coronary heart disease in the United States. ( Cannon, CP; McWilliams, JM; Opotowsky, AR, 2007) |
| " Poisson regression models were used to assess whether CAM use was independently associated with lower rates of aspirin, beta-blocker, and statin use in 596 patients with established coronary artery disease (CAD)." | 3.74 | Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. ( Banerjee, S; Buchanan, DM; Decker, C; Huddleston, J; Jones, A; Kosiborod, M; Spertus, JA; Stoner, C, 2007) |
| "To determine whether patients with documented myocardial infarction (MI) while on aspirin therapy (cases) were more likely to be aspirin resistant than were patients with coronary artery disease (CAD) who had no history of MI (controls) and to assess clinical predictors of aspirin resistance in patients with stable CAD." | 3.74 | Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. ( Colby, E; Dorsch, MP; Dunn, SP; Lee, JS; Lynch, DR; Montague, D; Rodgers, JE; Schwartz, T; Smyth, SS, 2007) |
| "To identify an interaction between hormone therapy (HT) and COX inhibition, we measured a priori the association between concomitant nonsteroidal anti-inflammatory drugs (NSAIDs), excluding aspirin, in peri- and postmenopausal women on HT and the incidence of myocardial infarction (MI) in a population-based epidemiological study." | 3.74 | Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? ( Egan, K; FitzGerald, GA; García Rodríguez, LA, 2007) |
| "In patients with myocardial infarction who are not eligible for angioplasty, adding clopidogrel to aspirin reduces the overall 15-day mortality rate, but the subsequent outcome is not known." | 3.74 | Clopidogrel: new indication. In combination with aspirin: marginal additional benefits. ( , 2007) |
| "Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated." | 3.74 | Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 3.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)." | 3.74 | Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008) |
| "The aim of the study was to investigate the effects of clopidogrel with or without abciximab on the expression of platelet surface receptors and platelet function in patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI." | 3.74 | Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone. ( Konopka, A; Pilichowska, I; Piotrowski, W; Sitkiewicz, D; Spychalska, J; Stepińska, J; Zdebska, E, 2007) |
| " Aspirin use has been shown to be effective in reducing the number of nonfatal myocardial infarction (MI) and fatal CHD, though studies of aspirin effects in women have found a significant reduction in ischemic stroke but no significant effect on fatal or nonfatal MI or CVD death." | 3.74 | Aspirin use in the prevention of cardiovascular events. ( Crutcher, JM; Daniels, C; Mallonee, S, 2007) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| " We sought to estimate the incremental cost-effectiveness of providing full coverage for aspirin, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination pharmacotherapy) to individuals enrolled in the Medicare drug benefit program after acute myocardial infarction." | 3.74 | Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. ( Antman, EM; Avorn, J; Choudhry, NK; Patrick, AR; Shrank, WH, 2008) |
| "To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 3.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 3.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| " Hospital charts review revealed key information for clinical variables, smoking, obesity and use of aspirin at admission." | 3.74 | Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. ( Aguado, J; Castellsague, J; Perez-Gutthann, S; Stang, MR; Tomas, L; Varas-Lorenzo, C, 2008) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 3.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)." | 3.73 | Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005) |
| "193 patients with their first non-Q-wave myocardial infarction (NQMI) were examined with the aim of studying the functional features of NQMI and estimate the influence of pre-hospital treatment with propranalol (PP), heparin and aspirin." | 3.73 | [Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease]. ( Baltabaev, TB; Beĭshenkulov, MT; Kudaĭbergenova, NT, 2005) |
| "The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding." | 3.73 | Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. ( Bertram, M; Liew, D; Nelson, MR; Vos, T, 2005) |
| "To determine whether specific limitations in electronic database studies may lead to biased estimates of the association between prescription, non-selective non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and myocardial infarction (MI) METHODS: Using our case-control study of NANSAIDs and first, non-fatal MI, we determined the odds ratio (OR) for prescription NANSAIDs and MI." | 3.73 | Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI). ( Berlin, JA; Hennessy, S; Ilkhanoff, L; Kimmel, SE; Lewis, JD, 2005) |
| "To determine whether patients taking aspirin for secondary prevention of myocardial infarction are at increased risk of recurrent disease when they take concomitant ibuprofen." | 3.73 | Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. ( Baron, M; Hudson, M; Pilote, L; Rahme, E, 2005) |
| " During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section." | 3.73 | [Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005) |
| "Rates of reperfusion therapy, coronary angiography, and in-hospital death after myocardial infarction, but not the use of aspirin and beta-blockers, vary according to race and sex, with no evidence that the differences have narrowed in recent years." | 3.73 | Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. ( Abramson, JL; Barron, HV; Frederick, PD; Krumholz, HM; Mallik, S; Manhapra, A; Rathore, SS; Vaccarino, V; Wenger, NK, 2005) |
| "We sought to assess the association between prior aspirin use and mortality, all-cause readmission, and condition-specific readmission at one month and six months in a national sample of Medicare beneficiaries hospitalized with a confirmed myocardial infarction (MI)." | 3.73 | Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction. ( Curtis, JP; Foody, JM; Krumholz, HM; Masoudi, FA; Portnay, EL; Rathore, SS; Wang, Y, 2005) |
| "Utilization rates of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins singly and as part of a multidrug regimen before hospitalization were measured in 109,540 patients with a history of coronary artery disease presenting with acute myocardial infarction to 1,283 hospitals participating in the National Registry of Myocardial Infarction-4." | 3.73 | Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Frederick, PD; Goldberg, RJ; Gore, JM; Spencer, FA; Tiefenbrunn, AJ, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 3.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| "The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin." | 3.73 | The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005) |
| "During the past 2 decades, randomized trials have proved the efficacy of several treatments for non-ST-elevation acute coronary syndromes (NSTE-ACSs), including aspirin, beta blockers, and coronary revascularization." | 3.73 | Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities. ( Coresh, J; Folsom, AR; Powe, N; Rosamond, W; Thiemann, D; Watkins, S, 2005) |
| "To compare the effects of an aspirin-clopidogrel combination with those of the specific glycoprotein IIb/IIIa inhibitor tirofiban on myocardial no-reflow, nitric oxide concentration and activity of nitric oxide synthase (NOS) isoforms in a mini-swine model of acute myocardial infarction and reperfusion." | 3.73 | Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. ( Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL, 2006) |
| "The authors studied 36 months of emergency care and measured quality indicators, including early mortality (deaths occurring after arrival in the ED or within 48 hours of hospital admission), frequency of return after ED discharge, time to thrombolysis in acute myocardial infarction (AMI), frequency of aspirin use in AMI, and performance of endotracheal intubation." | 3.73 | Quality of emergency care on the night shift. ( Kronick, SL; Lowell, MJ; Philpott, S; Silbergleit, R; Wagner, C, 2006) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 3.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 3.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "Inhibition of FXIII activation by aspirin is enhanced in the Leu34 carriers in vivo, suggesting that these subjects might benefit more than the Leu34-negative subjects from the reduction in risk for myocardial infarction with low-dose aspirin." | 3.72 | Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. ( Brummel, K; Mann, KG; Musial, J; Sydor, WJ; Szczeklik, A; Undas, A, 2003) |
| "We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 3.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
| "Although it has been well documented that aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering drugs are under-prescribed for patients with acute myocardial infarction (Am Heart J 2003;145:438-44." | 3.72 | Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. ( Beck, C; Eisenberg, MJ; Pilote, L; Richard, H; Simpson, E, 2003) |
| " Cardiac lesions induced by isoproterenol (ISO) are characterized by myocardial necrosis and exudative infiltration." | 3.72 | Effect of D-003 on isoproterenol-induced myocardial necrosis in rats. ( Arruzazabala, ML; Carbajal, D; González, J; Más, R; Mendoza, S; Molina, V; Noa, M, 2003) |
| "Aspirin provides benefit in nearly all groups of patients with clinical manifestations of coronary heart disease." | 3.72 | Aspirin for cardiovascular disease prevention. ( Hung, J, 2003) |
| "Aspirin is used in percutaneous coronary interventions (PCI) for acute myocardial infarction (AMI) to prevent thrombosis." | 3.72 | Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. ( Mohri, H; Niikawa, O; Nishiyama, A; Tsushima, M, 2003) |
| " Certain therapies were widely adopted in both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients (aspirin >94% of all patients; beta-blockers 85-95%) and changed only modestly over time." | 3.72 | From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). ( Anderson, FA; Budaj, A; Dabbous, OH; Flather, MD; Fox, KA; Goodman, SG; Gore, JM; Granger, CB; Moscucci, M; Spencer, F, 2003) |
| "5% in the ticlopidine group, and myocardial infarction (MI) was also reduced in the clopidogrel group (4." | 3.72 | Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. ( Albirini, A; Aronow, HD; Bhatt, DL; Cura, FA; Ellis, SG; L'Allier, PL; Schneider, JP; Topol, EJ, 2003) |
| "Experimental evidence raises the possibility that acetaminophen use could reduce the risk of myocardial infarction (MI)." | 3.72 | A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men. ( Palmer, JR; Rao, RS; Rosenberg, L, 2003) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "Patients suffering an acute myocardial infarction routinely receive morphine and nonsteroidal anti-inflammatory drugs (NSAIDs) alone or in combination." | 3.72 | Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. ( Gross, ER; Gross, GJ; Hsu, AK, 2004) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| "We compared six-month death, myocardial infarction (MI), and stroke in patients with unstable angina or acute MI discharged while receiving low (<150 mg) or intermediate (> or =150 mg) aspirin therapy in the GUSTO IIb and PURSUIT trials (n = 20,521)." | 3.72 | Aspirin dose and six-month outcome after an acute coronary syndrome. ( Aronow, HD; Bhatt, DL; Califf, RM; Harrington, RA; Kandzari, DE; Kleiman, NS; Kong, DF; Quinn, MJ; Sapp, S; Topol, EJ, 2004) |
| "This study was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) are associated with lower odds of myocardial infarction (MI) and if NANSAIDs, particularly ibuprofen, interfere with aspirin's cardioprotective effect." | 3.72 | The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2004) |
| "There does not seem to be an increased risk of myocardial infarction among patients simultaneously consuming aspirin and ibuprofen compared with aspirin alone." | 3.72 | Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. ( Goldberg, KC; Patel, TN, 2004) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "In this nonrandomized, prospective, multinational, multicenter study, adherence to aspirin, beta-blockers, statins, or angiotensin-converting enzyme (ACE) inhibitors 6 months after discharge for myocardial infarction or unstable angina was assessed in 21,408 patients aged 18 years or older." | 3.72 | Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. ( Avezum, A; Eagle, KA; Erickson, S; Flather, MD; Goodman, SG; Granger, CB; Gurfinkel, EP; Kline-Rogers, E; Steg, PG; White, K, 2004) |
| "1% was seen for the clopidogrel/ASA combination for the first primary outcome (death from cardiovascular causes, non-fatal myocardial infarction (MI), or stroke), compared to ASA alone." | 3.72 | A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes. ( Boucher, M; Pharand, C; Skidmore, B, 2004) |
| "A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI)." | 3.72 | Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study. ( Frilling, B; Gieseler, U; Gitt, AK; Glunz, HG; Jagodzinski, E; Schiele, R; Schneider, S; Senges, J; Zahn, R, 2004) |
| " Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the platelet function analyzer (PFA-100) may be enhanced in patients with myocardial infarction (MI) and whether it may predict the extent of myocardial damage as measured by creatine kinase (CK-MB) or troponin T (TnT) levels." | 3.72 | Platelet function predicts myocardial damage in patients with acute myocardial infarction. ( Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M, 2004) |
| "We examined the effect of aspirin use at the time of admission and discharge from a large-scale, prospective multicenter trial of patients who had been treated with primary percutaneous coronary intervention in acute myocardial infarction." | 3.72 | Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. ( Carroll, JD; Cox, DA; Fahy, M; Garcia, E; Griffin, JJ; Grines, CL; Kandzari, DE; Lansky, AJ; Mehran, R; Stone, GW; Stuckey, T; Tcheng, JE; Turco, M, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy." | 3.71 | Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002) |
| "The purpose of this study was to examine 2 decade-long trends in the use of aspirin and associated outcomes in patients hospitalized with acute myocardial infarction." | 3.71 | Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective. ( Goldberg, RJ; Gore, JM; Jackson, EA; Lessard, D; Sivasubramian, R; Spencer, FA; Yarzebski, J, 2002) |
| "Compared with patients with no renal insufficiency, patients with moderate renal insufficiency were less likely to receive aspirin, beta-blockers, thrombolytic therapy, angiography, and angioplasty during hospitalization." | 3.71 | Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. ( Browner, WS; Chertow, GM; Heidenreich, PA; McClellan, MB; Noguchi, H; Shlipak, MG, 2002) |
| " If not taking Aspirin, the probabilities of stroke, myocardial infarction (MI), and major bleeding were given." | 3.71 | Differences in treatment preferences between persons who enrol and do not enrol in a clinical trial. ( Berquist, R; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM, 2001) |
| " The coronary reperfusion was achieved in 59% patients with acute myocardial infarction (MI) treated with thrombolysis, but in 27% patients with MI treated only heparin and aspirin." | 3.71 | [Prospective analysis of conservative treatment of acute coronary syndrome]. ( Batyraliev, TA; Daniiarov, BS; Niiazova-Karben, ZA; Pershukov, IV; Pia, IuV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2002) |
| "Clinical trials have shown the efficacy of aspirin for acute myocardial infarction (AMI)." | 3.71 | Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies. ( Asbeck, F; Baumgärtel, B; Frilling, B; Gieseler, U; Gitt, AK; Glunz, HG; Schiele, R; Schneider, S; Senges, J; Zahn, R, 2001) |
| "The most recent published guidelines regarding management of patients surviving an acute myocardial infarction (AMI) advocate the administration of aspirin (ASA), beta blockers (BB), and angiotensin-converting enzyme inhibitors (ACEi) and discourages the use of calcium-channel blockers (CCB)." | 3.71 | Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction. ( Axtell, SS; Lope-Candales, P; Ludwig, E, 2001) |
| " We consider three methods currently used for estimation within the framework of a random effects model, and illustrate them by applying each method to a collection of six studies on the effect of aspirin after myocardial infarction." | 3.71 | A comparison of statistical methods for meta-analysis. ( Brockwell, SE; Gordon, IR, 2001) |
| "Aspirin and angiotensin-converting enzyme (ACE) inhibitors are recommended for secondary prevention after acute myocardial infarction (AMI), but several studies have suggested that the combination of these medications may produce a negative interaction." | 3.71 | Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. ( Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001) |
| "Provision of three treatments for acute myocardial infarction (emergent reperfusion, aspirin, and beta-blockers), death at 30 days, and long-term follow-up." | 3.71 | Treatment of patients with myocardial infarction who present with a paced rhythm. ( Gersh, BJ; Oetgen, WJ; Rathore, SS; Schulman, KA; Solomon, AJ; Weinfurt, KP, 2001) |
| "Aspirin's role in the management of suspected myocardial infarction has been well established." | 3.71 | A study of the use of aspirin by general practitioners in suspected myocardial infarction. ( O'Shea, EB, 2001) |
| "ASPIRIN AND HEPARIN: In several studies aspirin has been found to be very effective in unstable angina pectoris reducing fatal and non-fatal myocardial infarction by 50-70%." | 3.71 | [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. ( Huber, K; Niessner, A; Niessner, H, 2001) |
| " Proportional hazard models compared the association between mental disorders and mortality before and after adjusting 5 established quality indicators: reperfusion, aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and smoking cessation counseling." | 3.71 | Quality of medical care and excess mortality in older patients with mental disorders. ( Bradford, WD; Druss, BG; Krumholz, HM; Radford, MJ; Rosenheck, RA, 2001) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 3.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "Aspirin has been shown to be beneficial after a myocardial infarction and for other acute coronary syndromes." | 3.71 | Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? ( Elwood, P; Smith, A; Woollard, M, 2001) |
| "At the start of the eighties, in the wake of the good results obtained with aspirin in secondary prevention, two studies were launched aimed at testing the effect of aspirin on the primary prevention of myocardial infarction." | 3.71 | [Primary prevention of coronary thrombosis by antithrombotic agents]. ( Khettab, F; Lantelme, P; Lasserre-Remy, S; Mestre-Fernandes, C; Milon, H, 2001) |
| "Despite prospective randomized control trials showing that beta blockers, aspirin, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents improve survival rates after myocardial infarction (MI), these agents are routinely underutilized." | 3.71 | Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. ( Findley, K; Frohnapple, D; Mehta, JL; Mitra, S, 2002) |
| "Non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs) have complex effects that could either prevent or promote coronary heart disease." | 3.71 | Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. ( Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM, 2002) |
| "Unlike thrombolytic agents, there are conflicting data regarding the time-dependent effect of aspirin treatment on outcome in acute myocardial infarction (AMI)." | 3.71 | Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. ( Barbash, IM; Behar, S; Boyko, V; Freimark, D; Hod, H; Leor, J; Matetzky, S, 2002) |
| "Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction." | 3.71 | Clopidogrel--a myocardial infarction CURE? ( Bradley, C, 2001) |
| "The prescription of NSAID therapy at hospital discharge for elderly Medicare beneficiaries who survived acute myocardial infarction was associated with similarly lower 1-year mortality rates as compared with aspirin therapy." | 3.71 | Nonsteroidal antiinflammatory drugs after acute myocardial infarction. ( Berger, AK; Ko, D; Krumholz, HM; Radford, MJ; Wang, Y, 2002) |
| "Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low." | 3.71 | Underuse of aspirin in a referral population with documented coronary artery disease. ( Califf, RM; Chen, A; DeLong, ER; Hammill, BG; Kramer, JM; LaPointe, NA; McCants, CB; Muhlbaier, LH; Ostbye, T, 2002) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 3.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 3.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "The aim of this study was to investigate the influence of prehospital administration of aspirin and heparin on the initial patency of the infarct-related artery (IRA) in patients with acute myocardial infarction (MI)." | 3.71 | Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. ( Dambrink, JH; de Boer, MJ; Ernst, N; Hoorntje, JC; Nibbering, E; Suryapranata, H; van 't Hof, AW; Verheugt, FW; Zijlstra, F, 2002) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| "The cardioprotective involvement of bradykinin was evaluated using the ACE inhibitor, lisinopril, and the APP inhibitor, 2-mercaptoethanol alone and in combination in rats with experimental myocardial infarction." | 3.71 | Studies on the signal cascade mechanism mediating the cardioprotective actions of bradykinin. ( Akula, A; Kota, MK; Potharaju, S; Veeravalli, KK, 2002) |
| " He received 325 mg of aspirin daily for at least 6 years, suffered an AMI, and was successfully reperfused with alteplase, but after 44 hours developed a large hemorrhagic stroke resulting in paraplegia." | 3.70 | Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. ( Bahr, RD; Dalesandro, MR; Grabletz, LB; Gumbs, CI; Gurbel, PA; Ohman, EM; Serebruany, VL; Shustov, AR; Topol, EJ, 1998) |
| "In the Heparin in Early Patency (HEAP) pilot study, 108 patients with signs and symptoms of acute myocardial infarction < 6 h eligible for primary angioplasty received a single intravenous bolus of 300 U/kg of heparin together with aspirin (160 mg chewed) in the emergency room." | 3.70 | High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. ( Bronzwaer, JG; Liem, A; Marsh, RC; Veen, G; Verheugt, FW; Zijlstra, F, 1998) |
| "The equivalent of the clinically used low (= antiplatelet)-dose aspirin, inhibited collagen deposition in the non-infarcted myocardium in rats with myocardial infarction." | 3.70 | Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. ( Kalkman, EA; Saxena, PR; Schoemaker, RG, 1998) |
| "To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home." | 3.70 | Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998) |
| "Regular aspirin is beneficial after myocardial infarction (MI)." | 3.70 | Aspirin after myocardial infarction: the importance of over-the-counter use. ( Hopper, S; Pierce, M, 1998) |
| "There are conflicting views on how hospital mortality with respect to acute myocardial infarction (AMI) has changed since the introduction of thrombolytics and aspirin." | 3.70 | Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? European Secondary Prevention Study Group. ( Abdelnoor, M; Reikvam, A; Sivertssen, E, 1998) |
| "Aspirin therapy and platelet inhibition reduce the risk for the development of acute myocardial infarction (AMI)." | 3.70 | Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. ( Bahr, RD; Gurbel, PA; Lowry, DR; O'Connor, CM; Serebruany, VL, 1998) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 3.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| "Aspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina." | 3.70 | New antiplatelet agents. ( Ellis, CJ; French, JK; White, HD, 1998) |
| " One hundred two (15%) took aspirin for their chest pain before the arrival of EMS personnel." | 3.70 | Prevalence of aspirin use among patients calling 9-1-1 for chest pain. ( Eisenberg, MS; Jaffy, MB; Meischke, H, 1998) |
| " We reviewed the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers on entry and at discharge in patients enrolled in the MILIS, TIMI 1, 2, 4, 5, 6, and 9B trials with ST-elevation (and depression in MILIS) myocardial infarction for a period approaching 2 decades (August 1978 to September 1995)." | 3.70 | Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Inf ( Antman, EM; Cannon, CP; Davis, VG; Kizer, JR; McCabe, CH; Mueller, HS; Perritt, R; Schweiger, MJ, 1999) |
| " The aim of our study was to assess the effectiveness of intervention, aimed at changing prescribing behaviour of general practitioners (GPs) with regard to early low dose aspirin in patients with suspected acute myocardial infarction (MI)." | 3.70 | Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial infarction. ( Adhikari, AA; de Silva, HJ; Gunatilake, SB; Gunawardhana, P; Seneviratne, SL, 1998) |
| ", age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin." | 3.70 | Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. ( Gibbs, NM; Mahon, BD; Newman, MA; Sheminant, MR; Weightman, WM; Whitford, EG, 1999) |
| "For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death." | 3.70 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999) |
| "In April 1996, we surveyed 539 patients who had suffered a myocardial infarction in 1995 to determine whether the prescription and use of aspirin after myocardial infarction differs by patient age, sex, and type of health insurance." | 3.70 | Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? ( Hill, JW; Roglieri, JL; Warburton, SW, 1998) |
| "Controversy exists about the effect of recent aspirin use on infarct size and the likelihood of Q-wave infarction in patients who sustain myocardial infarction." | 3.70 | Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction. ( Goldberg, RJ; Maclure, M; Mittleman, MA; Mukamal, KJ; Muller, JE; Sherwood, JB, 1999) |
| "The objective of this study was to investigate how the introduction of thrombolytics and aspirin has affected hospital mortality (case fatality) among patients with acute myocardial infarction." | 3.70 | Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: results from a new analytical approach. European Secondary Prevention Study Group. ( Aursnes, I; Reikvam, A, 1999) |
| "SYMPHONY (Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes) was a randomized, double-blind, aspirin-controlled trial with 2 concentration regimens of sibrafiban, an oral peptidomimetic GP IIb/IIIa antagonist, for long-term treatment instead of aspirin in patients after an ACS." | 3.70 | Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) ( Newby, LK, 1999) |
| "We describe the mortality during the subsequent 5 years after development of acute myocardial infarction prior to and after the introduction of a more widespread use of thrombolytic agents and aspirin in the community of Göteborg." | 3.70 | Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin. ( Abrahamsson, P; Dellborg, M; Herlitz, J; Karlson, BW; Karlsson, T; Lindqvist, J, 1999) |
| "(1) Enoxaparin and dalteparin are the only low-molecular-weight heparins so far approved for the treatment of unstable angina and non Q-wave myocardial infarction." | 3.70 | Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin. ( , 1999) |
| "Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease." | 3.70 | Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999) |
| "The purpose of our study was to determine the frequency of aspirin administration among patients with acute myocardial infarction (MI) as dictated by physicians practicing in the United States." | 3.70 | Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. ( Becker, RC; Burns, M; French, W; Gore, JM; Lambrew, C; Rogers, WJ, 2000) |
| "In this study the beneficial effects of NCX 4016 and aspirin were evaluated in vitro in a model of myocardial ischemia-reperfusion of the rabbit and in vivo in a model of acute myocardial infarction of the same animal species." | 3.70 | Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. ( Bernareggi, M; Berti, F; Berti, M; Colonna, VD; Del Soldato, P; Rossoni, G, 2000) |
| "The Hypertension Optimal Treatment study was a large, randomized, multicenter study to determine the answers to two questions: 1) what is the optimal target blood pressure to be sought in the treatment of patients with moderate hypertension? and 2) does low dose aspirin therapy decrease morbidity and mortality in patients with hypertension? After 3." | 3.70 | The Hypertension Optimal Treatment Study: what did it give us? ( Bryg, RJ; Graettinger, WF, 1999) |
| "(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| " Finally, we illustrate the use of these testing procedures with an example of six randomized trials that assess the effects of aspirin on the prevention of death in post-myocardial infarction patients." | 3.70 | Tests for homogeneity of the risk ratio in a series of 2x2 tables. ( Kelly, C; Lui, KJ, 2000) |
| "This study has shown that women with acute myocardial infarction arrived later at the hospital, were less likely to be given aspirin therapy acutely, had longer door-to-needle times, and, on discharge from the hospital, were less likely to be prescribed beta-blockers for secondary prevention." | 3.70 | Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. ( Barakat, K; Ranjadayalan, K; Suliman, A; Timmis, A; Wilkinson, P, 2000) |
| "The objective of this work was to examine the association of hospital and physician volume with use of aspirin and reperfusion therapy in the management of acute myocardial infarction (AMI) in eligible patients." | 3.70 | Association of physician and hospital volume with use of aspirin and reperfusion therapy in acute myocardial infarction. ( Palmer, RH; Soumerai, SB; Willison, DJ, 2000) |
| "(1) Clopidogrel, an antiplatelet drug chemically similar to ticlopidine, is marketed in France for secondary prevention of thrombotic complications in patients with a history of myocardial infarction, ischaemic stroke or peripheral arterial disease." | 3.70 | Clopidogrel: new preparation. An alternative to aspirin. ( , 1999) |
| "Although aspirin is an effective, inexpensive, and safe treatment of acute myocardial infarction, the frequency of use of aspirin in actual medical practice is not known." | 3.69 | Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Kresowik, TF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1995) |
| "Aspirin, today, is an established drug in the regime for the prevention of myocardial infarction, especially in high-risk groups." | 3.69 | The mechanism of action of aspirin--is there anything beyond cyclo-oxygenase? ( Ghooi, RB; Joshi, PS; Thatte, SM, 1995) |
| "The aim of this study was to determine changes in treatment of myocardial infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, to assess the role of aspirin and antiaggregant therapy." | 3.69 | [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Richard, JL; Ruidavets, JB, 1995) |
| "Episodes of anger are capable of triggering the onset of acute myocardial infarction, but aspirin may reduce this risk." | 3.69 | Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. ( Benson, H; Friedman, R; Jacobs, SC; Maclure, M; Mittleman, MA; Muller, JE; Mulry, RP; Sherwood, JB; Tofler, GH, 1995) |
| "The present study was designed to investigate whether the prior use of aspirin could influence the severity of the manifestation of acute coronary artery syndromes, given the well-documented observations that aspirin can prevent myocardial infarction, stroke, and death in cardiovascular disease." | 3.69 | Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. ( Garcia-Dorado, D; Oliveras, J; Sambola, A; Santos, M; Soler Soler, J; Théroux, P; Tornos, P, 1995) |
| "A retrospective analysis without exclusion of 369 consecutive cases of myocardial infarction admitted between January 1988 and March 1992 studied the risk factors, previous medical history and treatment in this period during which medical practice seemed to be standardised with acknowledged benefits of thrombolysis, beta-blockade and aspirin therapy." | 3.69 | [Survival in acute myocardial infarction in a group of 369 patients consecutively admitted between 1988 and 1992. Analysis of risk factors and medical procedure]. ( Attali, P; Bousquet, P; Brandt, CM; Fincker, JL; Jobard, P; Nisand, G; Verdun, A; Wees-Ponchon, A, 1994) |
| " All patients were prescribed a twice-per-day regimen of low dose aspirin to reduce their risk for myocardial infarction." | 3.69 | Major depression and medication adherence in elderly patients with coronary artery disease. ( Carney, RM; Eisen, SA; Freedland, KE; Jaffe, AS; Rich, MW, 1995) |
| " The mechanism of the benefits of aspirin on survival after acute myocardial infarction is unknown." | 3.69 | Aspirin enhances the benefits of late reperfusion on infarct shape. A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction. ( Alhaddad, IA; Brown, EJ; Mir, R; Siddiqui, F; Tkaczevski, L, 1995) |
| "Beta-blockers, nitrates, aspirin and thrombolytic drugs have each separately been shown to reduce mortality in acute myocardial infarction, but the effect of these treatments combined during routine coronary care has not been assessed." | 3.69 | Declining hospital mortality in acute myocardial infarction. ( Dellborg, M; Eriksson, P; Riha, M; Swedberg, K, 1994) |
| " We therefore studied 11 patients who received intravenous streptokinase and oral aspirin for acute myocardial infarction and were subsequently started on the above heparin regimen." | 3.69 | Variable and circadian response to a fixed high-dose (12 500 IU twice daily) subcutaneous heparin regimen after thrombolytic therapy for acute myocardial infarction. ( Campbell, S; Gunn, J; Rowlands, L; Trudgill, NJ; Tsikaderis, D; Violaris, AG, 1994) |
| "To assess changes in trends in medication use in the setting of acute myocardial infarction (AMI) before and after publication of two large clinical trials: the Second International Study of Infarct Survival (ISIS-2) trial that supported the use of aspirin after AMI and the Multi-center Diltiazem Postinfarction Trial that reported no overall benefit from the use of calcium antagonists after AMI." | 3.69 | The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study. ( Col, NF; Goldberg, RJ; Gore, JM; Gurwitz, JH; Hosmer, DW; McLaughlin, TJ; Soumerai, SB; Yarzebski, J, 1996) |
| "To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival." | 3.69 | Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996) |
| " I illustrate the method to estimate the prevalence of aspirin use in a population at risk for myocardial infarction using data from 1,228 cases and an estimate of the relative risk for the effect of aspirin use from a published meta-analysis." | 3.69 | Estimation of exposure prevalence in a population at risk using data from cases and an external estimate of the relative risk. ( Mittleman, MA, 1995) |
| "In March 1994 a study in the British Medical Journal indicated a low rate of administration of aspirin and opiates by general practitioners in cases of suspected myocardial infarction." | 3.69 | The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction. ( Robertson, S; Strachan, DA, 1995) |
| "Low-dose aspirin (acetylsalicylic acid; ASA), inhibiting platelet thromboxane production in favor of endothelium formation of prostaglandins, is successfully used as primary or secondary prophylaxis against myocardial infarction." | 3.69 | Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. ( Kalkman, EA; Saxena, PR; Schoemaker, RG; van Dijk, JP; van Suylen, RJ, 1995) |
| "We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 3.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
| "Nine with myocardial infarction treated with both streptokinase and aspirin, and nine with acute chest pain but without myocardial infarction, who were treated with aspirin only." | 3.69 | Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase. ( Christiansen, I; Frandsen, NJ; McNair, P; Pedersen, F; Winther, K, 1996) |
| "On the basis of results of recent clinical trials, there may be under utilisation of some treatments for acute myocardial infarction including aspirin, thrombolytic therapy, beta-blockers and ACE inhibitors, while calcium antagonists may be over used." | 3.69 | Management of acute myocardial infarction in Auckland. ( French, J; Grant, J; Hart, H; Ingram, C; O'Brien, P; Poole, J; Sharpe, N; Wang, L; White, H; Williams, B; Williams, M; Woo, K, 1996) |
| " Those with acute myocardial infarction, radiolucent defects in coronary arteries suggestive of thrombus, and results that were not optimal after stent implantation were anticoagulated with warfarin and not Included in the study." | 3.69 | Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin. ( Aroney, CN; Bett, JH; McEniery, PT; Sankardas, MA, 1996) |
| " The purpose of the present study was to examine the formation and resolution of left ventricular thrombi during the first month in patients with acute anterior myocardial infarction treated with streptokinase and aspirin." | 3.69 | Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics. ( Eriksson, P; Karp, KH; Mooe, T; Teien, DE, 1995) |
| "A study was carried out on the effect of aspirin 175 mg/day on the plasma levels of 6 keto PGF 1 alpha and TXB2 in patients with acute myocardial infarction and in patients subjected to coronary artery bypass surgery." | 3.69 | Effect of aspirin treatment on plasma levels of keto PGF 1 alpha and thromboxane B2. ( Madan, ZM; Sainani, GS, 1995) |
| "We assessed whether audit might reduce the time taken to give thrombolysis and aspirin in patients with acute myocardial infarction (N = 116)." | 3.69 | Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. ( Currie, P; Gray, SM; Shaw, TR; Starkey, IR, 1994) |
| "With routine thrombolytic and aspirin treatment of anterior myocardial infarction, left ventricular thrombi usually resolve during the first month after hospital discharge." | 3.69 | Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. ( Eriksson, P; Karp, K; Mooe, T; Teien, D, 1996) |
| "Weight-adjusted duteplase infusion, together with oral aspirin and intravenous heparin, in acute myocardial infarction resulted in patency of the infarct-related coronary artery and a safety profile comparable to those reported for the other form of tissue-type plasminogen activator, alteplase." | 3.69 | ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. ( Keltai, M; Malcolm, AD; Walsh, MJ, 1996) |
| "Early low dose aspirin therapy is beneficial in myocardial infarction (MI)." | 3.69 | Use of early aspirin in suspected acute myocardial infarction by General Practitioners in Sri Lanka. ( de Silva, HJ; Gunatilake, SB; Seneviratne, SL, 1997) |
| "To assess the frequency and timing of aspirin administration in emergency department patients with possible myocardial infarction." | 3.69 | Emergency department use of aspirin in patients with possible acute myocardial infarction. ( Cannistra, L; Conte, FJ; Forman, DE; Garber, C; Leavitt, J; Miller, G; Noris, M; Parisi, AF; Saketkhou, BB; Sharma, SC; Tilkemeier, P, 1997) |
| "We present a series of fifteen patients treated with low dose aspirin for secondary prevention of ischemic heart disease who had upper GI bleeding and were admitted to our hospital because of unstable angina or myocardial infarction." | 3.69 | Aspirin for prevention of myocardial infarction. A double-edged sword. ( Amital, H; Bar-Dayan, Y; Levy, Y; Shoenfeld, Y, 1997) |
| "Recurrent chest pain with new ST-segment elevation was observed in 26 of 652 patients (4%) with myocardial infarction in a clinical trial of alteplase (recombinant tissue-type plasminogen activator; 100 mg) and aspirin with or without heparin." | 3.68 | Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. ( Arnout, J; Nÿssen, K; Simoons, ML; van den Brand, M; Verstraete, M, 1993) |
| "Platelet functional parameters (platelet aggregation, blood circulating reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a daily dose of 320 mg in relation to the outcome of the disease: Group 1, stabilization and Group 2, evolving myocardial infarction." | 3.68 | [Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system]. ( Shalaev, SV, 1992) |
| "To evaluate the impact of introducing thrombolytic and aspirin therapy into the management policy of a coronary care unit, with particular reference to its effects on the hospital course of nonselected patients with acute myocardial infarction." | 3.68 | Clinical impact of introducing thrombolytic and aspirin therapy into the management policy of a coronary care unit. ( Ranjadayalan, K; Timmis, AD; Umachandran, V, 1992) |
| "2 mg/100 g body wt orally for 30 days) on myocardial infarction induced by isoproterenol (200 mg/kg body wt, subcutaneously for 2 days) has been studied in rats using activities of creatine kinase, aspartate amino transaminase, alanine amino transaminase and lactate dehydrogenase and levels of lipid peroxides as standard markers." | 3.68 | Effect of aspirin on isoproterenol induced myocardial infarction--a pilot study. ( Devi, CS; Geetha, A; Manjula, TS, 1992) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 3.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| "1) Myocardial infarction (MI): Aspirin (160-300 mg/day) therapy started immediately after the onset, with or without simultaneous coronary arterial thrombolytic therapy, reduces the mortality rate in vascular diseases, including MI, and prevents reinfarction." | 3.68 | [Antiplatelet therapy in cardiac diseases]. ( Aosaki, M; Hosoda, S; Iwade, K; Kimata, S, 1992) |
| "A retrospective review was made of the early management of 50 consecutive patients admitted with an acute myocardial infarction to assess the potential suitability and actual application of thrombolysis, intravenous beta-blockade and aspirin therapy." | 3.68 | Early management of myocardial infraction: a report from the Waikato Hospital, New Zealand. ( Friedlander, DH; Ong, HT, 1991) |
| "Patients with acute myocardial infarction (AMI) admitted between 1986 and 1989 were divided into aspirin (ASA) group (216 cases) and control group (211 cases)." | 3.68 | [A clinical trial of the secondary prevention of reinfarction with low dose aspirin]. ( Chen, Z, 1991) |
| "The difference in the effectiveness of aspirin for the prevention of stroke and secondary prevention of myocardial infarction was discussed on the basis of inhibition of platelet aggregation." | 3.67 | Experimental basis of platelet aggregation inhibition by acetylsalicylic acid. ( Begent, NA; Born, GV; Görög, P, 1984) |
| " The Aspirin Myocardial Infarction Study is used as a case study to illustrate specific strengths and weaknesses of three types of adherence assessment methods, namely, assay of salicylates in the urine, platelet aggregation, and pill count." | 3.67 | Issues in medication adherence assessment in clinical trials of the National Heart, Lung, and Blood Institute. ( Friedman, LM; Mattson, ME, 1984) |
| "Thrombolytic treatment, combined with aspirin, has been shown to reduce mortality by half in patients in hospital with suspected acute myocardial infarction if it is given early after the onset of symptoms." | 3.67 | Role of the general practitioner in managing patients with myocardial infarction: impact of thrombolytic treatment. Report of a British Heart Foundation Working Group. ( , 1989) |
| " As an index of platelet activation, we assessed thromboxane A2 biosynthesis during coronary thrombolysis with intravenous t-PA in patients with acute myocardial infarction." | 3.67 | Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. ( Fitzgerald, DJ; FitzGerald, GA; Kerins, DM; Roy, L, 1989) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 3.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "We determined if the thromboxane A2 antagonist SQ 30,741 can reduce ultimate myocardial infarct size and reperfusion injury." | 3.67 | Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve. ( Grover, GJ; Schumacher, WA, 1989) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "The authors compared the action of small doses of aspirin (100-200 mg/day) and ticlopidine (500 mg/day) in multimodality therapy of acute myocardial infarction." | 3.67 | [Advantages and shortcomings of platelet antiaggregants in the treatment of myocardial infarction]. ( Bochko, II; Kuz'mina, LF; Martynov, IV; Nechaev, DD, 1988) |
| "In a cross-over study 6 healthy male subjects were given for 9 days the acetylsalicylic acid (ASA) preparations used in the Aspirin Myocardial Infarction Study (AMIS), Persantine-Aspirin Reinfarction Study (PARIS) and German-Austrian secondary heart attack prevention trials, exactly according to the original study protocols." | 3.67 | Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction. ( Breddin, HK; Mutschler, E; Rehders, K; Simrock, R; Spahn, H, 1988) |
| "The effects of aspirin on coronary hemodynamics and transcardiac concentrations of thromboxane B2 (the stable metabolite of thromboxane A2) were determined at rest and during pacing-induced myocardial ischemia in 11 patients with coronary disease." | 3.67 | Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia. ( Addonizio, VP; Fisher, CA; Harken, AH; Hirshfeld, JW; Laskey, WK; Martin, JL; Untereker, WJ, 1985) |
| " Surveys were undertaken among participants in the Beta-Blocker Heart Attack Trial (BHAT) and the Aspirin Myocardial Infarction Study (AMIS) to obtain data on these perceptions." | 3.67 | Participation in a clinical trial: the patients' point of view. ( Curb, JD; Mattson, ME; McArdle, R, 1985) |
| "Baseline white blood cell count (WCC) and haematocrit were examined in relation to recurrent coronary events and to all-cause mortality in 2026 persons enrolled in the first Persantin-Aspirin Reinfarction Study (PARIS-1) 2-60 months after myocardial infarction." | 3.67 | White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. ( Barton, BA; Forbes, CD; Krol, WF; Lowe, GD; Machado, SG, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 3.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| "The authors realized a retrospective clinical-statistical study about 121 cases of acute myocardial infarction (AMI), treated in the Department of general medicine with a pharmacological association of Lysine acetylsalicylate--Erythrityl tetranitrate--Papaverine hydrochloride, with the purpose of obtaining a vasodilatation on coronary arteries and a platelet antiaggregation, in the light of the new etiopathogenetic views about the prolonged coronary spasm and the platelet aggregation, in some cases of myocardial infarction with or without thrombosis." | 3.66 | [Clinical and statistical study of 121 cases of acute myocardial infarct from 1976 to 1981 (month of April). Critical review]. ( Carile, L; Di Falco, C; Laquaglia, GA; Marchionni, F; Martone, P, 1982) |
| "To assess whether aspirin reduces the risk of a first myocardial infarction (MI) in young women, we evaluated data from a case-control study among women less than 50 years of age without a prior MI: 48 of 551 cases of MI and 67 of 896 hospital controls had taken aspirin regularly for at least 12 weeks immediately before admission." | 3.66 | Aspirin and myocardial infarction in young women. ( Kaufman, DW; Miettinen, OS; Rosenberg, L; Shapiro, S; Slone, D; Stolley, PD, 1982) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a double-blind placebo-controlled trial to test the effect of aspirin on the survival of 4524 people who had experienced a prior heart attack." | 3.66 | How blind was the patient blind in AMIS? ( Hoover, JJ; Howard, J; Panos, M; Whittemore, AS, 1982) |
| "Four non-steroid anti-inflammatory drugs, sulfinpyrazone, acetylsalicylic acid, sodium salicylate and indomethacin were tested in the acute phase of experimental myocardial infarction in conscious rats." | 3.66 | Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats. ( Koltai, M; Leprán, I; Szekeres, L, 1981) |
| " Pretreatment with carbenicillin, which markedly inhibited platelet aggregation or estradiol cypionate, which induced severe thrombocytopenia, significantly reduced the incidence of sudden death to 9% and zero, respectively." | 3.66 | Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death. ( Franciosa, J; Heckel, R; Johnson, GJ; Leis, LA, 1981) |
| " suggest that the myocardial infarction induced by isoproterenol in the rat may be determined by phenomenons of intracoronaric platelets aggregation." | 3.66 | [The role of the platelets in myocardial infarction induced by isoproterenol in the rat (author's transl)]. ( Cacciapuoti, AA; Genovese, A; Giuffrida, G; Mazza, F; Polverino, W, 1979) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 3.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| " There was no lysozymuria with severe uraemic heart failure, aspirin and paracetamol poisoning, or severe jaundice, nor in two cases of acute glomerulonephritis." | 3.65 | Lysozymuria and acute disorders of renal function. ( De Silva, KL; Harrison, JF; Parker, RW, 1973) |
| "The results of two large independent studies involving a combined total of 776 patients treated in hospital with a discharge diagnosis of acute myocardial infarction and 13,898 patients with other discharge diagnoses showed a negative association between regular aspirin intake and non-fatal myocardial infarction." | 3.65 | Regular aspirin intake and acute myocardial infarction. ( , 1974) |
| " The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke." | 3.30 | Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra ( Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023) |
| "Stroke and bleeding are complications after transcatheter aortic valve replacement (TAVR)." | 3.30 | Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis. ( Brouwer, J; Nijenhuis, VJ; Ten Berg, JM; van Bergeijk, KH; van den Heuvel, AFM; van der Werf, HW; van Ginkel, DJ; Voors, AA; Wykrzykowska, JJ, 2023) |
| " The hazard of nonadherence to the assigned aspirin dosage was 46% higher in noninternet participants than internet participants." | 3.30 | Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. ( Benziger, CP; Effron, MB; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jones, WS; Kripalani, S; Mulder, H; Muñoz, D; Polonsky, TS; Robertson, HR; Rothman, RL; Sharlow, AG; Shen, R; VanWormer, JJ; Weissler, EH; Whittle, J; Wruck, L, 2023) |
| "Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events." | 3.01 | Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. ( Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV, 2023) |
| "Cardiac death (RR 0." | 3.01 | Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. ( Azhar, AZ; Baibhav, B; Cheung, JW; Rao, M; Tan, BE; Thakkar, S; Wong, PY, 2023) |
| "Aspirin was not associated with significant bleeding excess." | 3.01 | Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis. ( Dagenais, GR; Gao, P; Joseph, P; Malekzadeh, R; Pais, P; Roshandel, G; Yusuf, S, 2023) |
| "Aspirin users were at significantly lower risk of all-cause mortality compared to nonusers (HR = 0." | 3.01 | Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. ( Bond, M; Conant, A; Desai, N; Rahman, M; Wilson, B, 2021) |
| "Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question." | 2.94 | Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. ( Ahmad, FS; Alvarado, G; Benziger, CP; Berdan, LG; Bradley, SM; Daugherty, SE; Effron, MB; Farrehi, P; Faulkner, M; Fintel, DJ; Fonarow, GC; Ford, DE; Geary, C; Girotra, S; Goldberg, YH; Gupta, K; Hammill, BG; Harrington, RA; Haynes, K; Hernandez, AF; Jain, SK; Jones, WS; Kraschnewski, J; Kripalani, S; Lampert, BC; Marquis-Gravel, G; McClay, JC; McTigue, KM; Merritt, JG; Metkus, T; Muñoz, D; Nallamothu, BK; Nauman, E; Pencina, MJ; Re, RN; Robertson, HR; Roe, MT; Roger, VL; Rothman, R; Seifein, H; Shah, RC; VanWormer, JL; Whittle, J; Zhou, L, 2020) |
| "We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites." | 2.90 | Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. ( Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J, 2019) |
| "Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup." | 2.90 | Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "Major bleeding was the primary safety end point." | 2.90 | Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019) |
| " In terms of cardiovascular and cerebrovascular adverse events, other 3 interventions were higher than L-DAPT (Std-DAPT [OR = 1." | 2.82 | Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. ( Feng, T; Li, D; Luo, L; Ran, J; Tang, K; Wang, D; Wang, S; Wu, J; Xu, L; Yang, X; Zhang, L; Zhao, D, 2022) |
| "Myocardial infarction was assessed using the third universal definition." | 2.82 | Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. ( Beattie, WS; Carroll, J; Grewal, D; Harsha, P; Karkouti, K; Ragoonanan, T; Starzyk, Ł; Syed, S; Travis, G; Wąsowicz, M; Wijeysundera, DN, 2016) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) is a randomized, double-blind, event-driven trial and will include an estimated 13,600 participants randomized in 33 countries worldwide to collect 844 primary events." | 2.80 | Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wong, LK, 2015) |
| " We used enrollment data from the Dual Antiplatelet Therapy Study, a randomized trial designed to compare 12 versus 30 months of dual antiplatelet therapy after PCI, to quantify the variation in ASA dosing after PCI in the US subjects and assess the extent to which dose variability was attributable to patient characteristics." | 2.79 | Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). ( Cutlip, DE; Kereiakes, D; Massaro, J; Matteau, A; Mauri, L; Normand, SL; Orav, EJ; Steg, PG; Yeh, RW, 2014) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 2.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation." | 2.79 | Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014) |
| "Aspirin was prescribed indefinitely, and a thienopyridine for at least six months." | 2.78 | Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. ( Claessen, BE; Dangas, GD; Mehran, R; Stone, GW; Xu, K, 2013) |
| "Serious bleeding was associated with a significantly increased adjusted hazard ratio of 5." | 2.76 | Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- ( Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD, 2011) |
| "Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels." | 2.76 | Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. ( Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011) |
| "Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receive heparin." | 2.75 | Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. ( Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K, 2010) |
| " Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| "The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data." | 2.74 | Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. ( Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG, 2009) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "Myocardial infarction was more frequent in the early invasive strategy group (106 [18." | 2.73 | Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. ( Cornel, JH; de Winter, RJ; Hirsch, A; Tijssen, JG; Verheugt, FW; Windhausen, F, 2007) |
| "Aspirin resistance was defined as a mean aggregation of > or =70% with 10 microM ADP and > or =20% with 0." | 2.71 | A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. ( Gum, PA; Kottke-Marchant, K; Topol, EJ; Welsh, PA; White, J, 2003) |
| " It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors." | 2.71 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004) |
| "Death and myocardial infarction were recorded during 30 days of follow-up." | 2.71 | N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. ( Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD, 2004) |
| "Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)." | 2.71 | [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. ( Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004) |
| "Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high." | 2.71 | Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. ( Chen, YP; Chen, ZM; Collins, R; Jiang, LX; Liu, LS; Pan, HC; Peto, R; Xie, JX, 2005) |
| "Fibrinogen was significantly lower after rt-PA versus TNK-tPA (3 h: 163 +/- 27 versus 380 +/- 54 mg/dl; p < 0." | 2.70 | Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. ( Ehlers, R; Helber, U; Hoffmeister, HM; Kazmaier, S; Letsch, R; Szabo, S; Walter, T, 2002) |
| "Intravenous ASA in a dosage of 100 mg did not completely prevent TXA(2) production in AMI patients treated with streptokinase." | 2.70 | Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. ( Husted, SE; Jensen, HK; Kristensen, SD; Nielsen, HK; Vissinger, H; Ziegler, BK, 2001) |
| "Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed." | 2.69 | A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. ( , 1998) |
| "We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial." | 2.69 | Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. ( Cavalli, A; Negri, E; Santoro, L; Volpi, A, 1998) |
| "As Aspirin (ASA) has proven efficacy in preventing patients with CAD from complications related to cardiovascular diseases, most patients scheduled for CABG are treated with ASA therapy." | 2.69 | Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin. ( Beckmann, H; Dauben, HP; Elert, O; Gams, E; Keith, PR; Klein, M; Mayer, G; Schulte, HD, 1998) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| " In this study, the bioavailability of aspirin was compared in plain aspirin tablets, chewed tablets, effervescent tablets and Enteric-coated aspirin tablets." | 2.69 | A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. ( Sagar, KA; Smyth, MR, 1999) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| "In dalteparin-treated patients, delta vWf was elevated (+48 +/- 8%) and did not differ from the unfractionated heparin group (NS)." | 2.69 | Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. ( Ankri, A; Choussat, R; Collet, JP; Drobinski, G; Lison, L; Montalescot, G; Perlemuter, K; Philippe, F; Thomas, D; Vicaut, E, 2000) |
| " Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers." | 2.69 | Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study. ( Altmann, E; Cuffie-Jackson, CA; Molhoek, PG; Neuhaus, KL; Ronner, E; Simoons, ML; van der Wieken, LR; van Kesteren, HA; Zijnen, P, 2000) |
| " A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis." | 2.69 | A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000) |
| "Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs." | 2.68 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995) |
| "Aspirin was the most widely prescribed drug (79." | 2.68 | [Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study]. ( Boissel, JP; Gillet, J; Leizorovicz, A; Némoz, C, 1995) |
| "In addition, 6 transient ischemic attacks and 3 myocardial infarctions could be directly linked to CEA, for a total CEA event rate of 2." | 2.68 | An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. ( Broderick, JP; Cohen, SN; Dempsey, RJ; Ernst, CB; Hosking, JD; Moore, WS; Robertson, JT; Toole, JF; Young, B, 1996) |
| "Hypertension is associated with an increased risk of myocardial infarction, and borderline isolated systolic hypertension predicts a possible but more modest increase in risk." | 2.68 | Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. ( Ajani, U; Berger, K; Glynn, RJ; Hennekens, CH; Manson, JE; O'Donnell, CJ; Ridker, PM, 1997) |
| "Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease." | 2.68 | Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997) |
| " Blood samples were taken at frequent intervals for 24 hours after single dosing in 12 healthy volunteers and Tmax, Cmax and t1/2 measured." | 2.68 | The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. ( Clifford, JM; Hoare, RC; Muir, N; Nichols, JD; Stillings, MR, 1997) |
| "Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59." | 2.68 | [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997) |
| "Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients." | 2.67 | Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993) |
| "Three dosage regimens of a new recombinant glycosylated prourokinase (A-74187) were evaluated by measuring coronary artery patency at 90 min in patients with acute myocardial infarction." | 2.67 | New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. ( Anderson, JL; Hartmann, JR; Reddy, PS; Sasahara, AA; Sobolski, JC; Weaver, WD, 1994) |
| "Aspirin was effective only in complex and less severe lesions (< 90% stenosis)." | 2.67 | Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. ( de Swart, H; Lie, KI; Meyer, A; Michels, HR; van der Pol, JM; van Eenige, MJ; Veen, G; Verheugt, FW; Werter, CJ, 1993) |
| " Unfortunately, dosing strategies and monitoring have not kept pace with the rest of the field." | 2.67 | The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. ( Becker, RC; Gore, JM, 1993) |
| "In conclusion, LV thrombosis is frequent after thrombolytic therapy for AAMI, and impaired LV wall motion represents an independent predisposing factor." | 2.67 | Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy. ( Dale, J; Hegrenaes, L; Kontny, F; Lem, P; Morstøl, T; Søberg, T, 1993) |
| "Q-wave myocardial infarctions were increased in the aprotinin subgroups (17." | 2.67 | Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. ( Cosgrove, DM; Golding, LA; Heric, B; Loop, FD; Lytle, BW; McCarthy, PM; Novoa, R; Stewart, RW; Taylor, PC, 1992) |
| "Heparin is an effective, widely used treatment for unstable angina." | 2.67 | Reactivation of unstable angina after the discontinuation of heparin. ( Juneau, M; Lam, J; McCans, J; Théroux, P; Waters, D, 1992) |
| " At 24 hours, 202 patients were randomized to continue intravenous heparin therapy (n = 99) in full dosage or to discontinue heparin therapy and begin an oral antiplatelet regimen of aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)." | 2.67 | A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. ( Aylward, PE; Federman, J; Giles, RW; Harris, PJ; Hodge, RL; Nelson, GI; Thompson, PL; Thomson, A; Tonkin, AM; Walsh, WF, 1991) |
| "Aspirin intake was associated with a mean reduction in the incidence of infarction of 44." | 2.67 | Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. ( Buring, JE; Hennekens, CH; Manson, JE; Muller, JE; Ridker, PM, 1990) |
| "LV thrombosis was detected by echocardiography in 30 (33%) of the 92 evaluable patients (15 patients given ASA and 15 given placebo)." | 2.66 | Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction. ( den Hollander, W; Galema, TW; Küpper, AJ; Peels, CH; Roos, JP; Verheugt, FW, 1989) |
| "The aspirin component was terminated earlier than scheduled, and the preliminary findings were published." | 2.66 | Final report on the aspirin component of the ongoing Physicians' Health Study. ( , 1989) |
| "We conclude that patients with unstable angina pectoris have a similar outcome after two years whether they receive medical therapy alone or coronary bypass surgery plus medical therapy." | 2.66 | Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. ( Deupree, RH; Luchi, RJ; Scott, SM, 1987) |
| "Aspirin was associated with fewer non-fatal reinfarctions (3." | 2.66 | Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study. ( , 1987) |
| " A statistically significant superiority of the 30 mg aspirin dosage compared with the 1000 mg dosage was found in patients aged over 50 years, in male patients, in patients with angina pectoris in their anamnesis, in patients with ST-depression of greater than 0." | 2.66 | Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus. ( Förster, W; Hoffmann, W, 1988) |
| "The aspirin effect was the same across all risk-factor groups." | 2.66 | Controlled trial of aspirin in cerebral ischemia: an addendum. ( Fields, WS; Gary, HE; Lemak, NA, 1986) |
| "Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality." | 2.66 | Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. ( Berge, KG; Canner, PL; Friedewald, W; Friedman, L; Prineas, RJ; Stamler, J; Wenger, NK, 1986) |
| "Many such trials in coronary heart disease have terminated inconclusively or in controversy." | 2.65 | Are clinical trials in coronary heart disease oversold or undersold? ( Detre, KM; Mantel, N; Ware, J, 1981) |
| " Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding." | 2.58 | Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. ( Huang, J; Liu, L; Tang, X; Zhang, X, 2018) |
| " There were differences in the effect of aspirin by dosage and treatment duration on overall stroke outcomes (P for interaction for all < 0." | 2.55 | Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. ( Khunti, K; Kunutsor, SK; Seidu, S, 2017) |
| "Aspirin has been shown to lower the incidence and the mortality of vascular disease and cancer but its wider adoption appears to be seriously impeded by concerns about gastrointestinal (GI) bleeding." | 2.53 | Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. ( Chia, JW; Dolwani, S; Elwood, PC; Galante, J; Graziano, JM; Kelson, M; Lanas, A; Longley, M; Morgan, G; Morris, D; Phillips, CJ; Pickering, J; Roberts, SE; Soon, SS; Steward, W; Weightman, AL, 2016) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| " The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U." | 2.48 | Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012) |
| "Sudden cardiac death is a leading cause of death in Europe." | 2.46 | [Thrombolysis during cardio-pulmonary resuscitation]. ( Böttiger, BW; Padosch, SA; Spöhr, F; Teschendorf, P; Wetsch, WA, 2010) |
| "Systolic heart failure is a common syndrome whose incidence is expected to increase." | 2.45 | Systolic heart failure: a prothrombotic state. ( Büller, HR; de Peuter, OR; Kamphuisen, PW; Kok, WE; Torp-Pedersen, C, 2009) |
| "Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness." | 2.44 | Acute and long-term antiplatelet therapy. ( Goudevenos, JA; Mikhailidis, DP; Papathanasiou, AI; Tselepis, AD, 2008) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Aspirin has long been established as a useful analgesic and antipyretic." | 2.44 | The discovery of aspirin's antithrombotic effects. ( Hoffhines, A; Miner, J, 2007) |
| "Aspirin's ability to suppress platelet function varies widely among individuals and lesser suppression of platelet function is associated with increased risk of myocardial infarction, stroke and cardiovascular death." | 2.44 | Pharmacogenomics of platelet responsiveness to aspirin. ( Becker, DM; Becker, LC; Faraday, N, 2007) |
| " In secondary prevention, in a wide range of patients who have survived a prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, as well as other high-risk conditions, long-term use of aspirin confers statistically significant and clinically important reductions in MI, stroke and CVD death." | 2.44 | The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. ( Hennekens, CH; Schneider, WR, 2008) |
| " If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used." | 2.43 | [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005) |
| "Fibrinolysis is the reference treatment for most myocardial infarctions with ST-segment elevation; alternatives are angioplasty, with or without stent." | 2.43 | New anticoagulants in ischemic heart disease. ( Verheugt, FW, 2005) |
| "Aspirin will continue to be an important therapeutic agent and to generate considerable interest among the research community for the foreseeable future." | 2.43 | The established and emerging uses of aspirin. ( Morgan, G, 2006) |
| "Elderly patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction should be hospitalized." | 2.42 | Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients. ( Aronow, WS, 2003) |
| "Aspirin has been studied and used most extensively." | 2.42 | Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003) |
| " The Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent and Myocardial Damage (ESTEEM) trial, a placebo-controlled, double-blind study of post-MI patients, evaluated 4 dosing regimens of ximelagatran versus placebo in the initial months following an ACS and found an encouraging reduction in the end points of death, MI, and stroke with the use of an oral direct thrombin inhibitor." | 2.42 | Reducing cardiac events after acute coronary syndromes. ( Granger, CB; Weaver, WD, 2004) |
| "Aspirin reduced all-cause mortality by 18%." | 2.41 | Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. ( Graham, DY; Weisman, SM, 2002) |
| "Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality." | 2.41 | Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002) |
| "Myocardial infarction is dangerous." | 2.41 | Tackling myocardial infarction. ( , 2000) |
| "Kawasaki disease is the leading cause of acquired heart disease in childhood." | 2.41 | Long-term cardiac sequelae of Kawasaki disease. ( Fulton, DR; Newburger, JW, 2000) |
| "Myocardial infarction is the leading cause of death among persons with diabetes." | 2.41 | Managing myocardial infarction in the diabetic patient. ( Paty, BW, 2000) |
| "Aspirin has an essential place formally demonstrated in ISIS 2." | 2.41 | [Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents]. ( Coste, P; Jaïs, C; Labèque, JN; Lafitte, S; Perron, JM; Roudaut, R; Zabsonré, P, 2001) |
| "The National Heart Attack Alert Program established a Working Group to review the utility of critical pathways on quality of care and outcomes for patients with ACS." | 2.41 | Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. ( Bahr, R; Boden, WE; Cannon, CP; Christenson, R; Eagle, K; Gibler, WB; Hand, MH; Lambrew, CT; Lee, TH; MacLeod, B; Ornato, JP; Selker, HP; Steele, P; Zalenski, RJ, 2002) |
| "Aspirin treatment again has similar benefits to those in non-diabetic subjects, and should be administered at presentation." | 2.40 | Managing the diabetic patient with acute myocardial infarction. ( Yudkin, JS, 1998) |
| "Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid)." | 2.40 | Triflusal. ( Goa, KL; McNeely, W, 1998) |
| " Because of the need for frequent anticoagulation monitoring and dosage adjustment, the use of heparin is limited to short-term treatment during the acute in-hospital phase." | 2.40 | New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. ( Cohen, M, 1998) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 2.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| "and aspirin 325 mg o." | 2.40 | Antiplatelet drugs in secondary prevention after acute myocardial infarction. ( Thizon-de-Gaulle, I, 1998) |
| "The aim of the acute treatment of myocardial infarction is to restore, as promptly as possible, blood flow in the culprit vessel." | 2.40 | Advances in antithrombotic therapy of acute myocardial infarction. ( Comeglio, M; Falai, M; Gensini, GF, 1999) |
| "Aspirin was first discovered to have antiplatelet properties 30 years ago and since then many randomised clinical trials have sought to determine whether it (or other antiplatelet agents) can protect patients from heart attack or stroke." | 2.39 | Aspirin to prevent heart attack or stroke. ( , 1994) |
| "Treatment with aspirin leads to substantial and significant reductions in rates of mortality, reinfarction and stroke in patients with acute myocardial infarction, and the benefits are additive with those of thrombolytic therapy." | 2.39 | Antithrombotic therapy for acute myocardial infarction. ( Hebert, PR; Hennekens, CH; O'Donnell, CJ; Ridker, PM, 1995) |
| "Myocardial infarction is rare in pregnancy." | 2.39 | Myocardial infarction in a parturient. A case report with emphasis on medication and management. ( Haring, P; Hietakorpi, S; Koski, E; Nuutinen, LS; Purhonen, S; Söderlin, MK, 1994) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 2.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| "Myocardial infarction is common among the elderly." | 2.39 | Myocardial infarction. Considerations for geriatric patients. ( Sinclair, D, 1994) |
| "Thromboxane A2 is a potent stimulator of platelet aggregation and vasoconstriction and synthesis may be completely inhibited by a single oral dose of 150 mg acetylsalicylic acid or an intravenous dose of 100 mg." | 2.39 | Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction). ( Husted, SE; Vissinger, H; Winther, K, 1994) |
| " A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)." | 2.39 | [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents]. ( Aumont, MC; Seknadji, P, 1996) |
| "The myriad deleterious effects of hyperlipidemia that promote a prothrombotic and antifibrinolytic vascular milieu serve to elucidate the importance of lipid reduction as an additional secondary prevention measure." | 2.38 | Atherothrombotic insights into secondary prevention after acute myocardial infarction. ( Loscalzo, J; Rabbani, LE, 1993) |
| "All trials comparing thrombolytic treatment in acute myocardial infarction indicate that either streptokinase, APSAC, or rtPA reduce mortality significantly." | 2.38 | [Myocardial infarct: acute intervention]. ( Bode, C; Katus, HA; Scheffold, T, 1993) |
| " The bioavailability of plain ASA after oral administration amounts to 40-50% at therapeutic doses." | 2.38 | [Clinical pharmacology of acetylsalicylic acid]. ( Schröder, H; Schrör, K, 1992) |
| "Total prevention of mural thrombus in deeply injured arteries is impossible with aspirin or conventional antithrombotic therapy, which can reduce occlusive thrombus." | 2.38 | Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. ( Badimon, JJ; Badimon, L; Chesebro, JH; Roche, PC; Webster, MW; Zoldhelyi, P, 1992) |
| " There was disagreement concerning the dosage of heparin and the exact use of betablockers, aspirin, warfarin, ACE-inhibitors, magnesium and antiarrhythmics." | 2.38 | [Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy]. ( Amlie, JP; Aursnes, I; Osnes, JB; Platou, ES; Smiseth, OA, 1990) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 2.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| "In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 2.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
| "Acute myocardial infarction is most commonly initiated by fissuring of an atheromatous plaque." | 2.38 | Coronary thrombosis: pathogenesis and prevention. ( Born, GV, 1990) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 2.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| " The dosage of ASA in the majority of works has been about 1,000 mg daily while isolated investigations have shown good effect from doses as low as 60 mg daily." | 2.38 | [Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. ( Faergeman, O; Fasting, H; Husted, SE; Krusell, LR; Nielsen, HK, 1989) |
| "0 g of aspirin together with the long-lasting inhibition of TxA2, suggests that in the prophylaxis of thromboembolic events an intermittent dosage of 0." | 2.37 | Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans. ( Vesterqvist, O, 1988) |
| " The 100 mg dosage was predominant in patients with ischemic heart disease with (64%) and without (64%) angina, as well as those with myocardial infarction (61." | 1.91 | Adherence to European guidelines for the use of aspirin in primary health care. ( Corte-Real, S; Dantas, A; Ferreira Moita, C; Marau, G, 2023) |
| "Aspirin was administered to 180 (93." | 1.91 | Acute coronary syndrome in very elderly patients-a real-world experience. ( Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A, 2023) |
| " Large trials assessing use in the primary prevention setting and optimal dosing regimens were studied in the late 1990s and early 2000s." | 1.91 | Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention. ( Bortfeld, KS; Brown, MT; Sperling, LS; Wenger, NK, 2023) |
| "AMI patients with dementia have a higher mortality rate." | 1.91 | Impact of dementia and drug compliance on patients with acute myocardial infarction. ( Chae, IH; Jheon, KH; Kang, SH; Kim, SH; Lee, SY; Lee, W; Myung, W; Suh, JW; Yoon, CH; Youn, TJ, 2023) |
| "Predisposing conditions included fibromuscular dysplasia in 42." | 1.72 | Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. ( Alfadhel, M; Aymong, E; Bishop, H; Brass, N; Chaudhary, P; Ganesh, SK; Graham, J; Grewal, T; Har, B; Humphries, K; Ibrahim, R; Inohara, T; Ko, DT; Lavi, S; Lavoie, A; Madan, M; Mancini, GJ; Martucci, G; Matteau, A; McAlister, C; McGrath, BM; Minhas, K; Parolis, JA; Pearce, C; Renner, S; Samuel, R; Saw, J; Sheth, T; So, D; Starovoytov, A; Vijayaraghavan, R; Welsh, RC, 2022) |
| "Coronary angiogram however also revealed coronary aneurysms of all coronaries, identifying an episode of unexplained fever and vasculitis 4 years prior as Morbus Kawasaki." | 1.62 | [Myocardial Infarction and resuscitation of an adolescent: consequences of an unexplained disease]. ( de Jong, JJD; Slenter, RHJ; van Lierop, P; Wagenaar, LJ, 2021) |
| "We compared 482 STEMI patients who received aspirin, ticagrelor, and UFH loading in a non-PCI capable spoke hospital before transfer (NPHT) versus 227 prehospital triage setting (PTS) STEMI patients who received in-ambulance aspirin, followed by ticagrelor and UFH in the hub catheterization laboratory." | 1.62 | The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention. ( Bérubé, S; Couture, ÉL; d'Entremont, MA; Desgagnés, N; Huynh, T; Karzon, A; Laferrière, C; Lepage, S; Nguyen, M; Verreault-Julien, L, 2021) |
| "After thrombus aspiration and intracoronary administration of 0." | 1.62 | Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis. ( Chen, Y; Wang, B; Wang, W; Wei, S, 2021) |
| " Patients received alternative drug dosing or antiplatelet agents other than clopidogrel only if this was prescribed for another diagnosis or they had a preexisting contraindication." | 1.62 | Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. ( Hess, NR; Kilic, A; Sultan, I; Thoma, F; Wang, Y, 2021) |
| "Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease." | 1.56 | Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. ( Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020) |
| "Aspirin was prescribed in 99." | 1.56 | Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. ( Akboğa, M; Aktaş, I; Aladağ, N; Arın, CB; Asoğlu, R; Deveci, OS; Doğan, A; Dural, M; Erol, MK; Güneş, Y; Ince, O; Kayıkçıoğlu, M; Kılıçkap, M; Kurt, IH; Örnek, E; Özkan, E; Şen, T; Sinan, ÜY; Somuncu, MU; Tüner, H; Yenerçağ, M; Zeybey, U, 2020) |
| "After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events." | 1.56 | 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y ( Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J, 2020) |
| " We took into account several criteria like statin dosage (low versus high intensity) and presence of contraindication for consideration of optimal therapy." | 1.56 | Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. ( Bruggmann, C; Fesselet, R; Gex-Fabry, M; Iglesias, JF; Sadeghipour, F; Vogt, P; Voirol, P, 2020) |
| "Patients who are at increased risk for MI can be maintained on DAPT up to the time of CABG because surgery is safe when patients are offered PPT." | 1.51 | Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe? ( Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G, 2019) |
| "Aspirin resistance was evaluated in aspirin-treated patients from the outpatient department." | 1.48 | PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. ( Chen, HY; Chou, P, 2018) |
| "Previous studies have found that Panax quinquefolius saponins (PQS) combined with dual antiplatelet therapy (DAPT) of aspirin and clopidogrel enhances antithrombotic effects while reducing gastric mucosal injury induced by DAPT." | 1.48 | Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction. ( Kou, N; Miao, Y; Qu, H; Shi, DZ; Wang, MM; Xue, M; Yang, B; Yang, L; Zang, MX, 2018) |
| "Although depressive disorders have been associated with increased risk of worse outcomes with cardiovascular diseases (CVDs), its relation with access to and quality of cardiovascular care is not well studied." | 1.48 | Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. ( Butler, J; Lacey, M; Parikh, PB; Shroyer, AL; Srivastava, P, 2018) |
| "The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data." | 1.48 | Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. ( Connell, O; Douglas, I; Müllerová, H; Pearce, N; Quint, JK; Rothnie, KJ; Smeeth, L, 2018) |
| " Administration of ASA increased the infarct severity; however, concomitant dosing with NTG somewhat attenuated this effect." | 1.48 | Nitroglycerin application and coronary arteriogenesis. ( Bramlage, P; Buschmann, IR; Dawid, R; Dülsner, A; Gatzke, N; Gorath, M; Güc, N; Hillmeister, P; Pagonas, N; Smith, KH, 2018) |
| "Aspirin use was updated at each clinic visit and considered as a time-varying covariate." | 1.46 | Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. ( Bavry, AA; Bhatt, DL; Elbez, Y; Elgendy, IY; Mahmoud, AN; Sorbets, E; Steg, PG, 2017) |
| "Strokes were not observed in compliant patients who responded to antiplatelet agents." | 1.46 | Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses. ( Bermúdez, D; Galera, Á; Garcia Rinaldi, R; Quinones, J; Quinones, S; Rodriguez-Acosta, J, 2017) |
| "Age above 55 years was associated with recurrence of ACS in C2238/ANP-minor allele carriers (hazard ratio 1." | 1.43 | T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. ( Abbolito, S; Battistoni, A; Bianchi, F; Burocchi, S; Cangianiello, S; Caprinozzi, M; Comito, F; Cotugno, M; De Giusti, M; Di Castro, S; Dito, E; Farcomeni, A; Greco, ES; Marchitti, S; Pagliaro, B; Pierelli, G; Rubattu, S; Sciarretta, S; Stanzione, R; Volpe, M, 2016) |
| "Type A acute aortic dissection is a life-threatening vascular emergency because of its high morbidity and mortality." | 1.43 | Mean platelet volume to platelet count ratio predicts in-hospital complications and long-term mortality in type A acute aortic dissection. ( Chen, QJ; Gao, XM; Li, DZ; Ma, YT; Sun, HP; Yang, YN; Zeng, R; Zeng, Z, 2016) |
| " A dose-response relationship was observed between longer D2B and D2N times and shorter life expectancy after AMI." | 1.43 | Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries. ( Bucholz, EM; Butala, NM; Krumholz, HM; Normand, ST; Wang, Y, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "In isoproterenol-treated rats, Zn(ASA)2 treatment normalized significantly impaired left-ventricular contractility index (Emax 2." | 1.42 | Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction. ( Atmanli, A; Barnucz, E; Hegedűs, P; Hirschberg, K; Karck, M; Korkmaz, S; Li, S; Loganathan, S; Radovits, T; Szabó, G; Yasui, H; Yoshikawa, Y, 2015) |
| "Major bleeding was a significant correlate of DAPT ANA within 6 months." | 1.42 | Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015) |
| " With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group." | 1.42 | Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. ( Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015) |
| "CABG had similar rates of cardiac death compared with PCI group (HR=0." | 1.42 | Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015) |
| "Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality." | 1.42 | Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015) |
| "Aspirin fills were more common in younger veterans, Blacks, Hispanics, males, hypertensive veterans, mentally ill patients, those with no co-pay and those prescribed antiplatelets/anticoagulants in addition to aspirin postoperatively." | 1.42 | Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina. ( Copeland, LA; MacCarthy, DJ; McNeal, CJ; Mortensen, EM; Pugh, MJ; Rivera, CM, 2015) |
| "Smoking, alcohol abuse, and obesity were more common in patients with ST elevation myocardial infarction (STEMI) (P < 0." | 1.42 | Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study. ( Bandara, R; De Silva, C; Galgomuwa, MP; Medagama, A, 2015) |
| "Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years." | 1.40 | Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus. ( Bergström, L; Björklund, F; Jakobsson, S; Jernberg, T; Mooe, T; Söderström, L, 2014) |
| "Aspirin (150 mg/d) was administered every morning since 12 hours after CABG." | 1.40 | Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation. ( Mazur, P; Plicner, D; Sadowski, J; Stąpor, R; Undas, A; Ziętkiewicz, M, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 1.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "Cangrelor is an intravenous ATP analog that directly, selectively and reversibly inhibits P2Y12 receptors on platelets." | 1.40 | Cangrelor for treatment during percutaneous coronary intervention. ( Dobesh, PP; Oestreich, JH, 2014) |
| "adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability." | 1.40 | Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. ( George, MG; Gillespie, C; Jamal, A; Ritchey, MD; Wall, HK, 2014) |
| " Medication use was compared between transfer and direct-arrival patients to determine if these therapies were delayed or dosed in excess." | 1.40 | The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. ( Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014) |
| "Routine follow-up has revealed no recurrence of symptoms." | 1.40 | The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014) |
| "Acute myocardial infarction is rare in pregnancy; however, the emerging trend towards advanced maternal age and the rising prevalence of obesity and diabetes suggest that more cases of myocardial infarction are likely to be encountered in pregnancy." | 1.39 | Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy'). ( Dutton, P; Okunoye, GO, 2013) |
| "Aspirin twice daily was given in 28% of patients, clopidogrel double dose in 26%, and prasugrel in 31%." | 1.39 | Monitoring persistent platelet reactivity in patients with unprotected left main stenting. ( Bal Dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Kchaou, I; Logeart, D; Magkoutis, N; Manzo Silberman, S; Sideris, G; Voicu, S, 2013) |
| "Most of acute coronary thrombosis in KD occurred in LAD." | 1.39 | [Six Kawasaki disease patients with acute coronary artery thrombosis]. ( Gong, FQ; Liang, YG; Luo, JP; Qi, YQ; Wang, W; Zhou, SL, 2013) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 1.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| "Medical records of 659 patients treated for myocardial infarction at the 1st Department of Internal Medicine-Cardiology of Borsod-Abaúj-Zemplén County Hospital and University Hospital were analyzed." | 1.39 | Pharmaceutical care for patients with acute myocardial infarction in Hungary. ( Argay, M; Dormaeva, I; Hankó, B; Koós, I; Meskó, A; Takács, I; Zelkó, R, 2013) |
| "Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer." | 1.38 | Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. ( Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012) |
| "Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6." | 1.38 | The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012) |
| "Aspirin insensitivity was more common in type 2 diabetes (15% vs." | 1.38 | Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. ( Agha, A; Carmody, D; Foley, DP; Kavanagh, GF; Kenny, D; Mylotte, D; O'Reilly, M; Peace, AJ; Smith, D; Tedesco, AF; Thompson, CJ, 2012) |
| "Stent thrombosis is not unusual in a post-operative setting." | 1.38 | Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. ( Agnani, S; Akkus, NI; Rajpal, S, 2012) |
| "Eptifibatide was stopped for induction of labor." | 1.38 | Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. ( Bauer, ME; Bauer, ST; Mhyre, JM; Rabbani, AB, 2012) |
| "Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding." | 1.38 | Stroke and bleeding in atrial fibrillation with chronic kidney disease. ( Gislason, GH; Hommel, K; Kamper, AL; Køber, L; Lane, DA; Lindhardsen, J; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2012) |
| "Left ventricular thrombus (LVT) and rupture are important mechanical complications following myocardial infarction (MI) and are believed to be due to unrelated mechanisms." | 1.37 | Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. ( Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L, 2011) |
| "Aspirin (ASA) has been shown to reduce postoperative coronary artery bypass grafting (CABG) mortality and ischemic events; however, the timing of chronic ASA discontinuation before surgery is controversial because of concern about postoperative bleeding." | 1.37 | Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. ( Blackstone, E; Cho, L; Jacob, M; Smedira, N; Williams, S, 2011) |
| "Secondary outcomes included stroke, congestive heart failure, and myocardial infarction." | 1.37 | Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. ( Albert, CM; Buring, JE; Chae, CU; Conen, D; Everett, BM; Glynn, RJ; Tedrow, UB, 2011) |
| "Incidence of postoperative hemorrhage (early and delayed) was not significant (P = ." | 1.37 | Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. ( Bariol, SV; Brooks, AJ; Drummond, M; Lau, HM; McDonald, C; Patel, MI; Raj, MD; Wang, AC; Woo, HH, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "Sex disparities in the diagnosis and treatment of chest pain or suspected angina have been demonstrated in multiple clinical settings." | 1.36 | Influence of sex on the out-of-hospital management of chest pain. ( Armstrong, K; Facenda, K; Mechem, CC; Meisel, ZF; Peacock, N; Pollack, CV; Shofer, FS, 2010) |
| "Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation." | 1.36 | Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010) |
| "The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months." | 1.36 | Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010) |
| "Chronic obstructive pulmonary disease (COPD) is associated with unfavourable short- and long-term outcome in patients with coronary artery disease undergoing revascularisation procedures." | 1.36 | Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. ( Brzeziński, M; Dubiel, JS; Dudek, D; Dziewierz, A; Mielecki, W; Rakowski, T; Siudak, Z; Zdzienicka, J, 2010) |
| " This case shows that, in such particular conditions, a change in dipyridamole dosage can induce a myocardial infarction even if its blood level remains in the therapeutic range." | 1.36 | [Myocardial infarction after voluntary intoxication by drug interaction between dipyridamole and aspirin]. ( Amat, G; Brahic, H; Eschalier, A; Eschalier, R; Marcaggi, X; Ravan, R, 2010) |
| "This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment." | 1.36 | Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010) |
| " The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI." | 1.36 | Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. ( Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C, 2010) |
| "Women with CHD also had a higher rate of cerebral ischemia than did men (27." | 1.36 | Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010) |
| "Mortality from acute coronary syndrome has historically been higher in women as compared with men." | 1.35 | Reduction in sex-based mortality difference with implementation of new cardiology guidelines. ( Cutlip, DE; Jotkowitz, A; Lieberman, N; Novack, V; Porath, A, 2008) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Myocardial infarction is common in patients with a history of coronary artery disease." | 1.35 | [Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008) |
| " After 3 months, the patient is free from adverse events." | 1.35 | Drug-eluting stents in a patient with favism: is the aspirin administration safe? ( Capoluongo, E; Di Russo, C; Ferraiuolo, G; Giardina, B; Loschiavo, P; Minucci, A; Rigattieri, S; Silvestri, P, 2008) |
| "Bleeding was defined as non-coronary artery bypass graft-related Thrombolysis of Myocardial Infarction major/minor bleeding or transfusion among patients with baseline hematocrit > or =28%." | 1.35 | Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. ( Alexander, KP; Kosiborod, MN; Peterson, ED; Rao, SV; Rumsfeld, JS; Spertus, JA; Wang, TY; Xiao, L, 2008) |
| " No clear evidence exists regarding the ideal dosage of aspirin." | 1.35 | Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry. ( Cook, EF; Davies, R; Froeschl, M; Glover, C; Ha, A; Labinaz, M; Le May, M; Marquis, JF; O'Brien, E; So, D; Williams, W, 2009) |
| "Factor XI deficiency is a rare coagulopathy occurring primarily in Ashkenazi Jews, and is associated with bleeding diathesis." | 1.35 | Percutaneous coronary intervention in a patient with factor XI deficiency. ( Levi, E; Shimony, A; Zahger, D, 2009) |
| "Kawasaki disease is a systemic vasculitis occurring in children of all ages." | 1.35 | Acute myocardial infarction as the first manifestation of the incomplete Kawasaki disease in a young male. ( Farhang, S; Javadzadegan, H; Mehdizadeh Baghbani, J, 2009) |
| "Aspirin was used in 56." | 1.35 | Drug secondary prevention in postmenopausal women with ischemic heart disease. ( Cebanu, M; Pop, D; Sitar-Tăut, A; Zdrenghea, D; Zdrenghea, V, 2009) |
| "Age and left bundle branch block were strong negative predictors for early reperfusion therapy in patients with prior antithrombotic treatment." | 1.35 | Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Koeth, O; Senges, J; Towae, F; Zahn, R; Zeymer, U, 2009) |
| "Aspirin use was associated with a lower risk of cardiovascular events (adjusted hazard ratio, 0." | 1.35 | Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. ( Berger, JS; Brown, DL; Burke, GL; Kostis, JB; Langer, RD; Oberman, A; Wassertheil-Smoller, S; Wong, ND, 2009) |
| "Paroxysmal atrial fibrillation is considered a frequent complication of acute myocardial infarction and the patients with paroxysmal atrial fibrillation probably should be targeted for earlier and more aggressive treatment." | 1.35 | Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction. ( Chiribiri, A; Di Bella, G; Marte, F; Patanè, S, 2008) |
| "Up to 90% of cardiac arrests are due to acute myocardial infarction or severe myocardial ischaemia." | 1.35 | Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction. ( Arntz, HR; Breckwoldt, J; Dissmann, R; Marschalk, A; Müller, D; Wenzel, V, 2008) |
| "Warfarin treatment was an independent predictor of both primary endpoint (OR 1." | 1.34 | Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. ( Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A, 2007) |
| " We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
| "Aspirin was administered to 40% and BBs to 17% of patients with AMI." | 1.34 | National study on the quality of emergency department care in the treatment of acute myocardial infarction and pneumonia. ( Kelen, GD; Pham, JC; Pronovost, PJ, 2007) |
| "Aspirin use was also balanced among all drug exposure categories." | 1.33 | Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. ( Avorn, J; Glynn, RJ; Schneeweiss, S; Solomon, DH; Tsai, EH, 2005) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 1.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "The risk of stroke is reduced with primary PTCA (OR = 0." | 1.33 | Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. ( Massel, D, 2005) |
| " The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy." | 1.33 | Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005) |
| " This study suggests that short-term NG intubation is relatively safe and may be beneficial and indicated for acute GI bleeding after recent MI." | 1.33 | Safety and efficacy of nasogastric intubation for gastrointestinal bleeding after myocardial infarction: an analysis of 125 patients at two tertiary cardiac referral hospitals. ( Cappell, MS, 2005) |
| "Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded." | 1.33 | Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006) |
| "The epidemiologic pattern of sudden cardiac death (SCD) may have changed in the modern treatment era of patients after an acute myocardial infarction (AMI)." | 1.33 | Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. ( Barthel, P; Bauer, A; Huikuri, HV; Mäkikallio, TH; Perkiömäki, JS; Schmidt, G; Schneider, R; Tapanainen, JM; Tulppo, MP, 2006) |
| "Acute myocardial infarction is a rare complication of mitral stenosis." | 1.33 | Acute myocardial infarction in a patient with severe unrecognized mitral stenosis. ( Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events." | 1.33 | Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006) |
| " Examined a different way, the mean percentage of days that the correct aspirin dosage (1 pill per day for all patients) was taken was significantly lower in the persistently depressed patients (76." | 1.33 | Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. ( Burg, MM; Chaplin, WF; Davidson, KW; Gerin, W; Haas, D; Kronish, IM; Rieckmann, N; Vorchheimer, D, 2006) |
| "Women with coronary disease are at high risk for myocardial infarction or death from coronary heart disease even in the absence of other risk factors, and their risk increases up to sixfold when many risk factors are present." | 1.32 | Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. ( Barrett-Connor, E; Blumenthal, R; Furberg, CD; Hulley, S; Ireland, CC; Khan, SS; Shlipak, MG; Varosy, PD; Vittinghoff, E, 2003) |
| "Non-sustained VTs are only associated with poor prognosis if combined with frequent VPBs." | 1.32 | Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats. ( Drögemüller, A; Gitt, A; Gottwik, M; Poppe, C; Rettig-Stürmer, G; Schiele, R; Schneider, S; Seidl, K; Senges, J; von Leitner, ER, 2003) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| "Patients with mental illness were marginally less likely than those without mental illness to undergo in-hospital angiography (age-adjusted RR 0." | 1.32 | Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities? ( Druss, BG; Normand, SL; Petersen, LA; Rosenheck, RA, 2003) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 1.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Using the ESRD database and the Cooperative Cardiovascular Project (CCP) database, we identified AMI patients who were receiving either peritoneal dialysis or hemodialysis before admission." | 1.32 | Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. ( Berger, AK; Duval, S; Krumholz, HM, 2003) |
| "Bradykinin is a potent endothelium-dependent vasodilator in the coronary vascular bed." | 1.32 | Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. ( Akula, A; Veeravalli, KK, 2004) |
| "Systemic vasculitis has been reported in some cases." | 1.32 | [Myocardial infarction after influenza vaccination]. ( Bonz, A; Langenfeld, H; Ritter, O; Strotmann, J, 2003) |
| "Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT." | 1.32 | A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003) |
| "Concentric left ventricular hypertrophy after MI, defined as increased cross-sectional area of transversally cut Gomori stained myocytes, was indicated by almost double myocyte size (P<0." | 1.32 | Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts. ( Saxena, PR; Schoemaker, RG; Van Kerckhoven, R; van Veghel, R, 2004) |
| "Patients with complex coronary stenoses had a significantly (P<0." | 1.32 | Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. ( Christiansen, M; Cole, D; Cosin-Sales, J; Holt, DW; Kaminski, P; Kaski, JC; Overgaard, MT; Oxvig, C, 2004) |
| "Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication." | 1.32 | [Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003) |
| "Naproxen was associated with an OR of 0." | 1.32 | Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004) |
| "Sickle cell disease is considered protective against large vessel coronary artery disease." | 1.32 | Acute myocardial infarction in a young man with sickle cell disease. ( Sherman, SC; Sulé, HP, 2004) |
| "Hypertension was a more common risk factor in AS patients (69% AS patients vs." | 1.32 | Risk factors and in-hospital outcomes in stroke and myocardial infarction patients. ( Ivanusa, M; Ivanusa, Z, 2004) |
| "Myocardial infarction (MI) and congestive heart failure (CHF) were induced in rats by ligating the left coronary artery." | 1.32 | Inhibition of COX pathway in experimental myocardial infarction. ( Giaid, A; Hu, F; Huynh, T; Robinson, R; Rodger, IW; Saito, T, 2004) |
| "Previous myocardial infarction was found in 70 patients (28%)." | 1.32 | National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. ( Kitamura, S; Tsuda, E, 2004) |
| "Most patients with PAD die of either heart attacks or strokes and they die of the former conditions far earlier than controls." | 1.32 | [Antiplatelet therapy in patients with peripheral arterial disease (PAD)]. ( Diehm, C; Huber, R; Lawall, H, 2004) |
| "In patients with unstable angina pectoris or non-ST-elevation myocardial infarction treated with aspirin, heparin, and tirofiban, performance of an exercise or a pharmacologic stress test in selected patients within 48 to 72 hours after admission appears to be associated with a low risk of complications." | 1.32 | Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. ( Cannon, CP; Dibattiste, PM; Gibson, CM; Karha, J; Murphy, SA, 2004) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 1.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| "Patients with renal failure received adjunctive and reperfusion therapies less frequently than those with normal renal function (P < 0." | 1.31 | Acute myocardial infarction and renal dysfunction: a high-risk combination. ( Albright, RC; Dvorak, DL; Herzog, CA; Jaffe, AS; Kopecky, SL; Miller, WL; Murphy, JG; Reeder, GS; Williams, BA; Wright, RS, 2002) |
| "The long-term use of aspirin (ASA) reduces the risk of subsequent acute coronary syndromes in patients with coronary artery disease (CAD)." | 1.31 | Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]). ( Fox, KA; Goldberg, RJ; Gore, JM; Gurfinkel, EP; Moscucci, M; Santopinto, JJ; Spencer, FA; White, K, 2002) |
| "Acute myocardial infarction is the leading cause of death in the industrialized world and the paramount goal is establishing early, complete, and sustained reperfusion at the myocardial tissue level." | 1.31 | Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. ( Dauterman, K; Topol, E, 2002) |
| " Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1." | 1.31 | Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. ( García Rodríguez, LA; Patrono, C; Varas, C, 2000) |
| "Pre-treatment with aspirin lessened the number of CFRs but did not reduce platelet accumulation in LAD myocardium (483+/-148%)." | 1.31 | Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. ( Barrabés, JA; Garcia-Dorado, D; Garcia-Lafuente, A; Puigfel, Y; Solares, J; Soler-Soler, J; Soriano, B; Trobo, L, 2000) |
| "Myocardial infarction is rare during pregnancy." | 1.31 | [Myocardial infarction, pregnancy and anesthesia]. ( Diar, N; Rezig, K; Walcker, JL, 2000) |
| "Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4." | 1.31 | Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001) |
| "Aspirin has the potential to influence CRP release, either by its anti-inflammatory activity or by reducing myocardial necrosis." | 1.31 | The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. ( Clarke, H; Cooper, J; Kennon, S; Mills, PG; Price, CP; Ranjadayalan, K; Timmis, AD, 2001) |
| "Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2." | 1.31 | Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. ( Bing, RJ; Johnson, PE; Kakar, NR; Vina, ER; Yamamoto, T, 2001) |
| "A dry bothersome cough is the most common adverse class effect of all angiotensin-converting enzyme inhibitors (ACE-I)." | 1.31 | The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings. ( Fisman, EZ; Motro, M; Pines, A; Shapira, I; Tenenbaum, A, 2001) |
| " After controlling for age, prehospital dosage of epinephrine, and the duration of cardiac arrest we found a non significant trend towards good neurological recovery when thrombolytic therapy was given (OR 1." | 1.31 | Thrombolytic therapy after cardiac arrest and its effect on neurological outcome. ( Gabriel, D; Holzer, M; Kuerkciyan, I; Laggner, AN; Muellner, M; Schreiber, W; Sterz, F, 2002) |
| "Hydroxyurea was given to patients with ET with a positive history for major vascular complications or with an extreme thrombocytosis." | 1.30 | Acute coronary disease in essential thrombocythemia and polycythemia vera. ( Girolami, A; Randi, ML; Rinaldi, V; Rossi, C; Zerbinati, P, 1998) |
| "Approximately 50% of patients recovering from acute myocardial infarction have significant left ventricular systolic dysfunction and could benefit considerably from the long-term administration of angiotensin-converting enzyme inhibitors." | 1.30 | ACE inhibitors in acute myocardial infarction. ( McMurray, JJ; Murdoch, DR, 1998) |
| "0001), and higher dosage of aspirin (+100%, p < 0." | 1.30 | Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction. ( Badano, L; Burelli, C; Cassin, M; Macor, F; Solinas, L; Zanuttini, D, 1999) |
| "Aspirin was administered intravenously (iv) as water-soluble Aspisol, d-lysinmono (acetylsalicylate) (Bayer, Leverkusen, Germany) into an ear vein." | 1.30 | Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin. ( Bing, RJ; Cho, YK; Cohen, AM; Johnson, PE; Kakar, NR; Yamamoto, M; Yamamoto, T, 1999) |
| " Next, by drawing on data from the HOT trial, the mixture and dosage of drugs for each level of blood pressure control were estimated." | 1.30 | Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD. ( , 1998) |
| " The investigations were performed with different amounts of 4 different inducers (ADP, arachidonic acid, epinephrine and collagen) taking dose-response curves." | 1.30 | [The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis]. ( Barczi, V; Blaskó, G; Dinnyés, J; Hamvas, J; Jáger, R; Kinczel, A; Pál, A; Poór, F; Salamon, A; Tarján, J, 1999) |
| "Six cases of acute myocardial infarction are reported with early disease reactivation following the abrupt discontinuation of heparin infusion three days after alteplase thrombolysis and concomitant aspirin therapy." | 1.29 | Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. ( Di Tano, G; Mazzù, A, 1995) |
| "Aspirin was less likely to be prescribed to older patients at discharge (79%, 82%, 70%, and 62%, P < ." | 1.29 | Age-related differences in the utilization of therapies post acute myocardial infarction. ( Battiola, RJ; Goodwin, JS; Malone, ML; Nachodsky, JP; Sial, SH; Solomon, DJ, 1995) |
| " The dosage of aspirin decreased from 500 mg or more per day in 1986 to a daily dose of approximately 250 mg in 1989." | 1.29 | [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Ruidavets, JB, 1994) |
| "The essential goal of medical treatment following myocardial infarction with left ventricular dysfunction must be the prevention of secondary cardiac failure." | 1.29 | [What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?]. ( Caviezel, B; Cohen-Solal, A; Gourgon, R; Himbert, D; Laperche, T, 1994) |
| "Women with acute myocardial infarction have a worse prognosis than men but the excess risk is confined to the first 30 days and is only partly explained by age and other baseline variables." | 1.29 | Acute myocardial infarction in women: survival analysis in first six months. ( Laji, K; Parsons, L; Ranjadayalan, K; Timmis, AD; Wilkinson, P, 1994) |
| "Acute myocardial infarctions were registered in group 1 in 25% (11." | 1.29 | [Emergency intracoronary stent implantation: complications and experiences with 124 patients]. ( Arens, R; Heuer, H; Krakau, I; Müller, T; Rissel, U; Schulze-Waltrup, N; Willgeroth, W, 1994) |
| "When myocardial infarction is due to coronary embolism from endocarditic valves standard thrombolysis regimes should be avoided." | 1.29 | Acute coronary embolism complicating aortic valve endocarditis treated with streptokinase and aspirin. A case report. ( Connolly, DL; Crowley, JJ; Dardas, PS; Kenny, A; Petch, MC, 1994) |
| "Aspirin treatment is found to counteract the effect of isoproterenol on lipid and lipid peroxide formation and associated enzyme changes in heart mitochondria." | 1.29 | Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats. ( Devi, CS; Manjula, TS, 1993) |
| "Aspirin was used in more than 7 out of 10 patients during the acute phase in all MONICA centres, but at a variable dosage: doses greater than or equal to 250 mg per day were prescribed in Toulouse (97." | 1.29 | [Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990]. ( Amouyel, P; Arveiler, D; Bingham, A; Cambou, JP; Ferrières, J; Haas, B; Lablache Combier, B; Montayé, M; Richard, JL; Ruidavets, JB, 1995) |
| "Occurrence of acute myocardial infarction is even rarer in these patients." | 1.29 | Acute myocardial infarction in a patient with von Willebrand disease. ( Schreiber, TL; Wong, CB, 1996) |
| " Samples of venous blood were taken from all patients at the moment of hospitalization and after 2, 4, 6, 8, 10, 12 and 24 hours from the thrombolytic treatment (AMI + urokinase) or conventional therapy (AMI + nitroglycerin), for the dosage of creatinine kinase (CK) and adhesion molecules." | 1.29 | Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. ( Altavilla, D; Campo, GM; Canale, P; Caputi, AP; Di Tano, G; Ioculano, M; Mazzu, A; Saitta, A; Squadrito, F; Squadrito, G, 1996) |
| "Recurrent myocardial infarction is a common complication in the year following an initial event: the risk is higher when the diseased artery has been recanalized in the acute phase." | 1.28 | [Role of antithrombotic agents after myocardial infarction]. ( Albo, C; Castaigne, A; Perchet, H; Pham, I; Saal, JP; Verschuren, P, 1992) |
| "A 29-year-old man with congenital protein C deficiency and acute myocardial infarction is reported." | 1.28 | Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis. ( Kario, K; Matsuo, M; Matsuo, T; Miki, T; Sakamoto, S; Tai, S; Yamada, T, 1992) |
| "Aspirin treated rats showed marked reversal of these metabolic changes." | 1.28 | Effect of aspirin on serum lipoprotein profile in rats subjected to myocardial stress by isoproterenol. ( Devi, CS; Manjula, TS; Prema, A, 1992) |
| "A 23-year-old male with bronchial asthma developed eosinophilia (eosinophils greater than 2,000/mm3) and was observed at our hospital." | 1.28 | [Acute myocardial injury and repeated angina pectoris-like attacks in a young patient with Churg-Strauss syndrome]. ( Arai, Y; Fukushima, N; Isokane, N; Miyamoto, Y; Sano, Y; Suzuki, N, 1991) |
| " Newer dosing regimens for currently available thrombolytic agents, as well as new thrombolytic agents, are currently under active investigation and will be the subject of intense research over the next few years." | 1.28 | Thrombolytic therapy: then and now. ( Cole, PL, 1991) |
| " Whereas the death rate was nearly the same in all three former dosage groups the total reinfarction rate was higher (22." | 1.28 | Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study. ( Förster, W; Handreg, W; Hoffmann, W; Kampe, W; Muche, J; Nitschke, M, 1991) |
| "alteplase for the treatment of acute myocardial infarction (AMI) in two community hospitals is described." | 1.28 | Use of alteplase for myocardial infarction in two community hospitals. ( Finley, RC; Grabavoy, G; Hamid, I; Krichbaum, DW, 1990) |
| " The risk of therapy with acetyl salicylic acid (ASS) in low dosage is significantly smaller." | 1.28 | [Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct]. ( Dahn, G; Kothe, K, 1990) |
| "Aspirin treated rats showed lower mortality rate and smaller changes in the myocardium on histopathological examination when compared to corresponding animals given isoproterenol alone." | 1.28 | Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation. ( Menon, VP; Muraleedharan, D; Sushama Kumari, S; Varghese, A, 1990) |
| "Patients with Kawasaki disease are mostly in Japan, however, an increasing number of patients have recently been published in the foreign literatures, and this entity has become an important cause of heart disease in children." | 1.27 | [Kawasaki disease: new and important problems in cardiology]. ( Ichinose, E; Kato, H, 1983) |
| "Pretreatment with aspirin did not prevent this decrease in vascular conductance during maximal vasodilation." | 1.27 | No reflow and extent of infarction during maximal vasodilation in the porcine heart. ( Anselone, CG; Bristow, JD; Johnson, WB; Malone, SA; Pantely, GA, 1988) |
| "Kawasaki syndrome is a newly described, acute symptom complex of children that has a predictable clinical course." | 1.26 | Kawasaki syndrome: a new infectious disease? ( Melish, ME, 1981) |
| "Aspirin-treated dogs did not differ from control dogs in percent ventricle at risk (mean +/- standard error 37 +/- 2 versus 40 +/- 2), percent infarct weight/left ventricle (29 +/- 3 versus 31 +/- 2) or percent infarct weight/weight of ventricle at risk (78 +/- 4 versus 77 +/- 3)." | 1.26 | Lack of effect of aspirin on myocardial infarct size in the dog. ( Bonow, RO; Capurro, NL; Epstein, SE; Goldstein, RE; Isner, JM; Lipson, LC; Roberts, WC; Sheehan, FH, 1981) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| "Myocardial infarctions have decreased from 2." | 1.26 | Complications of percutaneous transfemoral coronary arteriography. ( Silverman, JF; Wexler, L, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 454 (13.13) | 18.7374 |
| 1990's | 820 (23.72) | 18.2507 |
| 2000's | 1127 (32.60) | 29.6817 |
| 2010's | 860 (24.88) | 24.3611 |
| 2020's | 196 (5.67) | 2.80 |
| Authors | Studies |
|---|---|
| Joseph, P | 3 |
| Roshandel, G | 3 |
| Gao, P | 6 |
| Pais, P | 6 |
| Lonn, E | 3 |
| Xavier, D | 4 |
| Avezum, A | 8 |
| Zhu, J | 7 |
| Liu, L | 4 |
| Sliwa, K | 1 |
| Gamra, H | 1 |
| Bangdiwala, SI | 5 |
| Teo, K | 2 |
| Diaz, R | 8 |
| Dans, A | 1 |
| Lopez-Jaramillo, P | 3 |
| Prabhakaran, D | 7 |
| Castellano, JM | 2 |
| Fuster, V | 23 |
| Rodgers, A | 2 |
| Huffman, MD | 3 |
| Bosch, J | 13 |
| Dagenais, GR | 9 |
| Malekzadeh, R | 3 |
| Yusuf, S | 44 |
| de Jong, JJD | 1 |
| Slenter, RHJ | 1 |
| van Lierop, P | 1 |
| Wagenaar, LJ | 1 |
| Vranckx, P | 21 |
| Valgimigli, M | 36 |
| Odutayo, A | 1 |
| Serruys, PW | 12 |
| Hamm, C | 21 |
| Steg, PG | 55 |
| Heg, D | 6 |
| Mc Fadden, EP | 1 |
| Onuma, Y | 10 |
| Benit, E | 5 |
| Janssens, L | 4 |
| Diletti, R | 1 |
| Ferrario, M | 7 |
| Huber, K | 19 |
| Räber, L | 3 |
| Windecker, S | 27 |
| Jüni, P | 13 |
| Viscusi, MM | 2 |
| Mangiacapra, F | 2 |
| Bressi, E | 2 |
| Sticchi, A | 1 |
| Colaiori, I | 2 |
| Capuano, M | 2 |
| Ricottini, E | 2 |
| Cavallari, I | 3 |
| Spoto, S | 2 |
| Di Sciascio, G | 2 |
| Ussia, GP | 1 |
| Grigioni, F | 1 |
| Pracoń, R | 1 |
| Demkow, M | 2 |
| Anthopolos, R | 2 |
| Mazurek, T | 2 |
| Drożdż, J | 1 |
| Witkowski, A | 2 |
| Gajos, G | 2 |
| Pruszczyk, P | 1 |
| Roik, M | 1 |
| Łoboz-Grudzień, K | 1 |
| Lesiak, M | 2 |
| Reczuch, K | 2 |
| Kalarus, Z | 1 |
| Kryczka, K | 1 |
| Henzel, J | 1 |
| Kaczmarska-Dyrda, E | 1 |
| Maksym, J | 1 |
| Jonik, S | 1 |
| Krekora, J | 1 |
| Celińska-Spodar, M | 1 |
| Jaroch, J | 1 |
| Łanocha, M | 1 |
| Szulik, M | 1 |
| Szwed, H | 1 |
| Rużyłło, W | 1 |
| Kim, CJ | 5 |
| Park, MW | 2 |
| Kim, MC | 3 |
| Choo, EH | 2 |
| Hwang, BH | 2 |
| Lee, KY | 2 |
| Choi, YS | 3 |
| Kim, HY | 3 |
| Yoo, KD | 3 |
| Jeon, DS | 5 |
| Shin, ES | 7 |
| Jeong, YH | 5 |
| Seung, KB | 9 |
| Jeong, MH | 13 |
| Yim, HW | 1 |
| Ahn, Y | 4 |
| Chang, K | 4 |
| Gupta, R | 2 |
| Lin, M | 1 |
| Mehta, A | 2 |
| Aedma, SK | 1 |
| Shah, R | 3 |
| Ranchal, P | 1 |
| Vyas, AV | 1 |
| Singh, S | 2 |
| Kluck, B | 1 |
| Combs, WG | 1 |
| Patel, NC | 1 |
| Murphy, E | 1 |
| Curneen, JMG | 1 |
| McEvoy, JW | 2 |
| Sun, X | 2 |
| Sun, R | 1 |
| Zhang, L | 10 |
| Marquis-Gravel, G | 4 |
| Hammill, BG | 6 |
| Mulder, H | 4 |
| Roe, MT | 20 |
| Robertson, HR | 4 |
| Wruck, LM | 4 |
| Sharlow, A | 2 |
| Harris, DF | 2 |
| Pohlman, FW | 1 |
| Hernandez, AF | 8 |
| Jones, WS | 11 |
| Mele, M | 2 |
| Tricarico, L | 1 |
| Ieva, R | 1 |
| Iacoviello, M | 1 |
| Di Biase, M | 4 |
| Brunetti, ND | 2 |
| O'Leary, K | 1 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 2 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 2 |
| Rodríguez-González, F | 2 |
| Tugores, A | 2 |
| Abbasi, J | 1 |
| Stolarek, W | 2 |
| Kasprzak, M | 3 |
| Sikora, J | 1 |
| Siemińska, E | 1 |
| Grześk, G | 2 |
| Jackson, J | 3 |
| Alkhalil, M | 1 |
| Ratcovich, H | 1 |
| Wilkinson, C | 1 |
| Mehran, R | 34 |
| Kunadian, V | 7 |
| Peng, R | 1 |
| Li, F | 1 |
| Ono, M | 4 |
| Hara, H | 4 |
| Kawashima, H | 4 |
| Gao, C | 5 |
| Wang, R | 5 |
| Wykrzykowska, JJ | 6 |
| Piek, JJ | 4 |
| Garg, S | 6 |
| Fabris, E | 1 |
| Menzio, S | 1 |
| Gregorio, C | 1 |
| Pezzato, A | 1 |
| Stolfo, D | 1 |
| Aleksova, A | 1 |
| Vitrella, G | 1 |
| Rakar, S | 1 |
| Perkan, A | 1 |
| Van't Hof, AW | 1 |
| Sinagra, G | 1 |
| Dehghani, P | 1 |
| Cao, D | 6 |
| Baber, U | 13 |
| Nicolas, J | 3 |
| Sartori, S | 8 |
| Pivato, CA | 2 |
| Zhang, Z | 5 |
| Dangas, G | 8 |
| Angiolillo, DJ | 17 |
| Briguori, C | 7 |
| Cohen, DJ | 12 |
| Collier, T | 5 |
| Dudek, D | 8 |
| Gibson, M | 4 |
| Gil, R | 3 |
| Kaul, U | 5 |
| Kornowski, R | 8 |
| Krucoff, MW | 8 |
| Mehta, S | 3 |
| Moliterno, DJ | 13 |
| Ohman, EM | 20 |
| Escaned, J | 6 |
| Sardella, G | 6 |
| Sharma, SK | 3 |
| Shlofmitz, R | 3 |
| Weisz, G | 12 |
| Witzenbichler, B | 13 |
| Pocock, S | 8 |
| D'Ascenzo, F | 4 |
| DE Filippo, O | 2 |
| Angelini, F | 1 |
| Piroli, F | 1 |
| DE Lio, G | 1 |
| Bocchino, PP | 1 |
| Baldetti, L | 2 |
| Melillo, F | 2 |
| Chieffo, A | 7 |
| Saglietto, A | 2 |
| Omedè, P | 1 |
| Montefusco, A | 2 |
| Conrotto, F | 1 |
| de Ferrari, GM | 3 |
| Tan, BE | 1 |
| Wong, PY | 1 |
| Baibhav, B | 1 |
| Thakkar, S | 1 |
| Azhar, AZ | 1 |
| Rao, M | 2 |
| Cheung, JW | 1 |
| Mohammadifard, N | 1 |
| Taheri, M | 1 |
| Haghighatdoost, F | 1 |
| Grau, N | 1 |
| Najafian, J | 1 |
| Sadeghi, M | 1 |
| Talaei, M | 1 |
| Sarrafzadegan, N | 1 |
| Eikelboom, JW | 26 |
| Connolly, SJ | 13 |
| Tyrwitt, J | 1 |
| Fox, KAA | 14 |
| Muehlhofer, E | 6 |
| Neumann, C | 1 |
| Tasto, C | 1 |
| Alings, M | 4 |
| Leong, DP | 3 |
| Lonn, EM | 1 |
| Piegas, LS | 1 |
| Widimsky, P | 15 |
| Parkhomenko, AN | 2 |
| Bhatt, DL | 63 |
| Branch, KRH | 2 |
| Probstfield, JL | 2 |
| Rydén, L | 3 |
| Pogosova, N | 2 |
| Keltai, K | 3 |
| Keltai, M | 4 |
| Ertl, G | 3 |
| Stoerk, S | 2 |
| Dans, AL | 2 |
| Lanas, F | 3 |
| Liang, Y | 4 |
| Torp-Pedersen, C | 16 |
| Maggioni, AP | 16 |
| Commerford, PJ | 5 |
| Guzik, TJ | 3 |
| Vanassche, T | 2 |
| Verhamme, P | 3 |
| O'Donnell, M | 6 |
| Tonkin, AM | 2 |
| Varigos, JD | 3 |
| Vinereanu, D | 8 |
| Felix, C | 3 |
| Kim, JH | 7 |
| Ibrahim, KS | 1 |
| Lewis, BS | 6 |
| Metsarinne, KP | 2 |
| Aboyans, V | 6 |
| Hori, M | 2 |
| Kakkar, A | 1 |
| Anand, SS | 15 |
| Lamy, A | 4 |
| Sharma, M | 1 |
| Mozaffarian, S | 1 |
| Taherpour, N | 1 |
| Sistanizad, M | 1 |
| Aghaali, M | 1 |
| Hashemi Nazari, SS | 1 |
| Gallagher, H | 1 |
| Dumbleton, J | 1 |
| Maishman, T | 1 |
| Whitehead, A | 2 |
| Moore, MV | 1 |
| Fuat, A | 1 |
| Fitzmaurice, D | 1 |
| Henderson, RA | 1 |
| Lord, J | 1 |
| Griffith, KE | 1 |
| Stevens, P | 1 |
| Taal, MW | 1 |
| Stevenson, D | 1 |
| Fraser, SD | 1 |
| Lown, M | 1 |
| Hawkey, CJ | 3 |
| Roderick, PJ | 1 |
| Davidson, KW | 3 |
| Barry, MJ | 2 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Chelmow, D | 1 |
| Coker, TR | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Jaén, CR | 1 |
| Krist, AH | 1 |
| Kubik, M | 1 |
| Li, L | 7 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Ruiz, JM | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| O'Leary, N | 1 |
| Żurakowski, A | 3 |
| Dominici, M | 4 |
| Buszman, P | 3 |
| Deliargyris, EN | 1 |
| Storey, RF | 18 |
| Wang, M | 6 |
| Yu, H | 1 |
| Li, Z | 3 |
| Gong, D | 1 |
| Liu, X | 4 |
| Smits, PC | 3 |
| Frigoli, E | 1 |
| Bongiovanni, D | 1 |
| Tijssen, J | 2 |
| Hovasse, T | 2 |
| Mafragi, A | 1 |
| Ruifrok, WT | 1 |
| Karageorgiev, D | 1 |
| Aminian, A | 2 |
| Garducci, S | 1 |
| Merkely, B | 5 |
| Routledge, H | 1 |
| Ando, K | 9 |
| Diaz Fernandez, JF | 1 |
| Cuisset, T | 5 |
| Nesa Malik, FT | 1 |
| Halabi, M | 1 |
| Belle, L | 3 |
| Din, J | 1 |
| Beygui, F | 5 |
| Abhyankar, A | 1 |
| Pedrazzini, G | 2 |
| Costa, TGR | 1 |
| Katz, M | 1 |
| Lemos Neto, PA | 1 |
| Guerra, JCC | 1 |
| Franken, M | 1 |
| Pesaro, AEP | 1 |
| Eroglu, TE | 1 |
| Blom, MT | 1 |
| Souverein, PC | 1 |
| Yasmina, A | 1 |
| de Boer, A | 2 |
| Tan, HL | 1 |
| Al-Abdouh, A | 1 |
| Abusnina, W | 1 |
| Mhanna, M | 1 |
| Radideh, Q | 1 |
| Alzu'bi, H | 1 |
| Rmilah, AA | 1 |
| Jabri, A | 1 |
| Barbarawi, M | 1 |
| Obeidat, K | 1 |
| Alabduh, T | 1 |
| Michos, ED | 2 |
| Alnabelsi, T | 1 |
| Paul, TK | 1 |
| Zhang, Q | 3 |
| Ding, Q | 1 |
| Yan, S | 1 |
| Yue, QY | 1 |
| Chen, S | 3 |
| Jiang, W | 1 |
| Wang, J | 3 |
| Tsaban, G | 1 |
| Alnsasra, H | 1 |
| El Nasasra, A | 1 |
| Abu-Salman, A | 1 |
| Abu-Dogosh, A | 1 |
| Weissberg, I | 1 |
| Golan, YB | 1 |
| Barrett, O | 1 |
| Westreich, R | 1 |
| Aboalhasan, E | 1 |
| Azuri, J | 1 |
| Hammerman, A | 1 |
| Arbel, R | 1 |
| Obayashi, Y | 1 |
| Watanabe, H | 4 |
| Morimoto, T | 6 |
| Yamamoto, K | 4 |
| Natsuaki, M | 5 |
| Domei, T | 2 |
| Yamaji, K | 2 |
| Suwa, S | 5 |
| Isawa, T | 1 |
| Yoshida, R | 1 |
| Sakamoto, H | 3 |
| Akao, M | 1 |
| Hata, Y | 2 |
| Morishima, I | 1 |
| Tokuyama, H | 1 |
| Yagi, M | 3 |
| Suzuki, H | 1 |
| Wakabayashi, K | 1 |
| Suematsu, N | 2 |
| Inada, T | 2 |
| Tamura, T | 2 |
| Okayama, H | 2 |
| Abe, M | 5 |
| Kawai, K | 3 |
| Nakao, K | 5 |
| Tanabe, K | 4 |
| Ikari, Y | 5 |
| Morino, Y | 3 |
| Kadota, K | 5 |
| Furukawa, Y | 4 |
| Nakagawa, Y | 5 |
| Kimura, T | 9 |
| Huang, HY | 2 |
| Lin, SY | 2 |
| Katz, AJ | 2 |
| Sheu, JJ | 1 |
| Lin, FJ | 2 |
| Wang, CC | 2 |
| Wu, CH | 2 |
| Beerkens, FJ | 1 |
| Claessen, B | 1 |
| Marx, S | 1 |
| Kastrati, A | 13 |
| Sharma, S | 2 |
| Gibson, CM | 22 |
| Kranendonk, J | 1 |
| Willems, LH | 1 |
| Vijver-Coppen, RV | 1 |
| Coenen, M | 1 |
| Adang, E | 1 |
| Donders, R | 1 |
| Zeebregts, CJ | 1 |
| Deneer, V | 1 |
| Reijnen, M | 1 |
| Kramers, C | 1 |
| Warlé, MC | 1 |
| Pocock, SJ | 4 |
| Quesada, AJ | 1 |
| Owen, R | 1 |
| Fernandez-Ortiz, A | 4 |
| Sanchez, PL | 1 |
| Marin Ortuño, F | 1 |
| Vazquez Rodriguez, JM | 1 |
| Domingo-Fernández, A | 1 |
| Lozano, I | 1 |
| Roncaglioni, MC | 2 |
| Baviera, M | 1 |
| Foresta, A | 1 |
| Ojeda-Fernandez, L | 1 |
| Colivicchi, F | 5 |
| Di Fusco, SA | 1 |
| Doehner, W | 1 |
| Meyer, A | 2 |
| Schiele, F | 5 |
| Ecarnot, F | 1 |
| Linhart, A | 1 |
| Lubanda, JC | 1 |
| Barczi, G | 1 |
| Ponikowski, P | 2 |
| Fernandez Alvira, JM | 1 |
| Andres, V | 1 |
| Bueno, H | 3 |
| Van de Werf, F | 15 |
| Perel, P | 1 |
| Rodriguez-Manero, M | 1 |
| Alonso Garcia, A | 1 |
| Proietti, M | 1 |
| Schoos, MM | 1 |
| Simon, T | 6 |
| Fernandez Ferro, J | 1 |
| Lopez, N | 1 |
| Beghi, E | 1 |
| Bejot, Y | 1 |
| Vivas, D | 1 |
| Cordero, A | 2 |
| Ibañez, B | 1 |
| Rao, SV | 5 |
| Kirsch, B | 1 |
| Budaj, A | 8 |
| Coppolecchia, R | 2 |
| Eikelboom, J | 6 |
| James, SK | 3 |
| Keller, L | 2 |
| Hermanides, RS | 3 |
| Campo, G | 10 |
| Ferreiro, JL | 2 |
| Shibasaki, T | 1 |
| Mundl, H | 2 |
| Alexander, JH | 7 |
| McFadyen, JD | 1 |
| Gardiner, EE | 1 |
| Moledina, SM | 1 |
| Mannan, F | 1 |
| Weight, N | 1 |
| Alisiddiq, Z | 1 |
| Elbadawi, A | 2 |
| Elgendy, IY | 3 |
| Fischman, DL | 2 |
| Mamas, MA | 2 |
| Kishi, T | 1 |
| Kitajima, A | 1 |
| Yamanouchi, K | 1 |
| Hirooka, Y | 1 |
| Toda, S | 1 |
| Takamori, A | 1 |
| Fujimoto, K | 4 |
| Kishi, C | 1 |
| Tomiyoshi, Y | 1 |
| Mathew, RO | 1 |
| Maron, DJ | 1 |
| Fleg, JL | 1 |
| O'Brien, SM | 1 |
| Rockhold, FW | 1 |
| Roik, MF | 1 |
| Malecki, R | 1 |
| Ye, Z | 1 |
| Miglinas, M | 1 |
| Stone, GW | 27 |
| Wald, R | 1 |
| Charytan, DM | 1 |
| Sidhu, MS | 2 |
| Hochman, JS | 6 |
| Bangalore, S | 5 |
| Oliva, A | 2 |
| Castiello, DS | 1 |
| Franzone, A | 5 |
| Condorelli, G | 4 |
| Colombo, A | 14 |
| Esposito, G | 3 |
| Stefanini, GG | 2 |
| Piccolo, R | 7 |
| Bonaca, MP | 13 |
| Szarek, M | 3 |
| Debus, ES | 1 |
| Nehler, MR | 1 |
| Patel, MR | 5 |
| Berkowitz, SD | 11 |
| Haskell, LP | 3 |
| Bauersachs, RM | 3 |
| Saw, J | 3 |
| Starovoytov, A | 2 |
| Aymong, E | 1 |
| Inohara, T | 1 |
| Alfadhel, M | 1 |
| McAlister, C | 1 |
| Samuel, R | 1 |
| Grewal, T | 1 |
| Parolis, JA | 1 |
| Sheth, T | 1 |
| So, D | 2 |
| Minhas, K | 1 |
| Brass, N | 1 |
| Lavoie, A | 1 |
| Bishop, H | 1 |
| Lavi, S | 1 |
| Pearce, C | 1 |
| Renner, S | 1 |
| Madan, M | 2 |
| Welsh, RC | 7 |
| McGrath, BM | 1 |
| Vijayaraghavan, R | 1 |
| Har, B | 1 |
| Ibrahim, R | 1 |
| Chaudhary, P | 1 |
| Ganesh, SK | 1 |
| Graham, J | 1 |
| Matteau, A | 2 |
| Martucci, G | 1 |
| Ko, DT | 1 |
| Humphries, K | 1 |
| Mancini, GJ | 1 |
| Abtan, J | 3 |
| Elbez, Y | 3 |
| Ducrocq, G | 3 |
| Goto, S | 7 |
| Smith, SC | 2 |
| Eagle, KA | 8 |
| Fox, K | 5 |
| Harrington, RA | 27 |
| Leiter, LA | 3 |
| Mehta, SR | 17 |
| Petrov, I | 2 |
| Sinnaeve, PR | 2 |
| Lev, E | 1 |
| Wilson, P | 1 |
| Luo, L | 1 |
| Wang, S | 2 |
| Tang, K | 1 |
| Yang, X | 1 |
| Wu, J | 1 |
| Wang, D | 2 |
| Xu, L | 3 |
| Feng, T | 1 |
| Li, D | 2 |
| Ran, J | 1 |
| Zhao, D | 2 |
| Beltrán de Heredia, S | 1 |
| Mases, A | 1 |
| Recasens, L | 1 |
| Sabaté, S | 2 |
| Núñez, M | 1 |
| Bosch, L | 1 |
| Roman, L | 1 |
| Rueda, M | 1 |
| Alonso, E | 1 |
| Gallart, L | 1 |
| O'Brien, EC | 1 |
| Curtis, LH | 2 |
| Wu, H | 2 |
| Zhao, X | 3 |
| Zhang, H | 4 |
| Cheng, K | 1 |
| Wang, X | 9 |
| Chen, M | 2 |
| Li, G | 3 |
| Huang, J | 2 |
| Lan, J | 1 |
| Wei, G | 1 |
| Zhang, C | 4 |
| Wang, Y | 32 |
| Qian, J | 4 |
| Ge, J | 5 |
| Kang, J | 4 |
| Park, KW | 10 |
| Lee, H | 3 |
| Hwang, D | 2 |
| Yang, HM | 4 |
| Rha, SW | 9 |
| Bae, JW | 4 |
| Lee, NH | 6 |
| Hur, SH | 9 |
| Han, JK | 3 |
| Koo, BK | 8 |
| Kim, HS | 17 |
| Case, BC | 1 |
| Torguson, R | 3 |
| Abramowitz, J | 1 |
| Shea, C | 1 |
| Sutton, JA | 1 |
| Deksissa, T | 1 |
| Satler, LF | 5 |
| Ben-Dor, I | 2 |
| Bernardo, NL | 1 |
| Hashim, H | 1 |
| Rogers, T | 2 |
| Waksman, R | 3 |
| Dalçóquio, TF | 1 |
| Alves Dos Santos, M | 1 |
| Silva Alves, L | 1 |
| Bittar Brito Arantes, F | 1 |
| Ferreira-Santos, L | 1 |
| Pinto Brandão Rondon, MU | 1 |
| Furtado, RHM | 2 |
| Gehlen Ferrari, A | 1 |
| Genestreti Rizzo, PR | 1 |
| Salsoso, R | 1 |
| Franci, A | 1 |
| Moreira Baracioli, L | 1 |
| de Nazare Nunes Alves, MJ | 1 |
| Negrão, CE | 1 |
| Nicolau, JC | 11 |
| Kim, HH | 3 |
| Yoo, KJ | 4 |
| Youn, YN | 4 |
| Gaba, P | 3 |
| Leong, D | 3 |
| Andò, G | 4 |
| De Santis, GA | 3 |
| Greco, A | 3 |
| Pistelli, L | 3 |
| Francaviglia, B | 3 |
| Capodanno, D | 9 |
| De Caterina, R | 14 |
| Capranzano, P | 5 |
| Dasa, O | 3 |
| Pepine, CJ | 10 |
| Pearson, TA | 7 |
| Govsyeyev, N | 2 |
| Nehler, M | 2 |
| Conte, MS | 2 |
| Debus, S | 2 |
| Chung, J | 2 |
| Dorigo, W | 2 |
| Gudz, I | 2 |
| Krievins, D | 2 |
| Mills, J | 2 |
| Moll, F | 2 |
| Norgren, L | 2 |
| Piffaretti, G | 2 |
| Powell, R | 2 |
| Szalay, D | 3 |
| Sillesen, H | 2 |
| Wohlauer, M | 2 |
| Capell, WH | 2 |
| Jaeger, N | 2 |
| Hess, CN | 3 |
| Shekhar, AC | 2 |
| Larkin, A | 2 |
| Fisher, B | 2 |
| Mann, NC | 2 |
| Caldeira, D | 2 |
| Marques Antunes, M | 2 |
| Alves, M | 2 |
| Pinto, FJ | 2 |
| Møller, AL | 1 |
| Rytgaard, HCW | 1 |
| Mills, EHA | 1 |
| Christensen, HC | 1 |
| Blomberg, SNF | 1 |
| Folke, F | 1 |
| Kragholm, KH | 1 |
| Lippert, F | 1 |
| Gislason, G | 3 |
| Køber, L | 9 |
| Gerds, TA | 2 |
| Chiarito, M | 3 |
| Spirito, A | 2 |
| Giustino, G | 4 |
| Beerkens, F | 1 |
| Camaj, A | 1 |
| Vogel, B | 5 |
| Kim, BK | 5 |
| Ferreira Moita, C | 1 |
| Marau, G | 1 |
| Corte-Real, S | 1 |
| Dantas, A | 1 |
| Wu, Y | 4 |
| Yin, J | 1 |
| Li, C | 3 |
| Zhang, W | 1 |
| Shen, L | 2 |
| Ge, L | 1 |
| Liu, S | 1 |
| Eckstein, J | 1 |
| Lam, A | 1 |
| Cheema, AN | 1 |
| Yuan, F | 1 |
| Connolly, S | 1 |
| Belanger, J | 1 |
| Marsden, T | 1 |
| Tang, C | 1 |
| Swaminathan, B | 1 |
| Renters, M | 1 |
| Dyal, L | 5 |
| Arambam, P | 1 |
| Sinha, SK | 1 |
| Abhaichand, R | 1 |
| Parida, AK | 1 |
| Banker, D | 1 |
| Mody, R | 1 |
| Khan, A | 1 |
| Sharma, R | 2 |
| Moorthy, N | 1 |
| Chandra, S | 1 |
| Koduganti, SC | 1 |
| Garg, R | 1 |
| Sarma, PR | 1 |
| Agrawal, DK | 1 |
| Reddy, KMK | 1 |
| Zheng, N | 1 |
| Zhong, J | 1 |
| Chen, X | 2 |
| Su, J | 2 |
| Liu, C | 2 |
| Jiang, L | 3 |
| Navarese, EP | 5 |
| Landi, A | 1 |
| Angiolillo, D | 2 |
| Atar, D | 2 |
| Halvorsen, S | 4 |
| James, S | 7 |
| Leonardi, S | 8 |
| Montalescot, G | 23 |
| Niebauer, J | 1 |
| Price, S | 1 |
| Völler, H | 1 |
| Zhou, T | 1 |
| Gong, Y | 3 |
| Li, J | 7 |
| Bianco, M | 1 |
| Mottola, FF | 1 |
| Cerrato, E | 3 |
| Giordana, F | 1 |
| Cinconze, S | 1 |
| Baralis, G | 1 |
| Verra, A | 1 |
| Musumeci, G | 7 |
| Rossini, R | 5 |
| Weissler, EH | 2 |
| Stebbins, A | 4 |
| Wruck, L | 2 |
| Muñoz, D | 6 |
| Gupta, K | 6 |
| Girotra, S | 6 |
| Whittle, J | 6 |
| Benziger, CP | 6 |
| Polonsky, TS | 5 |
| Bradley, SM | 5 |
| Merritt, JG | 3 |
| Zemon, DN | 2 |
| Verheugt, FWA | 3 |
| Manunga, J | 1 |
| Pedersen, C | 1 |
| Stanberry, L | 1 |
| Pai, A | 1 |
| Skeik, N | 1 |
| Sullivan, TM | 2 |
| Wang, Q | 3 |
| Wu, C | 2 |
| Qu, X | 1 |
| He, X | 1 |
| Ma, S | 1 |
| Qiu, M | 1 |
| Brown, MT | 2 |
| Bortfeld, KS | 1 |
| Sperling, LS | 1 |
| Wenger, NK | 5 |
| van Bergeijk, KH | 1 |
| van Ginkel, DJ | 1 |
| Brouwer, J | 1 |
| Nijenhuis, VJ | 1 |
| van der Werf, HW | 1 |
| van den Heuvel, AFM | 1 |
| Voors, AA | 1 |
| Ten Berg, JM | 13 |
| Pedersen, OB | 1 |
| Larsen, SB | 6 |
| Kristensen, SD | 18 |
| Hvas, AM | 8 |
| Grove, EL | 9 |
| Mehta, H | 1 |
| Kim, H | 1 |
| Effron, MB | 7 |
| Anderson, RD | 2 |
| Jain, SK | 4 |
| DeWalt, DA | 2 |
| Farrehi, P | 3 |
| Zhou, L | 3 |
| Knowlton, KU | 3 |
| Rothman, RL | 4 |
| Lee, YJ | 1 |
| Je, NK | 1 |
| Shen, R | 1 |
| Sharlow, AG | 2 |
| Kripalani, S | 3 |
| VanWormer, JJ | 2 |
| Chunawala, ZS | 1 |
| Caughey, MC | 1 |
| Hendrickson, M | 1 |
| Arora, S | 1 |
| Erwin, JP | 1 |
| Levisay, JP | 1 |
| Rosenberg, JR | 1 |
| Ricciardi, MJ | 1 |
| Blankstein, R | 1 |
| Matsushita, K | 1 |
| Smith, S | 1 |
| Qamar, A | 2 |
| Kumbhani, DJ | 2 |
| de Lemos, JA | 11 |
| Gragnano, F | 1 |
| Pirondini, L | 1 |
| von Scheidt, M | 3 |
| Pettersen, AR | 1 |
| Zhao, Q | 1 |
| Woodward, M | 4 |
| McFadden, EP | 2 |
| Seljeflot, I | 12 |
| Zhu, Y | 1 |
| Schunkert, H | 7 |
| Arnesen, H | 17 |
| Calabrò, P | 4 |
| Cesarini, D | 1 |
| Muraca, I | 1 |
| Berteotti, M | 1 |
| Gori, AM | 7 |
| Sorrentino, A | 1 |
| Bertelli, A | 1 |
| Marcucci, R | 9 |
| Valenti, R | 4 |
| Lee, W | 1 |
| Kang, SH | 3 |
| Kim, SH | 2 |
| Lee, SY | 5 |
| Myung, W | 1 |
| Jheon, KH | 1 |
| Yoon, CH | 1 |
| Suh, JW | 3 |
| Youn, TJ | 2 |
| Chae, IH | 7 |
| Presume, J | 1 |
| Gomes, DA | 1 |
| Ferreira, J | 1 |
| Albuquerque, F | 1 |
| Almeida, M | 1 |
| Uva, MS | 1 |
| Aguiar, C | 1 |
| Mendes, M | 1 |
| Sepanlou, SG | 1 |
| Mann, JFE | 1 |
| Sharafkhah, M | 1 |
| Kaldal, A | 1 |
| Tonstad, S | 1 |
| Jortveit, J | 1 |
| Ahn, SG | 1 |
| Cho, KH | 4 |
| Sim, DS | 4 |
| Hong, YJ | 3 |
| Lee, JW | 1 |
| Youn, YJ | 1 |
| Yakushin, SS | 1 |
| Pereverzeva, KG | 1 |
| Sleem, A | 1 |
| Re, RN | 3 |
| Farrehi, PM | 1 |
| Gao, JM | 1 |
| Guo, H | 2 |
| Zhang, YH | 1 |
| Li, LM | 1 |
| Xin, GJ | 1 |
| Liu, ZX | 1 |
| You, Y | 1 |
| Chen, YY | 1 |
| Liu, JX | 1 |
| Fu, JH | 1 |
| Han, YL | 3 |
| Krucoff, M | 2 |
| Moliterno, D | 3 |
| Shlofmitz, RA | 1 |
| Yang, S | 1 |
| Ahn, HS | 1 |
| Cha, KS | 2 |
| Jo, SH | 1 |
| Ryu, JK | 1 |
| Suh, IW | 1 |
| Choi, HH | 1 |
| Woo, SI | 1 |
| Gholami, M | 1 |
| Sadegh, M | 1 |
| Koroush-Arami, M | 1 |
| Norouzi, S | 1 |
| Arismani, RJ | 1 |
| Asadi, E | 1 |
| Amini, M | 1 |
| Khodayari, N | 1 |
| Her, AY | 3 |
| Kim, B | 1 |
| Hahn, JY | 7 |
| Song, YB | 7 |
| Lee, JM | 4 |
| Park, TK | 3 |
| Yang, JH | 5 |
| Choi, JH | 8 |
| Choi, SH | 7 |
| Lee, SH | 11 |
| Gwon, HC | 7 |
| Hu, X | 1 |
| Xu, H | 2 |
| Wang, C | 1 |
| Zhou, D | 2 |
| Zhu, Q | 2 |
| Xu, K | 6 |
| Yang, J | 2 |
| Jiang, N | 1 |
| Zhang, J | 5 |
| Fang, Z | 1 |
| Fu, G | 1 |
| Guo, Y | 2 |
| Li, Y | 7 |
| Feng, D | 2 |
| Niu, G | 1 |
| Zhang, E | 1 |
| Chen, Y | 7 |
| Ye, Y | 7 |
| Ma, L | 1 |
| Takahashi, K | 7 |
| Chichareon, P | 6 |
| Kogame, N | 5 |
| Tomaniak, M | 6 |
| Modolo, R | 5 |
| Chang, CC | 4 |
| Komiyama, H | 3 |
| Soliman, O | 2 |
| de Winter, RJ | 6 |
| Bolognese, L | 4 |
| Tumscitz, C | 6 |
| Stoll, HP | 3 |
| Liu, H | 3 |
| Yang, T | 1 |
| Ruan, Z | 1 |
| Xing, Y | 1 |
| Schrör, K | 10 |
| Stoyko, OA | 1 |
| Shalaev, SV | 4 |
| Elvira Ruiz, G | 1 |
| Caro Martínez, C | 1 |
| Flores Blanco, PJ | 1 |
| Cerezo Manchado, JJ | 1 |
| Albendín Iglesias, H | 1 |
| Lova Navarro, A | 1 |
| Arregui Montoya, F | 1 |
| García Alberola, A | 1 |
| Pascual Figal, DA | 1 |
| Bailén Lorenzo, JL | 1 |
| Manzano-Fernández, S | 2 |
| De Luca, L | 4 |
| Meessen, J | 2 |
| Uguccioni, M | 2 |
| Piscione, F | 3 |
| Bernabò, P | 1 |
| Lardieri, G | 1 |
| Granatelli, A | 1 |
| Gabrielli, D | 3 |
| Gulizia, MM | 3 |
| Held, C | 4 |
| Andersson, M | 2 |
| Himmelmann, A | 5 |
| Ridderstråle, W | 2 |
| Leonsson-Zachrisson, M | 2 |
| Liu, Y | 6 |
| Opolski, G | 3 |
| Zateyshchikov, D | 1 |
| Corbalán, R | 6 |
| Cornel, JH | 7 |
| de Vries, TI | 1 |
| Westerink, J | 1 |
| Dorresteijn, JAN | 2 |
| van der Graaf, Y | 3 |
| Visseren, FLJ | 2 |
| Shestakovska, O | 3 |
| Cook-Bruns, N | 1 |
| Hart, RG | 7 |
| Moayyedi, P | 1 |
| Al-Zakwani, I | 1 |
| Al-Lawati, J | 1 |
| Alsheikh-Ali, AA | 1 |
| Almahmeed, W | 1 |
| Rashed, W | 2 |
| Al-Mulla, A | 1 |
| Zubaid, M | 2 |
| Cha, JY | 1 |
| Džavík, V | 1 |
| Gurbel, P | 3 |
| Hamm, CW | 8 |
| Henry, T | 2 |
| Marx, SO | 1 |
| Oldroyd, K | 1 |
| Shiomi, H | 4 |
| Toyota, T | 2 |
| Ohya, M | 1 |
| Takagi, K | 1 |
| Nanasato, M | 3 |
| Yokomatsu, T | 1 |
| Takamisawa, I | 1 |
| Doi, M | 1 |
| Noda, T | 1 |
| Seino, Y | 1 |
| Tada, T | 4 |
| Hibi, K | 4 |
| Hanaoka, KI | 1 |
| Kozuma, K | 4 |
| Pandey, CP | 1 |
| Misra, A | 1 |
| Negi, MPS | 1 |
| Kanuri, BN | 1 |
| Chhonker, YS | 1 |
| Bhatta, RS | 1 |
| Narain, VS | 1 |
| Dikshit, M | 1 |
| Hwang, IC | 1 |
| Yoon, YE | 1 |
| Choi, IS | 2 |
| Kim, HL | 1 |
| Chang, HJ | 1 |
| Lee, JY | 3 |
| Choi, JA | 1 |
| Kim, HJ | 3 |
| Cho, GY | 1 |
| Park, JB | 1 |
| Lee, SP | 3 |
| Kim, HK | 2 |
| Kim, YJ | 4 |
| Sohn, DW | 1 |
| Kim, SM | 1 |
| Jung, JM | 2 |
| Kim, BJ | 2 |
| Lee, JS | 3 |
| Kwon, SU | 1 |
| Magro, M | 1 |
| Chowdhary, S | 1 |
| Eitel, I | 1 |
| Zweiker, R | 2 |
| Ong, P | 1 |
| Ottesen, MM | 1 |
| Tijssen, JGP | 3 |
| Carrie, D | 5 |
| Dannenberg, L | 2 |
| Metzen, D | 1 |
| Zako, S | 1 |
| Pöhl, M | 1 |
| Mourikis, P | 1 |
| Helten, C | 1 |
| Trojovsky, K | 1 |
| Naguib, D | 1 |
| Konsek, D | 1 |
| Knoop, B | 1 |
| Ayhan, A | 1 |
| Hohlfeld, T | 2 |
| Petzold, T | 1 |
| Levkau, B | 2 |
| Veulemans, V | 1 |
| Zeus, T | 3 |
| Kelm, M | 5 |
| Polzin, A | 3 |
| Spitzer, E | 1 |
| Yap, SC | 1 |
| Hoole, SP | 1 |
| Gori, T | 3 |
| Zaman, A | 1 |
| Frey, B | 1 |
| Ferreira, RC | 2 |
| Bertrand, OF | 3 |
| Koh, TH | 1 |
| Sousa, A | 1 |
| Moschovitis, A | 3 |
| van Geuns, RJ | 3 |
| Stefanescu Schmidt, AC | 2 |
| Yeh, RW | 15 |
| Kereiakes, DJ | 18 |
| Tanguay, JF | 5 |
| Hsieh, WH | 7 |
| Massaro, JM | 12 |
| Mauri, L | 18 |
| Cutlip, DE | 15 |
| Gelbenegger, G | 1 |
| Postula, M | 1 |
| Pecen, L | 1 |
| Schoergenhofer, C | 1 |
| Jilma, B | 6 |
| Hengstenberg, C | 2 |
| Siller-Matula, JM | 3 |
| Wernly, B | 2 |
| Rezar, R | 1 |
| Jung, C | 2 |
| Kerkmeijer, L | 1 |
| Moccetti, T | 2 |
| Talwar, S | 2 |
| Maillard, L | 4 |
| Barlis, P | 1 |
| Wykrzykowska, J | 2 |
| Peterson, ED | 20 |
| Bode, C | 7 |
| Gersh, B | 1 |
| Barbato, E | 5 |
| Neergaard-Petersen, S | 6 |
| Ajjan, RA | 1 |
| Sandner, SE | 1 |
| Wiedemann, D | 1 |
| Misfeld, M | 2 |
| Böning, A | 1 |
| Tebbe, U | 1 |
| Nowak, B | 1 |
| Stritzke, J | 1 |
| Laufer, G | 2 |
| Charif, F | 1 |
| Hamdan, R | 1 |
| Youness, G | 1 |
| El Zein, A | 1 |
| Issa, M | 1 |
| Jassar, Y | 1 |
| Younes, M | 1 |
| Saab, M | 1 |
| De Gennaro, L | 1 |
| Caldarola, P | 1 |
| Birnbaum, Y | 6 |
| Tran, D | 1 |
| Chen, H | 1 |
| Nylander, S | 2 |
| Sampaio, LC | 1 |
| Yang, H | 3 |
| Zhang, F | 1 |
| Zheng, M | 1 |
| Cao, R | 1 |
| Dai, Y | 1 |
| Yao, K | 2 |
| Gili, S | 2 |
| Bertaina, M | 1 |
| Iannaccone, M | 1 |
| Cammann, VL | 1 |
| Di Vece, D | 1 |
| Kato, K | 1 |
| Szawan, KA | 1 |
| Frangieh, AH | 1 |
| Boffini, B | 1 |
| Annaratone, M | 1 |
| Sarcon, A | 1 |
| Levinson, RA | 1 |
| Franke, J | 1 |
| Napp, LC | 1 |
| Jaguszewski, M | 1 |
| Noutsias, M | 1 |
| Münzel, T | 1 |
| Knorr, M | 1 |
| Heiner, S | 1 |
| Katus, HA | 4 |
| Burgdorf, C | 1 |
| Thiele, H | 1 |
| Bauersachs, J | 3 |
| Tschöpe, C | 1 |
| Pieske, BM | 1 |
| Rajan, L | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Cuneo, A | 1 |
| Jacobshagen, C | 2 |
| Hasenfuß, G | 1 |
| Karakas, M | 1 |
| Koenig, W | 2 |
| Rottbauer, W | 1 |
| Said, SM | 2 |
| Braun-Dullaeus, RC | 3 |
| Banning, A | 1 |
| Cuculi, F | 1 |
| Kobza, R | 1 |
| Fischer, TA | 2 |
| Vasankari, T | 1 |
| Airaksinen, KEJ | 1 |
| Dworakowski, R | 1 |
| MacCarthy, P | 2 |
| Kaiser, C | 1 |
| Osswald, S | 2 |
| Galiuto, L | 1 |
| Crea, F | 6 |
| Dichtl, W | 1 |
| Franz, WM | 1 |
| Empen, K | 1 |
| Felix, SB | 1 |
| Delmas, C | 1 |
| Lairez, O | 1 |
| El-Battrawy, I | 1 |
| Akin, I | 1 |
| Borggrefe, M | 2 |
| Horowitz, JD | 1 |
| Kozel, M | 1 |
| Tousek, P | 1 |
| Gilyarova, E | 1 |
| Shilova, A | 1 |
| Gilyarov, M | 1 |
| Biondi-Zoccai, G | 5 |
| Winchester, DE | 1 |
| Ukena, C | 1 |
| Neuhaus, M | 1 |
| Bax, JJ | 2 |
| Prasad, A | 2 |
| Di Mario, C | 2 |
| Böhm, M | 3 |
| Gasparini, M | 1 |
| Ruschitzka, F | 1 |
| Bossone, E | 1 |
| Citro, R | 1 |
| Rinaldi, M | 2 |
| Lüscher, T | 1 |
| Ghadri, JR | 1 |
| Templin, C | 3 |
| Schneider, DJ | 1 |
| McMahon, SR | 1 |
| Ehle, GL | 1 |
| Chava, S | 1 |
| Taatjes-Sommer, HS | 1 |
| Meagher, S | 1 |
| Willemsen, LM | 1 |
| Janssen, PWA | 1 |
| Hackeng, CM | 4 |
| Kelder, JC | 4 |
| van Straten, AHM | 1 |
| Soliman-Hamad, MA | 1 |
| Deneer, VHM | 1 |
| Daeter, EJ | 1 |
| Sonker, U | 1 |
| Klein, P | 1 |
| Kashou, AH | 1 |
| May, AM | 1 |
| Noseworthy, PA | 1 |
| Mercado-Lubo, R | 1 |
| Yarzebski, J | 10 |
| Lessard, D | 9 |
| Gore, J | 2 |
| Goldberg, RJ | 17 |
| Faggioni, M | 4 |
| Redfors, B | 2 |
| Crowley, A | 1 |
| Claessen, BE | 3 |
| Farhan, S | 5 |
| Mastoris, I | 2 |
| Maehara, A | 3 |
| Généreux, P | 5 |
| Ben-Yehuda, O | 4 |
| Kirtane, AJ | 10 |
| Wada, H | 1 |
| Ogita, M | 1 |
| Ozaki, Y | 1 |
| Kimura, K | 4 |
| Ako, J | 3 |
| Noguchi, T | 2 |
| Yasuda, S | 2 |
| Nakama, Y | 1 |
| Morita, T | 2 |
| Shimizu, W | 1 |
| Saito, Y | 3 |
| Hirohata, A | 2 |
| Morita, Y | 1 |
| Inoue, T | 1 |
| Okamura, A | 1 |
| Mano, T | 1 |
| Hirata, K | 1 |
| Shibata, Y | 1 |
| Owa, M | 1 |
| Tsujita, K | 3 |
| Funayama, H | 1 |
| Kokubu, N | 1 |
| Uemura, S | 2 |
| Toubaru, T | 1 |
| Saku, K | 1 |
| Oshima, S | 3 |
| Nishimura, K | 2 |
| Miyamoto, Y | 3 |
| Ogawa, H | 14 |
| Ishihara, M | 1 |
| Gitin, A | 1 |
| Pfeffer, MA | 4 |
| DeMets, DL | 1 |
| Hennekens, CH | 38 |
| Sessler, DI | 4 |
| Conen, D | 2 |
| Leslie, K | 3 |
| Popova, E | 3 |
| Graham, M | 2 |
| Kurz, A | 3 |
| Villar, JC | 3 |
| Mrkobrada, M | 5 |
| Sigamani, A | 4 |
| Biccard, BM | 5 |
| Meyhoff, CS | 4 |
| Parlow, JL | 3 |
| Guyatt, G | 3 |
| Chan, MTV | 5 |
| Kumar, PA | 3 |
| Forget, P | 2 |
| Malaga, G | 2 |
| Fleischmann, E | 3 |
| Amir, M | 3 |
| Torres, D | 2 |
| Wang, CY | 2 |
| Paniagua, P | 2 |
| Berwanger, O | 3 |
| Srinathan, S | 2 |
| Landoni, G | 3 |
| Manach, YL | 1 |
| Whitlock, R | 4 |
| Balasubramanian, K | 2 |
| Gilron, I | 1 |
| Turan, A | 1 |
| Pettit, S | 2 |
| Devereaux, PJ | 7 |
| Beller, JP | 1 |
| Chancellor, WZ | 1 |
| Mehaffey, JH | 1 |
| Hawkins, RB | 1 |
| Byler, MR | 1 |
| Speir, AM | 1 |
| Quader, MA | 1 |
| Kiser, AC | 1 |
| Yarboro, LT | 1 |
| Ailawadi, G | 1 |
| Teman, NR | 1 |
| Cucchiara, B | 1 |
| Elm, J | 1 |
| Easton, JD | 8 |
| Coutts, SB | 1 |
| Willey, JZ | 1 |
| Biros, MH | 1 |
| Ross, MA | 1 |
| Johnston, SC | 9 |
| Martí, D | 1 |
| Carballeira, D | 1 |
| Morales, MJ | 1 |
| Concepción, R | 1 |
| Del Castillo, H | 1 |
| Marschall, A | 1 |
| Delgado-Calva, FA | 1 |
| Dejuán-Bitriá, C | 1 |
| Pérez-Guzmán, J | 1 |
| López-Soberón, E | 1 |
| Palazuelos, J | 2 |
| Álvarez-Antón, S | 1 |
| Bhasin, V | 1 |
| Skopicki, HA | 1 |
| Parikh, PB | 2 |
| Benetou, DR | 1 |
| Varlamos, C | 1 |
| Mpahara, A | 1 |
| Alexopoulos, D | 3 |
| Belhassena, I | 1 |
| Nouari, W | 1 |
| Messaoud, A | 1 |
| Nouar, M | 1 |
| Brahimi, M | 1 |
| Lamara, SC | 1 |
| Aribi, M | 1 |
| Pencina, MJ | 3 |
| Berdan, LG | 2 |
| Faulkner, M | 1 |
| Fonarow, GC | 9 |
| Nallamothu, BK | 1 |
| Fintel, DJ | 2 |
| Ford, DE | 2 |
| Daugherty, SE | 2 |
| Nauman, E | 2 |
| Kraschnewski, J | 1 |
| Ahmad, FS | 2 |
| Haynes, K | 3 |
| Metkus, T | 1 |
| Shah, RC | 1 |
| McClay, JC | 2 |
| Geary, C | 1 |
| Lampert, BC | 1 |
| Seifein, H | 1 |
| Roger, VL | 4 |
| Alvarado, G | 1 |
| Goldberg, YH | 2 |
| VanWormer, JL | 1 |
| McTigue, KM | 2 |
| Rothman, R | 1 |
| Cainzos-Achirica, M | 1 |
| Miedema, MD | 2 |
| Al Rifai, M | 1 |
| Greenland, P | 2 |
| Dardari, Z | 1 |
| Budoff, M | 1 |
| Blumenthal, RS | 2 |
| Yeboah, J | 1 |
| Duprez, DA | 1 |
| Mortensen, MB | 1 |
| Dzaye, O | 1 |
| Hong, J | 1 |
| Nasir, K | 1 |
| Blaha, MJ | 1 |
| Shoji, S | 1 |
| Sawano, M | 1 |
| Sandhu, AT | 1 |
| Heidenreich, PA | 4 |
| Shiraishi, Y | 1 |
| Ikemura, N | 1 |
| Ueno, K | 1 |
| Suzuki, M | 1 |
| Numasawa, Y | 1 |
| Fukuda, K | 1 |
| Kohsaka, S | 1 |
| Kim, W | 2 |
| Kim, JS | 7 |
| Choi, BG | 2 |
| Jang, WY | 1 |
| Kang, DO | 2 |
| Park, Y | 4 |
| Choi, JY | 1 |
| Roh, SY | 1 |
| Na, JO | 2 |
| Choi, CU | 2 |
| Kim, EJ | 3 |
| Park, CG | 3 |
| Seo, HS | 3 |
| Choi, SY | 2 |
| Byun, JK | 2 |
| Cha, J | 1 |
| Oh, DJ | 3 |
| Gajanana, D | 1 |
| Weintraub, WS | 6 |
| Kolm, P | 3 |
| Iantorno, M | 1 |
| Khalid, N | 1 |
| Shlofmitz, E | 1 |
| Khan, JM | 1 |
| Musallam, A | 1 |
| Fox, KA | 28 |
| Moroni, F | 1 |
| Gallone, G | 1 |
| Pagnesi, M | 1 |
| Venuti, A | 1 |
| Beneduce, A | 1 |
| Calvo, F | 3 |
| Gramegna, M | 1 |
| Godino, C | 4 |
| Cappelletti, AM | 1 |
| Wu, XT | 1 |
| He, RR | 1 |
| Liang, SZ | 1 |
| Ye, GY | 1 |
| Ding, SB | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Gencer, B | 1 |
| Li, XS | 1 |
| Gurmu, Y | 2 |
| Morrow, DA | 8 |
| Cohen, M | 19 |
| Johanson, P | 4 |
| Wang, Z | 7 |
| Hazen, SL | 1 |
| Sabatine, MS | 17 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 3 |
| Ferrante, G | 2 |
| Venkateswaran, RV | 1 |
| Magnani, G | 5 |
| Dellborg, M | 9 |
| Kamensky, G | 3 |
| Isaza, D | 1 |
| Aylward, P | 3 |
| Gager, GM | 1 |
| Winter, MP | 1 |
| Lang, IM | 1 |
| Toma, A | 1 |
| Prüller, F | 1 |
| Wallner, M | 1 |
| Kolesnik, E | 1 |
| von Lewinski, D | 1 |
| Galuppo, J | 1 |
| Kowker, A | 1 |
| Rolfs, J | 1 |
| Nicholas, J | 1 |
| Schmidt, E | 1 |
| Formigli, D | 1 |
| Cosentino, N | 3 |
| Paolillo, C | 1 |
| Di Lenarda, A | 2 |
| Scherillo, M | 1 |
| Yan, H | 1 |
| Tiemuerniyazi, X | 1 |
| Song, Y | 4 |
| Xu, F | 3 |
| Feng, W | 2 |
| Erol, MK | 1 |
| Kayıkçıoğlu, M | 1 |
| Kılıçkap, M | 1 |
| Arın, CB | 1 |
| Kurt, IH | 1 |
| Aktaş, I | 1 |
| Güneş, Y | 1 |
| Özkan, E | 1 |
| Şen, T | 1 |
| Ince, O | 1 |
| Örnek, E | 1 |
| Asoğlu, R | 1 |
| Aladağ, N | 1 |
| Zeybey, U | 1 |
| Sinan, ÜY | 1 |
| Dural, M | 1 |
| Tüner, H | 1 |
| Doğan, A | 3 |
| Yenerçağ, M | 1 |
| Akboğa, M | 1 |
| Deveci, OS | 1 |
| Somuncu, MU | 1 |
| Cheng, D | 1 |
| Zhao, S | 1 |
| Hao, Y | 1 |
| Smilowitz, NR | 2 |
| Berger, JS | 7 |
| Sun, B | 1 |
| Xu, Y | 3 |
| Liu, ZY | 1 |
| Meng, WX | 1 |
| Chon, MK | 1 |
| Jung, SM | 1 |
| Hwang, KW | 1 |
| Park, YH | 1 |
| Chun, KJ | 1 |
| van Klaveren, D | 2 |
| Niethammer, M | 1 |
| Fontos, G | 1 |
| Angioi, M | 1 |
| Ribeiro, VG | 1 |
| Leandro, S | 1 |
| Verbeeck, J | 1 |
| Sharif, F | 2 |
| Darmon, A | 1 |
| Mas, JL | 4 |
| Cacoub, P | 3 |
| Billaut-Laden, I | 1 |
| Khan, SU | 2 |
| Singh, M | 1 |
| Valavoor, S | 1 |
| Khan, MU | 1 |
| Lone, AN | 1 |
| Khan, MZ | 1 |
| Khan, MS | 3 |
| Mani, P | 1 |
| Kapadia, SR | 1 |
| Kalra, A | 1 |
| Lanthier, L | 1 |
| Huard, G | 1 |
| Plourde, ME | 1 |
| Cauchon, M | 1 |
| d'Entremont, MA | 1 |
| Laferrière, C | 1 |
| Bérubé, S | 1 |
| Couture, ÉL | 1 |
| Lepage, S | 1 |
| Huynh, T | 3 |
| Verreault-Julien, L | 1 |
| Karzon, A | 1 |
| Desgagnés, N | 1 |
| Nguyen, M | 1 |
| Dobesh, PP | 2 |
| Finks, SW | 1 |
| Trujillo, TC | 1 |
| Masson, G | 1 |
| Lobo, M | 1 |
| Masson, W | 1 |
| Molinero, G | 1 |
| Gurbel, PA | 15 |
| Bliden, KP | 2 |
| Chaudhary, R | 1 |
| Tantry, US | 5 |
| Kaplovitch, E | 1 |
| Abola, MT | 1 |
| Makkar, RR | 1 |
| Saito, S | 5 |
| Neumann, FJ | 10 |
| Hermiller, J | 1 |
| Picon, H | 1 |
| Toelg, R | 1 |
| Maksoud, A | 1 |
| Chehab, BM | 1 |
| Wang, LJ | 1 |
| Thury, A | 1 |
| Suryapranata, H | 5 |
| Walsh, S | 2 |
| Cotton, J | 1 |
| Sabate, M | 7 |
| Steinwender, C | 1 |
| Leibundgut, G | 1 |
| Khan, N | 1 |
| Moss, A | 1 |
| Gorog, DA | 1 |
| Nightingale, P | 1 |
| Armesilla, A | 1 |
| Smallwood, A | 1 |
| Munir, S | 1 |
| Khogali, S | 1 |
| Wrigley, B | 1 |
| Cotton, JM | 1 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 1 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 24 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| Khera, A | 2 |
| Kinoshita, Y | 2 |
| Hioki, H | 1 |
| Ito, Y | 3 |
| Yamaguchi, J | 2 |
| Shiode, N | 1 |
| Sonoda, S | 1 |
| Lee, HL | 1 |
| Kim, JT | 1 |
| Park, MS | 1 |
| Choi, KH | 1 |
| Park, JM | 1 |
| Kang, K | 1 |
| Lee, SJ | 1 |
| Kim, JG | 1 |
| Cha, JK | 1 |
| Kim, DH | 1 |
| Park, TH | 4 |
| Park, SS | 1 |
| Lee, KB | 1 |
| Lee, J | 3 |
| Hong, KS | 1 |
| Cho, YJ | 1 |
| Park, HK | 2 |
| Lee, BC | 1 |
| Yu, KH | 1 |
| Sun Oh, M | 1 |
| Kim, DE | 1 |
| Ryu, WS | 1 |
| Choi, JC | 1 |
| Kwon, JH | 1 |
| Kim, WJ | 2 |
| Shin, DI | 2 |
| Sohn, SI | 1 |
| Hong, JH | 1 |
| Bae, HJ | 1 |
| Wang, HY | 1 |
| Cai, ZX | 1 |
| Yin, D | 1 |
| Yang, YJ | 2 |
| Song, WH | 1 |
| Dou, KF | 1 |
| Desai, N | 2 |
| Wilson, B | 1 |
| Bond, M | 1 |
| Conant, A | 1 |
| Rahman, M | 1 |
| Ullah, W | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Goldsweig, AM | 1 |
| Velagapudi, P | 1 |
| Fichman, DL | 1 |
| Alraies, MC | 1 |
| Wang, W | 5 |
| Wang, B | 2 |
| Wei, S | 1 |
| Yeh, JS | 1 |
| Hsu, CY | 2 |
| Huang, CY | 1 |
| Chen, WT | 1 |
| Hsieh, YC | 1 |
| Chien, LN | 1 |
| Sikharulidze, I | 1 |
| Chelidze, K | 1 |
| Mamatsashvili, I | 1 |
| Wittbrodt, E | 1 |
| Bhalla, N | 1 |
| Sundell, KA | 1 |
| Hunt, P | 1 |
| Wong, ND | 2 |
| Kuster, M | 1 |
| Mellström, C | 1 |
| Ardissino, D | 8 |
| Im, K | 2 |
| Oude Ophius, T | 1 |
| Goudev, A | 1 |
| Parkhomenko, A | 5 |
| López-Sendón, J | 7 |
| Braunwald, E | 35 |
| Tefferi, A | 1 |
| Szuber, N | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Vannucchi, AM | 1 |
| Barbui, T | 1 |
| Gangat, N | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Dillon, C | 1 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Hess, NR | 1 |
| Sultan, I | 1 |
| Thoma, F | 1 |
| Kilic, A | 1 |
| Biltaji, E | 1 |
| Walker, B | 1 |
| Au, TH | 1 |
| Rivers, Z | 1 |
| Ose, J | 1 |
| Li, CI | 1 |
| Brixner, DI | 1 |
| Stenehjem, DD | 1 |
| Ulrich, CM | 1 |
| Dalen, JE | 12 |
| Waterbrook, A | 1 |
| Wylie, L | 1 |
| Alpert, JS | 4 |
| Crenshaw, DL | 1 |
| Handberg, EM | 2 |
| Manning, BR | 1 |
| Riley, D | 1 |
| Hess, R | 1 |
| Kraschnewski, JL | 1 |
| Campbell, JR | 1 |
| Bell, DS | 1 |
| Paranjape, A | 1 |
| Qualls, LG | 1 |
| Modrow, MF | 1 |
| Marcus, GM | 1 |
| Carton, TW | 1 |
| Waitman, LR | 1 |
| Kho, AN | 1 |
| Shenkman, EA | 1 |
| Kaushal, R | 1 |
| Masoudi, FA | 11 |
| Antman, EM | 18 |
| Davidson, DR | 1 |
| Edgley, K | 1 |
| Brown, LS | 1 |
| McCormick, TE | 1 |
| Alikhaani, JD | 1 |
| Gregoire, KC | 1 |
| Bosch, JJ | 1 |
| Winkelmann, BR | 1 |
| Violi, F | 4 |
| Cammisotto, V | 1 |
| Pignatelli, P | 3 |
| Hamburg, NM | 1 |
| Creager, MA | 5 |
| Roberto, M | 1 |
| Radovanovic, D | 4 |
| Buttà, C | 1 |
| Tersalvi, G | 1 |
| Krüll, J | 1 |
| Erne, P | 5 |
| Rickli, H | 4 |
| Pedrazzini, GB | 1 |
| Moccetti, M | 1 |
| Lahu, S | 1 |
| Bristot, P | 1 |
| Gewalt, S | 1 |
| Goedel, A | 1 |
| Giacoppo, D | 4 |
| Schüpke, S | 1 |
| Sarafoff, N | 2 |
| Lin, Y | 3 |
| Yuan, J | 2 |
| Qin, H | 1 |
| Dong, S | 1 |
| Chen, Q | 1 |
| Lesén, E | 1 |
| Hewitt, C | 1 |
| Giannitsis, E | 2 |
| Hedberg, J | 1 |
| Jernberg, T | 4 |
| Lambrelli, D | 1 |
| Simeone, JC | 1 |
| Ariza-Solé, A | 2 |
| Ten Berg, J | 2 |
| Bonaca, M | 1 |
| Man, F | 1 |
| Pan, Q | 1 |
| Guo, L | 3 |
| Ye, R | 1 |
| Ma, Q | 2 |
| Li, WN | 1 |
| Liu, HY | 1 |
| Zhang, HY | 1 |
| Dong, JY | 1 |
| Tian, XL | 1 |
| Streif, W | 2 |
| Povsic, TJ | 1 |
| White, J | 3 |
| Rockhold, F | 1 |
| Plotnikov, A | 1 |
| Strony, J | 1 |
| Husted, S | 2 |
| Tendera, M | 6 |
| Bahit, MC | 3 |
| Claeys, MJ | 5 |
| Kiss, RG | 5 |
| Güray, Ü | 1 |
| Park, DW | 6 |
| Stolk, LM | 1 |
| de Vries, F | 1 |
| Ebbelaar, C | 1 |
| Schalekamp, T | 1 |
| Souverein, P | 1 |
| Ten Cate-Hoek, A | 1 |
| Burden, AM | 1 |
| Henry, TD | 12 |
| Ariti, C | 3 |
| Aquino, M | 3 |
| Chandrasekhar, J | 3 |
| Kini, AS | 2 |
| Pitts, R | 1 |
| Daugherty, SL | 2 |
| Tang, F | 1 |
| Jones, P | 1 |
| Ho, PM | 8 |
| Tsai, TT | 1 |
| Spertus, J | 2 |
| Maddox, TM | 2 |
| Alfonso, F | 4 |
| Jiménez-Borreguero, LJ | 1 |
| Mahmoud, AN | 2 |
| Elgendy, AY | 1 |
| Rambarat, C | 1 |
| Mahtta, D | 1 |
| Bavry, AA | 5 |
| Pandey, A | 1 |
| Golwala, H | 1 |
| Hall, HM | 2 |
| Wang, TY | 14 |
| Lu, D | 2 |
| Xian, Y | 2 |
| Chiswell, K | 2 |
| Joynt, KE | 1 |
| Goyal, A | 1 |
| Das, SR | 3 |
| Kumbhani, D | 1 |
| Julien, H | 1 |
| Secemsky, EA | 3 |
| Apruzzese, PK | 3 |
| Pagnotta, P | 2 |
| Moreno, E | 1 |
| Vázquez-Polo, FJ | 1 |
| Negrín, MA | 1 |
| Sorbets, E | 1 |
| Rodés-Cabau, J | 3 |
| Masson, JB | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 2 |
| Al-Qoofi, F | 1 |
| Maluenda, G | 1 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Choi, HI | 1 |
| Ahn, JM | 2 |
| Lee, PH | 2 |
| Kang, SJ | 4 |
| Lee, SW | 8 |
| Kim, YH | 9 |
| Lee, CW | 9 |
| Park, SW | 10 |
| Park, SJ | 11 |
| Richman, IB | 1 |
| Owens, DK | 1 |
| Li, R | 1 |
| Tang, X | 3 |
| Jing, Q | 2 |
| Yang, M | 2 |
| Han, X | 1 |
| Zhao, J | 1 |
| Yu, X | 3 |
| Olesen, KKW | 2 |
| Madsen, M | 2 |
| Egholm, G | 1 |
| Thim, T | 2 |
| Jensen, LO | 3 |
| Raungaard, B | 1 |
| Bøtker, HE | 3 |
| Sørensen, HT | 4 |
| Maeng, M | 7 |
| Gargiulo, G | 4 |
| Santucci, A | 2 |
| Ariotti, S | 3 |
| Baldo, A | 2 |
| Uzu, K | 1 |
| Shinke, T | 2 |
| Otake, H | 1 |
| Takaya, T | 1 |
| Osue, T | 1 |
| Iwasaki, M | 1 |
| Kinutani, H | 1 |
| Konishi, A | 1 |
| Kuroda, M | 1 |
| Takahashi, H | 1 |
| Terashita, D | 1 |
| Hirata, KI | 1 |
| Nakamura, M | 6 |
| Shite, J | 1 |
| Akasaka, T | 2 |
| Gonzini, L | 1 |
| Cavallini, C | 2 |
| Mauro, C | 2 |
| Cacciavillani, L | 1 |
| Savonitto, S | 2 |
| De Servi, S | 3 |
| Iijima, R | 1 |
| Okada, H | 2 |
| Anzai, H | 1 |
| Tanaka, H | 3 |
| Ueda, Y | 3 |
| Takiuchi, S | 1 |
| Nishida, Y | 2 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 1 |
| Ishiwata, S | 2 |
| Ochiai, M | 3 |
| Hamasaki, T | 1 |
| Yokoi, H | 5 |
| Didier, R | 1 |
| Morice, MC | 7 |
| Barragan, P | 3 |
| Noryani, AAL | 1 |
| Noor, HA | 1 |
| Majwal, T | 1 |
| Castellant, P | 2 |
| Schneeberger, M | 1 |
| Bressolette, E | 1 |
| Wojcik, J | 1 |
| Delarche, N | 3 |
| Blanchard, D | 4 |
| Jouve, B | 1 |
| Ormezzano, O | 1 |
| Paganelli, F | 1 |
| Levy, G | 2 |
| Sainsous, J | 1 |
| Furber, A | 3 |
| Berlan, J | 1 |
| Darremont, O | 1 |
| Le Breton, H | 2 |
| Lyuycx-Bore, A | 1 |
| Gommeaux, A | 2 |
| Cassat, C | 1 |
| Kermarrec, A | 1 |
| Cazaux, P | 2 |
| Druelles, P | 2 |
| Dauphin, R | 1 |
| Armengaud, J | 1 |
| Dupouy, P | 2 |
| Champagnac, D | 1 |
| Ohlmann, P | 2 |
| Ben Amer, H | 1 |
| Ungi, I | 1 |
| Gilard, M | 6 |
| Volpp, KG | 1 |
| Troxel, AB | 1 |
| Mehta, SJ | 1 |
| Norton, L | 1 |
| Lim, R | 1 |
| Marcus, N | 1 |
| Terwiesch, C | 1 |
| Caldarella, K | 1 |
| Levin, T | 1 |
| Relish, M | 1 |
| Negin, N | 1 |
| Smith-McLallen, A | 1 |
| Snyder, R | 1 |
| Spettell, CM | 1 |
| Drachman, B | 1 |
| Kolansky, D | 1 |
| Asch, DA | 2 |
| Kim, TH | 2 |
| Kim, JJ | 7 |
| Choi, IJ | 1 |
| Choi, Y | 1 |
| Park, HW | 3 |
| Koh, YS | 2 |
| Kim, PJ | 2 |
| Kim, MJ | 1 |
| Cho, JH | 3 |
| Jung, JI | 1 |
| Jiang, M | 1 |
| You, JHS | 1 |
| Im, E | 1 |
| Cho, YH | 2 |
| Suh, Y | 1 |
| Cho, DK | 1 |
| Lee, K | 4 |
| Kang, WC | 2 |
| Yun, KH | 1 |
| Yoo, SY | 1 |
| Cheong, SS | 3 |
| Shin, DH | 3 |
| Ahn, CM | 1 |
| Ko, YG | 3 |
| Choi, D | 3 |
| Jang, Y | 7 |
| Hong, MK | 13 |
| Amarenco, P | 4 |
| Albers, GW | 5 |
| Denison, H | 4 |
| Evans, SR | 3 |
| Held, P | 10 |
| Hill, MD | 2 |
| Jonasson, J | 2 |
| Kasner, SE | 1 |
| Ladenvall, P | 3 |
| Minematsu, K | 4 |
| Molina, CA | 4 |
| Wong, KSL | 2 |
| Karmali, KN | 1 |
| Meid, AD | 1 |
| Mächler, S | 1 |
| Haefeli, WE | 1 |
| Mikus, G | 1 |
| Subramanyam, P | 1 |
| Gianos, E | 1 |
| Reynolds, HR | 1 |
| Shah, B | 2 |
| Sedlis, SP | 1 |
| Blackwood, B | 1 |
| Lee, S | 4 |
| Liebmann, O | 1 |
| Binder, W | 1 |
| Wen, L | 1 |
| Stuckey, TD | 7 |
| Brodie, BR | 8 |
| Litherland, C | 1 |
| Rinaldi, MJ | 7 |
| Metzger, DC | 5 |
| Cox, DA | 8 |
| Duffy, PL | 4 |
| Mazzaferri, EL | 4 |
| Simonton, CA | 2 |
| Würtz, M | 4 |
| Harada, Y | 1 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Mayer, K | 1 |
| Emmer, R | 1 |
| Lahmann, AL | 1 |
| Colleran, R | 1 |
| Wolk, A | 1 |
| Han, Y | 4 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 1 |
| Zrenner, B | 1 |
| Wöhrle, J | 2 |
| Kufner, S | 1 |
| Morath, T | 1 |
| Ibrahim, T | 1 |
| Bernlochner, I | 1 |
| Fischer, M | 1 |
| Laugwitz, KL | 1 |
| Mehilli, J | 3 |
| Byrne, RA | 4 |
| Schulz-Schüpke, S | 1 |
| Feres, F | 4 |
| Abizaid, A | 3 |
| Palmerini, T | 5 |
| Fuku, Y | 1 |
| Amano, H | 1 |
| Kubo, S | 1 |
| Otsuru, S | 1 |
| Habara, S | 1 |
| Goto, T | 1 |
| Huang, WY | 1 |
| Shiels, MS | 1 |
| Purdue, MP | 1 |
| Freedman, ND | 1 |
| Abnet, CC | 1 |
| Hollenbeck, AR | 1 |
| Hayes, RB | 1 |
| Silverman, DT | 1 |
| Berndt, SI | 1 |
| Jawaid, H | 1 |
| Hussain, A | 1 |
| Imtiaz, F | 1 |
| He, RX | 1 |
| Zhou, TN | 1 |
| Yuan, WJ | 1 |
| Liu, YJ | 1 |
| Fu, WX | 1 |
| Jing, QM | 2 |
| Liu, HW | 1 |
| Wang, XZ | 1 |
| Sá, MPBO | 1 |
| Soares, AF | 1 |
| Miranda, RGA | 1 |
| Araújo, ML | 1 |
| Menezes, AM | 1 |
| Silva, FPV | 1 |
| Lima, RC | 1 |
| Schäfer, A | 3 |
| Chen, HY | 1 |
| Chou, P | 1 |
| Olin, J | 1 |
| Scirica, BS | 1 |
| Piazza, G | 1 |
| Goodrich, EL | 1 |
| Sindet-Pedersen, C | 2 |
| Staerk, L | 2 |
| Lamberts, M | 7 |
| Nissen Bonde, A | 2 |
| Langtved Pallisgaard, J | 1 |
| Hansen, ML | 6 |
| Gislason, GH | 10 |
| Bjerring Olesen, J | 1 |
| Hawks, MK | 1 |
| Dixon, MA | 1 |
| Graham, MM | 1 |
| Cook, DJ | 1 |
| Tandon, V | 1 |
| Alvarez-Garcia, J | 1 |
| Painter, TW | 1 |
| Le Manach, Y | 2 |
| Aphang-Lam, M | 1 |
| Cata, JP | 1 |
| Terblanche, NCS | 1 |
| Ramana, PV | 1 |
| Jamieson, KA | 1 |
| Bessissow, A | 1 |
| Mendoza, GR | 1 |
| Ramirez, S | 1 |
| Diemunsch, PA | 1 |
| Dagenais, G | 1 |
| Metsarinne, K | 1 |
| Ha, JW | 1 |
| Avezum, AA | 2 |
| Lisheng, L | 1 |
| Yusoff, K | 1 |
| Cook Bruns, N | 1 |
| Kakkar, AK | 1 |
| Störk, S | 1 |
| Misselwitz, F | 2 |
| Chen, E | 1 |
| Branch, K | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 2 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 2 |
| von Birgelen, C | 2 |
| Lazar, HL | 1 |
| Kim, JB | 1 |
| Ye, M | 1 |
| Wang, XF | 1 |
| Jia, P | 1 |
| Zeng, YJ | 1 |
| Robertson, L | 1 |
| Yeoh, SE | 1 |
| Ramli, A | 1 |
| Gaglia, MA | 1 |
| Lee, CH | 2 |
| Park, GM | 1 |
| Choi, YJ | 4 |
| Nam, CW | 2 |
| Shin, WY | 1 |
| Seo, JB | 1 |
| Choi, SW | 1 |
| Lee, JH | 4 |
| Min, PK | 1 |
| Her, SH | 2 |
| Elmariah, S | 2 |
| Doros, G | 2 |
| Benavente, OR | 2 |
| Steinhubl, SR | 13 |
| Gouveia, A | 1 |
| De Alencastro, L | 1 |
| Fierz, Y | 1 |
| Koehli, L | 1 |
| Béguelin, A | 1 |
| Pasche, O | 1 |
| Selby, K | 1 |
| Bodenmann, P | 1 |
| Pouwels, XGLV | 1 |
| Wolff, R | 1 |
| Ramaekers, BLT | 1 |
| Van Giessen, A | 1 |
| Lang, S | 1 |
| Ryder, S | 1 |
| Worthy, G | 1 |
| Duffy, S | 1 |
| Armstrong, N | 1 |
| Kleijnen, J | 1 |
| Joore, MA | 1 |
| Yeo, KK | 2 |
| Armstrong, EJ | 3 |
| López, JE | 1 |
| Chen, DC | 3 |
| Westin, GG | 2 |
| Li, CS | 1 |
| Anderson, D | 3 |
| Hua, A | 1 |
| Singapuri, A | 1 |
| Amsterdam, EA | 4 |
| Chiamvimonvat, N | 1 |
| Laird, JR | 3 |
| Mattioli, AV | 1 |
| Manenti, A | 1 |
| Farinetti, A | 1 |
| Schlögl, M | 1 |
| Hofmänner, D | 1 |
| Manka, R | 1 |
| Keller, DI | 1 |
| Kopin, D | 1 |
| Sherwood, MW | 1 |
| Wojdyla, DM | 3 |
| Wallentin, L | 22 |
| Granger, CB | 18 |
| Lopes, RD | 11 |
| McAndrew, T | 2 |
| Karl, S | 1 |
| Fallon, M | 1 |
| Palitsky, R | 1 |
| Martinez, JA | 1 |
| Gündel, H | 1 |
| O'Connor, MF | 1 |
| Godschalk, TC | 1 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 2 |
| Dewilde, WJ | 1 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 1 |
| Heestermans, T | 3 |
| Jermini-Gianinazzi, I | 1 |
| Gao, R | 2 |
| Su, G | 1 |
| Yuan, Z | 2 |
| Zhang, A | 1 |
| Zheng, Y | 1 |
| Chae, SC | 1 |
| Seong, IW | 4 |
| Chae, JK | 3 |
| Cho, MC | 4 |
| Kang, HJ | 5 |
| Grimaldi-Bensouda, L | 1 |
| Danchin, N | 13 |
| Dallongeville, J | 1 |
| Falissard, B | 1 |
| Cottin, Y | 1 |
| Bonello, L | 3 |
| Morel, O | 3 |
| Leclercq, F | 3 |
| Puymirat, E | 3 |
| Ghanem, F | 1 |
| Benichou, J | 1 |
| Abenhaim, L | 1 |
| Kou, N | 1 |
| Xue, M | 1 |
| Yang, L | 2 |
| Zang, MX | 1 |
| Qu, H | 1 |
| Wang, MM | 1 |
| Miao, Y | 2 |
| Yang, B | 2 |
| Shi, DZ | 1 |
| Srivastava, P | 1 |
| Butler, J | 1 |
| Shroyer, AL | 1 |
| Lacey, M | 1 |
| Lin, TT | 1 |
| Lai, HY | 1 |
| Chan, KA | 2 |
| Yang, YY | 1 |
| Lai, CL | 1 |
| Lai, MS | 1 |
| Ertaş, FS | 1 |
| Tokgozoglu, L | 1 |
| Park, JW | 1 |
| Kim, SU | 1 |
| Kwon, DY | 1 |
| Park, MH | 1 |
| Rothnie, KJ | 1 |
| Connell, O | 1 |
| Müllerová, H | 1 |
| Smeeth, L | 2 |
| Pearce, N | 1 |
| Douglas, I | 1 |
| Quint, JK | 2 |
| Wang, A | 2 |
| Wu, A | 1 |
| Wojdyla, D | 1 |
| Newby, LK | 14 |
| Newman, MF | 1 |
| Smith, PK | 2 |
| Farrant, M | 1 |
| Barsan, W | 1 |
| Conwit, RA | 1 |
| Elm, JJ | 1 |
| Kim, AS | 1 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 2 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 2 |
| Basra, SS | 1 |
| Simon, DN | 2 |
| Virani, SS | 1 |
| Alam, M | 1 |
| Nambi, V | 1 |
| Denktas, AE | 2 |
| Deswal, A | 1 |
| Bozkurt, B | 1 |
| Ballantyne, CM | 1 |
| Jneid, H | 1 |
| Zhang, X | 4 |
| Almas, A | 1 |
| Ghazni, MS | 1 |
| Hashmani, S | 1 |
| Mushtaq, Z | 1 |
| Talluri, S | 1 |
| Rahman, H | 1 |
| Lekkala, M | 1 |
| Riaz, H | 2 |
| Shah, H | 1 |
| Kaluski, E | 2 |
| Sattur, S | 1 |
| Tittley, JG | 1 |
| Rapanos, T | 1 |
| Harlock, J | 1 |
| Tiboni, ME | 1 |
| Vásquez, SM | 1 |
| Kabon, B | 1 |
| Mehra, BR | 1 |
| El Beheiry, H | 1 |
| Mata, E | 1 |
| Tena, B | 1 |
| Zainal Abidin, MK | 1 |
| Shah, VR | 1 |
| Donadini, MP | 1 |
| Bellesini, M | 1 |
| Squizzato, A | 1 |
| Southwell, BG | 1 |
| Eder, M | 1 |
| Finnegan, J | 1 |
| Hirsch, AT | 5 |
| Luepker, RV | 2 |
| Duval, S | 5 |
| Russell, C | 1 |
| O'Byrne, S | 1 |
| Zeymer, U | 13 |
| Schrage, B | 1 |
| Westermann, D | 1 |
| Gatzke, N | 1 |
| Hillmeister, P | 1 |
| Dülsner, A | 1 |
| Güc, N | 1 |
| Dawid, R | 1 |
| Smith, KH | 1 |
| Pagonas, N | 1 |
| Bramlage, P | 1 |
| Gorath, M | 1 |
| Buschmann, IR | 1 |
| Sakaguchi, K | 1 |
| Tokuda, Y | 1 |
| Ueda, P | 1 |
| Alfredsson, J | 1 |
| Erlinge, D | 4 |
| Omerovic, E | 1 |
| Persson, J | 2 |
| Ravn-Fischer, A | 2 |
| Tornvall, P | 3 |
| Svennblad, B | 1 |
| Varenhorst, C | 2 |
| Gaziano, JM | 8 |
| Brotons, C | 3 |
| Cricelli, C | 1 |
| Darius, H | 5 |
| Gorelick, PB | 1 |
| Howard, G | 3 |
| Rothwell, PM | 2 |
| Ruilope, LM | 1 |
| Tognoni, G | 11 |
| van Es, GA | 3 |
| van Meijeren, C | 1 |
| Möllmann, H | 2 |
| Slagboom, T | 4 |
| Smith, BB | 1 |
| Warner, MA | 1 |
| Warner, NS | 1 |
| Hanson, AC | 1 |
| Smith, MM | 1 |
| Rihal, CS | 1 |
| Gulati, R | 1 |
| Bell, MR | 2 |
| Nuttall, GA | 1 |
| Lucci, D | 1 |
| Mascia, F | 1 |
| Marinoni, B | 1 |
| Cirillo, P | 1 |
| Grosseto, D | 2 |
| Nardi, F | 1 |
| Geraci, G | 1 |
| Doshi, R | 1 |
| Vadher, A | 1 |
| Mithawala, P | 1 |
| Shah, P | 1 |
| Fathy, S | 1 |
| Shahin, MH | 1 |
| Langaee, T | 1 |
| Khalil, BM | 1 |
| Saleh, A | 1 |
| Sabry, NA | 1 |
| Schaalan, MF | 1 |
| El Wakeel, LL | 1 |
| Cavallari, LH | 1 |
| Garcia Rinaldi, R | 1 |
| Rodriguez-Acosta, J | 1 |
| Bermúdez, D | 1 |
| Galera, Á | 1 |
| Quinones, S | 1 |
| Quinones, J | 1 |
| Pallisgaard, JL | 1 |
| Lock Hansen, M | 1 |
| Olesen, JB | 8 |
| Lichtenauer, M | 1 |
| Hoppe, UC | 1 |
| Lauten, A | 1 |
| Weidmann, L | 1 |
| Obeid, S | 1 |
| Mach, F | 1 |
| Shahin, M | 1 |
| Yousif, N | 1 |
| Denegri, A | 1 |
| Muller, O | 1 |
| Matter, CM | 2 |
| Lüscher, TF | 4 |
| Brener, SJ | 5 |
| Myles, PS | 3 |
| Smith, JA | 2 |
| Kasza, J | 2 |
| Silbert, B | 2 |
| Jayarajah, M | 2 |
| Painter, T | 2 |
| Cooper, DJ | 2 |
| Marasco, S | 2 |
| McNeil, J | 2 |
| Bussières, JS | 2 |
| McGuinness, S | 2 |
| Wallace, S | 2 |
| Forbes, A | 2 |
| Nakabayashi, K | 1 |
| Jujo, K | 1 |
| Furuki, Y | 1 |
| Ishida, I | 1 |
| Ando, H | 1 |
| Shimizu, M | 1 |
| Hagiwara, N | 1 |
| Saito, K | 1 |
| Byrne, K | 1 |
| Soejima, H | 5 |
| Okada, S | 2 |
| Sakuma, M | 1 |
| Nakayama, M | 1 |
| Masuda, I | 1 |
| Doi, N | 1 |
| Jinnouchi, H | 1 |
| Sugiyama, S | 2 |
| Waki, M | 1 |
| Ferrières, J | 8 |
| Sugawara, M | 3 |
| Goto, Y | 1 |
| Yamazaki, T | 3 |
| Teramoto, T | 3 |
| Oikawa, S | 3 |
| Shimada, K | 3 |
| Uchiyama, S | 3 |
| Ishizuka, N | 3 |
| Murata, M | 3 |
| Yokoyama, K | 3 |
| Uemura, Y | 2 |
| Ikeda, Y | 6 |
| Dargham, BB | 1 |
| Baskar, A | 1 |
| Tejani, I | 1 |
| Cui, Z | 1 |
| Chauhan, S | 1 |
| Sum-Ping, J | 1 |
| Weideman, RA | 1 |
| Banerjee, S | 2 |
| Khan, SA | 1 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Rasmussen, DB | 1 |
| Bodtger, U | 1 |
| Nicolaisen, SK | 1 |
| Sessa, M | 1 |
| Capuano, A | 1 |
| Lange, P | 1 |
| Jensen, MT | 1 |
| Sang, W | 1 |
| Wei, M | 1 |
| Berkelmans, GFN | 1 |
| Gudbjörnsdottir, S | 1 |
| Wild, SH | 1 |
| Franzen, S | 1 |
| Chalmers, J | 2 |
| Davis, BR | 1 |
| Poulter, NR | 1 |
| Spijkerman, AM | 1 |
| Pressel, SL | 1 |
| Gupta, AK | 1 |
| van der Schouw, YT | 1 |
| Svensson, AM | 1 |
| Read, SH | 1 |
| Eliasson, B | 1 |
| Hangouche, AJE | 1 |
| Lamliki, O | 1 |
| Oukerraj, L | 1 |
| Dakka, T | 1 |
| Doghmi, N | 1 |
| Zarzur, J | 1 |
| Cherti, M | 1 |
| Zhou, Y | 2 |
| Yao, X | 1 |
| Liu, G | 1 |
| Jian, W | 1 |
| Yip, W | 1 |
| Coppens, M | 1 |
| Weitz, JI | 5 |
| Eikelboom, JWA | 1 |
| Lisowska, A | 1 |
| Makarewicz-Wujec, M | 1 |
| Dworakowska, AM | 1 |
| Kozłowska-Wojciechowska, M | 1 |
| Knutsson, M | 2 |
| Röther, J | 1 |
| Wessels, F | 1 |
| Kriegmair, MC | 1 |
| Oehme, A | 1 |
| Rassweiler-Seyfried, MC | 1 |
| Erben, P | 1 |
| Oberneder, R | 1 |
| Kriegmair, M | 1 |
| Ritter, M | 1 |
| Michel, MS | 1 |
| Honeck, P | 1 |
| Sumaya, W | 1 |
| Geisler, T | 1 |
| McFadden, E | 1 |
| Serruys, P | 1 |
| Liebetrau, C | 1 |
| Bryniarski, K | 1 |
| Vrolix, M | 3 |
| Naber, C | 1 |
| Prokopczuk, J | 1 |
| Steg, G | 2 |
| Nakai, M | 1 |
| Sumita, Y | 1 |
| Shishido, T | 1 |
| Anzai, T | 1 |
| Ito, H | 1 |
| Tsutsui, H | 1 |
| Komuro, I | 1 |
| Krzyzanowski, B | 1 |
| Manson, SM | 1 |
| Eder, MM | 1 |
| Kne, L | 1 |
| Oldenburg, N | 1 |
| Peterson, K | 1 |
| Sundaram, V | 1 |
| Alghanem, F | 1 |
| Clements, JM | 1 |
| Luo, WH | 1 |
| Huang, JW | 2 |
| Zhang, PD | 1 |
| Zheng, W | 1 |
| Tian, J | 1 |
| Xie, L | 1 |
| Mao, Q | 1 |
| Tong, W | 1 |
| Azzalini, L | 1 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 1 |
| Byra, WM | 1 |
| Cleland, JGF | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Mehra, MR | 1 |
| Nessel, CC | 3 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 1 |
| Vanden Boom, CM | 1 |
| Zannad, F | 1 |
| Spasov, AA | 1 |
| Kucheryavenko, AF | 1 |
| Sirotenko, VS | 1 |
| Anisimova, VA | 1 |
| Divaeva, LN | 1 |
| Kuz'menko, TA | 1 |
| Morkovnik, AS | 1 |
| Cortese, M | 1 |
| D Ascenzo, F | 1 |
| Raposeiras-Roubin, S | 1 |
| Abu-Assi, E | 1 |
| Kinnaird, T | 1 |
| Velicki, L | 1 |
| Xanthopoulou, I | 1 |
| Rognoni, A | 2 |
| Boccuzzi, G | 1 |
| Montabone, A | 1 |
| Taha, S | 1 |
| Durante, A | 1 |
| Autelli, M | 1 |
| Grosso, A | 1 |
| Blanco, PF | 1 |
| Garay, A | 1 |
| Quadri, G | 1 |
| Varbella, F | 1 |
| Queija, BC | 1 |
| Paz, RC | 1 |
| Fernández, MC | 1 |
| Pousa, IM | 1 |
| Gallo, D | 1 |
| Morbiducci, U | 1 |
| Dominguez-Rodriguez, A | 1 |
| Valdés, M | 2 |
| Cequier, A | 3 |
| Iñiguez-Romo, A | 1 |
| Chen, ZW | 1 |
| Wu, CK | 1 |
| Yang, YH | 2 |
| Wu, VC | 1 |
| Lee, JK | 2 |
| Chen, PC | 1 |
| Lin, YH | 1 |
| Lin, LY | 1 |
| Chung, H | 1 |
| Shambhu, S | 1 |
| Roe, M | 1 |
| Cziraky, M | 1 |
| Wong, KL | 1 |
| Nishikawa, M | 3 |
| Takeda, Y | 1 |
| Isomura, N | 1 |
| Tanigawa, T | 2 |
| Tsukahara, K | 3 |
| Takayama, T | 1 |
| Hirayama, A | 1 |
| Kato, M | 2 |
| Nishikawa, H | 1 |
| Nishimura, Y | 1 |
| Isshiki, T | 5 |
| Hariri, E | 1 |
| Rade, J | 1 |
| Goldberg, R | 1 |
| Xu, GM | 1 |
| Ding, J | 1 |
| Luu, NM | 1 |
| Dinh, AT | 1 |
| Nguyen, TTH | 1 |
| Nguyen, VH | 1 |
| Zheng, L | 1 |
| Yang, C | 2 |
| Xiang, L | 1 |
| Hao, Z | 1 |
| Im, KA | 1 |
| Oude Ophuis, T | 2 |
| Spinar, J | 4 |
| Kontny, F | 4 |
| Bengtsson, O | 2 |
| Patrono, C | 14 |
| Baigent, C | 10 |
| Bruggmann, C | 1 |
| Iglesias, JF | 2 |
| Gex-Fabry, M | 1 |
| Fesselet, R | 1 |
| Vogt, P | 1 |
| Sadeghipour, F | 1 |
| Voirol, P | 1 |
| Sharma, A | 2 |
| Hagström, E | 2 |
| Neely, ML | 5 |
| Goodman, SG | 12 |
| Tscharre, M | 1 |
| Bruno, V | 1 |
| Rohla, M | 1 |
| Egger, F | 1 |
| Weiss, TW | 2 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 1 |
| Geppert, A | 1 |
| Freynhofer, MK | 1 |
| Iakovou, I | 1 |
| Sorrentino, S | 1 |
| Stuckey, T | 6 |
| Dangas, GD | 6 |
| Wester, A | 1 |
| Attar, R | 1 |
| Mohammad, MA | 1 |
| Andell, P | 1 |
| Hofmann, R | 1 |
| Jensen, J | 1 |
| Szummer, K | 2 |
| Koul, S | 2 |
| Lanzillo, C | 2 |
| Di Roma, M | 1 |
| Sciahbasi, A | 2 |
| Minati, M | 1 |
| Maresca, L | 1 |
| Pendenza, G | 2 |
| Romagnoli, E | 3 |
| Summaria, F | 2 |
| Patrizi, R | 1 |
| Di Luozzo, M | 1 |
| Preziosi, P | 1 |
| Lioy, E | 2 |
| Romeo, F | 3 |
| Chen, F | 2 |
| He, J | 4 |
| Gao, Y | 2 |
| Luo, Y | 2 |
| Zhang, Y | 6 |
| Ren, X | 1 |
| Lv, S | 1 |
| Helft, G | 1 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Eltchaninoff, H | 2 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 3 |
| Cayla, G | 2 |
| Vicaut, E | 4 |
| Metzger, JP | 2 |
| Puri, A | 1 |
| Saireddy, R | 1 |
| McClean, D | 1 |
| Brendel, K | 1 |
| Weigel, G | 1 |
| Griesmacher, A | 1 |
| Pachinger, O | 1 |
| Mair, J | 1 |
| Deo, SV | 1 |
| Dunlay, SM | 1 |
| Shah, IK | 1 |
| Altarabsheh, SE | 1 |
| Erwin, PJ | 2 |
| Boilson, BA | 1 |
| Joyce, LD | 1 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Chang, PY | 1 |
| Chen, YJ | 1 |
| Chang, FH | 1 |
| Lu, J | 2 |
| Huang, WH | 1 |
| Yang, TC | 1 |
| Lee, YT | 2 |
| Chang, SF | 1 |
| Lu, SC | 1 |
| Chen, CH | 1 |
| Mogabgab, O | 1 |
| Wiviott, SD | 15 |
| Foody, JM | 5 |
| Cannon, CP | 36 |
| Li, S | 6 |
| Giugliano, RP | 7 |
| Williams, JB | 1 |
| Hafley, GE | 1 |
| Ferguson, TB | 1 |
| Mack, MJ | 1 |
| Mehta, RH | 4 |
| Borghi, C | 5 |
| Ambrosioni, E | 4 |
| Omboni, S | 3 |
| Cicero, AF | 1 |
| Bacchelli, S | 2 |
| Esposti, DD | 1 |
| Ambrosio, G | 6 |
| Zava, D | 1 |
| Tofler, GH | 5 |
| Spinaze, M | 1 |
| Shaw, E | 1 |
| Buckley, T | 1 |
| Tan, C | 1 |
| Chen, W | 1 |
| Lin, J | 2 |
| Lin, R | 1 |
| Tan, X | 1 |
| Wieczorek, P | 1 |
| Parma, R | 1 |
| Wojakowski, W | 2 |
| Kanth, R | 1 |
| Ittaman, S | 1 |
| Rezkalla, S | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Torpy, JM | 1 |
| Livingston, EH | 1 |
| Mostofsky, E | 1 |
| Maclure, M | 3 |
| Muller, JE | 7 |
| Mittleman, MA | 5 |
| Gao, YX | 1 |
| Yu, XZ | 1 |
| Yuan, YQ | 1 |
| Zhao, XY | 1 |
| Sun, TW | 1 |
| Kristensen, SL | 2 |
| Schjerning Olsen, AM | 1 |
| Mikkelsen, A | 1 |
| Christensen, CB | 1 |
| Lip, GY | 8 |
| Lane, DA | 2 |
| Raichand, S | 1 |
| Moore, D | 1 |
| Connock, M | 1 |
| Fry-Smith, A | 1 |
| Fitzmaurice, DA | 1 |
| Xia, JG | 1 |
| Qu, Y | 1 |
| Shen, H | 1 |
| Liu, XH | 1 |
| Santos, MT | 5 |
| Madrid, I | 1 |
| Moscardo, A | 4 |
| Latorre, AM | 1 |
| Bonastre, J | 1 |
| Ruano, M | 4 |
| Valles, J | 4 |
| Park, CS | 1 |
| Park, HJ | 1 |
| Seo, SM | 1 |
| Kim, DB | 1 |
| Chung, WS | 3 |
| Shin, JG | 1 |
| Dazy, K | 1 |
| Walters, D | 1 |
| Holland, C | 1 |
| Baldwin, J | 1 |
| Okunoye, GO | 1 |
| Dutton, P | 1 |
| Suh, SY | 1 |
| Oh, PC | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Han, SH | 1 |
| Ahn, T | 2 |
| Shin, EK | 1 |
| Ajjan, R | 1 |
| Hess, K | 1 |
| Bell, AD | 1 |
| Ackman, ML | 1 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 2 |
| Wong, G | 2 |
| DeFilippis, AP | 1 |
| Oloyede, OS | 1 |
| Andrikopoulou, E | 1 |
| Saenger, AK | 1 |
| Palachuvattil, JM | 1 |
| Fasoro, YA | 1 |
| Guallar, E | 2 |
| Kickler, TS | 1 |
| Jaffe, AS | 3 |
| Gerstenblith, G | 3 |
| Schulman, SP | 4 |
| Rade, JJ | 1 |
| Park, JJ | 1 |
| Park, BE | 1 |
| Rhew, JY | 2 |
| Jeon, HK | 2 |
| Oh, JH | 2 |
| Kim, S | 2 |
| Hwang, KK | 1 |
| Yoon, JH | 3 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Chiang, FT | 1 |
| Shyu, KG | 2 |
| Wu, CJ | 2 |
| Mar, GY | 1 |
| Hou, CJ | 1 |
| Li, AH | 1 |
| Wen, MS | 1 |
| Lai, WT | 1 |
| Lin, SJ | 2 |
| Kuo, CT | 2 |
| Kuo, C | 1 |
| Li, YH | 2 |
| Hwang, JJ | 1 |
| Tang, Y | 1 |
| Huang, X | 2 |
| Xie, Y | 1 |
| Ebert, AG | 1 |
| Casarosa, F | 1 |
| Limbruno, U | 2 |
| Sato, D | 1 |
| Koga, S | 1 |
| Yasunaga, T | 1 |
| Nakata, T | 1 |
| Takeno, M | 1 |
| Koide, Y | 1 |
| Ikeda, S | 2 |
| Ashizawa, N | 1 |
| Maemura, K | 1 |
| Mahaffey, KW | 8 |
| Stevens, SR | 1 |
| White, HD | 34 |
| Piccini, JP | 5 |
| Becker, RC | 13 |
| Halperin, JL | 3 |
| Hacke, W | 11 |
| Singer, DE | 3 |
| Hankey, GJ | 6 |
| Califf, RM | 24 |
| Breithardt, G | 2 |
| Bosch, X | 4 |
| Marrugat, J | 5 |
| Sanchis, J | 3 |
| Kohli, P | 1 |
| Udell, JA | 1 |
| Murphy, SA | 16 |
| García Rodríguez, LA | 6 |
| Johansson, S | 4 |
| Nagy, P | 1 |
| Cea Soriano, L | 1 |
| Tebaldi, M | 3 |
| Biscaglia, S | 3 |
| Ferrari, R | 7 |
| Rassaf, T | 1 |
| Böhm, A | 1 |
| Lüth, A | 1 |
| Kleuser, B | 1 |
| Kroemer, HK | 1 |
| Rauch, BH | 1 |
| Costa, RA | 1 |
| Leon, MB | 5 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 2 |
| Negoita, M | 1 |
| Liu, M | 5 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Bally, K | 1 |
| Buechel, RR | 1 |
| Buser, P | 1 |
| Tschudia, P | 1 |
| Martinaa, B | 1 |
| Zeller, A | 1 |
| Dillinger, JG | 1 |
| Sideris, G | 1 |
| Kchaou, I | 1 |
| Bal Dit Sollier, C | 2 |
| Manzo Silberman, S | 1 |
| Voicu, S | 1 |
| Magkoutis, N | 1 |
| Logeart, D | 1 |
| Drouet, L | 2 |
| Henry, P | 2 |
| Viviani Anselmi, C | 1 |
| Roncarati, R | 1 |
| Papa, L | 1 |
| Visconti, G | 1 |
| Focaccio, A | 2 |
| De Micco, F | 1 |
| Latronico, MV | 1 |
| Becatti, M | 1 |
| Fiorillo, C | 1 |
| Paniccia, R | 5 |
| Giusti, B | 4 |
| Gensini, GF | 10 |
| Abbate, R | 7 |
| Kereiakes, D | 1 |
| Orav, EJ | 2 |
| Massaro, J | 1 |
| Normand, SL | 4 |
| Sánchez-Salado, JC | 1 |
| Gracida, M | 1 |
| Marcano, AL | 1 |
| Roura, G | 1 |
| Ariza, A | 1 |
| Gómez-Lara, J | 1 |
| Lorente, V | 1 |
| Romaguera, R | 1 |
| Homs, S | 1 |
| Sánchez-Elvira, G | 1 |
| Teruel, L | 1 |
| Rivera, K | 1 |
| Sosa, SG | 1 |
| Gómez-Hospital, JA | 2 |
| Jakobsson, S | 1 |
| Bergström, L | 1 |
| Björklund, F | 1 |
| Söderström, L | 1 |
| Mooe, T | 3 |
| Zou, JJ | 1 |
| Chen, SL | 1 |
| Tan, J | 2 |
| Lin, L | 1 |
| Zhao, YY | 1 |
| Xu, HM | 1 |
| Lin, S | 1 |
| Fan, HW | 1 |
| Xie, HG | 1 |
| Moran, AE | 1 |
| Liu, J | 3 |
| Coxson, PG | 1 |
| Gu, D | 1 |
| Goldman, L | 2 |
| Mensah, GA | 1 |
| Sampson, UK | 1 |
| Arntz, HR | 4 |
| Boudriot, E | 1 |
| Garlichs, C | 1 |
| Hoffmann, S | 1 |
| Ince, H | 1 |
| Klingenheben, T | 1 |
| Weil, J | 1 |
| Zugck, C | 1 |
| Helms, TM | 1 |
| Silber, S | 2 |
| Miceli, A | 2 |
| Angelini, GD | 3 |
| Plicner, D | 1 |
| Ziętkiewicz, M | 1 |
| Mazur, P | 1 |
| Stąpor, R | 1 |
| Sadowski, J | 1 |
| Undas, A | 6 |
| Zaid, G | 1 |
| Dawod, S | 1 |
| Rosenschein, U | 1 |
| Waks, JW | 1 |
| Sloan, S | 1 |
| Scirica, BM | 2 |
| Verheugt, FW | 37 |
| Lewinter, C | 1 |
| Bland, JM | 1 |
| Crouch, S | 1 |
| Cleland, JG | 11 |
| Doherty, P | 1 |
| LeWinter, MM | 2 |
| Hall, AS | 4 |
| Gale, CP | 4 |
| Gianetti, J | 3 |
| Parri, MS | 1 |
| Della Pina, F | 1 |
| Marchi, F | 1 |
| Koni, E | 1 |
| De Caterina, A | 1 |
| Maffei, S | 1 |
| Berti, S | 2 |
| McMullan, KL | 1 |
| Wiedemann, S | 1 |
| Henke, C | 1 |
| Strasser, RH | 2 |
| Lassen, JF | 4 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 3 |
| Cheng, VE | 1 |
| Oppermen, A | 1 |
| Natarajan, D | 1 |
| Haikerwal, D | 1 |
| Pereira, J | 1 |
| Zhou, SL | 1 |
| Luo, JP | 1 |
| Qi, YQ | 1 |
| Liang, YG | 1 |
| Gong, FQ | 1 |
| Garay-Sánchez, P | 1 |
| Limiñana, JM | 1 |
| Saavedra, P | 1 |
| Belardi, JA | 1 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Kreutz, RP | 1 |
| Bitar, A | 1 |
| Owens, J | 1 |
| Desta, Z | 1 |
| Breall, JA | 3 |
| von der Lohe, E | 1 |
| Sinha, A | 2 |
| Vatta, M | 1 |
| Nystrom, P | 2 |
| Jin, Y | 1 |
| Flockhart, DA | 1 |
| Rubino, AS | 1 |
| Della Corte, A | 1 |
| Giordano, R | 1 |
| Menicanti, L | 1 |
| Sun, Y | 3 |
| Pang, W | 1 |
| Guo, X | 1 |
| Sun, Z | 1 |
| Cui, X | 1 |
| Li, H | 1 |
| Tao, G | 1 |
| Wang, L | 3 |
| Zhou, C | 2 |
| Shan, H | 1 |
| Yin, L | 1 |
| Hu, D | 2 |
| Samoš, M | 2 |
| Šimonová, R | 2 |
| Kovář, F | 2 |
| Duraj, L | 2 |
| Fedorová, J | 2 |
| Galajda, P | 1 |
| Staško, J | 2 |
| Fedor, M | 2 |
| Kubisz, P | 2 |
| Mokáň, M | 2 |
| Volkov, I | 1 |
| Bhatt, LK | 1 |
| Veeranjaneyulu, A | 1 |
| Holm, M | 1 |
| Dalén, M | 1 |
| van der Linden, J | 1 |
| Tisminetzky, M | 1 |
| Joffe, S | 1 |
| McManus, DD | 2 |
| Darling, C | 1 |
| Gore, JM | 21 |
| Ferlini, M | 2 |
| Mafrici, A | 1 |
| Marzegalli, M | 2 |
| Piccaluga, E | 2 |
| Sponzilli, C | 1 |
| Bramucci, E | 3 |
| Visconti, LO | 1 |
| Neuenschwander, FC | 1 |
| Lima Filho, A | 1 |
| Moreira, CM | 1 |
| Santos, ES | 1 |
| Reis, HJ | 1 |
| Romano, ER | 1 |
| Mattos, LA | 1 |
| Andrade, JP | 1 |
| Jensen, EC | 3 |
| Ivosević, TB | 1 |
| Kalezić, NK | 1 |
| Barović, S | 1 |
| Palibrk, IG | 1 |
| Karapandzić, VM | 1 |
| Marković, DZ | 1 |
| Ivanović, BA | 1 |
| Vaishnava, P | 1 |
| Alonso-Coello, P | 2 |
| Robinson, A | 1 |
| Garg, AX | 1 |
| Rodseth, RN | 1 |
| Botto, F | 1 |
| Lurati Buse, G | 1 |
| Chan, MT | 1 |
| Tiboni, M | 1 |
| Cook, D | 1 |
| Mizera, R | 1 |
| VanHelder, T | 1 |
| Pasin, L | 1 |
| Pogue, J | 7 |
| Kearon, C | 1 |
| Chow, C | 1 |
| Chrolavicius, S | 5 |
| Song, PS | 1 |
| Murray, AM | 1 |
| Keville, N | 1 |
| Gray, S | 1 |
| McCoach, CE | 1 |
| Bang, H | 1 |
| Geach, T | 1 |
| Pandit, A | 2 |
| Giri, S | 1 |
| Hakim, FA | 1 |
| Fortuin, FD | 2 |
| Parrinello, G | 4 |
| Ho, HH | 1 |
| Er Ching, M | 1 |
| Ong, PJ | 1 |
| Ooi, YW | 1 |
| Nanto, S | 1 |
| Takayama, M | 1 |
| Kitagawa, K | 1 |
| Miyazaki, S | 2 |
| Oestreich, JH | 1 |
| DiNicolantonio, JJ | 1 |
| Norgard, NB | 1 |
| Meier, P | 3 |
| Lavie, CJ | 1 |
| O'Keefe, JH | 1 |
| Niazi, AK | 1 |
| Chatterjee, S | 2 |
| Packard, KA | 1 |
| Fuchs, FD | 1 |
| Serebruany, VL | 11 |
| Tung, YC | 1 |
| Chang, GM | 1 |
| Chien, KL | 1 |
| Tu, YK | 1 |
| Sirois, C | 1 |
| Moisan, J | 1 |
| Poirier, P | 2 |
| Grégoire, JP | 1 |
| Rangé, G | 2 |
| Yayehd, K | 1 |
| Thuaire, C | 1 |
| Richard, P | 1 |
| Barbou, F | 1 |
| Köning, R | 1 |
| Chassaing, S | 1 |
| Teiger, E | 1 |
| Berthier, R | 1 |
| Decomis, MP | 1 |
| Claudel, JP | 1 |
| Brunel, P | 1 |
| De Poli, F | 1 |
| Albert, F | 1 |
| Collet, JP | 9 |
| Ross, S | 1 |
| Eriksson, N | 1 |
| Gerstein, HC | 2 |
| Rose, L | 1 |
| Ridker, PM | 20 |
| Chasman, DI | 1 |
| Paré, G | 1 |
| Lai, YS | 1 |
| Yang, LT | 1 |
| Kao Yang, YH | 1 |
| Liu, PY | 1 |
| Ayers, J | 1 |
| Mandell, R | 1 |
| Sanghvi, K | 1 |
| Aboujaoude, R | 1 |
| Hsi, DH | 1 |
| McCarthy, M | 1 |
| Treschan, TA | 1 |
| Kienbaum, P | 1 |
| Levitan, B | 1 |
| Burton, P | 2 |
| Poulos, C | 1 |
| Brett Hauber, A | 1 |
| Berlin, JA | 4 |
| Mitka, M | 1 |
| Chen, J | 4 |
| Meng, H | 1 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Ritchey, MD | 1 |
| Wall, HK | 1 |
| Gillespie, C | 1 |
| George, MG | 1 |
| Jamal, A | 1 |
| Yi, G | 1 |
| Joo, HC | 1 |
| Magid, DJ | 5 |
| Ting, HH | 1 |
| Alexander, KP | 7 |
| Parodi, G | 3 |
| Bellandi, B | 1 |
| Migliorini, A | 3 |
| Carrabba, N | 1 |
| Giurlani, L | 1 |
| Antoniucci, D | 4 |
| Tran, BA | 1 |
| Egbers, R | 1 |
| Lowe, L | 1 |
| Helfrich, YR | 1 |
| Wang, F | 1 |
| Cao, L | 1 |
| Sun, W | 2 |
| Bai, W | 1 |
| Cai, B | 1 |
| Xie, X | 1 |
| Duan, Z | 1 |
| Cai, Q | 1 |
| Liu, D | 1 |
| Xiong, Y | 1 |
| Ma, M | 1 |
| Xu, G | 1 |
| Juul, N | 1 |
| Karasoy, D | 2 |
| Christiansen, CB | 1 |
| Sorensen, R | 1 |
| Legrand, V | 2 |
| Chenu, P | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Magne, J | 1 |
| Wijns, W | 4 |
| Li, X | 2 |
| Hu, S | 2 |
| Spertus, JA | 7 |
| Gerstein, NS | 1 |
| Charlton, GA | 1 |
| Škorňová, I | 1 |
| Nanhwan, MK | 1 |
| Ling, S | 1 |
| Kodakandla, M | 1 |
| Wilcox, R | 3 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Ramos, Y | 1 |
| Parekh, P | 1 |
| Agrawal, N | 1 |
| Vasavada, A | 1 |
| Vinchurkar, M | 1 |
| Di Minno, G | 3 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 3 |
| Tremoli, E | 2 |
| Steurer, J | 1 |
| Bank, S | 2 |
| Jana, P | 1 |
| Maiti, S | 2 |
| Guha, S | 2 |
| Sinha, AK | 3 |
| Dasari, TW | 1 |
| Chen, AY | 3 |
| Saucedo, JF | 3 |
| Escobar, C | 1 |
| Divisón, JA | 1 |
| Seguí Díaz, M | 1 |
| Cuzick, J | 2 |
| Thorat, MA | 2 |
| Bosetti, C | 1 |
| Brown, PH | 1 |
| Burn, J | 1 |
| Cook, NR | 3 |
| Ford, LG | 1 |
| Jacobs, EJ | 1 |
| Jankowski, JA | 1 |
| La Vecchia, C | 1 |
| Law, M | 1 |
| Meyskens, F | 1 |
| Senn, HJ | 1 |
| Umar, A | 1 |
| Torjesen, I | 1 |
| Enriquez, JR | 2 |
| McGuire, DK | 5 |
| Peng, SA | 2 |
| Lader, E | 1 |
| Valente, S | 3 |
| Chiostri, M | 1 |
| Cau, V | 1 |
| Lazzeri, C | 1 |
| Figueredo, VM | 1 |
| Okusa, C | 1 |
| Kaneda, K | 1 |
| Inamura, Y | 1 |
| Miyamae, M | 1 |
| Yan, J | 1 |
| Xu, LJ | 1 |
| Cheng, CL | 1 |
| Chen, PS | 1 |
| Kaliyadan, A | 1 |
| Siu, H | 1 |
| Ruggiero, NJ | 1 |
| Jasti, B | 1 |
| Walinsky, P | 2 |
| Ogilby, JD | 1 |
| Savage, MP | 1 |
| Torborg, A | 1 |
| Ryan, L | 1 |
| Kantor, G | 1 |
| Syvolap, VV | 1 |
| Franskavichene, LV | 1 |
| Golukhova, EZ | 2 |
| Simms, AD | 1 |
| Weston, CF | 2 |
| West, RM | 1 |
| Batin, PD | 3 |
| Timmis, A | 6 |
| Hemingway, H | 4 |
| Mohamed, AR | 1 |
| El-Hadidy, WF | 1 |
| Mannaa, HF | 1 |
| Henke, PK | 1 |
| Zamora-Berridi, G | 1 |
| Englesbe, MJ | 1 |
| Cai, S | 1 |
| Brooks, L | 1 |
| McKeown, E | 1 |
| Phillips, L | 1 |
| Lau, W | 1 |
| Campbell, DC | 1 |
| Aryal, MR | 1 |
| Karmacharya, P | 1 |
| Hakim, F | 1 |
| Pathak, R | 1 |
| Mainali, NR | 1 |
| Ukaigwe, A | 1 |
| Mahmood, M | 1 |
| Badal, M | 1 |
| Rubattu, S | 1 |
| De Giusti, M | 1 |
| Farcomeni, A | 2 |
| Abbolito, S | 1 |
| Comito, F | 1 |
| Cangianiello, S | 1 |
| Greco, ES | 1 |
| Dito, E | 1 |
| Pagliaro, B | 1 |
| Cotugno, M | 1 |
| Stanzione, R | 1 |
| Marchitti, S | 1 |
| Bianchi, F | 1 |
| Di Castro, S | 1 |
| Battistoni, A | 1 |
| Burocchi, S | 1 |
| Caprinozzi, M | 1 |
| Pierelli, G | 1 |
| Sciarretta, S | 1 |
| Volpe, M | 1 |
| Vengoechea, F | 1 |
| Lemesle, G | 5 |
| Lamblin, N | 2 |
| Meurice, T | 2 |
| Tricot, O | 2 |
| Lallemant, R | 1 |
| Nugue, O | 1 |
| Delomez, M | 1 |
| Equine, O | 1 |
| Tondeux, S | 1 |
| Bauters, C | 3 |
| Murray, SW | 1 |
| Cooper, RM | 1 |
| Appleby, C | 1 |
| McCann, C | 1 |
| Binukrishnan, S | 1 |
| Radu, MD | 1 |
| Stables, RH | 1 |
| Kuwata, S | 1 |
| Yoneyama, K | 1 |
| Koyama, K | 1 |
| Saito, M | 3 |
| Sekiya, O | 1 |
| Mitarai, T | 1 |
| Kamijima, R | 1 |
| Kongoji, K | 1 |
| Tabata, H | 1 |
| Umano, S | 1 |
| Kobayashi, Y | 2 |
| Harada, T | 1 |
| Akashi, YJ | 1 |
| Desai, NR | 1 |
| Serak, J | 1 |
| Wang, MY | 1 |
| Abdullah, AS | 1 |
| Ibrahim, H | 1 |
| Kiernan, TJ | 1 |
| Timmers, L | 1 |
| Stella, PR | 2 |
| Agostoni, P | 1 |
| Christ, G | 1 |
| Francesconi, M | 1 |
| Dechant, C | 1 |
| Grohs, K | 1 |
| Podczeck-Schweighofer, A | 1 |
| Baysal, E | 1 |
| Çetin, M | 1 |
| Yaylak, B | 1 |
| Altntaş, B | 1 |
| Altndağ, R | 1 |
| Adyaman, Ş | 1 |
| Altaş, Y | 2 |
| Kaya, İ | 1 |
| Sevuk, U | 1 |
| Nitschmann, S | 2 |
| Garratt, KN | 2 |
| Weaver, WD | 8 |
| Jenkins, RG | 1 |
| Pow, TK | 1 |
| Winters, KJ | 6 |
| Christen, T | 1 |
| Allocco, DJ | 1 |
| Lee, DP | 3 |
| Elwood, P | 6 |
| Morgan, G | 5 |
| Rajani, AR | 1 |
| Mahmoud, WE | 1 |
| Murugesan, V | 1 |
| BinBrek, AS | 2 |
| Nizamuddin, SL | 1 |
| Broderick, DK | 1 |
| Minehart, RD | 1 |
| Kamdar, BB | 1 |
| Jeger, RV | 2 |
| Pfisterer, ME | 2 |
| von Felten, S | 1 |
| Alber, H | 1 |
| Bonetti, PO | 1 |
| Eberli, F | 1 |
| Galatius, S | 1 |
| Kaiser, CA | 2 |
| Cangemi, R | 1 |
| Casciaro, M | 1 |
| Rossi, E | 1 |
| Calvieri, C | 1 |
| Bucci, T | 1 |
| Calabrese, CM | 1 |
| Taliani, G | 1 |
| Falcone, M | 1 |
| Palange, P | 1 |
| Bertazzoni, G | 1 |
| Grieco, S | 1 |
| Huynh, K | 1 |
| Serpytis, P | 1 |
| Petrulioniene, Z | 1 |
| Gargalskaite, U | 1 |
| Gedminaite, A | 1 |
| Panaviene, V | 1 |
| Cooper-DeHoff, RM | 1 |
| Ferrario, MM | 1 |
| Veronesi, G | 1 |
| Merli, GJ | 1 |
| Weitz, HH | 1 |
| Wada, N | 1 |
| Okazaki, S | 1 |
| Kobayashi, S | 1 |
| Hashizume, K | 1 |
| Hori, J | 1 |
| Azumi, M | 1 |
| Kita, M | 1 |
| Iwata, T | 1 |
| Matsumoto, S | 2 |
| Kakizaki, H | 1 |
| Wu, IC | 2 |
| Hsieh, HM | 2 |
| Wu, MT | 2 |
| Megiddo, I | 1 |
| Nandi, A | 1 |
| Laxminarayan, R | 1 |
| Ma, W | 1 |
| Evans, RG | 1 |
| Weeks, PA | 1 |
| Sieg, A | 1 |
| Paruthi, C | 1 |
| Rajapreyar, I | 1 |
| Lee, HJ | 3 |
| Yu, CW | 2 |
| Choi, RK | 2 |
| Park, JS | 5 |
| Jang, HJ | 1 |
| Shim, WH | 2 |
| Roh, YM | 1 |
| Markun, S | 1 |
| Korkmaz, S | 1 |
| Atmanli, A | 2 |
| Radovits, T | 2 |
| Hegedűs, P | 2 |
| Barnucz, E | 1 |
| Hirschberg, K | 1 |
| Loganathan, S | 1 |
| Yoshikawa, Y | 2 |
| Yasui, H | 2 |
| Karck, M | 2 |
| Szabó, G | 3 |
| Bultas, J | 1 |
| Cegarra-Sanmartin, V | 1 |
| Paniagua-Iglesias, P | 1 |
| de Nadal Clanchet, M | 1 |
| Plou, P | 1 |
| Mata Mena, E | 1 |
| Fernández-Riveira, C | 1 |
| García del Valle, S | 1 |
| Tena Blanco, B | 1 |
| Sabaté Tenas, S | 1 |
| Font Gual, A | 1 |
| Maestre Hittinger, ML | 1 |
| González Rodríguez, R | 1 |
| Martin-Yuste, V | 1 |
| Alvarez-Contreras, L | 1 |
| Kelbaek, H | 3 |
| Saunamäki, K | 3 |
| Jørgensen, E | 2 |
| Kocka, V | 1 |
| Stoler, R | 1 |
| Dauerman, HL | 2 |
| Xiao, F | 1 |
| Sun, H | 1 |
| Pan, S | 1 |
| Xu, J | 1 |
| Costa, F | 5 |
| Moscarella, E | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 10 |
| Zalewski, J | 1 |
| Bogaert, J | 2 |
| Sadowski, M | 1 |
| Woznicka, O | 1 |
| Doulaptsis, K | 1 |
| Ntoumpanaki, M | 1 |
| Ząbczyk, M | 1 |
| Nessler, J | 1 |
| Kim, HD | 1 |
| Cho, JY | 1 |
| Joo, HJ | 1 |
| Park, JH | 2 |
| Hong, SJ | 2 |
| Lim, DS | 5 |
| Bansilal, S | 3 |
| Fish, MP | 1 |
| Theroux, P | 16 |
| Ruda, M | 4 |
| Pavasini, R | 1 |
| Malagù, M | 1 |
| Punzetti, S | 1 |
| Napoli, N | 1 |
| Guerzoni, F | 1 |
| Papi, A | 1 |
| Ceconi, C | 1 |
| Contoli, M | 1 |
| Gershlick, AH | 4 |
| Jacobs, A | 1 |
| Iancu, AC | 1 |
| Rajpurohit, N | 1 |
| Ayaz, SZ | 1 |
| Yee, J | 1 |
| Khan, MA | 1 |
| Stys, A | 1 |
| Shore, S | 1 |
| Jones, PG | 2 |
| Stolker, JM | 1 |
| Arnold, SV | 1 |
| Parashar, S | 1 |
| Peterson, P | 1 |
| Kuliczkowski, W | 3 |
| Gasior, M | 3 |
| Pres, D | 3 |
| Kaczmarski, J | 3 |
| Laszowska, A | 1 |
| Szewczyk, M | 2 |
| Hawranek, M | 2 |
| Tajstra, M | 2 |
| Zeglen, S | 2 |
| Polonski, L | 3 |
| Dentan, G | 1 |
| Meneveau, N | 1 |
| Motreff, P | 2 |
| Ravan, R | 2 |
| Ennezat, PV | 1 |
| Berard, L | 1 |
| Shizuta, S | 2 |
| Tazaki, J | 2 |
| Kato, Y | 1 |
| Hayano, M | 1 |
| Shirotani, M | 1 |
| Miki, S | 1 |
| Matsuda, M | 2 |
| Takahashi, M | 1 |
| Ishii, K | 1 |
| Tanaka, M | 1 |
| Aoyama, T | 1 |
| Doi, O | 1 |
| Hattori, R | 2 |
| Takizawa, A | 2 |
| Takatsu, Y | 1 |
| Shinoda, E | 1 |
| Eizawa, H | 2 |
| Takeda, T | 1 |
| Lee, JD | 1 |
| Inoko, M | 1 |
| Hamasaki, S | 1 |
| Horie, M | 1 |
| Nohara, R | 2 |
| Kambara, H | 2 |
| Fujiwara, H | 2 |
| Mitsudo, K | 2 |
| Nobuyoshi, M | 3 |
| Kita, T | 2 |
| Spence, JD | 2 |
| Murali, SB | 1 |
| Andreotti, F | 2 |
| Schulze, V | 1 |
| Kołodziejczak, M | 1 |
| Buffon, A | 2 |
| Brouwer, M | 1 |
| Kowalewski, M | 1 |
| Parati, G | 1 |
| Shah, NS | 1 |
| Ning, H | 1 |
| Lloyd-Jones, DM | 1 |
| Gandhi, S | 2 |
| Schwalm, JD | 2 |
| Velianou, JL | 1 |
| Natarajan, MK | 3 |
| Farkouh, ME | 3 |
| Ferguson, C | 1 |
| Bainey, KR | 1 |
| Park, TE | 1 |
| Yusuff, J | 1 |
| Lee, YS | 2 |
| Jin, CD | 1 |
| Kim, MH | 2 |
| Guo, LZ | 1 |
| Cho, YR | 1 |
| Park, K | 1 |
| Kim, YD | 1 |
| Martimucci, M | 1 |
| Maggi, A | 1 |
| Villella, A | 1 |
| Villella, M | 1 |
| Langialonga, T | 1 |
| Locatelli, A | 1 |
| Fumagalli, S | 1 |
| Del Medico, M | 1 |
| Montano, N | 1 |
| Rollini, F | 1 |
| Franchi, F | 1 |
| McCoy, LA | 1 |
| Bach, RG | 2 |
| Zettler, ME | 1 |
| Baker, BA | 2 |
| Stub, D | 1 |
| Smith, K | 1 |
| Bernard, S | 1 |
| Nehme, Z | 1 |
| Stephenson, M | 1 |
| Bray, JE | 1 |
| Cameron, P | 1 |
| Barger, B | 1 |
| Ellims, AH | 1 |
| Taylor, AJ | 3 |
| Meredith, IT | 2 |
| Kaye, DM | 1 |
| Abo-Salem, E | 1 |
| Alsidawi, S | 1 |
| Jamali, H | 1 |
| Effat, M | 1 |
| Helmy, T | 1 |
| Yudi, MB | 1 |
| Eccleston, D | 1 |
| Andrianopoulos, N | 1 |
| Farouque, O | 1 |
| Duffy, SJ | 1 |
| Brennan, A | 2 |
| Reid, C | 1 |
| Clark, DJ | 1 |
| Ajani, AE | 1 |
| Lettieri, C | 2 |
| Senni, M | 1 |
| Guagliumi, G | 6 |
| Valsecchi, O | 1 |
| Maillard, J | 1 |
| Cartier Faessler, V | 1 |
| Fontana, P | 1 |
| Bonhomme, F | 1 |
| Fanari, Z | 1 |
| Weiss, S | 1 |
| Fu, R | 1 |
| Bao, H | 1 |
| Yang, F | 1 |
| Luo, X | 1 |
| Hastings, S | 2 |
| Myles, P | 1 |
| McIlroy, D | 1 |
| Shang, Q | 1 |
| Shi, D | 1 |
| Mathews, R | 1 |
| Honeycutt, E | 1 |
| Zettler, M | 2 |
| Chang, M | 1 |
| Paixao, AR | 1 |
| Berry, JD | 1 |
| Kontos, MC | 1 |
| Kim, BS | 2 |
| Jang, WJ | 1 |
| Kim, WS | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Cao, H | 1 |
| Duceppe, E | 1 |
| Thomas, S | 1 |
| Rose, JJ | 1 |
| Voora, D | 1 |
| Cyr, DD | 2 |
| Lucas, JE | 1 |
| Zaas, AK | 1 |
| Woods, CW | 1 |
| Kraus, WE | 1 |
| Ginsburg, GS | 1 |
| Guimarães, PO | 1 |
| Tricoci, P | 2 |
| Dolan, JG | 1 |
| Cherkasky, OA | 1 |
| Chin, N | 1 |
| Veazie, PJ | 1 |
| Komaroff, AL | 1 |
| Fosbol, EL | 2 |
| Thomas, L | 3 |
| Ferreira-González, I | 1 |
| Carrillo, X | 1 |
| Martín, V | 1 |
| de la Torre Hernández, JM | 1 |
| Baz, JA | 1 |
| Navarro Manchón, J | 1 |
| Masotti, M | 1 |
| Cárdenas, M | 1 |
| Alfonso Manterola, F | 1 |
| Ahmed, Z | 1 |
| Bajwa, A | 1 |
| Bhardwaj, B | 1 |
| Laster, SB | 1 |
| Magalski, A | 1 |
| Grigorian, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Fortmann, S | 1 |
| Tsoi, MF | 1 |
| Cheung, CL | 1 |
| Cheung, TT | 1 |
| Wong, IC | 1 |
| Kumana, CR | 1 |
| Tse, HF | 2 |
| Cheung, BM | 1 |
| Buccheri, S | 1 |
| Tamburino, C | 3 |
| Wong, LK | 1 |
| Altman, DG | 1 |
| Keating, C | 3 |
| Rivera, CM | 1 |
| Copeland, LA | 1 |
| McNeal, CJ | 1 |
| Mortensen, EM | 1 |
| Pugh, MJ | 1 |
| MacCarthy, DJ | 1 |
| Pilgrim, T | 2 |
| Tal, K | 1 |
| Rossello, X | 1 |
| Julian, DG | 2 |
| Perl, L | 1 |
| Sasson, L | 1 |
| Weissler-Snir, A | 1 |
| Greenberg, G | 2 |
| Vaknin-Assa, H | 1 |
| Assali, A | 2 |
| Lev, EI | 2 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Morris, N | 4 |
| Rigg, K | 1 |
| Hogg, K | 1 |
| Arif, SA | 2 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Obońska, K | 1 |
| Ostrowska, M | 1 |
| Wiciński, M | 1 |
| Kubica, A | 2 |
| Kubica, J | 2 |
| Acibuca, A | 1 |
| Gerede, DM | 1 |
| Vurgun, VK | 1 |
| Vergallo, R | 1 |
| Aguirre, AD | 1 |
| Abtahian, F | 1 |
| Minami, Y | 2 |
| Soeda, T | 1 |
| Chatzizisis, YS | 1 |
| Croce, K | 1 |
| Jang, IK | 2 |
| Tarantini, G | 1 |
| D'Amico, G | 1 |
| Borghesi, M | 2 |
| Mohar, DS | 1 |
| Seto, AH | 1 |
| Kern, MJ | 1 |
| Peota, C | 1 |
| Medagama, A | 1 |
| Bandara, R | 1 |
| De Silva, C | 1 |
| Galgomuwa, MP | 1 |
| Korkmaz-Icöz, S | 1 |
| Ruppert, M | 1 |
| Brlecic, P | 1 |
| Bacquelin, R | 1 |
| Oger, E | 1 |
| Filippi, E | 1 |
| Hacot, JP | 1 |
| Auffret, V | 1 |
| Le Guellec, M | 1 |
| Coudert, I | 1 |
| Moquet, B | 1 |
| Rialan, A | 1 |
| Rouault, G | 1 |
| Boulanger, B | 1 |
| Treuil, J | 1 |
| Leurent, G | 1 |
| Bedossa, M | 2 |
| Boulmier, D | 1 |
| Avez, B | 1 |
| Ganeshan, R | 1 |
| Malm, B | 1 |
| Concato, J | 1 |
| Zlotnick, DM | 1 |
| Canty, JM | 1 |
| Li, DZ | 1 |
| Chen, QJ | 1 |
| Sun, HP | 1 |
| Zeng, R | 1 |
| Zeng, Z | 1 |
| Gao, XM | 2 |
| Ma, YT | 1 |
| Yang, YN | 1 |
| Tchwenko, S | 1 |
| Fleming, E | 1 |
| Perry, GS | 1 |
| Suwita, BM | 1 |
| Laksmi, PW | 1 |
| Wijaya, IP | 1 |
| D'Agostino, RB | 6 |
| Hoh, BL | 1 |
| McDonough, CW | 1 |
| Waters, MF | 1 |
| Royster, AJ | 1 |
| Sheehan, TO | 1 |
| Burkley, B | 1 |
| Langaee, TY | 1 |
| Mocco, J | 1 |
| Zuckerman, SL | 1 |
| Mummareddy, N | 1 |
| Stephens, ML | 1 |
| Ingram, C | 2 |
| Shaffer, CM | 1 |
| Denny, JC | 1 |
| Brilliant, MH | 1 |
| Kitchner, TE | 1 |
| Linneman, JG | 1 |
| Roden, DM | 1 |
| Johnson, JA | 1 |
| Samorodskaya, IV | 1 |
| Bolotova, EV | 1 |
| Boytsov, SA | 1 |
| Riley, RF | 1 |
| Don, CW | 1 |
| Aldea, GS | 1 |
| Mokadam, NA | 1 |
| Probstfield, J | 1 |
| Maynard, C | 3 |
| Goss, JR | 1 |
| Zaman, MJ | 1 |
| Fleetcroft, R | 1 |
| Bachmann, M | 1 |
| Sarev, T | 1 |
| Stirling, S | 1 |
| Clark, A | 1 |
| Myint, PK | 1 |
| Sáez, ME | 1 |
| González-Pérez, A | 2 |
| Garcia-Garcia, HM | 1 |
| Verbruggen, M | 1 |
| Mannaerts, D | 1 |
| Muys, J | 1 |
| Jacquemyn, Y | 1 |
| Strandmark, R | 1 |
| Herlitz, J | 7 |
| Axelsson, C | 1 |
| Claesson, A | 1 |
| Bremer, A | 1 |
| Karlsson, T | 4 |
| Jimenez-Herrera, M | 1 |
| Yu, FJ | 1 |
| Wu, MC | 1 |
| Wu, TS | 1 |
| Sasaki, T | 1 |
| Temmoku, J | 1 |
| Inukai, T | 1 |
| Sugiyama, T | 1 |
| Inokuchi, R | 1 |
| Shinohara, K | 1 |
| Jackson, LR | 2 |
| Ju, C | 1 |
| Messenger, JC | 1 |
| Effron, M | 1 |
| Lansky, AJ | 6 |
| Ayele, GM | 1 |
| Ahn, J | 1 |
| Carriere, KC | 1 |
| Schöffel, N | 1 |
| Gamayunov, A | 1 |
| Mutze, S | 1 |
| Groneberg, DA | 1 |
| Ekkernkamp, A | 1 |
| Thielemann, H | 1 |
| Wu, S | 1 |
| Liu, W | 1 |
| Novo, S | 3 |
| Hermiller, JB | 1 |
| Schurtz, G | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Ansell, J | 1 |
| Gersh, BJ | 4 |
| Go, AS | 3 |
| Hylek, EM | 1 |
| Kowey, P | 1 |
| Chang, P | 1 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Ohshima, K | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Son, R | 1 |
| Higuchi, T | 1 |
| Mizuno, A | 1 |
| Koyamada, R | 1 |
| Yamashiro, Y | 1 |
| Dormuth, CR | 1 |
| Filion, KB | 2 |
| Platt, RW | 1 |
| Sakr, HI | 1 |
| Alamri, HS | 1 |
| Almoghairi, AM | 1 |
| Alkhudair, AA | 1 |
| AlMasood, AS | 1 |
| Mrdovic, I | 3 |
| Čolić, M | 1 |
| Savic, L | 3 |
| Krljanac, G | 2 |
| Kruzliak, P | 1 |
| Lasica, R | 1 |
| Asanin, M | 3 |
| Stanković, S | 3 |
| Marinkovic, J | 3 |
| Beauloye, C | 1 |
| van de Borne, P | 1 |
| Vandendriessche, E | 1 |
| Parker, WA | 1 |
| Wąsowicz, M | 1 |
| Syed, S | 1 |
| Wijeysundera, DN | 1 |
| Starzyk, Ł | 1 |
| Grewal, D | 1 |
| Ragoonanan, T | 1 |
| Harsha, P | 1 |
| Travis, G | 1 |
| Carroll, J | 1 |
| Karkouti, K | 1 |
| Beattie, WS | 1 |
| Lee, M | 1 |
| Green, SA | 1 |
| Cherian, T | 1 |
| Devlin, G | 1 |
| Ueda, H | 1 |
| Kido, A | 1 |
| Matsuhisa, S | 1 |
| Asawa, K | 1 |
| Yoshida, N | 1 |
| Tsujimoto, M | 1 |
| Sasaki, Y | 1 |
| Kuga, Y | 1 |
| Yamasaki, M | 1 |
| Ueda, K | 1 |
| Shinohara, S | 1 |
| Li, YF | 1 |
| Gao, WQ | 1 |
| Li, YX | 1 |
| Feng, QZ | 1 |
| Zhu, P | 1 |
| Noh, Y | 1 |
| Shin, S | 1 |
| Lim, HS | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Kim, GJ | 1 |
| Wald, NJ | 1 |
| Luteijn, JM | 1 |
| Morris, JK | 1 |
| Taylor, D | 3 |
| Oppenheimer, P | 1 |
| Neely, B | 4 |
| Martinez, F | 3 |
| Armstrong, PW | 21 |
| Mancone, M | 2 |
| Holmes, DR | 3 |
| Brindis, RG | 1 |
| Trebacz, J | 1 |
| Vaduganathan, M | 2 |
| Cryer, BL | 1 |
| Lanas, A | 2 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Kristiansen, J | 1 |
| Rise, N | 1 |
| Camenzind, E | 1 |
| Kormos, W | 1 |
| Chin, CT | 1 |
| Boden, WE | 9 |
| Leiva-Pons, JL | 4 |
| Gottlieb, S | 6 |
| Dalby, AJ | 4 |
| Kuder, J | 1 |
| Goodrich, E | 2 |
| Dalby, A | 1 |
| Abola, MTB | 1 |
| Ruiz-Nodar, JM | 1 |
| Chasseriaud, W | 1 |
| Tearney, GJ | 1 |
| Montaudon, M | 1 |
| Fialon, B | 1 |
| Coste, P | 3 |
| Gerbaud, E | 2 |
| Elosua, R | 1 |
| Grau, M | 1 |
| Sayols-Baixeras, S | 1 |
| Dégano, IR | 1 |
| Kunutsor, SK | 1 |
| Seidu, S | 1 |
| Khunti, K | 2 |
| McIlroy, DR | 1 |
| Golukhova, E | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Cattaneo, M | 1 |
| Marciniak, TA | 3 |
| Xu, LX | 1 |
| Chen, KY | 2 |
| Liu, T | 1 |
| Zheng, XT | 1 |
| Jiao, ZQ | 1 |
| Bayley, E | 1 |
| Brown, S | 1 |
| Bhamber, NS | 1 |
| Howard, PW | 1 |
| Green, A | 1 |
| Pottegård, A | 1 |
| Broe, A | 1 |
| Diness, TG | 1 |
| Emneus, M | 1 |
| Hasvold, P | 1 |
| Hafley, G | 1 |
| Bucholz, EM | 1 |
| Butala, NM | 1 |
| Normand, ST | 1 |
| Navarro, MA | 1 |
| Gosch, KL | 1 |
| Rumsfeld, JS | 7 |
| Rubino, F | 1 |
| Dadjou, Y | 1 |
| Safavi, S | 1 |
| Kojuri, J | 2 |
| Whalen, JD | 1 |
| Davies, G | 3 |
| Du, M | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Aichinger, J | 1 |
| Speidl, WS | 1 |
| Watzinger, N | 1 |
| Alber, HF | 1 |
| Shimada, YJ | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Zang, H | 1 |
| Zhao, W | 1 |
| Rapsomaniki, E | 1 |
| Chung, SC | 1 |
| Pujades-Rodriguez, M | 1 |
| Moayyeri, A | 1 |
| Stogiannis, D | 1 |
| Shah, AD | 1 |
| Pasea, L | 1 |
| Denaxas, S | 1 |
| Emmas, C | 1 |
| Parvataneni, R | 1 |
| Terrosu, P | 1 |
| Ishii, M | 1 |
| Kaikita, K | 4 |
| Sato, K | 1 |
| Yamanaga, K | 1 |
| Miyazaki, T | 1 |
| Tabata, N | 1 |
| Arima, Y | 1 |
| Sueta, D | 1 |
| Sakamoto, K | 1 |
| Yamamoto, E | 1 |
| Yamamuro, M | 1 |
| Kojima, S | 3 |
| Hokimoto, S | 2 |
| Matsui, K | 2 |
| Dondo, TB | 1 |
| Hall, M | 1 |
| Timmis, AD | 8 |
| Yan, AT | 1 |
| Oliver, G | 1 |
| Alabas, OA | 1 |
| Norman, P | 1 |
| Deanfield, JE | 1 |
| Bloor, K | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Magnus Ohman, E | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 7 |
| Kedhi, E | 1 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 8 |
| De Luca, G | 3 |
| Harrison, RW | 1 |
| Simon, D | 1 |
| Miller, AL | 1 |
| Wise, J | 1 |
| Snyder, A | 1 |
| Essandoh, MK | 1 |
| Dalia, AA | 1 |
| George, BS | 1 |
| Flores, AS | 1 |
| Otey, AJ | 1 |
| Broderick, TM | 1 |
| Marino, M | 2 |
| Resor, CD | 1 |
| Nathan, A | 1 |
| Gabriel Steg, P | 3 |
| Ophuis, TO | 1 |
| Jensen, E | 1 |
| Basaraba, JE | 1 |
| Barry, AR | 1 |
| de Waha, A | 1 |
| Sandner, S | 1 |
| Boening, A | 1 |
| Koch-Buettner, K | 1 |
| Hammel, D | 1 |
| Hambrecht, R | 1 |
| Danner, BC | 1 |
| Schöndube, FA | 1 |
| Goerlach, G | 1 |
| Fischlein, T | 1 |
| Schmoeckel, M | 1 |
| Oberhoffer, M | 1 |
| Schulz, R | 1 |
| Walther, T | 1 |
| Ziegelhöffer, T | 1 |
| Knosalla, C | 1 |
| Schönrath, F | 1 |
| Beyersdorf, F | 1 |
| Siepe, M | 1 |
| Attmann, T | 1 |
| Mohr, FW | 1 |
| Sievers, HH | 1 |
| Joost, A | 1 |
| Putman, LM | 1 |
| Radke, PW | 3 |
| Lange, R | 1 |
| Cremer, J | 1 |
| Hellkamp, A | 1 |
| Lokhnygina, Y | 3 |
| Barillà, F | 1 |
| Pelliccia, F | 1 |
| Borzi, M | 1 |
| Camici, P | 1 |
| Cas, LD | 1 |
| Indolfi, C | 1 |
| Mercuro, G | 1 |
| Montemurro, V | 1 |
| Padeletti, L | 1 |
| Filardi, PP | 1 |
| Vizza, CD | 1 |
| Yao, Y | 1 |
| Zhang, JH | 1 |
| Tang, XF | 1 |
| He, C | 1 |
| Ma, YL | 1 |
| Xu, JJ | 1 |
| Liu, R | 1 |
| Meng, XM | 1 |
| Song, L | 1 |
| Gao, RL | 3 |
| Yuan, JQ | 1 |
| Ren, F | 1 |
| Mu, N | 1 |
| Dong, M | 1 |
| Kini, A | 2 |
| Saporito, R | 1 |
| Michael Gibson, C | 1 |
| Cohen, D | 1 |
| Luni, FK | 1 |
| Khan, AR | 1 |
| Riaz, T | 1 |
| Husnain, M | 1 |
| Riaz, IB | 1 |
| Taleb, M | 1 |
| Kanjwal, Y | 1 |
| Cooper, CJ | 1 |
| Khuder, SA | 1 |
| Aboul-Hassan, SS | 1 |
| Stankowski, T | 1 |
| Marczak, J | 1 |
| Cichon, R | 1 |
| Jakl, M | 1 |
| Sevcik, R | 1 |
| Fatorova, I | 1 |
| Horacek, JM | 1 |
| Pudil, R | 1 |
| Makam, RC | 1 |
| Erskine, N | 1 |
| Russo, M | 1 |
| Nardi, P | 1 |
| Saitto, G | 1 |
| Bovio, E | 1 |
| Pellegrino, A | 1 |
| Scafuri, A | 1 |
| Ruvolo, G | 1 |
| Ferri, LA | 1 |
| Morici, N | 2 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Tondi, S | 1 |
| Toso, A | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 2 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 2 |
| Moffa, N | 1 |
| Elwood, PC | 14 |
| Galante, J | 1 |
| Chia, JW | 1 |
| Dolwani, S | 1 |
| Graziano, JM | 1 |
| Kelson, M | 1 |
| Longley, M | 1 |
| Phillips, CJ | 1 |
| Pickering, J | 3 |
| Roberts, SE | 1 |
| Soon, SS | 1 |
| Steward, W | 1 |
| Morris, D | 1 |
| Weightman, AL | 1 |
| Wimmer, NJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Gagnon, DR | 1 |
| Quach, L | 1 |
| Ly, S | 1 |
| Do, JM | 1 |
| Ostrowski, S | 1 |
| Michael Gaziano, J | 1 |
| Faxon, DP | 3 |
| Kinlay, S | 2 |
| Carrero, JJ | 1 |
| Jensevik, K | 1 |
| Lagerqvist, B | 4 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Bretz, F | 1 |
| Guimarães, AH | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Isbye, D | 1 |
| Halle, BM | 1 |
| Pedersen, S | 1 |
| Itenov, TS | 1 |
| Taskiran, M | 1 |
| Gögenur, I | 1 |
| van Diepen, S | 1 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Ovbiagele, B | 5 |
| Pasala, T | 1 |
| Hoo, JS | 1 |
| Lockhart, MK | 1 |
| Waheed, R | 1 |
| Sengodan, P | 1 |
| Alexander, J | 2 |
| Della Riva, D | 1 |
| Benedetto, U | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Pufulete, M | 1 |
| Gitsels, LA | 1 |
| Kulinskaya, E | 1 |
| Steel, N | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Dong, K | 1 |
| Ji, X | 1 |
| Feher, A | 1 |
| Kampaktsis, PN | 1 |
| Parameswaran, R | 1 |
| Stein, EM | 1 |
| Steingart, R | 1 |
| Gupta, D | 1 |
| Chen, YT | 3 |
| Chen, HT | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Yu, J | 3 |
| Ooi, SY | 1 |
| Saad, M | 1 |
| Nairooz, R | 1 |
| Urban, P | 5 |
| Eberli, FR | 2 |
| Simon, R | 1 |
| Durán, J | 1 |
| Peloquin, C | 1 |
| Felson, DT | 1 |
| Singh, GD | 1 |
| Waldo, SW | 1 |
| Achilles, A | 1 |
| Mohring, A | 1 |
| Piayda, K | 1 |
| Lim, SW | 1 |
| Jeon, DW | 2 |
| Oh, SK | 1 |
| Chase, M | 1 |
| Ozan, MO | 1 |
| Zanchin, T | 1 |
| Steyerberg, EW | 2 |
| Novack, V | 1 |
| Jotkowitz, A | 1 |
| Lieberman, N | 1 |
| Porath, A | 3 |
| Papathanasiou, AI | 1 |
| Mikhailidis, DP | 1 |
| Hamilos, M | 1 |
| Sarma, J | 1 |
| Sarno, G | 1 |
| Wyffels, E | 1 |
| Vanderheyden, M | 1 |
| Bartunek, J | 1 |
| De Bruyne, B | 2 |
| de Cesare, N | 3 |
| Hamon, M | 4 |
| Ferrari, F | 1 |
| Furgieri, A | 3 |
| Repetto, A | 2 |
| Colangelo, S | 3 |
| Meliga, E | 3 |
| Kubbajeh, M | 2 |
| Percoco, G | 4 |
| Menon, V | 4 |
| Mosse, F | 1 |
| Zhao, L | 1 |
| Kaltoft, A | 2 |
| Hansen, HH | 1 |
| Bøttcher, M | 2 |
| Thayssen, P | 4 |
| Krusell, LR | 6 |
| Rasmussen, K | 2 |
| Pedersen, L | 1 |
| Johnsen, SP | 2 |
| Thuesen, L | 5 |
| Rakowski, T | 2 |
| Mielecki, W | 2 |
| Brzozowska-Czarnek, A | 1 |
| Dziewierz, A | 2 |
| Siudak, Z | 2 |
| Legutko, J | 2 |
| Rzeszutko, L | 2 |
| Urbanik, A | 1 |
| Dubiel, JS | 3 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Daskalopoulou, SS | 1 |
| Delaney, JA | 1 |
| Brophy, JM | 2 |
| Mayo, NE | 2 |
| Suissa, S | 1 |
| Nadareishvili, Z | 1 |
| Michaud, K | 2 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 2 |
| Bagatini, MD | 1 |
| Martins, CC | 1 |
| Battisti, V | 1 |
| Spanevello, RM | 1 |
| Gasparetto, D | 1 |
| Rosa, CS | 1 |
| Gonçalves, JF | 1 |
| Schetinger, MR | 1 |
| dos Santos, RB | 1 |
| Morsch, VM | 1 |
| Moran, A | 1 |
| Pride, YB | 2 |
| Aylward, PE | 8 |
| Col, JJ | 1 |
| Gulba, D | 2 |
| Bergovec, M | 2 |
| Zorkun, C | 1 |
| Buros, JL | 2 |
| Hellstrom, HR | 1 |
| Bousser, MG | 2 |
| Sacco, RL | 1 |
| Diener, HC | 6 |
| Cotton, D | 2 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 2 |
| Bath, P | 2 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 1 |
| Dahlöf, B | 2 |
| De Keyser, J | 2 |
| Donnan, GA | 2 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 2 |
| Lu, C | 1 |
| Machnig, T | 2 |
| Roberts, R | 6 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Durmaz, T | 1 |
| Keles, T | 1 |
| Ozdemir, O | 1 |
| Bayram, NA | 1 |
| Akcay, M | 1 |
| Yeter, E | 1 |
| Bozkurt, E | 1 |
| Silva-Orrego, P | 1 |
| Bigi, R | 1 |
| Colombo, P | 1 |
| De Marco, F | 1 |
| Oreglia, JA | 1 |
| Klugmann, S | 1 |
| Gregori, D | 1 |
| Schwartz, KA | 2 |
| Schwartz, DE | 2 |
| Barber, K | 2 |
| Reeves, M | 1 |
| De Franco, AC | 1 |
| Shantsila, E | 1 |
| Biggerstaff, BJ | 1 |
| Jackson, D | 1 |
| Engberding, N | 1 |
| Krausgrill, B | 1 |
| Erdmann, E | 2 |
| Flesch, M | 1 |
| Jolly, SS | 1 |
| Haladyn, K | 1 |
| Peters, RJ | 4 |
| Rupprecht, HJ | 7 |
| Hirsch, A | 2 |
| Windhausen, F | 2 |
| Tijssen, JG | 7 |
| Oude Ophuis, AJ | 1 |
| van der Giessen, WJ | 1 |
| van der Zee, PM | 1 |
| Tanaka, N | 1 |
| Terashima, M | 1 |
| Kimura, M | 1 |
| Nasu, K | 1 |
| Ehara, M | 1 |
| Tsuchikane, E | 1 |
| Matsubara, T | 1 |
| Asakura, Y | 1 |
| Katoh, O | 1 |
| Suzuki, T | 1 |
| Gogorishvili, I | 1 |
| Archvadze, A | 1 |
| Kipiani, V | 1 |
| Kipshidze, N | 1 |
| Ivandic, BT | 1 |
| Kurz, K | 1 |
| Keck, F | 1 |
| Staritz, P | 1 |
| Lehrke, S | 1 |
| Rigattieri, S | 1 |
| Silvestri, P | 1 |
| Minucci, A | 1 |
| Di Russo, C | 1 |
| Ferraiuolo, G | 1 |
| Giardina, B | 1 |
| Capoluongo, E | 1 |
| Loschiavo, P | 1 |
| Ramaraj, R | 1 |
| Jackevicius, CA | 1 |
| Tu, JV | 3 |
| Demers, V | 1 |
| Melo, M | 1 |
| Cox, J | 1 |
| Rinfret, S | 3 |
| Kalavrouziotis, D | 1 |
| Johansen, H | 2 |
| Behlouli, H | 1 |
| Newman, A | 1 |
| Pilote, L | 5 |
| Xiao, L | 1 |
| Kosiborod, MN | 1 |
| Bernardon, M | 1 |
| Limone, A | 1 |
| Businelli, C | 1 |
| Maso, GP | 1 |
| Piccoli, M | 1 |
| Alberico, S | 1 |
| Zhang, YF | 1 |
| Zhu, HM | 1 |
| Wang, HT | 1 |
| Tang, SW | 1 |
| Zhang, HX | 1 |
| Wu, XL | 1 |
| Wu, YL | 1 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 8 |
| Garcia, E | 4 |
| Tcheng, JE | 6 |
| Turco, M | 4 |
| Carroll, JD | 2 |
| Rutherford, BD | 1 |
| Moses, J | 1 |
| Latib, A | 2 |
| Cosgrave, J | 2 |
| Airoldi, F | 2 |
| Brambilla, N | 1 |
| Bonizzoni, E | 1 |
| Carlino, M | 2 |
| Bedogni, F | 1 |
| Montorfano, M | 2 |
| Sangiorgi, GM | 3 |
| Bassand, JP | 3 |
| Jolly, S | 2 |
| Skoric, B | 2 |
| Milicic, D | 3 |
| Lovric, D | 2 |
| Gornik, I | 2 |
| Skoric, KN | 1 |
| Sertic, J | 2 |
| Lemaitre, RN | 1 |
| Rice, K | 1 |
| Marciante, K | 1 |
| Bis, JC | 1 |
| Lumley, TS | 1 |
| Wiggins, KL | 1 |
| Smith, NL | 1 |
| Heckbert, SR | 1 |
| Psaty, BM | 1 |
| Molfese, M | 1 |
| Mihalcsik, L | 1 |
| Mantovani, P | 1 |
| Sirbu, V | 1 |
| Bass, TA | 3 |
| Della Rovere, F | 1 |
| Gavazzi, A | 1 |
| Kiyokuni, M | 1 |
| Kosuge, M | 1 |
| Ebina, T | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 1 |
| Maejima, N | 1 |
| Kusama, I | 1 |
| Komura, N | 1 |
| Nakayama, N | 1 |
| Umemura, S | 2 |
| Riezebos, RK | 1 |
| Ronner, E | 2 |
| Ter Bals, E | 1 |
| Kiemeneij, F | 1 |
| Patterson, MS | 1 |
| Suttorp, MJ | 2 |
| Laarman, GJ | 2 |
| Karnon, J | 1 |
| Holmes, MW | 1 |
| Williams, R | 1 |
| Bakhai, A | 1 |
| Scharf, RE | 1 |
| Schwarz, M | 1 |
| Saurbier, B | 1 |
| Csiba, L | 1 |
| Kovács, KR | 1 |
| Toth, PP | 1 |
| Horvath-Puho, E | 1 |
| Søgaard, KK | 1 |
| Christensen, S | 1 |
| Thomsen, RW | 1 |
| Prandoni, P | 2 |
| Baron, JA | 1 |
| De Labriolle, A | 1 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Suddath, WO | 1 |
| Kent, KM | 3 |
| Pichard, AD | 2 |
| Smit, JJ | 2 |
| van Oeveren, W | 1 |
| Ottervanger, JP | 6 |
| Slingerland, RJ | 1 |
| Remijn, JA | 1 |
| van 't Hof, AW | 9 |
| Milani, RV | 1 |
| Bildirici, U | 1 |
| Celikyurt, U | 1 |
| Ural, E | 1 |
| Freedman, JE | 1 |
| van den Bergh, PJ | 2 |
| Kievit, PC | 2 |
| Aengevaeren, WR | 3 |
| Veen, G | 6 |
| McCabe, CH | 14 |
| Cook, EF | 1 |
| Le May, M | 1 |
| Glover, C | 2 |
| Williams, W | 1 |
| Ha, A | 1 |
| Davies, R | 1 |
| Froeschl, M | 2 |
| Marquis, JF | 4 |
| O'Brien, E | 2 |
| Labinaz, M | 4 |
| Kammer, RT | 1 |
| Saracini, C | 1 |
| Sestini, I | 1 |
| Buonamici, P | 3 |
| Chandra, A | 2 |
| Glickman, SW | 1 |
| Ou, FS | 1 |
| Peacock, WF | 1 |
| McCord, JK | 1 |
| Cairns, CB | 1 |
| Gibler, WB | 3 |
| Massie, BM | 1 |
| Collins, JF | 1 |
| Ammon, SE | 1 |
| Ezekowitz, M | 4 |
| Jafri, SM | 3 |
| Krol, WF | 4 |
| O'Connor, CM | 7 |
| Schulman, KA | 2 |
| Warren, SR | 1 |
| Galesic, M | 1 |
| Garcia-Retamero, R | 1 |
| Gigerenzer, G | 1 |
| Stulman, J | 1 |
| McGinn, T | 1 |
| Korenstein, D | 1 |
| Escárcega, RO | 1 |
| Garcia-Carrasco, M | 1 |
| Jara, LJ | 1 |
| Cervera, R | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, M | 3 |
| Tóth-Zsamboki, E | 1 |
| Becker, D | 1 |
| Beres, BJ | 1 |
| Vargova, K | 1 |
| Fülöp, G | 1 |
| Kerecsen, G | 1 |
| Preda, I | 1 |
| Spaulding, C | 3 |
| Huisse, MG | 1 |
| Ajzenberg, N | 1 |
| Feldman, L | 1 |
| Guillin, MC | 1 |
| Kanakakis, J | 1 |
| Nanas, JN | 1 |
| Tsagalou, EP | 1 |
| Maroulidis, GD | 1 |
| Drakos, SG | 1 |
| Ntalianis, AS | 1 |
| Tzoumele, P | 1 |
| Skoumbourdis, E | 1 |
| Charbis, P | 1 |
| Rokas, S | 1 |
| Anastasiou-Nana, M | 1 |
| Akbulut, M | 1 |
| Kutlu, M | 1 |
| Ozbay, Y | 1 |
| Polat, V | 1 |
| Bilen, MN | 1 |
| Baydas, A | 1 |
| Rogacka, R | 1 |
| Michev, I | 1 |
| Castelli, A | 1 |
| Magni, V | 1 |
| Aranzulla, TC | 1 |
| Hu, PP | 1 |
| Peterson, KL | 1 |
| Tsimikas, S | 1 |
| Tousoulis, D | 2 |
| Briasoulis, A | 1 |
| Dhamrait, SS | 1 |
| Antoniades, C | 1 |
| Stefanadis, C | 3 |
| Cola, C | 1 |
| Brugaletta, S | 3 |
| Martín Yuste, V | 1 |
| Campos, B | 1 |
| Podolec, J | 1 |
| Budziaszek, Ł | 1 |
| Czaniecka, M | 1 |
| Kleczkoska, A | 1 |
| Zmudka', K | 1 |
| Sarkees, ML | 1 |
| Price, MJ | 1 |
| Zuern, CS | 1 |
| Lindemann, S | 1 |
| Gawaz, M | 2 |
| Chalaupka, FD | 1 |
| Densem, C | 1 |
| Jokhi, P | 1 |
| Fox, R | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Mancini, GB | 1 |
| Fung, A | 1 |
| Motovska, Z | 1 |
| Shil, AB | 1 |
| Strohm, MP | 1 |
| Fernández-Fernández, FJ | 1 |
| Pía, G | 1 |
| Sesma, P | 1 |
| Pena, A | 1 |
| Hulot, JS | 1 |
| Silvain, J | 2 |
| Barthélémy, O | 2 |
| Funck-Brentano, C | 1 |
| Rabbani, LE | 3 |
| Iyengar, S | 1 |
| Griffin, JJ | 3 |
| Stant, J | 1 |
| Fahy, M | 3 |
| Shah, N | 1 |
| DeLeon, D | 1 |
| Schwiebert, LP | 1 |
| Mold, JW | 1 |
| Sellers, MB | 1 |
| Carrescia, C | 1 |
| Carletti, R | 1 |
| Li, YJ | 1 |
| Poddar, KL | 1 |
| Jin, Z | 1 |
| Ahn, YK | 3 |
| Hong, TJ | 3 |
| Bae, JH | 3 |
| Choi, DH | 1 |
| Jang, YS | 1 |
| Campbell-Scherer, DL | 1 |
| Green, LA | 1 |
| Albouaini, K | 1 |
| Herold, J | 1 |
| Hahn, J | 1 |
| Brucks, S | 1 |
| Schmidt, H | 1 |
| Schmeisser, A | 1 |
| Prondzinsky, R | 1 |
| Sial, JA | 1 |
| Ferman, MT | 1 |
| Saghir, T | 1 |
| Rasool, SI | 1 |
| Patel, JH | 1 |
| Stoner, JA | 2 |
| Owora, A | 1 |
| Mathew, ST | 1 |
| Thadani, U | 3 |
| Mega, JL | 1 |
| Mohanavelu, S | 1 |
| Poulter, R | 1 |
| Hricak, V | 1 |
| Barnathan, ES | 1 |
| Bordes, P | 1 |
| Markov, V | 1 |
| Oppenheimer, L | 1 |
| Acikel, S | 2 |
| Yildirir, A | 2 |
| Aydinalp, A | 2 |
| Bal, U | 1 |
| Kaynar, G | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 2 |
| Ahmed, N | 1 |
| Meek, J | 1 |
| Davies, GJ | 1 |
| Harjai, KJ | 1 |
| Shenoy, C | 1 |
| Orshaw, P | 1 |
| Boura, J | 1 |
| Busk, M | 2 |
| Mortensen, LS | 3 |
| Steinmetz, ER | 1 |
| Nielsen, TT | 4 |
| Andersen, HR | 3 |
| Heestermans, AA | 2 |
| Van Werkum, JW | 8 |
| Dill, T | 2 |
| Gosselink, AT | 4 |
| Van Houwelingen, G | 3 |
| Hoorntje, JC | 4 |
| Koopmans, PC | 1 |
| Unger, EF | 1 |
| Shimony, A | 1 |
| Levi, E | 1 |
| Zahger, D | 3 |
| Aksu, H | 2 |
| Ozer, O | 2 |
| Unal, H | 1 |
| Hobikoglu, G | 1 |
| Norgaz, T | 2 |
| Buturak, A | 1 |
| Soylu, O | 1 |
| Narin, A | 2 |
| Javadzadegan, H | 1 |
| Mehdizadeh Baghbani, J | 1 |
| Farhang, S | 1 |
| de Peuter, OR | 1 |
| Kok, WE | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Calvin, AD | 1 |
| Aggarwal, NR | 1 |
| Murad, MH | 1 |
| Shi, Q | 1 |
| Elamin, MB | 1 |
| Geske, JB | 1 |
| Fernandez-Balsells, MM | 1 |
| Albuquerque, FN | 1 |
| Lampropulos, JF | 1 |
| Smith, SA | 1 |
| Montori, VM | 1 |
| Bagur, R | 2 |
| Larose, E | 2 |
| Nguyen, CM | 1 |
| Noel, B | 1 |
| Larochellière, RD | 1 |
| Costerousse, O | 2 |
| Roy, L | 4 |
| Saikia, PK | 1 |
| Chakrabarti, D | 1 |
| Chua, D | 2 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| Sanchez-Lopez, J | 1 |
| Muñoz-Cano, R | 1 |
| Bartra, J | 1 |
| Valero, A | 1 |
| Picado, C | 1 |
| Koeth, O | 3 |
| Zahn, R | 11 |
| Gitt, AK | 6 |
| Bauer, T | 5 |
| Juenger, C | 3 |
| Senges, J | 16 |
| Marshall, JK | 1 |
| Cheung, J | 1 |
| Rajala, J | 1 |
| Moroz, D | 1 |
| Stamm, M | 1 |
| Sandha, GS | 1 |
| Sudlow, CL | 1 |
| Mason, G | 1 |
| Maurice, JB | 1 |
| Wedderburn, CJ | 1 |
| Hennekens, C | 2 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| De Larochellière, R | 1 |
| Raymond, C | 1 |
| Zdrenghea, D | 1 |
| Pop, D | 1 |
| Sitar-Tăut, A | 1 |
| Cebanu, M | 1 |
| Zdrenghea, V | 1 |
| Yun, SC | 3 |
| Yang, JY | 2 |
| Lee, SG | 2 |
| Kim, KS | 2 |
| Yoon, J | 4 |
| Kan, LP | 1 |
| Chu, KM | 2 |
| Lin, GM | 4 |
| Guo, JJ | 1 |
| Xu, E | 1 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Zaninelli, A | 2 |
| Kaufholz, C | 2 |
| Schwappach, D | 2 |
| Gilchrist, IC | 1 |
| Fuset, MP | 3 |
| Aplin, R | 1 |
| Tiede, D | 1 |
| Lovitz, C | 1 |
| Gartner, M | 1 |
| Robinson, D | 2 |
| Martin, P | 1 |
| Erickson, B | 1 |
| Schmidt, W | 1 |
| Pelzel, J | 1 |
| Wendt, D | 1 |
| Mahowald, J | 1 |
| Abildstrom, SZ | 1 |
| Hvelplund, A | 1 |
| Andersson, C | 1 |
| Jørgensen, C | 1 |
| Madsen, JK | 5 |
| Hansen, PR | 3 |
| Arcieri, R | 1 |
| Quarto, M | 1 |
| Commisso, C | 1 |
| Penco, M | 1 |
| Gitt, A | 5 |
| Jünger, C | 4 |
| Towae, F | 2 |
| Bestehorn, K | 2 |
| Cudnik, MT | 1 |
| Frank Peacock, W | 1 |
| Diercks, DB | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Chhatriwalla, AK | 1 |
| Le May, MR | 2 |
| Wells, GA | 2 |
| Glover, CA | 1 |
| So, DY | 1 |
| O'Brien, ER | 2 |
| Turek, M | 2 |
| Thomas, A | 1 |
| Kass, M | 1 |
| Jadhav, S | 1 |
| Bilodeau, ML | 1 |
| Simon, DI | 3 |
| Dosh, K | 1 |
| Berger, PB | 9 |
| Marso, S | 1 |
| van Lente, F | 1 |
| Brennan, DM | 3 |
| Charnigo, R | 1 |
| Topol, EJ | 32 |
| Steinhubl, S | 4 |
| Brown, DL | 2 |
| Burke, GL | 1 |
| Oberman, A | 1 |
| Kostis, JB | 1 |
| Langer, RD | 1 |
| Wassertheil-Smoller, S | 1 |
| Venkitachalam, L | 1 |
| Kip, KE | 1 |
| Mulukutla, SR | 1 |
| Selzer, F | 1 |
| Laskey, W | 1 |
| Slater, J | 1 |
| Cohen, HA | 1 |
| Wilensky, RL | 1 |
| Williams, DO | 3 |
| Marroquin, OC | 1 |
| Sutton-Tyrrell, K | 1 |
| Bunker, CH | 1 |
| Kelsey, SF | 1 |
| Arruda-Olson, AM | 1 |
| Reeder, GS | 4 |
| Weston, SA | 2 |
| Tomoda, H | 1 |
| Thurston, SJ | 1 |
| Heeg, B | 1 |
| de Charro, F | 1 |
| van Hout, B | 1 |
| Meisel, ZF | 1 |
| Armstrong, K | 1 |
| Mechem, CC | 1 |
| Shofer, FS | 1 |
| Peacock, N | 1 |
| Facenda, K | 1 |
| Pollack, CV | 1 |
| Welchering, T | 1 |
| Han, CL | 3 |
| Zafar, MU | 1 |
| Paz-Yepes, M | 1 |
| Shimbo, D | 1 |
| Vilahur, G | 1 |
| Burg, MM | 2 |
| Chaplin, W | 1 |
| Badimon, JJ | 5 |
| Kim, SS | 1 |
| Lee, MG | 2 |
| Ko, JS | 2 |
| Park, KH | 2 |
| Yoon, NS | 2 |
| Yoon, HJ | 2 |
| Cho, JG | 3 |
| Park, JC | 4 |
| Kang, JC | 3 |
| Ghaffari, S | 1 |
| Pourafkari, L | 1 |
| Radcliff, TA | 2 |
| Levy, CR | 1 |
| Baldwin, LM | 1 |
| Chan, L | 2 |
| Andrilla, CH | 1 |
| Huff, ED | 1 |
| Hart, LG | 1 |
| Hu, DY | 1 |
| Frangione, A | 2 |
| Luccarelli, S | 1 |
| Cangiano, E | 2 |
| Cavazza, C | 2 |
| Fileti, L | 2 |
| Hwang, JY | 3 |
| Kim, IS | 3 |
| Hwang, SJ | 3 |
| Kwak, CH | 3 |
| Lønborg, J | 1 |
| Vejlstrup, N | 1 |
| Helqvist, S | 1 |
| Clemmensen, P | 4 |
| Holmvang, L | 2 |
| Treiman, M | 1 |
| Jensen, JS | 1 |
| Engstrøm, T | 1 |
| Akhter, M | 1 |
| Kothari, S | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Liistro, F | 2 |
| Fineschi, M | 2 |
| Grotti, S | 1 |
| Angioli, P | 1 |
| Carrera, A | 1 |
| Ducci, K | 1 |
| Falsini, G | 1 |
| Pierli, C | 2 |
| Niccoli, G | 4 |
| Spaziani, C | 1 |
| Pontecorvo, ML | 2 |
| Bacà, M | 2 |
| Porto, I | 2 |
| Leone, AM | 2 |
| Krane, V | 1 |
| Berger, M | 1 |
| Lilienthal, J | 1 |
| Winkler, K | 1 |
| Schambeck, C | 1 |
| Wanner, C | 1 |
| Kharbanda, R | 1 |
| Schmidt, MR | 1 |
| Kaltoft, AK | 1 |
| Terkelsen, CJ | 2 |
| Munk, K | 1 |
| Andersen, NH | 1 |
| Hansen, TM | 1 |
| Trautner, S | 1 |
| Christiansen, EH | 2 |
| Nielsen, SS | 1 |
| Rehling, M | 1 |
| Redington, AN | 1 |
| Sever, PS | 1 |
| Olomu, AB | 1 |
| Grzybowski, M | 1 |
| Ramanath, VS | 1 |
| Rogers, AM | 1 |
| Vautaw, BM | 1 |
| Chen, B | 1 |
| Roychoudhury, C | 1 |
| Jackson, EA | 2 |
| Moerenhout, CM | 1 |
| Haine, S | 1 |
| Miljoen, H | 1 |
| Bosmans, JM | 1 |
| Vertessen, F | 1 |
| Kluppels, K | 1 |
| Van der Planken, M | 1 |
| Vrints, CJ | 1 |
| Balbi, M | 1 |
| Fedele, M | 1 |
| Bezante, GP | 1 |
| Brunelli, C | 1 |
| Barsotti, A | 1 |
| Han, KH | 3 |
| Lee, BK | 1 |
| Nah, DY | 1 |
| Jang, JS | 3 |
| Park, HS | 2 |
| Rotheray, K | 1 |
| Burrill, PD | 1 |
| Meimoun, P | 1 |
| Boulanger, J | 1 |
| Luycx-Bore, A | 1 |
| Zemir, H | 1 |
| Elmkies, F | 1 |
| Malaquin, D | 1 |
| Doutrelan, L | 1 |
| Tribouilloy, C | 1 |
| Ansara, AJ | 1 |
| Nisly, SA | 1 |
| Koehler, JM | 1 |
| Nordmeyer, ST | 1 |
| Fuchs, I | 2 |
| Spiel, AO | 1 |
| Frossard, M | 2 |
| Derhaschnig, U | 1 |
| Riedmüller, E | 1 |
| Johansen, M | 1 |
| Afshari, A | 1 |
| Kristensen, BB | 1 |
| Brzeziński, M | 1 |
| Zdzienicka, J | 1 |
| Saidi, Y | 1 |
| Guesmi, F | 1 |
| Landolsi, M | 1 |
| Trabelsi, S | 1 |
| Khemiri, K | 1 |
| Ounalli, K | 1 |
| Dziri, C | 1 |
| Houissa, M | 1 |
| Kleiman, NS | 5 |
| Schneider, WR | 3 |
| Hebert, PR | 4 |
| Dato, I | 1 |
| Schopfer, D | 1 |
| Patel, V | 1 |
| Chiang, J | 1 |
| Kao, J | 1 |
| Daudelin, DH | 1 |
| Sayah, AJ | 2 |
| Kwong, M | 1 |
| Restuccia, MC | 1 |
| Porcaro, WA | 1 |
| Ruthazer, R | 1 |
| Goetz, JD | 1 |
| Lane, WM | 1 |
| Beshansky, JR | 1 |
| Selker, HP | 2 |
| Hiew, C | 1 |
| Williams, T | 1 |
| Hatton, R | 1 |
| Narasimhan, S | 1 |
| O'Connor, S | 1 |
| Baker, F | 1 |
| McElduff, P | 3 |
| Attia, J | 1 |
| Collins, N | 1 |
| Brackbill, ML | 1 |
| Kline, VT | 1 |
| Sytsma, CS | 1 |
| Call, JT | 1 |
| Fairman, KA | 1 |
| Curtiss, FR | 1 |
| Gresele, P | 1 |
| Tritto, I | 1 |
| Zuchi, C | 1 |
| Bertrand, ME | 2 |
| Lincoff, AM | 6 |
| Moses, JW | 3 |
| Shames, AB | 1 |
| Igonin, VA | 1 |
| Krashutskiĭ, VV | 1 |
| Ivanov, VA | 1 |
| Terekhin, SA | 1 |
| Campos-Outcalt, D | 1 |
| Mahmoody, Y | 1 |
| Zangbar Sabegh, B | 1 |
| Jannati, M | 1 |
| Mahboodi, A | 1 |
| Khalili, A | 1 |
| Burdess, A | 1 |
| Nimmo, AF | 1 |
| Garden, OJ | 1 |
| Murie, JA | 1 |
| Dawson, AR | 1 |
| Newby, DE | 1 |
| Logman, JF | 1 |
| Heeg, BM | 1 |
| van Hout, BA | 1 |
| Lee, R | 3 |
| Gershlick, A | 1 |
| Goldstein, P | 1 |
| Danays, T | 1 |
| Bluhmki, E | 1 |
| Long, B | 1 |
| Perez-Polo, JR | 3 |
| Pevzner, DV | 1 |
| Staroverov, II | 1 |
| Samko, AN | 1 |
| Frolova, NS | 1 |
| Mazurov, AV | 2 |
| Ruda, MY | 1 |
| Galiavich, AS | 2 |
| Makhiianova, ÉI | 1 |
| Sibbing, D | 1 |
| Sonntag, U | 1 |
| Ellert, J | 1 |
| Schulz, S | 2 |
| Schömig, A | 5 |
| Okura, H | 1 |
| Björck, L | 1 |
| Stenestrand, U | 2 |
| Lappas, G | 1 |
| Rosengren, A | 1 |
| Herzog, E | 1 |
| Javed, F | 1 |
| Breet, NJ | 3 |
| Bouman, HJ | 3 |
| Furuyama, H | 1 |
| Kinugawa, Y | 1 |
| Nakajima, M | 1 |
| Okajima, M | 1 |
| Okajima, S | 1 |
| Nakayama, T | 1 |
| Sawada, H | 1 |
| Ohta, Y | 1 |
| Lee, HY | 2 |
| Choi, DJ | 2 |
| Kwon, TG | 2 |
| Eschalier, R | 1 |
| Eschalier, A | 1 |
| Brahic, H | 1 |
| Marcaggi, X | 1 |
| Amat, G | 1 |
| Ghosh, R | 1 |
| Karmohapatra, SK | 1 |
| Bhattacharyya, M | 1 |
| Bhattacharya, R | 1 |
| Bhattacharya, G | 1 |
| Joyner, CD | 1 |
| Afzal, R | 1 |
| Lin, V | 1 |
| Holman, JR | 1 |
| Jamieson, B | 1 |
| van Kuijk, JP | 1 |
| Voute, MT | 1 |
| Flu, WJ | 1 |
| Schouten, O | 1 |
| Chonchol, M | 1 |
| Hoeks, SE | 1 |
| Boersma, EE | 1 |
| Verhagen, HJ | 1 |
| Poldermans, D | 1 |
| Memtsoudis, SG | 1 |
| Sharrock, NE | 1 |
| Preobrazhenskiĭ, DV | 3 |
| Sidorenko, BA | 3 |
| Fettser, DV | 1 |
| Batyraliev, TA | 3 |
| Niiazova-Karben, ZA | 2 |
| Besnili, F | 1 |
| Husted, SE | 10 |
| Nielsen, HK | 5 |
| Rothberg, MB | 2 |
| Pignone, M | 2 |
| Williams, CD | 1 |
| Rosenbaum, A | 1 |
| Rizvi, AZ | 1 |
| Alden, PB | 1 |
| Tretinyak, AS | 1 |
| Graber, JN | 1 |
| Goldman, JA | 1 |
| Slingerland, R | 1 |
| Wetsch, WA | 1 |
| Spöhr, F | 1 |
| Teschendorf, P | 1 |
| Böttiger, BW | 1 |
| Padosch, SA | 1 |
| Atar, I | 1 |
| Altin, C | 1 |
| Gülmez, O | 1 |
| Atar, A | 1 |
| Bozbaş, H | 1 |
| Ilhan, E | 1 |
| Demirci, D | 1 |
| Güvenç, TS | 1 |
| Calık, AN | 1 |
| Pokov, A | 1 |
| Hetzel, S | 1 |
| Demets, D | 1 |
| Serebruany, V | 2 |
| Schröder, H | 3 |
| Han, KR | 2 |
| Cho, BR | 1 |
| Russo, F | 1 |
| Solheim, S | 2 |
| Lunde, K | 1 |
| Bjørnerheim, R | 1 |
| Aakhus, S | 1 |
| Forfang, K | 1 |
| Ndrepepa, G | 1 |
| Braun, S | 1 |
| Tiroch, K | 1 |
| Sanchez-Ross, M | 1 |
| Waller, AH | 1 |
| Maher, J | 1 |
| Klapholz, M | 1 |
| Haider, B | 1 |
| Du, XJ | 1 |
| Shan, L | 1 |
| Kiriazis, H | 1 |
| Lobo, A | 1 |
| Head, GA | 1 |
| Dart, AM | 1 |
| Menown, IB | 2 |
| Delhaye, C | 2 |
| Sudre, A | 1 |
| Vanesson, L | 1 |
| Koussa, M | 1 |
| Fayad, G | 1 |
| Lablanche, JM | 3 |
| Modine, T | 1 |
| Kim, KH | 3 |
| Merella, P | 1 |
| Casu, G | 1 |
| Meloni, I | 1 |
| Ota, Y | 1 |
| Nagai, Y | 1 |
| Katsuta, Y | 1 |
| Nozaki, E | 1 |
| Onodera, T | 1 |
| Kotani, J | 1 |
| Kyo, E | 1 |
| Masumura, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Kodama, K | 1 |
| Stavrakis, S | 1 |
| Azar, M | 1 |
| Wayangankar, S | 1 |
| Kautzky-Willer, A | 1 |
| Kamyar, MR | 1 |
| Gerhat, D | 1 |
| Handisurya, A | 1 |
| Stemer, G | 1 |
| Hudson, S | 1 |
| Luger, A | 1 |
| Lemmens-Gruber, R | 1 |
| Cho, YS | 1 |
| Kamal, AK | 1 |
| Naqvi, I | 1 |
| Husain, MR | 1 |
| Khealani, BA | 1 |
| Christersson, C | 1 |
| Oldgren, J | 3 |
| Siegbahn, A | 3 |
| Beigel, R | 2 |
| Hod, H | 8 |
| Fefer, P | 2 |
| Asher, E | 1 |
| Novikov, I | 2 |
| Shenkman, B | 3 |
| Savion, N | 3 |
| Varon, D | 3 |
| Matetzky, S | 5 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 2 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Jacob, M | 1 |
| Smedira, N | 1 |
| Blackstone, E | 1 |
| Williams, S | 1 |
| Cho, L | 1 |
| Earnshaw, SR | 1 |
| Scheiman, J | 1 |
| Fendrick, AM | 1 |
| McDade, C | 1 |
| Mohammad, RA | 1 |
| Goldberg, T | 1 |
| Dorsch, MP | 2 |
| Cheng, JW | 1 |
| Fried, TR | 1 |
| Tinetti, ME | 1 |
| Towle, V | 1 |
| O'Leary, JR | 1 |
| Iannone, L | 1 |
| Filardo, G | 1 |
| Nicewander, D | 1 |
| Ballard, DJ | 1 |
| Peto, R | 11 |
| Lengenfelder, B | 1 |
| Boes, L | 1 |
| Strotmann, J | 2 |
| Voelker, W | 2 |
| Bonz, AW | 1 |
| Harmsze, AM | 1 |
| Bartolucci, AA | 2 |
| Good, CW | 1 |
| Park, KS | 1 |
| Yun, SE | 1 |
| Park, JR | 1 |
| Koh, EH | 1 |
| Lindbäck, J | 1 |
| Hofman-Bang, C | 1 |
| Samnegard, A | 1 |
| Chua, SK | 1 |
| Liao, CS | 1 |
| Hung, HF | 1 |
| Cheng, JJ | 1 |
| Chiu, CZ | 1 |
| Chang, CM | 1 |
| Lin, SC | 1 |
| Liou, JY | 1 |
| Lo, HM | 1 |
| Kuan, P | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Charlot, M | 1 |
| Ahlehoff, O | 2 |
| Selmer, C | 1 |
| Lindhardsen, J | 3 |
| McGrath, E | 1 |
| O'Conghaile, A | 1 |
| Dinneen, SF | 1 |
| Oczkowski, C | 1 |
| O'Donnell, MJ | 1 |
| Raju, N | 1 |
| Sobieraj-Teague, M | 1 |
| Hirsh, J | 17 |
| Hochholzer, W | 1 |
| Contant, CF | 1 |
| Guo, J | 1 |
| Chae, CU | 1 |
| Glynn, RJ | 5 |
| Tedrow, UB | 1 |
| Everett, BM | 1 |
| Buring, JE | 16 |
| Albert, CM | 1 |
| Motwani, M | 1 |
| Arya, S | 1 |
| MacDonald, JE | 1 |
| Lin, KW | 1 |
| Greif, M | 2 |
| Minelli, S | 1 |
| Carroll, K | 1 |
| Pieper, KS | 2 |
| Horrow, J | 2 |
| Smith, JG | 1 |
| Scherstén, F | 1 |
| Burkard, T | 1 |
| Brunner-La Rocca, H | 1 |
| Yazıcı, HU | 1 |
| Birdane, A | 1 |
| Nadiradze, A | 1 |
| Ünalır, A | 1 |
| Yameogo, NV | 1 |
| Ndiaye, MB | 1 |
| Mbaye, A | 1 |
| Bennani, R | 1 |
| Kagambega, LJ | 1 |
| Bodian, M | 1 |
| Diao, M | 1 |
| Sarr, M | 1 |
| Kane, A | 1 |
| Ba, SA | 1 |
| Cassese, S | 1 |
| Villari, B | 2 |
| Bellone, P | 1 |
| Alfieri, A | 2 |
| Montinaro, A | 1 |
| Quaranta, G | 1 |
| Marraccini, P | 1 |
| Corrales-Medina, VF | 1 |
| Musher, DM | 1 |
| Mosterd, A | 1 |
| Dambrink, JH | 5 |
| Koopmans, P | 1 |
| Rodríguez, LA | 1 |
| Cea-Soriano, L | 1 |
| Martín-Merino, E | 1 |
| Kilaru, R | 1 |
| He, Y | 1 |
| Mohan, P | 1 |
| Goodman, S | 3 |
| Flather, M | 4 |
| Liaw, D | 1 |
| Jansky, P | 1 |
| Cools, F | 2 |
| Ruzyllo, W | 3 |
| White, H | 4 |
| Geraldes, M | 1 |
| Lawrence, J | 1 |
| Khemasuwan, D | 1 |
| Chae, YK | 1 |
| Gupta, S | 1 |
| Carpio, A | 1 |
| Yun, JH | 1 |
| Neagu, S | 1 |
| Lucca, AB | 1 |
| Valsecchi, ME | 1 |
| Mora, JI | 1 |
| Albaladejo, P | 1 |
| Marret, E | 1 |
| Samama, CM | 1 |
| Abhay, K | 1 |
| Loutrel, O | 1 |
| Charbonneau, H | 1 |
| Jaber, S | 1 |
| Thoret, S | 1 |
| Bosson, JL | 1 |
| Piriou, V | 1 |
| Nandish, S | 1 |
| Wyatt, J | 1 |
| Bailon, O | 1 |
| Smith, M | 1 |
| Oliveros, R | 1 |
| Chilton, R | 1 |
| Di Minno, MN | 1 |
| Guida, A | 1 |
| Camera, M | 1 |
| Colli, S | 1 |
| Hoshida, S | 1 |
| Yuasa, F | 1 |
| Lim, YJ | 1 |
| Kijima, Y | 1 |
| Iwasaka, J | 1 |
| Iwasaka, T | 1 |
| Wong, CK | 5 |
| Gao, W | 4 |
| Stewart, RA | 4 |
| French, JK | 11 |
| Seo, JH | 1 |
| Hong, DM | 1 |
| Bahk, JH | 1 |
| Kim, KB | 1 |
| Jeon, Y | 1 |
| Shelton, RJ | 1 |
| Chitkara, K | 1 |
| Singh, R | 1 |
| Dorsch, MF | 1 |
| Somers, K | 1 |
| McLenachan, JM | 1 |
| Blaxill, JM | 1 |
| Wheatcroft, SB | 1 |
| Blackman, DJ | 1 |
| Greenwood, JP | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 3 |
| Hussain, F | 1 |
| Golian, M | 1 |
| Raj, MD | 1 |
| McDonald, C | 1 |
| Brooks, AJ | 1 |
| Drummond, M | 1 |
| Lau, HM | 1 |
| Patel, MI | 1 |
| Bariol, SV | 1 |
| Wang, AC | 1 |
| Woo, HH | 1 |
| Chiu, FC | 1 |
| Wang, TD | 1 |
| Shih, FY | 1 |
| Lin, JW | 1 |
| Huang, CH | 1 |
| Chen, WJ | 1 |
| Chen, MF | 1 |
| Stankovic, I | 1 |
| Vlahovic-Stipac, A | 1 |
| Ilic, I | 1 |
| Putnikovic, B | 1 |
| Neskovic, AN | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 2 |
| Turecki, G | 1 |
| Rahme, E | 3 |
| Kwa, AT | 1 |
| Narancic-Skoric, K | 1 |
| Larson, DM | 2 |
| Sharkey, SW | 1 |
| Garberich, RF | 2 |
| Madison, JD | 1 |
| Stokman, PJ | 1 |
| Dirks, TG | 1 |
| Westin, RK | 1 |
| Harris, JL | 1 |
| Ng, J | 1 |
| Hohnloser, S | 1 |
| Fang, MC | 1 |
| Koh, JS | 1 |
| Kwon, TJ | 1 |
| Sgueglia, GA | 1 |
| Burzotta, F | 2 |
| Trani, C | 1 |
| De Caterina, AR | 1 |
| Mazzari, MA | 1 |
| Mongiardo, R | 1 |
| Rebuzzi, AG | 2 |
| Eldrup, N | 1 |
| Budtz-Lilly, J | 1 |
| Laustsen, J | 1 |
| Bibby, BM | 1 |
| Paaske, WP | 1 |
| Grinfeld, L | 1 |
| Iadanza, A | 1 |
| Vinisko, R | 1 |
| Bath, PM | 3 |
| Dorresteijn, JA | 1 |
| Visseren, FL | 1 |
| Paynter, NP | 1 |
| Wassink, AM | 1 |
| Chitose, T | 1 |
| Miyao, Y | 1 |
| Shimomura, H | 3 |
| Tsunoda, R | 1 |
| Maruyama, H | 1 |
| Hirose, T | 1 |
| Mizobe, M | 1 |
| Nakamura, S | 1 |
| Mylotte, D | 1 |
| Kavanagh, GF | 1 |
| Peace, AJ | 1 |
| Tedesco, AF | 1 |
| Carmody, D | 1 |
| O'Reilly, M | 1 |
| Foley, DP | 1 |
| Thompson, CJ | 1 |
| Agha, A | 1 |
| Smith, D | 1 |
| Kenny, D | 1 |
| Rudež, G | 1 |
| Leebeek, FW | 1 |
| ten Cate, H | 1 |
| de Maat, MP | 1 |
| Felmeden, DC | 1 |
| Dwivedi, G | 1 |
| Chung, WY | 1 |
| Kim, BO | 1 |
| Park, SH | 1 |
| Nikolsky, E | 1 |
| Parise, H | 2 |
| Conti, G | 1 |
| Canali, E | 1 |
| Stio, R | 1 |
| Lucisano, L | 1 |
| Calcagno, S | 1 |
| de Carlo, C | 1 |
| Fedele, F | 1 |
| Krishnan, E | 1 |
| Pandya, BJ | 1 |
| Lingala, B | 1 |
| Hariri, A | 1 |
| Dabbous, O | 2 |
| Akkus, NI | 1 |
| Rajpal, S | 1 |
| Agnani, S | 1 |
| Wiesemann, S | 1 |
| Passlick, B | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Xu, JF | 1 |
| Qin, YY | 1 |
| Perera, M | 1 |
| Suarez, A | 1 |
| Luzardo, H | 1 |
| Lopez, J | 1 |
| Molero, T | 1 |
| Duerschmied, D | 1 |
| Ahrens, I | 1 |
| Mauler, M | 1 |
| Brandt, C | 1 |
| Weidner, S | 1 |
| Moser, M | 2 |
| Omar, HR | 1 |
| Mangar, D | 1 |
| Karlnoski, R | 1 |
| Abdelmalak, HD | 1 |
| Camporesi, EM | 1 |
| Trifunovic, D | 1 |
| Majkic-Singh, N | 1 |
| Ignjatovic, S | 1 |
| Matic, D | 1 |
| Ostojic, M | 1 |
| Vasiljevic, Z | 1 |
| Madsen, OR | 1 |
| Paikin, JS | 1 |
| Monti, M | 1 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Marchesini, J | 1 |
| Smith, LG | 1 |
| Tannenbaum, MA | 1 |
| Johnson Brown, S | 1 |
| Poulose, AK | 1 |
| Iannone, LA | 1 |
| Ghali, MG | 1 |
| Swiatkiewicz, I | 1 |
| Kozinski, M | 1 |
| Magielski, P | 1 |
| Gierach, J | 1 |
| Fabiszak, T | 1 |
| Sukiennik, A | 1 |
| Odrowaz-Sypniewska, G | 1 |
| Jia, XQ | 1 |
| Dong, CM | 1 |
| Qin, J | 2 |
| Häuptle, R | 1 |
| Weilenmann, D | 1 |
| Schneider, T | 1 |
| Haile, SR | 1 |
| Ammann, P | 1 |
| Knellwolf, C | 1 |
| Borovicka, J | 1 |
| Jesurum, JT | 1 |
| Fuller, CJ | 1 |
| Murinova, N | 1 |
| Truva, CM | 1 |
| Lucas, SM | 1 |
| Kishikawa, H | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Latry, P | 1 |
| Martin-Latry, K | 1 |
| Lafitte, M | 1 |
| Peter, C | 1 |
| Couffinhal, T | 1 |
| Codner, P | 1 |
| Rechavia, E | 1 |
| Iakobishvili, Z | 1 |
| Hasdai, D | 2 |
| Battler, A | 3 |
| Łaszewska, A | 1 |
| Icli, A | 1 |
| Varol, E | 1 |
| Erdogan, D | 1 |
| Subban, V | 1 |
| Kalidoss, L | 1 |
| Sankardas, MA | 2 |
| Werner, RM | 1 |
| Bradlow, ET | 1 |
| Stauffer, JC | 1 |
| Goy, JJ | 2 |
| Duvoisin, N | 1 |
| Longenecker, JC | 1 |
| Alfaddagh, A | 1 |
| Ridha, M | 1 |
| Alenezi, F | 1 |
| Alhamdan, R | 1 |
| Akbar, M | 1 |
| Bulbanat, BY | 1 |
| Al-Suwaidi, J | 1 |
| Bauer, ME | 1 |
| Bauer, ST | 1 |
| Rabbani, AB | 1 |
| Mhyre, JM | 1 |
| Swarbrick, M | 1 |
| Fitzgerald, C | 1 |
| Iwabuchi, M | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Nakano, A | 1 |
| Billimoria, AR | 1 |
| Dedhia, VM | 1 |
| Lawler, E | 2 |
| Young, M | 1 |
| Gaziano, M | 1 |
| Jin, HY | 2 |
| Yang, TH | 2 |
| Kim, DI | 1 |
| Chung, SR | 2 |
| Seo, JS | 2 |
| Kim, DK | 3 |
| Seol, SH | 1 |
| Kim, DS | 2 |
| Ueno, T | 2 |
| Igarashi, K | 1 |
| Kobayashi, M | 1 |
| Diego, A | 1 |
| de Prado, AP | 1 |
| Cuellas, C | 1 |
| de Miguel, A | 1 |
| Samaniego, B | 1 |
| Alonso-Rodríguez, D | 1 |
| Bangueses, R | 1 |
| Vega, B | 1 |
| Martín, J | 1 |
| Fernandez-Vazquez, F | 1 |
| Kilickesmez, KO | 1 |
| Kocas, C | 1 |
| Abaci, O | 1 |
| Okcun, B | 1 |
| Gorcin, B | 1 |
| Gurmen, T | 1 |
| Park, CB | 1 |
| Hwang, HJ | 1 |
| Cho, JM | 1 |
| Jo, BH | 1 |
| Meen, O | 1 |
| Brosstad, F | 2 |
| Liestøl, K | 1 |
| Kunszt, G | 1 |
| Bendz, B | 1 |
| Wettergreen, M | 1 |
| Schjelderup, NM | 1 |
| Andreassen, T | 1 |
| Erikssen, G | 1 |
| Duggan, SM | 1 |
| Aresu, G | 1 |
| de Siena, PM | 1 |
| Glauber, M | 1 |
| Caputo, M | 1 |
| Naderi, SH | 1 |
| Bestwick, JP | 1 |
| Wald, DS | 1 |
| Sharma, V | 1 |
| Kaul, S | 1 |
| Al-Hazzani, A | 1 |
| Alshatwi, AA | 1 |
| Jyothy, A | 1 |
| Munshi, A | 1 |
| Seaton, A | 1 |
| Douglas, IJ | 1 |
| Evans, SJ | 1 |
| Hingorani, AD | 1 |
| Grosso, AM | 1 |
| Choi, YH | 1 |
| Suh, SH | 1 |
| Choi, JS | 1 |
| Kim, CS | 1 |
| Bae, EH | 1 |
| Lim, SY | 1 |
| Ma, SK | 1 |
| Kim, SW | 1 |
| Funk, M | 1 |
| Palacio, S | 1 |
| Pearce, LA | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Barron, T | 1 |
| Clawson, J | 1 |
| Scott, G | 1 |
| Patterson, B | 1 |
| Shiner, R | 1 |
| Wrigley, F | 1 |
| Gummett, J | 1 |
| Olola, CH | 1 |
| Valeeva, DD | 1 |
| Minnetdinov, RSh | 1 |
| Arkhipova, AA | 1 |
| Akhmetov, II | 1 |
| Galiavi, RA | 1 |
| Jiang, J | 1 |
| Xiang, MX | 1 |
| Dong, L | 1 |
| Liu, XB | 1 |
| Hu, XY | 1 |
| Feng, Y | 1 |
| Wang, JA | 1 |
| Yano, H | 1 |
| Morita, S | 1 |
| Endo, T | 1 |
| Sugano, T | 2 |
| Himeno, H | 1 |
| Fukui, K | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Van Hattum, ES | 1 |
| Tangelder, MJ | 3 |
| Lawson, JA | 3 |
| Moll, FL | 1 |
| Algra, A | 9 |
| Raju, NC | 1 |
| Cohn, JN | 1 |
| Knickelbine, T | 1 |
| Graham, KJ | 1 |
| Kamper, AL | 1 |
| Hommel, K | 1 |
| Renda, G | 2 |
| Vavalle, JP | 1 |
| May, CH | 1 |
| Meade, T | 1 |
| Topacio, GO | 1 |
| Pavlides, G | 2 |
| Goudev, AR | 1 |
| Oto, A | 1 |
| Tseng, CD | 1 |
| Gasparovic, V | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Brown, EB | 1 |
| Pijls, NH | 1 |
| Kalesan, B | 1 |
| Tonino, PA | 1 |
| Piroth, Z | 1 |
| Jagic, N | 1 |
| Möbius-Winkler, S | 1 |
| Mobius-Winckler, S | 1 |
| Rioufol, G | 1 |
| Witt, N | 1 |
| Kala, P | 1 |
| Engström, T | 1 |
| Oldroyd, KG | 3 |
| Mavromatis, K | 1 |
| Manoharan, G | 2 |
| Verlee, P | 1 |
| Frobert, O | 1 |
| Curzen, N | 1 |
| Johnson, JB | 1 |
| Fearon, WF | 1 |
| Yan, G | 1 |
| Ma, Y | 1 |
| Wang, G | 1 |
| Zhu, G | 1 |
| Jiang, T | 1 |
| Guirguis-Blake, J | 1 |
| Shechter, M | 2 |
| Degli Esposti, D | 1 |
| Gharacholou, SM | 1 |
| Choi, KN | 1 |
| Do, U | 1 |
| Meyer, S | 1 |
| Neely, M | 1 |
| Chan, MY | 1 |
| Brown, E | 1 |
| Jakubowski, JA | 1 |
| Elhadad, S | 1 |
| Pouillot, C | 1 |
| Boueri, Z | 1 |
| Van Belle, E | 1 |
| Rousseau, H | 1 |
| Aubry, P | 3 |
| Monségu, J | 1 |
| Sabouret, P | 1 |
| O'Connor, SA | 1 |
| Kerneis, M | 1 |
| Saint-Etienne, C | 1 |
| Badri, M | 1 |
| Saeed, W | 1 |
| Sardar, MR | 1 |
| Yang, LX | 1 |
| Liu, HL | 1 |
| Qu, P | 1 |
| Li, WM | 1 |
| Jiang, TM | 1 |
| Li, SM | 1 |
| Zhang, QY | 1 |
| Xu, B | 1 |
| Petricevic, M | 1 |
| Biocina, B | 1 |
| Svetina, L | 1 |
| Seguy, B | 1 |
| Argay, M | 1 |
| Koós, I | 1 |
| Takács, I | 1 |
| Dormaeva, I | 1 |
| Meskó, A | 1 |
| Zelkó, R | 1 |
| Hankó, B | 1 |
| Grosser, T | 1 |
| Fries, S | 1 |
| Kapoor, SC | 1 |
| Grant, GR | 1 |
| FitzGerald, GA | 8 |
| Mravian, SR | 1 |
| Petrukhin, VA | 1 |
| Davydova, TV | 1 |
| Budykina, TS | 1 |
| Tishenina, RS | 1 |
| Pronina, VP | 1 |
| Grishin, VL | 1 |
| Funck-Jensen, KL | 1 |
| Dalsgaard, J | 1 |
| Yi, X | 1 |
| Zhou, Q | 1 |
| Chi, L | 1 |
| Yamagishi, M | 1 |
| Hara, K | 1 |
| Itoh, T | 1 |
| Hamanaka, I | 1 |
| Wakatsuki, T | 2 |
| Capuano, F | 1 |
| Loirat, P | 1 |
| Desplanques-Leperre, A | 1 |
| Derumeaux, G | 1 |
| Thebaut, JF | 1 |
| Gardel, C | 1 |
| Grenier, C | 1 |
| Ohkubo, K | 1 |
| Fujimoto, Y | 1 |
| Iwata, Y | 1 |
| Kitahara, H | 1 |
| Kadohira, T | 1 |
| Sugimoto, K | 1 |
| Morino, T | 1 |
| Han, JL | 1 |
| Li, HY | 1 |
| Qiao, R | 1 |
| Yu, HY | 1 |
| Zeng, H | 1 |
| Andrade, C | 1 |
| Martinussen, T | 1 |
| Vansteelandt, S | 1 |
| Bacci, MR | 1 |
| Santos, JA | 1 |
| Nogueira, LF | 1 |
| Namura, JJ | 1 |
| Cvetinovic, N | 1 |
| Brdar, N | 1 |
| Stojanovic, M | 1 |
| Djuricic, N | 1 |
| Perunicic, J | 1 |
| Tilsted, HH | 1 |
| Hansen, KN | 1 |
| Villadsen, AB | 1 |
| Ravkilde, J | 1 |
| Aarøe, J | 1 |
| Hofma, S | 1 |
| Togni, M | 1 |
| Vázquez, N | 2 |
| Voudris, V | 2 |
| Vuillomenet, A | 1 |
| Serra, A | 1 |
| Nouche, RT | 1 |
| den Heijer, P | 1 |
| van der Ent, M | 1 |
| Itagaki, BK | 1 |
| Brar, SS | 1 |
| Thompson, SG | 1 |
| Higgins, JP | 1 |
| Wallace, JL | 1 |
| Ignarro, LJ | 1 |
| Fiorucci, S | 1 |
| van Es, RF | 1 |
| Jonker, JJ | 1 |
| Deckers, JW | 3 |
| Grobbee, DE | 1 |
| Klein, W | 3 |
| Brieger, D | 2 |
| Lilly, LS | 1 |
| Rollins, G | 4 |
| Vacek, JL | 3 |
| Cohen, SE | 1 |
| Luijten, HE | 1 |
| Hertzberger, DP | 2 |
| van Boven, AJ | 1 |
| Vromans, RP | 1 |
| Uijen, GJ | 1 |
| McCullough, PA | 1 |
| Sandberg, KR | 1 |
| Borzak, S | 1 |
| Hudson, MP | 1 |
| Garg, M | 1 |
| Manley, HJ | 1 |
| Sivasubramian, R | 1 |
| Spencer, FA | 6 |
| Moschi, G | 1 |
| Trapani, M | 1 |
| Cerisano, G | 1 |
| Santoro, GM | 1 |
| Szabo, S | 1 |
| Letsch, R | 1 |
| Ehlers, R | 1 |
| Walter, T | 1 |
| Kazmaier, S | 1 |
| Helber, U | 1 |
| Hoffmeister, HM | 1 |
| Kong, DF | 2 |
| Hasselblad, V | 4 |
| Kandzari, DE | 4 |
| Marso, SP | 2 |
| Ringleb, PA | 3 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
| Mascitelli, L | 1 |
| Pezzetta, F | 1 |
| Hurlen, M | 13 |
| Abdelnoor, M | 5 |
| Smith, P | 2 |
| Erikssen, J | 1 |
| Shlipak, MG | 2 |
| Noguchi, H | 1 |
| Chertow, GM | 1 |
| Browner, WS | 2 |
| McClellan, MB | 1 |
| Wright, RS | 2 |
| Herzog, CA | 1 |
| Albright, RC | 1 |
| Williams, BA | 1 |
| Dvorak, DL | 1 |
| Miller, WL | 1 |
| Murphy, JG | 1 |
| Kopecky, SL | 4 |
| Manda, SO | 2 |
| Fliri, M | 1 |
| Sabatier, R | 1 |
| Prati, F | 1 |
| Boccanelli, A | 1 |
| Grollier, G | 1 |
| Loma-Osorio, A | 1 |
| García-Castrillo, L | 1 |
| Arós, F | 1 |
| Lopetegui, P | 1 |
| Recuerda, E | 1 |
| Epelde, F | 1 |
| Teo, KK | 2 |
| Kober, L | 1 |
| Hall, A | 1 |
| Latini, R | 4 |
| Collins, R | 12 |
| Talbert, RL | 1 |
| Spinler, SA | 1 |
| Nappi, JM | 1 |
| Bottorff, MB | 1 |
| Weisman, SM | 2 |
| Graham, DY | 1 |
| Choi, JW | 1 |
| Davidson, CJ | 2 |
| Man-Son-Hing, M | 1 |
| Berquist, R | 1 |
| O'Connor, AM | 1 |
| Laupacis, A | 3 |
| Zanchetti, A | 2 |
| Hansson, L | 4 |
| Julius, S | 1 |
| Ménard, J | 1 |
| Warnold, I | 2 |
| Wedel, H | 2 |
| Barbash, I | 1 |
| Freimark, D | 2 |
| Hasin, Y | 3 |
| Crystal, E | 1 |
| Boyko, V | 4 |
| Mandelzweig, L | 2 |
| Behar, S | 4 |
| Leor, J | 4 |
| Santopinto, JJ | 1 |
| Moscucci, M | 2 |
| White, K | 2 |
| Gurfinkel, EP | 7 |
| Bĕlohlávek, J | 1 |
| Aschermann, M | 1 |
| Howard, PA | 1 |
| Czuriga, I | 2 |
| Mann, JT | 1 |
| Fry, ET | 1 |
| DeLago, A | 1 |
| Wilmer, C | 1 |
| Motomiya, T | 2 |
| Nakamura, Y | 2 |
| Ishikawa, K | 6 |
| Nakai, S | 2 |
| Kübler, W | 4 |
| Comarow, A | 1 |
| Ferrini, R | 1 |
| Clark, B | 1 |
| Levenson, D | 2 |
| Simon, HB | 1 |
| O'Neill, JO | 1 |
| Nash, PJ | 1 |
| Bourke, W | 1 |
| McGarry, K | 1 |
| Bedford, D | 1 |
| Grenier, O | 2 |
| Cambou, JP | 7 |
| Thomas, D | 5 |
| Amelineau, E | 2 |
| Cantet, C | 2 |
| Underwood, P | 1 |
| Beck, P | 1 |
| Tereshchenko, SN | 1 |
| Aleksandriia, LG | 1 |
| Moiseev, VS | 1 |
| Pershukov, IV | 2 |
| Pia, IuV | 1 |
| Daniiarov, BS | 1 |
| Novikova, NA | 1 |
| Sydor, WJ | 1 |
| Brummel, K | 1 |
| Musial, J | 2 |
| Mann, KG | 2 |
| Szczeklik, A | 7 |
| Ornato, JP | 4 |
| Vittinghoff, E | 2 |
| Varosy, PD | 1 |
| Furberg, CD | 2 |
| Ireland, CC | 1 |
| Khan, SS | 1 |
| Blumenthal, R | 2 |
| Barrett-Connor, E | 1 |
| Hulley, S | 2 |
| Pullicino, P | 1 |
| Thompson, JL | 1 |
| Aronow, WS | 4 |
| Amit, G | 1 |
| Ilia, R | 2 |
| De Schryver, EL | 3 |
| van Gijn, J | 7 |
| Heller, RF | 5 |
| Edwards, R | 1 |
| Dauterman, K | 1 |
| Topol, E | 2 |
| Grand, A | 1 |
| Moustapha, A | 1 |
| Anderson, HV | 6 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 2 |
| Choussat, R | 5 |
| Ankri, A | 2 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 2 |
| Armstrong, EC | 1 |
| Andersen, K | 1 |
| Harrold, LR | 1 |
| Gurwitz, JH | 10 |
| Brandt, KD | 1 |
| Joost, HG | 1 |
| Drögemüller, A | 1 |
| Seidl, K | 1 |
| Schiele, R | 8 |
| Schneider, S | 5 |
| Gottwik, M | 4 |
| von Leitner, ER | 1 |
| Poppe, C | 1 |
| Rettig-Stürmer, G | 1 |
| Hughes, K | 1 |
| Zhao, F | 3 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Schreiber, W | 3 |
| Kittler, H | 1 |
| Pieper, O | 1 |
| Woisetschlaeger, C | 1 |
| Laggner, AN | 3 |
| Hirschl, MM | 1 |
| Christen, WG | 1 |
| Manson, JE | 8 |
| Sperduto, RD | 1 |
| Gille, J | 1 |
| Bernotat, J | 1 |
| Böhm, S | 1 |
| Behrens, P | 1 |
| Löhr, JF | 1 |
| Meyer, BJ | 2 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Matías-Guiu, J | 2 |
| Ferro, JM | 2 |
| Alvarez-Sabín, J | 2 |
| Torres, F | 3 |
| Jiménez, MD | 1 |
| Lago, A | 1 |
| Melo, T | 1 |
| Petersen, LA | 2 |
| Druss, BG | 3 |
| Rosenheck, RA | 3 |
| Gum, PA | 1 |
| Kottke-Marchant, K | 1 |
| Welsh, PA | 1 |
| Reikvam, A | 6 |
| Kvan, E | 2 |
| Aursnes, I | 5 |
| Jönsson, B | 2 |
| Stålhammar, NO | 1 |
| Rathore, SS | 6 |
| Radford, MJ | 10 |
| Ordin, DL | 1 |
| Simpson, E | 1 |
| Beck, C | 1 |
| Richard, H | 2 |
| Eisenberg, MJ | 3 |
| Al-Khatib, SM | 2 |
| Stebbins, AL | 2 |
| Lee, KL | 1 |
| Gharbi, M | 1 |
| Barakett, N | 1 |
| Lahidheb, DH | 1 |
| Smiri, Z | 1 |
| Fehri, W | 1 |
| Azzouzi, F | 1 |
| Rahal, N | 1 |
| Mhenni, H | 1 |
| Haouala, H | 1 |
| Guediche, M | 1 |
| Doggrell, SA | 2 |
| Shinmura, K | 2 |
| Kodani, E | 1 |
| Xuan, YT | 1 |
| Dawn, B | 1 |
| Tang, XL | 1 |
| Bolli, R | 2 |
| Przyklenk, K | 1 |
| Heusch, G | 1 |
| Zhu, BQ | 1 |
| Sievers, RE | 1 |
| Browne, AE | 1 |
| Lee, RJ | 1 |
| Chatterjee, K | 1 |
| Grossman, W | 1 |
| Karliner, JS | 1 |
| Parmley, WW | 1 |
| Landmark, K | 3 |
| Barzi, F | 1 |
| Marfisi, RM | 1 |
| Tavazzi, L | 3 |
| Valagussa, F | 2 |
| Marchioli, R | 2 |
| Hanania, G | 2 |
| Vaur, L | 2 |
| Guéret, P | 2 |
| Genès, N | 1 |
| Bergstrand, L | 1 |
| Fellenius, C | 3 |
| Lindahl, B | 3 |
| Lins, LE | 1 |
| Nilsson, T | 2 |
| Pehrsson, K | 1 |
| Swahn, E | 4 |
| Tani, S | 1 |
| Kanmatsuse, K | 2 |
| Biviano, AB | 1 |
| Paultre, F | 1 |
| Hurley, E | 1 |
| Sullivan, J | 1 |
| Giglio, J | 1 |
| Mosca, L | 1 |
| Akosah, KO | 1 |
| Larson, DE | 1 |
| Brown, WM | 1 |
| Paul, KM | 1 |
| Schaper, A | 1 |
| Green, RM | 1 |
| Barriales Alvarez, V | 2 |
| Alvarez Tamargo, JA | 1 |
| García Aguado, M | 1 |
| Suarez, E | 1 |
| Morís de la Tassa, C | 2 |
| Wang, FW | 1 |
| Osman, A | 1 |
| Otero, J | 1 |
| Stouffer, GA | 2 |
| Waxman, S | 1 |
| Afzal, A | 1 |
| Anzuini, A | 2 |
| Uretsky, BF | 2 |
| Sellmayer, A | 1 |
| Limmert, T | 1 |
| Hoffmann, U | 1 |
| Ziegler, BK | 2 |
| Rasmussen, LH | 1 |
| Hildebrandt, PR | 1 |
| Nattrass, M | 1 |
| Schechter, S | 1 |
| Carbajal, D | 1 |
| Noa, M | 1 |
| Molina, V | 1 |
| Arruzazabala, ML | 1 |
| Más, R | 1 |
| Mendoza, S | 1 |
| González, J | 1 |
| Bali, HK | 1 |
| Vijayvergiya, R | 1 |
| Banarjee, S | 1 |
| Kumar, N | 1 |
| Fries, R | 1 |
| Burwen, DR | 1 |
| Galusha, DH | 1 |
| Lewis, JM | 1 |
| Bedinger, MR | 1 |
| Scardi, S | 1 |
| Mazzone, C | 1 |
| Giallauria, F | 1 |
| Paragliola, T | 1 |
| Del Forno, D | 1 |
| Baiano, A | 1 |
| de Cristofaro, A | 1 |
| Rossi, M | 1 |
| Vigorito, C | 1 |
| Madsen, S | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Yarnell, J | 1 |
| O'Brien, JR | 3 |
| Ben Shlomo, Y | 1 |
| Berger, AK | 3 |
| Conti, CR | 1 |
| Wilson, SH | 1 |
| Fasseas, P | 2 |
| Orford, JL | 2 |
| Lennon, RJ | 1 |
| Horlocker, T | 1 |
| Charnoff, NE | 1 |
| Melby, S | 2 |
| Valettas, N | 1 |
| Herrmann, HC | 1 |
| Hung, J | 1 |
| Nishiyama, A | 1 |
| Niikawa, O | 1 |
| Mohri, H | 1 |
| Tsushima, M | 1 |
| Vesterlund, T | 1 |
| Grande, P | 6 |
| Abildgaard, U | 4 |
| Pedersen, F | 4 |
| Rogan, SV | 1 |
| Arablinskiĭ, AV | 1 |
| Solov'ev, OP | 1 |
| Imperadore, F | 1 |
| Spagnolli, W | 1 |
| Martinelli, L | 1 |
| Musuraca, G | 1 |
| De Girolamo, P | 1 |
| Maines, M | 1 |
| Vergara, G | 1 |
| Anderson, FA | 2 |
| Flather, MD | 6 |
| Spencer, F | 2 |
| Dabbous, OH | 3 |
| Clerson, P | 1 |
| L'Allier, PL | 1 |
| Aronow, HD | 2 |
| Cura, FA | 1 |
| Albirini, A | 1 |
| Schneider, JP | 2 |
| Ellis, SG | 2 |
| Hodgson, JM | 1 |
| Scheller, B | 1 |
| Hennen, B | 1 |
| Hammer, B | 1 |
| Walle, J | 1 |
| Hofer, C | 1 |
| Hilpert, V | 1 |
| Winter, H | 1 |
| Nickenig, G | 1 |
| Pasternak, R | 1 |
| Kurth, T | 2 |
| Walker, AM | 1 |
| Okmen, E | 1 |
| Cakmak, M | 1 |
| Tartan, Z | 1 |
| Cam, N | 1 |
| Karadag, B | 1 |
| Roffi, M | 2 |
| SoRelle, R | 1 |
| Kennon, S | 3 |
| Price, CP | 2 |
| Mills, PG | 2 |
| Macey, M | 1 |
| Cooper, J | 3 |
| Clarke, H | 2 |
| Averkov, OV | 4 |
| Wilcox, RG | 9 |
| Emanuelsson, H | 2 |
| Goodvin, A | 1 |
| Bylock, A | 2 |
| Eidelman, RS | 1 |
| Valentin, V | 2 |
| Dudderidge, TJ | 1 |
| Arya, M | 1 |
| Young, J | 1 |
| Davies, AJ | 1 |
| Demir, I | 1 |
| Yilmaz, H | 1 |
| Basarici, I | 1 |
| Sancaktar, O | 1 |
| Deger, N | 1 |
| Rosenberg, L | 2 |
| Rao, RS | 1 |
| Palmer, JR | 1 |
| Eikvar, L | 2 |
| Jeddy, AS | 1 |
| Gleason, BL | 1 |
| Chan, AW | 2 |
| DiBattiste, PM | 5 |
| Yakubov, SL | 1 |
| Sapp, SK | 2 |
| Wolski, K | 1 |
| Campbell, ME | 1 |
| Górecki, A | 1 |
| Chamiec, T | 1 |
| Bednarz, B | 1 |
| Maciejewski, P | 1 |
| Łukaszewicz, R | 1 |
| Ceremuzyński, L | 3 |
| Maritz, F | 1 |
| Timerman, A | 1 |
| Krzeminska-Pakula, M | 1 |
| Santopinto, J | 3 |
| Bigonzi, F | 3 |
| Hecquet, C | 1 |
| Vittori, L | 1 |
| Slavina, NN | 2 |
| Gratsianskiĭ, NA | 3 |
| Veeravalli, KK | 2 |
| Akula, A | 2 |
| Cook, TD | 1 |
| Fries, D | 1 |
| Innerhofer, P | 1 |
| Schobersberger, W | 1 |
| Margreiter, J | 1 |
| Antretter, H | 1 |
| Hörmann, C | 1 |
| Relos, RP | 1 |
| Hasinoff, IK | 1 |
| Beilman, GJ | 1 |
| Bonnefoy, E | 1 |
| Chabaud, S | 1 |
| Lapostolle, F | 2 |
| Dubien, PY | 1 |
| Cristofini, P | 1 |
| Leizorovicz, A | 5 |
| Touboul, P | 1 |
| Ritter, O | 1 |
| Bonz, A | 1 |
| Langenfeld, H | 1 |
| Lombardi, A | 2 |
| Vandelli, R | 1 |
| Cerè, E | 2 |
| Di Pasquale, G | 3 |
| Ortolani, P | 1 |
| Marzocchi, A | 2 |
| Gaiba, W | 1 |
| Neri, S | 1 |
| Marrozzini, C | 1 |
| Aquilina, M | 1 |
| Branzi, A | 1 |
| Agustí, A | 7 |
| Diògene, E | 2 |
| Kimmel, SE | 4 |
| Strom, BL | 4 |
| Curtis, JP | 3 |
| Portnay, EL | 2 |
| Havranek, EP | 3 |
| Waters, RE | 1 |
| Schreiber, M | 1 |
| Sechtem, U | 1 |
| Williams, A | 1 |
| Srichai, MB | 1 |
| Jaber, WA | 1 |
| Prior, DL | 1 |
| Houghtaling, PL | 1 |
| Simoons, ML | 11 |
| Hole, T | 2 |
| Weston, C | 1 |
| Rao, U | 1 |
| Shennib, H | 1 |
| Endo, M | 1 |
| Benhameid, O | 1 |
| Lange, RA | 3 |
| Hillis, LD | 6 |
| Adgey, AA | 3 |
| Teal, PA | 1 |
| Fleming, T | 1 |
| Nissen, SE | 1 |
| Borer, JS | 1 |
| Soulat, T | 1 |
| Gallois, V | 1 |
| Drobinski, G | 2 |
| Demopoulos, LA | 2 |
| Van Kerckhoven, R | 2 |
| van Veghel, R | 1 |
| Saxena, PR | 4 |
| Schoemaker, RG | 4 |
| Mintz, GS | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Garber, K | 1 |
| Holm, J | 3 |
| Peterson, M | 2 |
| Karlson, BW | 5 |
| Haglid Evander, M | 1 |
| Erhardt, L | 3 |
| Bax, M | 1 |
| Schotborgh, CE | 1 |
| Koch, KT | 1 |
| Meuwissen, M | 1 |
| Voskuil, M | 1 |
| Adams, R | 1 |
| Mulder, KJ | 1 |
| Robb-Nicholson, C | 2 |
| Eliasziw, M | 2 |
| Faraday, N | 2 |
| Braunstein, JB | 1 |
| Heldman, AW | 1 |
| Bolton, ED | 1 |
| Chiles, KA | 1 |
| Gross, ER | 1 |
| Hsu, AK | 1 |
| Gross, GJ | 1 |
| Meischke, H | 3 |
| Diehr, P | 2 |
| Rowe, S | 2 |
| Cagle, A | 2 |
| Eisenberg, M | 2 |
| Bestul, MB | 1 |
| McCollum, M | 1 |
| Stringer, KA | 1 |
| Burchenal, J | 1 |
| Burger, K | 1 |
| Gottenberg, JE | 1 |
| Sordet, C | 1 |
| Sibilia, J | 1 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Cosin-Sales, J | 1 |
| Christiansen, M | 1 |
| Kaminski, P | 1 |
| Oxvig, C | 1 |
| Overgaard, MT | 1 |
| Cole, D | 1 |
| Holt, DW | 1 |
| Kaski, JC | 1 |
| Quinn, MJ | 2 |
| Sapp, S | 2 |
| Reilly, M | 2 |
| Jaskowiak, J | 2 |
| Kishel, L | 2 |
| Chittams, J | 2 |
| Chen, WH | 2 |
| Lee, PY | 1 |
| Ng, W | 1 |
| Lau, CP | 1 |
| Rodgers, JE | 2 |
| Nagai, R | 1 |
| Watanabe, K | 1 |
| Nagao, K | 1 |
| Watanabe, I | 1 |
| Camerini, A | 1 |
| Chieffo, C | 1 |
| Griffo, R | 1 |
| Comaschi, M | 1 |
| Gattone, M | 1 |
| Mannucci, E | 1 |
| Faglia, E | 1 |
| Giorda, C | 1 |
| Biorci, ML | 1 |
| Fattirolli, F | 1 |
| Kurihara, H | 1 |
| Tamura, R | 1 |
| Yachiku, K | 1 |
| Nakata, A | 1 |
| Nakagawa, T | 1 |
| Yoshino, T | 1 |
| Matsuyama, T | 1 |
| Clappers, N | 1 |
| Deray, G | 1 |
| Alcindor, D | 1 |
| Krolikowski, JG | 1 |
| Pagel, PS | 1 |
| Warltier, DC | 1 |
| Kersten, JR | 1 |
| Patel, TN | 1 |
| Goldberg, KC | 1 |
| Al-Saadi, N | 1 |
| Abdel-Aty, H | 1 |
| Schulz-Menger, J | 1 |
| Messroghli, DR | 1 |
| Friedrich, MG | 1 |
| Steimle, AE | 1 |
| Arjomand, H | 1 |
| Ezekowitz, MD | 2 |
| Kido, S | 1 |
| Hasebe, N | 1 |
| Kikuchi, K | 1 |
| Xiao, Z | 1 |
| Guetta, V | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Pres, H | 1 |
| Banas, JS | 1 |
| Rao, NS | 1 |
| Neimane, D | 1 |
| Hatou, E | 1 |
| Abdulali, S | 1 |
| Sobel, BE | 4 |
| Wienbergen, H | 3 |
| Heer, T | 5 |
| Vogel, C | 1 |
| Varas-Lorenzo, C | 2 |
| Maguire, A | 1 |
| Bogaerts, K | 1 |
| Belmans, A | 1 |
| Armstrong, P | 1 |
| Adgey, JA | 1 |
| Soares-Piegas, L | 1 |
| Vahanian, A | 4 |
| Van De Werf, FJ | 2 |
| Müller, I | 1 |
| Besta, F | 1 |
| Bredie, SJ | 2 |
| Wollersheim, H | 1 |
| Thien, T | 2 |
| Otterstad, JE | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Webster, SE | 1 |
| Ross Naylor, A | 1 |
| Goodall, AH | 1 |
| Findlay, I | 1 |
| Jafri, S | 1 |
| Sutton, G | 2 |
| Falk, R | 1 |
| Bulpitt, C | 1 |
| Prentice, C | 1 |
| Ford, I | 1 |
| Trainer, A | 1 |
| Poole-Wilson, PA | 3 |
| Hugel, B | 1 |
| Jesel, L | 2 |
| Mallat, Z | 1 |
| Lanza, F | 1 |
| Douchet, MP | 1 |
| Zupan, M | 1 |
| Chauvin, M | 2 |
| Cazenave, JP | 1 |
| Tedgui, A | 1 |
| Freyssinet, JM | 1 |
| Toti, F | 1 |
| Sherman, SC | 1 |
| Sulé, HP | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Nakazawa, R | 1 |
| Kishino, S | 1 |
| Mochizuki, M | 1 |
| Shiga, T | 1 |
| Tepliakov, AT | 1 |
| Sankevich, qV | 1 |
| Stepacheva, TA | 1 |
| Garganeeva, AA | 1 |
| Filippov, EA | 1 |
| Pushnikova, EIu | 1 |
| Kaliuzhin, VV | 1 |
| Efimova, I | 1 |
| Zavadovskiĭ, KV | 1 |
| Kline-Rogers, E | 3 |
| Erickson, S | 1 |
| Ivanusa, M | 1 |
| Ivanusa, Z | 1 |
| Blazing, MA | 1 |
| Palmisano, J | 1 |
| Bilheimer, DW | 1 |
| Snapinn, SM | 1 |
| Ramsey, KE | 1 |
| Gardner, LH | 1 |
| Lewis, EF | 1 |
| Saito, T | 2 |
| Rodger, IW | 1 |
| Hu, F | 1 |
| Robinson, R | 1 |
| Giaid, A | 1 |
| Shen, YM | 1 |
| Frenkel, EP | 1 |
| Sawhney, N | 1 |
| Kuntz, RE | 3 |
| Popma, JJ | 1 |
| Bachinsky, W | 1 |
| Bass, T | 1 |
| DeMaio, S | 1 |
| Fry, E | 1 |
| Teirstein, PS | 2 |
| Aghababian, RV | 1 |
| Jennings, LK | 1 |
| Lorenz, DP | 2 |
| Cholera, S | 1 |
| Krishnan, R | 1 |
| Jelinski, SE | 1 |
| Ghali, WA | 2 |
| Parsons, GA | 1 |
| Maxwell, CJ | 1 |
| Boucher, M | 1 |
| Pharand, C | 2 |
| Skidmore, B | 1 |
| Perschbacher, JM | 1 |
| Jacobsen, SJ | 1 |
| Killian, JM | 1 |
| Slobodova, A | 1 |
| Wolski, KE | 1 |
| Frilling, B | 2 |
| Glunz, HG | 3 |
| Gieseler, U | 3 |
| Jagodzinski, E | 1 |
| Leitner, JM | 1 |
| Hsieh, K | 1 |
| Vlcek, M | 1 |
| Losert, H | 1 |
| Domanovits, H | 1 |
| Vorob'eva, NM | 1 |
| Sereshcheva, AKh | 1 |
| Petrik, ES | 1 |
| Akinina, SA | 1 |
| Tsuda, E | 1 |
| Kitamura, S | 1 |
| De Benedetti, E | 3 |
| Meade, TW | 4 |
| Vorchheimer, DA | 1 |
| Guyatt, GH | 2 |
| Goodman, SD | 1 |
| Schünemann, HJ | 2 |
| Stein, PD | 1 |
| Gutterman, D | 1 |
| Kassem-Moussa, H | 1 |
| Graffagnino, C | 1 |
| Tasissa, G | 1 |
| Sila, CA | 1 |
| Simes, RJ | 3 |
| Bhapkar, MV | 3 |
| Luchins, D | 1 |
| Blanchet, B | 1 |
| Tanguy, ML | 1 |
| Payot, L | 1 |
| Dyskin, IuA | 1 |
| Makarycheva, OV | 1 |
| Vasil'eva, EIu | 1 |
| Shpektor, AV | 1 |
| Schwimmbeck, PL | 1 |
| Diehm, C | 1 |
| Lawall, H | 1 |
| Huber, R | 1 |
| Smaha, LA | 1 |
| Stejskal, D | 1 |
| Prosková, J | 1 |
| Lacnák, B | 1 |
| Horalík, D | 1 |
| Hamplová, A | 1 |
| Oral, I | 1 |
| Hrabovská, I | 1 |
| Ochmanová, R | 1 |
| Adamovská, S | 1 |
| Juráková, R | 1 |
| Ozanová, G | 1 |
| Juchelka, J | 1 |
| Kulísková, O | 1 |
| Pĕnkavová, H | 1 |
| Karreman, AJ | 1 |
| Tran, CT | 1 |
| Mamdani, MM | 2 |
| Fang, CH | 1 |
| Li, JJ | 1 |
| Hui, RT | 1 |
| Heeschen, C | 2 |
| Mitrovic, V | 1 |
| Lantelme, NH | 1 |
| Chesebro, JH | 11 |
| Schnell, O | 1 |
| Standl, E | 1 |
| Lowe, GD | 2 |
| Francis, LM | 1 |
| Rumley, A | 1 |
| Cobbe, SM | 1 |
| Nicholls, C | 1 |
| Sani, M | 1 |
| Leonardi-Bee, J | 1 |
| Davalos, A | 1 |
| Guiraud-Chaumeil, B | 1 |
| Sivenius, J | 2 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Karha, J | 1 |
| Krause, MW | 1 |
| Massing, M | 1 |
| Kshirsagar, A | 1 |
| Rosamond, W | 2 |
| Simpson, RJ | 1 |
| Schneeweiss, S | 1 |
| Tsai, EH | 1 |
| Avorn, J | 2 |
| Solomon, DH | 2 |
| Schellinger, PD | 1 |
| Rajagopal, V | 1 |
| Fox, DJ | 1 |
| Gray, TP | 1 |
| Fath-Ordoubadi, F | 1 |
| Danna, P | 1 |
| Viecca, M | 1 |
| Sonson, JM | 1 |
| Lum, JJ | 1 |
| Madison, JR | 1 |
| Seto, TB | 1 |
| Spies, C | 1 |
| Katayama, T | 2 |
| Nakashima, H | 2 |
| Takagi, C | 2 |
| Honda, Y | 2 |
| Suzuki, S | 2 |
| Yano, K | 2 |
| Evander, MH | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Parsons, E | 1 |
| Shah, SH | 1 |
| Bushnell, CD | 1 |
| Ferrari, E | 1 |
| Benhamou, M | 1 |
| Cerboni, P | 1 |
| Marcel, B | 1 |
| Miser, WF | 2 |
| Waskowsky, WM | 1 |
| Brouwer, A | 1 |
| Massel, D | 2 |
| Campbell, CL | 1 |
| Austin, PC | 1 |
| Stukel, TA | 1 |
| Anderson, GM | 1 |
| Schleinitz, MD | 1 |
| Lim, MJ | 1 |
| Agnelli, G | 2 |
| Kline-Rogers, EM | 1 |
| Dibenedetto, D | 1 |
| Rachapalli, S | 1 |
| Lee, IM | 1 |
| Gordon, D | 1 |
| Levin, RI | 1 |
| López-Sendón, JL | 2 |
| Hill, KA | 1 |
| Skene, AM | 3 |
| Beĭshenkulov, MT | 1 |
| Kudaĭbergenova, NT | 1 |
| Baltabaev, TB | 1 |
| Eryonucu, B | 1 |
| Tuncer, M | 1 |
| Erkoc, R | 1 |
| Lee, RT | 1 |
| Luthi, JC | 1 |
| McClellan, WM | 1 |
| Flanders, WD | 1 |
| Pitts, SR | 1 |
| Burnand, B | 1 |
| Gorman, C | 1 |
| Pettersen, AA | 1 |
| Lévesque, LE | 1 |
| Zhang, B | 1 |
| Ghosheh, K | 1 |
| Reeves, MJ | 1 |
| DeFranco, A | 1 |
| Bansal, D | 1 |
| Gaddam, V | 1 |
| Aude, YW | 1 |
| Bissett, J | 1 |
| Fahdi, I | 1 |
| Garza, L | 1 |
| Joseph, J | 1 |
| Molavi, B | 1 |
| Pai, BV | 1 |
| Smith, ES | 1 |
| Mehta, JL | 2 |
| Buresly, K | 1 |
| Leroy, JE | 1 |
| Bensouda, C | 1 |
| Durand, E | 2 |
| Greffet, A | 1 |
| Scemama, A | 1 |
| Carli, P | 1 |
| Sauval, P | 1 |
| Chyrchel, M | 1 |
| Bartuś, S | 1 |
| Kawata, M | 1 |
| Kuramoto, E | 1 |
| Kataoka, T | 1 |
| Saito, A | 1 |
| Adachi, K | 2 |
| Matsuura, A | 1 |
| Sakamoto, S | 2 |
| Dieker, H | 1 |
| McNaughton, H | 1 |
| Barber, PA | 1 |
| Gommans, J | 1 |
| Nowitz, M | 1 |
| Kerényi, A | 1 |
| Soltész, P | 1 |
| Veres, K | 1 |
| Szegedi, G | 1 |
| Muszbek, L | 1 |
| Nelson, MR | 1 |
| Liew, D | 1 |
| Bertram, M | 1 |
| Vos, T | 1 |
| Graham, JJ | 1 |
| Ramdany, S | 1 |
| Deaner, A | 1 |
| Ranjadayalan, K | 9 |
| Knight, C | 1 |
| Kounis, NG | 2 |
| Kouni, SN | 1 |
| Koutsojannis, CM | 1 |
| Elsässer, A | 1 |
| Nef, H | 1 |
| Hansen, DB | 1 |
| Ilkhanoff, L | 1 |
| Lewis, JD | 2 |
| Hennessy, S | 1 |
| Brown, G | 2 |
| Okino, S | 1 |
| Nishiyama, K | 1 |
| Velasco, A | 1 |
| Fernández-Jarne, E | 1 |
| Coma-Canella, I | 2 |
| Lo, C | 1 |
| Babor, EM | 1 |
| Akowuah, E | 1 |
| Shrivastava, V | 1 |
| Jamnadas, B | 1 |
| Hopkinson, D | 1 |
| Sarkar, P | 1 |
| Storey, R | 1 |
| Braidley, P | 1 |
| Cooper, G | 1 |
| Fathi, RB | 1 |
| Ozgul, M | 1 |
| Ozaydin, M | 1 |
| Aslan, SM | 1 |
| Gedikli, O | 1 |
| Altinbas, A | 1 |
| Fischer, LM | 1 |
| Schlienger, RG | 1 |
| Jick, H | 3 |
| Meier, CR | 1 |
| Schwartz, DJ | 1 |
| Vinson, DR | 3 |
| van der Vlugt, TM | 2 |
| Padgett, TG | 2 |
| Tricomi, AJ | 3 |
| Lyons, EE | 3 |
| Crounse, L | 3 |
| Brand, DW | 2 |
| Ripa, RS | 1 |
| Sejersten, M | 1 |
| Wagner, GS | 2 |
| Kumar, A | 1 |
| Rubboli, A | 1 |
| Milandri, M | 1 |
| Castelvetri, C | 1 |
| Cosmi, B | 1 |
| Shih, WJ | 1 |
| Li, XY | 1 |
| Costa, J | 1 |
| Kriszbacher, I | 1 |
| Koppán, M | 1 |
| Bódis, J | 1 |
| Davies, RF | 1 |
| Leddy, D | 2 |
| Maloney, J | 1 |
| McKibbin, T | 1 |
| Quinn, B | 1 |
| Beanlands, RS | 1 |
| Williams, WL | 3 |
| Higginson, LA | 2 |
| Hudson, M | 2 |
| Baron, M | 1 |
| Peterson, E | 2 |
| Allegrone, J | 1 |
| Trappe, HJ | 1 |
| Perings, C | 1 |
| Bernstein, RA | 1 |
| Musiał, J | 3 |
| Sanak, M | 1 |
| Celestin, C | 1 |
| Fiore, LD | 2 |
| Cook, JR | 1 |
| Wahbi, K | 1 |
| Salengro, E | 1 |
| Galicier, L | 1 |
| Guillevin, L | 1 |
| Weber, S | 1 |
| Meune, C | 1 |
| Vaccarino, V | 2 |
| Frederick, PD | 2 |
| Abramson, JL | 1 |
| Barron, HV | 2 |
| Manhapra, A | 1 |
| Mallik, S | 1 |
| McQueen, MJ | 1 |
| Jancso, G | 1 |
| Cserepes, B | 1 |
| Gasz, B | 1 |
| Benko, L | 1 |
| Ferencz, A | 1 |
| Borsiczky, B | 1 |
| Lantos, J | 1 |
| Dureja, A | 1 |
| Kiss, K | 1 |
| Szeberényi, J | 1 |
| Roth, E | 1 |
| Ferguson, JJ | 5 |
| Rzeczuch, K | 1 |
| Szajn, G | 1 |
| Jankowska, E | 1 |
| Kaczmarek, A | 1 |
| Derkacz, A | 1 |
| Porada, A | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 2 |
| Beinart, SC | 1 |
| Veledar, E | 1 |
| Mahoney, EM | 1 |
| Bouin, O | 1 |
| Gabriel, S | 1 |
| Chen, R | 1 |
| Caro, J | 1 |
| Testa, L | 1 |
| Biondi-Zoccai, GG | 1 |
| Feuring, M | 1 |
| Schultz, A | 1 |
| Losel, R | 1 |
| Wehling, M | 1 |
| Crowe, B | 1 |
| Abbas, S | 1 |
| Meany, B | 1 |
| de Haan, J | 1 |
| Cahill, MR | 1 |
| O'Donnell, S | 1 |
| Condell, S | 1 |
| Begley, C | 1 |
| Fitzgerald, T | 1 |
| Iwasaki, Y | 1 |
| Bybee, KA | 1 |
| Powell, BD | 1 |
| Valeti, U | 1 |
| Rosales, AG | 1 |
| Mullany, C | 1 |
| Eriksson, P | 4 |
| Rothberg, M | 1 |
| Tiefenbrunn, AJ | 1 |
| Kaneda, H | 1 |
| Suzuki, J | 1 |
| Hosokawa, G | 1 |
| Tanaka, S | 2 |
| Hiroe, Y | 1 |
| Ouriel, K | 2 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 4 |
| Frentzko, M | 1 |
| Wechsler, L | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 1 |
| Blann, A | 1 |
| Zee, RY | 1 |
| Diehl, KA | 1 |
| Kim, JA | 1 |
| Yoon, D | 1 |
| Pijak, MR | 1 |
| Huzicka, I | 1 |
| Gazdik, F | 1 |
| Cappell, MS | 1 |
| Keough-Ryan, TM | 1 |
| Kiberd, BA | 1 |
| Dipchand, CS | 1 |
| Cox, JL | 1 |
| Rose, CL | 1 |
| Thompson, KJ | 1 |
| Clase, CM | 1 |
| Altman, R | 4 |
| Brown, DW | 1 |
| Shepard, D | 1 |
| Giles, WH | 1 |
| Greenlund, KJ | 1 |
| Croft, JB | 1 |
| Ringborg, A | 1 |
| Lindgren, P | 2 |
| Harrison, P | 1 |
| Mackie, I | 1 |
| Mathur, A | 1 |
| Robinson, MS | 1 |
| Hong, Y | 1 |
| Erusalimsky, JD | 1 |
| Machin, SJ | 2 |
| Martin, JF | 3 |
| von Pape, KW | 1 |
| Strupp, G | 1 |
| Bonzel, T | 1 |
| Bohner, J | 1 |
| Chen, ZM | 2 |
| Jiang, LX | 1 |
| Chen, YP | 1 |
| Xie, JX | 1 |
| Pan, HC | 1 |
| Liu, LS | 2 |
| Varma, C | 1 |
| Watkins, S | 1 |
| Thiemann, D | 1 |
| Coresh, J | 1 |
| Powe, N | 1 |
| Folsom, AR | 2 |
| Gill, SS | 1 |
| Landolfi, R | 1 |
| Quinlan, DJ | 1 |
| Turpie, AG | 6 |
| Tatu-Chiţoiu, G | 1 |
| Teodorescu, C | 1 |
| Dan, M | 1 |
| Guran, M | 1 |
| Căpraru, P | 1 |
| Istrăţescu, O | 1 |
| Tatu-Chiţoiu, A | 1 |
| Bumbu, A | 1 |
| Chioncel, V | 1 |
| Arvanitopol, S | 1 |
| Dorobanţu, M | 1 |
| Poston, RS | 1 |
| White, C | 2 |
| Gu, J | 1 |
| Brown, J | 1 |
| Gammie, J | 1 |
| Pierson, RN | 1 |
| Lee, A | 1 |
| Connerney, I | 1 |
| Avari, T | 1 |
| Christenson, R | 2 |
| Tandry, U | 1 |
| Griffith, BP | 1 |
| Robinson, CR | 1 |
| Martin, JL | 2 |
| Canham, RM | 1 |
| Abdullah, SM | 1 |
| Cigarroa, JE | 2 |
| Keeley, EC | 1 |
| Zhao, JL | 1 |
| You, SJ | 1 |
| Wu, YJ | 1 |
| Jing, ZC | 1 |
| Yang, WX | 1 |
| Meng, L | 1 |
| Wang, YW | 1 |
| Gurbuz, AT | 1 |
| Zia, AA | 1 |
| Vuran, AC | 1 |
| Cui, H | 1 |
| Aytac, A | 1 |
| Avanzini, F | 1 |
| Pangrazzi, I | 1 |
| Perrier, E | 1 |
| Manen, O | 1 |
| Cinquetti, G | 1 |
| Smith, EE | 1 |
| Murphy, S | 2 |
| Feske, SK | 1 |
| Schwamm, LH | 1 |
| Fitchett, DH | 1 |
| Langer, A | 6 |
| Tan, M | 1 |
| Mendelsohn, A | 1 |
| Chen, YG | 1 |
| Ji, QS | 1 |
| Lü, RJ | 1 |
| Li, RJ | 1 |
| Mäkikallio, TH | 1 |
| Barthel, P | 1 |
| Schneider, R | 1 |
| Bauer, A | 1 |
| Tapanainen, JM | 1 |
| Tulppo, MP | 1 |
| Perkiömäki, JS | 1 |
| Schmidt, G | 1 |
| Huikuri, HV | 1 |
| Buchanan, MR | 1 |
| Silbergleit, R | 1 |
| Kronick, SL | 1 |
| Philpott, S | 1 |
| Lowell, MJ | 1 |
| Wagner, C | 1 |
| Bajraktari, G | 1 |
| Kastrati, S | 1 |
| Manaj, R | 1 |
| Berisha, I | 1 |
| Thaqi, S | 1 |
| Beqiri, A | 1 |
| Elezi, S | 2 |
| Tulsyan, N | 1 |
| Kashyap, VS | 1 |
| Borja, J | 2 |
| García, O | 1 |
| Donado, E | 1 |
| Izquierdo, I | 2 |
| Bhala, N | 1 |
| Taggar, J | 1 |
| Asaro, PV | 1 |
| Sheldahl, AL | 1 |
| Char, DM | 1 |
| Black, HR | 2 |
| Cohen, EA | 2 |
| Haffner, SM | 1 |
| Mak, KH | 3 |
| Weber, MA | 2 |
| Fabry-Ribaudo, L | 2 |
| Booth, J | 1 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 2 |
| Sousa, JE | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Abbott, KC | 1 |
| Bohen, EM | 1 |
| Yuan, CM | 1 |
| Yeo, FE | 1 |
| Sawyers, ES | 1 |
| Perkins, RM | 1 |
| Lentine, KL | 1 |
| Oliver, DK | 1 |
| Galey, J | 1 |
| Sebastianelli, ME | 1 |
| Scally, JP | 1 |
| Boal, TR | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Byrne, M | 1 |
| Murphy, AW | 1 |
| Walsh, JC | 1 |
| Shryane, E | 1 |
| McGroarty, M | 1 |
| Kelleher, CC | 1 |
| Schaefer, A | 1 |
| Stumme, B | 1 |
| Drexler, H | 1 |
| von Depka, M | 1 |
| Ikeda, U | 1 |
| Shimamoto, K | 1 |
| Kawana, M | 1 |
| Umman, B | 3 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Lackey, SA | 1 |
| Jaarsma, W | 1 |
| Hautvast, RW | 1 |
| Rasoul, S | 1 |
| Miedema, K | 1 |
| Gosselink, M | 1 |
| Saver, JL | 2 |
| Lynn, MJ | 2 |
| Chimowitz, M | 1 |
| Buller, CE | 2 |
| Pate, GE | 1 |
| O'Neill, BJ | 1 |
| Gallo, R | 1 |
| Hawkey, GM | 1 |
| Everitt, S | 1 |
| Skelly, MM | 1 |
| Stack, WA | 1 |
| Gray, D | 2 |
| Shah, NR | 1 |
| Low, AF | 1 |
| Quek, SC | 1 |
| Yip, J | 1 |
| Poulsen, TS | 3 |
| Jørgensen, B | 2 |
| Korsholm, L | 2 |
| Licht, PB | 2 |
| Haghfelt, T | 2 |
| Mickley, H | 3 |
| Raffel, OC | 1 |
| Vafai, JJ | 1 |
| Aroesty, JM | 1 |
| Vavuranakis, M | 1 |
| Latsios, G | 1 |
| Aggelis, D | 1 |
| Bosinakou, I | 1 |
| Karambelas, I | 1 |
| Toutouzas, K | 1 |
| Ishikawa, T | 1 |
| Mutoh, M | 1 |
| Fuda, Y | 1 |
| Higashitani, M | 1 |
| Nakano, Y | 1 |
| Enta, K | 1 |
| Satoh, T | 1 |
| Imai, K | 1 |
| Horie, T | 1 |
| Mochizuki, S | 1 |
| Graff, LG | 1 |
| Borkowski, B | 1 |
| Tuozzo, K | 1 |
| Mannini, L | 1 |
| Antonucci, E | 2 |
| Giglioli, C | 2 |
| Prisco, D | 2 |
| Ee, PL | 1 |
| Kempen, PM | 1 |
| Ellerbeck, EF | 3 |
| Bhimaraj, A | 1 |
| Hall, S | 1 |
| Reid, KJ | 1 |
| Cooper, R | 1 |
| Aster, RH | 1 |
| Brassard, J | 1 |
| Charlesworth, A | 4 |
| Pamukcu, B | 2 |
| Oflaz, H | 2 |
| Oncul, A | 2 |
| Mercanoglu, F | 2 |
| Ozcan, M | 2 |
| Meric, M | 2 |
| Nisanci, Y | 2 |
| Peterson, PN | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Møller, JE | 1 |
| Mayr, FB | 1 |
| Descarries, LM | 1 |
| Leduc, L | 1 |
| Khairy, P | 1 |
| Mercier, LA | 1 |
| Fedi, S | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Gómez-Barrado, JJ | 1 |
| Vega, J | 1 |
| Turégano, S | 1 |
| Marcos, G | 1 |
| Rieckmann, N | 1 |
| Kronish, IM | 1 |
| Haas, D | 1 |
| Gerin, W | 1 |
| Chaplin, WF | 1 |
| Vorchheimer, D | 1 |
| Flaker, GC | 2 |
| Gruber, M | 1 |
| Goldman, S | 2 |
| Chaparro, S | 1 |
| Halinen, MO | 1 |
| Prasan, AM | 1 |
| Bhagwandeen, R | 1 |
| Solanki, VJ | 1 |
| Freedman, SB | 1 |
| Chrissoheris, MP | 1 |
| Mruthyunjayanna, V | 1 |
| Donohue, TJ | 1 |
| Tessone, A | 1 |
| Barbash, IM | 3 |
| Garty, M | 1 |
| Tenenbaum, A | 2 |
| Ioannidis, TI | 1 |
| Mazarakis, A | 1 |
| Notaras, SP | 1 |
| Karpeta, MZ | 1 |
| Tsintoni, AC | 1 |
| Kounis, GN | 1 |
| Rallis, DG | 1 |
| Cheng, X | 1 |
| Ruef, J | 2 |
| Kranzhöfer, R | 1 |
| Sharifkazemi, MB | 1 |
| Zamirian, M | 1 |
| Aslani, A | 1 |
| Jabaren, M | 1 |
| Desai, DM | 1 |
| Arabi, A | 1 |
| Kareti, G | 1 |
| Chen-Scarabelli, C | 1 |
| Rosman, HS | 2 |
| O'Donoghue, M | 1 |
| Ozdol, C | 1 |
| Gulec, S | 2 |
| Rahimov, U | 1 |
| Atmaca, Y | 1 |
| Turhan, S | 1 |
| Erol, C | 1 |
| Soulat, L | 1 |
| Lambert, Y | 1 |
| Adgey, J | 1 |
| Wang, XK | 1 |
| Yang, CM | 1 |
| Liu, GY | 1 |
| Bochenek, A | 1 |
| Wilczyński, M | 1 |
| Manthous, CA | 1 |
| Sarkiss, MG | 1 |
| Yusuf, SW | 1 |
| Warneke, CL | 1 |
| Botz, G | 1 |
| Lakkis, N | 2 |
| Hirch-Ginsburg, C | 1 |
| Champion, JC | 1 |
| Swafford, J | 1 |
| Shaw, AD | 1 |
| Lenihan, DJ | 1 |
| Durand, JB | 1 |
| Dieker, HJ | 1 |
| Joziasse, IC | 1 |
| Elliott, J | 1 |
| West, TM | 1 |
| Webber, BJ | 1 |
| Doubeni, C | 1 |
| Chen, JT | 1 |
| Pucino, F | 1 |
| Resman-Targoff, BH | 1 |
| Brüggenjürgen, B | 1 |
| Ehlken, B | 1 |
| Willich, SN | 2 |
| Kristensen, SR | 1 |
| Dickie, JS | 1 |
| Scott, LJ | 1 |
| Perez, F | 1 |
| Piñon, M | 1 |
| Breña, S | 1 |
| Aznar, J | 1 |
| Kozieradzka, A | 1 |
| Kamiński, KA | 1 |
| Pepiński, W | 1 |
| Janica, J | 1 |
| Korecki, J | 1 |
| Skolimowski, K | 1 |
| Frankowska, E | 1 |
| Kralisz, P | 1 |
| Bonda, TA | 1 |
| Dobrzycki, S | 1 |
| Musiał, WJ | 1 |
| Bonow, RO | 5 |
| Casey, DE | 3 |
| Gardner, TJ | 3 |
| Lockhart, PB | 3 |
| O'Gara, P | 3 |
| Halkes, PH | 1 |
| Kappelle, LJ | 4 |
| Koudstaal, PJ | 4 |
| Krüth, P | 1 |
| Carbone, G | 1 |
| Maione, A | 1 |
| Gregorio, G | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Morange, PE | 1 |
| Nait-Saidi, L | 1 |
| Mielot, C | 1 |
| Bali, L | 1 |
| Lambert, M | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 2 |
| Karjalainen, PP | 1 |
| Porela, P | 1 |
| Ylitalo, A | 1 |
| Vikman, S | 1 |
| Nyman, K | 1 |
| Vaittinen, MA | 1 |
| Airaksinen, TJ | 1 |
| Niemelä, M | 1 |
| Vahlberg, T | 1 |
| Airaksinen, KE | 1 |
| Martinez, JD | 1 |
| Huang, MH | 1 |
| Lui, CY | 1 |
| Onur, I | 1 |
| Einhäupl, K | 1 |
| Dobalian, A | 1 |
| Levy, C | 1 |
| Tran, H | 1 |
| Adamek, A | 1 |
| Hu, K | 1 |
| Bayer, B | 1 |
| Wagner, H | 1 |
| Frantz, S | 1 |
| Viellard, C | 1 |
| Faure, A | 1 |
| Desprez, D | 1 |
| Roul, G | 1 |
| Grunebaum, L | 1 |
| Bareiss, P | 1 |
| Stillman, MJ | 1 |
| Stillman, MT | 1 |
| Hobikoglu, GF | 1 |
| Erturk, M | 1 |
| Destegul, E | 1 |
| Akyuz, U | 1 |
| Unal Dai, S | 1 |
| Radojković, DD | 1 |
| Perisić, Z | 1 |
| Tomasević, M | 1 |
| Pavlović, M | 1 |
| Apostolović, S | 1 |
| Janković, R | 1 |
| Damjanović, M | 1 |
| Martinović, SS | 1 |
| Bozinović, N | 1 |
| Milenković, D | 1 |
| Opotowsky, AR | 1 |
| McWilliams, JM | 1 |
| Bailey, TC | 1 |
| Noirot, LA | 1 |
| Blickensderfer, A | 1 |
| Rachmiel, E | 1 |
| Schaiff, R | 1 |
| Kessels, A | 1 |
| Braverman, A | 1 |
| Goldberg, A | 1 |
| Waterman, B | 1 |
| Dunagan, WC | 1 |
| Decker, C | 1 |
| Huddleston, J | 1 |
| Kosiborod, M | 1 |
| Buchanan, DM | 1 |
| Stoner, C | 1 |
| Jones, A | 1 |
| Amory, JK | 1 |
| Amory, DW | 1 |
| Grossman, CM | 1 |
| Malek, LA | 1 |
| Grabowski, M | 1 |
| Spiewak, M | 1 |
| Filipiak, KJ | 1 |
| Szpotanska, M | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Bobilewicz, D | 1 |
| Bartorelli, AL | 1 |
| Trabattoni, D | 1 |
| Galassi, A | 1 |
| Serdoz, R | 1 |
| Sheiban, I | 2 |
| Piovaccari, G | 2 |
| Zimarino, M | 1 |
| Benassi, A | 2 |
| Sangiorgio, P | 1 |
| Chierchia, S | 2 |
| Finn, AV | 1 |
| Joner, M | 1 |
| Nakazawa, G | 1 |
| Kolodgie, F | 1 |
| Newell, J | 1 |
| John, MC | 1 |
| Gold, HK | 4 |
| Virmani, R | 1 |
| Jha, AK | 2 |
| Staiger, DO | 1 |
| Lucas, FL | 1 |
| Lynch, DR | 1 |
| Dunn, SP | 1 |
| Schwartz, T | 1 |
| Colby, E | 1 |
| Montague, D | 1 |
| Smyth, SS | 1 |
| Karlsson, G | 1 |
| Rehman, J | 1 |
| Kalaria, V | 1 |
| Hu, T | 1 |
| Kikano, GE | 1 |
| Egan, K | 1 |
| Fu, Y | 1 |
| Chen, WL | 1 |
| Moore, PK | 1 |
| Zhu, YZ | 1 |
| Majdoub, MA | 1 |
| Sauguet, A | 1 |
| Tchetche, D | 1 |
| Benamer, H | 1 |
| Himbert, D | 3 |
| Feldman, LJ | 1 |
| Juliard, JM | 4 |
| Pischon, T | 1 |
| Möhlig, M | 1 |
| Hoffmann, K | 1 |
| Spranger, J | 1 |
| Weikert, C | 1 |
| Pfeiffer, AF | 1 |
| Boeing, H | 1 |
| Blancas Gómez-Casero, R | 1 |
| Nevado Losada, E | 1 |
| López Matamala, B | 1 |
| Martínez Díaz, C | 1 |
| Serrano Castañeda, J | 1 |
| Yáñez Parareda, E | 1 |
| González Manzanares, JL | 1 |
| Chana García, M | 1 |
| Martín Delgado, C | 1 |
| Jiménez-Quevedo, P | 2 |
| Hernández-Antolín, R | 2 |
| SanMartín, M | 1 |
| Bañuelos, C | 2 |
| Moreno, R | 2 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Macaya, C | 3 |
| Saia, F | 1 |
| Manari, A | 1 |
| Aurier, E | 1 |
| Cremonesi, A | 1 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| Guastaroba, P | 1 |
| Grilli, R | 1 |
| Maresta, A | 1 |
| Epstein, AM | 1 |
| Skinner, JS | 2 |
| Cooper, A | 1 |
| Feder, GS | 1 |
| Minhas, R | 1 |
| Patane', S | 1 |
| Marte, F | 2 |
| Di Bella, G | 2 |
| Chiribiri, A | 2 |
| Chappell, LT | 1 |
| Herbert, JM | 1 |
| Miner, J | 1 |
| Hoffhines, A | 1 |
| Abdel-Wahab, M | 1 |
| El-Shahed, G | 1 |
| Awadalla, H | 1 |
| Amin, M | 1 |
| El-Hammady, W | 1 |
| Ayoub, A | 1 |
| Meinertz, T | 1 |
| Bhapker, MV | 1 |
| Pfisterer, M | 2 |
| Chimowitz, MI | 1 |
| Baglini, R | 1 |
| Mezzapelle, G | 1 |
| Baldari, D | 1 |
| Keating, N | 1 |
| Stiefelhagen, P | 1 |
| Wang, TH | 1 |
| Patanè, S | 1 |
| Helton, TJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Matsukawa, M | 1 |
| Soejima, K | 1 |
| Fuchigami, S | 1 |
| Honda, T | 1 |
| Nagayoshi, Y | 1 |
| Yoshimura, M | 2 |
| Nakagaki, T | 1 |
| Wenzel, V | 1 |
| Dissmann, R | 1 |
| Marschalk, A | 1 |
| Breckwoldt, J | 1 |
| Müller, D | 1 |
| Greenbaum, AB | 1 |
| Schneider, CA | 1 |
| Foussas, SG | 1 |
| Zairis, MN | 1 |
| Patsourakos, NG | 1 |
| Makrygiannis, SS | 1 |
| Adamopoulou, EN | 1 |
| Handanis, SM | 1 |
| Prekates, AA | 1 |
| Fakiolas, CN | 1 |
| Pissimissis, EG | 1 |
| Olympios, CD | 1 |
| Argyrakis, SK | 1 |
| Barnes, GD | 1 |
| Vedre, A | 1 |
| Armstrong, DF | 1 |
| Froehlich, JB | 1 |
| Gurm, HS | 1 |
| Pham, JC | 1 |
| Kelen, GD | 1 |
| Pronovost, PJ | 1 |
| Wilson, JM | 2 |
| Diez, J | 1 |
| Köth, O | 1 |
| Richard Conti, C | 1 |
| Bernardo, E | 1 |
| Costa, MA | 1 |
| Guzman, LA | 1 |
| Schmaier, AH | 1 |
| Smalling, RW | 2 |
| Giesler, GM | 1 |
| Julapalli, VR | 1 |
| Sdringola, SM | 1 |
| Vooletich, MT | 1 |
| McCarthy, JJ | 1 |
| Bradley, RN | 1 |
| Persse, DE | 1 |
| Richter, BK | 1 |
| Fujise, K | 1 |
| Yerman, T | 1 |
| Gan, WQ | 1 |
| Sin, DD | 1 |
| Isaka, N | 2 |
| Fujino, N | 1 |
| Matsumoto, T | 1 |
| Vigholt, E | 1 |
| Sztriha, LK | 1 |
| Sas, K | 1 |
| Seres, E | 1 |
| Boda, K | 1 |
| Lenti, L | 1 |
| Csifcsak, G | 1 |
| Kovacs, N | 1 |
| Vecsei, L | 1 |
| Owen, A | 1 |
| Schumann, SA | 1 |
| Ewigman, B | 1 |
| Becker, DM | 1 |
| Becker, LC | 2 |
| Michelson, AD | 2 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Chi, J | 1 |
| Smedema, JP | 1 |
| Berlion, AE | 1 |
| Morkel, H | 1 |
| Guneri, S | 1 |
| Jacob, AJ | 1 |
| Kim, JY | 1 |
| Shin, M | 1 |
| Ahn, M | 1 |
| Choe, H | 1 |
| Yoo, BS | 1 |
| Choe, KH | 1 |
| Berger, K | 2 |
| Hessel, F | 1 |
| Kreuzer, J | 2 |
| Smala, A | 1 |
| Birkhead, JS | 1 |
| Konopka, A | 1 |
| Spychalska, J | 1 |
| Sitkiewicz, D | 1 |
| Zdebska, E | 1 |
| Pilichowska, I | 1 |
| Piotrowski, W | 1 |
| Stepińska, J | 1 |
| Crutcher, JM | 1 |
| Mallonee, S | 1 |
| Daniels, C | 1 |
| van Wijk, I | 1 |
| Gorter, JW | 1 |
| Simmons, BB | 1 |
| Salzman, BE | 1 |
| Rocca, B | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Bessereau, J | 1 |
| Desvignes, O | 1 |
| Huon, B | 1 |
| Roudaut, JY | 1 |
| Picault, L | 1 |
| Blanc, JJ | 1 |
| Frison, L | 1 |
| Weaver, D | 1 |
| Mark, B | 1 |
| Fares, RR | 1 |
| Lansing, LS | 1 |
| Gallati, CA | 1 |
| Mousa, SA | 1 |
| Lord, E | 1 |
| Shui, A | 1 |
| Pinto, DS | 1 |
| Zimetbaum, PJ | 1 |
| Josephson, ME | 1 |
| van der Hoeven, BL | 1 |
| Liem, SS | 1 |
| Jukema, JW | 1 |
| Suraphakdee, N | 1 |
| Putter, H | 1 |
| Dijkstra, J | 1 |
| Atsma, DE | 1 |
| Bootsma, M | 1 |
| Zeppenfeld, K | 1 |
| Oemrawsingh, PV | 2 |
| van der Wall, EE | 3 |
| Schalij, MJ | 2 |
| Hoekstra, J | 1 |
| Miller, CD | 1 |
| Vik-Mo, H | 1 |
| Slette, M | 1 |
| Hegbom, K | 1 |
| Choudhry, NK | 1 |
| Patrick, AR | 1 |
| Shrank, WH | 1 |
| Zhao, Y | 1 |
| Shen, LH | 1 |
| Sun, JC | 1 |
| Cheng, J | 1 |
| Thabane, L | 1 |
| Crowther, MA | 1 |
| Teoh, KH | 1 |
| von Lewinski, F | 1 |
| Riggert, J | 1 |
| Paulus, W | 1 |
| Fu, XH | 1 |
| Hao, QQ | 1 |
| Jia, XW | 1 |
| Fan, WZ | 1 |
| Gu, XS | 1 |
| Wu, WL | 1 |
| Hao, GZ | 1 |
| Li, SQ | 1 |
| Jiang, YF | 1 |
| Geng, W | 1 |
| Aradi, D | 1 |
| Tökés-Füzesi, M | 1 |
| Paska, T | 1 |
| Komócsi, A | 1 |
| Christiaens, L | 1 |
| Ragot, S | 1 |
| Mergy, J | 1 |
| Allal, J | 1 |
| Macchi, L | 1 |
| Allen Lapointe, NM | 1 |
| Sun, JL | 1 |
| Kaplan, S | 1 |
| d'Almada, P | 1 |
| Andrade, J | 1 |
| Al Ali, A | 1 |
| Wong, GC | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Kapoor, JR | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Rastegarpanah, M | 1 |
| Malekzadeh, F | 1 |
| Thomas, GN | 1 |
| Mohagheghi, A | 1 |
| Cheng, KK | 1 |
| Marshall, T | 1 |
| Mikkelsson, J | 1 |
| Eskola, M | 1 |
| Nikus, K | 1 |
| Karhunen, PJ | 1 |
| Niemela, K | 1 |
| Smith, DA | 1 |
| Smith, PJ | 1 |
| Tekin, M | 1 |
| Gökaslan, S | 1 |
| Diker, E | 1 |
| Al-Aqeedi, RF | 1 |
| Al-Nabti, AD | 1 |
| Brodin, E | 1 |
| Appelbom, H | 1 |
| Hansen, JB | 1 |
| Bates, E | 1 |
| Bhatt, D | 1 |
| Furman, MI | 1 |
| Wiviott, S | 1 |
| Castellsague, J | 1 |
| Stang, MR | 1 |
| Tomas, L | 1 |
| Aguado, J | 1 |
| Perez-Gutthann, S | 1 |
| Voitk, J | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| Born, GV | 5 |
| Görög, P | 1 |
| Begent, NA | 1 |
| Ritter, JM | 1 |
| Walter, E | 7 |
| Staiger, C | 1 |
| Boissel, JP | 6 |
| Faucomprez, C | 1 |
| McNicol, GP | 1 |
| Genton, E | 5 |
| Schröder, R | 2 |
| Perrenoud, JJ | 1 |
| Kallio, V | 1 |
| de Bono, DP | 4 |
| Gross, F | 1 |
| Widimský, J | 1 |
| Mitchell, JR | 3 |
| Graham, IM | 1 |
| Silke, B | 1 |
| Nelson, GI | 2 |
| Taylor, SH | 1 |
| Friedewald, WT | 1 |
| Schoenberger, JA | 4 |
| Toshima, H | 1 |
| Chabali, R | 1 |
| Haynes, RE | 1 |
| Spann, JF | 1 |
| Kelton, JG | 2 |
| Offerhaus, L | 1 |
| Enjalbert, M | 1 |
| Bourassa, MG | 1 |
| Lewis, HD | 4 |
| Davis, JW | 2 |
| Archibald, DG | 1 |
| Steinke, WE | 1 |
| Smitherman, TC | 1 |
| Doherty, JE | 1 |
| Schnaper, HW | 1 |
| Linares, E | 1 |
| Pouget, JM | 1 |
| Sabharwal, SC | 1 |
| Chesler, E | 1 |
| DeMots, H | 1 |
| Burkart, F | 2 |
| Goldstein, S | 2 |
| Chodorowski, Z | 1 |
| Struckus, J | 1 |
| Gorlin, R | 1 |
| Kornitzer, M | 1 |
| Epstein, SE | 2 |
| Palmeri, ST | 1 |
| Caruzzo, C | 3 |
| Sechi, A | 1 |
| Monti, C | 1 |
| Campagna, G | 1 |
| Spinnler, MT | 1 |
| Bolte, HD | 2 |
| Buckler, P | 1 |
| Douglas, AS | 1 |
| Thiele, R | 1 |
| Sherry, S | 5 |
| Hashimoto, H | 1 |
| Ogawa, K | 2 |
| Flynn, PJ | 1 |
| Becker, WK | 1 |
| Vercellotti, GM | 1 |
| Weisdorf, DJ | 1 |
| Craddock, PR | 1 |
| Hammerschmidt, DE | 1 |
| Lillehei, RC | 1 |
| Jacob, HS | 1 |
| Gunby, P | 1 |
| Johnston, KM | 1 |
| MacLeod, BA | 1 |
| Walker, MJ | 1 |
| Khaja, F | 1 |
| Walton, JA | 1 |
| Brymer, JF | 1 |
| Lo, E | 1 |
| Osterberger, L | 1 |
| O'Neill, WW | 1 |
| Colfer, HT | 1 |
| Weiss, R | 1 |
| Lee, T | 1 |
| Kurian, T | 1 |
| Goldberg, AD | 1 |
| Pitt, B | 1 |
| Canner, PL | 3 |
| Breddin, K | 9 |
| Markiewicz, M | 1 |
| Rymar, B | 1 |
| Florkiewicz, H | 1 |
| Wysokiński, A | 1 |
| Biller, J | 1 |
| Martin, GJ | 1 |
| Rivey, MP | 1 |
| Alexander, MR | 1 |
| Taylor, JW | 1 |
| Willerson, JT | 4 |
| Campbell, WB | 1 |
| Winniford, MD | 1 |
| Schmitz, J | 1 |
| Apprill, P | 1 |
| Firth, BG | 1 |
| Ashton, J | 1 |
| Smitherman, T | 1 |
| Bush, L | 1 |
| Buja, LM | 1 |
| Ordinas, A | 1 |
| Hoffmann, W | 5 |
| Foerster, W | 1 |
| Mest, HJ | 1 |
| Taube, C | 1 |
| Block, HU | 1 |
| Braun, H | 1 |
| Dworski, R | 1 |
| Viinikka, L | 1 |
| Hodara, M | 1 |
| Samama, M | 2 |
| Volger, E | 1 |
| Theiss, W | 1 |
| Mustard, JF | 2 |
| Kinlough-Rathbone, RL | 2 |
| Packham, MA | 3 |
| Khalfen, ESh | 2 |
| Shvarts, IL | 1 |
| Ivanova, IA | 2 |
| Bornstein, A | 1 |
| Dalal, P | 1 |
| Tischler, J | 1 |
| Novack, S | 1 |
| Michaelson, S | 1 |
| Tilsner, V | 1 |
| Mattson, ME | 2 |
| Friedman, LM | 1 |
| Vesterqvist, O | 7 |
| Gréen, K | 6 |
| Mannucci, PM | 1 |
| Goldstein, J | 1 |
| Rimon, D | 1 |
| Cohen, L | 1 |
| Zukel, WJ | 1 |
| Kato, H | 1 |
| Ichinose, E | 1 |
| Van Aken, WG | 1 |
| Fisher, LD | 1 |
| Kennedy, JW | 1 |
| Verstraete, M | 10 |
| Verdecchia, P | 1 |
| Gryglewski, RJ | 2 |
| Loew, D | 6 |
| Lechner, K | 3 |
| Oberla, K | 1 |
| Green, D | 1 |
| Kucuk, O | 1 |
| Haring, O | 1 |
| Dyer, A | 1 |
| Rentrop, P | 1 |
| Blanke, H | 1 |
| Karsch, KR | 1 |
| Genovese, A | 2 |
| Chiariello, M | 2 |
| Latte, S | 1 |
| de Alfieri, W | 1 |
| Cacciapuoti, AA | 2 |
| Condorelli, M | 2 |
| Hampton, JR | 3 |
| Carile, L | 1 |
| Laquaglia, GA | 1 |
| Martone, P | 1 |
| Marchionni, F | 1 |
| Di Falco, C | 1 |
| Mann, GV | 1 |
| Brown, EJ | 2 |
| Kloner, RA | 2 |
| Schoen, FJ | 1 |
| Hammerman, H | 1 |
| Hale, S | 1 |
| Diamond, GA | 1 |
| Forrester, JS | 1 |
| Loeliger, EA | 3 |
| Karmazyn, M | 2 |
| Moffat, MP | 1 |
| Beamish, RE | 1 |
| Dhalla, NS | 1 |
| Poliwoda, H | 1 |
| White, GL | 1 |
| Marouf, AA | 1 |
| Marx, JL | 1 |
| Jones, RJ | 1 |
| Wood, L | 3 |
| Passamani, ER | 3 |
| May, GS | 1 |
| Uberla, K | 3 |
| Weber, E | 2 |
| Reuter, HD | 1 |
| Breddin, HK | 3 |
| Uberla, KK | 1 |
| Straub, PW | 1 |
| Kanazawa, T | 1 |
| Matsuoka, H | 1 |
| Jugdutt, BI | 1 |
| Newman, PE | 1 |
| Detre, KM | 1 |
| Ware, J | 1 |
| Mantel, N | 1 |
| Guermonprez, JL | 1 |
| Khalilullah, M | 1 |
| Sathyamurthy, I | 1 |
| Wessler, S | 2 |
| Kraska, T | 1 |
| Malanowicz, W | 1 |
| Skarzyńska, M | 1 |
| Tymińska, K | 1 |
| Lubsen, J | 3 |
| Prentice, CR | 3 |
| Kent, S | 1 |
| van de Loo, J | 1 |
| Castaldi, PA | 1 |
| Schbath, J | 1 |
| Destors, JM | 1 |
| Gillet, J | 3 |
| Halawa, B | 2 |
| Mazurek, W | 1 |
| Wasserman, AG | 1 |
| Bren, GB | 1 |
| Ross, AM | 6 |
| Richardson, DW | 1 |
| Hutchinson, RG | 2 |
| Rios, JC | 1 |
| Frishman, WH | 3 |
| Harbold, NB | 1 |
| Slone, D | 1 |
| Shapiro, S | 1 |
| Kaufman, DW | 1 |
| Miettinen, OS | 2 |
| Stolley, PD | 1 |
| Marshall, M | 1 |
| Howard, J | 1 |
| Whittemore, AS | 2 |
| Hoover, JJ | 1 |
| Panos, M | 1 |
| De Feyter, PJ | 1 |
| van Eenige, MJ | 3 |
| de Jong, JP | 1 |
| Dighton, DH | 1 |
| Roos, JP | 4 |
| Leprán, I | 1 |
| Koltai, M | 1 |
| Szekeres, L | 1 |
| Melish, ME | 1 |
| Kaufmann, W | 1 |
| Oster, P | 1 |
| Berman, J | 1 |
| Haffajee, CI | 1 |
| Yamasawa, I | 1 |
| Nohara, Y | 1 |
| Johnson, GJ | 1 |
| Heckel, R | 1 |
| Leis, LA | 1 |
| Franciosa, J | 1 |
| Dormandy, JA | 1 |
| Compostella, L | 1 |
| Russo, R | 1 |
| Nascimben, L | 1 |
| Schivazappa, L | 1 |
| Weiss, HJ | 3 |
| Werkö, L | 1 |
| Horwitz, DL | 2 |
| Culliton, BJ | 1 |
| Waterfall, WK | 1 |
| Manikeri, SR | 1 |
| Raghu, CN | 1 |
| Dadkar, VN | 1 |
| Sheth, UK | 1 |
| Ruf, W | 2 |
| McNamara, JJ | 2 |
| Suehiro, A | 2 |
| Suehiro, G | 1 |
| Wickline, SA | 1 |
| Klimt, CR | 3 |
| Sweetnam, PM | 2 |
| Faergeman, O | 3 |
| Davis, RF | 1 |
| Röhrer, H | 1 |
| Groh, R | 1 |
| Croveri, G | 1 |
| Taccola, A | 1 |
| Cipolli, PL | 1 |
| Bossi, MC | 1 |
| Lipson, LC | 1 |
| Sheehan, FH | 1 |
| Capurro, NL | 1 |
| Isner, JM | 1 |
| Roberts, WC | 1 |
| Goldstein, RE | 1 |
| Mirvis, DM | 1 |
| Saltissi, S | 1 |
| Mushahwar, SS | 1 |
| Meier, B | 4 |
| Johnson, N | 3 |
| Moher, M | 5 |
| Larsson, H | 3 |
| Areskog, M | 3 |
| Areskog, NH | 3 |
| Jonasson, T | 2 |
| Ringqvist, I | 2 |
| Murkin, JM | 1 |
| Lux, J | 1 |
| Shannon, NA | 1 |
| Guiraudon, GM | 1 |
| Menkis, AH | 1 |
| McKenzie, FN | 1 |
| Novick, RJ | 1 |
| Di Tano, G | 2 |
| Mazzù, A | 2 |
| Bulpitt, CJ | 1 |
| Falk, RH | 1 |
| Findlay, IN | 1 |
| Oakley, CM | 1 |
| Murray, G | 1 |
| Sutton, GC | 2 |
| Deeks, J | 1 |
| Watt, I | 1 |
| Freemantle, N | 2 |
| Smith, J | 2 |
| Channer, KS | 3 |
| Kamat, SG | 1 |
| Hennen, J | 2 |
| Meehan, TP | 2 |
| Petrillo, M | 2 |
| Kresowik, TF | 1 |
| Jencks, SF | 2 |
| Rumboldt, Z | 1 |
| Bozić, I | 1 |
| Sardelić, S | 1 |
| Ghooi, RB | 1 |
| Thatte, SM | 1 |
| Joshi, PS | 1 |
| Manos, EJ | 1 |
| Mejaíl, RI | 1 |
| Cerdá, MA | 1 |
| Duronto, EA | 1 |
| García, CN | 1 |
| Daroca, AM | 1 |
| Mautner, B | 3 |
| Thompson, MK | 1 |
| O'Sullivan, J | 1 |
| Jenkins, DP | 1 |
| Sumeray, M | 1 |
| Montgomery, HE | 2 |
| Chester, MR | 1 |
| Förster, W | 9 |
| Frölich, JC | 1 |
| Magnani, B | 1 |
| Semprini, F | 1 |
| Fuchs, J | 1 |
| Lablache-Combier, B | 2 |
| Marques-Vidal, P | 2 |
| Ruidavets, JB | 4 |
| Branchu, MP | 2 |
| Richard, JL | 2 |
| Bochner, F | 2 |
| Lloyd, JV | 1 |
| Day, L | 1 |
| Barnfield, M | 1 |
| Rasmanis, G | 4 |
| Henriksson, P | 4 |
| Sherwood, JB | 2 |
| Mulry, RP | 1 |
| Jacobs, SC | 1 |
| Friedman, R | 1 |
| Benson, H | 1 |
| Garcia-Dorado, D | 6 |
| Tornos, P | 1 |
| Sambola, A | 1 |
| Oliveras, J | 3 |
| Santos, M | 1 |
| Soler Soler, J | 1 |
| Wyllie, HR | 1 |
| Dunn, FG | 2 |
| Brewster, D | 1 |
| Pérez-Villa, F | 1 |
| Waters, D | 6 |
| Lespérance, J | 1 |
| Shabani, F | 1 |
| Bonan, R | 1 |
| Brandt, CM | 1 |
| Wees-Ponchon, A | 1 |
| Nisand, G | 1 |
| Verdun, A | 1 |
| Jobard, P | 1 |
| Attali, P | 1 |
| Bousquet, P | 1 |
| Fincker, JL | 1 |
| Viigimaa, M | 1 |
| Jôudu, T | 1 |
| Hendrikson, E | 1 |
| Shandrik, Y | 1 |
| Teesalu, R | 1 |
| Gulløv, AL | 1 |
| Koefoed, BG | 1 |
| Petersen, P | 1 |
| Moriarty, KT | 1 |
| Carney, RM | 1 |
| Freedland, KE | 1 |
| Eisen, SA | 1 |
| Rich, MW | 3 |
| Fowles, RE | 1 |
| Alhaddad, IA | 1 |
| Tkaczevski, L | 1 |
| Siddiqui, F | 1 |
| Mir, R | 1 |
| Schölmerich, J | 1 |
| Scheldewaert, R | 1 |
| Walters, EG | 1 |
| Coltart, DJ | 1 |
| Santoni, JP | 1 |
| Belgrave, G | 1 |
| Starkey, IR | 2 |
| O'Donnell, CJ | 4 |
| Marder, VJ | 2 |
| Malone, ML | 1 |
| Sial, SH | 1 |
| Battiola, RJ | 1 |
| Nachodsky, JP | 1 |
| Solomon, DJ | 1 |
| Goodwin, JS | 1 |
| Simmons, J | 1 |
| Willens, HJ | 1 |
| Kessler, KM | 1 |
| Karrillon, GJ | 1 |
| Hvass, U | 1 |
| Aumont, MC | 2 |
| Gourgon, R | 2 |
| Wilson, DG | 1 |
| Wisheart, JD | 1 |
| Stuart, AG | 1 |
| Col, NF | 2 |
| Yarzbski, J | 1 |
| Hamer, AW | 1 |
| Brown, MA | 2 |
| Williams, BF | 2 |
| Ormiston, JA | 1 |
| Cross, DB | 2 |
| Lee, LV | 1 |
| Söderlin, MK | 1 |
| Purhonen, S | 1 |
| Haring, P | 1 |
| Hietakorpi, S | 1 |
| Koski, E | 1 |
| Nuutinen, LS | 1 |
| Fresco, C | 2 |
| Franzosi, MG | 5 |
| Shorten, G | 1 |
| Comunale, ME | 1 |
| Johnson, RG | 1 |
| Sacks, FM | 1 |
| Willett, WC | 1 |
| Stampfer, MJ | 6 |
| Leung, M | 1 |
| Webb, J | 1 |
| Wielgosz, AT | 1 |
| Valentín Segura, V | 1 |
| Valls Grima, F | 1 |
| Broch Porcar, MJ | 1 |
| Miralles Serrano, L | 1 |
| Olivares Toledo, D | 1 |
| Alvarez Cebrián, F | 1 |
| Cohen-Solal, A | 2 |
| Caviezel, B | 1 |
| Laperche, T | 1 |
| McMurray, J | 1 |
| Rankin, A | 1 |
| Sámóczi, M | 1 |
| Farkas, A | 1 |
| Sipos, E | 1 |
| Tarján, J | 2 |
| Habib, GB | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Barnett, HJ | 3 |
| Feussner, JR | 1 |
| Whitford, DL | 1 |
| Southern, AJ | 1 |
| Cappelleri, JC | 1 |
| Lau, J | 1 |
| Kupelnick, B | 1 |
| Chalmers, TC | 1 |
| Görge, G | 1 |
| Haude, M | 1 |
| Caspari, G | 1 |
| Erbel, R | 1 |
| Gregor, RD | 1 |
| Bata, IR | 1 |
| Eastwood, BJ | 1 |
| Garner, JB | 1 |
| Guernsey, JR | 1 |
| MacKenzie, BR | 1 |
| Rautaharju, PM | 1 |
| Wolf, HK | 1 |
| Hampton, J | 1 |
| Skene, A | 2 |
| Fitch, LL | 1 |
| Buchwald, H | 1 |
| Matts, JP | 1 |
| Johnson, JW | 1 |
| Campos, CT | 1 |
| Long, JM | 1 |
| Xiong, J | 3 |
| Parry, G | 3 |
| Adams, PC | 4 |
| Chamberlain, D | 3 |
| Wieczorek, I | 3 |
| McBride, R | 1 |
| Singh, VN | 1 |
| Loscalzo, J | 2 |
| Decousus, H | 1 |
| Cairns, JA | 4 |
| Mancuso, GM | 1 |
| Forker, AD | 1 |
| Rodgers, KA | 1 |
| Riha, M | 1 |
| Swedberg, K | 2 |
| Tobé, TJ | 1 |
| Speechly-Dick, ME | 1 |
| Braunvald, Iu | 1 |
| Moĭe, LA | 1 |
| Basta, L | 1 |
| Kaddi, TE | 1 |
| Dévis, BR | 1 |
| Geltman, EM | 1 |
| Fleĭker, GS | 1 |
| Tsuyuki, RT | 2 |
| Ikuta, RM | 1 |
| Bay, KS | 1 |
| Greenwood, PV | 1 |
| Montague, TJ | 1 |
| Sinclair, D | 1 |
| Arnau, JM | 4 |
| Laporte, JR | 4 |
| Bonnier, JJ | 1 |
| Post, D | 1 |
| Campbell, RW | 1 |
| Clarke, KW | 1 |
| Keating, NA | 1 |
| Wilkinson, P | 6 |
| Laji, K | 1 |
| Parsons, L | 1 |
| Gans, M | 1 |
| Hartmann, JR | 1 |
| Anderson, JL | 3 |
| Reddy, PS | 2 |
| Sobolski, JC | 1 |
| Sasahara, AA | 1 |
| Lasserre, B | 1 |
| Périat, M | 1 |
| Torr-Brown, SR | 1 |
| Nachowiak, D | 1 |
| Fujii, S | 1 |
| Gill, S | 1 |
| Hilton, JD | 1 |
| Talley, JD | 1 |
| Diver, DJ | 2 |
| Herson, S | 1 |
| Greene, RM | 1 |
| Shah, PK | 2 |
| Sequeira, RF | 1 |
| Leya, F | 1 |
| Kirshenbaum, JM | 1 |
| Magorien, RD | 1 |
| Zateĭshchikov, DA | 1 |
| Logutov, IuA | 1 |
| Iavelov, IS | 1 |
| Ianus, Vm | 1 |
| Kronmal, R | 1 |
| Holdright, D | 1 |
| Patel, D | 1 |
| Cunningham, D | 1 |
| Thomas, R | 1 |
| Hubbard, W | 1 |
| Hendry, G | 1 |
| Winther, K | 2 |
| Vissinger, H | 2 |
| Britton, M | 1 |
| Michel, PL | 1 |
| Shetty, BK | 1 |
| Chollet, F | 1 |
| Moise, A | 1 |
| Roos, M | 1 |
| Rissel, U | 1 |
| Müller, T | 1 |
| Schulze-Waltrup, N | 1 |
| Krakau, I | 1 |
| Arens, R | 1 |
| Willgeroth, W | 1 |
| Heuer, H | 1 |
| Tranchesi, B | 1 |
| Pileggi, F | 1 |
| Vercammen, E | 1 |
| Pizzetti, G | 1 |
| Belotti, G | 1 |
| Chierchia, SL | 2 |
| Svendsen, JH | 2 |
| Saunamäki, KI | 1 |
| Pedersen, FH | 1 |
| Clemmensen, PM | 1 |
| Haedersdal, C | 2 |
| Granborg, J | 2 |
| Round, A | 1 |
| Marshall, AJ | 1 |
| Connolly, DL | 1 |
| Dardas, PS | 1 |
| Crowley, JJ | 1 |
| Kenny, A | 1 |
| Petch, MC | 2 |
| Vogel, RA | 1 |
| Deedwania, PC | 1 |
| Carbajal, EV | 1 |
| Knapp, JC | 1 |
| Valenti, LA | 1 |
| Dobson, AJ | 4 |
| Roth, GJ | 2 |
| Calverley, DC | 1 |
| Juillière, Y | 1 |
| Kettani, C | 1 |
| Buffet, P | 1 |
| Anconina, J | 1 |
| Cuillière, M | 1 |
| Cherrier, F | 1 |
| Herbert, P | 1 |
| Moher, D | 1 |
| Havelock, P | 1 |
| Schweiger, MJ | 2 |
| Gibson, RS | 3 |
| Mueller, HS | 2 |
| Haugland, JM | 1 |
| Sullivan, JL | 1 |
| Scheffold, T | 1 |
| Jonas, MA | 3 |
| Grambow, DW | 1 |
| Valentini, VV | 1 |
| Armstrong, WF | 1 |
| Short, AD | 1 |
| West, B | 1 |
| Violaris, AG | 1 |
| Trudgill, NJ | 1 |
| Rowlands, L | 1 |
| Gunn, J | 1 |
| Tsikaderis, D | 1 |
| Campbell, S | 1 |
| Santos, JM | 1 |
| Mourão, L | 1 |
| Neves, JL | 1 |
| Santos, AL | 1 |
| Luís, AS | 1 |
| Qiu, S | 1 |
| McCans, J | 3 |
| de Guise, P | 1 |
| Juneau, M | 3 |
| Toupin, LR | 1 |
| Blanchard, DG | 1 |
| Werter, CJ | 2 |
| de Swart, H | 1 |
| Lie, KI | 2 |
| van der Pol, JM | 2 |
| Michels, HR | 1 |
| Jin, L | 2 |
| Xu, SH | 1 |
| Yan, XW | 1 |
| Strain, J | 1 |
| Keller, C | 1 |
| Sleight, P | 7 |
| Dale, J | 4 |
| Hegrenaes, L | 2 |
| Lem, P | 2 |
| Søberg, T | 1 |
| Morstøl, T | 2 |
| Kennedy, C | 1 |
| Nyman, I | 2 |
| Goodnight, SH | 1 |
| Coull, BM | 1 |
| McAnulty, JH | 2 |
| Taylor, LM | 2 |
| Riekkinen, PJ | 1 |
| Lowenthal, A | 2 |
| Smets, P | 1 |
| Laakso, M | 1 |
| Bleich, SD | 2 |
| Rolston, WA | 1 |
| Tilton, GD | 1 |
| Mailander, L | 1 |
| Norris, RM | 2 |
| Woo, KS | 1 |
| Maslowski, AH | 1 |
| Caruana, MP | 1 |
| Hart, HH | 2 |
| Williams, B | 2 |
| Sandercock, PA | 1 |
| Kolanski, D | 1 |
| Setaro, J | 1 |
| Brennan, J | 1 |
| Cabin, H | 1 |
| Cleman, M | 1 |
| Remetz, M | 1 |
| Rubenzahl, S | 1 |
| Stevenson, R | 1 |
| Wind, J | 1 |
| Manjula, TS | 3 |
| Devi, CS | 3 |
| Golino, P | 1 |
| Ragni, M | 1 |
| Pace, L | 1 |
| de Clerk, F | 1 |
| Kanter, MC | 1 |
| Sherman, DG | 1 |
| Hobson, RW | 1 |
| Krupski, WC | 1 |
| Weiss, DG | 1 |
| Nugent, JW | 1 |
| Luria, MH | 1 |
| Sapoznikov, D | 1 |
| Gilon, D | 2 |
| Weinstein, JM | 1 |
| Weiss, AT | 1 |
| Gotsman, MS | 1 |
| Arnout, J | 1 |
| van den Brand, M | 1 |
| Nÿssen, K | 1 |
| Saitoh, S | 1 |
| Asakura, T | 1 |
| Kanke, M | 1 |
| Owada, K | 1 |
| Maruyama, Y | 1 |
| Bogousslavsky, J | 1 |
| Meijer, A | 2 |
| Yedinak, KC | 1 |
| Sproat, TT | 1 |
| King, R | 1 |
| Denne, J | 1 |
| McLaughlin, TJ | 7 |
| Soumerai, SB | 8 |
| Hosmer, DW | 1 |
| Némoz, C | 2 |
| Caruzzo, E | 1 |
| Cimminiello, C | 3 |
| Soncini, M | 1 |
| Casazza, F | 1 |
| Molhoek, GP | 1 |
| Lok, DJ | 1 |
| Luz, CM | 1 |
| Kingma, JH | 2 |
| Van den Bos, AA | 1 |
| Zijnen, P | 2 |
| Bosma, AH | 1 |
| Takens, LH | 1 |
| Möckel, M | 1 |
| Störk, T | 1 |
| Malaterre, HR | 1 |
| Daver, L | 1 |
| Djiane, P | 1 |
| Langford, EJ | 1 |
| Wainwright, RJ | 1 |
| Sapsford, RJ | 1 |
| Robinson, MB | 1 |
| Xu, S | 1 |
| Yan, X | 1 |
| Zhang, S | 1 |
| Venturini, F | 2 |
| Romero, M | 2 |
| Strachan, DA | 1 |
| Robertson, S | 1 |
| Rouvier, J | 3 |
| Gurfinkel, E | 2 |
| Kalkman, EA | 3 |
| van Suylen, RJ | 1 |
| van Dijk, JP | 1 |
| Yanagihara, T | 1 |
| Whisnant, JP | 2 |
| Meldrum, H | 1 |
| Shahar, E | 1 |
| Romm, FJ | 1 |
| Bisgard, KM | 1 |
| Metcalf, PA | 1 |
| Crum, L | 1 |
| McGovern, PG | 1 |
| Heiss, G | 1 |
| Willison, DJ | 5 |
| Borbas, C | 4 |
| Guadagnoli, E | 3 |
| McLaughlin, B | 4 |
| Cheng, SC | 1 |
| Hauptman, PJ | 2 |
| Antman, E | 1 |
| Casey, L | 1 |
| Asinger, R | 2 |
| Gobel, F | 3 |
| Meese, RB | 1 |
| McNulty, S | 1 |
| Lucas, KD | 1 |
| Carney, RJ | 1 |
| LeBoeuf, RM | 1 |
| Maddox, W | 1 |
| Bethea, CF | 1 |
| Shadoff, N | 1 |
| Trahey, TF | 1 |
| Heinsimer, JA | 1 |
| Burks, JM | 1 |
| O'Donnell, G | 1 |
| Flapan, AD | 1 |
| Peters, FP | 1 |
| Doevendans, PA | 1 |
| Erdkamp, FL | 1 |
| Van Der Ent, FW | 1 |
| De Heer, F | 1 |
| Bar Dayan, Y | 1 |
| Amital, H | 2 |
| Levy, Y | 2 |
| Shoenfeld, Y | 2 |
| Forman, R | 1 |
| Cottier, C | 1 |
| Frandsen, NJ | 1 |
| Christiansen, I | 1 |
| McNair, P | 1 |
| Zampieri, P | 1 |
| Aggio, S | 1 |
| Roncon, L | 1 |
| Rinuncini, M | 1 |
| Canova, C | 1 |
| Zanazzi, G | 1 |
| Fiorencis, R | 1 |
| Zonzin, P | 1 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Kala, R | 1 |
| Balli, E | 2 |
| Giomi, A | 2 |
| Del Citerna, F | 1 |
| Topal, EJ | 1 |
| French, J | 1 |
| Hart, H | 1 |
| Woo, K | 1 |
| Grant, J | 1 |
| O'Brien, P | 1 |
| Poole, J | 1 |
| Sharpe, N | 3 |
| Williams, M | 1 |
| Swadzba, J | 1 |
| Gora, PF | 1 |
| Piwowarska, W | 1 |
| Duplaga, M | 1 |
| Ricou, FJ | 1 |
| Arroyo, JF | 1 |
| Creutzig, A | 1 |
| Ranke, C | 1 |
| Bradshaw, C | 2 |
| Parr, JH | 1 |
| Eccles, MP | 1 |
| Whitty, P | 1 |
| Murray, E | 1 |
| Broderick, W | 1 |
| Courtenay, HL | 1 |
| Royle, J | 1 |
| McEniery, PT | 1 |
| Aroney, CN | 1 |
| Bett, JH | 1 |
| Polasek, J | 2 |
| MacMahon, S | 3 |
| Teien, DE | 1 |
| Karp, KH | 1 |
| Hosokawa, FG | 1 |
| Kim, K | 1 |
| Miyake, S | 1 |
| Barrabés, JA | 2 |
| González, MA | 1 |
| Ruiz-Meana, M | 1 |
| Solares, J | 2 |
| Burillo, AG | 1 |
| Lidón, RM | 1 |
| Antolín, M | 1 |
| Castell, J | 1 |
| Soler-Soler, J | 3 |
| Oler, A | 1 |
| Whooley, MA | 1 |
| Oler, J | 1 |
| Grady, D | 3 |
| Mehta, PJ | 1 |
| Deo, AM | 1 |
| Bichile, SK | 1 |
| Madan, ZM | 1 |
| Sainani, GS | 1 |
| Hardern, RD | 1 |
| Currie, P | 1 |
| Gray, SM | 1 |
| Shaw, TR | 1 |
| Amouyel, P | 1 |
| Arveiler, D | 1 |
| Bingham, A | 1 |
| Montayé, M | 1 |
| Haas, B | 1 |
| Lablache Combier, B | 1 |
| Avizohar, O | 1 |
| Roth, A | 4 |
| Hollander, JE | 1 |
| Teien, D | 1 |
| Karp, K | 1 |
| Casaccia, M | 1 |
| Bertello, F | 1 |
| De Bernardi, A | 1 |
| Sicuro, M | 1 |
| Scacciatella, P | 1 |
| Wong, CB | 1 |
| Schreiber, TL | 6 |
| Remvig, L | 1 |
| Mortensen, S | 1 |
| Appleby, P | 2 |
| Godwin, J | 1 |
| Squadrito, F | 1 |
| Saitta, A | 1 |
| Altavilla, D | 1 |
| Ioculano, M | 1 |
| Canale, P | 1 |
| Campo, GM | 1 |
| Squadrito, G | 1 |
| Caputi, AP | 1 |
| Noguchi, Y | 1 |
| Yamaguchi, I | 1 |
| Sugishita, Y | 1 |
| Lowenthal, MN | 1 |
| Rota, S | 1 |
| Flynn, PD | 1 |
| Wareham, NJ | 1 |
| Baglin, TP | 1 |
| Byrne, CD | 1 |
| Rapaport, E | 2 |
| Gheorghiade, M | 2 |
| Goldschmidt-Clermont, PJ | 1 |
| Navetta, FI | 1 |
| Chandra, NC | 1 |
| Guerci, AD | 2 |
| Yakubov, SJ | 1 |
| Bray, PF | 1 |
| Bahr, RD | 3 |
| Wolfe, CL | 1 |
| Yock, PG | 2 |
| Nygaard, TW | 2 |
| Mason, SJ | 1 |
| Fatterpacker, A | 1 |
| Raskin, S | 1 |
| Brashears, L | 1 |
| Gottdiener, P | 1 |
| du Mee, C | 1 |
| Kitt, MM | 1 |
| Malcolm, AD | 1 |
| Walsh, MJ | 1 |
| Forman, DE | 2 |
| Golden, WE | 1 |
| Sanchez, N | 1 |
| Ducimetière, P | 2 |
| Seknadji, P | 1 |
| Metz, BK | 1 |
| Ring, BL | 1 |
| Brophy, J | 1 |
| Blankfield, RP | 1 |
| Young, B | 1 |
| Moore, WS | 1 |
| Robertson, JT | 1 |
| Toole, JF | 1 |
| Ernst, CB | 1 |
| Cohen, SN | 1 |
| Broderick, JP | 1 |
| Dempsey, RJ | 1 |
| Hosking, JD | 1 |
| Chamberlain, DA | 2 |
| Walter, H | 3 |
| Schühlen, H | 2 |
| Hadamitzky, M | 3 |
| Zitzmann-Roth, EM | 1 |
| Dirschinger, J | 1 |
| Hausleiter, J | 1 |
| Blasini, R | 1 |
| Schmitt, C | 1 |
| Alt, E | 1 |
| Biadi, O | 1 |
| Santiago, T | 1 |
| Chasuk, R | 1 |
| Allison, JJ | 1 |
| Kiefe, CI | 1 |
| Centor, RM | 1 |
| Box, JB | 1 |
| Farmer, RM | 1 |
| Lenkovsky, F | 1 |
| Neirinck, LG | 1 |
| Glezer, SV | 1 |
| Ketley, D | 1 |
| Woods, KL | 1 |
| Toplak, H | 1 |
| Bahadori, B | 1 |
| Wascher, TC | 1 |
| Schmitz, C | 1 |
| Lindpaintner, K | 1 |
| Gao, X | 4 |
| Passman, R | 1 |
| Kimmel, S | 1 |
| Simonetti, I | 1 |
| Gensini, G | 2 |
| Klein, LW | 1 |
| Wahid, F | 1 |
| VandenBerg, BJ | 1 |
| Parrillo, JE | 1 |
| Calvin, JE | 1 |
| Drobac, M | 1 |
| Sternberg, L | 2 |
| Marwick, C | 1 |
| Godfried, SL | 1 |
| de Lorgeril, M | 1 |
| Salen, P | 1 |
| Caillat-Vallet, E | 1 |
| Hanauer, MT | 1 |
| Barthelemy, JC | 1 |
| Mamelle, N | 1 |
| Seneviratne, SL | 2 |
| Gunatilake, SB | 2 |
| de Silva, HJ | 2 |
| Catella-Lawson, F | 1 |
| Ajani, U | 1 |
| Shulman, ST | 1 |
| Bendet, M | 1 |
| Kanamasa, K | 1 |
| Hama, J | 1 |
| Ogawa, I | 1 |
| Takenaka, T | 1 |
| Naito, T | 1 |
| Yamamoto, T | 6 |
| Oyaizu, M | 1 |
| Kimura, A | 2 |
| Katori, R | 1 |
| Seaton, TL | 1 |
| Bruhn, HD | 2 |
| Cushman, M | 1 |
| Tracy, RP | 3 |
| Fava, S | 1 |
| Azzopardi, J | 1 |
| Agius-Muscat, H | 1 |
| Kher, A | 1 |
| Samama, MM | 3 |
| Dippel, DW | 2 |
| Garabedian, HD | 2 |
| Dinsmore, RE | 1 |
| Guerrero, LJ | 1 |
| Palacios, IF | 1 |
| Leinbach, RC | 2 |
| Parratt, JR | 1 |
| Bashour, TT | 1 |
| Espinosa, E | 1 |
| Blumenthal, J | 1 |
| Wong, T | 1 |
| Mason, DT | 1 |
| Ulm, K | 1 |
| Sayer, JW | 1 |
| Ray, S | 1 |
| Marchant, B | 1 |
| Hunziker, P | 1 |
| Bertel, O | 1 |
| Gunter, N | 1 |
| Moore, L | 1 |
| Odom, P | 1 |
| Rodríguez Blanco, VM | 1 |
| Nguyen, KN | 1 |
| Kjekshus, J | 2 |
| Richardson, J | 1 |
| Truman, C | 1 |
| Parmar, R | 1 |
| Schädlich, PK | 1 |
| Brecht, JG | 1 |
| Lee, HS | 1 |
| Brooks, N | 1 |
| Jennings, K | 1 |
| Saketkhou, BB | 1 |
| Conte, FJ | 1 |
| Noris, M | 1 |
| Tilkemeier, P | 1 |
| Miller, G | 1 |
| Cannistra, L | 1 |
| Leavitt, J | 1 |
| Sharma, SC | 1 |
| Garber, C | 1 |
| Parisi, AF | 1 |
| Schuster, S | 1 |
| Koch, A | 1 |
| Burczyk, U | 1 |
| Wagner, S | 3 |
| Heinrich, F | 1 |
| Stuby, K | 1 |
| Berg, G | 1 |
| Voigtländer, T | 1 |
| Jakob, M | 1 |
| Hauptmann, P | 1 |
| Buchwald, A | 1 |
| Hillis, SE | 1 |
| Monrad, S | 1 |
| Sanz, G | 1 |
| van der Meer, J | 1 |
| Olaisson, E | 1 |
| Undeland, S | 1 |
| Ludwig, K | 1 |
| Williams, MJ | 2 |
| Morison, IM | 1 |
| Parker, JH | 1 |
| Demers, C | 1 |
| Fromell, GJ | 1 |
| Premmereur, J | 1 |
| Jacobi, J | 1 |
| Diez-Ewald, M | 1 |
| Robinson, J | 1 |
| Sessa, F | 1 |
| Muir, N | 1 |
| Nichols, JD | 1 |
| Clifford, JM | 1 |
| Stillings, MR | 1 |
| Hoare, RC | 1 |
| Frey, MJ | 2 |
| Nair, R | 1 |
| Hillis, WS | 1 |
| Shalev, Y | 1 |
| Maraganore, J | 1 |
| Adelman, B | 1 |
| Sinzinger, H | 1 |
| Kritz, H | 1 |
| Peverill, RE | 2 |
| Harper, RW | 2 |
| Smolich, JJ | 1 |
| Dyken, ML | 1 |
| Monassier, JP | 1 |
| Elias, J | 1 |
| Raynaud, P | 2 |
| Cribier, A | 1 |
| Lefevre, T | 2 |
| Faugier, JP | 1 |
| Masquet, C | 1 |
| Rioux, P | 1 |
| Joly, P | 2 |
| Petiteau, PY | 1 |
| Royer, T | 1 |
| Roriz, R | 1 |
| Meyer, P | 1 |
| Khalifé, K | 1 |
| Maxwell, S | 2 |
| Jordaens, L | 1 |
| Tavernier, R | 1 |
| Roitman-Johnson, B | 1 |
| Allen, J | 1 |
| Butler, RN | 1 |
| Shustov, AR | 1 |
| Dalesandro, MR | 1 |
| Gumbs, CI | 1 |
| Grabletz, LB | 1 |
| Gascón Ramón, G | 1 |
| Bertomeu i Blanch, F | 1 |
| Baño Aracil, M | 1 |
| Madrigal, JA | 1 |
| Kobusiak-Prokopowicz, M | 1 |
| Mysiak, A | 2 |
| Rosanio, S | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Bonnier, H | 1 |
| Kulbertus, HE | 1 |
| Liem, A | 2 |
| Marsh, RC | 1 |
| Bronzwaer, JG | 1 |
| Voss, R | 1 |
| Tillmanns, H | 1 |
| Prasad, N | 1 |
| Srikanthan, VS | 1 |
| Wright, A | 1 |
| Edris, DW | 1 |
| Oetgen, WJ | 2 |
| Molinari, GF | 1 |
| Bruna, C | 1 |
| Rossetti, G | 1 |
| Vado, A | 1 |
| Racca, E | 1 |
| Steffenino, G | 1 |
| Dellavalle, A | 1 |
| Ribichini, F | 1 |
| Ferrero, V | 1 |
| Menardi, E | 1 |
| Uslenghi, E | 1 |
| Melniker, LA | 1 |
| Leo, PJ | 1 |
| Heintzen, MP | 1 |
| Heidland, UE | 1 |
| Klimek, WJ | 1 |
| Michel, CJ | 1 |
| Leschke, M | 1 |
| Schwartzkopff, B | 1 |
| Vester, EG | 1 |
| Strauer, BE | 1 |
| Rustige, J | 1 |
| Gödicke, J | 1 |
| Marsalek, P | 1 |
| Ball, SG | 1 |
| Chauhan, A | 2 |
| Vu, E | 1 |
| Ricci, DR | 1 |
| Moscovich, MD | 1 |
| Monkman, S | 1 |
| Penn, IM | 1 |
| Nohria, A | 1 |
| Rimmer, J | 1 |
| Fahey, T | 1 |
| Bailey, D | 1 |
| Rossi, G | 1 |
| Noth, J | 1 |
| Garnier, LF | 1 |
| Bar-Dayan, Y | 1 |
| Gutstein, DE | 1 |
| Eccles, M | 2 |
| Mason, J | 1 |
| Parish, S | 1 |
| Saniabadi, AR | 1 |
| Takeich, S | 1 |
| Yukawa, N | 1 |
| Nakajima, Y | 1 |
| Umemura, K | 1 |
| Nakashima, M | 1 |
| Hartford, M | 1 |
| Källström, G | 1 |
| Yudkin, JS | 1 |
| MacDonald, TM | 1 |
| Butler, R | 1 |
| Newton, RW | 1 |
| Morris, AD | 1 |
| Gonzalez, ER | 2 |
| Kannel, WB | 1 |
| Olin, JW | 1 |
| Raps, EC | 1 |
| Oosterga, M | 1 |
| Anthonio, RL | 1 |
| de Kam, PJ | 1 |
| Crijns, HJ | 1 |
| van Gilst, WH | 1 |
| Miller, DP | 1 |
| Aguirre, FV | 1 |
| Anderson, KM | 1 |
| Weisman, HF | 1 |
| Hopper, S | 1 |
| Pierce, M | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| Sivertssen, E | 1 |
| Udayachalerm, W | 1 |
| Bruschke, AV | 1 |
| Boersma, E | 1 |
| Van der Vlugt, MJ | 1 |
| Martínez Elbal, L | 1 |
| López Mínguez, JR | 1 |
| Alonso, M | 1 |
| Calvo, I | 1 |
| Insa, L | 1 |
| Lezaun, R | 1 |
| Colman, T | 1 |
| Esplugas, E | 1 |
| Picó, F | 1 |
| Amaro, A | 1 |
| Chabrillat, Y | 1 |
| Amor, M | 1 |
| Dumas, P | 1 |
| Benveniste, E | 1 |
| Lim, LL | 1 |
| Tesfay, GM | 1 |
| Asirvatham, S | 1 |
| Sebastian, C | 2 |
| Martínez, M | 1 |
| Vidal, X | 2 |
| Lowry, DR | 4 |
| Rossi, C | 1 |
| Randi, ML | 1 |
| Zerbinati, P | 1 |
| Rinaldi, V | 1 |
| Girolami, A | 1 |
| Michaels, AD | 1 |
| Every, NR | 1 |
| Volpi, A | 1 |
| Cavalli, A | 1 |
| Santoro, L | 1 |
| Negri, E | 1 |
| Parving, HH | 1 |
| McAlister, FA | 1 |
| Pearson, S | 2 |
| Hauptman, P | 1 |
| Boschat, J | 1 |
| Larlet, JM | 1 |
| Klootwijk, P | 1 |
| Meij, S | 1 |
| Melkert, R | 1 |
| Lenderink, T | 1 |
| Liron, M | 1 |
| Alvarez, JM | 1 |
| Ellis, CJ | 3 |
| de May, MR | 1 |
| Laramee, LA | 1 |
| Jelley, J | 1 |
| Reid, F | 1 |
| Roseto, J | 1 |
| Suh, KY | 1 |
| Cohen, AM | 2 |
| Bing, RJ | 7 |
| Murdoch, DR | 1 |
| McMurray, JJ | 1 |
| Alderman, EL | 1 |
| Levy, JH | 1 |
| Rich, JB | 1 |
| Nili, M | 1 |
| Vidne, B | 1 |
| Schaff, H | 1 |
| Uretzky, G | 1 |
| Pettersson, G | 1 |
| Thiis, JJ | 1 |
| Hantler, CB | 1 |
| Chaitman, B | 1 |
| Nadel, A | 1 |
| Salvioni, A | 1 |
| Giraldi, F | 1 |
| Assanelli, E | 1 |
| Lauri, G | 1 |
| Grazi, M | 1 |
| Pardea, S | 1 |
| Marenzi, G | 1 |
| Wall, TC | 1 |
| Kissling, G | 1 |
| Hansen, CJ | 1 |
| Muncy, DB | 1 |
| Weintraub, RA | 1 |
| Kelly, TA | 1 |
| Bautista Paloma, FJ | 1 |
| Muñoz Muñoz, N | 1 |
| Gordillo Rueda, E | 1 |
| Santos Ramos, B | 1 |
| Cobos García, FJ | 1 |
| Guerrero Aznar, MD | 1 |
| Braga, JC | 1 |
| Esteves, FP | 1 |
| Esteves, JP | 1 |
| Latado, AL | 1 |
| Godinho, AG | 1 |
| Azevedo Júnior, A | 1 |
| Brito, JC | 1 |
| Silva, PR | 1 |
| Teixeira, MS | 1 |
| Souza, VP | 1 |
| Rabelo Júnior, A | 1 |
| Rocha, MS | 1 |
| Berry, SM | 1 |
| Scherlag, M | 1 |
| Kugelmass, A | 1 |
| Schechter, E | 1 |
| Saucedo, J | 1 |
| Greenberg, A | 1 |
| Bedell, SE | 1 |
| Graboys, TB | 1 |
| Ravid, S | 1 |
| Ottani, F | 1 |
| Biancoli, S | 1 |
| Sassone, B | 1 |
| Ibsen, H | 1 |
| Klein, M | 1 |
| Keith, PR | 1 |
| Dauben, HP | 1 |
| Schulte, HD | 1 |
| Beckmann, H | 1 |
| Mayer, G | 1 |
| Elert, O | 1 |
| Gams, E | 1 |
| Cascant, P | 1 |
| Ribera, A | 1 |
| Moral, I | 2 |
| Permanyer-Miralda, G | 2 |
| Whelton, PK | 1 |
| Vu, B | 1 |
| Klag, MJ | 1 |
| Müller, A | 1 |
| Jaffy, MB | 1 |
| Eisenberg, MS | 1 |
| Maldonado, J | 1 |
| Nordt, TK | 2 |
| Kohler, B | 1 |
| Peter, K | 2 |
| Evans, MF | 1 |
| Chiamvimonvat, V | 1 |
| Kizer, JR | 1 |
| Davis, VG | 1 |
| Perritt, R | 1 |
| Segal, J | 1 |
| Dibuz, M | 1 |
| Szabó, T | 1 |
| Monoki, E | 1 |
| Nagymélykuti, L | 1 |
| Illyés, M | 1 |
| Varga, E | 1 |
| Csípö, L | 1 |
| Adhikari, AA | 1 |
| Gunawardhana, P | 1 |
| Ariyo, A | 1 |
| Carlson, JE | 1 |
| Pislaru, SV | 1 |
| Ni, Y | 1 |
| Pislaru, C | 1 |
| Bosmans, H | 1 |
| Dymarkowski, S | 1 |
| Semmler, W | 1 |
| Marchal, G | 1 |
| Gabriel, HM | 1 |
| Soares-Costa, JT | 1 |
| Soares-Costa, TJ | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Sheminant, MR | 1 |
| Whitford, EG | 1 |
| Mahon, BD | 1 |
| Newman, MA | 1 |
| Thizon-de-Gaulle, I | 1 |
| Badano, L | 1 |
| Cassin, M | 1 |
| Solinas, L | 1 |
| Burelli, C | 1 |
| Macor, F | 1 |
| Zanuttini, D | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Isles, C | 1 |
| Norrie, J | 1 |
| Paterson, J | 1 |
| Ritchie, L | 1 |
| Alamgir, F | 1 |
| McCormick, D | 2 |
| Savageau, J | 1 |
| Evéquoz, D | 1 |
| Davie, AP | 1 |
| Rosenberg, R | 1 |
| Keith, A | 1 |
| Petticrew, M | 1 |
| Turner-Boutle, M | 1 |
| Sheldon, T | 1 |
| Hill, JW | 1 |
| Roglieri, JL | 1 |
| Warburton, SW | 1 |
| Ma, J | 1 |
| Kakar, NR | 3 |
| Yamamoto, M | 2 |
| Johnson, PE | 3 |
| Cho, YK | 1 |
| Campreciós, M | 1 |
| Rojas-Fernandez, CH | 1 |
| Kephart, GC | 1 |
| Sketris, IS | 1 |
| Kass, K | 1 |
| Bloom, JM | 1 |
| Ergin, A | 1 |
| Abaci, A | 1 |
| Sakalli, A | 1 |
| Eryol, NK | 1 |
| Oguzhan, A | 1 |
| Unal, S | 1 |
| Cetin, S | 1 |
| Yasue, H | 3 |
| Masuda, Y | 1 |
| Yamaguchi, T | 1 |
| Tamura, Y | 1 |
| Merlini, PA | 1 |
| Lucreziotti, S | 1 |
| Poli, A | 1 |
| Cantù, F | 1 |
| Gobbi, G | 1 |
| Mussini, A | 1 |
| Matsuzaki, K | 1 |
| Haraguchi, N | 1 |
| Nagano, I | 1 |
| Okabe, H | 1 |
| Asou, T | 1 |
| van den Merkhof, LF | 1 |
| Olsson, H | 1 |
| Grip, L | 1 |
| Bär, FW | 1 |
| van den Brand, MJ | 1 |
| Meyer, J | 2 |
| Mukamal, KJ | 1 |
| Vetrano, A | 1 |
| Milani, M | 1 |
| Corsini, G | 1 |
| Coca, A | 1 |
| Moynihan, JL | 1 |
| Al-Mousa, EN | 1 |
| Campsey, M | 1 |
| Gandhi, R | 1 |
| Mattson, S | 1 |
| Ryan, KA | 1 |
| Mesley, R | 1 |
| Swanson, J | 1 |
| Arshad, MN | 1 |
| Marble, SJ | 1 |
| Posada, IS | 1 |
| Barriales, V | 1 |
| Bradley, JP | 1 |
| Taylor, DW | 1 |
| Haynes, RB | 1 |
| Ferguson, GG | 1 |
| Sackett, DL | 1 |
| Thorpe, KE | 1 |
| Simard, D | 1 |
| Silver, FL | 1 |
| Hachinski, V | 2 |
| Clagett, GP | 2 |
| Barnes, R | 1 |
| Schaefer, OP | 1 |
| Chowdhury, TA | 1 |
| Lasker, SS | 1 |
| Dyer, PH | 1 |
| D'Sa, S | 1 |
| Takazoe, K | 2 |
| Sakamoto, T | 2 |
| Arai, H | 1 |
| Moriyama, Y | 1 |
| Hirai, N | 1 |
| Misumi, K | 1 |
| Hosoda, K | 1 |
| Salomon, P | 1 |
| Sorrie, R | 1 |
| Jennings, S | 1 |
| Farooqi, A | 1 |
| Comeglio, M | 1 |
| Falai, M | 1 |
| Wilkes, MS | 1 |
| Middlekauff, H | 1 |
| Hoffman, JR | 1 |
| Gollub, SB | 1 |
| Heller, R | 1 |
| Alexander, H | 1 |
| Colley, P | 1 |
| D'Este, K | 1 |
| Hyde, TA | 1 |
| Straznicky, IT | 2 |
| Whitlock, RM | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Kausar, SA | 1 |
| Murugesan, SR | 1 |
| Walls, RM | 1 |
| Jauhar, R | 1 |
| Bergman, G | 1 |
| Savino, S | 1 |
| Deutsch, E | 2 |
| Shaknovich, A | 1 |
| Parikh, M | 1 |
| Sanborn, TA | 1 |
| Sulter, G | 1 |
| Willenbrock, R | 1 |
| Monti, J | 1 |
| Dietz, R | 1 |
| Remskar, M | 1 |
| Mozina, H | 1 |
| Noc, M | 1 |
| Zorman, D | 1 |
| Stepec, S | 1 |
| Christiansen, CL | 1 |
| Ross-Degnan, D | 1 |
| Harker, LA | 3 |
| Pilgrim, AJ | 1 |
| Gent, M | 4 |
| Eikelboom, BC | 2 |
| Fitzgerald, DJ | 4 |
| Silveira, C | 1 |
| Quininha, J | 1 |
| Ferreira, Mde L | 1 |
| Gonçalves, JM | 1 |
| Ramos, JS | 1 |
| Figueiredo, L | 1 |
| Antunes, AM | 1 |
| Kakar, R | 1 |
| Cohen, A | 1 |
| Meyer, MI | 1 |
| Kuhn, M | 1 |
| Bühler, H | 1 |
| Bertschinger, P | 1 |
| Abrahamsson, P | 1 |
| Lindqvist, J | 2 |
| Danenberg, HD | 1 |
| Fischer, F | 2 |
| Dehn, H | 1 |
| Grube, R | 1 |
| Becker, G | 1 |
| Baumgärtel, B | 2 |
| Altmann, E | 2 |
| Salamon, A | 1 |
| Jáger, R | 1 |
| Poór, F | 1 |
| Barczi, V | 1 |
| Dinnyés, J | 1 |
| Hamvas, J | 1 |
| Kinczel, A | 1 |
| Pál, A | 1 |
| Blaskó, G | 1 |
| Eto, K | 2 |
| Takeshita, S | 2 |
| Yokoyama, N | 1 |
| Oshima, A | 2 |
| Kondo, K | 1 |
| Sato, T | 2 |
| Steiner, M | 1 |
| Rifai, N | 1 |
| Coyne, KS | 1 |
| Reiner, JS | 1 |
| Greenhouse, SW | 1 |
| Fink, C | 1 |
| Frey, A | 1 |
| Moreyra, E | 1 |
| Traboulsi, M | 1 |
| Racine, N | 1 |
| Riba, AL | 1 |
| Thompson, MA | 1 |
| Rohrbeck, S | 1 |
| Lundergan, CF | 2 |
| Hillarp, A | 1 |
| Berntorp, E | 1 |
| Lipinska, I | 1 |
| Murillo, J | 1 |
| McKenna, C | 1 |
| Salomon, F | 1 |
| Yoon, Y | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Cianciolo, C | 1 |
| Ferro, D | 1 |
| Basili, S | 1 |
| Roccaforte, S | 1 |
| Di Franco, M | 1 |
| Cipollone, F | 1 |
| Ciabattoni, G | 2 |
| Davì, G | 1 |
| Goldhammer, E | 1 |
| Kharash, L | 1 |
| Abinader, EG | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| Bayés de Luna, A | 1 |
| Cruz-Fernández, JM | 1 |
| López-Bescós, L | 1 |
| López García-Aranda, V | 1 |
| Cabadés, A | 1 |
| Martín-Jadraque, L | 1 |
| Velasco, JA | 1 |
| Castro-Beiras, A | 1 |
| Marfil, F | 1 |
| Navarro, E | 1 |
| Fox, KM | 1 |
| Vyshlov, EV | 1 |
| Panfilova, EV | 1 |
| Markov, VA | 1 |
| Sagar, KA | 1 |
| Smyth, MR | 1 |
| Awtry, EH | 1 |
| Burns, M | 1 |
| Lambrew, C | 1 |
| French, W | 1 |
| Rogers, WJ | 3 |
| Fuzailov, SY | 1 |
| Levine, DJ | 1 |
| Rossoni, G | 2 |
| Berti, M | 1 |
| Colonna, VD | 2 |
| Bernareggi, M | 2 |
| Del Soldato, P | 2 |
| Berti, F | 2 |
| Aksoy, M | 1 |
| Kepekçi, Y | 1 |
| Göktekin, O | 1 |
| Akdemir, I | 1 |
| Gürsürer, M | 1 |
| Emre, A | 1 |
| Bilge, M | 1 |
| Yesilçimen, K | 1 |
| Ersek, B | 1 |
| Masson, C | 1 |
| Vallée, JP | 1 |
| Karila-Cohen, D | 1 |
| Elalamy, I | 1 |
| Foussas, S | 1 |
| Olympios, C | 1 |
| Hatzimiltiadis, S | 1 |
| Sionis, D | 1 |
| Vavouranakis, E | 1 |
| Vrahatis, A | 1 |
| Fakiolas, C | 1 |
| Pissimisis, E | 1 |
| Stefanidis, A | 1 |
| Zairis, M | 1 |
| Vitakis, S | 1 |
| Louridas, G | 1 |
| Cokkinos, D | 2 |
| Toutouzas, P | 1 |
| Kitai, T | 1 |
| Okinaka, T | 1 |
| Makino, K | 1 |
| Ito, M | 1 |
| Shiku, H | 1 |
| Nakano, T | 1 |
| McMullan, MR | 1 |
| Andrews, J | 1 |
| Green, CL | 1 |
| Maas, AC | 1 |
| Lund, M | 1 |
| Hovland, A | 1 |
| Nielsen, EW | 1 |
| Neuhaus, KL | 3 |
| Kjeldsen, SE | 1 |
| Kolloch, RE | 1 |
| Leonetti, G | 1 |
| Mallion, JM | 1 |
| Elmfeldt, D | 1 |
| Pizzetti, F | 1 |
| Santoro, E | 2 |
| Ritzmann, P | 1 |
| Frey, R | 1 |
| Rüttimann, S | 1 |
| Leifer, D | 1 |
| Gibson, NE | 1 |
| Skjodt, NM | 1 |
| Ford, DC | 1 |
| Quan, H | 1 |
| Hirsch, H | 1 |
| Lazar, J | 1 |
| Marzo, KP | 1 |
| Steingart, RM | 1 |
| Tuohy, ER | 1 |
| Barakat, K | 3 |
| Suliman, A | 3 |
| MacCallum, PK | 1 |
| Klijn, CJ | 1 |
| van Buren, PA | 1 |
| Tulleken, CA | 1 |
| Bozovich, GE | 2 |
| Quispe, A | 1 |
| Strinna, A | 1 |
| Thun, MJ | 1 |
| Varas, C | 1 |
| Brennan, PJ | 1 |
| Gan, SC | 1 |
| Beaver, SK | 1 |
| Houck, PM | 1 |
| MacLehose, RF | 1 |
| Lawson, HW | 1 |
| Caspi, A | 1 |
| Berink, P | 1 |
| Toman, J | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Coyne, K | 2 |
| Hammond, M | 1 |
| Scazziota, A | 1 |
| Lison, L | 1 |
| Perlemuter, K | 1 |
| Philippe, F | 1 |
| Janzon, L | 1 |
| Lancellotti, P | 1 |
| Piérard, LA | 1 |
| Alderman, E | 1 |
| Fitzgerald, PJ | 1 |
| Hayase, M | 1 |
| Metz, JA | 1 |
| Bailey, SR | 1 |
| Baim, DS | 3 |
| Cleman, MW | 1 |
| Oesterle, SN | 1 |
| Overlie, PA | 1 |
| Safian, RD | 1 |
| Shani, J | 1 |
| Zidar, JP | 1 |
| Yeung, AC | 1 |
| Brewster, GS | 1 |
| Herbert, ME | 1 |
| Soriano, B | 1 |
| Puigfel, Y | 1 |
| Trobo, L | 1 |
| Garcia-Lafuente, A | 1 |
| Chadow, HL | 1 |
| Hauptman, RE | 1 |
| VanAuker, M | 1 |
| Rafii, SE | 1 |
| Gunsburg, MY | 1 |
| Giarraffa, L | 1 |
| Strom, JA | 1 |
| Thomas, DP | 1 |
| Vina, ER | 2 |
| van Kesteren, HA | 1 |
| Molhoek, PG | 2 |
| van der Wieken, LR | 1 |
| Cuffie-Jackson, CA | 1 |
| Rezig, K | 1 |
| Diar, N | 1 |
| Walcker, JL | 1 |
| Bryg, RJ | 1 |
| Graettinger, WF | 1 |
| Miyamoto, S | 1 |
| Kajiwara, I | 1 |
| Kugiyama, K | 1 |
| Pesonen, E | 1 |
| Thilen, U | 1 |
| Sandström, S | 1 |
| Arheden, H | 1 |
| Koul, B | 1 |
| Olsson, SE | 1 |
| Wilson, RF | 2 |
| Toher, C | 1 |
| Bank, A | 1 |
| Bass, J | 1 |
| Moshfegh, K | 1 |
| Redondo, M | 1 |
| Julmy, F | 1 |
| Wuillemin, WA | 1 |
| Gebauer, MU | 1 |
| Haeberli, A | 1 |
| Bell, DM | 1 |
| Nappi, J | 1 |
| Guize, L | 1 |
| Consoli, SM | 1 |
| Kolsky, H | 1 |
| Walch, JM | 1 |
| Paul-Dauphin, A | 1 |
| Duprat-Lomon, I | 1 |
| Brasileiro, AL | 1 |
| Peterson, JG | 1 |
| Young, JB | 1 |
| Lauer, MS | 3 |
| Lui, KJ | 1 |
| Kelly, C | 1 |
| Qasim, A | 1 |
| More, RS | 1 |
| Bo-Linn, GW | 1 |
| French, WJ | 1 |
| Barr, E | 1 |
| Snapinn, S | 1 |
| Ghannam, AF | 1 |
| Sax, FL | 1 |
| Palmer, RH | 1 |
| Hansen, C | 1 |
| Muncy, D | 1 |
| Cutler, SS | 1 |
| Araujo, R | 1 |
| Gebalska, J | 1 |
| Wolk, R | 1 |
| Akkerhuis, KM | 1 |
| Boland, JL | 1 |
| Hoffmann, J | 1 |
| Baardman, T | 1 |
| Nehmiz, G | 1 |
| Roth, U | 1 |
| Klootwijk, AP | 1 |
| Kang, KT | 1 |
| Kim, NH | 1 |
| Bae, Y | 1 |
| Fulton, DR | 1 |
| Newburger, JW | 1 |
| Tiffany, BR | 1 |
| Barrali, R | 1 |
| Olivella, P | 1 |
| Hézard, N | 1 |
| Metz, D | 1 |
| Garnotel, R | 1 |
| Droullé, C | 1 |
| Potron, G | 1 |
| Nguyen, P | 1 |
| Paty, BW | 1 |
| Lairikyengbam, SK | 1 |
| Davies, AG | 1 |
| Anderson, MH | 1 |
| Asbeck, F | 2 |
| Sanmuganathan, PS | 1 |
| Ghahramani, P | 1 |
| Jackson, PR | 1 |
| Wallis, EJ | 1 |
| Ramsay, LE | 1 |
| Skerrett, PJ | 1 |
| Kight, L | 1 |
| Alkhenizan, A | 1 |
| Ornato, J | 1 |
| Schütt, M | 1 |
| Klüter, H | 1 |
| Wiedemann, GJ | 1 |
| Richardt, G | 1 |
| Caires, G | 1 |
| Pereira, D | 1 |
| Freitas, AD | 1 |
| Teixeira, F | 1 |
| Leite, R | 1 |
| Araújo, JJ | 1 |
| Cardoso, A | 1 |
| Pereira, AC | 1 |
| Macedo, ME | 1 |
| Diniz, M | 1 |
| Chew, DP | 2 |
| Sandén, W | 1 |
| Sjölin, M | 1 |
| Rolka, DB | 1 |
| Fagot-Campagna, A | 1 |
| Narayan, KM | 1 |
| Axtell, SS | 1 |
| Ludwig, E | 1 |
| Lope-Candales, P | 1 |
| Qureshi, AM | 1 |
| McDonald, L | 1 |
| Primrose, WR | 1 |
| Sheikh, K | 1 |
| Bullock, C | 1 |
| Yip, HK | 1 |
| Chang, HW | 1 |
| Chen, MC | 1 |
| Hang, CL | 1 |
| Fang, CY | 1 |
| Hsieh, KY | 1 |
| Woodward, S | 2 |
| Hyams, J | 1 |
| Tanner, L | 1 |
| Ford, E | 1 |
| Gray, H | 1 |
| Yousaf, N | 1 |
| Sonaglia, F | 1 |
| Brockwell, SE | 1 |
| Gordon, IR | 1 |
| Manfredi, B | 1 |
| Chorzempa, A | 1 |
| Tabloski, P | 1 |
| Gawlinski, A | 1 |
| Moughrabi, S | 1 |
| Tillisch, JH | 1 |
| Torres, V | 1 |
| Marcos, E | 1 |
| Edmunds, E | 1 |
| Beevers, DG | 1 |
| Scrutinio, D | 1 |
| Marubini, E | 1 |
| Pitzalis, MV | 1 |
| Rizzon, P | 1 |
| Weinfurt, KP | 1 |
| Solomon, AJ | 1 |
| Yang, HS | 1 |
| Terry, P | 1 |
| Davies, M | 1 |
| Terakura, M | 1 |
| Handa, S | 1 |
| O'Shea, EB | 1 |
| Mukawa, H | 1 |
| Sone, T | 1 |
| Tsuboi, H | 1 |
| Kondo, J | 1 |
| Kosokabe, T | 1 |
| Uesugi, M | 1 |
| Imai, H | 1 |
| Einecke, D | 1 |
| Heidebrink, JL | 1 |
| Auer, J | 1 |
| Berent, R | 1 |
| Maurer, E | 1 |
| Mayr, H | 1 |
| Weber, T | 1 |
| Eber, B | 1 |
| Niessner, A | 1 |
| Niessner, H | 1 |
| Jackson, G | 1 |
| Bertrand-Hardy, JM | 2 |
| Humphreys, M | 2 |
| Pugh, PJ | 1 |
| McCarty, D | 1 |
| Walsh, SJ | 1 |
| Nurden, P | 1 |
| Bradford, WD | 1 |
| Hombach, V | 1 |
| Kochs, M | 1 |
| Sexton, RC | 1 |
| Jolobe, OM | 1 |
| Vicari, R | 1 |
| Robertson, DH | 1 |
| DeLucca, PT | 1 |
| Majumdar, SR | 1 |
| Inui, TS | 1 |
| Gillman, MW | 1 |
| Wan Po, AL | 1 |
| Bogaty, P | 1 |
| Nasmith, J | 1 |
| Solymoss, S | 1 |
| Walters, MR | 1 |
| Lees, KR | 1 |
| Seddon, ME | 1 |
| Ayanian, JZ | 1 |
| Landrum, MB | 1 |
| Cleary, PD | 1 |
| Peterson, EA | 1 |
| Gahart, MT | 1 |
| McNeil, BJ | 2 |
| Prieto, JC | 1 |
| Nazza, C | 1 |
| Chávez, E | 1 |
| Bartolucci, J | 1 |
| Cumsille, F | 1 |
| Fleming, DJ | 1 |
| Jacques, PF | 1 |
| Wilson, PW | 2 |
| Wood, RJ | 1 |
| Spickler, W | 1 |
| Olson, J | 1 |
| Huntington, J | 1 |
| Molhoek, P | 1 |
| Lundergan, C | 1 |
| Knudtson, M | 1 |
| Draoui, Y | 1 |
| Regalado, L | 1 |
| Le Louer, V | 1 |
| Schwartz, W | 1 |
| de Jong, E | 1 |
| Malmberg, K | 1 |
| Rupprecht, H | 1 |
| Copland, I | 1 |
| Gattis, WA | 1 |
| Hellkamp, AS | 1 |
| Larsen, RL | 1 |
| O'Gara, PT | 1 |
| Daly, R | 1 |
| Frances, CD | 1 |
| Alperin, P | 1 |
| Adler, JS | 1 |
| Haldemann, R | 1 |
| Szucs, TD | 1 |
| Lassila, R | 1 |
| Fisman, EZ | 1 |
| Shapira, I | 1 |
| Motro, M | 2 |
| Pines, A | 1 |
| Robbins, MA | 1 |
| Mukherjee, D | 1 |
| Wehrmacher, WH | 1 |
| Scleparis, G | 1 |
| Lowe, HC | 1 |
| Kumar, RK | 1 |
| Chesterman, CN | 1 |
| Fahmy, RG | 1 |
| Khachigian, LM | 1 |
| Fessler, HE | 1 |
| Fihn, SD | 1 |
| Williams, SV | 1 |
| Daley, J | 1 |
| Gibbons, RJ | 1 |
| Bratzler, DW | 1 |
| Oehlert, WH | 1 |
| Walkingstick, K | 1 |
| Murray, CK | 1 |
| Shook, C | 1 |
| Jensen, HK | 1 |
| Gheeraert, PJ | 1 |
| Henriques, JP | 1 |
| De Buyzere, ML | 1 |
| De Pauw, M | 1 |
| Taeymans, Y | 1 |
| Woollard, M | 1 |
| Smith, A | 1 |
| Beohar, N | 1 |
| Weigold, G | 1 |
| Goodreau, L | 1 |
| Benzuly, KH | 1 |
| Dymicka-Piekarska, V | 3 |
| Kemona, H | 3 |
| Mantur, M | 3 |
| Stogowski, A | 3 |
| Kemona-Chetnik, I | 3 |
| Bychowski, J | 2 |
| Bittl, JA | 1 |
| Chaitman, BR | 3 |
| Feit, F | 3 |
| Kimball, W | 1 |
| O'Connor, FF | 1 |
| Shields, DC | 1 |
| Fitzgerald, A | 1 |
| Hayat, J | 1 |
| Dihmis, WC | 1 |
| Leape, LL | 1 |
| Doughty, M | 1 |
| Mehta, R | 1 |
| Bruckman, D | 1 |
| Das, S | 1 |
| Karavite, D | 1 |
| Tsai, T | 1 |
| Eagle, K | 2 |
| Villareal, RP | 1 |
| Kim, P | 1 |
| Nordt, T | 1 |
| Campbell, P | 1 |
| Milon, H | 1 |
| Lantelme, P | 1 |
| Khettab, F | 1 |
| Mestre-Fernandes, C | 1 |
| Lasserre-Remy, S | 1 |
| Jaïs, C | 1 |
| Labèque, JN | 1 |
| Perron, JM | 1 |
| Lafitte, S | 1 |
| Zabsonré, P | 1 |
| Roudaut, R | 1 |
| Teuma, X | 1 |
| Botosezzy, I | 1 |
| Bouvier, JL | 1 |
| Comet, B | 1 |
| Commeau, P | 1 |
| Macaluso, G | 1 |
| Roquebert, PO | 1 |
| Gabriel, D | 1 |
| Sterz, F | 1 |
| Muellner, M | 1 |
| Kuerkciyan, I | 1 |
| Holzer, M | 1 |
| Morais, J | 1 |
| Mitra, S | 1 |
| Findley, K | 1 |
| Frohnapple, D | 1 |
| Ray, WA | 2 |
| Stein, CM | 1 |
| Hall, K | 1 |
| Daugherty, JR | 1 |
| Griffin, MR | 1 |
| Wollersheim, HC | 1 |
| Brophy, MT | 1 |
| Sacco, J | 1 |
| Peduzzi, P | 1 |
| Schweiger, C | 1 |
| Desai, MM | 1 |
| Perlin, JB | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Bradley, C | 1 |
| Murray, KT | 1 |
| Ko, D | 1 |
| Syvänne, M | 1 |
| DeLong, ER | 1 |
| Ostbye, T | 1 |
| Muhlbaier, LH | 1 |
| Chen, A | 1 |
| LaPointe, NA | 1 |
| McCants, CB | 1 |
| Kramer, JM | 1 |
| Cole, SR | 1 |
| Hernán, MA | 1 |
| Blakely, T | 1 |
| Poerner, TC | 1 |
| Kralev, S | 1 |
| Sueselbeck, T | 1 |
| Latsch, A | 1 |
| Pfleger, S | 1 |
| Schumacher, B | 1 |
| Haase, KK | 1 |
| Darbà, J | 1 |
| Pontes, C | 1 |
| Navas, C | 1 |
| Rovira, J | 1 |
| Johnston, M | 1 |
| Yi, Q | 1 |
| Libby, P | 1 |
| Wainwright, CL | 1 |
| Miller, AM | 1 |
| Work, LM | 1 |
| Howlett, M | 1 |
| Blankenberg, S | 1 |
| Espinola-Klein, C | 1 |
| Schultheiss, HP | 1 |
| Cambria-Kiely, JA | 1 |
| Gandhi, PJ | 1 |
| Ernst, N | 1 |
| Nibbering, E | 1 |
| Cantor, WJ | 1 |
| Christenson, RH | 1 |
| Tuttle, RH | 1 |
| Cruickshank, MK | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Ball, SP | 1 |
| Hand, MH | 1 |
| Bahr, R | 1 |
| Lambrew, CT | 2 |
| Lee, TH | 1 |
| MacLeod, B | 1 |
| Steele, P | 1 |
| Zalenski, RJ | 1 |
| Maranian, AM | 1 |
| Julian, D | 1 |
| Potharaju, S | 1 |
| Kota, MK | 1 |
| Haberl, R | 1 |
| Einecke, U | 1 |
| Kristinsson, A | 1 |
| Dimas, AP | 1 |
| Klein, WW | 1 |
| Rossignol, P | 1 |
| La Batida Alanore, A | 1 |
| Roueff, S | 1 |
| Bobrie, G | 1 |
| Plouin, PF | 1 |
| Aviles, RJ | 1 |
| Askari, AT | 1 |
| Jia, G | 1 |
| Berger, P | 1 |
| Herrington, D | 1 |
| Bittner, V | 1 |
| Davidson, M | 1 |
| Hlatky, M | 1 |
| Hsia, J | 3 |
| Herd, A | 1 |
| Khan, S | 1 |
| Wenger, N | 1 |
| Ben-Ami, R | 1 |
| Sheinman, G | 1 |
| Yedgar, S | 1 |
| Eldor, A | 1 |
| Berliner, AS | 1 |
| Barshtein, G | 1 |
| Saleh, N | 1 |
| Hansson, LO | 1 |
| Kohut, M | 1 |
| Hollister, LE | 1 |
| Marx, R | 1 |
| Haft, JI | 2 |
| Loo, J | 1 |
| Horrobin, DF | 1 |
| Ally, A | 1 |
| Swift, A | 1 |
| Manku, MS | 1 |
| Morgan, RO | 1 |
| Karmali, RA | 1 |
| Vogel, G | 1 |
| Fischer, C | 1 |
| Huyke, R | 1 |
| Atanasov, K | 1 |
| Yovkova, T | 1 |
| Tzvetkova, T | 1 |
| Lessof, MH | 1 |
| Gryglewski, R | 1 |
| Jhawar, BK | 1 |
| Trivedi, HH | 1 |
| Bhargava, RK | 1 |
| Misra, NP | 1 |
| Yasunaga, K | 2 |
| Williams, WO | 2 |
| Gantmacher, ML | 1 |
| Oelz, O | 1 |
| Olszańska-Skorek, T | 1 |
| Mazurowa, A | 1 |
| Połczyńska, I | 1 |
| Chojnowski, K | 1 |
| Eichelkraut, A | 1 |
| Kuźmicka, J | 1 |
| Grodzińska, L | 1 |
| Serwońska, M | 1 |
| Marcinkiewicz, E | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Armitage, P | 1 |
| Giuffrida, G | 1 |
| Mazza, F | 1 |
| Polverino, W | 1 |
| Blakely, JA | 1 |
| Heikinheimo, R | 1 |
| Pasotti, C | 2 |
| Belli, R | 1 |
| Beasci, R | 1 |
| Linos, A | 1 |
| Worthington, JW | 1 |
| O'Fallon, W | 1 |
| Kurland, LT | 1 |
| Halle, J | 1 |
| Grgicević, D | 1 |
| Pistotnik, M | 1 |
| Vuletić, J | 1 |
| Loncar, S | 1 |
| Capra, A | 1 |
| Stormorken, H | 1 |
| Czaplicki, S | 1 |
| Gietka, J | 1 |
| Sułek, K | 1 |
| Stornello, M | 1 |
| Aloisi, B | 1 |
| Stuto, A | 1 |
| Vinci, E | 1 |
| Bozzanca, L | 1 |
| Krantz, JC | 1 |
| Bucher, HJ | 1 |
| Doub, PH | 1 |
| Doub, NH | 1 |
| Gallus, AS | 1 |
| Aledort, LM | 1 |
| Hoak, JC | 2 |
| Wu, KK | 2 |
| Fry, GL | 1 |
| Broustet, JP | 1 |
| Boisseau, M | 1 |
| Bouloumie, J | 1 |
| Emeriau, JP | 1 |
| Bricaud, H | 1 |
| Guyton, JR | 1 |
| Silverman, JF | 1 |
| Wexler, L | 1 |
| Kraikitpanitch, S | 1 |
| Haygood, CC | 1 |
| Baxter, DJ | 1 |
| Yunice, AA | 1 |
| Lindeman, RD | 1 |
| Fleming, JS | 1 |
| Buchanan, JO | 1 |
| Buyniski, JP | 1 |
| Boullon, F | 1 |
| Raca, R | 1 |
| de la Fuente, L | 1 |
| Favaloro, R | 1 |
| Heuchel, G | 1 |
| Hässler, W | 1 |
| Bainton, D | 1 |
| Hammond, EC | 1 |
| Garfinkel, L | 1 |
| Cooper, EE | 1 |
| Martyniuk, RA | 1 |
| Semenova, LA | 1 |
| Tsellarius, IuG | 1 |
| Cosgrove, DM | 1 |
| Heric, B | 1 |
| Lytle, BW | 1 |
| Taylor, PC | 1 |
| Novoa, R | 1 |
| Golding, LA | 1 |
| Stewart, RW | 1 |
| McCarthy, PM | 1 |
| Loop, FD | 1 |
| Willard, JE | 1 |
| Grodecki, J | 1 |
| Castaigne, A | 2 |
| Albo, C | 1 |
| Verschuren, P | 1 |
| Perchet, H | 1 |
| Pham, I | 1 |
| Saal, JP | 1 |
| Li, WG | 1 |
| Chui, ZC | 1 |
| Zhoa, YJ | 1 |
| Tubaro, M | 1 |
| Cavallo, G | 1 |
| Pensa, V | 1 |
| Chessa, MA | 1 |
| Natale, E | 1 |
| Ricci, R | 1 |
| Milazzotto, F | 1 |
| Tubaro, E | 1 |
| Chang, TW | 1 |
| Umachandran, V | 1 |
| Hannaford, PC | 1 |
| Kay, CR | 1 |
| Hoberg, E | 1 |
| Weber, R | 1 |
| Landreneau, JW | 1 |
| Amanullah, AM | 1 |
| Lindvall, K | 1 |
| Thompson, PL | 2 |
| Parsons, RW | 1 |
| Jamrozik, K | 2 |
| Hockey, RL | 1 |
| Hobbs, MS | 1 |
| Broadhurst, RJ | 1 |
| van Pampus, EC | 1 |
| Huijgens, PC | 1 |
| Langenhuijsen, MM | 1 |
| Pop, GA | 1 |
| van Latum, JC | 1 |
| Manske, CL | 1 |
| Rector, T | 1 |
| White, CW | 1 |
| Juul-Möller, S | 1 |
| Edvardsson, N | 1 |
| Jahnmatz, B | 1 |
| Rosén, A | 1 |
| Sørensen, S | 1 |
| Omblus, R | 1 |
| Jones, LA | 1 |
| Bleecker, GC | 1 |
| Strauss, MJ | 1 |
| Rubowitz, AH | 1 |
| Rasche, H | 1 |
| Harker, LB | 1 |
| Salzman, EW | 2 |
| Levine, MN | 1 |
| Wheeler, HB | 1 |
| Rizik, D | 1 |
| Sharma, GV | 1 |
| Cowley, M | 2 |
| Macina, G | 3 |
| Kantounis, L | 1 |
| Timmis, GC | 1 |
| Margulis, A | 1 |
| Lam, JY | 1 |
| Webster, MW | 1 |
| Zoldhelyi, P | 1 |
| Roche, PC | 1 |
| Badimon, L | 2 |
| Geetha, A | 1 |
| Kimata, S | 2 |
| Kario, K | 1 |
| Matsuo, T | 1 |
| Tai, S | 1 |
| Yamada, T | 1 |
| Miki, T | 1 |
| Matsuo, M | 1 |
| Ramires, JA | 3 |
| Edhag, O | 3 |
| Rosamond, TL | 1 |
| Kramer, PH | 1 |
| Crouse, LJ | 1 |
| Robuck, OW | 1 |
| White, JL | 1 |
| Beauchamp, GD | 1 |
| Geraci, E | 1 |
| Cosmi, F | 1 |
| López Bescós, L | 1 |
| Cortadellas, J | 1 |
| Figueras, J | 1 |
| Cobbe, S | 1 |
| Prema, A | 1 |
| Liu, GS | 1 |
| Stanley, AW | 1 |
| Downey, J | 1 |
| Bory, M | 1 |
| Roux, S | 1 |
| Christeller, S | 1 |
| Lüdin, E | 1 |
| Tosteson, H | 1 |
| Satterfield, S | 1 |
| Hebert, P | 1 |
| O'Connor, GT | 1 |
| Lamas, GA | 1 |
| Hamm, P | 1 |
| Wertheimer, J | 1 |
| Rouleau, JL | 1 |
| Natale, A | 1 |
| Bianchi, C | 1 |
| Albanese, S | 1 |
| Lanza, GA | 1 |
| Coppola, E | 1 |
| Cherng, WJ | 1 |
| Chiang, CW | 1 |
| Lee, CP | 1 |
| Yawn, BP | 1 |
| Simon, JA | 1 |
| Hulley, SB | 1 |
| Terres, W | 1 |
| Ruchelka, A | 1 |
| Weilepp, A | 1 |
| Kupper, W | 1 |
| Ohmuro, S | 1 |
| Tsukada, Y | 1 |
| Taga, F | 1 |
| Ohkubo, H | 1 |
| Uchida, H | 1 |
| Green, BK | 1 |
| Gordon, GD | 1 |
| Horak, AR | 1 |
| Millar, RN | 1 |
| Kleiman, N | 2 |
| Aguirre, F | 1 |
| Lam, J | 1 |
| Hattori, A | 1 |
| Aosaki, M | 1 |
| Iwade, K | 1 |
| Hosoda, S | 1 |
| Botolova, EN | 1 |
| Golikova, AA | 1 |
| Gruzdev, AK | 1 |
| Sergienko, IV | 1 |
| Basinski, AS | 1 |
| Naylor, CD | 3 |
| Fudo, T | 1 |
| Ono, S | 1 |
| Sharma, SN | 1 |
| Alexander, HM | 2 |
| Steele, PL | 2 |
| Malcolm, JA | 2 |
| Lange, J | 1 |
| Nesvold, A | 1 |
| Mitchell, JM | 1 |
| Wheeler, WS | 1 |
| O'Riordan, M | 1 |
| Kingston, S | 1 |
| O'Regan, P | 1 |
| Ong, HT | 1 |
| Friedlander, DH | 1 |
| Walters, BL | 1 |
| MacGowan, GA | 1 |
| O'Callaghan, D | 1 |
| Horgan, JH | 1 |
| Kerins, DM | 2 |
| Sullivan, AT | 1 |
| Baker, DJ | 1 |
| Drew, GM | 1 |
| Gibbons, KJ | 1 |
| Guterman, LR | 1 |
| Ahuja, A | 1 |
| Hopkins, LN | 1 |
| Cobb, JL | 1 |
| Wolf, PA | 1 |
| Gulba, DC | 1 |
| Granger, C | 1 |
| Malacrida, R | 2 |
| Neches, RB | 1 |
| Goldfarb, AM | 1 |
| Saviano, GJ | 1 |
| Mahon, J | 1 |
| Steel, K | 1 |
| Feagan, BG | 1 |
| Pederson, LL | 1 |
| Nylander, E | 1 |
| Hlatky, MA | 1 |
| Rønnevik, PK | 1 |
| Følling, M | 1 |
| Pedersen, D | 1 |
| Rodt, SA | 1 |
| von der Lippe, G | 2 |
| Chen, Z | 2 |
| Yu, Q | 1 |
| Kou, W | 1 |
| Lu, Z | 1 |
| Jia, Y | 1 |
| Duan, B | 1 |
| Shushliapin, OI | 1 |
| Shelest, AN | 1 |
| Khosseĭn Shakhavat, AF | 1 |
| Ferlito, S | 1 |
| Uberti, T | 1 |
| Fiorista, F | 1 |
| Suzuki, N | 1 |
| Arai, Y | 1 |
| Isokane, N | 1 |
| Fukushima, N | 1 |
| Sano, Y | 1 |
| Hoffman, W | 1 |
| Mase, K | 1 |
| Basinski, A | 2 |
| Vecchio, C | 1 |
| Chiarella, F | 1 |
| Lupi, G | 1 |
| Bellotti, P | 1 |
| Domenicucci, S | 1 |
| Goldhaber, SZ | 2 |
| Check, WA | 1 |
| Ip, JH | 1 |
| Kurata, JH | 2 |
| Marks, J | 1 |
| Abbey, D | 1 |
| Toft, E | 1 |
| Vyberg, M | 1 |
| Therkelsen, K | 1 |
| Arnold, AE | 3 |
| Rutsch, W | 1 |
| Mohler, ER | 1 |
| Stark, KS | 1 |
| Babb, JD | 1 |
| Frederick, M | 2 |
| McCall, NT | 1 |
| Schafer, AI | 1 |
| Williams, GH | 1 |
| Federman, J | 1 |
| Giles, RW | 1 |
| Harris, PJ | 1 |
| Hodge, RL | 1 |
| Thomson, A | 1 |
| Walsh, WF | 1 |
| Kay, C | 1 |
| Hancock, EW | 1 |
| Zuber, M | 1 |
| Wenzel, R | 1 |
| Barbash, GI | 2 |
| Kaplinsky, E | 1 |
| Laniado, S | 1 |
| Keren, G | 1 |
| Bovill, EG | 1 |
| Terrin, ML | 1 |
| Stump, DC | 1 |
| Berke, AD | 1 |
| Collen, D | 2 |
| Cole, PL | 1 |
| Bland, R | 1 |
| Doedar, H | 1 |
| Vaidya, K | 1 |
| Merino, A | 1 |
| Hawkins, L | 2 |
| Greenberg, S | 1 |
| Monrad, ES | 1 |
| Cornélissen, G | 1 |
| Halberg, F | 1 |
| Prikryl, P | 1 |
| Danková, E | 1 |
| Siegelová, J | 1 |
| Dusek, J | 1 |
| Wallentin, LC | 1 |
| Carpenter, AL | 1 |
| Caravalho, J | 1 |
| Cohen, LS | 4 |
| Neri Serneri, GG | 1 |
| Poggesi, L | 1 |
| Trotta, F | 1 |
| Modesti, PA | 1 |
| Boddi, M | 1 |
| Ieri, A | 1 |
| Margheri, M | 1 |
| Casolo, GC | 1 |
| Bini, M | 1 |
| Brecker, SJ | 1 |
| Quyyumi, AA | 1 |
| McMahon, S | 1 |
| Trenkwalder, P | 1 |
| Lydtin, H | 1 |
| Levy, AR | 1 |
| Osnes, JB | 1 |
| Platou, ES | 1 |
| Smiseth, OA | 1 |
| Amlie, JP | 1 |
| Salewski, B | 1 |
| Diaz, N | 1 |
| Boudoulas, H | 1 |
| Nitschke, M | 1 |
| Muche, J | 1 |
| Kampe, W | 1 |
| Handreg, W | 1 |
| Lekstrom, JA | 1 |
| Bell, WR | 1 |
| Baumann, PC | 1 |
| Atakhanova, LZ | 1 |
| Katsenovich, ER | 1 |
| Karpov, IuA | 1 |
| Kostko, SZ | 1 |
| Repin, VS | 1 |
| Ruda, MIa | 1 |
| Vine, DL | 1 |
| Iñiguez, A | 1 |
| Hernández, RA | 1 |
| Ferrero, J | 1 |
| Herrero, C | 1 |
| Casado, J | 1 |
| Zarco, P | 1 |
| Patscheke, H | 1 |
| Hornberger, W | 1 |
| Zehender, H | 1 |
| Knatterud, GL | 2 |
| Robertson, TL | 1 |
| Solomon, RE | 1 |
| Radomski, M | 1 |
| Herbaczyńska-Cedro, K | 1 |
| Krichbaum, DW | 1 |
| Grabavoy, G | 1 |
| Finley, RC | 1 |
| Hamid, I | 1 |
| Degré, SG | 1 |
| Fang, ZY | 1 |
| Sobolski, J | 1 |
| Abramowicz, M | 1 |
| Unger, P | 1 |
| Berkenboom, G | 1 |
| Hamilton, WP | 1 |
| Ro, KG | 1 |
| Fears, R | 1 |
| Ferres, H | 1 |
| Greenwood, HC | 1 |
| Warlow, C | 3 |
| Abbey, DE | 1 |
| van der Laarse, A | 1 |
| Funke-Küpper, AJ | 1 |
| Sterkman, LG | 1 |
| Galema, TW | 3 |
| Clyne, CA | 1 |
| Charvát, J | 1 |
| Fiserová, J | 1 |
| Hockings, B | 1 |
| Cox, RA | 1 |
| Wagner, NB | 1 |
| Berge, PG | 1 |
| Höpp, HW | 1 |
| Schapiro, JM | 1 |
| Arber, N | 1 |
| Sidi, Y | 1 |
| Bach, M | 1 |
| Dahn, G | 1 |
| Kothe, K | 1 |
| Jonas, S | 1 |
| Bourke, JP | 1 |
| Young, AA | 1 |
| Richards, DA | 1 |
| Uther, JB | 1 |
| Midttun, M | 1 |
| Grauholt, AM | 1 |
| Penkov, N | 1 |
| Sirakova, V | 1 |
| Brittain, E | 1 |
| Wittes, J | 2 |
| Bichan, NA | 1 |
| Gol'dberg, GA | 1 |
| Sternon, J | 1 |
| Kouvaras, G | 1 |
| Chronopoulos, G | 1 |
| Soufras, G | 1 |
| Sofronas, G | 1 |
| Solomos, D | 1 |
| Bakirtzis, A | 1 |
| Pissimissis, E | 1 |
| Tzonou, A | 1 |
| al-Roomi, KA | 1 |
| Ricou, F | 1 |
| Nukta, E | 1 |
| Shi, Y | 1 |
| Zalewski, A | 1 |
| Goldberg, S | 1 |
| Vincent, R | 1 |
| Miller, DH | 3 |
| Silvasi, D | 1 |
| McNulty, A | 3 |
| Zola, BE | 2 |
| Hornung, RS | 1 |
| Jones, AM | 1 |
| Andrews, NP | 1 |
| Dawes, PT | 1 |
| Carson, PH | 1 |
| Bunnell, P | 2 |
| Tenney, RD | 1 |
| Kikel, M | 2 |
| Tracy, R | 1 |
| Stump, D | 1 |
| Sushama Kumari, S | 1 |
| Varghese, A | 1 |
| Muraleedharan, D | 1 |
| Menon, VP | 1 |
| Wehmeier, A | 1 |
| Schneider, W | 1 |
| Lembo, NJ | 1 |
| Black, AJ | 1 |
| Roubin, GS | 1 |
| Wilentz, JR | 1 |
| Mufson, LH | 1 |
| Douglas, JS | 1 |
| Baluda, VP | 1 |
| Lukoianova, TI | 1 |
| Deianov, I | 1 |
| Johnson, WB | 1 |
| Malone, SA | 1 |
| Pantely, GA | 1 |
| Anselone, CG | 1 |
| Bristow, JD | 1 |
| Oates, JA | 1 |
| Stein, B | 1 |
| Glasziou, P | 1 |
| Trevethick, MA | 1 |
| Brown, AK | 1 |
| Wright, G | 1 |
| Strong, P | 1 |
| Rath, S | 1 |
| Miller, HI | 1 |
| Har-Zahav, Y | 1 |
| Modan, M | 1 |
| Rotstein, Z | 1 |
| Batler, A | 1 |
| Zivelin, A | 1 |
| Gimple, LW | 1 |
| Coller, BS | 1 |
| Werner, W | 1 |
| Yasuda, T | 1 |
| Johns, JA | 1 |
| Ziskind, AA | 1 |
| Finkelstein, D | 1 |
| Peterson, JE | 1 |
| Emmot, WW | 1 |
| Slama, M | 1 |
| Spriet, A | 1 |
| Paganini-Hill, A | 1 |
| Chao, A | 1 |
| Ross, RK | 1 |
| Henderson, BE | 1 |
| Grover, GJ | 1 |
| Schumacher, WA | 1 |
| Bates, ER | 1 |
| Bergstrand, R | 1 |
| Ulvenstam, G | 1 |
| Aberg, A | 1 |
| Wilhelmsen, L | 2 |
| Horton, RC | 1 |
| Kendall, MJ | 1 |
| Al-Mondhiry, H | 1 |
| Pierce, WS | 1 |
| Pennock, JL | 1 |
| Johannessen, KA | 1 |
| Stratton, JR | 1 |
| Taulow, E | 1 |
| Osterud, B | 1 |
| Resnekov, L | 2 |
| Chediak, J | 2 |
| Zichner, R | 1 |
| Weihrauch, TR | 1 |
| Koster, RW | 1 |
| Küpper, AJ | 2 |
| Peels, CH | 1 |
| den Hollander, W | 1 |
| Leor, Y | 1 |
| Feldman, S | 1 |
| Rabinowitz, B | 1 |
| Silberberg, JS | 1 |
| McGregor, M | 1 |
| Hartney, TJ | 1 |
| Goodman, SN | 1 |
| Fasting, H | 1 |
| Sandercock, P | 1 |
| Bang, NU | 1 |
| Wilhelm, OG | 1 |
| Clayman, MD | 1 |
| Mayo, G | 1 |
| Price, P | 1 |
| Takahara, K | 1 |
| Kraemmer Nielsen, H | 1 |
| Amtoft, A | 1 |
| Deding, A | 1 |
| Hansen, JN | 1 |
| Hilden, M | 1 |
| Hornum, I | 1 |
| Jensen, T | 1 |
| Lindskov, J | 1 |
| Duval-Moulin, AM | 1 |
| Dutoit, C | 1 |
| Kinoshenko, EI | 1 |
| Aliavi, AL | 1 |
| Vlasenko, MA | 1 |
| Stock, E | 1 |
| Rado, Iu | 1 |
| Chikvashvili, DI | 1 |
| Miller, GJ | 1 |
| Bentsen, N | 1 |
| Devereux, RB | 1 |
| Tenney, R | 1 |
| Zola, B | 1 |
| Yeager, RA | 1 |
| Moneta, GL | 1 |
| McConnell, DB | 1 |
| Neuwelt, EA | 1 |
| Porter, JM | 1 |
| Cohen, B | 1 |
| Borhani, NO | 2 |
| Bélanger, GL | 1 |
| Lavallée, JP | 1 |
| Lenis, J | 1 |
| Ouellet, CA | 1 |
| Hamsten, A | 1 |
| Svensson, J | 1 |
| Walldius, G | 1 |
| Szamosi, A | 1 |
| de Faire, U | 1 |
| Stamler, J | 2 |
| Gelman, JS | 1 |
| Mehta, J | 1 |
| Holman, RT | 1 |
| Evans, AE | 1 |
| Follath, F | 1 |
| Luchi, RJ | 1 |
| Scott, SM | 1 |
| Deupree, RH | 1 |
| Betriu, A | 1 |
| Col, J | 1 |
| Dougherty, FC | 1 |
| von Essen, R | 1 |
| Lambertz, H | 1 |
| Perry, RA | 1 |
| Shiu, MF | 1 |
| Hirschhorn, N | 1 |
| Davenport, J | 1 |
| Whittaker, K | 1 |
| Vallance, P | 1 |
| Goldberg, RK | 1 |
| Levine, S | 1 |
| Fenster, PE | 1 |
| Slany, J | 1 |
| Miller, KP | 2 |
| Hayashida, N | 1 |
| Feldman, RL | 1 |
| Nechaev, DD | 1 |
| Bochko, II | 1 |
| Martynov, IV | 1 |
| Kuz'mina, LF | 1 |
| Friedman, L | 2 |
| Ouimet, H | 1 |
| Latour, JG | 1 |
| Pelletier, E | 1 |
| Stasiak, J | 1 |
| deGuise, P | 1 |
| Telichowski, C | 1 |
| Metner, E | 1 |
| Góral, J | 1 |
| Petruk, J | 1 |
| Zebrowski, J | 1 |
| Lloyd, J | 1 |
| Gray, R | 1 |
| Wheatley, K | 1 |
| Hafner, B | 1 |
| Thompson, E | 1 |
| Norton, S | 1 |
| Mullane, KM | 1 |
| Fornabaio, D | 1 |
| Livesey, SA | 1 |
| Douzinas, M | 1 |
| Lennox, SC | 1 |
| Giannessi, D | 4 |
| Bernini, W | 4 |
| Boem, A | 2 |
| Patrignani, P | 4 |
| Filabozzi, P | 3 |
| Shimizu, Y | 1 |
| Tanaka, T | 1 |
| Takayama, Y | 1 |
| Hayashi, T | 1 |
| Ida, T | 1 |
| Sakakibara, T | 1 |
| Obunai, Y | 1 |
| Dubach, P | 1 |
| Rezzonico, M | 1 |
| Clara, F | 1 |
| Riva, A | 1 |
| Tanzi, F | 1 |
| Genoni, M | 1 |
| Catella, F | 1 |
| Relman, AS | 2 |
| Stalder, M | 1 |
| Bachmann, F | 1 |
| Rumore, MM | 1 |
| Goldstein, GS | 1 |
| Hansen, JF | 1 |
| Hansen, BF | 1 |
| Hutchison, GB | 1 |
| Doll, R | 1 |
| Lee, NC | 1 |
| Hays, LJ | 1 |
| Beller, GA | 1 |
| Moore, CA | 1 |
| Burwell, LR | 1 |
| Craddock, GB | 1 |
| Gascho, JA | 1 |
| Smucker, ML | 1 |
| Tedesco, C | 1 |
| Simrock, R | 1 |
| Rehders, K | 1 |
| Spahn, H | 1 |
| Mutschler, E | 1 |
| Allen, TW | 1 |
| Young, FE | 1 |
| Nightingale, SL | 1 |
| Temple, RA | 1 |
| Houser, HB | 1 |
| Thelle, DS | 1 |
| Uhl, D | 1 |
| O'Konski, MS | 1 |
| White, FC | 1 |
| Longhurst, J | 1 |
| Roth, D | 1 |
| Bloor, CM | 1 |
| Herie Kingma, J | 1 |
| Maseri, A | 1 |
| Lewis, D | 1 |
| Lemak, NA | 1 |
| Fields, WS | 1 |
| Gary, HE | 1 |
| Nicolas, G | 1 |
| Colwell, JA | 2 |
| Bingham, SF | 2 |
| David, JL | 1 |
| Teichmann, W | 1 |
| Brix, E | 1 |
| Meyer, E | 1 |
| Stabenow, I | 1 |
| Panzner, B | 1 |
| Busse, HJ | 1 |
| Krebbel, A | 1 |
| Hagert, M | 1 |
| Metzner, H | 1 |
| Rode, B | 1 |
| Valladares, BK | 1 |
| Lemberg, L | 1 |
| Berge, KG | 1 |
| Prineas, RJ | 1 |
| Friedewald, W | 1 |
| Lijnen, P | 1 |
| Ito, T | 1 |
| Shekelle, RB | 1 |
| Gale, M | 1 |
| Norusis, M | 1 |
| Rühle, H | 1 |
| Singer, J | 1 |
| Finnie, KJ | 1 |
| Froggatt, GM | 1 |
| Holder, DA | 1 |
| Jablonsky, G | 1 |
| Kostuk, WJ | 1 |
| Melendez, LJ | 1 |
| Myers, MG | 1 |
| Davies, JA | 1 |
| Abraira, C | 1 |
| Anderson, JW | 1 |
| Kwaan, HC | 1 |
| Gazzetti, P | 2 |
| Michelassi, C | 3 |
| L'Abbate, A | 3 |
| Donato, L | 2 |
| Keber, I | 1 |
| Keber, D | 1 |
| Jouve, R | 1 |
| Larrue, J | 1 |
| Courillon-Mallet, A | 1 |
| Wautier, JL | 1 |
| Suehiro, GT | 1 |
| Fisher, CA | 1 |
| Untereker, WJ | 1 |
| Laskey, WK | 1 |
| Hirshfeld, JW | 1 |
| Harken, AH | 1 |
| Addonizio, VP | 1 |
| Curb, JD | 1 |
| McArdle, R | 1 |
| Borer, J | 1 |
| Dalen, J | 1 |
| Dodge, HT | 1 |
| Francis, CK | 1 |
| Knatterud, G | 1 |
| Ludbrook, P | 1 |
| Battaglia, D | 1 |
| Dell'Amico, F | 1 |
| Machado, SG | 1 |
| Barton, BA | 1 |
| Forbes, CD | 1 |
| Isomäki, HA | 1 |
| Fiedler, H | 3 |
| Thiele, G | 3 |
| Kingdon, HS | 1 |
| Etherington, M | 1 |
| Jamieson, S | 1 |
| Lawford, P | 1 |
| Boyd, NF | 1 |
| Weser, C | 1 |
| Scheidler, K | 1 |
| Iurenev, PN | 1 |
| Semenovich, NI | 1 |
| Gormsen, J | 1 |
| Andersen, LA | 1 |
| Barucha, EP | 1 |
| Sherman, LA | 1 |
| Cochrane, AL | 1 |
| Burr, ML | 1 |
| Williams, G | 1 |
| Welsby, E | 1 |
| Hughes, SJ | 1 |
| Renton, R | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Pozzi, L | 1 |
| Terreni, F | 1 |
| Gershengorn, K | 1 |
| Kranz, PD | 1 |
| Oestreicher, R | 1 |
| Burkhardt, H | 1 |
| Röll, G | 1 |
| Harrison, JF | 1 |
| Parker, RW | 1 |
| De Silva, KL | 1 |
| Boss, N | 1 |
| Chmiel, H | 1 |
| Kachel, V | 1 |
| Ruhenstroth-Bauer, G | 1 |
| Scharrer, I | 2 |
| Oliver, MF | 1 |
| Wellmer, HK | 1 |
| Baer, U | 1 |
| Merguet, H | 1 |
| Rumpf, P | 1 |
| Petersen, H | 1 |
| Bromig, G | 1 |
| Persch, WF | 1 |
| Marx, FJ | 1 |
| von Bary, SM | 1 |
| Bamalob, Z | 1 |
| Huttman, DH | 1 |
| Schepping, M | 1 |
| Campanacci, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabili[NCT02018055] | Phase 4 | 2,590 participants (Actual) | Interventional | 2014-02-14 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Aspirin to Target Arterial Events in Chronic Kidney Disease[NCT03796156] | Phase 3 | 25,210 participants (Anticipated) | Interventional | 2019-02-25 | Recruiting | ||
| Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen[NCT03023020] | 4,579 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent[NCT03462498] | Phase 4 | 3,008 participants (Actual) | Interventional | 2018-04-02 | Active, not recruiting | ||
| ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study[NCT02619760] | Phase 4 | 3,045 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Secondary Prevention of Cardiovascular Disease in the Elderly Trial[NCT02596126] | Phase 3 | 2,499 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction[NCT04304534] | Phase 2 | 1,601 participants (Actual) | Interventional | 2020-06-17 | Completed | ||
| International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial[NCT01985360] | Phase 4 | 777 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti[NCT01991795] | Phase 3 | 19,271 participants (Actual) | Interventional | 2014-02-10 | Completed | ||
| Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness[NCT02697916] | 15,076 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Effect of Exercise Training on the Autonomic Nervous System and Its Correlation With Platelet Aggregability in a Post-myocardial Infarction Population[NCT02958657] | 90 participants (Actual) | Interventional | 2016-10-30 | Completed | |||
| HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864] | 22,000 participants (Anticipated) | Interventional | 2021-11-17 | Recruiting | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG[NCT01755520] | Phase 3 | 1,893 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to DSMB Interim Analyses) | ||
| A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease[NCT03008083] | Phase 4 | 2,446 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| International Multicenter Registry on Takotsubo Cardiomyopathy[NCT01947621] | 4,000 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| Novel Biomarkers of Thrombotic Risk[NCT02505217] | 200 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)[NCT02352402] | Phase 3 | 487 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| STable Coronary Artery Diseases RegisTry[NCT03796741] | 5,070 participants (Actual) | Observational | 2016-03-17 | Completed | |||
| A Single-dose, Open-label, Randomized, Multi-center, 2-treatment Crossover Study to Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Hea[NCT05625334] | Phase 1 | 86 participants (Actual) | Interventional | 2022-10-14 | Completed | ||
| XIENCE 28 Global Study[NCT03355742] | 963 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.[NCT03218787] | 2,047 participants (Actual) | Interventional | 2017-07-19 | Completed | |||
| XIENCE 28 USA Study[NCT03815175] | 1,605 participants (Actual) | Interventional | 2019-02-25 | Completed | |||
| ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis[NCT02328677] | 5,000 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| National Registry of Acute Myocardial Infarction in Switzerland[NCT01305785] | 60,000 participants (Anticipated) | Observational | 1997-01-31 | Recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry[NCT02015624] | 2,597 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Financial Support in an Underserved and Low-Income Population With Heart Failure[NCT05928026] | 120 participants (Anticipated) | Interventional | 2023-06-09 | Recruiting | |||
| Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)[NCT01800201] | 1,509 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study[NCT01557075] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event[NCT01082874] | Phase 3 | 10,010 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984] | Phase 3 | 20,976 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)[NCT01870921] | Phase 4 | 2,004 participants (Actual) | Interventional | 2013-06-26 | Completed | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular [NCT00501059] | Phase 3 | 12,546 participants (Actual) | Interventional | 2007-07-05 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| [NCT01075867] | 2,498 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation[NCT00673036] | 3,750 participants (Actual) | Observational | 2005-10-31 | Active, not recruiting | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418] | 3,700 participants (Anticipated) | Observational | 2010-10-31 | Active, not recruiting | |||
| French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015[NCT02566200] | 5,000 participants (Actual) | Observational [Patient Registry] | 2015-10-31 | Active, not recruiting | |||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease[NCT02607917] | 10,800 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome[NCT00831441] | Phase 3 | 7,484 participants (Actual) | Interventional | 2009-03-31 | Terminated | ||
| Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform[NCT02311231] | Phase 4 | 6,012 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR): a Prospective, Multi-centre Cohort Observational Study- Presepsin (sCD14-ST) for Perioperative Risk Prediction Nested Cohort Study[NCT03489486] | 1,695 participants (Anticipated) | Observational | 2018-06-15 | Recruiting | |||
| MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR) Observational Multicentre Study[NCT03016936] | 15,000 participants (Actual) | Observational | 2017-08-01 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753] | 1,001 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| Rapid Activity of Platelet Inhibitor Drugs Study (RAPID 2)[NCT01805570] | Phase 4 | 50 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction[NCT03487445] | Phase 2 | 48 participants (Actual) | Interventional | 2018-07-10 | Completed | ||
| Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial[NCT04912518] | 250 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | |||
| Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction[NCT02512978] | Phase 4 | 160 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Chinese People's Liberation Army General Hospital[NCT02826616] | 240 participants (Anticipated) | Interventional | 2016-07-31 | Enrolling by invitation | |||
| A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493] | 1,066 participants (Actual) | Observational [Patient Registry] | 2015-05-28 | Completed | |||
| The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883] | 18,000 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System[NCT00997503] | 4,199 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| Effect of Corticosteroids On MyocardiaL Injury Among Patients Hospitalized for Community-AcquirEd PneUMonia - COLOSSEUM TRIAL[NCT03745664] | Phase 3 | 122 participants (Anticipated) | Interventional | 2021-01-10 | Recruiting | ||
| Major Adverse Cardiac and Cerebrovascular Events in Hospitalized Patients With Community-acquired Pneumonia[NCT01773863] | 500 participants (Anticipated) | Observational | 2011-10-31 | Recruiting | |||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003] | Phase 4 | 2,272 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction[NCT02075125] | Phase 3 | 39 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Enrolling participants has halted prematurely and will not resume) | ||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)[NCT01272713] | 638 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | |||
| Strategy to Avoid Excessive Oxygen in Major Burn Patients (SAVE-O2)[NCT04534972] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2021-04-15 | Active, not recruiting | ||
| Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients (SAVE-O2)[NCT04534959] | Phase 3 | 6,000 participants (Anticipated) | Interventional | 2020-10-15 | Active, not recruiting | ||
| DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry[NCT01787110] | Phase 3 | 6,629 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| BEta Blocker dEprescription Following Coronary Artery Bypass Graft sURGERy: Feasibility and Safety Pilot (BEEFBURGER Trial)[NCT04788186] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-08-23 | Recruiting | ||
| GLOBAL LEADERS Adjudication Sub-Study[NCT03231059] | 7,365 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients[NCT01171404] | 10,568 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery[NCT01707459] | 201 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study[NCT02436187] | 389,057 participants (Actual) | Observational [Patient Registry] | 2003-01-31 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Morphological and Functional Changes, Risk Stratification and Prognosis of Patients With Compete Left Bundle Branch Block[NCT03096678] | 500 participants (Anticipated) | Observational [Patient Registry] | 2010-01-01 | Recruiting | |||
| Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients[NCT01402804] | 85 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| "Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733] | 1,000 participants (Actual) | Observational [Patient Registry] | 2018-06-18 | Completed | |||
| Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803] | Phase 4 | 2,808 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766] | 150 participants (Anticipated) | Observational | 2020-09-30 | Not yet recruiting | |||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial[NCT02000336] | Phase 3 | 395 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT01158846] | Phase 4 | 800 participants (Anticipated) | Interventional | 2010-08-31 | Not yet recruiting | ||
| Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial[NCT04259853] | 1,016 participants (Anticipated) | Interventional | 2020-01-30 | Enrolling by invitation | |||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463] | Phase 4 | 263 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832] | Phase 4 | 951 participants (Anticipated) | Interventional | 2011-07-31 | Active, not recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597] | Phase 2 | 3,490 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification[NCT02225834] | Phase 4 | 50 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome[NCT01354808] | Phase 4 | 220 participants (Anticipated) | Interventional | 2010-07-31 | Completed | ||
| Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.[NCT02158468] | 600 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction[NCT00507156] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| [NCT03018873] | 400 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | |||
| Cardiopulmonary Protection of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery[NCT03010839] | 86 participants (Actual) | Interventional | 2016-11-05 | Completed | |||
| The Effect of Remote Preconditioning in Primary Percutaneous Intervention of Acute ST Elevation Myocardial Infarction[NCT00435266] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| Evaluation of Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty[NCT02313961] | 516 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial[NCT02548377] | 60 participants (Actual) | Interventional | 2015-09-29 | Completed | |||
| [NCT02843464] | 220 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | |||
| The Effect of Remote Ischemic Conditioning on the Metabolomic Profile of NSTEMI Patients[NCT03097419] | 300 participants (Anticipated) | Interventional | 2012-11-28 | Active, not recruiting | |||
| A Single Centre Double-blinded Randomized Placebo Controlled Pilot Study Investigating the Effect of Remote Ischaemic preConditioning in ONCology Patients Undergoing Chemotherapy (ERIC-ONC)[NCT02471885] | 128 participants (Anticipated) | Interventional | 2015-12-16 | Recruiting | |||
| Effects of Remote Limb Ischemic Conditioning to Enhance Muscle Power, Dynamic Balance, and Walking Performance in Children With Cerebral Palsy[NCT04598711] | 24 participants (Actual) | Interventional | 2021-06-15 | Completed | |||
| The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events[NCT05733208] | 766 participants (Anticipated) | Interventional | 2023-05-06 | Recruiting | |||
| COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial[NCT02404376] | Phase 3 | 378 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Remote Ischemic Conditioning as a Treatment for Traumatic Brain Injury: a Prospective Randomized Controlled Trial.[NCT03176823] | 40 participants (Anticipated) | Interventional | 2019-05-03 | Recruiting | |||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993] | Phase 3 | 336 participants (Actual) | Interventional | 2017-03-18 | Completed | ||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910] | Phase 3 | 392 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion[NCT00794014] | 258 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241] | Phase 3 | 280 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
| Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-04-01 | Not yet recruiting | ||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study[NCT02597205] | Early Phase 1 | 190 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850] | 1,312 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)[NCT03328845] | Phase 4 | 300 participants (Actual) | Interventional | 2017-01-20 | Completed | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?[NCT01383304] | 906 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| Study of Adherence to Antihypertensive Drugs and Statins in the Population of Subjects With Hypertension Followed at SIIA Centers, Using an Innovative Monitoring Based on Hair Analysis[NCT05347823] | 200 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| A Prospective, Multicenter, Blinded, Randomized, Noninferiority Clinical Trial of Coronary Angiography Fractional Flow Reserve (caFFR) Versus Fractional Flow Reserve (FFR) to Guide Percutaneous Coronary Intervention（Flash FFR Ⅱ ）[NCT04575207] | 2,132 participants (Anticipated) | Interventional | 2021-01-12 | Recruiting | |||
| The Impact of Coronary Revascularization on Absolute Myocardial Blood Flow as Assessed by Stress Myocardial Positron Tomography[NCT02931331] | 50 participants (Anticipated) | Observational [Patient Registry] | 2016-03-31 | Enrolling by invitation | |||
| FLOW 3 - The Association Between Catheter-based Absolute Coronary Flow and Resistance and 15O-H2O Positron Emission Tomography Scan-based Absolute Myocardial Blood Flow in the Coronary Artery Territory.[NCT04973410] | 40 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | |||
| Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI (REFINE PCI)[NCT05491668] | 107 participants (Anticipated) | Observational | 2022-10-11 | Recruiting | |||
| Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease[NCT01132495] | 1,170 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.[NCT02892903] | 1,100 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | |||
| RELATionship bEtween Lesion-level Invasive Fractional Flow Reserve AND Endothelial Wall Shear Stress the RELATE FFR and WSS Study[NCT04048005] | 200 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)[NCT03656848] | 3,847 participants (Actual) | Interventional | 2018-12-25 | Active, not recruiting | |||
| Assessment of NOn-culprit Lesions With dobutamiNe Stress eChocardiography, compUted Tomography and Fractional fLow Reserve in Patients With Acute[NCT03988881] | 100 participants (Anticipated) | Observational | 2017-03-30 | Recruiting | |||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| Prognostic Impact of Fractional Flow Reserve in Chronic Coronary Syndrome: Quasi-Experimental Findings Using a Regression Discontinuity Design[NCT05592535] | 5,000 participants (Actual) | Observational | 2015-06-01 | Completed | |||
| Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive Cardiolens FFR-CT Pro Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities. A Multicentre[NCT04777513] | 450 participants (Anticipated) | Observational [Patient Registry] | 2020-08-06 | Recruiting | |||
| Comparison of Dobutamine Stress Echocardiography and Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease: Stable and Non-culprit Lesions Investigation[NCT03383718] | 200 participants (Actual) | Observational | 2014-12-01 | Completed | |||
| A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI.[NCT01764334] | Phase 4 | 350 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | ||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131] | Phase 4 | 1,856 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147] | 400 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| Mechanism Based Resistance to Aspirin[NCT00948987] | Phase 1 | 400 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance[NCT00023374] | 98 participants (Actual) | Interventional | 2000-08-31 | Completed | |||
| Platelet Inhibition in the Acute Phase of ST-segment Elevation Myocardial Infarction[NCT01144819] | 46 participants (Actual) | Observational | 2009-10-31 | Completed | |||
| Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966] | Phase 3 | 3,602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)[NCT01739556] | Phase 3 | 242 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to An interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined.) | ||
| Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease[NCT01254981] | Phase 4 | 2,504 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study[NCT01233453] | Phase 4 | 2,700 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| [NCT00005196] | 0 participants | Observational | 1986-12-31 | Completed | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)[NCT01218178] | 520 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| In-hospital Versus After-discharge Complete Revascularization in STEMI Patients With Multivessel Disease.[NCT04743154] | 250 participants (Actual) | Interventional | 2018-01-20 | Completed | |||
| Prognostic Models for People With Stable Coronary Artery Disease[NCT01609465] | 300,000 participants (Anticipated) | Observational | 2010-01-31 | Active, not recruiting | |||
| Southwest German Interventional Study in Acute Myocardial Infarction III[NCT01124890] | Phase 4 | 197 participants (Actual) | Interventional | 1998-07-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery[NCT02410473] | 200 participants (Actual) | Observational | 2015-04-30 | Active, not recruiting | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Coronary Disease Morbidity and Mortality in a Population[NCT00005502] | 5,476 participants (Actual) | Observational | 2002-10-31 | Completed | |||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain[NCT00869245] | 124 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| Randomized Investigation of Chest Pain Diagnostic Strategies[NCT01035047] | 105 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain[NCT00678639] | 110 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy[NCT00714961] | Phase 3 | 3,491 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study[NCT01111071] | 316,648 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| The Role of Routine Placement of Nasogastric Tube in Patients With Suspected Upper Gastrointestinal Hemorrhage[NCT00689754] | 282 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients[NCT00651521] | 1,000 participants (Actual) | Observational | 2009-04-30 | Active, not recruiting | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Clopidogrel Or Metoprolol in Myocardial Infarction Trial[NCT00222573] | Phase 4 | 46,000 participants | Interventional | 1999-07-31 | Completed | ||
| Warfarin After Anterior ST-Elevation Myocardial Infarction[NCT00662467] | 20 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Finnish-German Prospective, Observational Follow-up Study on Risk Assessment of Mortality After Myocardial Infarction[NCT00828698] | 0 participants | Observational | 1996-01-31 | Completed | |||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study[NCT00121446] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Adherence, Pharmacists and Secondary Prevention in Acute Myocardial Infarction: A Pilot Controlled Clinical Trial on the Role of Community Pharmacist in Monitoring Medication Adherence and Improving Clinical Outcomes in Post-infarction[NCT03621111] | 120 participants (Anticipated) | Interventional | 2018-02-19 | Recruiting | |||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Behavioral Economics-Based Telehealth Intervention to Improve Post-MI Medication Adherence[NCT03022266] | 130 participants (Actual) | Interventional | 2017-02-01 | Completed | |||
| Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931] | 9,501 participants (Actual) | Interventional | 2019-07-01 | Active, not recruiting | |||
| Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563] | 208 participants (Anticipated) | Observational [Patient Registry] | 2023-01-17 | Recruiting | |||
| ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial[NCT00161070] | Phase 4 | 4,500 participants | Interventional | 1997-07-31 | Completed | ||
| Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852] | 312 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
| Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Phase III Clinical Trial of the Effectiveness of Adherence Data and Motivational Interviewing to Improve Medication Adherence and Both Glycated Hemoglobin and Cholesterol Control[NCT00754741] | Phase 3 | 1,692 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy[NCT00603590] | Phase 2 | 475 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [NCT00000491] | Phase 3 | 0 participants | Interventional | 1974-10-31 | Completed | ||
| Gender Differences in Prevention Strategies and Therapeutic Adherence After Acute Myocardial Infarction - GENAMI PREVENTION[NCT05619601] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2023-03-08 | Recruiting | |||
| [NCT00005243] | 0 participants | Observational | 1989-04-30 | Completed | |||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| [NCT00000490] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233] | 400 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction[NCT05892042] | 320 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency[NCT00136032] | 63 participants (Actual) | Interventional | 2002-01-31 | Completed | |||
| A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation[NCT02666508] | 61 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Correlation Between Oral Health and Systemic Inflammation (COHESION)[NCT03641989] | 112 participants (Actual) | Interventional | 2018-09-17 | Completed | |||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| [NCT00005496] | 0 participants | Observational | 1998-09-30 | Completed | |||
| Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.[NCT00399646] | Phase 2 | 145 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises[NCT02698761] | 3 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Standard of care changed) | |||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.[NCT01895751] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial[NCT00245648] | Phase 3 | 0 participants | Interventional | 2001-06-30 | Completed | ||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study[NCT04471597] | 48 participants (Actual) | Interventional | 2020-07-20 | Completed | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University[NCT03266328] | 117 participants (Anticipated) | Observational | 2017-09-01 | Not yet recruiting | |||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice[NCT00761969] | 1,455 participants (Actual) | Observational | 2004-12-31 | Completed | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| [NCT00000482] | Phase 3 | 0 participants | Interventional | 1965-04-30 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [NCT00000505] | Phase 3 | 0 participants | Interventional | 1983-04-30 | Completed | ||
| Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting[NCT01360242] | Phase 3 | 160 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Effect of High Omega-3 Fish Intake on Lipid Peroxidation[NCT01183520] | 30 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| [NCT00000483] | 0 participants | Interventional | 1981-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
(NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 10 |
| Asundexian 20 mg | 7 |
| Asundexian 50 mg | 10 |
| Placebo | 7 |
"CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.~Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.~ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 27 |
| Asundexian 20 mg | 24 |
| Asundexian 50 mg | 22 |
| Placebo | 22 |
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 7 |
| Asundexian 20 mg | 4 |
| Asundexian 50 mg | 5 |
| Placebo | 2 |
Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 18 |
| Asundexian 20 mg | 20 |
| Asundexian 50 mg | 18 |
| Placebo | 17 |
"ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 5 |
| Asundexian 50 mg | 4 |
| Placebo | 4 |
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 0 |
| Placebo | 2 |
All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 30 |
| Asundexian 20 mg | 32 |
| Asundexian 50 mg | 42 |
| Placebo | 36 |
| Pooled Asundexian | 104 |
Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 5 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 3 |
| Placebo | 5 |
This measure represents the estimated cumulative probability of experiencing Death from any cause or Myocardial Infarction within the indicated timeframe in each treatment group. The interpretation of the measure is similar to Kaplan-Meier event rates. Estimates are expressed as percentages ranging from 0% (endpoint is certain not to occur) to 100% (endpoint is certain to occur). (NCT01985360)
Timeframe: 3 years
| Intervention | cumulative event rate - % (Number) |
|---|---|
| Invasive Strategy | 36.4 |
| Conservative Strategy | 36.7 |
(NCT01985360)
Timeframe: 2.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Invasive Strategy | 123 |
| Conservative Strategy | 129 |
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 579 |
| Ticagrelor Placebo | 592 |
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 736 |
| Ticagrelor Placebo | 818 |
Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 364 |
| Ticagrelor Placebo | 357 |
Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 152 |
| Ticagrelor Placebo | 191 |
Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 274 |
| Ticagrelor Placebo | 328 |
Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 466 |
| Ticagrelor Placebo | 125 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 310 |
| Ticagrelor Placebo | 145 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 206 |
| Ticagrelor Placebo | 100 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 285 |
| Ticagrelor Placebo | 129 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 315 |
| ASA 325mg | 357 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 590 |
| ASA 325mg | 569 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 53 |
| ASA 325mg | 44 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 228 |
| ASA 325mg | 213 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 102 |
| ASA 325mg | 92 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 471 |
| ASA 325mg | 446 |
Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure. (NCT02697916)
Timeframe: 2 years
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Describe Current Health | Able to Run Errands and Shop | In the past 7 Days, Felt Depressed | In the past 7 Days, Felt Fatigued | In the past 7 Days, Problems with Sleep | Trouble doing Regular Activities | In the past 7 Days, Pain interfered | |
| ASA 325mg | 2.8 | 1.66 | 1.7 | 2.27 | 2.10 | 1.88 | 2.02 |
| ASA 81mg | 2.77 | 1.65 | 1.69 | 2.25 | 2.06 | 1.84 | 2.06 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
number of participants with the occurrence of a bleeding event leading the participant to seek medical attention (NCT02505217)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 6 |
| Low FcγRIIa Expression | 6 |
number of participants with myocardial infarction, stroke, and/or death (NCT02505217)
Timeframe: average duration of follow-up 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 17 |
| Low FcγRIIa Expression | 6 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 43 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 13 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 30 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 27 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 6 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 9 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 5 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 45 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 121 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 55 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 42 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 44 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 61 | 27 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 19 | 7 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 44 | 20 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2 | 5 | 10 | 15 | 40 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 54 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 48 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 26 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 67 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding or autopsy or imaging confirmation" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 66 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI: CK-MB > URL or Troponin > URL with baseline value < UR~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.4 | 6.7 | 4.0 | 3.6 | 5.8 | 6.9 |
"Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: ICH; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood or packed RBC within 48h;Chest tube output ≥ 2L within 24h~Type 5: Fatal bleeding~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.1 | 3.9 | 2.7 | 5.4 | 6.0 | 7.7 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 64 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 40 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 24 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 8 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 15 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 14 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 103 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 46 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 57 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 68 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 49 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 69 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 34 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 77 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 38 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 39 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.5 | 4.3 | 4.1 | 2.6 | 2.7 | 3.9 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 6.7 | 4.3 | 6.7 | 6.0 | 7.9 | 8.4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.2 | 0.0 | 2.7 | 3.4 | 5.5 | 4.4 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 7.1 | 6.5 | 6.8 | 5.4 | 6.8 | 10.1 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2.5 | 2.2 | 1.4 | 3.1 | 2.0 | 3.7 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 4.9 | 4.3 | 5.5 | 2.3 | 5.2 | 7.0 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
Primary outcome variable(s): 1- year survival probability rate for vascular inpatient readmission or death (NCT01800201)
Timeframe: Date of enrollment + 12 months
| Intervention | proportion of participants (Number) |
|---|---|
| Control | .91 |
| Intervention | .91 |
1 year survival probability rate for all cause readmissions (NCT01800201)
Timeframe: Date of enrollment + 12 months
| Intervention | proportion of participants (Number) |
|---|---|
| Control | .65 |
| Intervention | .69 |
"Calculated by the proportion of days in which a patient has an active medication for all three medications (statin, beta blocker and antiplatelet). It is not the weighted average of the individual medication. This reflects the intermediate definition of adherence: our intermediate definition assumed that patients had been prescribed a medication for the entire study period if they ever filled that medication after discharge" (NCT01800201)
Timeframe: 12 months
| Intervention | PDC, mean (Mean) |
|---|---|
| Control | .58 |
| Intervention | .61 |
This is the number of vascular inpatient admission events control vs. intervention (NCT01800201)
Timeframe: Date of enrollment + 12 months
| Intervention | readmissions (Number) |
|---|---|
| Control | 62 |
| Intervention | 119 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
(NCT01082874)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Active Clonidine and Active ASA | 173 |
| Active Clonidine and Placebo ASA | 194 |
| Placebo Clonidine and Active ASA | 178 |
| Placebo Clonidine and Placebo ASA | 161 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 2356 |
| Warfarin | 3060 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 327 |
| Warfarin | 462 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 603 |
| Warfarin | 669 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 613 |
| Warfarin | 877 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 459 |
| Warfarin | 608 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 229 |
| Warfarin | 285 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.52 |
| Warfarin | 3.94 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 2.13 |
| Warfarin | 3.09 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 1.27 |
| Warfarin | 1.60 |
"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 18.08 |
| Warfarin | 25.82 |
(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.21 |
| Warfarin | 4.06 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events / 100 patient years (Number) |
|---|---|
| Apixaban | 4.07 |
| Warfarin | 6.01 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.01 |
| Warfarin | 4.09 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE | Discontinuations due to AE | Deaths | |
| Apixaban | 7406 | 3182 | 2288 | 688 | 429 |
| Warfarin | 7521 | 3302 | 2961 | 758 | 468 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) | ||
|---|---|---|---|
| Ischemic or Unspecified Stroke | Hemorrhagic Stroke | Systemic Embolism | |
| Apixaban | 159 | 38 | 15 |
| Warfarin | 173 | 76 | 16 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Severe (n=80, 172)) | Severe or Moderate (n=199, 328) | |
| Apixaban | 0.52 | 1.29 |
| Warfarin | 1.13 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Major (n=148, 256) | Major or Minor (n=239, 370) | |
| Apixaban | 0.96 | 1.55 |
| Warfarin | 1.69 | 2.46 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||
|---|---|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | Hemorrhagic Stroke (n=40, 78) | Systemic Embolism (n=15, 17) | Myocardial Infarction (n=90, 102) | |
| Apixaban | 0.97 | 0.24 | 0.09 | 0.53 |
| Warfarin | 1.05 | 0.47 | 0.10 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | Stroke / SE / All-Cause Death (ACD) (n=752, 837) | Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | Stroke / SE / MI / ACD (n=810, 906) | Ischemic or Unspecified Stroke / ACD (n=725, 796) | Hemorrhagic Stroke / ACD (n=622, 703) | SE / ACD (n=613, 679) | MI / ACD (n=663, 740) | |
| Apixaban | 3.17 | 4.49 | 6.13 | 4.85 | 4.32 | 3.68 | 3.63 | 3.93 |
| Warfarin | 4.11 | 5.04 | 7.20 | 5.49 | 4.78 | 4.20 | 4.05 | 4.43 |
Combination of CV death, MI, and stroke (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 85 |
SAEs except the blending events which have aleady been reported as SAEs. (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 116 |
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Fatal/life threatening | Major | Major + minor | Major + minor + minimal | |
| Ticargrelor | 17 | 27 | 93 | 426 |
(NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| all-cause mortality | all cancers excluding non-melanoma skin cancer | colon cancer | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 2.55 | 4.02 | 0.48 |
| Placebo | 2.57 | 3.76 | 0.41 |
*all other CV death without fatal MI and fatal stroke. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| MI, stroke, CV death, UA or TIA | MI, stroke or CV death | MI | Non-fatal MI | Stroke | CV death* | UA | TIA | All-cause mortality | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol | 3.40 | 2.72 | 0.98 | 0.84 | 1.06 | 0.69 | 0.21 | 0.50 | 2.85 |
| Placebo Per-protocol | 4.19 | 3.45 | 1.84 | 1.53 | 0.95 | 0.66 | 0.28 | 0.49 | 2.58 |
(NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| MI, stroke, CV death, UA or TIA | MI, stroke or CV death | non-fatal MI | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 4.29 | 3.32 | 1.40 |
| Placebo | 4.48 | 3.47 | 1.56 |
The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. *all other CV death without fatal MI and fatal stroke (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| MI | stroke | CV death* | UA | TIA | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 1.52 | 1.20 | 0.61 | 0.32 | 0.67 |
| Placebo | 1.78 | 1.07 | 0.62 | 0.32 | 0.72 |
(NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Total | Mild | Moderate | Severe | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 61 | 42 | 15 | 4 |
| Placebo | 29 | 22 | 5 | 2 |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Days (Count of Units) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days until 1% subjects had all-cause mortality | Days until 2% subjects had all-cause mortality | Days until 3% subjects had all-cause mortality | Days until 4% subjects had all-cause mortality | Days until 1% subjects had all cancer excl. NMSC | Days until 2% subjects had all cancer excl. NMSC | Days until 3% subjects had all cancer excl. NMSC | Days until 4% subjects had all cancer excl. NMSC | Days until 1% subjects had colon cancer | Days until 2% subjects had colon cancer | Days until 3% subjects had colon cancer | Days until 4% subjects had colon cancer | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 838 | 1493 | 1970 | NA | 374 | 849 | 1164 | 1542 | NA | NA | NA | NA |
| Placebo | 938 | 1460 | 1963 | NA | 420 | 805 | 1276 | 1751 | NA | NA | NA | NA |
The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Days (Count of Units) | |||
|---|---|---|---|---|
| Days until 1% subjects had an efficacy event | Days until 2% subjects had an efficacy event | Days until 3% subjects had an efficacy event | Days until 4% subjects had an efficacy event | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 678 | 1167 | 1599 | 1949 |
| Placebo | 522 | 1053 | 1501 | 1930 |
The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Days (Count of Units) | |||
|---|---|---|---|---|
| Days until 1% subjects had an efficacy event | Days until 2% subjects had an efficacy event | Days until 3% subjects had an efficacy event | Days until 4% subjects had an efficacy event | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 528 | 889 | 1225 | 1630 |
| Placebo | 381 | 796 | 1134 | 1582 |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Days (Count of Units) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days until 1% subjects had non-fatal MI | Days until 2% subjects had non-fatal MI | Days until 1% subjects had total MI | Days until 2% subjects had total MI | Days until 1% subjects had non-fatal stroke | Days until 2% subjects had non-fatal stroke | Days until 1% subjects had total stroke | Days until 2% subjects had total stroke | Days until 1% subjects had cardiovascular death | Days until 2% subjects had cardiovascular death | Days until 1% subjects had UA | Days until 2% subjects had UA | Days until 1% subjects had TIA | Days until 2% subjects had TIA | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 1309 | NA | 1216 | 2128 | 1576 | NA | 1543 | NA | NA | NA | NA | NA | NA | NA |
| Placebo | 1085 | 2121 | 1014 | 1906 | 1650 | NA | 1627 | NA | NA | NA | NA | NA | NA | NA |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 16.33 |
| Apixaban 5 mg BID | 39.98 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 13.96 |
| Apixaban 5 mg BID | 13.20 |
"Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.~CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination)." (NCT00831441)
Timeframe: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 15.65 |
| Apixaban 5 mg BID | 15.48 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 14.27 |
| Apixaban 5 mg BID | 13.97 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 17.95 |
| Apixaban 5 mg BID | 16.92 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.29 |
| Apixaban 5 mg BID | 6.15 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.04 |
| Apixaban 5 mg BID | 5.13 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 0.91 |
| Apixaban 5 mg BID | 2.40 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 9.20 |
| Apixaban 5 mg BID | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.21 |
| Apixaban 5 mg BID | 1.61 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 1.85 |
| Apixaban 5 mg BID | 1.65 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 4.21 |
| Apixaban 5 mg BID | 3.95 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
"The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.~The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles." (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Selatogrel 8 mg | 390.1 |
| Selatogrel 16 mg | 672.6 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 18 |
| Selatogrel 16 mg | 19 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 21 |
| Selatogrel 16 mg | 21 |
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | hours (Median) |
|---|---|
| Selatogrel 8 mg | 1.00 |
| Selatogrel 16 mg | 0.97 |
The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection
| Intervention | P2Y12 reaction units (PRU) (Median) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 181 | 9 | 9 | 7 |
| Selatogrel 8 mg | 194 | 51 | 59 | 9 |
The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU < 100, i.e., considering as a response a PRU < 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 0 | 21 | 21 | 22 |
| Selatogrel 8 mg | 1 | 18 | 21 | 18 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 8 mg | 3 | 18 | 14 | 7 | 5 | 8 | 8 | 8 | 13 | 21 | 14 | 7 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | Chronic kidney disease at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 16 mg | 4 | 17 | 17 | 4 | 8 | 9 | 4 | 5 | 16 | 3 | 18 | 11 | 10 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
Cardiac death or myocardial infarction in the TAXUS Liberte Post-Approval Study enrolled population. For pooled data from the TAXUS Liberté and TAXUS Express patient populations, please see the citations. (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Libertē Post-Approval Study Enrolled Population | 2.1 |
"Stent Thrombosis (protocol definition):~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 1-2 years
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Libertē: Overall Enrolled Population | 1.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.7 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.4 |
- Binary Rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.1 |
- Binary Rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.1 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.1 |
MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke. (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.1 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 7.8 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.7 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.9 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 7.3 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.3 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.9 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.1 |
"Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.6 |
"Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.0 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.0 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
"ARC - Academic Research Consortium~Binary Rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.8 |
"ARC - Academic Research Consortium~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.6 |
"-Binary rate~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
"-Binary rate~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.6 |
-Binary Rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.5 |
-Binary Rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.4 |
"Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 6.4 |
"Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.~Binary Rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.9 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 5.8 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.3 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.5 |
Target vessel failure (TVF) for TAXUS Libertē Post-Approval Study medically-treated diabetic population. For pooled data from the TAXUS Liberté population, please see the citations (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Medically Treated Diabetic Population | 6.1 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.8 |
| Thienopyridine Therapy | 2.0 |
| Surveillance Arm | 4.8 |
"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.0 |
| Thienopyridine Therapy | 0.5 |
| Surveillance Arm | 2.4 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 4.3 |
| Thienopyridine Therapy | 4.8 |
| Surveillance Arm | 16.9 |
Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU). (NCT02075125)
Timeframe: Baseline
| Intervention | PRU units (Median) |
|---|---|
| Prasugrel | 259 |
| Ticagrelor | 261 |
Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI). (NCT02075125)
Timeframe: Baseline
| Intervention | percentage (Median) |
|---|---|
| Prasugrel | 51.2 |
| Ticagrelor | 47.5 |
Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) >235 and platelet reactivity index (PRI) >50%. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU>235 | VASP-PRI>50% | |
| Prasugrel | 0 | 0 |
| Ticagrelor | 0 | 0 |
Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) <85 and platelet reactivity index (PRI)<16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU<85 | VASP-PRI<16% | |
| Prasugrel | 18 | 16 |
| Ticagrelor | 19 | 16 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 83 |
| Riva 5 mg Total Daily Dose (TDD) | 23 |
| Riva 10 mg TDD | 55 |
| Riva 15 mg TDD | 27 |
| Riva 20 mg TDD | 36 |
The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 63 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 21 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 88 |
| Riva 5 mg Total Daily Dose (TDD) | 24 |
| Riva 10 mg TDD | 71 |
| Riva 15 mg TDD | 35 |
| Riva 20 mg TDD | 48 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 66 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 22 |
The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 18 |
| Riva 5 mg Total Daily Dose (TDD) | 11 |
| Riva 10 mg TDD | 9 |
| Riva 15 mg TDD | 4 |
| Riva 20 mg TDD | 9 |
The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 36 |
| Riva 5 mg Total Daily Dose (TDD) | 17 |
| Riva 10 mg TDD | 109 |
| Riva 15 mg TDD | 43 |
| Riva 20 mg TDD | 89 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization. (NCT01132495)
Timeframe: 24 Month
| Intervention | percentage of subjects with SAEs (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Non Urgent Revascularization | Death or Myocardial Infarction | Myocardial Infarction | Unplanned Hospitalizations with urgent revasc | Death | Cerebrovascular Event | Other Serious Adverse Event (SAE) | |
| Cohort A - OMT Alone | 32.7 | 12.2 | 9.3 | 13.4 | 3.9 | 1.4 | 0.7 |
| Cohort A - PCI Plus OMT | 6.7 | 9.4 | 6.7 | 1.8 | 3.6 | 2.2 | 0.2 |
Individual components of the primary end point, cardiac death, and nonurgent revascularization (NCT01132495)
Timeframe: 3 years
| Intervention | percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Overall MACE | Death from any cause | Myocardial infarction | Urgent revascularization | Any revascularization | Nonurgent revascularization | Cardiac death | |
| Cohort A: OMT Alone | 22 | 3.6 | 7.7 | 17.2 | 44.2 | 30.2 | 1.1 |
| Cohort A: PCI Plus OMT | 10.1 | 2.7 | 6.3 | 4.3 | 10.3 | 6.3 | 1.1 |
| Cohort B: Registry Cohort | 12.7 | 3.0 | 6.6 | 6.6 | 14.5 | 9.0 | 1.8 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 379 |
| Pharmacology Arm - Unfractionated Heparin | 377 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 98 |
| Pharmacology Arm - Unfractionated Heparin | 99 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 166 |
| Pharmacology Arm - Unfractionated Heparin | 218 |
Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 89 |
| Pharmacology Arm - Unfractionated Heparin | 149 |
Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 181 |
| Stent Arm - Bare Metal Stent | 59 |
Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 98 |
| Stent Arm - Bare Metal Stent | 54 |
Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 102 |
| Stent Arm - Bare Metal Stent | 76 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
(NCT01035047)
Timeframe: Index Hospitalization discharge through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 0 |
| Inpatient Care | 3 |
(NCT01035047)
Timeframe: Duration of Index Hospitalization, an average of 1-2 days
| Intervention | hours (Median) |
|---|---|
| CDU-CMR Protocol | 21.1 |
| Inpatient Care | 26.3 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 0 |
| Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 1 |
| Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 7 |
| Inpatient Care | 20 |
Any event leading to early termination of the MRI acquisition, or requiring intervention by a physician, will be considered an adverse event related to MRI, excluding physician termination of image acquisition due to concerns of cardiac ischemia. (NCT00678639)
Timeframe: Occuring in the MRI scanning suite or within 30 minutes of the last image acquisition.
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 3 |
| Usual Care | 1 |
Participants with ACS and admitted or not experiencing ACS and discharged will be considered a correct admission decision. Remaining participants will be considered to have incorrect admission decisions. (NCT00678639)
Timeframe: 30 Days
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 43 |
| Usual Care | 6 |
Index hospitalization refers to the hospital visit during which the participant was enrolled in the trial. The primary outcome is examining the cost for this visit. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge, median length of stay was 28.1 hours
| Intervention | US Dollars (Median) |
|---|---|
| Emergency Department (ED) Observation Unit | 2062 |
| Usual Care | 2680 |
The number of participants able to complete the planned imaging sequences will be measured. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 46 |
Measured as self report, assessed during telephone follow-up. (NCT00678639)
Timeframe: 30d, 3mo, 6mo, and 1 year
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Cardiac related office visit | Cardiac related ED visit | Cardiac related hospitalization | Cardiac related procedures | Cardiac Catheterization | Stress Test | Resting Echocardiogram | |
| Emergency Department (ED) Observation Unit | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Usual Care | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
| NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
| Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 12 months post randomization represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.69 |
| Adherence Information Plus Motivational Interviewing | 0.69 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 18 months post randomization represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.70 |
| Adherence Information Plus Motivational Interviewing | 0.70 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 6 months post randomization represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.69 |
| Adherence Information Plus Motivational Interviewing | 0.69 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 12 months post randomization represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.74 |
| Adherence Information Plus Motivational Interviewing | 0.74 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 18 months post randomization represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.73 |
| Adherence Information Plus Motivational Interviewing | 0.73 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 6 months post randomization represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.74 |
| Adherence Information Plus Motivational Interviewing | 0.74 |
(NCT00754741)
Timeframe: at 24 months post randomization
| Intervention | participants (Number) |
|---|---|
| Usual Care | 63 |
| Adherence Information | 80 |
| Adherence Information Plus Motivational Interviewing | 58 |
(NCT00754741)
Timeframe: at 36 months post randomization
| Intervention | participants (Number) |
|---|---|
| Usual Care | 101 |
| Adherence Information | 112 |
| Adherence Information Plus Motivational Interviewing | 99 |
(NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.94 |
| Adherence Information | 7.96 |
| Adherence Information Plus Motivational Interviewing | 7.84 |
(NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.88 |
| Adherence Information | 7.91 |
| Adherence Information Plus Motivational Interviewing | 7.79 |
(NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.81 |
| Adherence Information | 7.90 |
| Adherence Information Plus Motivational Interviewing | 7.81 |
(NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 90.63 |
| Adherence Information | 90.70 |
| Adherence Information Plus Motivational Interviewing | 87.43 |
(NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 92.92 |
| Adherence Information | 92.07 |
| Adherence Information Plus Motivational Interviewing | 91.23 |
(NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 89.02 |
| Adherence Information | 87.27 |
| Adherence Information Plus Motivational Interviewing | 85.56 |
Mean of two seated diastolic blood pressures (NCT00603590)
Timeframe: One year
| Intervention | mm Hg (Mean) |
|---|---|
| Polypill | 77.6 |
| Control | 81.3 |
Serum LDL cholesterol (NCT00603590)
Timeframe: One year
| Intervention | mg/dL (Mean) |
|---|---|
| Polypill | 87.8 |
| Control | 112.0 |
Systolic blood pressure. Mean of two seated measurements. (NCT00603590)
Timeframe: One year
| Intervention | mm Hg (Mean) |
|---|---|
| Polypill | 121.7 |
| Control | 129.7 |
"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline
| Intervention | log(mg/L) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | 0.04 |
| Non-plaque Identifying Toothpaste | 0.22 |
"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline. -PSS analysis" (NCT02666508)
Timeframe: Baseline to 30-60 days post
| Intervention | log(mg/L) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -0.40 |
| Non-plaque Identifying Toothpaste | 0.14 |
"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline
| Intervention | log(percentage) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -1.05 |
| Non-plaque Identifying Toothpaste | -0.03 |
"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline for the Pre-Specified Subgroup (PSS)." (NCT02666508)
Timeframe: Baseline to 30-60 days post
| Intervention | log(percentage) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -1.05 |
| Non-plaque Identifying Toothpaste | -0.10 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia. (NCT00761969)
Timeframe: 5 years:
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Death of all causes | Cardiovascular death | Non-fatal myocardial infarction | Non-fatal ischemic stroke | Critical limb ischemia | |
| Control | 47 | 17 | 21 | 14 | 0 |
| Peripheral Arterial Disease | 112 | 51 | 50 | 22 | 11 |
Incidence of coronary, carotid and peripheral arterial revascularization procedures (NCT00761969)
Timeframe: 5 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Peripheral arterial revascularization | Coronary revascularization | carotid revascularization | Abdominal aortic revascularization | |
| Control | 2 | 20 | 8 | 0 |
| Peripheral Arterial Disease | 183 | 64 | 31 | 6 |
701 reviews available for aspirin and Myocardial Infarction
| Article | Year |
|---|---|
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di | 2023 |
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di | 2023 |
Aspirin in the Modern Era of Cardiovascular Disease Prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2021 |
Aspirin in the Modern Era of Cardiovascular Disease Prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2021 |
Meta-Regression Analysis of the Impact of Medical Therapy on Long-Term Mortality in Type 2 Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Dual Anti-Platelet Therapy; Humans; Hydroxymethylglutaryl-CoA | 2022 |
Meta-Regression Analysis of the Impact of Medical Therapy on Long-Term Mortality in Type 2 Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Dual Anti-Platelet Therapy; Humans; Hydroxymethylglutaryl-CoA | 2022 |
Evidence base for the management of women with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ma | 2022 |
Evidence base for the management of women with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ma | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarctio | 2023 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarctio | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; P | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; P | 2023 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Hemorrhage; Humans; Intr | 2022 |
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Hemorrhage; Humans; Intr | 2022 |
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Percut | 2022 |
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Percut | 2022 |
P2Y12 Inhibitors Monotherapy in Patients Undergoing Complex vs Non-Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
P2Y12 Inhibitors Monotherapy in Patients Undergoing Complex vs Non-Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Agg | 2023 |
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Agg | 2023 |
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim | 2023 |
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Inf | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Inf | 2023 |
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Hemorrhage; Huma | 2023 |
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Hemorrhage; Huma | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
P2Y
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary I | 2023 |
P2Y
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary I | 2023 |
Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2023 |
Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2023 |
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial | 2023 |
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial | 2023 |
Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cytokines; Humans; | 2023 |
Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cytokines; Humans; | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; H | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; H | 2023 |
A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury.
Topics: Acute Kidney Injury; Aspirin; Cause of Death; Coma; Coronary Artery Bypass; Heart Arrest; Heart Bloc | 2019 |
A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury.
Topics: Acute Kidney Injury; Aspirin; Cause of Death; Coma; Coronary Artery Bypass; Heart Arrest; Heart Bloc | 2019 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA | 2019 |
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA | 2019 |
Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2020 |
Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2020 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Percut | 2021 |
Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Percut | 2021 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage | 2020 |
Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Aspirin; Cause of Death; Heart Diseases; Humans; Myocardial Infarction; Outcome Assessment, Health C | 2020 |
Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Aspirin; Cause of Death; Heart Diseases; Humans; Myocardial Infarction; Outcome Assessment, Health C | 2020 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Kawasaki disease: Shedding light on a mysterious diagnosis.
Topics: Aspirin; Autoimmunity; Child, Preschool; Coronary Aneurysm; Coronary Vessels; Female; Follow-Up Stud | 2020 |
Kawasaki disease: Shedding light on a mysterious diagnosis.
Topics: Aspirin; Autoimmunity; Child, Preschool; Coronary Aneurysm; Coronary Vessels; Female; Follow-Up Stud | 2020 |
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 2020 |
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 2020 |
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Humans; Incidence; Myocardial Infarction; Per | 2020 |
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Humans; Incidence; Myocardial Infarction; Per | 2020 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2020 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2020 |
Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Ischemic Stroke; M | 2020 |
Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Ischemic Stroke; M | 2020 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets.
Topics: Aspirin; Blood Platelets; COVID-19; COVID-19 Drug Treatment; Humans; Myocardial Infarction; SARS-CoV | 2021 |
Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets.
Topics: Aspirin; Blood Platelets; COVID-19; COVID-19 Drug Treatment; Humans; Myocardial Infarction; SARS-CoV | 2021 |
Contemporary Medical Management of Peripheral Artery Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr | 2021 |
Contemporary Medical Management of Peripheral Artery Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr | 2021 |
Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; | 2022 |
Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; | 2022 |
Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis.
Topics: Aspirin; Coronary Vasospasm; Humans; Myocardial Infarction; Prospective Studies; Retrospective Studi | 2021 |
Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis.
Topics: Aspirin; Coronary Vasospasm; Humans; Myocardial Infarction; Prospective Studies; Retrospective Studi | 2021 |
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.
Topics: Aged; Aspirin; Humans; Medicare; Myocardial Infarction; Observational Studies as Topic; Percutaneous | 2021 |
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.
Topics: Aged; Aspirin; Humans; Medicare; Myocardial Infarction; Observational Studies as Topic; Percutaneous | 2021 |
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials.
Topics: Aged; Aspirin; Bayes Theorem; Chi-Square Distribution; Coronary Disease; Coronary Thrombosis; Drug A | 2017 |
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials.
Topics: Aged; Aspirin; Bayes Theorem; Chi-Square Distribution; Coronary Disease; Coronary Thrombosis; Drug A | 2017 |
Aspirin for Primary Prevention.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest | 2017 |
Aspirin for Primary Prevention.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest | 2017 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
Stopping versus continuing acetylsalicylic acid before coronary artery bypass surgery: A systematic review and meta-analysis of 14 randomized controlled trials with 4499 patients.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Postoperative Hemorrhage; Randomized | 2017 |
Stopping versus continuing acetylsalicylic acid before coronary artery bypass surgery: A systematic review and meta-analysis of 14 randomized controlled trials with 4499 patients.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Postoperative Hemorrhage; Randomized | 2017 |
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Mortality; Myocardi | 2017 |
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Mortality; Myocardi | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; He | 2018 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; He | 2018 |
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; England; Humans; Models, Economic; Myocar | 2018 |
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; England; Humans; Models, Economic; Myocar | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse | 2018 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Use of online promotion to encourage patient awareness of aspirin use to prevent heart attack and stroke.
Topics: Aspirin; Health Knowledge, Attitudes, Practice; Health Promotion; Humans; Myocardial Infarction; Sea | 2018 |
Use of online promotion to encourage patient awareness of aspirin use to prevent heart attack and stroke.
Topics: Aspirin; Health Knowledge, Attitudes, Practice; Health Promotion; Humans; Myocardial Infarction; Sea | 2018 |
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Topics: Acute Coronary Syndrome; Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Ther | 2018 |
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Topics: Acute Coronary Syndrome; Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Ther | 2018 |
Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review.
Topics: Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention | 2019 |
Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review.
Topics: Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention | 2019 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Kounis syndrome induced by oral intake of aspirin: case report and literature review.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Kounis Syndrome; Mast Cells; Middle Aged; My | 2018 |
Kounis syndrome induced by oral intake of aspirin: case report and literature review.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Kounis Syndrome; Mast Cells; Middle Aged; My | 2018 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl | 2013 |
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl | 2013 |
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi | 2013 |
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
Aspirin allergy in patients with myocardial infarction: the allergist's role.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Immun | 2014 |
Aspirin allergy in patients with myocardial infarction: the allergist's role.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Immun | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
[Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Administration, Oral; Aspirin; Coronary Angiography; Hemorrhage; Humans; Myocardial Infarction; Perc | 2014 |
[Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Administration, Oral; Aspirin; Coronary Angiography; Hemorrhage; Humans; Myocardial Infarction; Perc | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2014 |
Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Coronary Thrombosis; Drug Administratio | 2015 |
Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Coronary Thrombosis; Drug Administratio | 2015 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2014 |
Current developments in dual antiplatelet therapy after stenting.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Percutaneous | 2014 |
Current developments in dual antiplatelet therapy after stenting.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Percutaneous | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Estimates of benefits and harms of prophylactic use of aspirin in the general population.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Male; | 2015 |
Estimates of benefits and harms of prophylactic use of aspirin in the general population.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Male; | 2015 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi | 2014 |
Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mainte | 2015 |
Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mainte | 2015 |
Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardi | 2015 |
Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardi | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Review of acute coronary syndromes: diagnosis and management of unstable angina and non ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzym | 2015 |
Review of acute coronary syndromes: diagnosis and management of unstable angina and non ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzym | 2015 |
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
Topics: Aspirin; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Drug Ther | 2015 |
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
Topics: Aspirin; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Drug Ther | 2015 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2015 |
Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
Topics: Aspirin; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting | 2015 |
Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
Topics: Aspirin; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting | 2015 |
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.
Topics: Acute Coronary Syndrome; Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrinolytic Age | 2015 |
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.
Topics: Acute Coronary Syndrome; Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrinolytic Age | 2015 |
Aspirin and coronary artery surgery: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac S | 2015 |
Aspirin and coronary artery surgery: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac S | 2015 |
Role of aspirin for prevention and treatment of perioperative cardiovascular events.
Topics: Animals; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Hemorrhage; Humans; Myocardia | 2015 |
Role of aspirin for prevention and treatment of perioperative cardiovascular events.
Topics: Animals; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Hemorrhage; Humans; Myocardia | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl | 2015 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazol | 2015 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazol | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials.
Topics: Aspirin; Clinical Trials as Topic; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoc | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials.
Topics: Aspirin; Clinical Trials as Topic; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoc | 2015 |
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomedical Research; | 2015 |
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomedical Research; | 2015 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction?
Topics: Acute Coronary Syndrome; Aspirin; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Hu | 2015 |
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction?
Topics: Acute Coronary Syndrome; Aspirin; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Hu | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review.
Topics: Aged; Aspirin; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Ste | 2015 |
Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review.
Topics: Aged; Aspirin; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Ste | 2015 |
[Acetylsalicylic acid for the prevention of primary myocardial infarction and ischemic stroke].
Topics: Aspirin; Chemoprevention; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
[Acetylsalicylic acid for the prevention of primary myocardial infarction and ischemic stroke].
Topics: Aspirin; Chemoprevention; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C | 2016 |
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C | 2016 |
Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Cardiomyopathies; Evidence-Based M | 2017 |
Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Cardiomyopathies; Evidence-Based M | 2017 |
Aspirin and coronary artery surgery: an updated meta-analysis.
Topics: Aspirin; Coronary Vessels; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postopera | 2016 |
Aspirin and coronary artery surgery: an updated meta-analysis.
Topics: Aspirin; Coronary Vessels; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postopera | 2016 |
Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.
Topics: Aspirin; Austria; Drug Administration Schedule; Evidence-Based Medicine; Humans; Myocardial Infarcti | 2016 |
Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.
Topics: Aspirin; Austria; Drug Administration Schedule; Evidence-Based Medicine; Humans; Myocardial Infarcti | 2016 |
Aspirin use for primary prevention in elderly patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregat | 2016 |
Aspirin use for primary prevention in elderly patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregat | 2016 |
Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
Topics: Aged; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2017 |
Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
Topics: Aged; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2017 |
Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Chi-Square Distribution; Coronary Art | 2017 |
Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Chi-Square Distribution; Coronary Art | 2017 |
What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting?
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardia | 2017 |
What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting?
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardia | 2017 |
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.
Topics: Aspirin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Hemorrhage; Humans; Myoca | 2016 |
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.
Topics: Aspirin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Hemorrhage; Humans; Myoca | 2016 |
[Practical management of troponin screening after non-cardiac surgery].
Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Inf | 2017 |
[Practical management of troponin screening after non-cardiac surgery].
Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Inf | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial | 2017 |
Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Acute and long-term antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Plate | 2008 |
Acute and long-term antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Plate | 2008 |
Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008.
Topics: Aspirin; Awards and Prizes; Biomedical Research; CADASIL; Cardiovascular Agents; Cardiovascular Dise | 2008 |
Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008.
Topics: Aspirin; Awards and Prizes; Biomedical Research; CADASIL; Cardiovascular Agents; Cardiovascular Dise | 2008 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardia | 2008 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardia | 2008 |
[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelet Disorders; Blood Platelets; Coronar | 2008 |
[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelet Disorders; Blood Platelets; Coronar | 2008 |
[Anticoagulant and thrombolytic agents in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight | 2008 |
[Anticoagulant and thrombolytic agents in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight | 2008 |
[Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinoly | 2009 |
[Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinoly | 2009 |
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet A | 2009 |
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet A | 2009 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2008 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2008 |
Acute coronary syndrome (unstable angina and non-ST elevation MI).
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Oral; Angina, Unstable; Aspirin; Calcium Cha | 2009 |
Acute coronary syndrome (unstable angina and non-ST elevation MI).
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Oral; Angina, Unstable; Aspirin; Calcium Cha | 2009 |
Bedside evaluation of thienopyridine antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Cl | 2009 |
Bedside evaluation of thienopyridine antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Cl | 2009 |
Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
Topics: Age Factors; Animals; Aspirin; Clinical Trials as Topic; Female; Gonadal Steroid Hormones; Humans; M | 2009 |
Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
Topics: Age Factors; Animals; Aspirin; Clinical Trials as Topic; Female; Gonadal Steroid Hormones; Humans; M | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia | 2009 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
[Takotsubo syndrome from original description up to now].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; A | 2009 |
[Takotsubo syndrome from original description up to now].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; A | 2009 |
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr | 2009 |
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr | 2009 |
[100 years of successful drug discovery. The history of aspirin].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Germany; History, 19th Century | 2009 |
[100 years of successful drug discovery. The history of aspirin].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Germany; History, 19th Century | 2009 |
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Sche | 2009 |
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Sche | 2009 |
Platelet-directed therapies and coronary artery bypass grafting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation In | 2009 |
Platelet-directed therapies and coronary artery bypass grafting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation In | 2009 |
Systolic heart failure: a prothrombotic state.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Systolic heart failure: a prothrombotic state.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; Humans; Hypert | 2009 |
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; Humans; Hypert | 2009 |
Clinical evidence for Japanese population based on prospective studies--linking clinical trials and clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Asian People; Aspirin; Atherosclerosis; Calcium Channel Blockers; | 2009 |
Clinical evidence for Japanese population based on prospective studies--linking clinical trials and clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Asian People; Aspirin; Atherosclerosis; Calcium Channel Blockers; | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Red | 2007 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Red | 2007 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Acute myocardial infarction in a patient with post-splenectomy thrombocytosis: a case report and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Male; Myocar | 2010 |
Acute myocardial infarction in a patient with post-splenectomy thrombocytosis: a case report and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Male; Myocar | 2010 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Adding clopidogrel to standard treatment for acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Emergency Service, Hospital; Evidence-Based Emergen | 2010 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Adding clopidogrel to standard treatment for acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Emergency Service, Hospital; Evidence-Based Emergen | 2010 |
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.
Topics: Aspirin; Atherosclerosis; Carotid Artery Diseases; Dose-Response Relationship, Drug; Endothelium, Va | 2010 |
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.
Topics: Aspirin; Atherosclerosis; Carotid Artery Diseases; Dose-Response Relationship, Drug; Endothelium, Va | 2010 |
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru | 2010 |
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru | 2010 |
[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].
Topics: Aspirin; Cerebral Hemorrhage; Germany; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregati | 2010 |
[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].
Topics: Aspirin; Cerebral Hemorrhage; Germany; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregati | 2010 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic | 2010 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic | 2010 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Hepa | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Hepa | 2010 |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Drug Resistance; Female; Gastrointes | 2010 |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Drug Resistance; Female; Gastrointes | 2010 |
[Thrombolysis during cardio-pulmonary resuscitation].
Topics: Aspirin; Cardiopulmonary Resuscitation; Contraindications; Death, Sudden, Cardiac; Fibrinolytic Agen | 2010 |
[Thrombolysis during cardio-pulmonary resuscitation].
Topics: Aspirin; Cardiopulmonary Resuscitation; Contraindications; Death, Sudden, Cardiac; Fibrinolytic Agen | 2010 |
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2010 |
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2010 |
Aspirin for the prevention of cardiovascular morbidity.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction | 2010 |
Aspirin for the prevention of cardiovascular morbidity.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrino | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrino | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Huma | 2010 |
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Huma | 2010 |
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pr | 2011 |
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pr | 2011 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial I | 2011 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial I | 2011 |
Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibi | 2011 |
Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibi | 2011 |
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cause of Death; Female; Gastrointestinal Hemorrhage; Hu | 2011 |
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cause of Death; Female; Gastrointestinal Hemorrhage; Hu | 2011 |
[Acute myocardial infarction: diagnosis and treatment].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Electrocardiography; Emer | 2011 |
[Acute myocardial infarction: diagnosis and treatment].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Electrocardiography; Emer | 2011 |
Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Community-Acquire | 2011 |
Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Community-Acquire | 2011 |
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus.
Topics: Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Vessels; Diabetic Angiopathies; Disease Prog | 2011 |
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus.
Topics: Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Vessels; Diabetic Angiopathies; Disease Prog | 2011 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension; | 2011 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension; | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2012 |
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
The aspirin controversy in primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Myocardial Infarction; | 2012 |
The aspirin controversy in primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Myocardial Infarction; | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Coronary Arte | 2012 |
Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Coronary Arte | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocard | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocard | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Antiplatelet agents in ischemic heart disease.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascular | 2012 |
Antiplatelet agents in ischemic heart disease.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascular | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2012 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2012 |
Long-term clinical experience with zofenopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aspirin; Captopril; Coro | 2012 |
Long-term clinical experience with zofenopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aspirin; Captopril; Coro | 2012 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc | 2012 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc | 2012 |
Controversies in the use & implementation of drug-eluting stent technology.
Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa | 2012 |
Controversies in the use & implementation of drug-eluting stent technology.
Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa | 2012 |
Potential cardioprotective actions of no-releasing aspirin.
Topics: Animals; Apoptosis; Arteriosclerosis; Aspirin; Caspase Inhibitors; Cell Adhesion; Cyclic GMP; Cytoki | 2002 |
Potential cardioprotective actions of no-releasing aspirin.
Topics: Animals; Apoptosis; Arteriosclerosis; Aspirin; Caspase Inhibitors; Cell Adhesion; Cyclic GMP; Cytoki | 2002 |
Classic Q wave myocardial infarction. Aggressive, early intervention has dramatic results.
Topics: Adrenergic beta-Antagonists; Analgesics; Aspirin; Biomarkers; Calcium Channel Blockers; Electrocardi | 2002 |
Classic Q wave myocardial infarction. Aggressive, early intervention has dramatic results.
Topics: Adrenergic beta-Antagonists; Analgesics; Aspirin; Biomarkers; Calcium Channel Blockers; Electrocardi | 2002 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug | 2002 |
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug | 2002 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H | 2002 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H | 2002 |
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; My | 2002 |
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; My | 2002 |
Spontaneous multivessel coronary artery dissection in a long-distance runner successfully treated with oral antiplatelet therapy.
Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Exercise; Female; Humans; Myocard | 2002 |
Spontaneous multivessel coronary artery dissection in a long-distance runner successfully treated with oral antiplatelet therapy.
Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Exercise; Female; Humans; Myocard | 2002 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2002 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2002 |
[Coronary thrombolysis with urokinase and t-PA--comparison of intracoronary thrombolysis and intravenous coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Vessels; Drug Therapy, Combination; Hemorrhage; Heparin; Humans; I | 1994 |
[Coronary thrombolysis with urokinase and t-PA--comparison of intracoronary thrombolysis and intravenous coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Vessels; Drug Therapy, Combination; Hemorrhage; Heparin; Humans; I | 1994 |
[Follow up antithrombotic therapy after thrombolysis].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Restenosis; Heparin; Humans; Myocardi | 1994 |
[Follow up antithrombotic therapy after thrombolysis].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Restenosis; Heparin; Humans; Myocardi | 1994 |
[Anticoagulants and antiplatelets].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Heparin; Humans; | 1994 |
[Anticoagulants and antiplatelets].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Heparin; Humans; | 1994 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
Aspirin and its rivals. As your options increase, your choices get harder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Hu | 2002 |
Aspirin and its rivals. As your options increase, your choices get harder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Hu | 2002 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2002 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2002 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
[Treatment of coronary insufficiency in diabetics: Part 2: acute coronary insufficiency].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiot | 1999 |
[Treatment of coronary insufficiency in diabetics: Part 2: acute coronary insufficiency].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiot | 1999 |
Contemporary view of the acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 2003 |
Contemporary view of the acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 2003 |
[The best of thrombosis in 2002].
Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
[The best of thrombosis in 2002].
Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
Oral anticoagulants in patients with coronary artery disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Int | 2003 |
Oral anticoagulants in patients with coronary artery disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Int | 2003 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2003 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2003 |
[Role of low-molecular-weight heparin in acute coronary syndromes].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Administration Sche | 2002 |
[Role of low-molecular-weight heparin in acute coronary syndromes].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Administration Sche | 2002 |
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2002 |
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2002 |
Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 2003 |
Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 2003 |
[GP IIb/IIIa receptor prevention medicine].
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Eptifibatide; Humans; | 2003 |
[GP IIb/IIIa receptor prevention medicine].
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Eptifibatide; Humans; | 2003 |
[Anti thrombotic therapy after coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari | 2003 |
[Anti thrombotic therapy after coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari | 2003 |
[Anticoagulant, antiplatelet agents].
Topics: Anticoagulants; Aspirin; Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Heparin; H | 2003 |
[Anticoagulant, antiplatelet agents].
Topics: Anticoagulants; Aspirin; Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Heparin; H | 2003 |
Oral anticoagulation after myocardial infarction.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; International Normalized Ratio; Myocardia | 2003 |
Oral anticoagulation after myocardial infarction.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; International Normalized Ratio; Myocardia | 2003 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Drug Therapy, Combination; Fi | 2003 |
[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Drug Therapy, Combination; Fi | 2003 |
Choosing a drug from within a class.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Aspirin; Australia; Decision Making; Drug Costs; | 2003 |
Choosing a drug from within a class.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Aspirin; Australia; Decision Making; Drug Costs; | 2003 |
The role of platelets and platelet inhibition in acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Fibrinolytic Agents; Humans; Membrane Glycoproteins; | 2003 |
The role of platelets and platelet inhibition in acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Fibrinolytic Agents; Humans; Membrane Glycoproteins; | 2003 |
[Stent thrombosis in patients with myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Age | 2003 |
[Stent thrombosis in patients with myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Age | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Intera | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Intera | 2003 |
An update on aspirin in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2003 |
An update on aspirin in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2003 |
Aspirin and warfarin versus aspirin monotherapy after myocardial infarction.
Topics: Aspirin; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Warfarin | 2003 |
Aspirin and warfarin versus aspirin monotherapy after myocardial infarction.
Topics: Aspirin; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Warfarin | 2003 |
Critical pathways for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Critical Pathways; Humans; Myocardial Infarcti | 2003 |
Critical pathways for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Critical Pathways; Humans; Myocardial Infarcti | 2003 |
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic | 2003 |
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Silent acute myocardial infarction following a wasp sting.
Topics: Aged; Animals; Aspirin; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocard | 2003 |
Silent acute myocardial infarction following a wasp sting.
Topics: Aged; Animals; Aspirin; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocard | 2003 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
[Recent progress in diagnosis of and therapy for angina pectoris].
Topics: Angina Pectoris; Aspirin; Biomarkers; Catheterization; Coronary Artery Bypass; Creatine Kinase; Crea | 2004 |
[Recent progress in diagnosis of and therapy for angina pectoris].
Topics: Angina Pectoris; Aspirin; Biomarkers; Catheterization; Coronary Artery Bypass; Creatine Kinase; Crea | 2004 |
Adjunctive treatment in patients treated with thrombolytic therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Calc | 2004 |
Adjunctive treatment in patients treated with thrombolytic therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Calc | 2004 |
[Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relations | 2004 |
[Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relations | 2004 |
[Primary prevention of acute myocardial infarction with aspirin].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction | 2004 |
[Primary prevention of acute myocardial infarction with aspirin].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction | 2004 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
[Myocardial infarction in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Creatine | 2004 |
[Myocardial infarction in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Creatine | 2004 |
Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Heparin, Low-Molecular | 2004 |
Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Heparin, Low-Molecular | 2004 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2003 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2003 |
Low-dose aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggre | 2003 |
Low-dose aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggre | 2003 |
Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combin | 2004 |
Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combin | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Thrombosis and a hypercoagulable state in HIV-infected patients.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; | 2004 |
Thrombosis and a hypercoagulable state in HIV-infected patients.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D | 2004 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D | 2004 |
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Evidence-Ba | 2004 |
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Evidence-Ba | 2004 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Acute coronary syndromes: pathogenesis, acute diagnosis with risk stratification, and treatment.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Exercise Test; Heparin; Hu | 2004 |
Acute coronary syndromes: pathogenesis, acute diagnosis with risk stratification, and treatment.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Exercise Test; Heparin; Hu | 2004 |
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon | 2004 |
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon | 2004 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
A marriage of enhancement: fibrinolysis and conjunctive therapy.
Topics: Animals; Antithrombins; Aspirin; Blood Platelets; Cell Adhesion; Clinical Trials as Topic; Dose-Resp | 2004 |
A marriage of enhancement: fibrinolysis and conjunctive therapy.
Topics: Animals; Antithrombins; Aspirin; Blood Platelets; Cell Adhesion; Clinical Trials as Topic; Dose-Resp | 2004 |
Reducing cardiac events after acute coronary syndromes.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Heparin; Humans; Myocardial Infarction; Platelet | 2004 |
Reducing cardiac events after acute coronary syndromes.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Heparin; Humans; Myocardial Infarction; Platelet | 2004 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera | 2005 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera | 2005 |
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergi | 2004 |
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergi | 2004 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans | 2005 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans | 2005 |
Variability in response to aspirin: do we understand the clinical relevance?
Topics: Acute Disease; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials a | 2005 |
Variability in response to aspirin: do we understand the clinical relevance?
Topics: Acute Disease; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials a | 2005 |
[Long-term management after myocardial infarction (Part 2.): Medical interventions].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2004 |
[Long-term management after myocardial infarction (Part 2.): Medical interventions].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2004 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Calcium Channe | 2004 |
Acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Calcium Channe | 2004 |
[Antithrombotic therapy during percutaneous coronary interventions].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Fibrinolyti | 2005 |
[Antithrombotic therapy during percutaneous coronary interventions].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Fibrinolyti | 2005 |
Management problems of spontaneous ICH.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso | 2005 |
Management problems of spontaneous ICH.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
Aspirin for everyone older than 50? For.
Topics: Aged; Aspirin; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; Risk Factors | 2005 |
Aspirin for everyone older than 50? For.
Topics: Aged; Aspirin; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; Risk Factors | 2005 |
Aspirin for everyone older than 50? Against.
Topics: Aged; Aspirin; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Middle Aged; Myocardial Inf | 2005 |
Aspirin for everyone older than 50? Against.
Topics: Aged; Aspirin; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Middle Aged; Myocardial Inf | 2005 |
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2005 |
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2005 |
Triflusal for preventing serious vascular events in people at high risk.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2005 |
Triflusal for preventing serious vascular events in people at high risk.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2005 |
[Acute chest pain].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Algorithms; Angina, Unstable; Angioplasty, Balloon | 2005 |
[Acute chest pain].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Algorithms; Angina, Unstable; Angioplasty, Balloon | 2005 |
Aspirin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Aspirin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; | 2006 |
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; | 2006 |
New anticoagulants in ischemic heart disease.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Cerebral Hemorrhage; Coronary Thrombosis; Drug Th | 2005 |
New anticoagulants in ischemic heart disease.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Cerebral Hemorrhage; Coronary Thrombosis; Drug Th | 2005 |
Anticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter, why not?
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Risk Factor | 2006 |
Anticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter, why not?
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Risk Factor | 2006 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Topics: Aspirin; Drug Therapy, Combination; Electrocardiography; Heparin; Heparin, Low-Molecular-Weight; Hum | 2005 |
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Topics: Aspirin; Drug Therapy, Combination; Electrocardiography; Heparin; Heparin, Low-Molecular-Weight; Hum | 2005 |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Aspirin to prevent heart attack and stroke: what's the right dose?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; H | 2006 |
Aspirin to prevent heart attack and stroke: what's the right dose?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; H | 2006 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz | 2006 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
[Acute coronary syndrome risk management].
Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans | 2006 |
[Acute coronary syndrome risk management].
Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans | 2006 |
[Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet | 2006 |
[Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2006 |
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2006 |
Myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Calcium Channe | 2006 |
Myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Calcium Channe | 2006 |
The established and emerging uses of aspirin.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 2006 |
The established and emerging uses of aspirin.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 2006 |
Current developments in anti-platelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Clopidogrel; Drug Resistance; | 2006 |
Current developments in anti-platelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Clopidogrel; Drug Resistance; | 2006 |
The first randomized trial of aspirin for heart attack and the advent of systematic overviews of trials.
Topics: Aspirin; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Top | 2006 |
The first randomized trial of aspirin for heart attack and the advent of systematic overviews of trials.
Topics: Aspirin; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Top | 2006 |
Clopidogrel response variability, resistance, or both?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Plat | 2006 |
Clopidogrel response variability, resistance, or both?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Plat | 2006 |
Aspirin resistance or variable response or both?
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 2006 |
Aspirin resistance or variable response or both?
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 2006 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; | 2006 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; | 2006 |
[Antiplatelet agents--problem for cardiac surgeon].
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dipyridamole; Fibrinolytic Agents; Humans; Myocardial | 2006 |
[Antiplatelet agents--problem for cardiac surgeon].
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dipyridamole; Fibrinolytic Agents; Humans; Myocardial | 2006 |
Evolving management of ST-segment elevation myocardial infarction: update on recent data.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; | 2006 |
Evolving management of ST-segment elevation myocardial infarction: update on recent data.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; | 2006 |
Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Decisi | 2006 |
Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Decisi | 2006 |
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy | 2006 |
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy | 2006 |
Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Combi | 2006 |
Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Combi | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr | 2006 |
Accelerating time to reperfusion in acute myocardial infarction: prehospital and emergency department strategies, systems of care, and pharmacologic interventions.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelet | 2006 |
Accelerating time to reperfusion in acute myocardial infarction: prehospital and emergency department strategies, systems of care, and pharmacologic interventions.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelet | 2006 |
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coro | 2006 |
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coro | 2006 |
Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Secondary prevention for patients following a myocardial infarction: summary of NICE guidance.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Exercise Therapy; Hu | 2007 |
Secondary prevention for patients following a myocardial infarction: summary of NICE guidance.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Exercise Therapy; Hu | 2007 |
Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chelating Agents; Clopidogrel; Drug Implants; Edetic Acid; | 2007 |
Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chelating Agents; Clopidogrel; Drug Implants; Edetic Acid; | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinica | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinica | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
The discovery of aspirin's antithrombotic effects.
Topics: Animals; Aspirin; Awards and Prizes; California; Fibrinolytic Agents; History, 18th Century; History | 2007 |
The discovery of aspirin's antithrombotic effects.
Topics: Animals; Aspirin; Awards and Prizes; California; Fibrinolytic Agents; History, 18th Century; History | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th | 2007 |
The influence of gender on the effects of aspirin in preventing myocardial infarction.
Topics: Adolescent; Adult; Aged; Aspirin; Female; Humans; Incidence; Linear Models; Male; Middle Aged; Myoca | 2007 |
The influence of gender on the effects of aspirin in preventing myocardial infarction.
Topics: Adolescent; Adult; Aged; Aspirin; Female; Humans; Incidence; Linear Models; Male; Middle Aged; Myoca | 2007 |
[Myocardial infarction in infants and children].
Topics: Adolescent; Aspirin; Child; Child, Preschool; Coronary Artery Bypass; gamma-Globulins; Humans; Infan | 2007 |
[Myocardial infarction in infants and children].
Topics: Adolescent; Aspirin; Child; Child, Preschool; Coronary Artery Bypass; gamma-Globulins; Humans; Infan | 2007 |
[Postmyocardial infarction syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Diagnostic Imaging; Endoc | 2007 |
[Postmyocardial infarction syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Diagnostic Imaging; Endoc | 2007 |
[Unrecognized myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aging; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme In | 2007 |
[Unrecognized myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aging; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme In | 2007 |
Pharmacogenomics of platelet responsiveness to aspirin.
Topics: Adult; Aspirin; Blood Platelets; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Huma | 2007 |
Pharmacogenomics of platelet responsiveness to aspirin.
Topics: Adult; Aspirin; Blood Platelets; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Huma | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2007 |
Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2007 |
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination | 2008 |
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination | 2008 |
[Aspirin in patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Drug Administration Schedule; Hemorrhage; | 2007 |
[Aspirin in patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Drug Administration Schedule; Hemorrhage; | 2007 |
Aspirin: promise and resistance in the new millennium.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2008 |
Aspirin: promise and resistance in the new millennium.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2008 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci | 2007 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci | 2007 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinol | 2008 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinol | 2008 |
Oral anticoagulation after myocardial infarction.
Topics: Administration, Oral; Anticoagulants; Aspirin; Comorbidity; Drug Therapy, Combination; Fibrinolytic | 2008 |
Oral anticoagulation after myocardial infarction.
Topics: Administration, Oral; Anticoagulants; Aspirin; Comorbidity; Drug Therapy, Combination; Fibrinolytic | 2008 |
[Antithrombotic therapy after percutanous coronary intervention with stenting].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Fibrinoly | 2008 |
[Antithrombotic therapy after percutanous coronary intervention with stenting].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Fibrinoly | 2008 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu | 2008 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu | 2008 |
The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies.
Topics: Aged; Aspirin; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Ma | 2008 |
The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies.
Topics: Aged; Aspirin; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Ma | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
Topics: Adrenergic beta-Antagonists; Alprenolol; Anti-Arrhythmia Agents; Aspirin; Dipyridamole; Female; Fibr | 1981 |
[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
Topics: Adrenergic beta-Antagonists; Alprenolol; Anti-Arrhythmia Agents; Aspirin; Dipyridamole; Female; Fibr | 1981 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
[Prevention of myocardial infarction by chemotherapy].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Blood Platelets | 1982 |
[Prevention of myocardial infarction by chemotherapy].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Blood Platelets | 1982 |
Cardiovascular involvement in Kawasaki syndrome.
Topics: Adrenal Cortex Hormones; Age Factors; Arrhythmias, Cardiac; Arteritis; Aspirin; Cardiovascular Disea | 1983 |
Cardiovascular involvement in Kawasaki syndrome.
Topics: Adrenal Cortex Hormones; Age Factors; Arrhythmias, Cardiac; Arteritis; Aspirin; Cardiovascular Disea | 1983 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
[Perspectives of the preventive treatment of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Death, Sudden; Exercise Therapy; Humans; Myo | 1984 |
[Perspectives of the preventive treatment of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Death, Sudden; Exercise Therapy; Humans; Myo | 1984 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Clinical aspects of the arachidonic acid--thromboxane pathway.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Epoprost | 1983 |
Clinical aspects of the arachidonic acid--thromboxane pathway.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Epoprost | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
[Primary thrombocyte reactions in hemostasis and thrombogenesis and the possibilities of influencing them by drugs].
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; | 1984 |
[Primary thrombocyte reactions in hemostasis and thrombogenesis and the possibilities of influencing them by drugs].
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; | 1984 |
Cardiogenic cerebral embolism.
Topics: Anticoagulants; Aspirin; Cardiac Surgical Procedures; Cerebral Hemorrhage; Cerebral Infarction; Dipy | 1984 |
Cardiogenic cerebral embolism.
Topics: Anticoagulants; Aspirin; Cardiac Surgical Procedures; Cerebral Hemorrhage; Cerebral Infarction; Dipy | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
[Blood platelets and myocardial infarction].
Topics: Aspirin; Blood Platelets; Dipyridamole; Epoprostenol; Humans; Myocardial Infarction; Platelet Aggreg | 1984 |
[Blood platelets and myocardial infarction].
Topics: Aspirin; Blood Platelets; Dipyridamole; Epoprostenol; Humans; Myocardial Infarction; Platelet Aggreg | 1984 |
An antagonist of prostaglandin synthesis in cardiovascular diseases.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Brain Diseases; Cardiovascular Diseases; Con | 1984 |
An antagonist of prostaglandin synthesis in cardiovascular diseases.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Brain Diseases; Cardiovascular Diseases; Con | 1984 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Prostaglandins, platelets, and atherosclerosis.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Circulation; Blood Vessels; Carotid Art | 1980 |
Prostaglandins, platelets, and atherosclerosis.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Circulation; Blood Vessels; Carotid Art | 1980 |
Presentation and analysis of the results of clinical trials in cardiovascular disease.
Topics: Aspirin; Clinical Trials as Topic; Disopyramide; Home Care Services; Hospitalization; Humans; Myocar | 1981 |
Presentation and analysis of the results of clinical trials in cardiovascular disease.
Topics: Aspirin; Clinical Trials as Topic; Disopyramide; Home Care Services; Hospitalization; Humans; Myocar | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
[Myocardial infarct: secondary prevention with drugs and their effects].
Topics: Alprenolol; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Prognosis; Sulfinpyrazone | 1980 |
[Myocardial infarct: secondary prevention with drugs and their effects].
Topics: Alprenolol; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Prognosis; Sulfinpyrazone | 1980 |
Prostaglandin inhibition and myocardial infarct size.
Topics: Acute Disease; Animals; Aspirin; Coronary Disease; Humans; Ibuprofen; Indomethacin; Models, Biologic | 1981 |
Prostaglandin inhibition and myocardial infarct size.
Topics: Acute Disease; Animals; Aspirin; Coronary Disease; Humans; Ibuprofen; Indomethacin; Models, Biologic | 1981 |
The coronary collateral circulation: determinants and functional significance in ischemic heart disease.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Col | 1981 |
The coronary collateral circulation: determinants and functional significance in ischemic heart disease.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Col | 1981 |
Myocardial infarction.
Topics: Anticoagulants; Aspirin; Blood Platelets; Death, Sudden; Dipyridamole; Fibrinolytic Agents; Humans; | 1981 |
Myocardial infarction.
Topics: Anticoagulants; Aspirin; Blood Platelets; Death, Sudden; Dipyridamole; Fibrinolytic Agents; Humans; | 1981 |
[Interference in platelet-fibrinogen system for prevention and therapy of myocardial infarct].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Fibrinolysis; Humans; Myocardial Infarction; Recurrence | 1982 |
[Interference in platelet-fibrinogen system for prevention and therapy of myocardial infarct].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Fibrinolysis; Humans; Myocardial Infarction; Recurrence | 1982 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antiplatelet therapy in coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disor | 1982 |
Antiplatelet therapy in coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disor | 1982 |
Current research in statistical methodology for clinical trials.
Topics: Aspirin; Clinical Trials as Topic; Data Collection; Ethics, Medical; Humans; Myocardial Infarction; | 1982 |
Current research in statistical methodology for clinical trials.
Topics: Aspirin; Clinical Trials as Topic; Data Collection; Ethics, Medical; Humans; Myocardial Infarction; | 1982 |
Current status of platelet inhibitor therapy in coronary artery disease.
Topics: Aspirin; Coronary Disease; Female; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; | 1982 |
Current status of platelet inhibitor therapy in coronary artery disease.
Topics: Aspirin; Coronary Disease; Female; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; | 1982 |
The management of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Humans; M | 1995 |
The management of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Humans; M | 1995 |
[Blood thinning in heart patients].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Aspirin; Atrial Fibrillation; Clini | 1995 |
[Blood thinning in heart patients].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Aspirin; Atrial Fibrillation; Clini | 1995 |
New directions in anticoagulant and antiplatelet treatment.
Topics: Angina, Unstable; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Myocardial Infarction | 1995 |
New directions in anticoagulant and antiplatelet treatment.
Topics: Angina, Unstable; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Myocardial Infarction | 1995 |
Some issues concerning treatment in patients after myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Myocardial Infarction; Recurrence; Time F | 1995 |
Some issues concerning treatment in patients after myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Myocardial Infarction; Recurrence; Time F | 1995 |
Is aspirin safe for patients with heart failure?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Drug Interactions; Heart | 1995 |
Is aspirin safe for patients with heart failure?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Drug Interactions; Heart | 1995 |
Platelets and platelet inhibitors in acute myocardial infarction.
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation I | 1995 |
Platelets and platelet inhibitors in acute myocardial infarction.
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation I | 1995 |
[Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Pla | 1995 |
[Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Pla | 1995 |
Aspirin to prevent heart attack or stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1994 |
Aspirin to prevent heart attack or stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1994 |
Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 1995 |
Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 1995 |
Who should be taking daily aspirin?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Randomized Controlled Trials as T | 1995 |
Who should be taking daily aspirin?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Randomized Controlled Trials as T | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
Adjunctive therapy in the management of patients with acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmi | 1995 |
Adjunctive therapy in the management of patients with acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmi | 1995 |
Myocardial infarction in the 1990s. The importance of early thrombolytic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic | 1995 |
Myocardial infarction in the 1990s. The importance of early thrombolytic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic | 1995 |
Current issues concerning thrombolytic therapy for acute myocardial infarction.
Topics: Anistreplase; Aspirin; Cerebrovascular Disorders; Forecasting; Humans; Myocardial Infarction; Random | 1995 |
Current issues concerning thrombolytic therapy for acute myocardial infarction.
Topics: Anistreplase; Aspirin; Cerebrovascular Disorders; Forecasting; Humans; Myocardial Infarction; Random | 1995 |
Antithrombotic therapy for acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Hirudin Therapy; Humans; Myocardia | 1995 |
Antithrombotic therapy for acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Hirudin Therapy; Humans; Myocardia | 1995 |
Myocardial infarction in a parturient. A case report with emphasis on medication and management.
Topics: Adult; Aspirin; Atenolol; Delivery, Obstetric; Drug Therapy, Combination; Female; Humans; Myocardial | 1994 |
Myocardial infarction in a parturient. A case report with emphasis on medication and management.
Topics: Adult; Aspirin; Atenolol; Delivery, Obstetric; Drug Therapy, Combination; Female; Humans; Myocardial | 1994 |
What do we really know about secondary prevention after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Humans; Life Style; Myocardial Infarction | 1995 |
What do we really know about secondary prevention after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Humans; Life Style; Myocardial Infarction | 1995 |
Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 1994 |
Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 1994 |
Current status of thrombolysis in acute myocardial infarction. Part III. Optimalization of adjunctive therapy after thrombolytic therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarct | 1995 |
Current status of thrombolysis in acute myocardial infarction. Part III. Optimalization of adjunctive therapy after thrombolytic therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarct | 1995 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Gastroint | 1995 |
Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Gastroint | 1995 |
[Reperfusion therapy in acute myocardial infarct].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Heparin; Humans; Myocardial Infarction; Myocardial Re | 1995 |
[Reperfusion therapy in acute myocardial infarct].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Heparin; Humans; Myocardial Infarction; Myocardial Re | 1995 |
Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1993 |
Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1993 |
Atherothrombotic insights into secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 1993 |
Atherothrombotic insights into secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 1993 |
Adjunctive medical therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 1994 |
Adjunctive medical therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 1994 |
Managing patients with myocardial infarction after hospital discharge.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aftercare; Angiotensin-Converting Enzyme In | 1994 |
Managing patients with myocardial infarction after hospital discharge.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aftercare; Angiotensin-Converting Enzyme In | 1994 |
Adjunctive pharmacologic therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 1994 |
Adjunctive pharmacologic therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 1994 |
Myocardial infarction. Considerations for geriatric patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; A | 1994 |
Myocardial infarction. Considerations for geriatric patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; A | 1994 |
Post infarct heart failure: what to do in addition to ACE inhibition.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1994 |
Post infarct heart failure: what to do in addition to ACE inhibition.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1994 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; | 1993 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; | 1993 |
Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction).
Topics: Administration, Oral; Angina Pectoris; Antithrombins; Aspirin; Humans; Injections, Intravenous; Male | 1994 |
Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction).
Topics: Administration, Oral; Angina Pectoris; Antithrombins; Aspirin; Humans; Injections, Intravenous; Male | 1994 |
[Coronary disease: benefits of aspirin. What dose for which disease?].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; | 1994 |
[Coronary disease: benefits of aspirin. What dose for which disease?].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; | 1994 |
[From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dementia, Vascular; Humans; Ischemic Attack, Transient | 1994 |
[From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dementia, Vascular; Humans; Ischemic Attack, Transient | 1994 |
Antiplatelet and antithrombin therapy.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Pla | 1994 |
Antiplatelet and antithrombin therapy.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Pla | 1994 |
Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?
Topics: Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1993 |
Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?
Topics: Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1993 |
Aspirin, platelets, and thrombosis: theory and practice.
Topics: Animals; Aspirin; Blood Platelets; Cerebrovascular Disorders; Humans; Models, Biological; Myocardial | 1994 |
Aspirin, platelets, and thrombosis: theory and practice.
Topics: Animals; Aspirin; Blood Platelets; Cerebrovascular Disorders; Humans; Models, Biological; Myocardial | 1994 |
[Myocardial infarct: acute intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Combined Modality Therapy; Eme | 1993 |
[Myocardial infarct: acute intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Combined Modality Therapy; Eme | 1993 |
GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.
Topics: Aspirin; Clinical Trials as Topic; Heparin; Humans; Myocardial Infarction; Randomized Controlled Tri | 1994 |
GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.
Topics: Aspirin; Clinical Trials as Topic; Heparin; Humans; Myocardial Infarction; Randomized Controlled Tri | 1994 |
The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Thrombolytic Therapy; United States | 1994 |
The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Thrombolytic Therapy; United States | 1994 |
Thrombolysis: state of the art.
Topics: Adult; Aged; Anistreplase; Aspirin; Clinical Trials as Topic; Female; Heparin; Humans; Male; Middle | 1993 |
Thrombolysis: state of the art.
Topics: Adult; Aged; Anistreplase; Aspirin; Clinical Trials as Topic; Female; Heparin; Humans; Male; Middle | 1993 |
Myocardial infarction in association with misuse of anabolic steroids.
Topics: Adult; Anabolic Agents; Aspirin; Atenolol; Doping in Sports; Echocardiography; Electrocardiography; | 1993 |
Myocardial infarction in association with misuse of anabolic steroids.
Topics: Adult; Anabolic Agents; Aspirin; Atenolol; Doping in Sports; Echocardiography; Electrocardiography; | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Adjunctive therapy in thrombolysis for acute myocardial infarction.
Topics: Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Thr | 1993 |
Adjunctive therapy in thrombolysis for acute myocardial infarction.
Topics: Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Thr | 1993 |
Thrombolysis in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Fibrinolytic A | 1993 |
Thrombolysis in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Fibrinolytic A | 1993 |
Strategies for preventing stroke.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Hu | 1993 |
Strategies for preventing stroke.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Hu | 1993 |
[Platelet aggregation inhibitor and brain infarct: quo vadis?].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Plate | 1993 |
[Platelet aggregation inhibitor and brain infarct: quo vadis?].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Plate | 1993 |
Heparin and warfarin therapy after acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Injections, Intraven | 1993 |
Heparin and warfarin therapy after acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Injections, Intraven | 1993 |
[Secondary prevention of ischemic cardiopathy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
[Secondary prevention of ischemic cardiopathy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1995 |
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1995 |
Adjunctive therapy for myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1995 |
Adjunctive therapy for myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1995 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; | 1995 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; | 1995 |
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Topics: Aspirin; Death, Sudden, Cardiac; Depression, Chemical; Female; Fibrinolysis; Fibrinolytic Agents; Hu | 1995 |
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Topics: Aspirin; Death, Sudden, Cardiac; Depression, Chemical; Female; Fibrinolysis; Fibrinolytic Agents; Hu | 1995 |
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts.
Topics: Aspirin; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, | 1996 |
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts.
Topics: Aspirin; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, | 1996 |
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio | 1996 |
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
Management after a first myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Decision | 1996 |
Management after a first myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Decision | 1996 |
Therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 1996 |
Therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 1996 |
Management of postmyocardial infarction in the elderly patient.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Arrhyth | 1996 |
Management of postmyocardial infarction in the elderly patient.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Arrhyth | 1996 |
[Magnesium sulfate in acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
[Magnesium sulfate in acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Hospitalization; Humans; Myocardial In | 1996 |
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Hospitalization; Humans; Myocardial In | 1996 |
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath | 1996 |
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath | 1996 |
Aspirin augmentation of the efficacy of thrombolysis.
Topics: Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 1995 |
Aspirin augmentation of the efficacy of thrombolysis.
Topics: Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 1995 |
Antiplatelet therapy and the prevention of thrombosis.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trial | 1996 |
Antiplatelet therapy and the prevention of thrombosis.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trial | 1996 |
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He | 1996 |
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He | 1996 |
[Anticoagulation in cardiology].
Topics: 4-Hydroxycoumarins; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial | 1995 |
[Anticoagulation in cardiology].
Topics: 4-Hydroxycoumarins; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial | 1995 |
Cocaine-associated myocardial infarction.
Topics: Adult; Aged; Aspirin; Benzodiazepines; Cocaine; Humans; Middle Aged; Myocardial Infarction; Myocardi | 1996 |
Cocaine-associated myocardial infarction.
Topics: Adult; Aged; Aspirin; Benzodiazepines; Cocaine; Humans; Middle Aged; Myocardial Infarction; Myocardi | 1996 |
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc | 1996 |
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc | 1996 |
Pharmacologic therapies after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
Pharmacologic therapies after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Heparin, Low-Mol | 1996 |
Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Heparin, Low-Mol | 1996 |
Angiographic studies demonstrating the need for conjunctive anticoagulation.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Angiography; Heparin; Hirudin Therapy; H | 1996 |
Angiographic studies demonstrating the need for conjunctive anticoagulation.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Angiography; Heparin; Hirudin Therapy; H | 1996 |
Management of acute myocardial infarction in the elderly.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Conver | 1996 |
Management of acute myocardial infarction in the elderly.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Conver | 1996 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyp | 1996 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyp | 1996 |
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Platelet Ag | 1996 |
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Platelet Ag | 1996 |
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Myocardial I | 1995 |
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Myocardial I | 1995 |
[The use of acetylsalicylic acid in IHD].
Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 1996 |
[The use of acetylsalicylic acid in IHD].
Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 1996 |
[Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cost-Benefit | 1996 |
[Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cost-Benefit | 1996 |
Antithrombotic and thrombolytic therapies for acute myocardial infarction.
Topics: Anistreplase; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Streptokinase; T | 1996 |
Antithrombotic and thrombolytic therapies for acute myocardial infarction.
Topics: Anistreplase; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Streptokinase; T | 1996 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Hepa | 1997 |
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Hepa | 1997 |
Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Female; Humans; Immunoglobulins, Intravenous; In | 1997 |
Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Female; Humans; Immunoglobulins, Intravenous; In | 1997 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol | 1997 |
The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol | 1997 |
[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct].
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Lung Diseases; Male; Mi | 1997 |
[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct].
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Lung Diseases; Male; Mi | 1997 |
Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Catheterization; Coronary Disease; Humans; Immuno | 1997 |
Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Catheterization; Coronary Disease; Humans; Immuno | 1997 |
Platelet activation and inhibition in unstable coronary syndromes.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation | 1997 |
Platelet activation and inhibition in unstable coronary syndromes.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation | 1997 |
Treatment of acute myocardial infarction today.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1997 |
Treatment of acute myocardial infarction today.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1997 |
[Acetylsalicylic acid after myocardial infarct].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinolytic Agents; Humans | 1997 |
[Acetylsalicylic acid after myocardial infarct].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinolytic Agents; Humans | 1997 |
Coronary heart disease: an older woman's major health risk.
Topics: Aged; Angina Pectoris; Aspirin; Cholesterol; Coronary Disease; Estrogen Replacement Therapy; Female; | 1997 |
Coronary heart disease: an older woman's major health risk.
Topics: Aged; Angina Pectoris; Aspirin; Cholesterol; Coronary Disease; Estrogen Replacement Therapy; Female; | 1997 |
Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1997 |
Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1997 |
[Thrombolytic therapy of ischemic heart disease].
Topics: Aspirin; Clinical Trials as Topic; Europe; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 1997 |
[Thrombolytic therapy of ischemic heart disease].
Topics: Aspirin; Clinical Trials as Topic; Europe; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 1997 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
[Current aspects of thrombolytic therapy in unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Gl | 1997 |
[Current aspects of thrombolytic therapy in unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Gl | 1997 |
Gender differences in mortality after myocardial infarction. Why women fare worse than men.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Female; Fibrinolytic Agents; Hospital Morta | 1998 |
Gender differences in mortality after myocardial infarction. Why women fare worse than men.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Female; Fibrinolytic Agents; Hospital Morta | 1998 |
[Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
Topics: Aspirin; Circadian Rhythm; Gastrointestinal Diseases; Humans; Myocardial Infarction; Platelet Aggreg | 1997 |
[Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
Topics: Aspirin; Circadian Rhythm; Gastrointestinal Diseases; Humans; Myocardial Infarction; Platelet Aggreg | 1997 |
Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1998 |
Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1998 |
Secondary prevention in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1998 |
Secondary prevention in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1998 |
Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Europe; Humans; Japan; Myocardial Infarction; P | 1998 |
Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Europe; Humans; Japan; Myocardial Infarction; P | 1998 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
Managing the diabetic patient with acute myocardial infarction.
Topics: Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Humans; Myocardial Infarction; Ri | 1998 |
Managing the diabetic patient with acute myocardial infarction.
Topics: Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Humans; Myocardial Infarction; Ri | 1998 |
Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 1998 |
Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 1998 |
Triflusal.
Topics: Adult; Angina Pectoris; Animals; Aspirin; Carotid Stenosis; Humans; In Vitro Techniques; Middle Aged | 1998 |
Triflusal.
Topics: Adult; Angina Pectoris; Animals; Aspirin; Carotid Stenosis; Humans; In Vitro Techniques; Middle Aged | 1998 |
Beyond aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarc | 1998 |
Beyond aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarc | 1998 |
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Hematologic Agents; Heparin; He | 1998 |
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Hematologic Agents; Heparin; He | 1998 |
Reperfusion therapy for acute myocardial infarction. Which strategy for which patient?
Topics: Angioplasty; Aspirin; Costs and Cost Analysis; Fibrinolytic Agents; Humans; Myocardial Infarction; M | 1998 |
Reperfusion therapy for acute myocardial infarction. Which strategy for which patient?
Topics: Angioplasty; Aspirin; Costs and Cost Analysis; Fibrinolytic Agents; Humans; Myocardial Infarction; M | 1998 |
Choosing the most appropriate treatment for stable angina. Safety considerations.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 1998 |
Choosing the most appropriate treatment for stable angina. Safety considerations.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 1998 |
Clinical potential of antithrombotic drugs in coronary syndromes.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1998 |
Clinical potential of antithrombotic drugs in coronary syndromes.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1998 |
[Antithrombotic agents in acute myocardial infarction].
Topics: Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Heparin; Humans; Integrins; Myocar | 1998 |
[Antithrombotic agents in acute myocardial infarction].
Topics: Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Heparin; Humans; Integrins; Myocar | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial I | 1998 |
Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial I | 1998 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1998 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1998 |
Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combinatio | 1998 |
Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combinatio | 1998 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agent | 1998 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agent | 1998 |
[Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
Topics: Administration, Oral; Anticoagulants; Aspirin; Controlled Clinical Trials as Topic; Follow-Up Studie | 1998 |
[Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
Topics: Administration, Oral; Anticoagulants; Aspirin; Controlled Clinical Trials as Topic; Follow-Up Studie | 1998 |
Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation In | 1998 |
Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation In | 1998 |
Coronary artery disease in women.
Topics: Adult; Age Factors; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin-Converting En | 1998 |
Coronary artery disease in women.
Topics: Adult; Age Factors; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin-Converting En | 1998 |
[Gastric and duodenal intramural hematoma: report of two cases].
Topics: Adult; Aspirin; Chronic Disease; Duodenal Diseases; Gastric Mucosa; Hematoma; Humans; Intestinal Muc | 1998 |
[Gastric and duodenal intramural hematoma: report of two cases].
Topics: Adult; Aspirin; Chronic Disease; Duodenal Diseases; Gastric Mucosa; Hematoma; Humans; Intestinal Muc | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Aspirin and its friends: an old standby with new prospects.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Colo | 1999 |
Aspirin and its friends: an old standby with new prospects.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Colo | 1999 |
[Thrombolytic treatment of acute myocardial infarct. 3].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1998 |
[Thrombolytic treatment of acute myocardial infarct. 3].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1998 |
Antiplatelet drugs in secondary prevention after acute myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation | 1998 |
Antiplatelet drugs in secondary prevention after acute myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation | 1998 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Preve | 1999 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Preve | 1999 |
Is aspirin underused in myocardial infarction?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization; Humans; Myocardial Infarction | 1997 |
Is aspirin underused in myocardial infarction?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization; Humans; Myocardial Infarction | 1997 |
Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Fibrinolytic Agents; H | 1999 |
Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Fibrinolytic Agents; H | 1999 |
Clinical profile of saruplase: angiographic findings.
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Fibrinolytic Agents; Heparin; Humans; Myoca | 1998 |
Clinical profile of saruplase: angiographic findings.
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Fibrinolytic Agents; Heparin; Humans; Myoca | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Advances in antithrombotic therapy of acute myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1999 |
Advances in antithrombotic therapy of acute myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1999 |
How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Follow-Up Studies; H | 1999 |
How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Follow-Up Studies; H | 1999 |
Heart failure: Part II.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 1999 |
Heart failure: Part II.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 1999 |
Prehospital thrombolysis: an idea whose time has come.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial | 1999 |
Prehospital thrombolysis: an idea whose time has come.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial | 1999 |
Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1999 |
Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1999 |
[Drug therapy for prognostic improvement after acute myocardial infarct].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 1999 |
[Drug therapy for prognostic improvement after acute myocardial infarct].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 1999 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Emergency management of acute myocardial infarction.
Topics: Acute Disease; Angioplasty; Aspirin; Emergency Medical Services; Humans; Male; Middle Aged; Myocardi | 1999 |
Emergency management of acute myocardial infarction.
Topics: Acute Disease; Angioplasty; Aspirin; Emergency Medical Services; Humans; Male; Middle Aged; Myocardi | 1999 |
Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery.
Topics: Administration, Oral; Amputation, Surgical; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Huma | 1999 |
Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery.
Topics: Administration, Oral; Amputation, Surgical; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Huma | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
New look at myocardial infarction: toward a better aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Combinations; Drug | 1999 |
New look at myocardial infarction: toward a better aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Combinations; Drug | 1999 |
Heart disease. A new theory of heart attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction | 1999 |
Heart disease. A new theory of heart attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction | 1999 |
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; | 1999 |
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; | 1999 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Targeting treatment for optimal outcome.
Topics: Age Factors; Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Clinical Protocols; Daltep | 2000 |
Targeting treatment for optimal outcome.
Topics: Age Factors; Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Clinical Protocols; Daltep | 2000 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
Aspirin.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Digestive System; Humans; Myocardial Infarctio | 2000 |
Aspirin.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Digestive System; Humans; Myocardial Infarctio | 2000 |
Diabetes and myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Huma | 1999 |
Diabetes and myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Huma | 1999 |
[Aspirin and prevention of cardiovascular risk].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Ste | 2000 |
[Aspirin and prevention of cardiovascular risk].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Ste | 2000 |
[Aspirin and hemostasis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitor | 2000 |
[Aspirin and hemostasis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitor | 2000 |
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Cerebral Hemorrhage; Clinical Trials, Phase | 2000 |
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Cerebral Hemorrhage; Clinical Trials, Phase | 2000 |
Tackling myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Humans; Myocardial Infarction; | 2000 |
Tackling myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Humans; Myocardial Infarction; | 2000 |
Percutaneous revascularization for unstable angina in the elderly.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu | 2000 |
Percutaneous revascularization for unstable angina in the elderly.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu | 2000 |
Anti-thrombotic therapy for elderly patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardia | 2000 |
Anti-thrombotic therapy for elderly patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardia | 2000 |
Secondary prevention of myocardial infarction: beneficial effect of combining oral anticoagulant plus aspirin: therapy based on evidence.
Topics: Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarct | 2000 |
Secondary prevention of myocardial infarction: beneficial effect of combining oral anticoagulant plus aspirin: therapy based on evidence.
Topics: Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarct | 2000 |
Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy.
Topics: Aspirin; Coronary Circulation; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Humans; | 2000 |
Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy.
Topics: Aspirin; Coronary Circulation; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Humans; | 2000 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trial | 2000 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trial | 2000 |
Myocardial infarction in women: a critical appraisal of gender differences in outcomes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Fibrinolytic | 2000 |
Myocardial infarction in women: a critical appraisal of gender differences in outcomes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Fibrinolytic | 2000 |
Failed thrombolysis in myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 2000 |
Failed thrombolysis in myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 2000 |
Nitric oxide donors.
Topics: Animals; Aspirin; Drug Tolerance; Heart; Humans; In Vitro Techniques; Molsidomine; Myocardial Infarc | 2000 |
Nitric oxide donors.
Topics: Animals; Aspirin; Drug Tolerance; Heart; Humans; In Vitro Techniques; Molsidomine; Myocardial Infarc | 2000 |
Long-term cardiac sequelae of Kawasaki disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Catheterization; Child; Child, Pres | 2000 |
Long-term cardiac sequelae of Kawasaki disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Catheterization; Child; Child, Pres | 2000 |
Advances in the pharmacology of acute coronary syndrome. Platelet inhibition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Corona | 2000 |
Advances in the pharmacology of acute coronary syndrome. Platelet inhibition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Corona | 2000 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal | 2000 |
Managing myocardial infarction in the diabetic patient.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 2000 |
Managing myocardial infarction in the diabetic patient.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 2000 |
Present treatment options for unstable angina and non-Q-wave myocardial infarction.
Topics: Algorithms; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Coro | 2001 |
Present treatment options for unstable angina and non-Q-wave myocardial infarction.
Topics: Algorithms; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Coro | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
Low-molecular-weight heparins in the management of unstable angina.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug Admi | 2000 |
Low-molecular-weight heparins in the management of unstable angina.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug Admi | 2000 |
Post myocardial infarction treatment in the older adult.
Topics: Adrenergic beta-Antagonists; Aftercare; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; | 2001 |
Post myocardial infarction treatment in the older adult.
Topics: Adrenergic beta-Antagonists; Aftercare; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; | 2001 |
Should patients with hypertension receive antithrombotic therapy?
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors | 2001 |
Should patients with hypertension receive antithrombotic therapy?
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors | 2001 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; | 2001 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; | 2001 |
[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin | 2001 |
[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin | 2001 |
Current management issues in angina.
Topics: Angina Pectoris; Aspirin; Coronary Angiography; Diagnosis, Differential; Exercise Test; Humans; Hypo | 2001 |
Current management issues in angina.
Topics: Angina Pectoris; Aspirin; Coronary Angiography; Diagnosis, Differential; Exercise Test; Humans; Hypo | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifi | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifi | 2001 |
Myocardial ischemia and infarction: growth of ideas.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2001 |
Myocardial ischemia and infarction: growth of ideas.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2001 |
[Acute heart infarct: epidemiology and pre-hospitalization phase].
Topics: Age Distribution; Anticoagulants; Aspirin; Emergency Medical Services; Europe; Heparin; Humans; Inci | 2001 |
[Acute heart infarct: epidemiology and pre-hospitalization phase].
Topics: Age Distribution; Anticoagulants; Aspirin; Emergency Medical Services; Europe; Heparin; Humans; Inci | 2001 |
[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2001 |
[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2001 |
Aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarc | 2001 |
Aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarc | 2001 |
Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Dogs; Fibrin; Fibrinolysis; Fibrinolytic Agents | 2001 |
Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Dogs; Fibrin; Fibrinolysis; Fibrinolytic Agents | 2001 |
New data in treatment of acute coronary syndromes.
Topics: Anticoagulants; Antithrombin III; Aspirin; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, | 2001 |
New data in treatment of acute coronary syndromes.
Topics: Anticoagulants; Antithrombin III; Aspirin; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, | 2001 |
Medical interventions in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Fibrinolytic Agents; Heart Rupture, Post-Infarction; | 1990 |
Medical interventions in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Fibrinolytic Agents; Heart Rupture, Post-Infarction; | 1990 |
Management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Convertin | 2001 |
Management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Convertin | 2001 |
Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myo | 2001 |
Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myo | 2001 |
The acute management of myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; C | 2001 |
The acute management of myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; C | 2001 |
Reducing the risk: heart disease, stroke and aspirin.
Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D | 2001 |
Reducing the risk: heart disease, stroke and aspirin.
Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D | 2001 |
Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy.
Topics: Adenosine Diphosphate; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Dr | 2001 |
Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy.
Topics: Adenosine Diphosphate; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Dr | 2001 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
[Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents].
Topics: Aspirin; Cerebral Hemorrhage; Drug Costs; Electrocardiography; Fibrinolytic Agents; Hirudin Therapy; | 2001 |
[Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents].
Topics: Aspirin; Cerebral Hemorrhage; Drug Costs; Electrocardiography; Fibrinolytic Agents; Hirudin Therapy; | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
[Advances and perspectives in the prevention of venous thromboembolic disease].
Topics: Anesthesia, Conduction; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial I | 2001 |
[Advances and perspectives in the prevention of venous thromboembolic disease].
Topics: Anesthesia, Conduction; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial I | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Hyperlipidemias; Hype | 2002 |
[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Hyperlipidemias; Hype | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; | 2002 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
[Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
[Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
[Preclinical management of acute coronary syndrome].
Topics: Aspirin; Clinical Trials as Topic; Electrocardiography; Emergency Medical Services; Heparin; Humans; | 2002 |
[Preclinical management of acute coronary syndrome].
Topics: Aspirin; Clinical Trials as Topic; Electrocardiography; Emergency Medical Services; Heparin; Humans; | 2002 |
Possible mechanisms of aspirin resistance.
Topics: Animals; Arachidonic Acid; Aspirin; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggrega | 2002 |
Possible mechanisms of aspirin resistance.
Topics: Animals; Arachidonic Acid; Aspirin; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggrega | 2002 |
Clinical practice. Aspirin for primary prevention of coronary events.
Topics: Algorithms; Aspirin; Cholesterol; Contraindications; Coronary Disease; Evidence-Based Medicine; Huma | 2002 |
Clinical practice. Aspirin for primary prevention of coronary events.
Topics: Algorithms; Aspirin; Cholesterol; Contraindications; Coronary Disease; Evidence-Based Medicine; Huma | 2002 |
Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Myocardial Infa | 2002 |
Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Myocardial Infa | 2002 |
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
Topics: Administration, Oral; Aspirin; Coronary Disease; Death, Sudden, Cardiac; Humans; Myocardial Infarcti | 2002 |
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
Topics: Administration, Oral; Aspirin; Coronary Disease; Death, Sudden, Cardiac; Humans; Myocardial Infarcti | 2002 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Care Un | 2002 |
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Care Un | 2002 |
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase | 2002 |
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase | 2002 |
[Management of atherosclerotic renal artery stenoses].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Cardiovascular Agents; Combined | 2002 |
[Management of atherosclerotic renal artery stenoses].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Cardiovascular Agents; Combined | 2002 |
Effective use of analgesic drugs.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ast | 1976 |
Effective use of analgesic drugs.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ast | 1976 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
[Prevention of venous embolism and thrombosis].
Topics: Adult; Age Factors; Anticoagulants; Aspirin; Batroxobin; Dextrans; Dihydroergotamine; Heparin; Hip J | 1977 |
[Prevention of venous embolism and thrombosis].
Topics: Adult; Age Factors; Anticoagulants; Aspirin; Batroxobin; Dextrans; Dihydroergotamine; Heparin; Hip J | 1977 |
[Indications and uncertainties of antiaggregating agents].
Topics: Anticoagulants; Aspirin; Clofibrate; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregati | 1977 |
[Indications and uncertainties of antiaggregating agents].
Topics: Anticoagulants; Aspirin; Clofibrate; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregati | 1977 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
[Anticoagulation therapy in myocardial infarction (author's transl)].
Topics: Anticoagulants; Aspirin; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; Leg; Myocardial Inf | 1975 |
[Anticoagulation therapy in myocardial infarction (author's transl)].
Topics: Anticoagulants; Aspirin; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; Leg; Myocardial Inf | 1975 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Platelets and thromboembolism.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Dext | 1976 |
Platelets and thromboembolism.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Dext | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Aspirin, haemostasis and thrombosis.
Topics: Aspirin; Hemostasis; Humans; Myocardial Infarction; Platelet Aggregation; Prostaglandin Antagonists; | 1975 |
Aspirin, haemostasis and thrombosis.
Topics: Aspirin; Hemostasis; Humans; Myocardial Infarction; Platelet Aggregation; Prostaglandin Antagonists; | 1975 |
The use of aspirin in ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Myocardial Revascularizat | 1992 |
The use of aspirin in ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Myocardial Revascularizat | 1992 |
[Clinical pharmacology of acetylsalicylic acid].
Topics: Administration, Oral; Animals; Aspirin; Biological Availability; Coronary Artery Bypass; Dose-Respon | 1992 |
[Clinical pharmacology of acetylsalicylic acid].
Topics: Administration, Oral; Animals; Aspirin; Biological Availability; Coronary Artery Bypass; Dose-Respon | 1992 |
[Fibrinolytic treatment of myocardial infarction. Adjunctive therapy].
Topics: Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1992 |
[Fibrinolytic treatment of myocardial infarction. Adjunctive therapy].
Topics: Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1992 |
The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Humans; Hypert | 1992 |
The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Humans; Hypert | 1992 |
[Therapeutic possibilities, respective implications in silent ischemia].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Coronary Artery Byp | 1992 |
[Therapeutic possibilities, respective implications in silent ischemia].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Coronary Artery Byp | 1992 |
Pharmacologic adjunctive therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Chemotherapy, Adjuvant; Heparin; Hum | 1992 |
Pharmacologic adjunctive therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Chemotherapy, Adjuvant; Heparin; Hum | 1992 |
Beyond the mega-trial: certainty and uncertainty.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Meta-Analysi | 1992 |
Beyond the mega-trial: certainty and uncertainty.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Meta-Analysi | 1992 |
Antithrombotic therapy. Introduction.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis; Warfarin | 1992 |
Antithrombotic therapy. Introduction.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis; Warfarin | 1992 |
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug; | 1992 |
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug; | 1992 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Bandages; Cerebrovascular Disorders; Gravity Suits; Humans; Myocardial Infa | 1992 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Bandages; Cerebrovascular Disorders; Gravity Suits; Humans; Myocardial Infa | 1992 |
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Topics: Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Lipid Metabolism; | 1992 |
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Topics: Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Lipid Metabolism; | 1992 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Heparin; Humans; Myocardi | 1992 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Heparin; Humans; Myocardi | 1992 |
[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; | 1992 |
[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; | 1992 |
[The future of fibrinolysis: from fibrinolytic treatment to reperfusion therapy].
Topics: Aspirin; Blood Coagulation Factors; Cholinesterase Reactivators; Chromogenic Compounds; Clinical Tri | 1992 |
[The future of fibrinolysis: from fibrinolytic treatment to reperfusion therapy].
Topics: Aspirin; Blood Coagulation Factors; Cholinesterase Reactivators; Chromogenic Compounds; Clinical Tri | 1992 |
Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.
Topics: Angina Pectoris; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Female; Humans; Male; Meta-An | 1992 |
Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.
Topics: Angina Pectoris; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Female; Humans; Male; Meta-An | 1992 |
The primary prevention of myocardial infarction.
Topics: Alcohol Drinking; Aspirin; Blood Glucose; Cholesterol; Estrogen Replacement Therapy; Female; Humans; | 1992 |
The primary prevention of myocardial infarction.
Topics: Alcohol Drinking; Aspirin; Blood Glucose; Cholesterol; Estrogen Replacement Therapy; Female; Humans; | 1992 |
Prophylactic aspirin and the elderly population.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Male; Middle Aged; Myoca | 1992 |
Prophylactic aspirin and the elderly population.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Male; Middle Aged; Myoca | 1992 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
[Coronary thrombolysis in patients with acute myocardial infarction].
Topics: Animals; Aspirin; Dipyridamole; Heparin; Humans; Myocardial Infarction; Plasminogen Activators; Reco | 1992 |
[Coronary thrombolysis in patients with acute myocardial infarction].
Topics: Animals; Aspirin; Dipyridamole; Heparin; Humans; Myocardial Infarction; Plasminogen Activators; Reco | 1992 |
The golden hours of the myocardial infarction: nonthrombolytic interventions.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Lidocaine; Myocardial Infarc | 1991 |
The golden hours of the myocardial infarction: nonthrombolytic interventions.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Lidocaine; Myocardial Infarc | 1991 |
Thrombolytic therapy in acute myocardial infarction: an emergency department perspective.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Chemotherapy, Ad | 1991 |
Thrombolytic therapy in acute myocardial infarction: an emergency department perspective.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Chemotherapy, Ad | 1991 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Male; Myocardial Infarction; Platelet Ag | 1991 |
Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Male; Myocardial Infarction; Platelet Ag | 1991 |
Perspectives on therapeutic interventions in patients with acute myocardial infarction: viewpoints after the GISSI-2 results.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Recurrence; Streptokinas | 1991 |
Perspectives on therapeutic interventions in patients with acute myocardial infarction: viewpoints after the GISSI-2 results.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Recurrence; Streptokinas | 1991 |
Thrombolytic therapy in acute myocardial infarction following prolonged cardiopulmonary resuscitation.
Topics: Aspirin; Cardiopulmonary Resuscitation; Electrocardiography; Female; Heparin; Humans; Middle Aged; M | 1991 |
Thrombolytic therapy in acute myocardial infarction following prolonged cardiopulmonary resuscitation.
Topics: Aspirin; Cardiopulmonary Resuscitation; Electrocardiography; Female; Heparin; Humans; Middle Aged; M | 1991 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
Antiplatelet and anticoagulant therapy in acute myocardial infarction.
Topics: Aspirin; Dipyridamole; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulf | 1991 |
Antiplatelet and anticoagulant therapy in acute myocardial infarction.
Topics: Aspirin; Dipyridamole; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulf | 1991 |
Antiaggregating therapy in acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Platelet Activation; Pla | 1991 |
Antiaggregating therapy in acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Platelet Activation; Pla | 1991 |
What is the role of invasive intervention after coronary thrombolysis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Heparin; Humans; Myocardial Infa | 1991 |
What is the role of invasive intervention after coronary thrombolysis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Heparin; Humans; Myocardial Infa | 1991 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepa | 1991 |
[Coronary insufficiency and heparin].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepa | 1991 |
Activation of thromboxane and prostacyclin biosynthesis in humans.
Topics: Aspirin; Epoprostenol; Humans; Myocardial Infarction; Reference Values; Thromboxane A2 | 1991 |
Activation of thromboxane and prostacyclin biosynthesis in humans.
Topics: Aspirin; Epoprostenol; Humans; Myocardial Infarction; Reference Values; Thromboxane A2 | 1991 |
Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy.
Topics: Aspirin; Drug Synergism; Fibrinolysis; Humans; Meta-Analysis as Topic; Myocardial Infarction; Strept | 1991 |
Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy.
Topics: Aspirin; Drug Synergism; Fibrinolysis; Humans; Meta-Analysis as Topic; Myocardial Infarction; Strept | 1991 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
Long-term antiplatelet therapy for the prevention of vascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Evaluation Studies as Topic; Humans; Long-Term Care; Myocardial | 1991 |
Long-term antiplatelet therapy for the prevention of vascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Evaluation Studies as Topic; Humans; Long-Term Care; Myocardial | 1991 |
Managing patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers | 1990 |
Managing patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers | 1990 |
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Humans; Lidocai | 1990 |
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Humans; Lidocai | 1990 |
[Secondary prevention after myocardial infarct].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Anti-Arrhythmia Agents; Anticoagulants; Antihyper | 1990 |
[Secondary prevention after myocardial infarct].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Anti-Arrhythmia Agents; Anticoagulants; Antihyper | 1990 |
[Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; He | 1990 |
[Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; He | 1990 |
Aspirin in the prevention of thrombosis.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis | 1991 |
Aspirin in the prevention of thrombosis.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis | 1991 |
[Thrombolysis in acute myocardial infarct. An established therapy with open questions].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Heparin; Humans; Myocardial Infarction; Myocardial Reperfus | 1991 |
[Thrombolysis in acute myocardial infarct. An established therapy with open questions].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Heparin; Humans; Myocardial Infarction; Myocardial Reperfus | 1991 |
A review of secondary coronary prevention with dipyridamole and aspirin.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1990 |
A review of secondary coronary prevention with dipyridamole and aspirin.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1990 |
Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin.
Topics: Angina, Unstable; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Thrombosis; Humans; | 1990 |
Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin.
Topics: Angina, Unstable; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Thrombosis; Humans; | 1990 |
Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition.
Topics: Angina, Unstable; Animals; Aspirin; Humans; Myocardial Infarction; Prostaglandin Endoperoxides, Synt | 1990 |
Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition.
Topics: Angina, Unstable; Animals; Aspirin; Humans; Myocardial Infarction; Prostaglandin Endoperoxides, Synt | 1990 |
Coronary thrombosis: pathogenesis and prevention.
Topics: Aspirin; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation | 1990 |
Coronary thrombosis: pathogenesis and prevention.
Topics: Aspirin; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation | 1990 |
Haemorrhagic aspects of thrombolytic therapy.
Topics: Anistreplase; Aspirin; Cerebral Hemorrhage; Heparin; Humans; Incidence; Myocardial Infarction; Strep | 1990 |
Haemorrhagic aspects of thrombolytic therapy.
Topics: Anistreplase; Aspirin; Cerebral Hemorrhage; Heparin; Humans; Incidence; Myocardial Infarction; Strep | 1990 |
Thrombolytic therapy in acute MI. Weighing the risks and benefits.
Topics: Acute Disease; Anistreplase; Aspirin; Clinical Trials as Topic; Contraindications; Heparin; Humans; | 1990 |
Thrombolytic therapy in acute MI. Weighing the risks and benefits.
Topics: Acute Disease; Anistreplase; Aspirin; Clinical Trials as Topic; Contraindications; Heparin; Humans; | 1990 |
Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet | 1990 |
Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet | 1990 |
Aspirin in chronic cardiovascular disease and acute myocardial infarction.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Humans; Myocardial Infarction; Pla | 1990 |
Aspirin in chronic cardiovascular disease and acute myocardial infarction.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Humans; Myocardial Infarction; Pla | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Antithrombotic therapy in the primary and secondary prevention of coronary-related death and infarction: focus on gender differences.
Topics: Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Humans; Male; Myocardial Inf | 1990 |
Antithrombotic therapy in the primary and secondary prevention of coronary-related death and infarction: focus on gender differences.
Topics: Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Humans; Male; Myocardial Inf | 1990 |
The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting.
Topics: Aspirin; Blood Loss, Surgical; Calcium Channel Blockers; Cardiopulmonary Bypass; Coronary Artery Byp | 1990 |
The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting.
Topics: Aspirin; Blood Loss, Surgical; Calcium Channel Blockers; Cardiopulmonary Bypass; Coronary Artery Byp | 1990 |
Aspirin and thrombolytic therapy in the management of acute myocardial infarction.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombolytic Therapy | 1990 |
Aspirin and thrombolytic therapy in the management of acute myocardial infarction.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombolytic Therapy | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
[Aspirin in ischemic heart disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Po | 1990 |
[Aspirin in ischemic heart disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Po | 1990 |
[Platelet aggregation, coronary insufficiency and aspirin].
Topics: Arteriosclerosis; Aspirin; Drug Administration Schedule; Heart Failure; Humans; Myocardial Infarctio | 1990 |
[Platelet aggregation, coronary insufficiency and aspirin].
Topics: Arteriosclerosis; Aspirin; Drug Administration Schedule; Heart Failure; Humans; Myocardial Infarctio | 1990 |
[Current aspects of arterial anti-thrombosis prophylaxis].
Topics: Adult; Aged; Aspirin; Contraindications; Dipyridamole; Humans; Middle Aged; Myocardial Infarction; P | 1990 |
[Current aspects of arterial anti-thrombosis prophylaxis].
Topics: Adult; Aged; Aspirin; Contraindications; Dipyridamole; Humans; Middle Aged; Myocardial Infarction; P | 1990 |
[Acetylsalicylic acid of fish oil for the prevention of degenerative circulatory diseases?].
Topics: Aspirin; Fatty Acids, Omega-3; Fish Oils; Humans; Myocardial Infarction; Vascular Diseases | 1990 |
[Acetylsalicylic acid of fish oil for the prevention of degenerative circulatory diseases?].
Topics: Aspirin; Fatty Acids, Omega-3; Fish Oils; Humans; Myocardial Infarction; Vascular Diseases | 1990 |
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoids; Humans; Myocardial Infar | 1990 |
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoids; Humans; Myocardial Infar | 1990 |
Role of platelet inhibitor therapy in myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulfinpyrazon | 1989 |
Role of platelet inhibitor therapy in myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Sulfinpyrazon | 1989 |
Acute myocardial infarction: a true medical emergency.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Emergencies; Evaluation Studies as Top | 1989 |
Acute myocardial infarction: a true medical emergency.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Emergencies; Evaluation Studies as Top | 1989 |
[Effects of thrombolytic treatments on the mortality of myocardial infarction. Characteristics of large-scale trials, main results].
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle Aged; Mu | 1989 |
[Effects of thrombolytic treatments on the mortality of myocardial infarction. Characteristics of large-scale trials, main results].
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle Aged; Mu | 1989 |
[Optimal therapy following thrombolysis: aggressively or conservatively?].
Topics: Angioplasty, Balloon; Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Heparin; Humans; Myocard | 1989 |
[Optimal therapy following thrombolysis: aggressively or conservatively?].
Topics: Angioplasty, Balloon; Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Heparin; Humans; Myocard | 1989 |
Thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Clinical Trials as Topic; Combined | 1989 |
Thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Clinical Trials as Topic; Combined | 1989 |
Morning increase of onset of myocardial infarction. Implications concerning triggering events.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Pressure; Circadian Rhythm; Humans; Myocardial Infarctio | 1989 |
Morning increase of onset of myocardial infarction. Implications concerning triggering events.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Pressure; Circadian Rhythm; Humans; Myocardial Infarctio | 1989 |
Management of acute non-Q-wave myocardial infarction: role of prophylactic pharmacotherapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Electrocardiog | 1989 |
Management of acute non-Q-wave myocardial infarction: role of prophylactic pharmacotherapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Electrocardiog | 1989 |
Antithrombotic agents in coronary artery disease.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet | 1989 |
Antithrombotic agents in coronary artery disease.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet | 1989 |
[Optimal dosage of acetylsalicylic acid. I: Use in primary and secondary prevention of myocardial infarct and following aortocoronary bypass operation].
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Po | 1989 |
[Optimal dosage of acetylsalicylic acid. I: Use in primary and secondary prevention of myocardial infarct and following aortocoronary bypass operation].
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Po | 1989 |
[Aspirin in coronary heart disease].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
[Aspirin in coronary heart disease].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Aspirin and prevention of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1989 |
Aspirin and prevention of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1989 |
Polypharmacologic interactions in the management of thrombosis.
Topics: Animals; Aspirin; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation; Platelet | 1989 |
Polypharmacologic interactions in the management of thrombosis.
Topics: Animals; Aspirin; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation; Platelet | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation].
Topics: Aspirin; Cardiac Surgical Procedures; Diabetic Angiopathies; Female; Glomerulonephritis, Membranopro | 1989 |
[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation].
Topics: Aspirin; Cardiac Surgical Procedures; Diabetic Angiopathies; Female; Glomerulonephritis, Membranopro | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
After coronary thrombolysis and reperfusion, what next?
Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myoca | 1989 |
After coronary thrombolysis and reperfusion, what next?
Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myoca | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
[Platelet antiaggregants and coronary pathology].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
[Platelet antiaggregants and coronary pathology].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Mal | 1989 |
Aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Mal | 1989 |
Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myoca | 1985 |
Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myoca | 1985 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Control of polyunsaturated acids in tissue lipids.
Topics: Acrodermatitis; alpha-Linolenic Acid; Arachidonic Acid; Arachidonic Acids; Aspirin; Child; Crohn Dis | 1986 |
Control of polyunsaturated acids in tissue lipids.
Topics: Acrodermatitis; alpha-Linolenic Acid; Arachidonic Acid; Arachidonic Acids; Aspirin; Child; Crohn Dis | 1986 |
Primary prevention of vascular disease by aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; | 1988 |
Primary prevention of vascular disease by aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; | 1988 |
Management of unstable angina soon after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Anticoagulants | 1988 |
Management of unstable angina soon after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Anticoagulants | 1988 |
Secondary prevention in elderly survivors of heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cholesterol; Female; Humans; Hypertension; Male; Myocard | 1988 |
Secondary prevention in elderly survivors of heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cholesterol; Female; Humans; Hypertension; Male; Myocard | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
[The state of thrombolytic therapy in acute myocardial infarct].
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Coronary Artery Bypass; Coronary Vessels; Creatine | 1985 |
[The state of thrombolytic therapy in acute myocardial infarct].
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Coronary Artery Bypass; Coronary Vessels; Creatine | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Th | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Th | 1986 |
Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
Topics: Angina, Unstable; Aspirin; Blood Pressure; Cholesterol; Exercise; Heart Diseases; Heart Failure; Hum | 1988 |
Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
Topics: Angina, Unstable; Aspirin; Blood Pressure; Cholesterol; Exercise; Heart Diseases; Heart Failure; Hum | 1988 |
Antiplatelet therapy for ischemic heart disease in the elderly.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Humans; Myocardial Infarction; Platelet Agg | 1988 |
Antiplatelet therapy for ischemic heart disease in the elderly.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Humans; Myocardial Infarction; Platelet Agg | 1988 |
Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Vessel Prosthesis; Epoprostenol; Heart, Arti | 1988 |
Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Vessel Prosthesis; Epoprostenol; Heart, Arti | 1988 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
Topics: Aspirin; Blood Platelets; Blood Vessels; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cycloo | 1986 |
Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
Topics: Aspirin; Blood Platelets; Blood Vessels; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cycloo | 1986 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
[Aspirin as a platelet antiaggregant: indications and controversies].
Topics: Arteriovenous Shunt, Surgical; Aspirin; Coronary Artery Bypass; Female; Heart Valve Prosthesis; Huma | 1987 |
[Aspirin as a platelet antiaggregant: indications and controversies].
Topics: Arteriovenous Shunt, Surgical; Aspirin; Coronary Artery Bypass; Female; Heart Valve Prosthesis; Huma | 1987 |
Prevention of recurrent myocardial infarction and sudden death with aspirin therapy.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Prognosis; Recurrence | 1987 |
Prevention of recurrent myocardial infarction and sudden death with aspirin therapy.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Prognosis; Recurrence | 1987 |
[Unstable angina pectoris, acute myocardial infarct, sudden heart death. Patho-anatomy and pathophysiology].
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Calcium Channel Blockers; Coronary Angiography; Coronary | 1987 |
[Unstable angina pectoris, acute myocardial infarct, sudden heart death. Patho-anatomy and pathophysiology].
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Calcium Channel Blockers; Coronary Angiography; Coronary | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Pathophysiology of coronary occlusion in acute infarction.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Vasospasm; Coronary Vessels; Death, Sudden; Human | 1986 |
Pathophysiology of coronary occlusion in acute infarction.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Vasospasm; Coronary Vessels; Death, Sudden; Human | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
[Anti-aggregating agents: for which patients?].
Topics: Angina, Unstable; Aspirin; Coronary Artery Bypass; Heart Valve Prosthesis; Humans; Myocardial Infarc | 1986 |
[Anti-aggregating agents: for which patients?].
Topics: Angina, Unstable; Aspirin; Coronary Artery Bypass; Heart Valve Prosthesis; Humans; Myocardial Infarc | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
[Analogs of prostaglandin-related substances and inhibitors of their synthesis and metabolism. Clinical application: cardiovascular diseases].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Epoprostenol; Humans; Hypertension; Methacrylates; Myoca | 1985 |
[Analogs of prostaglandin-related substances and inhibitors of their synthesis and metabolism. Clinical application: cardiovascular diseases].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Epoprostenol; Humans; Hypertension; Methacrylates; Myoca | 1985 |
Antiplatelet aggregant agents and thrombolytic compounds in myocardial infarction: current status.
Topics: Anticoagulants; Aspirin; Blood Coagulation Factors; Coumarins; Dextrans; Dipyridamole; Fibrinolytic | 1972 |
Antiplatelet aggregant agents and thrombolytic compounds in myocardial infarction: current status.
Topics: Anticoagulants; Aspirin; Blood Coagulation Factors; Coumarins; Dextrans; Dipyridamole; Fibrinolytic | 1972 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
834 trials available for aspirin and Myocardial Infarction
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual An | 2021 |
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual An | 2021 |
Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholester | 2021 |
Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholester | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Age | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Age | 2021 |
Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.
Topics: Aspirin; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.
Topics: Aspirin; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary | 2022 |
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary | 2022 |
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2022 |
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2022 |
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Infant; Myocardial Infarction; Peripheral Arterial Disea | 2022 |
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Infant; Myocardial Infarction; Peripheral Arterial Disea | 2022 |
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S | 2022 |
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S | 2022 |
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2022 |
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2022 |
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarcti | 2022 |
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarcti | 2022 |
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarctio | 2022 |
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarctio | 2022 |
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Peripheral | 2022 |
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Peripheral | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hem | 2022 |
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hem | 2022 |
Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
Topics: Aspirin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarc | 2022 |
Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
Topics: Aspirin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarc | 2022 |
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarc | 2022 |
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarc | 2022 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome | 2023 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome | 2023 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic S | 2023 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic S | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2023 |
Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial | 2023 |
Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarc | 2023 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2023 |
The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2023 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Perc | 2023 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Perc | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; | 2023 |
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient-Centered Care; Peripheral | 2023 |
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient-Centered Care; Peripheral | 2023 |
Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Female; Hemorrhage; Humans; Male; Myoc | 2023 |
Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Female; Hemorrhage; Humans; Male; Myoc | 2023 |
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.
Topics: Aged; Aspirin; Female; Humans; Internet; Male; Myocardial Infarction; Stroke | 2023 |
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.
Topics: Aged; Aspirin; Female; Humans; Internet; Male; Myocardial Infarction; Stroke | 2023 |
Sex differences in secondary preventive follow-up after coronary heart events.
Topics: Aspirin; Female; Follow-Up Studies; Heart; Humans; Male; Myocardial Infarction; Sex Characteristics | 2023 |
Sex differences in secondary preventive follow-up after coronary heart events.
Topics: Aspirin; Female; Follow-Up Studies; Heart; Humans; Male; Myocardial Infarction; Sex Characteristics | 2023 |
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Ma | 2023 |
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Ma | 2023 |
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2023 |
Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percuta | 2023 |
Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percuta | 2023 |
Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.
Topics: Anticoagulants; Aspirin; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggre | 2023 |
Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.
Topics: Anticoagulants; Aspirin; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggre | 2023 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combinat | 2019 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combinat | 2019 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reva | 2019 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reva | 2019 |
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).
Topics: Aged; Analysis of Variance; Aspirin; Asymptomatic Diseases; Coronary Angiography; Drug Therapy, Comb | 2019 |
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).
Topics: Aged; Analysis of Variance; Aspirin; Asymptomatic Diseases; Coronary Angiography; Drug Therapy, Comb | 2019 |
Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study).
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Dual Anti-P | 2019 |
Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study).
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Dual Anti-P | 2019 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Topics: Absorbable Implants; Aspirin; China; Clinical Trials, Phase IV as Topic; Coronary Angiography; Coron | 2019 |
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Topics: Absorbable Implants; Aspirin; China; Clinical Trials, Phase IV as Topic; Coronary Angiography; Coron | 2019 |
A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
Topics: Aged; Aspirin; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Death, | 2020 |
A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
Topics: Aged; Aspirin; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Death, | 2020 |
One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery.
Topics: Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Female; Follow-Up Stu | 2020 |
One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery.
Topics: Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Female; Follow-Up Stu | 2020 |
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2020 |
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2020 |
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad | 2021 |
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad | 2021 |
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting | 2020 |
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting | 2020 |
First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid.
Topics: Administration, Inhalation; Aged; Aspirin; Female; Humans; Male; Mastication; Middle Aged; Myocardia | 2020 |
First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid.
Topics: Administration, Inhalation; Aged; Aspirin; Female; Humans; Male; Mastication; Middle Aged; Myocardia | 2020 |
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Stenosis; Drug-Eluting Stents; Dual Anti-Platelet T | 2021 |
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Stenosis; Drug-Eluting Stents; Dual Anti-Platelet T | 2021 |
Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, | 2021 |
Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, | 2021 |
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-U | 2021 |
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-U | 2021 |
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Hemorrhage; Hospitalization; Humans | 2021 |
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Hemorrhage; Hospitalization; Humans | 2021 |
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Topics: Aged; Aspirin; Coronary Disease; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Dura | 2021 |
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Topics: Aged; Aspirin; Coronary Disease; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Dura | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedu | 2017 |
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedu | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascul | 2018 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascul | 2018 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar | 2018 |
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar | 2018 |
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Clonidine; Drug Administration Schedule; Drug Th | 2018 |
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Clonidine; Drug Administration Schedule; Drug Th | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female | 2018 |
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female | 2018 |
Topics: Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Percu | 2018 |
Topics: Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Percu | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; | 2018 |
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relations | 2018 |
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relations | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2).
Topics: Aged; Aspirin; Constriction, Pathologic; Female; Humans; Male; Myocardial Infarction; Perioperative | 2018 |
Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2).
Topics: Aged; Aspirin; Constriction, Pathologic; Female; Humans; Male; Myocardial Infarction; Perioperative | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; | 2019 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type | 2019 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type | 2019 |
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Topics: Aspirin; Coronary Artery Disease; Drug Administration Routes; Drug Therapy, Combination; Endpoint De | 2019 |
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Topics: Aspirin; Coronary Artery Disease; Drug Administration Routes; Drug Therapy, Combination; Endpoint De | 2019 |
Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
Topics: Aged; Aspirin; Cardiovascular Agents; Community Health Services; Cross-Over Studies; Female; Geograp | 2019 |
Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
Topics: Aged; Aspirin; Cardiovascular Agents; Community Health Services; Cross-Over Studies; Female; Geograp | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb | 2019 |
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer | 2019 |
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
Topics: Aged; Aspirin; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibito | 2019 |
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
Topics: Aged; Aspirin; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibito | 2019 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Art | 2013 |
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Art | 2013 |
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Captopril; Europe; Female; Humans; Hypertens | 2013 |
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Captopril; Europe; Female; Humans; Hypertens | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2013 |
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Co | 2013 |
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Co | 2013 |
Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Creatinine; Cyclooxygenase 1; Cyclooxygenas | 2013 |
Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Creatinine; Cyclooxygenase 1; Cyclooxygenas | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema | 2014 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2014 |
Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Dru | 2014 |
Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Dru | 2014 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Injections, Intravenous; Lysophosph | 2013 |
Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Injections, Intravenous; Lysophosph | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study).
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2014 |
Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study).
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2014 |
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin | 2014 |
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin | 2014 |
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male | 2013 |
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male | 2013 |
HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Pressure; China; Coronary Angiography; Electrocardiograp | 2014 |
HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Pressure; China; Coronary Angiography; Electrocardiograp | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Aspirin in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peri | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Clonidine; Double-Blind Method; Female; Humans; Intraoperative Complications; Male; M | 2014 |
Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Clonidine; Double-Blind Method; Female; Humans; Intraoperative Complications; Male; M | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Human | 2014 |
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cohort Studies; Cyclooxygenase 1; Female; Gene Frequency; Ge | 2014 |
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cohort Studies; Cyclooxygenase 1; Female; Gene Frequency; Ge | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; C | 2015 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; C | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Drugs, Ge | 2014 |
Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Drugs, Ge | 2014 |
Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; France | 2014 |
Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; France | 2014 |
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2015 |
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2015 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
Platelet activation is associated with myocardial infarction in patients with pneumonia.
Topics: Aged; Aspirin; Biomarkers; CD40 Ligand; Community-Acquired Infections; Electrocardiography; Female; | 2014 |
[Primary prevention with acetylsalicylic acid: large study, hardly any effects].
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
[Primary prevention with acetylsalicylic acid: large study, hardly any effects].
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
[Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)].
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clo | 2015 |
[Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)].
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clo | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
Topics: Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous | 2015 |
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
Topics: Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; | 2015 |
[The POISE-2 Aspirin trial].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Dose-Response Relationship, Drug; Human | 2015 |
[The POISE-2 Aspirin trial].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Dose-Response Relationship, Drug; Human | 2015 |
[The POISE-2 Clonidine trial].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Dose-Response Relationship, Drug; Doubl | 2015 |
[The POISE-2 Clonidine trial].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonidine; Dose-Response Relationship, Drug; Doubl | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internation | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internation | 2015 |
Causes of late mortality with dual antiplatelet therapy after coronary stents.
Topics: Aspirin; Cause of Death; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; | 2016 |
Causes of late mortality with dual antiplatelet therapy after coronary stents.
Topics: Aspirin; Cause of Death; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combin | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combin | 2016 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 2016 |
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 2016 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Met | 2016 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Met | 2016 |
Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Blood Platelets; Blood Pressure; Creatine Kinase; Female; Heart Rate; Hemorrhage; Hum | 2016 |
Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Blood Platelets; Blood Pressure; Creatine Kinase; Female; Heart Rate; Hemorrhage; Hum | 2016 |
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study.
Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Cohort Studies; Female; Heart Diseases; Humans; | 2016 |
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study.
Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Cohort Studies; Female; Heart Diseases; Humans; | 2016 |
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy | 2016 |
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationshi | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationshi | 2016 |
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Ma | 2016 |
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Ma | 2016 |
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect | 2016 |
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
Topics: Aspirin; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; M | 2016 |
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
Topics: Aspirin; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; M | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor | 2016 |
Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; China; Cilostazol; Clopidogrel; Drug Administrat | 2016 |
Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; China; Cilostazol; Clopidogrel; Drug Administrat | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Double-Blin | 2016 |
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Double-Blin | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations | 2017 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistan | 2008 |
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistan | 2008 |
Long-term cost-effectiveness of clopidogrel in STEMI patients.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Huma | 2009 |
Long-term cost-effectiveness of clopidogrel in STEMI patients.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Huma | 2009 |
Effects of early abciximab administration before primary percutaneous coronary intervention on left ventricular function assessed by cardiac magnetic resonance.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Female; Follow-Up Studies; | 2008 |
Effects of early abciximab administration before primary percutaneous coronary intervention on left ventricular function assessed by cardiac magnetic resonance.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Female; Follow-Up Studies; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Biomarkers; Coronary Angiograph | 2009 |
Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Biomarkers; Coronary Angiograph | 2009 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incid | 2009 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incid | 2009 |
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial | 2009 |
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial | 2009 |
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm | 2009 |
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary A | 2009 |
Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary A | 2009 |
Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.
Topics: Aspirin; C-Reactive Protein; Clopidogrel; Coronary Circulation; Creatine Kinase, MB Form; Drug Thera | 2009 |
Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.
Topics: Aspirin; C-Reactive Protein; Clopidogrel; Coronary Circulation; Creatine Kinase, MB Form; Drug Thera | 2009 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Confidence Interva | 2009 |
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Confidence Interva | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Confidence Interva | 2009 |
Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Confidence Interva | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atorvastatin; Blood Platelets; Drug Therapy, Combination; F | 2009 |
Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atorvastatin; Blood Platelets; Drug Therapy, Combination; F | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myoca | 2010 |
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myoca | 2010 |
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells, | 2010 |
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells, | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Dia | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Dia | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclo | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Dr | 2010 |
Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Dr | 2010 |
Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance".
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Tolerance; Hu | 2010 |
Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance".
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Tolerance; Hu | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square D | 2010 |
Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square D | 2010 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
The efficacy and safety of clopidogrel in vascular surgery patients with immediate postoperative asymptomatic troponin T release for the prevention of late cardiac events: Rationale and design of the Dutch Echocardiographic Cardiac Risk Evaluation Applyin
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Echocardiography, Stress; Humans; Myo | 2010 |
The efficacy and safety of clopidogrel in vascular surgery patients with immediate postoperative asymptomatic troponin T release for the prevention of late cardiac events: Rationale and design of the Dutch Echocardiographic Cardiac Risk Evaluation Applyin
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Echocardiography, Stress; Humans; Myo | 2010 |
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, | 2010 |
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, | 2010 |
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; | 2010 |
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; | 2010 |
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elec | 2010 |
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elec | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Aspirin; Azetidines; Benzylamines; Bio | 2011 |
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Aspirin; Azetidines; Benzylamines; Bio | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi | 2011 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; | 2011 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2011 |
Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactio | 2012 |
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactio | 2012 |
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cor | 2011 |
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cor | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction.
Topics: Aged; Antithrombins; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; H | 2012 |
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction.
Topics: Aged; Antithrombins; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; H | 2012 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2011 |
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Hemorrhage; Humans; Mi | 2011 |
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Hemorrhage; Humans; Mi | 2011 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati | 2012 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZO
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Dose-Response Relationship, Dru | 2012 |
Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZO
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Dose-Response Relationship, Dru | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle A | 2012 |
P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle A | 2012 |
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Double- | 2012 |
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Double- | 2012 |
Association of COX-2 rs20417 with aspirin resistance.
Topics: Adult; Aged; Alleles; Aspirin; Brain Ischemia; Cyclooxygenase 2; Drug Resistance; Female; Follow-Up | 2013 |
Association of COX-2 rs20417 with aspirin resistance.
Topics: Adult; Aged; Alleles; Aspirin; Brain Ischemia; Cyclooxygenase 2; Drug Resistance; Female; Follow-Up | 2013 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb | 2012 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Midd | 2013 |
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Midd | 2013 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1; | 2013 |
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1; | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard | 2013 |
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard | 2013 |
Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Inter | 2012 |
Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Inter | 2012 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy | 2014 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy | 2014 |
Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
Topics: Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2013 |
Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
Topics: Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2013 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutane | 2013 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutane | 2013 |
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Corona | 2013 |
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Corona | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thr | 2013 |
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Netherlands; | 2002 |
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Netherlands; | 2002 |
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Disease-Free Survival; D | 2002 |
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Disease-Free Survival; D | 2002 |
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Topics: Aged; alpha-2-Antiplasmin; Anticoagulants; Antifibrinolytic Agents; Antithrombin III; Aspirin; Bioma | 2002 |
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Topics: Aged; alpha-2-Antiplasmin; Anticoagulants; Antifibrinolytic Agents; Antithrombin III; Aspirin; Bioma | 2002 |
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Double-Blind Met | 2002 |
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Double-Blind Met | 2002 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi | 2002 |
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi | 2002 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Disease-Free Survival; Drug Therapy, Combination; Female; Hemorrhage; | 2002 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Disease-Free Survival; Drug Therapy, Combination; Female; Hemorrhage; | 2002 |
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac | 2002 |
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac | 2002 |
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Bayes Theorem; Clinical Trials, Ph | 2002 |
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Bayes Theorem; Clinical Trials, Ph | 2002 |
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Humans; Hypertension; Myocardial I | 2002 |
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Humans; Hypertension; Myocardial I | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
[Use of trimetazidine in the combined therapy of myocardial infarction with left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Diur | 2002 |
[Use of trimetazidine in the combined therapy of myocardial infarction with left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Diur | 2002 |
[Effect of calcium antagonists on long-term prognosis of patients with myocardial infarction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium Channel Blockers; Drug Therapy, Combinatio | 2002 |
[Effect of calcium antagonists on long-term prognosis of patients with myocardial infarction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium Channel Blockers; Drug Therapy, Combinatio | 2002 |
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Resistance; F | 2002 |
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Resistance; F | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
A randomized trial of beta carotene and age-related cataract in US physicians.
Topics: Adult; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspiri | 2003 |
A randomized trial of beta carotene and age-related cataract in US physicians.
Topics: Adult; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspiri | 2003 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Huma | 2003 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Huma | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy | 2003 |
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy | 2003 |
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
Topics: Acute Disease; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Hospi | 2003 |
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
Topics: Acute Disease; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Hospi | 2003 |
Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; International Normalized Ratio; Myocar | 2003 |
Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; International Normalized Ratio; Myocar | 2003 |
Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial.
Topics: Adrenergic beta-Antagonists; Aged; Animals; Aspirin; Cause of Death; Diet, Mediterranean; Female; Fi | 2003 |
Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial.
Topics: Adrenergic beta-Antagonists; Aged; Animals; Aspirin; Cause of Death; Diet, Mediterranean; Female; Fi | 2003 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F | 2003 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F | 2003 |
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Artery Di | 2003 |
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Artery Di | 2003 |
Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Electrocardiography; Fibrinolyti | 2003 |
Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Electrocardiography; Fibrinolyti | 2003 |
Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Algorithms; Aspirin; Coronary Angiography; Female; Fibrinolytic Agents; Hep | 2003 |
Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Algorithms; Aspirin; Coronary Angiography; Female; Fibrinolytic Agents; Hep | 2003 |
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Coh | 2003 |
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Coh | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Hepari | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Hepari | 2003 |
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Topics: Administration, Oral; Aged; Aspirin; Azetidines; Benzylamines; Double-Blind Method; Drug Therapy, Co | 2003 |
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Topics: Administration, Oral; Aged; Aspirin; Azetidines; Benzylamines; Double-Blind Method; Drug Therapy, Co | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biomarkers; C-Reactiv | 2003 |
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biomarkers; C-Reactiv | 2003 |
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo | 2003 |
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat | 2003 |
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Emergency Medic | 2003 |
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Emergency Medic | 2003 |
Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Double-Blind Method; Eptifibatide; Female; | 2004 |
Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Double-Blind Method; Eptifibatide; Female; | 2004 |
Soluble tissue factor as predictor of future events in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male | 2003 |
Soluble tissue factor as predictor of future events in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male | 2003 |
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
Topics: Aged; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fem | 2004 |
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
Topics: Aged; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fem | 2004 |
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2004 |
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2004 |
Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Flow Velocity; Cohort Studies; Corona | 2004 |
Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Flow Velocity; Cohort Studies; Corona | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri | 2004 |
Evaluation of a public education program delivered by firefighters on early recognition of a heart attack.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Emergency Medical Service Communication Systems; Fema | 2004 |
Evaluation of a public education program delivered by firefighters on early recognition of a heart attack.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Emergency Medical Service Communication Systems; Fema | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 2004 |
Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 2004 |
Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Drug Therapy, Combination; Female; Hemo | 2004 |
Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Drug Therapy, Combination; Female; Hemo | 2004 |
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; CD40 Ligand; Clopidogrel; Enzyme-Linked Immunosorbe | 2004 |
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; CD40 Ligand; Clopidogrel; Enzyme-Linked Immunosorbe | 2004 |
Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Creatine Kinase; Creatine Kinase, MM Form; Dose-Response Relationship, Drug; F | 2004 |
Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Creatine Kinase; Creatine Kinase, MM Form; Dose-Response Relationship, Drug; F | 2004 |
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Drug Administration Schedule; D | 2004 |
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Drug Administration Schedule; D | 2004 |
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
Topics: Aged; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Feasibility Studies; Female; Hospitalization | 2004 |
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
Topics: Aged; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Feasibility Studies; Female; Hospitalization | 2004 |
Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Mon | 2004 |
Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Mon | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
[Anti-ischemic effects of trimetazidine in patients with post-infarction heart failure].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Female; Heart Failure; | 2004 |
[Anti-ischemic effects of trimetazidine in patients with post-infarction heart failure].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Female; Heart Failure; | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary | 2004 |
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Drug Therapy, Comb | 2004 |
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Drug Therapy, Comb | 2004 |
[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; | 2004 |
[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; | 2004 |
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Ba | 2004 |
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Ba | 2004 |
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa | 2004 |
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa | 2004 |
High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; F | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; F | 2004 |
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogr | 2004 |
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogr | 2004 |
Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; Follow- | 2005 |
Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; Follow- | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.
Topics: Arachidonic Acid; Aspirin; Drug Resistance; Humans; Myocardial Infarction; Patient Compliance; Plate | 2005 |
Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.
Topics: Arachidonic Acid; Aspirin; Drug Resistance; Humans; Myocardial Infarction; Patient Compliance; Plate | 2005 |
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal | 2004 |
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal | 2004 |
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In | 2005 |
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In | 2005 |
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics | 2005 |
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics | 2005 |
Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; Fe | 2005 |
Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; Fe | 2005 |
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Dalteparin; Electrocardiography; Female; | 2005 |
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Dalteparin; Electrocardiography; Female; | 2005 |
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Confidence Intervals; Coro | 2005 |
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Confidence Intervals; Coro | 2005 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Fe | 2005 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Fe | 2005 |
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Fem | 2005 |
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Fem | 2005 |
Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; | 2006 |
Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; | 2006 |
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myoca | 2005 |
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myoca | 2005 |
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste | 2005 |
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste | 2005 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
Platelet hyper-function in acute coronary syndromes.
Topics: Administration, Oral; Angina, Unstable; Aspirin; Bleeding Time; Female; Humans; Male; Myocardial Inf | 2005 |
Platelet hyper-function in acute coronary syndromes.
Topics: Administration, Oral; Angina, Unstable; Aspirin; Bleeding Time; Female; Humans; Male; Myocardial Inf | 2005 |
Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Mid | 2005 |
Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Mid | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combinatio | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera | 2005 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag | 2005 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag | 2005 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male; | 2006 |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male; | 2006 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; | 2006 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; | 2006 |
A community intervention by firefighters to increase 911 calls and aspirin use for chest pain.
Topics: Aged; Aspirin; Chest Pain; Emergency Medical Service Communication Systems; Emergency Medical Servic | 2006 |
A community intervention by firefighters to increase 911 calls and aspirin use for chest pain.
Topics: Aged; Aspirin; Chest Pain; Emergency Medical Service Communication Systems; Emergency Medical Servic | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
Topics: Aged; Aspirin; Clopidogrel; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administrat | 2006 |
Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
Topics: Aged; Aspirin; Clopidogrel; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administrat | 2006 |
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male; | 2006 |
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male; | 2006 |
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug | 2006 |
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug | 2006 |
Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Resistance; Female | 2007 |
Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Resistance; Female | 2007 |
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Hiru | 2006 |
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Hiru | 2006 |
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Bli | 2006 |
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Bli | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; Humans; Middle Aged; Myocardial Inf | 2006 |
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; Humans; Middle Aged; Myocardial Inf | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
Serial angiography in patients with acute coronary syndromes: effect of antithrombotic therapy on angiographic lesion severity.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Steno | 2006 |
Serial angiography in patients with acute coronary syndromes: effect of antithrombotic therapy on angiographic lesion severity.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Steno | 2006 |
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Administration Sch | 2007 |
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Administration Sch | 2007 |
Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive P | 2007 |
Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive P | 2007 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me | 2007 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me | 2007 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; Disease Progression; Drug Therapy, Co | 2007 |
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; Disease Progression; Drug Therapy, Co | 2007 |
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
[Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation].
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiogra | 2007 |
[Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation].
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiogra | 2007 |
Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Cardiac Catheterization; C | 2007 |
Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Cardiac Catheterization; C | 2007 |
An intervention to improve secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Pharm | 2007 |
An intervention to improve secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Pharm | 2007 |
Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Drug Resistance; Female; Humans; In | 2007 |
Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Drug Resistance; Female; Humans; In | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infar | 2007 |
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infar | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cardiovascular Agents; Evidence-Based Medicine; | 2007 |
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cardiovascular Agents; Evidence-Based Medicine; | 2007 |
Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Constriction, Pathologic; Female; Humans; Intracranial Arterio | 2007 |
Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Constriction, Pathologic; Female; Humans; Intracranial Arterio | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Hirudin Therapy; Hirudins; Humans; Male; Mid | 2007 |
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Hirudin Therapy; Hirudins; Humans; Male; Mid | 2007 |
Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention:
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response R | 2007 |
Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention:
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response R | 2007 |
The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Fibrinolytic Age | 2008 |
The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Fibrinolytic Age | 2008 |
Stroke prevention: age alone does not rule out warfarin.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrilla | 2007 |
Stroke prevention: age alone does not rule out warfarin.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrilla | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; CD40 Antigens; Cilostazo | 2007 |
Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; CD40 Antigens; Cilostazo | 2007 |
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2008 |
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2008 |
Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Cerebral Hemorrhage; Cerebral In | 2008 |
Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Cerebral Hemorrhage; Cerebral In | 2008 |
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; | 2008 |
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; | 2008 |
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati | 2008 |
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati | 2008 |
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2008 |
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2008 |
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2008 |
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2008 |
Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; | 2008 |
Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; | 2008 |
Less benefit from warfarin in diabetics after myocardial infarction?
Topics: Aged; Anticoagulants; Aspirin; Confounding Factors, Epidemiologic; Diabetes Complications; Drug Ther | 2008 |
Less benefit from warfarin in diabetics after myocardial infarction?
Topics: Aged; Anticoagulants; Aspirin; Confounding Factors, Epidemiologic; Diabetes Complications; Drug Ther | 2008 |
Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Humans; International N | 2009 |
Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Humans; International N | 2009 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
Sulphinpyrazone, aspirin, and uric acid.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone; Uric Acid | 1980 |
Sulphinpyrazone, aspirin, and uric acid.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Sulfinpyrazone; Uric Acid | 1980 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Aspirin after myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Placebos; Prognosis | 1980 |
Aspirin after myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Death, Sudden; Humans; Myocardial Infarction; Placebos; Prognosis | 1980 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Prophylaxis of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Inf | 1981 |
Prophylaxis of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Inf | 1981 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top | 1983 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top | 1983 |
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clinical Trials as Topic; Death, Sudden; Dou | 1983 |
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clinical Trials as Topic; Death, Sudden; Dou | 1983 |
The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Fem | 1984 |
The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Fem | 1984 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Aspirin curbs MIs in unstable angina cases.
Topics: Angina Pectoris, Variant; Aspirin; Clinical Trials as Topic; Coronary Vasospasm; Double-Blind Method | 1983 |
Aspirin curbs MIs in unstable angina cases.
Topics: Angina Pectoris, Variant; Aspirin; Clinical Trials as Topic; Coronary Vasospasm; Double-Blind Method | 1983 |
Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial.
Topics: Adult; Aged; Angiography; Aspirin; Clinical Enzyme Tests; Clinical Trials as Topic; Coronary Circula | 1983 |
Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial.
Topics: Adult; Aged; Angiography; Aspirin; Clinical Enzyme Tests; Clinical Trials as Topic; Coronary Circula | 1983 |
British studies of aspirin and myocardial infarction.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1983 |
British studies of aspirin and myocardial infarction.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1983 |
Aspirin in coronary heart disease. Comparison of six clinical trials.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle | 1983 |
Aspirin in coronary heart disease. Comparison of six clinical trials.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
[Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
Topics: Acenocoumarol; Adult; Ambulatory Care; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyrida | 1983 |
[Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
Topics: Acenocoumarol; Adult; Ambulatory Care; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyrida | 1983 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Reduced side effects by low dose of acetylsalicylic acid (ASA) in patients with myocardial infarction; estimations of serum thromboxane B2 and PGF2 alpha.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dinoprost; Female; Follow-Up Studies; Humans; Male; | 1984 |
Reduced side effects by low dose of acetylsalicylic acid (ASA) in patients with myocardial infarction; estimations of serum thromboxane B2 and PGF2 alpha.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dinoprost; Female; Follow-Up Studies; Humans; Male; | 1984 |
Variation in the use of angiography and carotid endarterectomy by neurologists in the UK-TIA aspirin trial.
Topics: Aged; Angiography; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; E | 1983 |
Variation in the use of angiography and carotid endarterectomy by neurologists in the UK-TIA aspirin trial.
Topics: Aged; Angiography; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; E | 1983 |
[Long-term antithrombotic treatment in coronary disease].
Topics: 4-Hydroxycoumarins; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Fibrinolyti | 1983 |
[Long-term antithrombotic treatment in coronary disease].
Topics: 4-Hydroxycoumarins; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Fibrinolyti | 1983 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
[Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
[Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Aspirin; Austria; Clinical Trials as Topic; Death, Sudden; | 1980 |
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Aspirin; Austria; Clinical Trials as Topic; Death, Sudden; | 1980 |
The factor VIII complex in atherosclerosis: effects of aspirin.
Topics: Adult; Aged; Antigens; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Factor VIII; Female; Hum | 1981 |
The factor VIII complex in atherosclerosis: effects of aspirin.
Topics: Adult; Aged; Antigens; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Factor VIII; Female; Hum | 1981 |
Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Humans; Male; Middle Aged; Myocardial Infarction; Ra | 1981 |
Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Humans; Male; Middle Aged; Myocardial Infarction; Ra | 1981 |
Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Epoprostenol; Humans; H | 1982 |
Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Epoprostenol; Humans; H | 1982 |
[Study on secondary prevention of myocardial infarct (EPSIM). Work of the EPSIM research group].
Topics: 4-Hydroxycoumarins; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Female; France; | 1982 |
[Study on secondary prevention of myocardial infarct (EPSIM). Work of the EPSIM research group].
Topics: 4-Hydroxycoumarins; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Female; France; | 1982 |
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarc | 1980 |
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarc | 1980 |
AMIS negative on aspirin and heart attacks.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Transient; Ma | 1980 |
AMIS negative on aspirin and heart attacks.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Transient; Ma | 1980 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infar | 1980 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infar | 1980 |
Secondary prevention of myocardial infarction--the present state of the ART.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1980 |
Secondary prevention of myocardial infarction--the present state of the ART.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1980 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Clinical trials of platelet-active drugs in coronary heart disease: summary of design features.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electroca | 1980 |
Clinical trials of platelet-active drugs in coronary heart disease: summary of design features.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electroca | 1980 |
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
Topics: Aspirin; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1980 |
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
Topics: Aspirin; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1980 |
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Middl | 1980 |
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Middl | 1980 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarction | 1981 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarction | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
[Prevention of sequelae after myocardial infarct. Results, methods and problems of a prospective multi-center study of the effect of acetylsalicylic acid, phenprocoumon and placebo].
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myoc | 1980 |
[Prevention of sequelae after myocardial infarct. Results, methods and problems of a prospective multi-center study of the effect of acetylsalicylic acid, phenprocoumon and placebo].
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myoc | 1980 |
[The platelet inhibitor problem].
Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1981 |
[The platelet inhibitor problem].
Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1981 |
Are clinical trials in coronary heart disease oversold or undersold?
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; Random Allocatio | 1981 |
Are clinical trials in coronary heart disease oversold or undersold?
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; Random Allocatio | 1981 |
[Review of recent investigations on platelet regulators following infarction].
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarcti | 1981 |
[Review of recent investigations on platelet regulators following infarction].
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarcti | 1981 |
Current status of antithrombotic agents in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Heparin; Humans; Myocardial | 1981 |
Current status of antithrombotic agents in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Heparin; Humans; Myocardial | 1981 |
Drug prophylaxis for arterial thromboembolism--1981.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Decision M | 1981 |
Drug prophylaxis for arterial thromboembolism--1981.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Decision M | 1981 |
[Results of prevention of second myocardial infarct with syncumar or aspirin].
Topics: Acenocoumarol; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Middle Aged; Myoc | 1981 |
[Results of prevention of second myocardial infarct with syncumar or aspirin].
Topics: Acenocoumarol; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Middle Aged; Myoc | 1981 |
[Various observations on the results of the "Aspirin myocardial infarction study" and the "Persantine-aspirin reinfarction study" in the United States].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Humans; M | 1981 |
[Various observations on the results of the "Aspirin myocardial infarction study" and the "Persantine-aspirin reinfarction study" in the United States].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Humans; M | 1981 |
Can aspirin prevent recurrence of heart attacks and strokes?
Topics: Adult; Aged; Antithrombins; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Hu | 1982 |
Can aspirin prevent recurrence of heart attacks and strokes?
Topics: Adult; Aged; Antithrombins; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Hu | 1982 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Data Collectio | 1981 |
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Data Collectio | 1981 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
Prognostic implications of diagnostic Q waves after myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Electrocardiography; Humans; Middle Aged; Myocardial | 1982 |
Prognostic implications of diagnostic Q waves after myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Electrocardiography; Humans; Middle Aged; Myocardial | 1982 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Death, Sudden; | 1982 |
A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Death, Sudden; | 1982 |
Does chronic aspirin treatment increase blood pressure in man?
Topics: Aspirin; Blood Pressure; Humans; Hypertension; Myocardial Infarction; Platelet Aggregation | 1981 |
Does chronic aspirin treatment increase blood pressure in man?
Topics: Aspirin; Blood Pressure; Humans; Hypertension; Myocardial Infarction; Platelet Aggregation | 1981 |
Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution.
Topics: Adult; Aged; Aspirin; Dextropropoxyphene; Female; Humans; Indomethacin; Male; Middle Aged; Myocardia | 1981 |
Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution.
Topics: Adult; Aged; Aspirin; Dextropropoxyphene; Female; Humans; Indomethacin; Male; Middle Aged; Myocardia | 1981 |
Persantine-aspirin reinfarction study. Design, methods and baseline results. By the persantine-aspirin reinfarction study research group.
Topics: Adult; Aged; Animals; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Electrocar | 1980 |
Persantine-aspirin reinfarction study. Design, methods and baseline results. By the persantine-aspirin reinfarction study research group.
Topics: Adult; Aged; Animals; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Electrocar | 1980 |
[Long term prophylaxis of re-infarct. Results of the persantin-acetylsalicylic acid re-infarct study].
Topics: Adult; Aged; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 1980 |
[Long term prophylaxis of re-infarct. Results of the persantin-acetylsalicylic acid re-infarct study].
Topics: Adult; Aged; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 1980 |
The anturane reinfarction trial.
Topics: Aspirin; Blood Platelets; Death, Sudden; Female; Humans; Male; Myocardial Infarction; Placebos; Sulf | 1980 |
The anturane reinfarction trial.
Topics: Aspirin; Blood Platelets; Death, Sudden; Female; Humans; Male; Myocardial Infarction; Placebos; Sulf | 1980 |
Aspirin and secondary mortality after myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Female; Hemoglobins; Humans; Ma | 1980 |
Aspirin and secondary mortality after myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Female; Hemoglobins; Humans; Ma | 1980 |
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Topics: Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male | 1980 |
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Topics: Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male | 1980 |
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos | 1995 |
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos | 1995 |
Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations.
Topics: Aged; Aprotinin; Aspirin; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cardiac Surgical Pr | 1994 |
Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations.
Topics: Aged; Aprotinin; Aspirin; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cardiac Surgical Pr | 1994 |
Aspirin and acute myocardial infarction: clarifying the message.
Topics: Aspirin; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Thrombolytic Therapy | 1995 |
Aspirin and acute myocardial infarction: clarifying the message.
Topics: Aspirin; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Thrombolytic Therapy | 1995 |
Secondary prevention of myocardial infarction: impact of clinical trials on clinical practice.
Topics: Aspirin; Calcium Channel Blockers; Drug Utilization; Humans; Myocardial Infarction; Nitrates | 1995 |
Secondary prevention of myocardial infarction: impact of clinical trials on clinical practice.
Topics: Aspirin; Calcium Channel Blockers; Drug Utilization; Humans; Myocardial Infarction; Nitrates | 1995 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Doub | 1995 |
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Doub | 1995 |
Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Coronary Angiography; Dose-Response Relationship, Drug; Double-Bli | 1995 |
Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Coronary Angiography; Dose-Response Relationship, Drug; Double-Bli | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating
Topics: Adolescent; Adult; Aged; Aspirin; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Drug | 1995 |
Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating
Topics: Adolescent; Adult; Aged; Aspirin; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Drug | 1995 |
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Dipyridamole; Double-Blind Method | 1995 |
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Dipyridamole; Double-Blind Method | 1995 |
Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
Topics: Adult; Aged; Aspirin; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Infusions, Intravenous; Ma | 1995 |
Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
Topics: Adult; Aged; Aspirin; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Infusions, Intravenous; Ma | 1995 |
A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians.
Topics: Adjuvants, Immunologic; Aspirin; beta Carotene; Carotenoids; Case-Control Studies; Cholesterol Ester | 1995 |
A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians.
Topics: Adjuvants, Immunologic; Aspirin; beta Carotene; Carotenoids; Case-Control Studies; Cholesterol Ester | 1995 |
Evaluation of myocardial infarction therapy at a Canadian tertiary referral hospital.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Drug T | 1995 |
Evaluation of myocardial infarction therapy at a Canadian tertiary referral hospital.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Drug T | 1995 |
[Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina].
Topics: Acenocoumarol; Angina, Unstable; Aspirin; Drug Synergism; Drug Therapy, Combination; Female; Hemorrh | 1995 |
[Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina].
Topics: Acenocoumarol; Angina, Unstable; Aspirin; Drug Synergism; Drug Therapy, Combination; Female; Hemorrh | 1995 |
Audit of secondary prophylaxis after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aftercare; Aspirin; Community Health Services; England; Hospitalization | 1994 |
Audit of secondary prophylaxis after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aftercare; Aspirin; Community Health Services; England; Hospitalization | 1994 |
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
Topics: Aged; Animals; Aspirin; Cause of Death; Female; Heart Rupture, Post-Infarction; Heparin; Humans; Inc | 1995 |
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
Topics: Aged; Animals; Aspirin; Cause of Death; Female; Heart Rupture, Post-Infarction; Heparin; Humans; Inc | 1995 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy | 1993 |
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low | 1993 |
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low | 1993 |
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; | 1994 |
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; | 1994 |
New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
Topics: Aspirin; Blood Coagulation Tests; Coronary Angiography; Dose-Response Relationship, Drug; Enzyme Pre | 1994 |
New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
Topics: Aspirin; Blood Coagulation Tests; Coronary Angiography; Dose-Response Relationship, Drug; Enzyme Pre | 1994 |
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Topics: Aged; Anistreplase; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studi | 1994 |
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Topics: Aged; Anistreplase; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studi | 1994 |
[Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)].
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up | 1993 |
[Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)].
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up | 1993 |
Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adult; Angina, Unstable; Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Epoprosten | 1994 |
Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adult; Angina, Unstable; Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Epoprosten | 1994 |
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Diltiazem; Drug Therapy, Combinatio | 1994 |
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Diltiazem; Drug Therapy, Combinatio | 1994 |
The role of autopsy findings in multicenter treatment evaluations as exemplified by two aspirin trials.
Topics: Aspirin; Autopsy; Cause of Death; Cerebral Infarction; Death, Sudden, Cardiac; Diagnostic Errors; Do | 1993 |
The role of autopsy findings in multicenter treatment evaluations as exemplified by two aspirin trials.
Topics: Aspirin; Autopsy; Cause of Death; Cerebral Infarction; Death, Sudden, Cardiac; Diagnostic Errors; Do | 1993 |
Aspirin versus heparin in the acute phase of unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Linear Models; Logistic Models; Myocardial Infarction | 1994 |
Aspirin versus heparin in the acute phase of unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Linear Models; Logistic Models; Myocardial Infarction | 1994 |
Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.
Topics: Aspirin; Coronary Angiography; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged | 1994 |
Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.
Topics: Aspirin; Coronary Angiography; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged | 1994 |
[The effect of thrombolytic therapy on the outcome of early exercise test in patients with acute myocardial infarction].
Topics: Aspirin; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Infusions, Intravenous; My | 1994 |
[The effect of thrombolytic therapy on the outcome of early exercise test in patients with acute myocardial infarction].
Topics: Aspirin; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Infusions, Intravenous; My | 1994 |
Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Confidence Intervals; Drug Hypersensiti | 1993 |
Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Confidence Intervals; Drug Hypersensiti | 1993 |
Secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cholesterol; Exercise; Female; Humans; Male; Midd | 1993 |
Secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cholesterol; Exercise; Female; Humans; Male; Midd | 1993 |
Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; | 1994 |
Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; | 1994 |
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aspirin; Coronary Angiography; Dose-Response Relationship, Dru | 1994 |
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aspirin; Coronary Angiography; Dose-Response Relationship, Dru | 1994 |
[Improvement of prostacyclin-thromboxane A2 balance in patients with acute myocardial infarction by intermittent aspirin].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Male; Middle | 1993 |
[Improvement of prostacyclin-thromboxane A2 balance in patients with acute myocardial infarction by intermittent aspirin].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Male; Middle | 1993 |
[The evaluation of the hemodynamic effects of captopril one year after a myocardial infarct].
Topics: Adult; Aged; Aspirin; Captopril; Drug Therapy, Combination; Female; Hemodynamics; Humans; Isosorbide | 1994 |
[The evaluation of the hemodynamic effects of captopril one year after a myocardial infarct].
Topics: Adult; Aged; Aspirin; Captopril; Drug Therapy, Combination; Female; Hemodynamics; Humans; Isosorbide | 1994 |
Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Factor Ana | 1993 |
Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Factor Ana | 1993 |
Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis.
Topics: Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Multivariate | 1993 |
Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis.
Topics: Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Multivariate | 1993 |
The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.
Topics: Administration, Oral; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Com | 1993 |
The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.
Topics: Administration, Oral; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Com | 1993 |
[The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Ag | 1993 |
[The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Ag | 1993 |
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agen | 1994 |
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agen | 1994 |
Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy.
Topics: Age Factors; Aspirin; Echocardiography; Embolism; Heart Diseases; Heart Failure; Heart Ventricles; H | 1993 |
Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy.
Topics: Age Factors; Aspirin; Echocardiography; Embolism; Heart Diseases; Heart Failure; Heart Ventricles; H | 1993 |
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspir
Topics: Aged; Aspirin; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Penta | 1994 |
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspir
Topics: Aged; Aspirin; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Penta | 1994 |
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography; Exercise Test; Hemodynamics; | 1993 |
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography; Exercise Test; Hemodynamics; | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event.
Topics: Aged; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemi | 1993 |
Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event.
Topics: Aged; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemi | 1993 |
Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.
Topics: Aged; Aspirin; Clinical Enzyme Tests; Creatine Kinase; Drug Therapy, Combination; Female; Humans; Ma | 1993 |
Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.
Topics: Aged; Aspirin; Clinical Enzyme Tests; Creatine Kinase; Drug Therapy, Combination; Female; Humans; Ma | 1993 |
Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.
Topics: Aspirin; Carotid Artery, External; Carotid Stenosis; Cerebrovascular Disorders; Chi-Square Distribut | 1993 |
Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.
Topics: Aspirin; Carotid Artery, External; Carotid Stenosis; Cerebrovascular Disorders; Chi-Square Distribut | 1993 |
Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; | 1993 |
Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; | 1993 |
[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Drug Prescr | 1995 |
[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Drug Prescr | 1995 |
Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Administration Routes; Drug Therapy, Combination; F | 1995 |
Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Administration Routes; Drug Therapy, Combination; F | 1995 |
The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI).
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inh | 1995 |
The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI).
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inh | 1995 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
Topics: Anistreplase; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction | 1996 |
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
Topics: Anistreplase; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression.
Topics: Aged; Aspirin; Biphenyl Compounds; Coronary Care Units; Double-Blind Method; Electrocardiography; Fe | 1996 |
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression.
Topics: Aged; Aspirin; Biphenyl Compounds; Coronary Care Units; Double-Blind Method; Electrocardiography; Fe | 1996 |
[Comparison of thrombolytic therapy and direct percutaneous transluminal coronary angioplasty for acute myocardial infarction: prospective multicenter trial at 16 clinical centers in Ibaraki prefecture TUGMI. Tsukuba University Group for Myocardial Infarc
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myocardia | 1996 |
[Comparison of thrombolytic therapy and direct percutaneous transluminal coronary angioplasty for acute myocardial infarction: prospective multicenter trial at 16 clinical centers in Ibaraki prefecture TUGMI. Tsukuba University Group for Myocardial Infarc
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myocardia | 1996 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Platelet Ag | 1996 |
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Heparin; Humans; Myocardial Infarction; Platelet Ag | 1996 |
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther | 1996 |
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther | 1996 |
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
Topics: Anistreplase; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Female; Heparin; Humans; Male; Myocar | 1996 |
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
Topics: Anistreplase; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Female; Heparin; Humans; Male; Myocar | 1996 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coronary Angi | 1997 |
Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coronary Angi | 1997 |
Control of bias in dietary trial to prevent coronary recurrences: The Lyon Diet Heart Study.
Topics: Adrenergic beta-Antagonists; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Control of bias in dietary trial to prevent coronary recurrences: The Lyon Diet Heart Study.
Topics: Adrenergic beta-Antagonists; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Cereb | 1997 |
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Cereb | 1997 |
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid | 1997 |
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon; Animals; Antibodies, Monoclonal; Aspirin; Coronary Cir | 1997 |
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon; Animals; Antibodies, Monoclonal; Aspirin; Coronary Cir | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
[Secondary prevention in chronic coronary heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Convertin | 1997 |
[Secondary prevention in chronic coronary heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Convertin | 1997 |
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 1997 |
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 1997 |
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation Tests; | 1997 |
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation Tests; | 1997 |
Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Angiography; Coronary Vessels; Double-Blind Meth | 1997 |
Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Angiography; Coronary Vessels; Double-Blind Meth | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Respo | 1997 |
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Respo | 1997 |
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind | 1997 |
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind | 1997 |
The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use.
Topics: Adult; Aspirin; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Monitor | 1997 |
The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use.
Topics: Adult; Aspirin; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Monitor | 1997 |
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Adm | 1997 |
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Adm | 1997 |
Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Feasibility Studies; Female | 1997 |
Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Feasibility Studies; Female | 1997 |
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
Topics: Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Case-Control Studies; Double-Blind Method; H | 1998 |
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
Topics: Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Case-Control Studies; Double-Blind Method; H | 1998 |
[Myoglobin concentration in serum as an early marker of reperfusion in patients with acute myocardial infarction after thrombolytic therapy].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Creatine Kinase; Female; Heparin; Humans; Male; | 1997 |
[Myoglobin concentration in serum as an early marker of reperfusion in patients with acute myocardial infarction after thrombolytic therapy].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Creatine Kinase; Female; Heparin; Humans; Male; | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca | 1998 |
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca | 1998 |
Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Co | 1998 |
Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Co | 1998 |
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro | 1997 |
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro | 1997 |
[Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angina, Unstable | 1997 |
[Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angina, Unstable | 1997 |
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Adult; Aged; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; | 1998 |
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Adult; Aged; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; | 1998 |
One-year mortality after acute myocardial infarction prior to and after the implementation of a widespread use of thrombolysis and aspirin. Experiences from the community of Göteborg, Sweden.
Topics: Aged; Aspirin; Coronary Care Units; Female; Fibrinolytic Agents; Follow-Up Studies; Hospitals, Commu | 1998 |
One-year mortality after acute myocardial infarction prior to and after the implementation of a widespread use of thrombolysis and aspirin. Experiences from the community of Göteborg, Sweden.
Topics: Aged; Aspirin; Coronary Care Units; Female; Fibrinolytic Agents; Follow-Up Studies; Hospitals, Commu | 1998 |
Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aspirin; Cardiology; Cardiology Service, Hospit | 1998 |
Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aspirin; Cardiology; Cardiology Service, Hospit | 1998 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Female; Humans; Hydroxybutyrate | 1998 |
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Female; Humans; Hydroxybutyrate | 1998 |
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu | 1998 |
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu | 1998 |
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl
Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male | 1998 |
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl
Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male | 1998 |
One-month results of coronary stenting in patients > or = 75 years of age.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; He | 1998 |
One-month results of coronary stenting in patients > or = 75 years of age.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; He | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atenolol; Drug Administration Routes; Electrocardio | 1998 |
Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atenolol; Drug Administration Routes; Electrocardio | 1998 |
Is there something more behind atherosclerotic plaque inflammation?
Topics: Antibodies, Bacterial; Aspirin; Chlamydia Infections; Chlamydophila pneumoniae; Coronary Artery Dise | 1998 |
Is there something more behind atherosclerotic plaque inflammation?
Topics: Antibodies, Bacterial; Aspirin; Chlamydia Infections; Chlamydophila pneumoniae; Coronary Artery Dise | 1998 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin | 1998 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin | 1998 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Topics: Aged; Antithrombins; Aspirin; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Human | 1998 |
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Topics: Aged; Antithrombins; Aspirin; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Human | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.
Topics: Adult; Aged; Analysis of Variance; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Follo | 1998 |
The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.
Topics: Adult; Aged; Analysis of Variance; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Follo | 1998 |
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aprotinin; Aspirin; Blood Loss, Surgical; Card | 1998 |
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aprotinin; Aspirin; Blood Loss, Surgical; Card | 1998 |
[Platelet activation in the early phases of acute myocardial infarction].
Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Blood Platelets; Data Interpretation, Statistical; Femal | 1998 |
[Platelet activation in the early phases of acute myocardial infarction].
Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Blood Platelets; Data Interpretation, Statistical; Femal | 1998 |
Confirmation that heparin is an alternative means of promoting early reperfusion.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug | 1998 |
Confirmation that heparin is an alternative means of promoting early reperfusion.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug | 1998 |
Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin.
Topics: Aprotinin; Aspirin; Blood Loss, Surgical; Coronary Artery Bypass; Creatine Kinase; Double-Blind Meth | 1998 |
Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin.
Topics: Aprotinin; Aspirin; Blood Loss, Surgical; Coronary Artery Bypass; Creatine Kinase; Double-Blind Meth | 1998 |
[Recommended article of the month: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial].
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cerebrovascular Disorders; Female; Humans; Hypertensi | 1998 |
[Recommended article of the month: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial].
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cerebrovascular Disorders; Female; Humans; Hypertensi | 1998 |
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1998 |
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study.
Topics: Aspirin; Case-Control Studies; Cohort Studies; Double-Blind Method; Humans; Hyperlipidemias; Lipopro | 1998 |
Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study.
Topics: Aspirin; Case-Control Studies; Cohort Studies; Double-Blind Method; Humans; Hyperlipidemias; Lipopro | 1998 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Risk of major gastrointestinal bleeding with aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Delayed-Action Pr | 1999 |
Risk of major gastrointestinal bleeding with aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Delayed-Action Pr | 1999 |
Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Confid | 1999 |
Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Confid | 1999 |
[Comparison of invasive and drug therapy approaches in non-transmural acute infarct].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Diltiazem; Humans; Myocardial Infar | 1999 |
[Comparison of invasive and drug therapy approaches in non-transmural acute infarct].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Diltiazem; Humans; Myocardial Infar | 1999 |
Influence of a critical path management tool in the treatment of acute myocardial infarction. Clinical Quality Improvement Network Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Canada; Critical Pathways; Female; Humans; Male; Multiva | 1998 |
Influence of a critical path management tool in the treatment of acute myocardial infarction. Clinical Quality Improvement Network Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Canada; Critical Pathways; Female; Humans; Male; Multiva | 1998 |
A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cholesterol, HDL; Double-Blind Method; Fibrinog | 1999 |
A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cholesterol, HDL; Double-Blind Method; Fibrinog | 1999 |
Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Channel Blo | 1999 |
Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Channel Blo | 1999 |
Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators.
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 1999 |
Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators.
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 1999 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism?
Topics: Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Dr | 1999 |
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism?
Topics: Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Dr | 1999 |
Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Flow Velocity; Coronary Angiography; Coronary Circu | 1999 |
Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Flow Velocity; Coronary Angiography; Coronary Circu | 1999 |
Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Human | 1999 |
Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Human | 1999 |
[Repercussions in clinical practice of the results of the HOT (Hypertension Optimal Treatment) study].
Topics: Aged; Aspirin; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; | 1999 |
[Repercussions in clinical practice of the results of the HOT (Hypertension Optimal Treatment) study].
Topics: Aged; Aspirin; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administratio | 1999 |
Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administratio | 1999 |
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators.
Topics: Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-B | 1999 |
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators.
Topics: Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-B | 1999 |
Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Antithrombin III; Aspirin; Coronar | 1999 |
Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Antithrombin III; Aspirin; Coronar | 1999 |
[Sodium efflux through lymphocytic cell membranes in patients with acute myocardial infarction].
Topics: Adult; Aged; Aspirin; Cell Membrane; Female; Furosemide; H(+)-K(+)-Exchanging ATPase; Humans; Lympho | 1998 |
[Sodium efflux through lymphocytic cell membranes in patients with acute myocardial infarction].
Topics: Adult; Aged; Aspirin; Cell Membrane; Female; Furosemide; H(+)-K(+)-Exchanging ATPase; Humans; Lympho | 1998 |
Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms.
Topics: Aged; Aspirin; Cohort Studies; Confidence Intervals; Electrocardiography; Female; Fibrinolytic Agent | 1999 |
Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms.
Topics: Aged; Aspirin; Cohort Studies; Confidence Intervals; Electrocardiography; Female; Fibrinolytic Agent | 1999 |
Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution.
Topics: Absorption; Administration, Oral; Adult; Aspirin; Buffers; Chromatography, High Pressure Liquid; Cit | 1999 |
Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution.
Topics: Absorption; Administration, Oral; Adult; Aspirin; Buffers; Chromatography, High Pressure Liquid; Cit | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug | 1999 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug | 1999 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Canada; Coronary A | 1999 |
Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Canada; Coronary A | 1999 |
[The use of Abciximab in patients with acute myocardial infarction undergoing direct percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Female; | 1999 |
[The use of Abciximab in patients with acute myocardial infarction undergoing direct percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Female; | 1999 |
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Female; Fibr | 1999 |
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Female; Fibr | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; C-Reactive Protein; Case-Control Stud | 1999 |
Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; C-Reactive Protein; Case-Control Stud | 1999 |
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Tria
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Doub | 1999 |
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Tria
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Doub | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Effect of short-term aspirin use on C-reactive protein.
Topics: Acute-Phase Proteins; Adult; Aspirin; C-Reactive Protein; Double-Blind Method; Exercise; Humans; Mal | 2000 |
Effect of short-term aspirin use on C-reactive protein.
Topics: Acute-Phase Proteins; Adult; Aspirin; C-Reactive Protein; Double-Blind Method; Exercise; Humans; Mal | 2000 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.
Topics: Aged; Aspirin; Biomarkers; Cause of Death; Drug Therapy, Combination; Electrocardiography; Female; F | 1999 |
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.
Topics: Aged; Aspirin; Biomarkers; Cause of Death; Drug Therapy, Combination; Electrocardiography; Female; F | 1999 |
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antigens; Aspirin; Cross-Sectional Studies; Dose-Response Relat | 1999 |
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antigens; Aspirin; Cross-Sectional Studies; Dose-Response Relat | 1999 |
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; My | 2000 |
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; My | 2000 |
[Aspirin vs ticlid and their combination in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar | 2000 |
[Aspirin vs ticlid and their combination in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar | 2000 |
A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Biological Availability; | 1999 |
A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Biological Availability; | 1999 |
Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction.
Topics: Aged; Alcohol Drinking; Aspirin; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Ethanol; Female; | 2000 |
Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction.
Topics: Aged; Alcohol Drinking; Aspirin; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Ethanol; Female; | 2000 |
[What dose of acetylsalicylic acid to use after carotid endarterectomy?].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet Aggregat | 2000 |
[What dose of acetylsalicylic acid to use after carotid endarterectomy?].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet Aggregat | 2000 |
Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting.
Topics: Acenocoumarol; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coron | 2000 |
Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting.
Topics: Acenocoumarol; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coron | 2000 |
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial | 2000 |
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial | 2000 |
ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy.
Topics: Aged; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardi | 2000 |
ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy.
Topics: Aged; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardi | 2000 |
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascul | 2000 |
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascul | 2000 |
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Co | 2000 |
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Co | 2000 |
Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.
Topics: Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle | 2000 |
Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.
Topics: Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle | 2000 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
Topics: Aged; Aspirin; Blood Pressure; Death, Sudden, Cardiac; Humans; Male; Middle Aged; Myocardial Infarct | 2000 |
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
Topics: Aged; Aspirin; Blood Pressure; Death, Sudden, Cardiac; Humans; Male; Middle Aged; Myocardial Infarct | 2000 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.
Topics: Aspirin; Drug Administration Routes; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Hep | 2000 |
Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.
Topics: Aspirin; Drug Administration Routes; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Hep | 2000 |
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Daltepa | 2000 |
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Daltepa | 2000 |
Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Coumarins; Female; Fibrinolytic A | 2000 |
Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Coumarins; Female; Fibrinolytic A | 2000 |
Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin.
Topics: Aged; Aspirin; Blood Coagulation Factors; Exercise; Female; Fibrinolysis; Hemostasis; Humans; Male; | 2000 |
Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin.
Topics: Aged; Aspirin; Blood Coagulation Factors; Exercise; Female; Fibrinolysis; Hemostasis; Humans; Male; | 2000 |
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Eptifibatide; Female; Fibrinol | 2000 |
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Eptifibatide; Female; Fibrinol | 2000 |
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Respon | 2000 |
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Respon | 2000 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double | 2000 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double | 2000 |
Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.
Topics: Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic A | 2000 |
Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.
Topics: Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic A | 2000 |
Isosorbide dinitrate inhibits platelet adhesion and aggregation in nonthrombolyzed patients with acute myocardial infarction.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Chi-Square Distribution; Double-Blind Method; Fibrinolyt | 2000 |
Isosorbide dinitrate inhibits platelet adhesion and aggregation in nonthrombolyzed patients with acute myocardial infarction.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Chi-Square Distribution; Double-Blind Method; Fibrinolyt | 2000 |
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biphenyl Compounds; Double-Blind Method; Female; He | 2000 |
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biphenyl Compounds; Double-Blind Method; Female; He | 2000 |
Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; D | 2000 |
Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; D | 2000 |
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Anticoagulants; Aspirin; Dose-Response Relation | 2001 |
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Anticoagulants; Aspirin; Dose-Response Relation | 2001 |
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2000 |
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2000 |
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dose-Response Relationship, Drug; Dr | 2001 |
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dose-Response Relationship, Drug; Dr | 2001 |
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; | 2001 |
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; | 2001 |
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2001 |
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2001 |
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Monophosphate; Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Te | 2001 |
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Monophosphate; Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Te | 2001 |
[Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Female; Heparin; Humans; Male; M | 2001 |
[Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Female; Heparin; Humans; Male; M | 2001 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2001 |
Too much, too little, or none at all: dealing with substandard and fake drugs.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Dose-Response Relationship, | 2001 |
Too much, too little, or none at all: dealing with substandard and fake drugs.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Dose-Response Relationship, | 2001 |
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Dose-Response Relationship, | 2001 |
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Dose-Response Relationship, | 2001 |
Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Drug T | 2001 |
Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Drug T | 2001 |
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action | 2001 |
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action | 2001 |
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
Topics: Adult; Anticoagulants; Aspirin; Canada; Coronary Angiography; Dose-Response Relationship, Drug; Drug | 2001 |
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
Topics: Adult; Anticoagulants; Aspirin; Canada; Coronary Angiography; Dose-Response Relationship, Drug; Drug | 2001 |
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Enoxaparin; Female; Heparin; He | 2001 |
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Enoxaparin; Female; Heparin; He | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroc | 2001 |
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroc | 2001 |
Does a fixed physician reminder system improve the care of patients with coronary artery disease? A randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; California; Cholesterol, LDL; Cohort Studies; Cor | 2001 |
Does a fixed physician reminder system improve the care of patients with coronary artery disease? A randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; California; Cholesterol, LDL; Cohort Studies; Cor | 2001 |
Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial.
Topics: Aged; Aspirin; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Female; Humans; Injections, Intravenous | 2001 |
Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial.
Topics: Aged; Aspirin; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Female; Humans; Injections, Intravenous | 2001 |
Flow cytometric analysis of CD 62P expression in patients with acute myocardial infarction.
Topics: Aspirin; Biomarkers; Female; Flow Cytometry; Heparin; Humans; Male; Middle Aged; Myocardial Infarcti | 2000 |
Flow cytometric analysis of CD 62P expression in patients with acute myocardial infarction.
Topics: Aspirin; Biomarkers; Female; Flow Cytometry; Heparin; Humans; Male; Middle Aged; Myocardial Infarcti | 2000 |
Platelet factor 4 as a marker of platelet activation in patients with acute myocardial infarction.
Topics: Aspirin; Biological Factors; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2000 |
Platelet factor 4 as a marker of platelet activation in patients with acute myocardial infarction.
Topics: Aspirin; Biological Factors; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2000 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; | 2002 |
Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; | 2002 |
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
Topics: Acute Disease; Aspirin; Double-Blind Method; Drug Costs; Humans; Myocardial Infarction; Platelet Agg | 2002 |
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
Topics: Acute Disease; Aspirin; Double-Blind Method; Drug Costs; Humans; Myocardial Infarction; Platelet Agg | 2002 |
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Creatine Kinase; Creatine Kin | 2002 |
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Creatine Kinase; Creatine Kin | 2002 |
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Topics: Aged; Aspirin; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; | 2002 |
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Topics: Aged; Aspirin; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; | 2002 |
Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability.
Topics: Aged; Aspirin; Dextrans; Erythrocyte Aggregation; Female; Fibrin Fibrinogen Degradation Products; Fi | 2002 |
Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability.
Topics: Aged; Aspirin; Dextrans; Erythrocyte Aggregation; Female; Fibrin Fibrinogen Degradation Products; Fi | 2002 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
Topics: Adult; Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Dose-Response Rela | 1975 |
[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
Topics: Adult; Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Dose-Response Rela | 1975 |
[Prevention of reinfarction with acetylsalicylic acid].
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Prospectiv | 1979 |
[Prevention of reinfarction with acetylsalicylic acid].
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Prospectiv | 1979 |
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |
An intervention study-the aspirin myocardial infarction study.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; | 1977 |
An intervention study-the aspirin myocardial infarction study.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; | 1977 |
[Less myocardial infarcts with Colfarit--a new double blind study].
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1977 |
[Less myocardial infarcts with Colfarit--a new double blind study].
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1977 |
Three large-scale clinical trials of aspirin in the USA.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therapy, Com | 1977 |
Three large-scale clinical trials of aspirin in the USA.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therapy, Com | 1977 |
[Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Humans; Lipids; Longitudinal Studies; M | 1978 |
[Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Humans; Lipids; Longitudinal Studies; M | 1978 |
Preliminary study of effect of aspirin and dipyridamole on platelet adhesiveness and fibrinolytic activity in acute myocardial infarction.
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Evaluation; F | 1978 |
Preliminary study of effect of aspirin and dipyridamole on platelet adhesiveness and fibrinolytic activity in acute myocardial infarction.
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Evaluation; F | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Human Experimentation; Humans; | 1979 |
Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Human Experimentation; Humans; | 1979 |
A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarction; Random Allocation; R | 1979 |
A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarction; Random Allocation; R | 1979 |
Prevention of death from myocardial infarction by aspirin and other platelet active drugs.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation; Sulfinpyrazo | 1979 |
Prevention of death from myocardial infarction by aspirin and other platelet active drugs.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation; Sulfinpyrazo | 1979 |
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Austria; Blood Platelets; Double-Blind Method; Evaluation Studies | 1979 |
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Austria; Blood Platelets; Double-Blind Method; Evaluation Studies | 1979 |
Aspirin, platelets and myocardial infarction--proposal for a trial.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Humans; Male; Myocardial Infar | 1975 |
Aspirin, platelets and myocardial infarction--proposal for a trial.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Humans; Male; Myocardial Infar | 1975 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
Clinical trials in thrombosis: secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Prospe | 1976 |
Aspirin in coronary heart disease. The Coronary Drug Project Research Group.
Topics: Aspirin; Clinical Trials as Topic; Dextrothyroxine; Drug Evaluation; Estrogens; Humans; Middle Aged; | 1976 |
Aspirin in coronary heart disease. The Coronary Drug Project Research Group.
Topics: Aspirin; Clinical Trials as Topic; Dextrothyroxine; Drug Evaluation; Estrogens; Humans; Middle Aged; | 1976 |
Letter: Will controls in trials of aspirin really avoid aspirin?
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1975 |
Letter: Will controls in trials of aspirin really avoid aspirin?
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1975 |
Can aspirin prevent myocardial infarction?
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregat | 1975 |
Can aspirin prevent myocardial infarction?
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregat | 1975 |
Editorial: aspirin and myocardial infarction: a new national cooperative trial.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Informed Consent; Male; Middle Aged; | 1975 |
Editorial: aspirin and myocardial infarction: a new national cooperative trial.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Informed Consent; Male; Middle Aged; | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.
Topics: Aged; Aprotinin; Aspartate Aminotransferases; Aspirin; Blood Loss, Surgical; Blood Transfusion; Ches | 1992 |
Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.
Topics: Aged; Aprotinin; Aspartate Aminotransferases; Aspirin; Blood Loss, Surgical; Blood Transfusion; Ches | 1992 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Humans; Ischemic Attack, Transient; Myocardial Infarct | 1992 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Humans; Ischemic Attack, Transient; Myocardial Infarct | 1992 |
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Surviva
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; | 1992 |
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Surviva
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; | 1992 |
After ISIS-3.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; | 1992 |
After ISIS-3.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; | 1992 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure.
Topics: Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary | 1992 |
Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure.
Topics: Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary | 1992 |
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.
Topics: Aged; Angina Pectoris; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Male; Myocardial In | 1992 |
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.
Topics: Aged; Angina Pectoris; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Male; Myocardial In | 1992 |
Adjunctive medications in patients receiving thrombolytic therapy: a multicenter prospective assessment. The Virginia Multicenter Thrombolytic Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; | 1992 |
Adjunctive medications in patients receiving thrombolytic therapy: a multicenter prospective assessment. The Virginia Multicenter Thrombolytic Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; | 1992 |
Randomized trial of thrombolysis versus heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Female; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarct | 1992 |
Randomized trial of thrombolysis versus heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Female; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarct | 1992 |
[Does reperfusion modify the risk of heart rupture? Effects of early reperfusion].
Topics: Administration, Oral; Age Factors; Aged; Aspirin; Female; Heart Rupture, Post-Infarction; Humans; In | 1992 |
[Does reperfusion modify the risk of heart rupture? Effects of early reperfusion].
Topics: Administration, Oral; Age Factors; Aged; Aspirin; Female; Heart Rupture, Post-Infarction; Humans; In | 1992 |
[Thrombolytic therapy of myocardial infarction: practical management].
Topics: Aspirin; Clinical Protocols; Humans; Myocardial Infarction; Myocardial Reperfusion; Plasminogen Acti | 1992 |
[Thrombolytic therapy of myocardial infarction: practical management].
Topics: Aspirin; Clinical Protocols; Humans; Myocardial Infarction; Myocardial Reperfusion; Plasminogen Acti | 1992 |
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
Topics: Adult; Aged; Aspirin; Calcium Channel Blockers; Captopril; Cardiomegaly; Cardiovascular Agents; Dilt | 1992 |
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
Topics: Adult; Aged; Aspirin; Calcium Channel Blockers; Captopril; Cardiomegaly; Cardiovascular Agents; Dilt | 1992 |
Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis.
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet | 1992 |
Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis.
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet | 1992 |
A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Drug Therapy, Combination; Electrocardiography; Heparin; Humans; I | 1992 |
A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Drug Therapy, Combination; Electrocardiography; Heparin; Humans; I | 1992 |
Diagnostic and prognostic importance of ST recording after an episode of unstable angina or non-Q-wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Coronary Care Units; Double-Blind Meth | 1992 |
Diagnostic and prognostic importance of ST recording after an episode of unstable angina or non-Q-wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Coronary Care Units; Double-Blind Meth | 1992 |
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therapy, Combina | 1992 |
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therapy, Combina | 1992 |
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Topics: Aspirin; Coronary Angiography; Coronary Vessels; Hemorrhage; Heparin; Humans; Myocardial Infarction; | 1992 |
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Topics: Aspirin; Coronary Angiography; Coronary Vessels; Hemorrhage; Heparin; Humans; Myocardial Infarction; | 1992 |
Reactivation of unstable angina after the discontinuation of heparin.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He | 1992 |
Reactivation of unstable angina after the discontinuation of heparin.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He | 1992 |
[Effect of acetylsalicylic acid on the indicators of thrombocytic hemostasis in patients with myocardial infarction].
Topics: Administration, Oral; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregat | 1992 |
[Effect of acetylsalicylic acid on the indicators of thrombocytic hemostasis in patients with myocardial infarction].
Topics: Administration, Oral; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregat | 1992 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1992 |
[More about aspirin in cardiology].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Humans; International Cooperation; Myocardial Infarction | 1992 |
[More about aspirin in cardiology].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Humans; International Cooperation; Myocardial Infarction | 1992 |
Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation; Echocardiography; Female; H | 1991 |
Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation; Echocardiography; Female; H | 1991 |
Medical management of acute myocardial infarction in Ireland: information from the Second International Study of Infarct Survival (ISIS-2).
Topics: Adrenergic beta-Antagonists; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Ireland; M | 1991 |
Medical management of acute myocardial infarction in Ireland: information from the Second International Study of Infarct Survival (ISIS-2).
Topics: Adrenergic beta-Antagonists; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Ireland; M | 1991 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?
Topics: Angina, Unstable; Aspirin; Double-Blind Method; Electrocardiography; Exercise Test; Follow-Up Studie | 1991 |
Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?
Topics: Angina, Unstable; Aspirin; Double-Blind Method; Electrocardiography; Exercise Test; Follow-Up Studie | 1991 |
Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Ma | 1991 |
Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Ma | 1991 |
Secondary prevention of myocardial reinfarction with low dose aspirin.
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Plate | 1991 |
Secondary prevention of myocardial reinfarction with low dose aspirin.
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Plate | 1991 |
[Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure].
Topics: 6-Ketoprostaglandin F1 alpha; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Glycosides; | 1991 |
[Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure].
Topics: 6-Ketoprostaglandin F1 alpha; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Glycosides; | 1991 |
Two year Cottbus reinfarction study with 30 mg aspirin per day.
Topics: Aged; Aspirin; Dinoprost; Follow-Up Studies; Gastrointestinal Diseases; Germany; Hospitals, District | 1991 |
Two year Cottbus reinfarction study with 30 mg aspirin per day.
Topics: Aged; Aspirin; Dinoprost; Follow-Up Studies; Gastrointestinal Diseases; Germany; Hospitals, District | 1991 |
Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy.
Topics: Aspirin; Drug Synergism; Fibrinolysis; Humans; Meta-Analysis as Topic; Myocardial Infarction; Strept | 1991 |
Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy.
Topics: Aspirin; Drug Synergism; Fibrinolysis; Humans; Meta-Analysis as Topic; Myocardial Infarction; Strept | 1991 |
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.
Topics: Adult; Aged; Aspirin; Atenolol; Embolism; Female; Fibrinolytic Agents; Heart; Heart Diseases; Heart | 1991 |
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.
Topics: Adult; Aged; Aspirin; Atenolol; Embolism; Female; Fibrinolytic Agents; Heart; Heart Diseases; Heart | 1991 |
Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy.
Topics: Adult; Aged; Aspirin; Cardiac Catheterization; Creatine Kinase; Dose-Response Relationship, Drug; El | 1991 |
Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy.
Topics: Adult; Aged; Aspirin; Cardiac Catheterization; Creatine Kinase; Dose-Response Relationship, Drug; El | 1991 |
One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease.
Topics: Adult; Aged; Aspirin; Cholelithiasis; Double-Blind Method; Female; Hospitalization; Humans; Male; Mi | 1991 |
One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease.
Topics: Adult; Aged; Aspirin; Cholelithiasis; Double-Blind Method; Female; Hospitalization; Humans; Male; Mi | 1991 |
Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Heart; Heparin; Humans; Myocardial Contraction; Myocardial | 1991 |
Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Heart; Heparin; Humans; Myocardial Contraction; Myocardial | 1991 |
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
Topics: Aged; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Co | 1991 |
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
Topics: Aged; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Co | 1991 |
The effect of enteric-coated aspirin on the morning increase in platelet activity.
Topics: Adult; Aspirin; Blood Platelets; Circadian Rhythm; Humans; Male; Myocardial Infarction; Platelet Agg | 1991 |
The effect of enteric-coated aspirin on the morning increase in platelet activity.
Topics: Adult; Aspirin; Blood Platelets; Circadian Rhythm; Humans; Male; Myocardial Infarction; Platelet Agg | 1991 |
A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dipyridamole; Female; Heparin; Humans; Injections, In | 1991 |
A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dipyridamole; Female; Heparin; Humans; Injections, In | 1991 |
Results of ISIS-3 reported at ACC annual meeting.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; | 1991 |
Results of ISIS-3 reported at ACC annual meeting.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; | 1991 |
Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery Byp | 1991 |
Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery Byp | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Coronary Artery Disease; Co | 1991 |
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Coronary Artery Disease; Co | 1991 |
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in
Topics: Administration, Oral; Angina, Unstable; Aspirin; Coronary Angiography; Electrocardiography; Follow-U | 1991 |
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in
Topics: Administration, Oral; Angina, Unstable; Aspirin; Coronary Angiography; Electrocardiography; Follow-U | 1991 |
Managing patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers | 1990 |
Managing patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers | 1990 |
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
Topics: Administration, Oral; Aged; Analysis of Variance; Angina Pectoris; Angina, Unstable; Aspirin; Double | 1990 |
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
Topics: Administration, Oral; Aged; Analysis of Variance; Angina Pectoris; Angina, Unstable; Aspirin; Double | 1990 |
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Echocardiog | 1990 |
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Echocardiog | 1990 |
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Humans; Lidocai | 1990 |
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Humans; Lidocai | 1990 |
The GISSI-2 trial: premises, results, epidemiological (and other) implications. Gruppo Italiano per lo Studio delia Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Italy; Myocardial Infarction; Random Allocation; Resea | 1990 |
The GISSI-2 trial: premises, results, epidemiological (and other) implications. Gruppo Italiano per lo Studio delia Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Italy; Myocardial Infarction; Random Allocation; Resea | 1990 |
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.
Topics: Administration, Oral; Aged; Angina Pectoris, Variant; Aspirin; Drug Administration Schedule; Electro | 1990 |
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.
Topics: Administration, Oral; Aged; Angina Pectoris, Variant; Aspirin; Drug Administration Schedule; Electro | 1990 |
[Drug prescription in myocardial postinfarction: results of the EPPI (étude de prescription postinfarctus). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Card | 1990 |
[Drug prescription in myocardial postinfarction: results of the EPPI (étude de prescription postinfarctus). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Card | 1990 |
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; beta Carotene; Cardiovascular Diseases; Ca | 1991 |
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; beta Carotene; Cardiovascular Diseases; Ca | 1991 |
Secondary prevention of myocardial infarction in the first European Stroke Prevention Study.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Europe; Humans; Myocard | 1990 |
Secondary prevention of myocardial infarction in the first European Stroke Prevention Study.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Europe; Humans; Myocard | 1990 |
Role of aspirin with thrombolytic therapy in acute myocardial infarction.
Topics: Aspirin; Double-Blind Method; Heparin; Humans; Multicenter Studies as Topic; Myocardial Infarction; | 1990 |
Role of aspirin with thrombolytic therapy in acute myocardial infarction.
Topics: Aspirin; Double-Blind Method; Heparin; Humans; Multicenter Studies as Topic; Myocardial Infarction; | 1990 |
Haemorrhagic aspects of thrombolytic therapy.
Topics: Anistreplase; Aspirin; Cerebral Hemorrhage; Heparin; Humans; Incidence; Myocardial Infarction; Strep | 1990 |
Haemorrhagic aspects of thrombolytic therapy.
Topics: Anistreplase; Aspirin; Cerebral Hemorrhage; Heparin; Humans; Incidence; Myocardial Infarction; Strep | 1990 |
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Topics: Administration, Oral; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Infus | 1990 |
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Topics: Administration, Oral; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Infus | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Hospitalizatio | 1990 |
The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Hospitalizatio | 1990 |
Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Follow-Up Studies; Hu | 1990 |
Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Follow-Up Studies; Hu | 1990 |
Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Circadian Rhythm; Humans; Male; Middle Aged; Myocardial Inf | 1990 |
Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Circadian Rhythm; Humans; Male; Middle Aged; Myocardial Inf | 1990 |
[Anticoagulantion and antiaggregation therapy in patients with unstableangina pectoris].
Topics: Angina, Unstable; Aspirin; Dipyridamole; Drug Therapy, Combination; Electrocardiography; Female; Hep | 1990 |
[Anticoagulantion and antiaggregation therapy in patients with unstableangina pectoris].
Topics: Angina, Unstable; Aspirin; Dipyridamole; Drug Therapy, Combination; Electrocardiography; Female; Hep | 1990 |
Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts.
Topics: Aspirin; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Regression A | 1990 |
Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts.
Topics: Aspirin; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Regression A | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery | 1990 |
Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery | 1990 |
Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution.
Topics: Aspirin; Cardiac Pacing, Artificial; Drug Therapy, Combination; Female; Humans; Incidence; Male; Mid | 1990 |
Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution.
Topics: Aspirin; Cardiac Pacing, Artificial; Drug Therapy, Combination; Female; Humans; Incidence; Male; Mid | 1990 |
The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Echocardiography; Embol | 1990 |
The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Echocardiography; Embol | 1990 |
Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Biomechanical Phenomena; Cerebral Hem | 1990 |
Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Biomechanical Phenomena; Cerebral Hem | 1990 |
Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combina | 1990 |
Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combina | 1990 |
Acute myocardial infarction: a true medical emergency.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Emergencies; Evaluation Studies as Top | 1989 |
Acute myocardial infarction: a true medical emergency.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Emergencies; Evaluation Studies as Top | 1989 |
[Effects of thrombolytic treatments on the mortality of myocardial infarction. Characteristics of large-scale trials, main results].
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle Aged; Mu | 1989 |
[Effects of thrombolytic treatments on the mortality of myocardial infarction. Characteristics of large-scale trials, main results].
Topics: Aged; Anistreplase; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Middle Aged; Mu | 1989 |
Fibrinolysis for myocardial infarction: the ISIS-2 and asset trials.
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Tissue Plasminogen Acti | 1989 |
Fibrinolysis for myocardial infarction: the ISIS-2 and asset trials.
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Tissue Plasminogen Acti | 1989 |
Thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Clinical Trials as Topic; Combined | 1989 |
Thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Clinical Trials as Topic; Combined | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therap | 1989 |
Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therap | 1989 |
[ISIS-2, an international study of survival after a heart infarct: the power of large numbers?].
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Infusions, Int | 1989 |
[ISIS-2, an international study of survival after a heart infarct: the power of large numbers?].
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Infusions, Int | 1989 |
Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Echocardiography; Heart; Humans; Indium R | 1989 |
Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Echocardiography; Heart; Humans; Indium R | 1989 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Circulation; Humans; | 1989 |
Final report on the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disor | 1989 |
Final report on the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disor | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
Meta-analysis and evidence.
Topics: Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Meta-Analysis as Topic; | 1989 |
Meta-analysis and evidence.
Topics: Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Meta-Analysis as Topic; | 1989 |
Aspirin and thrombolytic therapy for acute myocardial infarction. Should the combination now be a routine therapy?
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Myocardial Infarction; Random Alloca | 1989 |
Aspirin and thrombolytic therapy for acute myocardial infarction. Should the combination now be a routine therapy?
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Myocardial Infarction; Random Alloca | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial.
Topics: Aspirin; Clinical Trials as Topic; Creatine Kinase; Dose-Response Relationship, Drug; Female; Follow | 1989 |
Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial.
Topics: Aspirin; Clinical Trials as Topic; Creatine Kinase; Dose-Response Relationship, Drug; Female; Follow | 1989 |
[Reduction of mortality in acute myocardial infarction with streptokinase and aspirin therapy. Results of ISIS-2].
Topics: Aged; Aspirin; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; Middle Aged; Multi | 1989 |
[Reduction of mortality in acute myocardial infarction with streptokinase and aspirin therapy. Results of ISIS-2].
Topics: Aged; Aspirin; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; Middle Aged; Multi | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Antithrombotic therapy in the primary prevention of acute myocardial infarction.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Male; Mi | 1989 |
Antithrombotic therapy in the primary prevention of acute myocardial infarction.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Male; Mi | 1989 |
Superior prevention of reinfarction by 30 mg per day aspirin compared with 1000 mg: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Female; Follow-Up Studies; Germany, East; Humans; Male; Middle Aged; Myocardial Infar | 1989 |
Superior prevention of reinfarction by 30 mg per day aspirin compared with 1000 mg: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Female; Follow-Up Studies; Germany, East; Humans; Male; Middle Aged; Myocardial Infar | 1989 |
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electro | 1989 |
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electro | 1989 |
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C | 1985 |
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C | 1985 |
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Dig | 1986 |
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Dig | 1986 |
Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Clinical Trial | 1987 |
Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Clinical Trial | 1987 |
Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study.
Topics: Administration, Oral; Aspirin; Female; Heparin; Humans; Injections, Intravenous; Male; Myocardial In | 1987 |
Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study.
Topics: Administration, Oral; Aspirin; Female; Heparin; Humans; Injections, Intravenous; Male; Myocardial In | 1987 |
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Cor | 1988 |
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Cor | 1988 |
Primary prevention of vascular disease by aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; | 1988 |
Primary prevention of vascular disease by aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; | 1988 |
Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction.
Topics: Administration, Oral; Aged; Aspirin; Drug Administration Schedule; Epoprostenol; Female; Follow-Up S | 1988 |
Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction.
Topics: Administration, Oral; Aged; Aspirin; Drug Administration Schedule; Epoprostenol; Female; Follow-Up S | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studie | 1988 |
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studie | 1988 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heparin; Hu | 1988 |
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heparin; Hu | 1988 |
[ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke].
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myo | 1988 |
[ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke].
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myo | 1988 |
Aspirin, heparin, or both to treat acute unstable angina.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Me | 1988 |
Aspirin, heparin, or both to treat acute unstable angina.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Me | 1988 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Middle Aged; Myoc | 1988 |
Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Middle Aged; Myoc | 1988 |
[Arrhythmia in patients with aspirin-treated myocardial infarction].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Female; Humans; Mal | 1988 |
[Arrhythmia in patients with aspirin-treated myocardial infarction].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Female; Humans; Mal | 1988 |
Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
Topics: Aspirin; Blood Platelets; Blood Vessels; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cycloo | 1986 |
Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
Topics: Aspirin; Blood Platelets; Blood Vessels; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cycloo | 1986 |
Randomised trial of prophylactic daily aspirin in British male doctors.
Topics: Aspirin; Cerebrovascular Disorders; Drug Evaluation; Humans; Male; Myocardial Infarction; Random All | 1988 |
Randomised trial of prophylactic daily aspirin in British male doctors.
Topics: Aspirin; Cerebrovascular Disorders; Drug Evaluation; Humans; Male; Myocardial Infarction; Random All | 1988 |
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Cerebral Hemorrhage; Clinical Trials as Topic; Coronary Angiography; Double-Bl | 1988 |
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Cerebral Hemorrhage; Clinical Trials as Topic; Coronary Angiography; Double-Bl | 1988 |
[Systemic thrombolysis using streptokinase. Experiences at the Civic Hospital of Lugano in the framework of the ISIS-2 study].
Topics: Administration, Oral; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; My | 1988 |
[Systemic thrombolysis using streptokinase. Experiences at the Civic Hospital of Lugano in the framework of the ISIS-2 study].
Topics: Administration, Oral; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; My | 1988 |
Aspirin for the primary prevention of myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Myoc | 1988 |
Aspirin for the primary prevention of myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Myoc | 1988 |
Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1988 |
Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1988 |
Usefulness of aspirin for coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Graft Occ | 1988 |
Usefulness of aspirin for coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Graft Occ | 1988 |
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Double-Blind | 1988 |
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Double-Blind | 1988 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Arte | 1987 |
Recruitment experience in the Aspirin Myocardial Infarction Study.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Ag | 1987 |
Recruitment experience in the Aspirin Myocardial Infarction Study.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Ag | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Aspirin to prevent myocardial infarction and death.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1986 |
Aspirin to prevent myocardial infarction and death.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Aspirin and the prevention of stroke after transient ischaemic attack.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind | 1986 |
Aspirin and the prevention of stroke after transient ischaemic attack.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind | 1986 |
Aspirin and ischaemic heart disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction | 1986 |
Aspirin and ischaemic heart disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction | 1986 |
[Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Death, Sudden; Female; Follow-Up Studies; Humans; Ma | 1986 |
[Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Death, Sudden; Female; Follow-Up Studies; Humans; Ma | 1986 |
Aspirin and myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Myocardial Infarction; | 1987 |
Aspirin and myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Myocardial Infarction; | 1987 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
[Coronarography findings following systemic short-term lysis of acute myocardial infarct].
Topics: Aspirin; Coronary Angiography; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; | 1987 |
[Coronarography findings following systemic short-term lysis of acute myocardial infarct].
Topics: Aspirin; Coronary Angiography; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; | 1987 |
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Topics: Adult; Aspirin; Clofibrate; Dextrothyroxine; Estrogens; Follow-Up Studies; Humans; Male; Middle Aged | 1986 |
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Topics: Adult; Aspirin; Clofibrate; Dextrothyroxine; Estrogens; Follow-Up Studies; Humans; Male; Middle Aged | 1986 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1985 |
Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1985 |
[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Fibrinolytic A | 1985 |
[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Fibrinolytic A | 1985 |
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1985 |
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1985 |
Unstable angina: status of aspirin and other forms of therapy.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Double | 1985 |
Unstable angina: status of aspirin and other forms of therapy.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Double | 1985 |
Secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1985 |
Secondary prevention of myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1985 |
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1985 |
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1985 |
Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.
Topics: Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Cyclooxygenase Inhibitors; Double-Blind Method | 1985 |
Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.
Topics: Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Cyclooxygenase Inhibitors; Double-Blind Method | 1985 |
[Eicosanoids, myocardial ischemia and sudden death].
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Coronary Disease; Cyclooxygenase I | 1985 |
[Eicosanoids, myocardial ischemia and sudden death].
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Coronary Disease; Cyclooxygenase I | 1985 |
[Therapeutic prospects and prostaglandins in vascular pathology].
Topics: Angina Pectoris; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteritis; Aspirin; | 1985 |
[Therapeutic prospects and prostaglandins in vascular pathology].
Topics: Angina Pectoris; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteritis; Aspirin; | 1985 |
Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction.
Topics: Administration, Oral; Aged; Aspirin; Bleeding Time; Blood Platelets; Female; Fibrinolytic Agents; Hu | 1985 |
Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction.
Topics: Administration, Oral; Aged; Aspirin; Bleeding Time; Blood Platelets; Female; Fibrinolytic Agents; Hu | 1985 |
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Middle Aged; | 1974 |
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Middle Aged; | 1974 |
[Lysine acetylsalicylate in the treatment of pain syndrome in the acute phase of myocardial infarct].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Lysine; Male; Middle Aged; Myocardia | 1974 |
[Lysine acetylsalicylate in the treatment of pain syndrome in the acute phase of myocardial infarct].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Lysine; Male; Middle Aged; Myocardia | 1974 |
[Function of thrombocytes during myocardial infarct and the possible effects of acetylsalicylic acid].
Topics: Aspirin; Coumarins; Humans; Myocardial Infarction; Platelet Adhesiveness | 1972 |
[Function of thrombocytes during myocardial infarct and the possible effects of acetylsalicylic acid].
Topics: Aspirin; Coumarins; Humans; Myocardial Infarction; Platelet Adhesiveness | 1972 |
[Prevention of postoperative thrombo-embolism with acetylsalicyclic acid (author's transl)].
Topics: Age Factors; Angina Pectoris; Aspirin; Body Weight; Diabetes Complications; Female; Follow-Up Studie | 1974 |
[Prevention of postoperative thrombo-embolism with acetylsalicyclic acid (author's transl)].
Topics: Age Factors; Angina Pectoris; Aspirin; Body Weight; Diabetes Complications; Female; Follow-Up Studie | 1974 |
1974 other studies available for aspirin and Myocardial Infarction
| Article | Year |
|---|---|
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gastrointestina | 2021 |
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gastrointestina | 2021 |
[Myocardial Infarction and resuscitation of an adolescent: consequences of an unexplained disease].
Topics: Adolescent; Aspirin; Coronary Aneurysm; Humans; Immunoglobulins, Intravenous; Male; Mucocutaneous Ly | 2021 |
[Myocardial Infarction and resuscitation of an adolescent: consequences of an unexplained disease].
Topics: Adolescent; Aspirin; Coronary Aneurysm; Humans; Immunoglobulins, Intravenous; Male; Mucocutaneous Ly | 2021 |
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Pe | 2022 |
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Pe | 2022 |
The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; China; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 2022 |
The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; China; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 2022 |
Rethinking aspirin for heart health.
Topics: Aspirin; Humans; Myocardial Infarction; Practice Guidelines as Topic | 2021 |
Rethinking aspirin for heart health.
Topics: Aspirin; Humans; Myocardial Infarction; Practice Guidelines as Topic | 2021 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia.
Topics: Administration, Oral; American Heart Association; Apolipoprotein B-100; Aspirin; Biomarkers; Dementi | 2022 |
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia.
Topics: Administration, Oral; American Heart Association; Apolipoprotein B-100; Aspirin; Biomarkers; Dementi | 2022 |
High on-treatment platelet reactivity to aspirin in patients after myocardial infarction.
Topics: Aged; Aspirin; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 2022 |
High on-treatment platelet reactivity to aspirin in patients after myocardial infarction.
Topics: Aged; Aspirin; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 2022 |
The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2022 |
The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2022 |
Effect of prehospital treatment in STEMI patients undergoing primary PCI.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Percutaneou | 2022 |
Effect of prehospital treatment in STEMI patients undergoing primary PCI.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Percutaneou | 2022 |
Egg consumption and risk of cardiovascular events among Iranians: results from Isfahan Cohort Study (ICS).
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Eggs; Follow-Up Studies; Humans; Iran; Myoc | 2022 |
Egg consumption and risk of cardiovascular events among Iranians: results from Isfahan Cohort Study (ICS).
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Eggs; Follow-Up Studies; Humans; Iran; Myoc | 2022 |
Short- and Long-term Myocardial Infarction Survival Rate According to the Type of Drugs Prescribed at the Time of Discharge: A Study Using Iran National Registry Data.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2022 |
Short- and Long-term Myocardial Infarction Survival Rate According to the Type of Drugs Prescribed at the Time of Discharge: A Study Using Iran National Registry Data.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2022 |
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor.
Topics: Adenosine Diphosphate; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2022 |
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor.
Topics: Adenosine Diphosphate; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2022 |
Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study.
Topics: Aspirin; Calcium; Cardiopulmonary Resuscitation; Case-Control Studies; Female; Humans; Male; Myocard | 2022 |
Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study.
Topics: Aspirin; Calcium; Cardiopulmonary Resuscitation; Case-Control Studies; Female; Humans; Male; Myocard | 2022 |
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase.
Topics: Aspirin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Myocardial Infarction; Pl | 2022 |
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase.
Topics: Aspirin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Myocardial Infarction; Pl | 2022 |
A young patient with recurrent myocardial infarction within a half month.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Percutaneous C | 2022 |
A young patient with recurrent myocardial infarction within a half month.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Percutaneous C | 2022 |
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation I | 2022 |
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation I | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrh | 2022 |
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrh | 2022 |
An Aspirin a Day….
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2022 |
An Aspirin a Day….
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2022 |
Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry).
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; M | 2022 |
Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry).
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; M | 2022 |
Low Body Mass Index without Malnutrition Is an Independent Risk Factor for Major Cardiovascular Events in Patients with Hemodialysis.
Topics: Albumins; Aspirin; Blood Proteins; Body Mass Index; Cardiovascular Diseases; Cholesterol; Heart Fail | 2022 |
Low Body Mass Index without Malnutrition Is an Independent Risk Factor for Major Cardiovascular Events in Patients with Hemodialysis.
Topics: Albumins; Aspirin; Blood Proteins; Body Mass Index; Cardiovascular Diseases; Cholesterol; Heart Fail | 2022 |
Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes.
Topics: Adult; Aftercare; Aspirin; Canada; Cohort Studies; Coronary Angiography; Coronary Vessels; Female; F | 2022 |
Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes.
Topics: Adult; Aftercare; Aspirin; Canada; Cohort Studies; Coronary Angiography; Coronary Vessels; Female; F | 2022 |
Mortality and incidence of cardiovascular events in patients treated with aspirin and statins at one year after myocardial injury in noncardiac surgery: a prospective observational study.
Topics: Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Myocardi | 2023 |
Mortality and incidence of cardiovascular events in patients treated with aspirin and statins at one year after myocardial injury in noncardiac surgery: a prospective observational study.
Topics: Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Myocardi | 2023 |
Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.
Topics: Aged; Aspirin; Electronic Health Records; Female; Hemorrhage; Humans; Male; Myocardial Infarction; P | 2022 |
Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.
Topics: Aged; Aspirin; Electronic Health Records; Female; Hemorrhage; Humans; Male; Myocardial Infarction; P | 2022 |
Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Internationality; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary P | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Hypothetical interventions on emergency ambulance and prehospital acetylsalicylic acid administration in myocardial infarction patients presenting without chest pain.
Topics: Ambulances; Aspirin; Chest Pain; Heart Failure; Humans; Myocardial Infarction | 2022 |
Hypothetical interventions on emergency ambulance and prehospital acetylsalicylic acid administration in myocardial infarction patients presenting without chest pain.
Topics: Ambulances; Aspirin; Chest Pain; Heart Failure; Humans; Myocardial Infarction | 2022 |
Adherence to European guidelines for the use of aspirin in primary health care.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myoc | 2023 |
Adherence to European guidelines for the use of aspirin in primary health care.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myoc | 2023 |
A hybrid automated event adjudication system for clinical trials.
Topics: Aspirin; Double-Blind Method; Embolic Stroke; Embolism; Factor Xa; Factor Xa Inhibitors; Humans; Myo | 2023 |
A hybrid automated event adjudication system for clinical trials.
Topics: Aspirin; Double-Blind Method; Embolic Stroke; Embolism; Factor Xa; Factor Xa Inhibitors; Humans; Myo | 2023 |
Optimal Antiplatelet Therapy Revisited: When Is a Single Better Than a Double?
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Optimal Antiplatelet Therapy Revisited: When Is a Single Better Than a Double?
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; | 2023 |
MASTER-DAPT: A Further Step Toward Long-Term P2Y
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
MASTER-DAPT: A Further Step Toward Long-Term P2Y
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard | 2023 |
Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Fibrinolytic Agents; Huma | 2023 |
Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Fibrinolytic Agents; Huma | 2023 |
Immature platelets and cardiovascular events in patients with stable coronary artery disease.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Ischemic Stroke; Myocardial Infarction; P | 2023 |
Immature platelets and cardiovascular events in patients with stable coronary artery disease.
Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Humans; Ischemic Stroke; Myocardial Infarction; P | 2023 |
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Renal Insufficien | 2023 |
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Renal Insufficien | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |
Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance.
Topics: Aspirin; Diabetes Mellitus; Hospitalization; Humans; Myocardial Infarction; Prognosis; Risk Factors | 2023 |
Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance.
Topics: Aspirin; Diabetes Mellitus; Hospitalization; Humans; Myocardial Infarction; Prognosis; Risk Factors | 2023 |
The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2023 |
Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2023 |
Impact of dementia and drug compliance on patients with acute myocardial infarction.
Topics: Aspirin; Dementia; Humans; Medication Adherence; Myocardial Infarction; Retrospective Studies | 2023 |
Impact of dementia and drug compliance on patients with acute myocardial infarction.
Topics: Aspirin; Dementia; Humans; Medication Adherence; Myocardial Infarction; Retrospective Studies | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneo | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneo | 2023 |
Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016-2019 and Associations with Prognosis.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Inpatients; Myocardial Infarction; Prescr | 2023 |
Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016-2019 and Associations with Prognosis.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Inpatients; Myocardial Infarction; Prescr | 2023 |
[Mechanism of Buyang Huanwu Decoction in protecting ischemic myocardium by regulating platelet autophagy in rats with acute myocardial infarction].
Topics: Animals; Aspirin; Drugs, Chinese Herbal; Membrane Proteins; Mitochondrial Proteins; Myocardial Infar | 2023 |
[Mechanism of Buyang Huanwu Decoction in protecting ischemic myocardium by regulating platelet autophagy in rats with acute myocardial infarction].
Topics: Animals; Aspirin; Drugs, Chinese Herbal; Membrane Proteins; Mitochondrial Proteins; Myocardial Infar | 2023 |
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitor | 2023 |
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitor | 2023 |
[Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregati | 2019 |
[Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregati | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Comb | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Comb | 2019 |
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study.
Topics: Aged; Aspirin; Cardiologists; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; | 2019 |
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study.
Topics: Aged; Aspirin; Cardiologists; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; | 2019 |
Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cardiovascular System; Clopidogrel; Female; Humans; L | 2020 |
Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cardiovascular System; Clopidogrel; Female; Humans; L | 2020 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug | 2019 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug | 2019 |
Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction.
Topics: Aged; Alleles; Aspirin; CD40 Ligand; Clopidogrel; Cyclooxygenase 1; Cytochrome P-450 Enzyme System; | 2019 |
Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction.
Topics: Aged; Alleles; Aspirin; CD40 Ligand; Clopidogrel; Cyclooxygenase 1; Cytochrome P-450 Enzyme System; | 2019 |
Risk stratification of non-obstructive coronary artery disease for guidance of preventive medical therapy.
Topics: Aged; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Risk stratification of non-obstructive coronary artery disease for guidance of preventive medical therapy.
Topics: Aged; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; My | 2020 |
Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; My | 2020 |
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Re | 2020 |
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Re | 2020 |
Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Blood Coagulation; Coronary Artery Disease; Fibrin; Fibrinolysis; Follow-Up Studies; | 2020 |
Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Blood Coagulation; Coronary Artery Disease; Fibrin; Fibrinolysis; Follow-Up Studies; | 2020 |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Stroke; Tic | 2020 |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Stroke; Tic | 2020 |
Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Combined Modality The | 2019 |
Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Combined Modality The | 2019 |
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administratio | 2019 |
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administratio | 2019 |
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion.
Topics: Animals; Apoptosis; Aspirin; Atrial Natriuretic Factor; Disease Models, Animal; Drug Therapy, Combin | 2019 |
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion.
Topics: Animals; Apoptosis; Aspirin; Atrial Natriuretic Factor; Disease Models, Animal; Drug Therapy, Combin | 2019 |
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat | 2020 |
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat | 2020 |
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C | 2020 |
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C | 2020 |
85-Year-Old Man With Chest Pain.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Chest Pain; Colchicine; Diagnosis, Differentia | 2020 |
85-Year-Old Man With Chest Pain.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Chest Pain; Colchicine; Diagnosis, Differentia | 2020 |
Changing Trends in the Landscape of Patients Hospitalized With Acute Myocardial Infarction (2001 to 2011) (from the Worcester Heart Attack Study).
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin Receptor Antagon | 2020 |
Changing Trends in the Landscape of Patients Hospitalized With Acute Myocardial Infarction (2001 to 2011) (from the Worcester Heart Attack Study).
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin Receptor Antagon | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Electrocardiogr | 2020 |
Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Electrocardiogr | 2020 |
Aspirin in Primary Prevention: Needs Individual Clinical Judgments.
Topics: Aspirin; Clinical Decision-Making; Evidence-Based Medicine; Humans; Myocardial Infarction; Patient S | 2020 |
Aspirin in Primary Prevention: Needs Individual Clinical Judgments.
Topics: Aspirin; Clinical Decision-Making; Evidence-Based Medicine; Humans; Myocardial Infarction; Patient S | 2020 |
Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Drug Therapy, | 2020 |
Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Drug Therapy, | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Male; Medication Adherenc | 2020 |
Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Male; Medication Adherenc | 2020 |
Aspirin enhances regulatory functional activities of monocytes and downregulates CD16 and CD40 expression in myocardial infarction autoinflammatory disease.
Topics: Anti-Inflammatory Agents; Aspirin; Autoimmune Diseases; Calcium; CD40 Antigens; Cells, Cultured; Cyt | 2020 |
Aspirin enhances regulatory functional activities of monocytes and downregulates CD16 and CD40 expression in myocardial infarction autoinflammatory disease.
Topics: Anti-Inflammatory Agents; Aspirin; Autoimmune Diseases; Calcium; CD40 Antigens; Cells, Cultured; Cyt | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Dise | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Dise | 2020 |
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Registries; Rivaroxaban | 2021 |
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Registries; Rivaroxaban | 2021 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual An | 2020 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual An | 2020 |
Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2020 |
Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2020 |
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infa | 2020 |
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infa | 2020 |
Autophagy assuages myocardial infarction through Nrf2 signaling activation-mediated reactive oxygen species clear.
Topics: Animals; Apoptosis; Aspirin; Autophagy; Autophagy-Related Proteins; Disease Models, Animal; Male; Mi | 2020 |
Autophagy assuages myocardial infarction through Nrf2 signaling activation-mediated reactive oxygen species clear.
Topics: Animals; Apoptosis; Aspirin; Autophagy; Autophagy-Related Proteins; Disease Models, Animal; Male; Mi | 2020 |
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Topics: Aspirin; Data Interpretation, Statistical; Dual Anti-Platelet Therapy; Endpoint Determination; Equiv | 2020 |
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Topics: Aspirin; Data Interpretation, Statistical; Dual Anti-Platelet Therapy; Endpoint Determination; Equiv | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; | 2020 |
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; | 2020 |
The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.
Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggreg | 2021 |
The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.
Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggreg | 2021 |
Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients.
Topics: Aspirin; Blood Platelets; Electrocardiography; Hospital Mortality; Humans; Myocardial Infarction; No | 2020 |
Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients.
Topics: Aspirin; Blood Platelets; Electrocardiography; Hospital Mortality; Humans; Myocardial Infarction; No | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2020 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2020 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platel | 2020 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platel | 2020 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angi | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angi | 2021 |
The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Dual Anti-Plate | 2021 |
The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Dual Anti-Plate | 2021 |
CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary | 2020 |
CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary | 2020 |
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
Topics: Aspirin; Coronary Artery Disease; Cost of Illness; Delivery of Health Care; Diabetes Mellitus, Type | 2021 |
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
Topics: Aspirin; Coronary Artery Disease; Cost of Illness; Delivery of Health Care; Diabetes Mellitus, Type | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dual Anti-Platelet Therapy; Female; Humans; Male | 2021 |
Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dual Anti-Platelet Therapy; Female; Humans; Male | 2021 |
Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?
Topics: Aspirin; Colorectal Neoplasms; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationshi | 2021 |
Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?
Topics: Aspirin; Colorectal Neoplasms; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationshi | 2021 |
Should Senior Citizens Take Aspirin Daily to Prevent Heart Attacks or Strokes?
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibi | 2021 |
Should Senior Citizens Take Aspirin Daily to Prevent Heart Attacks or Strokes?
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibi | 2021 |
Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Myo | 2021 |
Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Myo | 2021 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabet | 2021 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabet | 2021 |
Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat.
Topics: Animals; Aspirin; Ischemia; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reper | 2023 |
Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat.
Topics: Animals; Aspirin; Ischemia; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reper | 2023 |
Expression of NLR and IL-1β and their predictive efficacy value in acute myocardial infarction patients treated with aspirin combined with clopidogrel.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Expression of NLR and IL-1β and their predictive efficacy value in acute myocardial infarction patients treated with aspirin combined with clopidogrel.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Myocardial infarction in a neonate. Lessons for neonatal and internal medicine.
Topics: Aspirin; Cardiotonic Agents; Child, Preschool; Combined Modality Therapy; Coronary Thrombosis; Echoc | 2017 |
Myocardial infarction in a neonate. Lessons for neonatal and internal medicine.
Topics: Aspirin; Cardiotonic Agents; Child, Preschool; Combined Modality Therapy; Coronary Thrombosis; Echoc | 2017 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrin | 2017 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrin | 2017 |
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Administration | 2017 |
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Administration | 2017 |
Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |
Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |
Optimizing dual antiplatelet therapy duration after myocardial infarction: evidence-based, precision, or personalized medicine?
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2017 |
Optimizing dual antiplatelet therapy duration after myocardial infarction: evidence-based, precision, or personalized medicine?
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2017 |
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Trea
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2017 |
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Trea
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infa | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infa | 2017 |
Bayesian meta-analysis: The role of the between-sample heterogeneity.
Topics: Aspirin; Bayes Theorem; Humans; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; | 2018 |
Bayesian meta-analysis: The role of the between-sample heterogeneity.
Topics: Aspirin; Bayes Theorem; Humans; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; | 2018 |
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2017 |
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment.
Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Coronary Angiography; Coronary Artery Disease; Denmark; | 2017 |
Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment.
Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Coronary Angiography; Coronary Artery Disease; Denmark; | 2017 |
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitaliz
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; | 2017 |
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitaliz
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; | 2017 |
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes.
Topics: Aged; Aspirin; Cholesterol; Computed Tomography Angiography; Coronary Angiography; Coronary Artery D | 2017 |
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes.
Topics: Aged; Aspirin; Cholesterol; Computed Tomography Angiography; Coronary Angiography; Coronary Artery D | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
I Do Not Have Heart Disease-Should I Be Taking Aspirin?
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidel | 2017 |
I Do Not Have Heart Disease-Should I Be Taking Aspirin?
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidel | 2017 |
Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Myocardial Infarction; Vitamin K | 2017 |
Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Myocardial Infarction; Vitamin K | 2017 |
Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2018 |
Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2018 |
A soccer mom with chest pain: Spontaneous coronary artery dissection in a young woman.
Topics: Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Diagn | 2017 |
A soccer mom with chest pain: Spontaneous coronary artery dissection in a young woman.
Topics: Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Diagn | 2017 |
Upper Gastrointestinal Complications and Cardiovascular/Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Diseases; Humans; Logistic Models; Male; | 2017 |
Upper Gastrointestinal Complications and Cardiovascular/Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Diseases; Humans; Logistic Models; Male; | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi | 2017 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
Topics: Aged; Aspirin; Death; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 2017 |
Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
Topics: Aged; Aspirin; Death; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 2017 |
Aspirin Use and Mortality in Two Contemporary US Cohorts.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Male; Middle | 2018 |
Aspirin Use and Mortality in Two Contemporary US Cohorts.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Male; Middle | 2018 |
Cardiovascular events associated with proton pump inhibitors.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Heart Failure; Humans; Mortality; Myocard | 2017 |
Cardiovascular events associated with proton pump inhibitors.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Heart Failure; Humans; Mortality; Myocard | 2017 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
Risk stratification with the DAPT score: Carefully read the instructions and use as intended.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronar | 2017 |
Risk stratification with the DAPT score: Carefully read the instructions and use as intended.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronar | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2017 |
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Drug Resistance; Fema | 2018 |
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Drug Resistance; Fema | 2018 |
Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Stents | 2018 |
Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Stents | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
The use of preoperative aspirin in cardiac surgery: The ruling on the field stands.
Topics: Acute Kidney Injury; Aspirin; Coronary Artery Bypass; Erythrocyte Transfusion; Hemorrhage; Humans; M | 2017 |
The use of preoperative aspirin in cardiac surgery: The ruling on the field stands.
Topics: Acute Kidney Injury; Aspirin; Coronary Artery Bypass; Erythrocyte Transfusion; Hemorrhage; Humans; M | 2017 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise | 2018 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise | 2018 |
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platel | 2017 |
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platel | 2017 |
Warfarin Prophylaxis for Anterior Infarction: Another Black Mark for Triple Therapy.
Topics: Anterior Wall Myocardial Infarction; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Inf | 2017 |
Warfarin Prophylaxis for Anterior Infarction: Another Black Mark for Triple Therapy.
Topics: Anterior Wall Myocardial Infarction; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Inf | 2017 |
[General internal medicine : 2017 scientific breakthroughs in ambulatory care].
Topics: Ambulatory Care; Aspirin; Humans; Internal Medicine; Myocardial Infarction; Platelet Aggregation Inh | 2018 |
[General internal medicine : 2017 scientific breakthroughs in ambulatory care].
Topics: Ambulatory Care; Aspirin; Humans; Internal Medicine; Myocardial Infarction; Platelet Aggregation Inh | 2018 |
Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Aryldialkylphosphatase; Aspirin; | 2018 |
Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Aryldialkylphosphatase; Aspirin; | 2018 |
Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; | 2018 |
Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; | 2018 |
A foreign older diabetic woman with an acute myocardial infarction: when cognitive biases in clinical decision-making become especially important.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Decision-Making | 2018 |
A foreign older diabetic woman with an acute myocardial infarction: when cognitive biases in clinical decision-making become especially important.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Decision-Making | 2018 |
Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2018 |
Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2018 |
Low-Dose Aspirin for Prevention of Cardiovascular Risk in Bereavement: Results from a Feasibility Study.
Topics: Aspirin; Bereavement; Depression; Feasibility Studies; Female; Heart Rate; Humans; Male; Middle Aged | 2018 |
Low-Dose Aspirin for Prevention of Cardiovascular Risk in Bereavement: Results from a Feasibility Study.
Topics: Aspirin; Bereavement; Depression; Feasibility Studies; Female; Heart Rate; Humans; Male; Middle Aged | 2018 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatient | 2018 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatient | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Fr | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Fr | 2018 |
Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Clopidogrel; Cyclooxygenase 2; Gast | 2018 |
Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Clopidogrel; Cyclooxygenase 2; Gast | 2018 |
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiogra | 2018 |
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiogra | 2018 |
Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Female; Follow-Up Studies; Human | 2018 |
Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Female; Follow-Up Studies; Human | 2018 |
Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Diffusion Magnetic | 2018 |
Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Diffusion Magnetic | 2018 |
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard | 2018 |
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard | 2018 |
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Prescriptions; Drug Therapy, Combination; Female; Guide | 2018 |
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Prescriptions; Drug Therapy, Combination; Female; Guide | 2018 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Aspirin in Primary Prevention of Myocardial Infarction/Angina and Stroke in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cardiovascular Diseases; Cross-Sectional S | 2018 |
Aspirin in Primary Prevention of Myocardial Infarction/Angina and Stroke in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cardiovascular Diseases; Cross-Sectional S | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
Nitroglycerin application and coronary arteriogenesis.
Topics: Animals; Aorta, Thoracic; Aspirin; Coronary Occlusion; Coronary Vessels; Disease Models, Animal; Hum | 2018 |
Nitroglycerin application and coronary arteriogenesis.
Topics: Animals; Aorta, Thoracic; Aspirin; Coronary Occlusion; Coronary Vessels; Disease Models, Animal; Hum | 2018 |
Left shoulder pain in patients with old myocardial infarction could be a neuropathic pain from spinal epidural haematoma.
Topics: Aged; Anticoagulants; Aspirin; Diagnosis, Differential; Hematoma, Epidural, Spinal; Humans; Laminect | 2018 |
Left shoulder pain in patients with old myocardial infarction could be a neuropathic pain from spinal epidural haematoma.
Topics: Aged; Anticoagulants; Aspirin; Diagnosis, Differential; Hematoma, Epidural, Spinal; Humans; Laminect | 2018 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combinat | 2018 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combinat | 2018 |
Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents.
Topics: Adult; Aged; Aspirin; Drug-Eluting Stents; Electronic Health Records; Female; Humans; Incidence; Mal | 2019 |
Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents.
Topics: Adult; Aged; Aspirin; Drug-Eluting Stents; Electronic Health Records; Female; Humans; Incidence; Mal | 2019 |
Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiologists; Cross-Sectional Studies; Dise | 2018 |
Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiologists; Cross-Sectional Studies; Dise | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2018 |
Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Clopidogrel; Female; Follow-Up Studies; Heart | 2017 |
Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Clopidogrel; Female; Follow-Up Studies; Heart | 2017 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar | 2018 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar | 2018 |
Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; C-Reactive Protein; Coronary Angiography; Electr | 2019 |
Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; C-Reactive Protein; Coronary Angiography; Electr | 2019 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Technique | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Technique | 2018 |
Variations in the eicosapentaenoic acid-arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Age Factors; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biomarkers; Eicosapentaenoic Acid; | 2019 |
Variations in the eicosapentaenoic acid-arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Age Factors; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biomarkers; Eicosapentaenoic Acid; | 2019 |
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Electrocardiography; Female; Fibrinolytic | 2019 |
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Electrocardiography; Female; Fibrinolytic | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Cl | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Cl | 2019 |
Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Cross-Sectional Studies; Denmark; Dru | 2020 |
Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Cross-Sectional Studies; Denmark; Dru | 2020 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
Level and variation on quality of care in China: a cross-sectional study for the acute myocardial infarction patients in tertiary hospitals in Beijing.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Cross-S | 2019 |
Level and variation on quality of care in China: a cross-sectional study for the acute myocardial infarction patients in tertiary hospitals in Beijing.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Cross-S | 2019 |
Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL-ACS).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitor | 2019 |
Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL-ACS).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitor | 2019 |
Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Case-Control Studie | 2019 |
Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Case-Control Studie | 2019 |
Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2019 |
Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2019 |
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary A | 2019 |
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary A | 2019 |
Chronic obstructive pulmonary disease and myocardial infarction: when will we get our act together?
Topics: Aspirin; Denmark; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pul | 2020 |
Chronic obstructive pulmonary disease and myocardial infarction: when will we get our act together?
Topics: Aspirin; Denmark; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pul | 2020 |
Narrowing performance gap between rural and urban hospitals for acute myocardial infarction care.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electrocardiography; Female; Healthcare Disp | 2020 |
Narrowing performance gap between rural and urban hospitals for acute myocardial infarction care.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electrocardiography; Female; Healthcare Disp | 2020 |
Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome? A Large Retrospective Cohort Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Related Side E | 2019 |
Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome? A Large Retrospective Cohort Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Related Side E | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocar | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocar | 2019 |
Antithrombotic Activity of a Novel Diazepino[1,2-α] Benzimidazole Derivative on Arterial Thrombosis Model in Rats without Concomitant Pathology and in Rats with Experimental Myocardial Infarction.
Topics: Animals; Animals, Outbred Strains; Aspirin; Azepines; Benzimidazoles; Blood Coagulation Tests; Chlor | 2019 |
Antithrombotic Activity of a Novel Diazepino[1,2-α] Benzimidazole Derivative on Arterial Thrombosis Model in Rats without Concomitant Pathology and in Rats with Experimental Myocardial Infarction.
Topics: Animals; Animals, Outbred Strains; Aspirin; Azepines; Benzimidazoles; Blood Coagulation Tests; Chlor | 2019 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Europe; Female; Humans; Male; Myocardial Infarction; Platele | 2019 |
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Europe; Female; Humans; Male; Myocardial Infarction; Platele | 2019 |
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2019 |
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2019 |
Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
Topics: Administrative Claims, Healthcare; Aged; Aspirin; Cardiovascular Diseases; Electronic Health Records | 2019 |
Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
Topics: Administrative Claims, Healthcare; Aged; Aspirin; Cardiovascular Diseases; Electronic Health Records | 2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myoca | 2020 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myoca | 2020 |
Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Prescriptions; Drug Utilization; Dual Anti-Plate | 2020 |
Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Prescriptions; Drug Utilization; Dual Anti-Plate | 2020 |
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Myocardial Infarction; Ticagrelor | 2019 |
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Myocardial Infarction; Ticagrelor | 2019 |
Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute.
Topics: Adult; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Heart; Humans; Income; Male; Medicatio | 2019 |
Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute.
Topics: Adult; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Heart; Humans; Income; Male; Medicatio | 2019 |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage; | 2019 |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage; | 2019 |
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2020 |
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2020 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug-Eluting Stents; Europe; Female | 2019 |
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug-Eluting Stents; Europe; Female | 2019 |
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Aspirin; Case-Control Studies; Dual Anti-P | 2019 |
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Aspirin; Case-Control Studies; Dual Anti-P | 2019 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra | 2013 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Aspirin not effective in some people. Failure to take the drug may be the most common reason.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Administrat | 2012 |
Aspirin not effective in some people. Failure to take the drug may be the most common reason.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Administrat | 2012 |
Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Electrocar | 2013 |
Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Electrocar | 2013 |
Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug | 2013 |
Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug | 2013 |
Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction.
Topics: Aged; Apoptosis; Aspirin; Base Sequence; Cardiovascular Agents; Case-Control Studies; Cell Survival; | 2013 |
Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction.
Topics: Aged; Apoptosis; Aspirin; Base Sequence; Cardiovascular Agents; Case-Control Studies; Cell Survival; | 2013 |
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin Receptor Antagonists; Aspirin; Card | 2013 |
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin Receptor Antagonists; Aspirin; Card | 2013 |
Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Death, Sudden, Cardiac; Drug Therapy, | 2013 |
Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Death, Sudden, Cardiac; Drug Therapy, | 2013 |
Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart.
Topics: Animals; Aspirin; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship | 2013 |
Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart.
Topics: Animals; Aspirin; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship | 2013 |
Primary PCI with endothelial progenitor cell-capture stent in patient with skull base fracture and aspirin allergy.
Topics: Aged; Aspirin; Contraindications; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrocardiogra | 2013 |
Primary PCI with endothelial progenitor cell-capture stent in patient with skull base fracture and aspirin allergy.
Topics: Aged; Aspirin; Contraindications; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrocardiogra | 2013 |
Circadian patterns of ST elevation myocardial infarction in the new millennium.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiology; Circa | 2013 |
Circadian patterns of ST elevation myocardial infarction in the new millennium.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiology; Circa | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
JAMA patient page. Aspirin therapy.
Topics: Aspirin; Contraindications; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Agg | 2013 |
JAMA patient page. Aspirin therapy.
Topics: Aspirin; Contraindications; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Agg | 2013 |
Relation of outbursts of anger and risk of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anger; Aspirin; Case-Control Studies; Cohort Studies; Cros | 2013 |
Relation of outbursts of anger and risk of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anger; Aspirin; Case-Control Studies; Cohort Studies; Cros | 2013 |
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2013 |
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2013 |
The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Female; Humans; Male; Middle Aged; My | 2014 |
The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Female; Humans; Male; Middle Aged; My | 2014 |
Aspirin after heart attack or stroke.
Topics: Aftercare; Aspirin; Dose-Response Relationship, Drug; Health Promotion; Humans; Myocardial Infarctio | 2013 |
Aspirin after heart attack or stroke.
Topics: Aftercare; Aspirin; Dose-Response Relationship, Drug; Health Promotion; Humans; Myocardial Infarctio | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S | 2013 |
Anaphylaxis mediated myocardial infarction in a coronary graft: a new variant of Kounis syndrome (a case report).
Topics: Aged; Anaphylaxis; Aspirin; Asthma, Aspirin-Induced; Coronary Artery Bypass; Humans; Male; Myocardia | 2013 |
Anaphylaxis mediated myocardial infarction in a coronary graft: a new variant of Kounis syndrome (a case report).
Topics: Aged; Anaphylaxis; Aspirin; Asthma, Aspirin-Induced; Coronary Artery Bypass; Humans; Male; Myocardia | 2013 |
Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy').
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Adult; Aspirin; Bisoprolol; Ch | 2013 |
Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy').
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Adult; Aspirin; Bisoprolol; Ch | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.
Topics: Aged; Aspirin; Blood Coagulation; Blood Platelets; C-Reactive Protein; Coronary Artery Disease; Fema | 2013 |
Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.
Topics: Aged; Aspirin; Blood Coagulation; Blood Platelets; C-Reactive Protein; Coronary Artery Disease; Fema | 2013 |
Testing for the 'ulcer bug' makes daily aspirin safer.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; He | 2013 |
Testing for the 'ulcer bug' makes daily aspirin safer.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; He | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
[Primary angioplasty in a patient with acute inferior myocardial infarction: the unexpected trap].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortography; Aspirin; Cardiac Catheterization; Clopi | 2013 |
[Primary angioplasty in a patient with acute inferior myocardial infarction: the unexpected trap].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortography; Aspirin; Cardiac Catheterization; Clopi | 2013 |
Culprit segments identified by optical coherence tomography in patients with acute myocardial infarction: two case reports.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary A | 2012 |
Culprit segments identified by optical coherence tomography in patients with acute myocardial infarction: two case reports.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary A | 2012 |
Discontinuation of secondary prevention medication after myocardial infarction - the role of general practitioners and patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angio | 2013 |
Discontinuation of secondary prevention medication after myocardial infarction - the role of general practitioners and patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angio | 2013 |
Monitoring persistent platelet reactivity in patients with unprotected left main stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh | 2013 |
Monitoring persistent platelet reactivity in patients with unprotected left main stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inh | 2013 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas | 2013 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas | 2013 |
Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Drug Adminis | 2013 |
Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Drug Adminis | 2013 |
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; | 2014 |
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; | 2014 |
Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Diabetes Complications; Female; Follow-Up Studies; Humans; Hydroxy | 2014 |
Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Diabetes Complications; Female; Follow-Up Studies; Humans; Hydroxy | 2014 |
Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
Topics: Aged; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Drug Combinations; Female; | 2014 |
Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
Topics: Aged; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Drug Combinations; Female; | 2014 |
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Coronary mortality in China: fence, ambulance, or hospital treatments?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Hu | 2014 |
Coronary mortality in China: fence, ambulance, or hospital treatments?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Hu | 2014 |
Reply to Rubino et al.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2014 |
Reply to Rubino et al.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2014 |
Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation.
Topics: Aspirin; beta-Thromboglobulin; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial | 2014 |
Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation.
Topics: Aspirin; beta-Thromboglobulin; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial | 2014 |
Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Disease Management; Fema | 2013 |
Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Disease Management; Fema | 2013 |
Evidence-based co-medication in heart failure: necessary or bystander?
Topics: Aspirin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inpatients; Male; My | 2014 |
Evidence-based co-medication in heart failure: necessary or bystander?
Topics: Aspirin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inpatients; Male; My | 2014 |
Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients.
Topics: Aged; Aged, 80 and over; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Follow-Up St | 2014 |
Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients.
Topics: Aged; Aged, 80 and over; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Follow-Up St | 2014 |
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy.
Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hem | 2014 |
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy.
Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hem | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarct | 2014 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarct | 2014 |
[Six Kawasaki disease patients with acute coronary artery thrombosis].
Topics: Acute Disease; Anticoagulants; Aspirin; Child, Preschool; Coronary Aneurysm; Coronary Thrombosis; Ec | 2013 |
[Six Kawasaki disease patients with acute coronary artery thrombosis].
Topics: Acute Disease; Anticoagulants; Aspirin; Child, Preschool; Coronary Aneurysm; Coronary Thrombosis; Ec | 2013 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Fe | 2014 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Fe | 2014 |
Impact of preoperative antiplatelet therapy on in-hospital outcomes after coronary artery bypass grafting.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2014 |
Impact of preoperative antiplatelet therapy on in-hospital outcomes after coronary artery bypass grafting.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis | 2014 |
Modern clinical research: guidelines for the practicing clinician or source of confusion?
Topics: Aspirin; Biomedical Research; Cardiovascular Agents; Evidence-Based Medicine; Family Practice; Guide | 2013 |
Modern clinical research: guidelines for the practicing clinician or source of confusion?
Topics: Aspirin; Biomedical Research; Cardiovascular Agents; Evidence-Based Medicine; Family Practice; Guide | 2013 |
Enhancement of matrix metalloproteinase 2 and 9 inhibitory action of minocycline by aspirin: an approach to attenuate outcome of acute myocardial infarction in diabetes.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Drug Synergism; Hemodynamics; Male; Matrix Metall | 2014 |
Enhancement of matrix metalloproteinase 2 and 9 inhibitory action of minocycline by aspirin: an approach to attenuate outcome of acute myocardial infarction in diabetes.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Drug Synergism; Hemodynamics; Male; Matrix Metall | 2014 |
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; P | 2013 |
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; P | 2013 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Hu | 2014 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Hu | 2014 |
Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2014 |
Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2014 |
Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Conver | 2014 |
Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Conver | 2014 |
[Aspirin withdrawal in high risk cardiac patients before the operation of total colectomy with resection of ileum--case report].
Topics: Aspirin; Colectomy; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperat | 2013 |
[Aspirin withdrawal in high risk cardiac patients before the operation of total colectomy with resection of ileum--case report].
Topics: Aspirin; Colectomy; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperat | 2013 |
The yin and yang of perioperative medicine.
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
The yin and yang of perioperative medicine.
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca | 2014 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca | 2014 |
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
Topics: Aged; Amputation, Surgical; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Guideline Adh | 2014 |
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
Topics: Aged; Amputation, Surgical; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Guideline Adh | 2014 |
Surgery: Low-dose aspirin and clonidine--no benefit during surgery.
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
Surgery: Low-dose aspirin and clonidine--no benefit during surgery.
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2015 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2015 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thromb | 2014 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thromb | 2014 |
The relationships among physician and hospital volume, processes, and outcomes of care for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Coronary | 2014 |
The relationships among physician and hospital volume, processes, and outcomes of care for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Coronary | 2014 |
Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Databases, Factual; Diabetes | 2014 |
Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Databases, Factual; Diabetes | 2014 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha | 2014 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha | 2014 |
Association of cyclooxygenase-2 genetic variant with cardiovascular disease.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; He | 2014 |
Association of cyclooxygenase-2 genetic variant with cardiovascular disease.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; He | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An | 2014 |
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An | 2014 |
FDA questions use of aspirin for primary prevention of stroke and heart attack.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
FDA questions use of aspirin for primary prevention of stroke and heart attack.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
[Comments on: perioperative administration of clonidine or aspirin].
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
[Comments on: perioperative administration of clonidine or aspirin].
Topics: Adrenergic alpha-2 Receptor Agonists; Aspirin; Clonidine; Female; Humans; Hypotension; Male; Myocard | 2014 |
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Card | 2014 |
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Card | 2014 |
Myocardial infarction risks remain for patients undergoing noncardiac elective surgery.
Topics: Antihypertensive Agents; Aspirin; Clonidine; Elective Surgical Procedures; Humans; Myocardial Infarc | 2014 |
Myocardial infarction risks remain for patients undergoing noncardiac elective surgery.
Topics: Antihypertensive Agents; Aspirin; Clonidine; Elective Surgical Procedures; Humans; Myocardial Infarc | 2014 |
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch | 2014 |
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coron | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coron | 2014 |
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Me | 2014 |
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Me | 2014 |
Cholesterol embolization syndrome with an atypical proximal presentation simulating calciphylaxis.
Topics: Aspirin; Back; Buttocks; Calciphylaxis; Cardiac Catheterization; Clopidogrel; Diagnosis, Differentia | 2014 |
Cholesterol embolization syndrome with an atypical proximal presentation simulating calciphylaxis.
Topics: Aspirin; Back; Buttocks; Calciphylaxis; Cardiac Catheterization; Clopidogrel; Diagnosis, Differentia | 2014 |
Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups.
Topics: Age Distribution; Age Factors; Aged; Aspirin; Cause of Death; Clopidogrel; Denmark; Drug Therapy, Co | 2017 |
Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups.
Topics: Age Distribution; Age Factors; Aged; Aspirin; Cause of Death; Clopidogrel; Denmark; Drug Therapy, Co | 2017 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mor | 2015 |
Questions linger over POISE-2 and perioperative aspirin management.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Questions linger over POISE-2 and perioperative aspirin management.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor An | 2014 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor An | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu | 2014 |
[Aspirin does not prevent myocardial infarcts in and after non-cardiac operations].
Topics: Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complic | 2014 |
[Aspirin does not prevent myocardial infarcts in and after non-cardiac operations].
Topics: Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complic | 2014 |
Dermcidin isoform-2 induced nullification of the effect of acetyl salicylic acid in platelet aggregation in acute myocardial infarction.
Topics: Adult; Aspirin; Case-Control Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pept | 2014 |
Dermcidin isoform-2 induced nullification of the effect of acetyl salicylic acid in platelet aggregation in acute myocardial infarction.
Topics: Adult; Aspirin; Case-Control Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pept | 2014 |
Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program.
Topics: Aged; American Heart Association; Aspirin; Databases, Factual; Electrocardiography; Female; Health S | 2014 |
Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program.
Topics: Aged; American Heart Association; Aspirin; Databases, Factual; Electrocardiography; Female; Health S | 2014 |
[Utility of aspirin in patients undergoing noncardiac surgery. Commentary].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
[Utility of aspirin in patients undergoing noncardiac surgery. Commentary].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Daily aspirin reduces risk of developing and dying from cancer, researchers find.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2014 |
Daily aspirin reduces risk of developing and dying from cancer, researchers find.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2014 |
Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR).
Topics: Acute Disease; Aged; Aspirin; Drug Dosage Calculations; Female; Guidelines as Topic; Humans; Male; M | 2014 |
Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR).
Topics: Acute Disease; Aged; Aspirin; Drug Dosage Calculations; Female; Guidelines as Topic; Humans; Male; M | 2014 |
ACP Journal Club. In noncardiac surgery, perioperative aspirin did not reduce death or MI at 30 d but increased major bleeding.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
ACP Journal Club. In noncardiac surgery, perioperative aspirin did not reduce death or MI at 30 d but increased major bleeding.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Female; Follow-Up Studies; Humans; | 2014 |
Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Female; Follow-Up Studies; Humans; | 2014 |
Regular dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury: is it time to revisit PARIS?
Topics: Animals; Aspirin; Cardiotonic Agents; Dipyridamole; Drug Therapy, Combination; Guinea Pigs; Male; My | 2014 |
Regular dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury: is it time to revisit PARIS?
Topics: Animals; Aspirin; Cardiotonic Agents; Dipyridamole; Drug Therapy, Combination; Guinea Pigs; Male; My | 2014 |
Effects of new regional cooperative rescue model on patients with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studi | 2014 |
Effects of new regional cooperative rescue model on patients with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studi | 2014 |
Validation of acute myocardial infarction cases in the national health insurance research database in taiwan.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Coding; Clopidogrel; Cross-Sectional Studies; Databases, | 2014 |
Validation of acute myocardial infarction cases in the national health insurance research database in taiwan.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Coding; Clopidogrel; Cross-Sectional Studies; Databases, | 2014 |
"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Inciden | 2014 |
"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Inciden | 2014 |
The pharmacoeconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after non-cardiac surgery.
Topics: Aspirin; Cost-Benefit Analysis; Economics, Pharmaceutical; Hospital Costs; Humans; Hydroxymethylglut | 2014 |
The pharmacoeconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after non-cardiac surgery.
Topics: Aspirin; Cost-Benefit Analysis; Economics, Pharmaceutical; Hospital Costs; Humans; Hydroxymethylglut | 2014 |
Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Convertin | 2015 |
Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Convertin | 2015 |
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Dru | 2014 |
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Dru | 2014 |
A case-cohort study of postoperative myocardial infarction: impact of anemia and cardioprotective medications.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anemia; Aspirin; Cardiotonic Agents; Ca | 2014 |
A case-cohort study of postoperative myocardial infarction: impact of anemia and cardioprotective medications.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anemia; Aspirin; Cardiotonic Agents; Ca | 2014 |
Discussion.
Topics: Adrenergic beta-Antagonists; Anemia; Aspirin; Cardiotonic Agents; Female; Humans; Male; Myocardial I | 2014 |
Discussion.
Topics: Adrenergic beta-Antagonists; Anemia; Aspirin; Cardiotonic Agents; Female; Humans; Male; Myocardial I | 2014 |
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female | 2016 |
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female | 2016 |
Double jeopardy: multi-modality imaging of monozygotic "twin cap" atherosclerosis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atherosclerosis; Coronary Vessels; Disease | 2014 |
Double jeopardy: multi-modality imaging of monozygotic "twin cap" atherosclerosis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atherosclerosis; Coronary Vessels; Disease | 2014 |
Aspirin: still a wonder drug? Sorting out aspirin's role in heart attack and stroke prevention.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
Aspirin: still a wonder drug? Sorting out aspirin's role in heart attack and stroke prevention.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
A string-like red thrombus assessed by coronary angioscopy after using an aspiration catheter caused microvascular obstruction in a patient with ST-elevated myocardial infarction.
Topics: Aged; Angioscopy; Aspirin; Atrioventricular Block; Balloon Embolectomy; Coronary Angiography; Corona | 2014 |
A string-like red thrombus assessed by coronary angioscopy after using an aspiration catheter caused microvascular obstruction in a patient with ST-elevated myocardial infarction.
Topics: Aged; Angioscopy; Aspirin; Atrioventricular Block; Balloon Embolectomy; Coronary Angiography; Corona | 2014 |
Opportunities for improving global cardiovascular quality of care and outcomes.
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Female; Global Health; Healthcare Disp | 2014 |
Opportunities for improving global cardiovascular quality of care and outcomes.
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Female; Global Health; Healthcare Disp | 2014 |
Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study.
Topics: Adult; Age Factors; Aged; Aspirin; China; Cohort Studies; Confidence Intervals; Dose-Response Relati | 2014 |
Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study.
Topics: Adult; Age Factors; Aged; Aspirin; China; Cohort Studies; Confidence Intervals; Dose-Response Relati | 2014 |
Weighing the risks of perioperative aspirin.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Weighing the risks of perioperative aspirin.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
Spontaneous coronary artery dissection: a complete resolution with medical treatment.
Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; H | 2014 |
Spontaneous coronary artery dissection: a complete resolution with medical treatment.
Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; H | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio | 2015 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Er | 2015 |
Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Er | 2015 |
[Perioperative aspirin treatment in patients undergoing surgery: Perioperative Ischemic Evaluation 2 (POISE-2)].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
[Perioperative aspirin treatment in patients undergoing surgery: Perioperative Ischemic Evaluation 2 (POISE-2)].
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative | 2014 |
When should aspirin be used for prevention of cardiovascular events?
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2014 |
When should aspirin be used for prevention of cardiovascular events?
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2014 |
Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
The harms of low-dose aspirin prophylaxis are overstated.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
The harms of low-dose aspirin prophylaxis are overstated.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio | 2014 |
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio | 2014 |
Spontaneous coronary artery dissection in a parturient with Nail-Patella syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antidiuretic | 2015 |
Spontaneous coronary artery dissection in a parturient with Nail-Patella syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antidiuretic | 2015 |
Atherosclerosis: low-dose aspirin failed to improve cardiovascular outcomes.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Atherosclerosis: low-dose aspirin failed to improve cardiovascular outcomes.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Myocardial infarction associated with Kawasaki disease in adult man: case report and review of literature.
Topics: Adolescent; Anti-Inflammatory Agents; Aspirin; Coronary Aneurysm; Drug-Eluting Stents; Echocardiogra | 2015 |
Myocardial infarction associated with Kawasaki disease in adult man: case report and review of literature.
Topics: Adolescent; Anti-Inflammatory Agents; Aspirin; Coronary Aneurysm; Drug-Eluting Stents; Echocardiogra | 2015 |
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; My | 2015 |
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; My | 2015 |
Aspirin use in women for primary prevention.
Topics: Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Platelet Agg | 2015 |
Aspirin use in women for primary prevention.
Topics: Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Platelet Agg | 2015 |
Aspirin for first-line heart attack prevention. These is still no consensus; the benefits must be weighed against the risks.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Preve | 2014 |
Aspirin for first-line heart attack prevention. These is still no consensus; the benefits must be weighed against the risks.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Preve | 2014 |
Web Exclusives. The consult guys--balancing the medication portfolio 5 years after a heart attack.
Topics: Adrenergic beta-1 Receptor Antagonists; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Ba | 2014 |
Web Exclusives. The consult guys--balancing the medication portfolio 5 years after a heart attack.
Topics: Adrenergic beta-1 Receptor Antagonists; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Ba | 2014 |
[Perioperative complications of transurethral resection of bladder tumor in patients receiving antithrombotic therapy].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cystectomy; Female; Fibrinolytic Agents; Hemorrha | 2014 |
[Perioperative complications of transurethral resection of bladder tumor in patients receiving antithrombotic therapy].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cystectomy; Female; Fibrinolytic Agents; Hemorrha | 2014 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammator | 2014 |
Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammator | 2014 |
"Frankly, my dear, I don't give a damn".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomedical Research; Breast Neoplasms; Clinical Tr | 2014 |
"Frankly, my dear, I don't give a damn".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomedical Research; Breast Neoplasms; Clinical Tr | 2014 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimu | 2015 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimu | 2015 |
Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coordination Complexes; Electrocardiograp | 2015 |
Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coordination Complexes; Electrocardiograp | 2015 |
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Dev | 2015 |
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Dev | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D | 2015 |
Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients.
Topics: Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Female; Humans; Male; Midd | 2015 |
Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients.
Topics: Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Female; Humans; Male; Midd | 2015 |
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary | 2015 |
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary | 2015 |
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi | 2015 |
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi | 2015 |
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Creatinine; Disease Progression; Fema | 2015 |
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Creatinine; Disease Progression; Fema | 2015 |
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2015 |
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2015 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
Topics: Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platel | 2015 |
Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
Topics: Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platel | 2015 |
Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2015 |
Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Long-term survival following bariatric surgery in the VA health system.
Topics: Aspirin; Bariatric Surgery; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Ob | 2015 |
Long-term survival following bariatric surgery in the VA health system.
Topics: Aspirin; Bariatric Surgery; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Ob | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients--reply.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients--reply.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012.
Topics: Aged; Aspirin; Blood Glucose; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperc | 2015 |
Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012.
Topics: Aged; Aspirin; Blood Glucose; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperc | 2015 |
Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Re | 2016 |
Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Re | 2016 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog | 2015 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog | 2015 |
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Body Mass Index; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Body Mass Index; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Topics: Aspirin; Europe; Evidence-Based Medicine; Humans; Myocardial Infarction; Percutaneous Coronary Inter | 2015 |
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Topics: Aspirin; Europe; Evidence-Based Medicine; Humans; Myocardial Infarction; Percutaneous Coronary Inter | 2015 |
Double antiplatelet therapy duration: standardize or personalize?
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Double antiplatelet therapy duration: standardize or personalize?
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; He | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; He | 2015 |
Assessing the Quality of Care for Patients With Acute Myocardial Infarction in China.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Clopido | 2015 |
Assessing the Quality of Care for Patients With Acute Myocardial Infarction in China.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Clopido | 2015 |
Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction.
Topics: Animals; Aspirin; Clopidogrel; Coronary Vessels; Endothelial Cells; Humans; Male; Myocardial Infarct | 2015 |
Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction.
Topics: Animals; Aspirin; Clopidogrel; Coronary Vessels; Endothelial Cells; Humans; Male; Myocardial Infarct | 2015 |
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2015 |
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2015 |
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc | 2015 |
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc | 2015 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2015 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.
Topics: Aged; Aspirin; Blood Platelets; Cardiac Catheterization; Female; Humans; Influenza A Virus, H1N1 Sub | 2015 |
Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.
Topics: Aged; Aspirin; Blood Platelets; Cardiac Catheterization; Female; Humans; Influenza A Virus, H1N1 Sub | 2015 |
Decision Aids: The Effect of Labeling Options on Patient Choices and Decision Making.
Topics: Adult; Aspirin; Choice Behavior; Decision Support Techniques; Drug Labeling; Female; Humans; Hydroxy | 2015 |
Decision Aids: The Effect of Labeling Options on Patient Choices and Decision Making.
Topics: Adult; Aspirin; Choice Behavior; Decision Support Techniques; Drug Labeling; Female; Humans; Hydroxy | 2015 |
Ask the doctor. The other night I work up at about 2 a.m., and my heart was pumping hard and my lower jaw ached. It lasted about an hour, even though I took an aspirin. Then I fell asleep. In the morning everything was fine. Was that a heart attack?
Topics: Anticoagulants; Aspirin; Heart; Heart Rate; Humans; Jaw; Myocardial Infarction; Pain | 2015 |
Ask the doctor. The other night I work up at about 2 a.m., and my heart was pumping hard and my lower jaw ached. It lasted about an hour, even though I took an aspirin. Then I fell asleep. In the morning everything was fine. Was that a heart attack?
Topics: Anticoagulants; Aspirin; Heart; Heart Rate; Humans; Jaw; Myocardial Infarction; Pain | 2015 |
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe | 2015 |
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe | 2015 |
Interhospital Variability in Drug Prescription After Acute Coronary Syndrome: Insights From the ACDC Study.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Prescriptions; Drug | 2016 |
Interhospital Variability in Drug Prescription After Acute Coronary Syndrome: Insights From the ACDC Study.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Prescriptions; Drug | 2016 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antag | 2015 |
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antag | 2015 |
ISIS and the emergence of large, simple trials.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Randomized C | 2015 |
ISIS and the emergence of large, simple trials.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Randomized C | 2015 |
The social history of ISIS-2: the early history.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; History, 20th Century; Humans; Myocardial I | 2015 |
The social history of ISIS-2: the early history.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; History, 20th Century; Humans; Myocardial I | 2015 |
The social history of ISIS-2: triumph and the path not taken.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; History, 20th Century; Humans; Multicenter | 2015 |
The social history of ISIS-2: triumph and the path not taken.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; History, 20th Century; Humans; Multicenter | 2015 |
The social history of ISIS-2: trial and tribulation.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myoca | 2015 |
The social history of ISIS-2: trial and tribulation.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myoca | 2015 |
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Evidence-Based | 2015 |
Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Evidence-Based | 2015 |
Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Geriatrics; Hospitals; Humans; M | 2015 |
Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Geriatrics; Hospitals; Humans; M | 2015 |
Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; F | 2015 |
Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; F | 2015 |
Acetylsalicylic acid resistance risk factors in patients with myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Drug Resistance; Female; | 2015 |
Acetylsalicylic acid resistance risk factors in patients with myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Drug Resistance; Female; | 2015 |
Bare-metal stent thrombosis two decades after stenting.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Electr | 2015 |
Bare-metal stent thrombosis two decades after stenting.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Electr | 2015 |
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H | 2016 |
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H | 2016 |
[The PEGASUS-TIMI 54 study].
Topics: Adenosine; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y R | 2015 |
[The PEGASUS-TIMI 54 study].
Topics: Adenosine; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y R | 2015 |
Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Concurrent Active Gastrointestinal Bleeding.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Cardiopulmonary Resuscitation; Dopamine; Drug-E | 2015 |
Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Concurrent Active Gastrointestinal Bleeding.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Cardiopulmonary Resuscitation; Dopamine; Drug-E | 2015 |
Ask about aspirin.
Topics: Aspirin; beta Carotene; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Healt | 2015 |
Ask about aspirin.
Topics: Aspirin; beta Carotene; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Healt | 2015 |
Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study.
Topics: Acute Coronary Syndrome; Aged; Alcoholism; Angina, Unstable; Aspirin; Delayed Diagnosis; Developing | 2015 |
Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study.
Topics: Acute Coronary Syndrome; Aged; Alcoholism; Angina, Unstable; Aspirin; Delayed Diagnosis; Developing | 2015 |
Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.
Topics: Animals; Antioxidants; Aspirin; Glutathione Peroxidase; Heart Injuries; Heart Ventricles; Male; Myoc | 2016 |
Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.
Topics: Animals; Antioxidants; Aspirin; Glutathione Peroxidase; Heart Injuries; Heart Ventricles; Male; Myoc | 2016 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2016 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2016 |
Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Editorial Commentary: Striking a balance: Individualizing antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarcti | 2016 |
Editorial Commentary: Striking a balance: Individualizing antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarcti | 2016 |
Mean platelet volume to platelet count ratio predicts in-hospital complications and long-term mortality in type A acute aortic dissection.
Topics: Adrenergic beta-Antagonists; Adult; Aorta; Aortic Aneurysm; Aortic Dissection; Aspirin; Biomarkers; | 2016 |
Mean platelet volume to platelet count ratio predicts in-hospital complications and long-term mortality in type A acute aortic dissection.
Topics: Adrenergic beta-Antagonists; Adult; Aorta; Aortic Aneurysm; Aortic Dissection; Aspirin; Biomarkers; | 2016 |
Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.
Topics: Aged; Aspirin; Behavioral Risk Factor Surveillance System; Diabetes Mellitus; Humans; Hypercholester | 2015 |
Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.
Topics: Aged; Aspirin; Behavioral Risk Factor Surveillance System; Diabetes Mellitus; Humans; Hypercholester | 2015 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
Recent Trends in Adherence to Secondary Prevention Guidelines for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical Outcomes Assessment Program (COAP) Registry.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2012 |
Recent Trends in Adherence to Secondary Prevention Guidelines for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical Outcomes Assessment Program (COAP) Registry.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2012 |
Association of increasing age with receipt of specialist care and long-term mortality in patients with non-ST elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2016 |
Association of increasing age with receipt of specialist care and long-term mortality in patients with non-ST elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2016 |
Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Coronary Artery Disease; Dose-Response Relationshi | 2016 |
Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Coronary Artery Disease; Dose-Response Relationshi | 2016 |
Use of ticagrelor in human pregnancy, the first experience.
Topics: Adenosine; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platele | 2015 |
Use of ticagrelor in human pregnancy, the first experience.
Topics: Adenosine; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platele | 2015 |
Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Analgesics, Opioid; Anticoagulants; Aspirin; Clopidogrel; Electro | 2015 |
Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Analgesics, Opioid; Anticoagulants; Aspirin; Clopidogrel; Electro | 2015 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
Acute myocardial infarction after trauma: potency of percutaneous coronary intervention with transcatheter arterial embolization.
Topics: Accidents, Traffic; Aged; Aspirin; Coronary Angiography; Embolization, Therapeutic; Humans; Male; My | 2016 |
Acute myocardial infarction after trauma: potency of percutaneous coronary intervention with transcatheter arterial embolization.
Topics: Accidents, Traffic; Aged; Aspirin; Coronary Angiography; Embolization, Therapeutic; Humans; Male; My | 2016 |
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I | 2016 |
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I | 2016 |
[A rare differential diagnosis of acute lower gastrointestinal bleeding: Small-bowel diverticulosis].
Topics: Accidental Falls; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-S | 2015 |
[A rare differential diagnosis of acute lower gastrointestinal bleeding: Small-bowel diverticulosis].
Topics: Accidental Falls; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-S | 2015 |
Durlaza--a 24-hour extended-release aspirin.
Topics: Aspirin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Costs; Humans; Myocardial Infa | 2016 |
Durlaza--a 24-hour extended-release aspirin.
Topics: Aspirin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Costs; Humans; Myocardial Infa | 2016 |
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; | 2016 |
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; | 2016 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti | 2016 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
A Newly Characterized Hemoglobin Variant with a High Oxygen Affinity, Hb Fuchu-II, Presenting with Acute Myocardial Infarction.
Topics: Aged; Anticoagulants; Aspirin; Chest Pain; Coronary Angiography; Hemoglobins, Abnormal; Humans; Male | 2016 |
A Newly Characterized Hemoglobin Variant with a High Oxygen Affinity, Hb Fuchu-II, Presenting with Acute Myocardial Infarction.
Topics: Aged; Anticoagulants; Aspirin; Chest Pain; Coronary Angiography; Hemoglobins, Abnormal; Humans; Male | 2016 |
Likelihood ratio meta-analysis: New motivation and approach for an old method.
Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl | 2016 |
Likelihood ratio meta-analysis: New motivation and approach for an old method.
Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; C | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; C | 2016 |
Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Belgium | 2016 |
Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Belgium | 2016 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adhe | 2015 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adhe | 2015 |
Management of acute perioperative myocardial infarction: a case report of concomitant acute myocardial infarction and tumor bleeding in the transverse colon.
Topics: Aged; Aspirin; Colon, Transverse; Colonic Neoplasms; Colonoscopy; Coronary Angiography; Disease Mana | 2016 |
Management of acute perioperative myocardial infarction: a case report of concomitant acute myocardial infarction and tumor bleeding in the transverse colon.
Topics: Aged; Aspirin; Colon, Transverse; Colonic Neoplasms; Colonoscopy; Coronary Angiography; Disease Mana | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient.
Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; | 2016 |
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient.
Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; | 2016 |
Effect of remote ischaemic conditioning on coagulation and fibrinolysis.
Topics: Adult; Arm; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cross-Over Studies; Fibrin Clot Lys | 2016 |
Effect of remote ischaemic conditioning on coagulation and fibrinolysis.
Topics: Adult; Arm; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cross-Over Studies; Fibrin Clot Lys | 2016 |
On call. Is it true that in some people, low-dose aspirin doesn't help to prevent heart attacks? Should I take a higher dose to make sure it works?
Topics: Aspirin; Humans; Myocardial Infarction | 2013 |
On call. Is it true that in some people, low-dose aspirin doesn't help to prevent heart attacks? Should I take a higher dose to make sure it works?
Topics: Aspirin; Humans; Myocardial Infarction | 2013 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocard | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocard | 2016 |
Isolated septal myocardial infarction due to spontaneous coronary artery dissection.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Vessel Anomalies; Diagnosis, Differential; Drug Thera | 2016 |
Isolated septal myocardial infarction due to spontaneous coronary artery dissection.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Vessel Anomalies; Diagnosis, Differential; Drug Thera | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combinati | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combinati | 2016 |
Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2016 |
Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Mal | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Mal | 2016 |
Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Clinical Audit; Elec | 2016 |
Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Clinical Audit; Elec | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescription | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescription | 2016 |
Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Follow-Up Studies; Guideline Adherence; Hospital | 2016 |
Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Follow-Up Studies; Guideline Adherence; Hospital | 2016 |
Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction.
Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Coho | 2016 |
Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction.
Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Coho | 2016 |
Medical research: Time to think differently about diabetes.
Topics: Adipose Tissue; Animals; Aspirin; Bariatric Surgery; Bile Acids and Salts; Biomedical Research; Bloo | 2016 |
Medical research: Time to think differently about diabetes.
Topics: Adipose Tissue; Animals; Aspirin; Bariatric Surgery; Bile Acids and Salts; Biomedical Research; Bloo | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
Adapting DAPT to Improve Outcomes After Coronary Stenting.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronar | 2016 |
Adapting DAPT to Improve Outcomes After Coronary Stenting.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronar | 2016 |
Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Disease; Coronary Vasospasm; Female; Follow-Up Studie | 2016 |
Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Disease; Coronary Vasospasm; Female; Follow-Up Studie | 2016 |
Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Echocardiography; England; Female; Guideline Adher | 2016 |
Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Echocardiography; England; Female; Guideline Adher | 2016 |
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2016 |
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2016 |
NICE recommends ticagrelor with aspirin for three years post-MI.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation I | 2016 |
NICE recommends ticagrelor with aspirin for three years post-MI.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation I | 2016 |
Philip Majerus.
Topics: Aspirin; Blood Coagulation; Faculty, Medical; Fibrinolytic Agents; Hematology; History, 20th Century | 2016 |
Philip Majerus.
Topics: Aspirin; Blood Coagulation; Faculty, Medical; Fibrinolytic Agents; Hematology; History, 20th Century | 2016 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid | 2016 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid | 2016 |
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism | 2016 |
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism | 2016 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Human | 2017 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Human | 2017 |
Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; China; Clopidogrel; Female; Humans; Male; Mid | 2016 |
Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; China; Clopidogrel; Female; Humans; Male; Mid | 2016 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos | 2016 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos | 2016 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Czech Republic; Female; Humans; M | 2017 |
High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Czech Republic; Female; Humans; M | 2017 |
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combinati | 2017 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combinati | 2017 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa | 2017 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa | 2017 |
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet | 2016 |
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet | 2016 |
TRIAD system catalase, insulin, and low dose aspirin neutralize the effect of dermcidin isoform-2 and prevent cell death in acute myocardial infarction and recurrence of the disease.
Topics: Aspirin; Catalase; Cell Death; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Peptides | 2016 |
TRIAD system catalase, insulin, and low dose aspirin neutralize the effect of dermcidin isoform-2 and prevent cell death in acute myocardial infarction and recurrence of the disease.
Topics: Aspirin; Catalase; Cell Death; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Peptides | 2016 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans | 2017 |
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans | 2017 |
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema | 2016 |
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema | 2016 |
Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channe | 2017 |
Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channe | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocard | 2017 |
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocard | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Clinica | 2017 |
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Clinica | 2017 |
Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aspirin; Bundle-Branch Block; Coh | 2017 |
Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aspirin; Bundle-Branch Block; Coh | 2017 |
Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Aspirin: A Case-crossover Study and a Propensity Score-matched Cohort Study.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Cross-Over Studies; Databases, Factual; Fem | 2017 |
Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Aspirin: A Case-crossover Study and a Propensity Score-matched Cohort Study.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Cross-Over Studies; Databases, Factual; Fem | 2017 |
Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Coronary Artery Disease; Diabetes Mellitus; | 2017 |
Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Coronary Artery Disease; Diabetes Mellitus; | 2017 |
Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Aspirin; Chest Pain; Coronary Artery Disease; Dip | 2017 |
Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Aspirin; Chest Pain; Coronary Artery Disease; Dip | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
Reduction in sex-based mortality difference with implementation of new cardiology guidelines.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2008 |
Reduction in sex-based mortality difference with implementation of new cardiology guidelines.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2008 |
Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Confidence Intervals; Elective Surgical Procedures; Fem | 2008 |
Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Confidence Intervals; Elective Surgical Procedures; Fem | 2008 |
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Evidence-Based Medicine; Fibrinolytic | 2008 |
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Evidence-Based Medicine; Fibrinolytic | 2008 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma | 2008 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma | 2008 |
Dangers of skipping medications after a heart attack.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2008 |
Dangers of skipping medications after a heart attack.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Discontinuation of statin therapy following an acute myocardial infarction: a population-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-Co | 2008 |
Discontinuation of statin therapy following an acute myocardial infarction: a population-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-Co | 2008 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aspirin | 2008 |
Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aspirin | 2008 |
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C | 2009 |
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C | 2009 |
More evidence standard preventative measures can prevent COX-2 inhibitor-induced infarctions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2008 |
More evidence standard preventative measures can prevent COX-2 inhibitor-induced infarctions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2008 |
Heart rate variability in patients with stable coronary artery disease and aspirin resistance.
Topics: Adult; Aged; Aspirin; Circadian Rhythm; Coronary Artery Disease; Cyclooxygenase Inhibitors; Drug Res | 2008 |
Heart rate variability in patients with stable coronary artery disease and aspirin resistance.
Topics: Adult; Aged; Aspirin; Circadian Rhythm; Coronary Artery Disease; Cyclooxygenase Inhibitors; Drug Res | 2008 |
Direct stenting after thrombus removal before primary angioplasty in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Female; Heparin; Humans; Male; Middle | 2008 |
Direct stenting after thrombus removal before primary angioplasty in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Female; Heparin; Humans; Male; Middle | 2008 |
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive A | 2008 |
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive A | 2008 |
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Age | 2008 |
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Age | 2008 |
'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregati | 2008 |
'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregati | 2008 |
The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis.
Topics: Aspirin; Biometry; Confidence Intervals; Diuretics; Esophageal and Gastric Varices; Female; Glycerol | 2008 |
The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis.
Topics: Aspirin; Biometry; Confidence Intervals; Diuretics; Esophageal and Gastric Varices; Female; Glycerol | 2008 |
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Crea | 2008 |
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Crea | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessel | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessel | 2008 |
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol | 2008 |
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol | 2008 |
Drug-eluting stents in a patient with favism: is the aspirin administration safe?
Topics: Administration, Oral; Anemia, Hemolytic; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiograp | 2008 |
Drug-eluting stents in a patient with favism: is the aspirin administration safe?
Topics: Administration, Oral; Anemia, Hemolytic; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiograp | 2008 |
Re: Gender disparity in cardiac procedures and medication use for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Distribution; Angiotensin-Converting Enzyme Inhibitors; Anticoagula | 2008 |
Re: Gender disparity in cardiac procedures and medication use for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Distribution; Angiotensin-Converting Enzyme Inhibitors; Anticoagula | 2008 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding.
Topics: Acute Disease; Adult; Aged; Aspirin; Female; Follow-Up Studies; Hematocrit; Hemorrhage; Hospitals; H | 2008 |
Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding.
Topics: Acute Disease; Adult; Aged; Aspirin; Female; Follow-Up Studies; Hematocrit; Hemorrhage; Hospitals; H | 2008 |
Acute myocardial infarction in pregnancy.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Apgar Score; Aspirin; Cesarean Section; Coron | 2008 |
Acute myocardial infarction in pregnancy.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Apgar Score; Aspirin; Cesarean Section; Coron | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
[Protective effect of Tongxinluo Ultramicro-pulverization on experimental myocardial infarction of rats].
Topics: Adenosine Diphosphate; Animals; Aspirin; Diltiazem; Drugs, Chinese Herbal; Female; Male; Medicine, C | 2008 |
[Protective effect of Tongxinluo Ultramicro-pulverization on experimental myocardial infarction of rats].
Topics: Adenosine Diphosphate; Animals; Aspirin; Diltiazem; Drugs, Chinese Herbal; Female; Male; Medicine, C | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Confidence Intervals; Drug Therapy, Combination; Drug | 2008 |
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Confidence Intervals; Drug Therapy, Combination; Drug | 2008 |
Initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction is related to platelet response to aspirin.
Topics: Aspirin; Blood Platelets; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation | 2010 |
Initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction is related to platelet response to aspirin.
Topics: Aspirin; Blood Platelets; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation | 2010 |
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Topics: Adult; Aged; Arachidonate Lipoxygenases; Aspirin; Brain Ischemia; Case-Control Studies; Cyclooxygena | 2009 |
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Topics: Adult; Aged; Arachidonate Lipoxygenases; Aspirin; Brain Ischemia; Case-Control Studies; Cyclooxygena | 2009 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Diabetes and aspirin: beware of underpowered negative trials.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Complications; Fibrinolytic Agents; Humans; Myocardial I | 2009 |
Diabetes and aspirin: beware of underpowered negative trials.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Complications; Fibrinolytic Agents; Humans; Myocardial I | 2009 |
Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Creatine Kinas | 2009 |
Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Creatine Kinas | 2009 |
A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Follow-Up Studies; Humans; Markov Chains; M | 2010 |
A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Follow-Up Studies; Humans; Markov Chains; M | 2010 |
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Case-Control Studies; Female; Humans; | 2009 |
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Case-Control Studies; Female; Humans; | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrino | 2009 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrino | 2009 |
Be alert to heart attack symptoms--it may save your life. An alarming number of patients with a history of heart attack still don't know the warning signs and underestimate their risk.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction | 2008 |
Be alert to heart attack symptoms--it may save your life. An alarming number of patients with a history of heart attack still don't know the warning signs and underestimate their risk.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction | 2008 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adjuvant; | 2009 |
Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adjuvant; | 2009 |
Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Canada; Combined Modality Therapy; Dose-Response Relationsh | 2009 |
Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Canada; Combined Modality Therapy; Dose-Response Relationsh | 2009 |
Successful clopidogrel desensitization after drug-eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Desensitization, Immunologic; Drug-Eluting Ste | 2009 |
Successful clopidogrel desensitization after drug-eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Desensitization, Immunologic; Drug-Eluting Ste | 2009 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb | 2009 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb | 2009 |
An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence.
Topics: Accreditation; Adrenergic beta-Antagonists; Aged; Aspirin; Clinical Protocols; Drug Utilization; Ele | 2009 |
An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence.
Topics: Accreditation; Adrenergic beta-Antagonists; Aged; Aspirin; Clinical Protocols; Drug Utilization; Ele | 2009 |
Using icon arrays to communicate medical risks: overcoming low numeracy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph | 2009 |
Using icon arrays to communicate medical risks: overcoming low numeracy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph | 2009 |
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Age Factors; Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cost of Illness; Female; Gastro | 2009 |
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Age Factors; Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cost of Illness; Female; Gastro | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality.
Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; E | 2009 |
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality.
Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; E | 2009 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh | 2009 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh | 2009 |
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi | 2008 |
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi | 2008 |
Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency.
Topics: Aged; Aspirin; Coronary Artery Bypass; Drug-Eluting Stents; Fibrinolytic Agents; Graft Occlusion, Va | 2009 |
Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency.
Topics: Aged; Aspirin; Coronary Artery Bypass; Drug-Eluting Stents; Fibrinolytic Agents; Graft Occlusion, Va | 2009 |
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibito | 2009 |
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibito | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Acute myocardial infarction with sumatriptan: a case report and review of the literature.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Coronary Vasospasm; Coronary Vessels; Echocardi | 2009 |
Acute myocardial infarction with sumatriptan: a case report and review of the literature.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Coronary Vasospasm; Coronary Vessels; Echocardi | 2009 |
Aspirin for prevention of myocardial infarction and stroke: is the right dose 81 or 160 mg/day?
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2009 |
Aspirin for prevention of myocardial infarction and stroke: is the right dose 81 or 160 mg/day?
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; | 2009 |
Risks of proton-pump inhibitors: what every doctor should know. Comment.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Hu | 2009 |
Risks of proton-pump inhibitors: what every doctor should know. Comment.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Hu | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2009 |
Does anticoagulation benefit patients with congestive heart failure (CHF) who have reduced left ventricular ejection fraction (LVEF) and are in normal sinus rhythm?
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Meta-Analysis | 2009 |
Does anticoagulation benefit patients with congestive heart failure (CHF) who have reduced left ventricular ejection fraction (LVEF) and are in normal sinus rhythm?
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Meta-Analysis | 2009 |
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male | 2010 |
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male | 2010 |
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C | 2009 |
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C | 2009 |
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
Topics: Antihypertensive Agents; Aspirin; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Electro | 2009 |
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
Topics: Antihypertensive Agents; Aspirin; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Electro | 2009 |
Coronary embolism causing acute myocardial infarction in a patient with mitral valve prosthesis: successful management with angioplasty.
Topics: Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; A | 2009 |
Coronary embolism causing acute myocardial infarction in a patient with mitral valve prosthesis: successful management with angioplasty.
Topics: Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; A | 2009 |
The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Comorbidity; Drug Resistance; Electrocardi | 2009 |
The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Comorbidity; Drug Resistance; Electrocardi | 2009 |
Plasma salicylate level and aspirin resistance in survivors of myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug | 2010 |
Plasma salicylate level and aspirin resistance in survivors of myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug | 2010 |
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; D | 2009 |
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; D | 2009 |
Experts recommend low-dose aspirin to prevent stroke in women. Lower doses are as effective as higher doses and are likely to be safer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Health Knowledge, Atti | 2009 |
Experts recommend low-dose aspirin to prevent stroke in women. Lower doses are as effective as higher doses and are likely to be safer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Health Knowledge, Atti | 2009 |
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastr | 2009 |
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastr | 2009 |
Technology diffusion in health care.
Topics: Adrenergic beta-Antagonists; Angioplasty; Aspirin; Cost-Benefit Analysis; Diffusion of Innovation; H | 2009 |
Technology diffusion in health care.
Topics: Adrenergic beta-Antagonists; Angioplasty; Aspirin; Cost-Benefit Analysis; Diffusion of Innovation; H | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clini | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clini | 2009 |
Percutaneous coronary intervention in a patient with factor XI deficiency.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Factor XI Deficiency; Human | 2009 |
Percutaneous coronary intervention in a patient with factor XI deficiency.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Factor XI Deficiency; Human | 2009 |
Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Size; Drug Resistance; Fem | 2009 |
Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Size; Drug Resistance; Fem | 2009 |
Acute myocardial infarction as the first manifestation of the incomplete Kawasaki disease in a young male.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Captopril; Child; Coronary Angiograph | 2009 |
Acute myocardial infarction as the first manifestation of the incomplete Kawasaki disease in a young male.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Captopril; Child; Coronary Angiograph | 2009 |
Aspirin in the primary prevention of vascular disease.
Topics: Aspirin; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Ag | 2009 |
Aspirin in the primary prevention of vascular disease.
Topics: Aspirin; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Ag | 2009 |
Headache as the sole presenting symptom of acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headac | 2009 |
Headache as the sole presenting symptom of acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headac | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Desensitization to clopidogrel: a growing need.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Desensitization, Immunologic; Drug Therapy, Combinati | 2010 |
Desensitization to clopidogrel: a growing need.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Desensitization, Immunologic; Drug Therapy, Combinati | 2010 |
Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; E | 2009 |
Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; E | 2009 |
Myocardial infarction, peptic ulcer and acetylsalicylic acid: of good and evil.
Topics: Aspirin; Endoscopy, Digestive System; Gastroenterology; Gastrointestinal Hemorrhage; Humans; Myocard | 2009 |
Myocardial infarction, peptic ulcer and acetylsalicylic acid: of good and evil.
Topics: Aspirin; Endoscopy, Digestive System; Gastroenterology; Gastrointestinal Hemorrhage; Humans; Myocard | 2009 |
Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding.
Topics: Aged; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Female; Gastrointestinal Hemorrhage; | 2009 |
Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding.
Topics: Aged; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Female; Gastrointestinal Hemorrhage; | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Drug secondary prevention in postmenopausal women with ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Humans | 2009 |
Drug secondary prevention in postmenopausal women with ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Humans | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Europe; Female; Guideline Adherence; | 2009 |
Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Europe; Female; Guideline Adherence; | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
A regional system for delivery of primary percutaneous coronary intervention in ST-elevation myocardial infarction: STEMI-St. Cloud.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Delivery of He | 2009 |
A regional system for delivery of primary percutaneous coronary intervention in ST-elevation myocardial infarction: STEMI-St. Cloud.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Delivery of He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function.
Topics: Aged; Anticholesteremic Agents; Aspirin; Confidence Intervals; Female; Glomerular Filtration Rate; H | 2010 |
Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function.
Topics: Aged; Anticholesteremic Agents; Aspirin; Confidence Intervals; Female; Glomerular Filtration Rate; H | 2010 |
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal | 2009 |
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal | 2009 |
Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac | 2009 |
Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac | 2009 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, | 2009 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B | 2009 |
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
Topics: Aged; Angina Pectoris; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Dose-Response Relat | 2009 |
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
Topics: Aged; Angina Pectoris; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Dose-Response Relat | 2009 |
Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; An | 2009 |
Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; An | 2009 |
Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Cell Count; Cohort Studies; Coronary Ar | 2009 |
Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Cell Count; Cohort Studies; Coronary Ar | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; | 2009 |
Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Female; Humans; Male; Model | 2010 |
Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Female; Humans; Male; Model | 2010 |
Influence of sex on the out-of-hospital management of chest pain.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Aspirin; Chest Pain; Emergency Medical Services; Fem | 2010 |
Influence of sex on the out-of-hospital management of chest pain.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Aspirin; Chest Pain; Emergency Medical Services; Fem | 2010 |
[A rare disease with varied manifestations. Here threaten blindness, stroke, myocardial infarction].
Topics: Aged; Aspirin; Biopsy; Blindness; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibi | 2009 |
[A rare disease with varied manifestations. Here threaten blindness, stroke, myocardial infarction].
Topics: Aged; Aspirin; Biopsy; Blindness; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibi | 2009 |
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Meta-Analys | 2010 |
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Meta-Analys | 2010 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectio | 2010 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectio | 2010 |
Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose?
Topics: Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myocardial Infarction; Strok | 2010 |
Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose?
Topics: Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myocardial Infarction; Strok | 2010 |
Long-term clinical course of patients with isolated myocardial bridge.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Angiography; Coronary Vasospasm; Female; Follow-Up Studies; | 2010 |
Long-term clinical course of patients with isolated myocardial bridge.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Angiography; Coronary Vasospasm; Female; Follow-Up Studies; | 2010 |
Examining guideline-concordant care for acute myocardial infarction (AMI): the case of hospitalized post-acute and long-term care (PAC/LTC) residents.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Geriatrics; Guideline Adher | 2010 |
Examining guideline-concordant care for acute myocardial infarction (AMI): the case of hospitalized post-acute and long-term care (PAC/LTC) residents.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Geriatrics; Guideline Adher | 2010 |
Quality of care for myocardial infarction in rural and urban hospitals.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2010 |
Quality of care for myocardial infarction in rural and urban hospitals.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2010 |
Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Asia-Pacific.
Topics: Asia; Aspirin; Attitude of Health Personnel; Health Care Surveys; Humans; Internet; Middle East; Myo | 2010 |
Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Asia-Pacific.
Topics: Asia; Aspirin; Attitude of Health Personnel; Health Care Surveys; Humans; Internet; Middle East; Myo | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up | 2010 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary | 2010 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary | 2010 |
Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Coronary Angiography; Coronary Thromb | 2010 |
Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Coronary Angiography; Coronary Thromb | 2010 |
Aspirin and primary prevention. BHS reaffirms its guidance.
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2010 |
Aspirin and primary prevention. BHS reaffirms its guidance.
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2010 |
Evidence of disparity in the application of quality improvement efforts for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice Initiative in Michigan.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Counseling; Drug Pres | 2010 |
Evidence of disparity in the application of quality improvement efforts for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice Initiative in Michigan.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Counseling; Drug Pres | 2010 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; | 2010 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; | 2010 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2011 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2011 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2010 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2010 |
Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?
Topics: Aspirin; Coronary Artery Disease; Drug Industry; Humans; Myocardial Infarction; Platelet Aggregation | 2010 |
Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?
Topics: Aspirin; Coronary Artery Disease; Drug Industry; Humans; Myocardial Infarction; Platelet Aggregation | 2010 |
Aspirin in primary prevention. Evidence is lacking.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2010 |
Aspirin in primary prevention. Evidence is lacking.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2010 |
Do healthy people need an aspirin a day? The healthier your heart and arteries, the less you need aspirin.
Topics: Aspirin; Drug Administration Schedule; Health Knowledge, Attitudes, Practice; Health Status; Humans; | 2010 |
Do healthy people need an aspirin a day? The healthier your heart and arteries, the less you need aspirin.
Topics: Aspirin; Drug Administration Schedule; Health Knowledge, Attitudes, Practice; Health Status; Humans; | 2010 |
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular adverse remodelling.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Echocardiography; Female; Fractional Flow Rese | 2010 |
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular adverse remodelling.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Echocardiography; Female; Fractional Flow Rese | 2010 |
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Female; Health Services Accessibility; Hospital Mortality; | 2010 |
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Female; Health Services Accessibility; Hospital Mortality; | 2010 |
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopido | 2010 |
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopido | 2010 |
Resistance or resistors? Has Ohm's law come to antiplatelet therapy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Tolerance; Humans; Myocardial Infarction; Pat | 2010 |
Resistance or resistors? Has Ohm's law come to antiplatelet therapy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Tolerance; Humans; Myocardial Infarction; Pat | 2010 |
Spontaneous coronary dissection as cause of recurring myocardial infarction.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Coronary Aneurysm; Coronary Angiography; Drug Therapy, C | 2011 |
Spontaneous coronary dissection as cause of recurring myocardial infarction.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Coronary Aneurysm; Coronary Angiography; Drug Therapy, C | 2011 |
Hospitals with percutaneous coronary intervention capability have greater adherence to established myocardial infarction guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers | 2010 |
Hospitals with percutaneous coronary intervention capability have greater adherence to established myocardial infarction guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers | 2010 |
Improving use of prehospital 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Early Diagnosis; Electrocardiography; Eme | 2010 |
Improving use of prehospital 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Early Diagnosis; Electrocardiography; Eme | 2010 |
Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction.
Topics: Age Distribution; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2010 |
Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction.
Topics: Age Distribution; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2010 |
Intervention to increase the proportion of acute myocardial infarction or coronary artery bypass graft patients receiving an order for aspirin at hospital discharge.
Topics: Acute Disease; Adult; Aged; Aspirin; Coronary Artery Bypass; Decision Support Systems, Clinical; Fem | 2010 |
Intervention to increase the proportion of acute myocardial infarction or coronary artery bypass graft patients receiving an order for aspirin at hospital discharge.
Topics: Acute Disease; Adult; Aged; Aspirin; Coronary Artery Bypass; Decision Support Systems, Clinical; Fem | 2010 |
Clinical quality indicators and provider financial incentives: does money matter?
Topics: Aspirin; Humans; Managed Care Programs; Motivation; Myocardial Infarction; Quality of Health Care; R | 2010 |
Clinical quality indicators and provider financial incentives: does money matter?
Topics: Aspirin; Humans; Managed Care Programs; Motivation; Myocardial Infarction; Quality of Health Care; R | 2010 |
[Experience of treatment of patients with myocardial infarction without raise of ST segment on ECG of high risk of cardiocomplications by method of coronary angioplasty].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Elect | 2010 |
[Experience of treatment of patients with myocardial infarction without raise of ST segment on ECG of high risk of cardiocomplications by method of coronary angioplasty].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Elect | 2010 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
[Interview with Prof. Uwe Zeymer, Ludwgshaven Clinic. Infarct register reveals high "loss ratios" in treatment (interview by Sonja Bohm)].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Germany; G | 2010 |
[Interview with Prof. Uwe Zeymer, Ludwgshaven Clinic. Infarct register reveals high "loss ratios" in treatment (interview by Sonja Bohm)].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Germany; G | 2010 |
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Topics: Aged; Aspirin; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Cha | 2010 |
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Topics: Aged; Aspirin; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Cha | 2010 |
Ask the doctor. I've heard you should take an aspirin if you think you are having a heart attack. I already take aspirin (325 mg) every day. Should I still take an aspirin if I feel a heart attack coming on?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Health Knowledge | 2009 |
Ask the doctor. I've heard you should take an aspirin if you think you are having a heart attack. I already take aspirin (325 mg) every day. Should I still take an aspirin if I feel a heart attack coming on?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Health Knowledge | 2009 |
Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin.
Topics: Animals; Aspirin; CREB-Binding Protein; Dipyridamole; Dose-Response Relationship, Drug; Drug Interac | 2010 |
Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin.
Topics: Animals; Aspirin; CREB-Binding Protein; Dipyridamole; Dose-Response Relationship, Drug; Drug Interac | 2010 |
[The problems of antiaggregant therapy of patients with acute myocardial infarction. Experience with the use of clopidogrel].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drugs, Generic; Electrocardiography; Health Care Co | 2010 |
[The problems of antiaggregant therapy of patients with acute myocardial infarction. Experience with the use of clopidogrel].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drugs, Generic; Electrocardiography; Health Care Co | 2010 |
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2010 |
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2010 |
Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2010 |
Primary prevention of myocardial infarction: putting the evidence to use.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiov | 2010 |
Primary prevention of myocardial infarction: putting the evidence to use.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiov | 2010 |
High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; | 2010 |
High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; | 2010 |
Congenital atresia of left main coronary artery followed up for ages as a sequela of Kawasaki disease.
Topics: Abnormalities, Multiple; Adolescent; Aortography; Aspirin; Cardiac Catheterization; Coronary Angiogr | 2010 |
Congenital atresia of left main coronary artery followed up for ages as a sequela of Kawasaki disease.
Topics: Abnormalities, Multiple; Adolescent; Aortography; Aspirin; Cardiac Catheterization; Coronary Angiogr | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
What's the difference between aspirin and nitroglycerin for heart attack prevention and treatment?
Topics: Aspirin; Humans; Myocardial Infarction; Nitroglycerin; Platelet Aggregation Inhibitors; Vasodilator | 2010 |
What's the difference between aspirin and nitroglycerin for heart attack prevention and treatment?
Topics: Aspirin; Humans; Myocardial Infarction; Nitroglycerin; Platelet Aggregation Inhibitors; Vasodilator | 2010 |
[Myocardial infarction after voluntary intoxication by drug interaction between dipyridamole and aspirin].
Topics: Aspirin; Dipyridamole; Drug Interactions; Humans; Male; Middle Aged; Myocardial Infarction; Suicide, | 2010 |
[Myocardial infarction after voluntary intoxication by drug interaction between dipyridamole and aspirin].
Topics: Aspirin; Dipyridamole; Drug Interactions; Humans; Male; Middle Aged; Myocardial Infarction; Suicide, | 2010 |
The appearance of dermcidin isoform 2, a novel platelet aggregating agent in the circulation in acute myocardial infarction that inhibits insulin synthesis and the restoration by acetyl salicylic acid of its effects.
Topics: Animals; Aspirin; Coagulants; Female; Humans; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; | 2011 |
The appearance of dermcidin isoform 2, a novel platelet aggregating agent in the circulation in acute myocardial infarction that inhibits insulin synthesis and the restoration by acetyl salicylic acid of its effects.
Topics: Animals; Aspirin; Coagulants; Female; Humans; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; | 2011 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Anticoagulation can reduce nonfatal myocardial infarction.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Stroke | 2010 |
Anticoagulation can reduce nonfatal myocardial infarction.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Stroke | 2010 |
Surviving a heart attack: know the signs and save a life.
Topics: Aspirin; Chest Pain; Coronary Angiography; Dizziness; Dyspnea; Echocardiography; Electrocardiography | 2010 |
Surviving a heart attack: know the signs and save a life.
Topics: Aspirin; Chest Pain; Coronary Angiography; Dizziness; Dyspnea; Echocardiography; Electrocardiography | 2010 |
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endar | 2011 |
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endar | 2011 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect | 2010 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect | 2010 |
Platelet function analysis with two different doses of aspirin.
Topics: Analysis of Variance; Aspirin; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Hea | 2010 |
Platelet function analysis with two different doses of aspirin.
Topics: Analysis of Variance; Aspirin; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Hea | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatin | 2010 |
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatin | 2010 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; | 2011 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; | 2011 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Moda | 2010 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Moda | 2010 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopid | 2010 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopid | 2010 |
The role of fibrinolysis in the era of primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Cardiology; Female; Fibrinolysis; | 2011 |
The role of fibrinolysis in the era of primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Cardiology; Female; Fibrinolysis; | 2011 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Middle Aged; Myoc | 2011 |
Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Middle Aged; Myoc | 2011 |
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Female; Hospital Mor | 2011 |
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Female; Hospital Mor | 2011 |
Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Calcium Signaling; Cells | 2011 |
Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Calcium Signaling; Cells | 2011 |
Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Topics: Aged; Aspirin; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Gastr | 2011 |
Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Topics: Aged; Aspirin; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Gastr | 2011 |
Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Drug-Related Side Eff | 2011 |
Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Drug-Related Side Eff | 2011 |
Changes over six years in administration of aspirin and beta blockers on arrival and timely reperfusion and in in-hospital and 30-day postadmission mortality in patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Guideline Adherence; Humans; Male; Myocardial In | 2011 |
Changes over six years in administration of aspirin and beta blockers on arrival and timely reperfusion and in in-hospital and 30-day postadmission mortality in patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Guideline Adherence; Humans; Male; Myocardial In | 2011 |
Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Precision Medicine | 2011 |
Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Precision Medicine | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Female; Gastrointestinal Hemor | 2011 |
Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Female; Gastrointestinal Hemor | 2011 |
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti | 2011 |
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti | 2011 |
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cause of Death; Female; Follow-Up Studies; Health Personnel; Heart Fai | 2011 |
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cause of Death; Female; Follow-Up Studies; Health Personnel; Heart Fai | 2011 |
Myocardial bridging with a coronary artery aneurysm and left ventricular stunning.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Aneurysm; Exercise Test; Exercise Tolerance; Fibrinol | 2011 |
Myocardial bridging with a coronary artery aneurysm and left ventricular stunning.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Aneurysm; Exercise Test; Exercise Tolerance; Fibrinol | 2011 |
Aspirin for the prevention of cardiovascular disease: recommendation statement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhag | 2011 |
Aspirin for the prevention of cardiovascular disease: recommendation statement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhag | 2011 |
Aspirin for the prevention of cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Decision Making; Evidence-Based Medicine; | 2011 |
Aspirin for the prevention of cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Decision Making; Evidence-Based Medicine; | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Aspirin in the primary prevention of myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; History, 19th Century; History, 20th Century; Hist | 2012 |
Aspirin in the primary prevention of myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; History, 19th Century; History, 20th Century; Hist | 2012 |
Late bare-metal stent thrombosis in a patient with Crohn's disease.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial | 2011 |
Late bare-metal stent thrombosis in a patient with Crohn's disease.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial | 2011 |
[Myocardial infarction in the young adult--retrospective analysis of cases compile at the University Hospital of Dakar].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Contraceptive | 2010 |
[Myocardial infarction in the young adult--retrospective analysis of cases compile at the University Hospital of Dakar].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Contraceptive | 2010 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Coronary Disease; Humans; Medication Adheren | 2011 |
Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Coronary Disease; Humans; Medication Adheren | 2011 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
Topics: Aspirin; Atherosclerosis; Drug Delivery Systems; Drug Design; Hemorrhage; Humans; Myocardial Infarct | 2011 |
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
Topics: Aspirin; Atherosclerosis; Drug Delivery Systems; Drug Design; Hemorrhage; Humans; Myocardial Infarct | 2011 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Resistance; | 2011 |
Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Resistance; | 2011 |
Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Drug-Elu | 2011 |
Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Drug-Elu | 2011 |
Desperate times, desperate measures: rotablating dissections in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Atherectomy, Coron | 2011 |
Desperate times, desperate measures: rotablating dissections in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Atherectomy, Coron | 2011 |
Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications.
Topics: Aged; Angina Pectoris; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Blood Transfusion; Humans; Isc | 2011 |
Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications.
Topics: Aged; Angina Pectoris; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Blood Transfusion; Humans; Isc | 2011 |
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug T | 2011 |
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug T | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle | 2012 |
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle | 2012 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
If at first you don't perceive….the importance of repeating an ECG when a myocardial infarction is suspected.
Topics: Aspirin; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; | 2011 |
If at first you don't perceive….the importance of repeating an ECG when a myocardial infarction is suspected.
Topics: Aspirin; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; | 2011 |
Ask the doctor. I had a heart attack three years ago at age 78. My doctor started me on lisinopril, carvedilol, and aspirin. My total cholesterol is 190, and my LDL is 128. Should I be taking a statin?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carbazoles; Carvedil | 2011 |
Ask the doctor. I had a heart attack three years ago at age 78. My doctor started me on lisinopril, carvedilol, and aspirin. My total cholesterol is 190, and my LDL is 128. Should I be taking a statin?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carbazoles; Carvedil | 2011 |
Platelet response to standard aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute ST-elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fe | 2011 |
Platelet response to standard aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute ST-elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fe | 2011 |
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T | 2012 |
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T | 2012 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2011 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2011 |
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asia, Eastern; Asian People; Aspirin; Blood Platelets; | 2011 |
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asia, Eastern; Asian People; Aspirin; Blood Platelets; | 2011 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl | 2012 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl | 2012 |
Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Aspirin; Chi-Square Distribution; Denmark; Female; Fibrinolytic Ag | 2012 |
Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Aspirin; Chi-Square Distribution; Denmark; Female; Fibrinolytic Ag | 2012 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Management of acute coronary syndromes in developing countries: acute coronary events-a multinational survey of current management strategies.
Topics: Acute Coronary Syndrome; Adrenergic Antagonists; Africa; Aged; Angiotensin-Converting Enzyme Inhibit | 2011 |
Management of acute coronary syndromes in developing countries: acute coronary events-a multinational survey of current management strategies.
Topics: Acute Coronary Syndrome; Adrenergic Antagonists; Africa; Aged; Angiotensin-Converting Enzyme Inhibit | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood | 2012 |
Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood | 2012 |
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Genetic Variation; Hum | 2012 |
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Genetic Variation; Hum | 2012 |
Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2012 |
Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic | 2012 |
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com | 2012 |
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn | 2012 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn | 2012 |
Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stent | 2012 |
Simultaneous left anterior descending and right coronary stent thrombosis after aspirin withdrawal.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stent | 2012 |
Daily aspirin prevents dangerous clots. Yet only half the people who should take it, do.
Topics: Aspirin; Drug Administration Schedule; Health Behavior; Humans; Myocardial Infarction; Platelet Aggr | 2012 |
Daily aspirin prevents dangerous clots. Yet only half the people who should take it, do.
Topics: Aspirin; Drug Administration Schedule; Health Behavior; Humans; Myocardial Infarction; Platelet Aggr | 2012 |
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Chemical Analysis; Clo | 2012 |
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Chemical Analysis; Clo | 2012 |
Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Arthritis, Rheumatoid; Aspirin; Cohort Studies; Female; Humans; H | 2012 |
Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Arthritis, Rheumatoid; Aspirin; Cohort Studies; Female; Humans; H | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Are the results of a regional ST-elevation myocardial infarction system reproducible?
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clop | 2012 |
Are the results of a regional ST-elevation myocardial infarction system reproducible?
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clop | 2012 |
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom | 2012 |
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom | 2012 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang | 2012 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang | 2012 |
Aspirin's effect on platelet inhibition in migraineurs.
Topics: Adult; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Migraine Disorders; Myocardial I | 2012 |
Aspirin's effect on platelet inhibition in migraineurs.
Topics: Adult; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Migraine Disorders; Myocardial I | 2012 |
[Aspirin].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Female; Humans; Male; Myocardial Infarction | 2011 |
[Aspirin].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Female; Humans; Male; Myocardial Infarction | 2011 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat | 2012 |
Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Drug | 2012 |
Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Drug | 2012 |
Clopidogrel response up to six months after acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; P | 2012 |
Clopidogrel response up to six months after acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; P | 2012 |
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction.
Topics: Aged; Aspirin; Coronary Artery Disease; Disease Progression; Drug Resistance; Female; Humans; Male; | 2012 |
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction.
Topics: Aged; Aspirin; Coronary Artery Disease; Disease Progression; Drug Resistance; Female; Humans; Male; | 2012 |
I've taken aspirin for years to prevent heart attack, and now I've developed an ulcer. My doctor told me to keep taking aspirin along with Prilosec. Why keep taking aspirin if it caused my ulcer?
Topics: Anti-Ulcer Agents; Aspirin; Humans; Myocardial Infarction; Omeprazole; Peptic Ulcer; Platelet Aggreg | 2012 |
I've taken aspirin for years to prevent heart attack, and now I've developed an ulcer. My doctor told me to keep taking aspirin along with Prilosec. Why keep taking aspirin if it caused my ulcer?
Topics: Anti-Ulcer Agents; Aspirin; Humans; Myocardial Infarction; Omeprazole; Peptic Ulcer; Platelet Aggreg | 2012 |
Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Clopidogrel; Diabetic Cardiomyopathies; Elec | 2012 |
Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Clopidogrel; Diabetic Cardiomyopathies; Elec | 2012 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi | 2012 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi | 2012 |
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiograph | 2012 |
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiograph | 2012 |
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care?
Topics: Anti-Bacterial Agents; Aspirin; Benchmarking; Cardiovascular Agents; Heart Failure; Hospital Adminis | 2008 |
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care?
Topics: Anti-Bacterial Agents; Aspirin; Benchmarking; Cardiovascular Agents; Heart Failure; Hospital Adminis | 2008 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogr | 2012 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogr | 2012 |
Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort | 2013 |
Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort | 2013 |
Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction.
Topics: Adult; Analgesia, Obstetrical; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Eptifibatide; F | 2012 |
Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction.
Topics: Adult; Analgesia, Obstetrical; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Eptifibatide; F | 2012 |
The Million Hearts™ initiative: why psychosocial nurses should care.
Topics: Aspirin; Cholesterol; Comorbidity; Health Promotion; Humans; Hypertension; Mental Disorders; Myocard | 2012 |
The Million Hearts™ initiative: why psychosocial nurses should care.
Topics: Aspirin; Cholesterol; Comorbidity; Health Promotion; Humans; Hypertension; Mental Disorders; Myocard | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
Acute myocardial infarction--the changing face.
Topics: Aspirin; Cardiology Service, Hospital; Echocardiography; Electrocardiography; Exercise Therapy; Fibr | 2011 |
Acute myocardial infarction--the changing face.
Topics: Aspirin; Cardiology Service, Hospital; Echocardiography; Electrocardiography; Exercise Therapy; Fibr | 2011 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera | 2012 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera | 2012 |
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Huma | 2013 |
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Huma | 2013 |
Follow-up of aspirin-resistant patients with end-stage kidney disease.
Topics: Aged; Angina, Unstable; Area Under Curve; Aspirin; Cause of Death; Cohort Studies; Drug Resistance; | 2013 |
Follow-up of aspirin-resistant patients with end-stage kidney disease.
Topics: Aged; Angina, Unstable; Area Under Curve; Aspirin; Cause of Death; Cohort Studies; Drug Resistance; | 2013 |
Acute myocardial infarction patient with recurrent vomiting: what is the best treatment?
Topics: Aspirin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Treatment Outcom | 2013 |
Acute myocardial infarction patient with recurrent vomiting: what is the best treatment?
Topics: Aspirin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Treatment Outcom | 2013 |
Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 2012 |
Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 2012 |
Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Fema | 2013 |
Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Fema | 2013 |
A sovereign remedy to all diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dust; England; Folklore; Humans; Industry; Myocard | 2012 |
A sovereign remedy to all diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dust; England; Folklore; Humans; Industry; Myocard | 2012 |
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analy | 2012 |
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analy | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin diagnostic and instruction tool.
Topics: Acute Coronary Syndrome; Aspirin; Chest Pain; Emergency Medical Service Communication Systems; Emerg | 2013 |
Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin diagnostic and instruction tool.
Topics: Acute Coronary Syndrome; Aspirin; Chest Pain; Emergency Medical Service Communication Systems; Emerg | 2013 |
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2012 |
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Ar | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Ar | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Cardiovascular Agents; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA | 2012 |
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Cardiovascular Agents; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor | 2013 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor | 2013 |
Bimodal response to aspirin loading in acute ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Electrocardiography; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Bimodal response to aspirin loading in acute ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Electrocardiography; Female; Humans; Male; Middle Aged; Myoc | 2013 |
Stick with your aspirin therapy to reduce heart attack risks. New research shows that discontinuation of aspirin can raise the risk of non-fatal heart attack by 60 percent.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2011 |
Stick with your aspirin therapy to reduce heart attack risks. New research shows that discontinuation of aspirin can raise the risk of non-fatal heart attack by 60 percent.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2011 |
Dual antiplatelet therapy after stenting. More than 12 months of treatment might not be necessary.
Topics: Aspirin; Coronary Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combinat | 2012 |
Dual antiplatelet therapy after stenting. More than 12 months of treatment might not be necessary.
Topics: Aspirin; Coronary Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combinat | 2012 |
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; C | 2012 |
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; C | 2012 |
Rapid health impact assessment of aspirin promotion for the secondary prophylaxis of vascular events in Wales.
Topics: Anticoagulants; Aspirin; Health Impact Assessment; Humans; Myocardial Infarction; Randomized Control | 2012 |
Rapid health impact assessment of aspirin promotion for the secondary prophylaxis of vascular events in Wales.
Topics: Anticoagulants; Aspirin; Health Impact Assessment; Humans; Myocardial Infarction; Randomized Control | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
The role of aspirin in primary prevention of vascular events.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
The role of aspirin in primary prevention of vascular events.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
Clopidogrel and aspirin administration management prior to coronary artery surgery requires an individual approach.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2013 |
Clopidogrel and aspirin administration management prior to coronary artery surgery requires an individual approach.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation I | 2013 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angi | 2012 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angi | 2012 |
Pharmaceutical care for patients with acute myocardial infarction in Hungary.
Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Comb | 2013 |
Pharmaceutical care for patients with acute myocardial infarction in Hungary.
Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Comb | 2013 |
[Peculiarities of pregnancy management after multiple stenting of coronary arteries].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cesarean Section; Coronary Vessels; Diagnosis, Diffe | 2012 |
[Peculiarities of pregnancy management after multiple stenting of coronary arteries].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cesarean Section; Coronary Vessels; Diagnosis, Diffe | 2012 |
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Femal | 2013 |
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Femal | 2013 |
Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Th | 2013 |
Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Th | 2013 |
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged; | 2012 |
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged; | 2012 |
On collapsibility and confounding bias in Cox and Aalen regression models.
Topics: Adult; Aged; Aspirin; Bias; Biostatistics; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; L | 2013 |
On collapsibility and confounding bias in Cox and Aalen regression models.
Topics: Adult; Aged; Aspirin; Bias; Biostatistics; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; L | 2013 |
Missing out on aspirin therapy? Research finds most people skip the proven measure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2012 |
Missing out on aspirin therapy? Research finds most people skip the proven measure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2012 |
What you should know about: aspirin during a heart attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2012 |
What you should know about: aspirin during a heart attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Health Behavior; Hea | 2012 |
Acute myocardial infarction and heart block: a challenge to emergency physicians.
Topics: Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heart Block; Humans; Mal | 2013 |
Acute myocardial infarction and heart block: a challenge to emergency physicians.
Topics: Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heart Block; Humans; Mal | 2013 |
How should meta-regression analyses be undertaken and interpreted?
Topics: Adrenergic beta-Antagonists; Aminoglycosides; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-S | 2002 |
How should meta-regression analyses be undertaken and interpreted?
Topics: Adrenergic beta-Antagonists; Aminoglycosides; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-S | 2002 |
[New US guidelines. Myocardial infarct is now treated more aggressively].
Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myoc | 2002 |
[New US guidelines. Myocardial infarct is now treated more aggressively].
Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myoc | 2002 |
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Australia; Canada; E | 2002 |
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Australia; Canada; E | 2002 |
How much daily aspirin should I take to prevent a heart attack or stroke?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2002 |
How much daily aspirin should I take to prevent a heart attack or stroke?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2002 |
VHA heart attack initiative increases aspirin and beta blocker usage.
Topics: Adrenergic beta-Antagonists; Aspirin; Community-Institutional Relations; Evidence-Based Medicine; Ho | 2001 |
VHA heart attack initiative increases aspirin and beta blocker usage.
Topics: Adrenergic beta-Antagonists; Aspirin; Community-Institutional Relations; Evidence-Based Medicine; Ho | 2001 |
Implantable cardiac defibrillators.
Topics: Anti-Arrhythmia Agents; Aspirin; Combined Modality Therapy; Defibrillators, Implantable; Humans; Myo | 2002 |
Implantable cardiac defibrillators.
Topics: Anti-Arrhythmia Agents; Aspirin; Combined Modality Therapy; Defibrillators, Implantable; Humans; Myo | 2002 |
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis | 2002 |
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis | 2002 |
Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective.
Topics: Age Distribution; Aged; Aspirin; Drug Utilization; Female; Hospitalization; Humans; Longitudinal Stu | 2002 |
Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective.
Topics: Age Distribution; Aged; Aspirin; Drug Utilization; Female; Hospitalization; Humans; Longitudinal Stu | 2002 |
Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Cohort Studies; Contraindications; Coronary Angiog | 2002 |
Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Cohort Studies; Contraindications; Coronary Angiog | 2002 |
[ASA therapy or not?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Dose-Response Relationshi | 2002 |
[ASA therapy or not?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Dose-Response Relationshi | 2002 |
Aspirin for the primary prevention of coronary events.
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Fact | 2002 |
Aspirin for the primary prevention of coronary events.
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Fact | 2002 |
Antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Plate | 2002 |
Antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Plate | 2002 |
Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Acute myocardial infarction and renal dysfunction: a high-risk combination.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
Acute myocardial infarction and renal dysfunction: a high-risk combination.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
Summaries for patients. Kidney disease and heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Summaries for patients. Kidney disease and heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Summaries for patients. The influence of kidney disease on outcomes of patients with heart attack.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
Summaries for patients. The influence of kidney disease on outcomes of patients with heart attack.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
[Platelet aggregation inhibitor in general practice. Every 3rd infarct prevented--reinfarction rate cut in half].
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Rate; | 2002 |
[Platelet aggregation inhibitor in general practice. Every 3rd infarct prevented--reinfarction rate cut in half].
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Rate; | 2002 |
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation | 2002 |
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation | 2002 |
[Role of emergency departments in acute myocardial infarction care. EVICURE study].
Topics: Aged; Angina, Unstable; Aspirin; Coronary Care Units; Diagnosis, Differential; Emergency Service, Ho | 2002 |
[Role of emergency departments in acute myocardial infarction care. EVICURE study].
Topics: Aged; Angina, Unstable; Aspirin; Coronary Care Units; Diagnosis, Differential; Emergency Service, Ho | 2002 |
Aspirin with bypass surgery--from taboo to new standard of care.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedule; Humans; Inflammatio | 2002 |
Aspirin with bypass surgery--from taboo to new standard of care.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedule; Humans; Inflammatio | 2002 |
Differences in treatment preferences between persons who enrol and do not enrol in a clinical trial.
Topics: Aspirin; Attitude to Health; Humans; Myocardial Infarction; Patient Participation; Patient Selection | 2001 |
Differences in treatment preferences between persons who enrol and do not enrol in a clinical trial.
Topics: Aspirin; Attitude to Health; Humans; Myocardial Infarction; Patient Participation; Patient Selection | 2001 |
Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Data Collection; Fe | 2002 |
Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Data Collection; Fe | 2002 |
Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]).
Topics: Aged; Argentina; Aspirin; Australia; Brazil; Canada; Europe; Female; Hospital Mortality; Hospitaliza | 2002 |
Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]).
Topics: Aged; Argentina; Aspirin; Australia; Brazil; Canada; Europe; Female; Hospital Mortality; Hospitaliza | 2002 |
[Acetylsalicylic acid and ACE inhibitors in heart disease--a phenomenon in dogs and cats?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Brain Ischemia; Drug Interactions; Human | 2002 |
[Acetylsalicylic acid and ACE inhibitors in heart disease--a phenomenon in dogs and cats?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Brain Ischemia; Drug Interactions; Human | 2002 |
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecu | 2002 |
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecu | 2002 |
Staying alive after heart bypass.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Renal Insufficiency; Stroke; Surviva | 2002 |
Staying alive after heart bypass.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Renal Insufficiency; Stroke; Surviva | 2002 |
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hum | 2002 |
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hum | 2002 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Coronary Artery Disease; Evidence-Based Medicine; Humans; Male; Middle Aged; Myocardial Inf | 2002 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Coronary Artery Disease; Evidence-Based Medicine; Humans; Male; Middle Aged; Myocardial Inf | 2002 |
Program improves compliance with heart attack guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronar | 2002 |
Program improves compliance with heart attack guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronar | 2002 |
On call. I've read that aspirin may help prevent colon cancer as well as heart attacks. I take an aspirin every day, and I wonder if it may also help with prostate cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Humans | 2002 |
On call. I've read that aspirin may help prevent colon cancer as well as heart attacks. I take an aspirin every day, and I wonder if it may also help with prostate cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Humans | 2002 |
The management of acute myocardial infarction--practical problems in implementing the evidence.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Evidence-Based | 2002 |
The management of acute myocardial infarction--practical problems in implementing the evidence.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Evidence-Based | 2002 |
[Baseline characteristics and management of patients less than 45 years of age hospitalized for acute coronary syndromes: results from the nationwide French PREVENIR 1 and PREVENIR 2 studies].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Angina, Unstable; Angiotensin-Converting Enzyme Inh | 2002 |
[Baseline characteristics and management of patients less than 45 years of age hospitalized for acute coronary syndromes: results from the nationwide French PREVENIR 1 and PREVENIR 2 studies].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Angina, Unstable; Angiotensin-Converting Enzyme Inh | 2002 |
Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[Prospective analysis of conservative treatment of acute coronary syndrome].
Topics: Acute Disease; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cor | 2002 |
[Prospective analysis of conservative treatment of acute coronary syndrome].
Topics: Acute Disease; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cor | 2002 |
Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin.
Topics: Angina, Unstable; Aspirin; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 1999 |
Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin.
Topics: Angina, Unstable; Aspirin; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 1999 |
Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism.
Topics: Adult; Aspirin; Bleeding Time; Blood Coagulation; Blotting, Western; Cardiotonic Agents; Factor XIII | 2003 |
Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism.
Topics: Adult; Aspirin; Bleeding Time; Blood Coagulation; Blotting, Western; Cardiotonic Agents; Factor XIII | 2003 |
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2002 |
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2002 |
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Summaries for patients. Risk factors and treatment in women with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Summaries for patients. Risk factors and treatment in women with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregat | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregat | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 2003 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2002 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2002 |
Implementing guidelines in primary care: can population impact measures help?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular | 2003 |
Implementing guidelines in primary care: can population impact measures help?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular | 2003 |
Heart attack and stroke prevention guidelines emphasize lifestyle factors.
Topics: Adult; Age Factors; American Heart Association; Aspirin; Diabetes Mellitus, Type 2; Diet; Exercise; | 2002 |
Heart attack and stroke prevention guidelines emphasize lifestyle factors.
Topics: Adult; Age Factors; American Heart Association; Aspirin; Diabetes Mellitus, Type 2; Diet; Exercise; | 2002 |
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia | 2002 |
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia | 2002 |
[Aspirin inhibited the adhesion of platelets to neutrophil in patients with acute myocardiac infarction].
Topics: Aspirin; Blood Platelets; Cell Adhesion; Fibrinolytic Agents; Humans; Myocardial Infarction; Neutrop | 1999 |
[Aspirin inhibited the adhesion of platelets to neutrophil in patients with acute myocardiac infarction].
Topics: Aspirin; Blood Platelets; Cell Adhesion; Fibrinolytic Agents; Humans; Myocardial Infarction; Neutrop | 1999 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; F | 2003 |
Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; F | 2003 |
Key questions concerning paracetamol and NSAIDs for OA.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; I | 2003 |
Key questions concerning paracetamol and NSAIDs for OA.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; I | 2003 |
[Which interactions are there for equal doses of acetylsalicylic acid and ACE inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug I | 2003 |
[Which interactions are there for equal doses of acetylsalicylic acid and ACE inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug I | 2003 |
Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cause of Death; Drug | 2003 |
Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cause of Death; Drug | 2003 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2003 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2003 |
Prediction of 24 h, nonfatal complications in patients with acute myocardial infarction receiving thrombolytic therapy by calculation of the ST segment deviation score.
Topics: Adult; Aged; Arrhythmias, Cardiac; Aspirin; Electrocardiography; Fibrinolytic Agents; Heart Failure; | 2003 |
Prediction of 24 h, nonfatal complications in patients with acute myocardial infarction receiving thrombolytic therapy by calculation of the ST segment deviation score.
Topics: Adult; Aged; Arrhythmias, Cardiac; Aspirin; Electrocardiography; Fibrinolytic Agents; Heart Failure; | 2003 |
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; C | 2003 |
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; C | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2003 |
Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2003 |
Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Quality of care of Medicare beneficiaries with acute myocardial infarction: who is included in quality improvement measurement?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2003 |
Quality of care of Medicare beneficiaries with acute myocardial infarction: who is included in quality improvement measurement?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2003 |
Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2003 |
Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2003 |
Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aspi | 2003 |
Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aspi | 2003 |
Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase | 2003 |
Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase | 2003 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2003 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2003 |
Antihypertensive therapy at the onset of an acute myocardial infarction predicts in-hospital mortality.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotens | 2003 |
Antihypertensive therapy at the onset of an acute myocardial infarction predicts in-hospital mortality.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotens | 2003 |
[Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme In | 2003 |
[Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme In | 2003 |
Usefulness of an acute coronary syndrome pathway to improve adherence to secondary prevention guidelines.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspir | 2003 |
Usefulness of an acute coronary syndrome pathway to improve adherence to secondary prevention guidelines.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspir | 2003 |
Using a systemwide care path to enhance compliance with guidelines for acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Benchmarking; Cardiology Service, Hospital; Cli | 2003 |
Using a systemwide care path to enhance compliance with guidelines for acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Benchmarking; Cardiology Service, Hospital; Cli | 2003 |
Left intraventricular pressure gradient induced by cardiac tamponade after thrombolysis for acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Cardiac Tamponade; Echocardiography; Female; Fibrinolytic Agents; | 2003 |
Left intraventricular pressure gradient induced by cardiac tamponade after thrombolysis for acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Cardiac Tamponade; Echocardiography; Female; Fibrinolytic Agents; | 2003 |
Management of hyperglycaemia in the patient with acute myocardial infarction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; | 2003 |
Management of hyperglycaemia in the patient with acute myocardial infarction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; | 2003 |
Naproxen's interaction with aspirin may affect its cardioprotective effect.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Synergism; Drug Th | 2003 |
Naproxen's interaction with aspirin may affect its cardioprotective effect.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Synergism; Drug Th | 2003 |
Effect of D-003 on isoproterenol-induced myocardial necrosis in rats.
Topics: Animals; Aspirin; Disease Models, Animal; Fatty Acids; Isoproterenol; Male; Myocardial Infarction; M | 2003 |
Effect of D-003 on isoproterenol-induced myocardial necrosis in rats.
Topics: Animals; Aspirin; Disease Models, Animal; Fatty Acids; Isoproterenol; Male; Myocardial Infarction; M | 2003 |
Study identifies risk factors for women's coronary heart disease.
Topics: Aspirin; Blood Pressure; Coronary Disease; Diabetes Complications; Ethnicity; Exercise; Female; Huma | 2003 |
Study identifies risk factors for women's coronary heart disease.
Topics: Aspirin; Blood Pressure; Coronary Disease; Diabetes Complications; Ethnicity; Exercise; Female; Huma | 2003 |
Gunshot injury of the heart: an unusual cause of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Coronary Angiography; Coronary Thrombos | 2003 |
Gunshot injury of the heart: an unusual cause of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Coronary Angiography; Coronary Thrombos | 2003 |
National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin-Co | 2003 |
National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin-Co | 2003 |
[Cardiac rehabilitation: a plus value for secondary prevention?].
Topics: Aspirin; Clinical Trials as Topic; Humans; Life Style; Myocardial Infarction; Risk Factors; Secondar | 2003 |
[Cardiac rehabilitation: a plus value for secondary prevention?].
Topics: Aspirin; Clinical Trials as Topic; Humans; Life Style; Myocardial Infarction; Risk Factors; Secondar | 2003 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therap | 2003 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therap | 2003 |
[Prevention of myocardial infarct and heart failure in the diabetic].
Topics: Aspirin; Diabetes Complications; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation | 2003 |
[Prevention of myocardial infarct and heart failure in the diabetic].
Topics: Aspirin; Diabetes Complications; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation | 2003 |
Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study.
Topics: Aged; Aspirin; Bleeding Time; Follow-Up Studies; Hemostasis; Humans; Male; Middle Aged; Myocardial I | 2003 |
Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study.
Topics: Aged; Aspirin; Bleeding Time; Follow-Up Studies; Hemostasis; Humans; Male; Middle Aged; Myocardial I | 2003 |
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analys | 2003 |
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analys | 2003 |
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2003 |
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2003 |
Management of patients with acute myocardial infarction and end-stage renal disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Kidney Failu | 2003 |
Management of patients with acute myocardial infarction and end-stage renal disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Kidney Failu | 2003 |
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Transfusion; Coronary Angiograp | 2003 |
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Transfusion; Coronary Angiograp | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio | 2003 |
Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement.
Topics: Aged; Aspirin; Blood Platelets; Collagen; Coronary Angiography; Humans; Male; Middle Aged; Myocardia | 2003 |
Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement.
Topics: Aged; Aspirin; Blood Platelets; Collagen; Coronary Angiography; Humans; Male; Middle Aged; Myocardia | 2003 |
Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; | 2003 |
Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; | 2003 |
Cardiac tamponade mimicking ventricular rupture after thrombolysis for acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Cardiac Tamponade; Diagnosis, Differential; Female; Heart Rupture; Humans; | 2003 |
Cardiac tamponade mimicking ventricular rupture after thrombolysis for acute myocardial infarction.
Topics: Anticoagulants; Aspirin; Cardiac Tamponade; Diagnosis, Differential; Female; Heart Rupture; Humans; | 2003 |
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac | 2003 |
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac | 2003 |
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France; | 2003 |
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France; | 2003 |
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Dose- | 2003 |
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Dose- | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
The discharge.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myocardi | 2003 |
The discharge.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myocardi | 2003 |
Ask the doctor. Almost every day I read how important it is for people with heart disease to take an aspirin. Unfortunately, I am allergic to aspirin. There must be others with the same problem. Are there viable alternatives to aspirin? It's discouraging
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Fatty Acids, Omega-3; Humans; Myocardial Infarction; Pl | 2003 |
Ask the doctor. Almost every day I read how important it is for people with heart disease to take an aspirin. Unfortunately, I am allergic to aspirin. There must be others with the same problem. Are there viable alternatives to aspirin? It's discouraging
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Fatty Acids, Omega-3; Humans; Myocardial Infarction; Pl | 2003 |
Acute myocardial infarction care improved, but still inadequate.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Medicare; My | 2003 |
Acute myocardial infarction care improved, but still inadequate.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Medicare; My | 2003 |
Distal emboli protection intervention in native coronary artery occlusion.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Balloon Occlusion; Coron | 2003 |
Distal emboli protection intervention in native coronary artery occlusion.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Balloon Occlusion; Coron | 2003 |
Percutaneous intervention a winner--even in patients with stable, single-vessel disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Congresses as Topic; Contraindications; Coronary Artery Dis | 2003 |
Percutaneous intervention a winner--even in patients with stable, single-vessel disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Congresses as Topic; Contraindications; Coronary Artery Dis | 2003 |
The central role of platelet activation in determining the severity of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activa | 2003 |
The central role of platelet activation in determining the severity of acute coronary syndromes.
Topics: Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activa | 2003 |
Stop those anti-platelet drugs before surgery!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Myocardial Infarction; Platelet Aggregatio | 2003 |
Stop those anti-platelet drugs before surgery!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Myocardial Infarction; Platelet Aggregatio | 2003 |
Primary percutaneous coronary interventions in acute myocardial infarction in diabetic versus non-diabetic patients. In-hospital and long-term results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Coronary Angiography; | 2003 |
Primary percutaneous coronary interventions in acute myocardial infarction in diabetic versus non-diabetic patients. In-hospital and long-term results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Coronary Angiography; | 2003 |
A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Aspirin; Humans; Male; Middle Aged; Myocardial Infar | 2003 |
A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Aspirin; Humans; Male; Middle Aged; Myocardial Infar | 2003 |
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo | 2003 |
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Mo | 2003 |
Is preinfarction angina associated with better outcome after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Anti-I | 2003 |
Is preinfarction angina associated with better outcome after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Anti-I | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction.
Topics: Animals; Aspirin; Bradykinin; Disease Models, Animal; Drug Therapy, Combination; Enalapril; Female; | 2004 |
Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction.
Topics: Animals; Aspirin; Bradykinin; Disease Models, Animal; Drug Therapy, Combination; Enalapril; Female; | 2004 |
Methods for mid-course corrections in clinical trials with survival outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Computer Simulation; Humans; Marko | 2003 |
Methods for mid-course corrections in clinical trials with survival outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Computer Simulation; Humans; Marko | 2003 |
Coagulation monitoring and management of anticoagulation during cardiac assist device support.
Topics: Acenocoumarol; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Blood Coa | 2003 |
Coagulation monitoring and management of anticoagulation during cardiac assist device support.
Topics: Acenocoumarol; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Blood Coa | 2003 |
Moderately elevated serum troponin concentrations are associated with increased morbidity and mortality rates in surgical intensive care unit patients.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Hospital Mortality; H | 2003 |
Moderately elevated serum troponin concentrations are associated with increased morbidity and mortality rates in surgical intensive care unit patients.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Hospital Mortality; H | 2003 |
[Myocardial infarction after influenza vaccination].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Artery Disease; Cortisone; Diagnosis, Differen | 2003 |
[Myocardial infarction after influenza vaccination].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Artery Disease; Cortisone; Diagnosis, Differen | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
[Interaction of angiotensin-converting enzyme inhibitors with aspirin].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactions; Heart Failure; Humans; Myocard | 2003 |
[Interaction of angiotensin-converting enzyme inhibitors with aspirin].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactions; Heart Failure; Humans; Myocard | 2003 |
Giving aspirin and ibuprofen after myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Drug Interactions; Humans; Ibup | 2003 |
Giving aspirin and ibuprofen after myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Drug Interactions; Humans; Ibup | 2003 |
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2003 |
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2003 |
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies.
Topics: Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Clinical Trials as Topic; Combined Modality T | 2003 |
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies.
Topics: Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Clinical Trials as Topic; Combined Modality T | 2003 |
[Can patients without coronary heart disease prevent a heart infarct with 30 or 50 mg acetylsalicylic acid?].
Topics: Aspirin; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Myo | 2003 |
[Can patients without coronary heart disease prevent a heart infarct with 30 or 50 mg acetylsalicylic acid?].
Topics: Aspirin; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Myo | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.
Topics: Acetanilides; Angina Pectoris; Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Drug | 2004 |
Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.
Topics: Acetanilides; Angina Pectoris; Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Drug | 2004 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid | 2004 |
Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Capillaries; Captopril; | 2004 |
Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Capillaries; Captopril; | 2004 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Aspirin for cancer chemoprevention: still a headache?
Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor | 2004 |
Aspirin for cancer chemoprevention: still a headache?
Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor | 2004 |
By the way, doctor. My husband takes an aspirin every day to reduce his risk of another heart attack. I'm 60 and healthy. Is there any reason I shouldn't do the same to avoid a heart attack or stroke?
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; Stroke | 2004 |
By the way, doctor. My husband takes an aspirin every day to reduce his risk of another heart attack. I'm 60 and healthy. Is there any reason I shouldn't do the same to avoid a heart attack or stroke?
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; Stroke | 2004 |
Throw away the aspirin and take nonsteroidal anti-inflammatory drugs for the primary prevention of myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Drug Interactions; Humans; Likelih | 2004 |
Throw away the aspirin and take nonsteroidal anti-inflammatory drugs for the primary prevention of myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Drug Interactions; Humans; Likelih | 2004 |
Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 12-Lipoxygenase; Aspirin; Blood Press | 2004 |
Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 12-Lipoxygenase; Aspirin; Blood Press | 2004 |
Impact of a critical pathway on acute myocardial infarction quality indicators.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angio | 2004 |
Impact of a critical pathway on acute myocardial infarction quality indicators.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angio | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction; Rheum | 2004 |
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction; Rheum | 2004 |
[Pharmacological aspects of secondary prevention post-MI].
Topics: Aftercare; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clinical Trials | 2004 |
[Pharmacological aspects of secondary prevention post-MI].
Topics: Aftercare; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clinical Trials | 2004 |
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Biomarkers; Blood Proteins; C-Reactive Protein; Coro | 2004 |
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Biomarkers; Blood Proteins; C-Reactive Protein; Coro | 2004 |
Aspirin dose and six-month outcome after an acute coronary syndrome.
Topics: Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Humans; Ireland; Male; Middle A | 2004 |
Aspirin dose and six-month outcome after an acute coronary syndrome.
Topics: Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Humans; Ireland; Male; Middle A | 2004 |
The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Drug Interactio | 2004 |
The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Drug Interactio | 2004 |
The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2004 |
The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2004 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase | 2004 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase | 2004 |
Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial.
Topics: Aged; Anticoagulants; Aspirin; Biomarkers; Coronary Circulation; Creatine Kinase; Creatine Kinase, M | 2004 |
Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial.
Topics: Aged; Anticoagulants; Aspirin; Biomarkers; Coronary Circulation; Creatine Kinase; Creatine Kinase, M | 2004 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
Therapeutic failure or resistance to aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Myocardial Infarctio | 2004 |
Therapeutic failure or resistance to aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Myocardial Infarctio | 2004 |
Painkillers appear to weaken aspirin's primary protection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2003 |
Painkillers appear to weaken aspirin's primary protection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2003 |
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anesthetics, Inhalation; Animals; Aspirin; Celecoxib; C | 2004 |
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anesthetics, Inhalation; Animals; Aspirin; Celecoxib; C | 2004 |
Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Female; Humans; I | 2004 |
Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Female; Humans; I | 2004 |
2 drugs team up for protection. Old standby joins relative newcomer to battle heart disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2003 |
2 drugs team up for protection. Old standby joins relative newcomer to battle heart disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2003 |
"Super aspirin" cuts risks after multiple cardiac events.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prev | 2004 |
"Super aspirin" cuts risks after multiple cardiac events.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prev | 2004 |
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
Antiplatelet therapy for ischemic heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combinati | 2004 |
Antiplatelet therapy for ischemic heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combinati | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Long-term management of patients with unstable angina and non-ST-elevation MI.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA R | 2004 |
Long-term management of patients with unstable angina and non-ST-elevation MI.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA R | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
[Antithrombotic treatment of acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2004 |
[Antithrombotic treatment of acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2004 |
Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?
Topics: Aged; Aged, 80 and over; Angioplasty; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studi | 2004 |
Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?
Topics: Aged; Aged, 80 and over; Angioplasty; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studi | 2004 |
Acute myocardial infarction in a young man with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Aspirin; Chest Pain; Diagnosis, Differential; Electrocardiography; Emerg | 2004 |
Acute myocardial infarction in a young man with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Aspirin; Chest Pain; Diagnosis, Differential; Electrocardiography; Emerg | 2004 |
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Americas; Angiotensin-Convertin | 2004 |
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Americas; Angiotensin-Convertin | 2004 |
Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Croa | 2004 |
Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Croa | 2004 |
Ask the doctors. After I had a heart attack, my cardiologist put me on aspirin. I need a procedure next month, and my surgeon told me stop my aspirin a week beforehand. Is there any risk to stopping?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Surgical Procedures, Operative | 2004 |
Ask the doctors. After I had a heart attack, my cardiologist put me on aspirin. I need a procedure next month, and my surgeon told me stop my aspirin a week beforehand. Is there any risk to stopping?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Surgical Procedures, Operative | 2004 |
Inhibition of COX pathway in experimental myocardial infarction.
Topics: Animals; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease | 2004 |
Inhibition of COX pathway in experimental myocardial infarction.
Topics: Animals; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease | 2004 |
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; E | 2004 |
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; E | 2004 |
Absence of sex differences in pharmacotherapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Absence of sex differences in pharmacotherapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Tri | 2004 |
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Tri | 2004 |
Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2004 |
Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2004 |
More on: aspirin resistance.
Topics: Alleles; Aspirin; Drug Resistance; Factor XIII; Fibrinolytic Agents; Genotype; Humans; Hypercholeste | 2004 |
More on: aspirin resistance.
Topics: Alleles; Aspirin; Drug Resistance; Factor XIII; Fibrinolytic Agents; Genotype; Humans; Hypercholeste | 2004 |
Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.
Topics: Aged; Aspirin; Contraindications; Female; Follow-Up Studies; Germany; Humans; Logistic Models; Male; | 2004 |
Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.
Topics: Aged; Aspirin; Contraindications; Female; Follow-Up Studies; Germany; Humans; Logistic Models; Male; | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu | 2004 |
Aspirin use lags in high-risk women.
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction | 2004 |
Aspirin use lags in high-risk women.
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction | 2004 |
Guidelines for pre-hospital administration of fibrinolytic therapy in New Zealand general practitioners.
Topics: Algorithms; Aspirin; Contraindications; Drug Therapy, Combination; Emergency Medical Services; Famil | 2004 |
Guidelines for pre-hospital administration of fibrinolytic therapy in New Zealand general practitioners.
Topics: Algorithms; Aspirin; Contraindications; Drug Therapy, Combination; Emergency Medical Services; Famil | 2004 |
National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Angioplasty, Balloon, Coronary; Aspirin; Ch | 2004 |
National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Angioplasty, Balloon, Coronary; Aspirin; Ch | 2004 |
Typical versus atypical antipsychotics.
Topics: Antipsychotic Agents; Aspirin; Drug Costs; Humans; Myocardial Infarction; Prevalence; Schizophrenia; | 2004 |
Typical versus atypical antipsychotics.
Topics: Antipsychotic Agents; Aspirin; Drug Costs; Humans; Myocardial Infarction; Prevalence; Schizophrenia; | 2004 |
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 2004 |
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Ther | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Ther | 2004 |
[The Use of Clopidogrel in Conjunction With Thrombolytic Therapy in PatientsWith ST-Elevation Acute Myocardial Infarction.].
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Ventricular Function, L | 2004 |
[The Use of Clopidogrel in Conjunction With Thrombolytic Therapy in PatientsWith ST-Elevation Acute Myocardial Infarction.].
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Ventricular Function, L | 2004 |
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocar | 2004 |
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocar | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia | 2004 |
NRMI and current treatment patterns for ST-elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2004 |
NRMI and current treatment patterns for ST-elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2004 |
The American Heart Association Get With The Guidelines program.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
The American Heart Association Get With The Guidelines program.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
[Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Infarction | 2004 |
[Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Infarction | 2004 |
Effect of age on the use of evidence-based therapies for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2004 |
Effect of age on the use of evidence-based therapies for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2004 |
Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Inflammatory Agents; Aspirin; C-Reactive Protein; Clinical Trials as Topic; Coro | 2005 |
Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Inflammatory Agents; Aspirin; C-Reactive Protein; Clinical Trials as Topic; Coro | 2005 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient | 2004 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient | 2004 |
I've been taking aspirin daily for 25 years, and clopidogrel fro several years. In spite of this, I've had a number of heart attacks. You reported recently on people who can't benefit from aspirin, and I think I may be one of them. What should I do?
Topics: Aspirin; Blood Coagulation Disorders; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; P | 2004 |
I've been taking aspirin daily for 25 years, and clopidogrel fro several years. In spite of this, I've had a number of heart attacks. You reported recently on people who can't benefit from aspirin, and I think I may be one of them. What should I do?
Topics: Aspirin; Blood Coagulation Disorders; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; P | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Inf | 2004 |
Regional variations in racial differences in the treatment of elderly patients hospitalized with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Black People; Cardiac Catheterization; Female; Humans; I | 2004 |
Regional variations in racial differences in the treatment of elderly patients hospitalized with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Black People; Cardiac Catheterization; Female; Humans; I | 2004 |
Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2004 |
Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2004 |
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cyclooxygenase Inhibitors; | 2005 |
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cyclooxygenase Inhibitors; | 2005 |
Myocardial infarction after aspirin treatment.
Topics: Aspirin; Asthma; Coronary Angiography; Coronary Vasospasm; Echocardiography; Female; Fibrinolytic Ag | 2005 |
Myocardial infarction after aspirin treatment.
Topics: Aspirin; Asthma; Coronary Angiography; Coronary Vasospasm; Echocardiography; Female; Fibrinolytic Ag | 2005 |
A case of life-saving pharmacologic and mechanical coronary dethrombosis.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; | 2004 |
A case of life-saving pharmacologic and mechanical coronary dethrombosis.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; | 2004 |
Gender differences in therapy for patients admitted for unstable angina and myocardial infarction with underlying chronic kidney disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; | 2004 |
Gender differences in therapy for patients admitted for unstable angina and myocardial infarction with underlying chronic kidney disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; | 2004 |
Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock.
Topics: Angioplasty, Balloon; Aspirin; C-Reactive Protein; Cholesterol; Electrocardiography; Hormones; Human | 2005 |
Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock.
Topics: Angioplasty, Balloon; Aspirin; C-Reactive Protein; Cholesterol; Electrocardiography; Hormones; Human | 2005 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Postmenopausal hormone use in women with acute coronary syndromes.
Topics: Aged; Aspirin; Attitude to Health; Coronary Disease; Estrogen Replacement Therapy; Female; Global He | 2004 |
Postmenopausal hormone use in women with acute coronary syndromes.
Topics: Aged; Aspirin; Attitude to Health; Coronary Disease; Estrogen Replacement Therapy; Female; Global He | 2004 |
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusio | 2005 |
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusio | 2005 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo | 2005 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo | 2005 |
Aspirin use for prevention of CHD: an FP's story.
Topics: Advisory Committees; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Drug Labeling; Hum | 2005 |
Aspirin use for prevention of CHD: an FP's story.
Topics: Advisory Committees; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Drug Labeling; Hum | 2005 |
Aspirin resistance: a worry?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Drug Resistance; Fibrinolytic Age | 2005 |
Aspirin resistance: a worry?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Drug Resistance; Fibrinolytic Age | 2005 |
Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Forecasting; Humans; Mo | 2005 |
Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Forecasting; Humans; Mo | 2005 |
The use of the propensity score for estimating treatment effects: administrative versus clinical data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Female; Humans; Likelihood Functions; | 2005 |
The use of the propensity score for estimating treatment effects: administrative versus clinical data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Female; Humans; Likelihood Functions; | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
After a heart attack, don't leave the hospital without aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors | 2005 |
After a heart attack, don't leave the hospital without aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors | 2005 |
Myocardial infarction after aspirin.
Topics: Anaphylaxis; Aspirin; Catecholamines; Coronary Vasospasm; Drug Hypersensitivity; Fibrinolytic Agents | 2005 |
Myocardial infarction after aspirin.
Topics: Anaphylaxis; Aspirin; Catecholamines; Coronary Vasospasm; Drug Hypersensitivity; Fibrinolytic Agents | 2005 |
The puzzle of aspirin and sex.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Myocardial Infarc | 2005 |
The puzzle of aspirin and sex.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Myocardial Infarc | 2005 |
Concurrent antiplatelet and fibrinolytic therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2005 |
Concurrent antiplatelet and fibrinolytic therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2005 |
[Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease].
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Data Interpretation, Statistical; Elect | 2005 |
[Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease].
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Data Interpretation, Statistical; Elect | 2005 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedul | 2004 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedul | 2004 |
Ask the doctor. I am a 60-year-old man with several risk factors for heart disease. I take Aleve twice a day. Do I still need to take aspirin, or is the Aleve enough? I often take ibuprofen for my headaches or aching back. Now my doctor wants me to start
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Huma | 2005 |
Ask the doctor. I am a 60-year-old man with several risk factors for heart disease. I take Aleve twice a day. Do I still need to take aspirin, or is the Aleve enough? I often take ibuprofen for my headaches or aching back. Now my doctor wants me to start
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Huma | 2005 |
Variations in the quality of care of patients with acute myocardial infarction among Swiss university hospitals.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty, | 2005 |
Variations in the quality of care of patients with acute myocardial infarction among Swiss university hospitals.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty, | 2005 |
Aspirin anomaly.
Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Myocardial Infarction; United States; Women's Hea | 2005 |
Aspirin anomaly.
Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Myocardial Infarction; United States; Women's Hea | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Summaries for patients. Risk for heart attacks with different NSAIDs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Confounding Factors, Epidemiologic; Cyclooxy | 2005 |
Summaries for patients. Risk for heart attacks with different NSAIDs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Confounding Factors, Epidemiologic; Cyclooxy | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Confou | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Confou | 2005 |
Trends in the care of patients with acute myocardial infarction at a university-affiliated Veterans Affairs Medical Center.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arkansas; Aspirin; Cardiology | 2005 |
Trends in the care of patients with acute myocardial infarction at a university-affiliated Veterans Affairs Medical Center.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arkansas; Aspirin; Cardiology | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug | 2005 |
[Prehospital management of very elderly patients with ST segment elevation in Paris by mobile intensive care units (Samu)].
Topics: Age Factors; Aged; Aged, 80 and over; Ambulances; Anticoagulants; Aspirin; Chi-Square Distribution; | 2005 |
[Prehospital management of very elderly patients with ST segment elevation in Paris by mobile intensive care units (Samu)].
Topics: Age Factors; Aged; Aged, 80 and over; Ambulances; Anticoagulants; Aspirin; Chi-Square Distribution; | 2005 |
[Female, young, healthy. ASS does not protect from myocardial infarct].
Topics: Adult; Age Factors; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Placebos; Platelet A | 2005 |
[Female, young, healthy. ASS does not protect from myocardial infarct].
Topics: Adult; Age Factors; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Placebos; Platelet A | 2005 |
[After the disappointing ASS primary prevention trial. "Holding back in women"].
Topics: Adult; Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarc | 2005 |
[After the disappointing ASS primary prevention trial. "Holding back in women"].
Topics: Adult; Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarc | 2005 |
Cost-effectiveness of clopidogrel.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Embolism, Cholesterol; Humans | 2004 |
Cost-effectiveness of clopidogrel.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Embolism, Cholesterol; Humans | 2004 |
Aspirin and women--age matters. Aspirin can help healthy women over age 56 prevent both strokes and heart attacks. For younger women, the hazards of aspirin outweigh the benefits.
Topics: Age Factors; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infar | 2005 |
Aspirin and women--age matters. Aspirin can help healthy women over age 56 prevent both strokes and heart attacks. For younger women, the hazards of aspirin outweigh the benefits.
Topics: Age Factors; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infar | 2005 |
Monitoring platelet function by PFA-100 closure time measurements during thrombolytic therapy of patients with myocardial infarction.
Topics: Aspirin; Blood Platelets; Case-Control Studies; Humans; Myocardial Infarction; Platelet Function Tes | 2005 |
Monitoring platelet function by PFA-100 closure time measurements during thrombolytic therapy of patients with myocardial infarction.
Topics: Aspirin; Blood Platelets; Case-Control Studies; Humans; Myocardial Infarction; Platelet Function Tes | 2005 |
Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; | 2005 |
Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; | 2005 |
Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Catheterizat | 2006 |
Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Catheterizat | 2006 |
Myocardial infarction after aspirin treatment, and Kounis syndrome.
Topics: Angina Pectoris; Aspirin; Coronary Vasospasm; Fibrinolytic Agents; Humans; Mast Cells; Myocardial In | 2005 |
Myocardial infarction after aspirin treatment, and Kounis syndrome.
Topics: Angina Pectoris; Aspirin; Coronary Vasospasm; Fibrinolytic Agents; Humans; Mast Cells; Myocardial In | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Body Mass Index; Databases, Fac | 2005 |
Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Body Mass Index; Databases, Fac | 2005 |
Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Echocardiography; Electrocardio | 2005 |
Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Echocardiography; Electrocardio | 2005 |
[Myocardial infarction and subacute intrastent thrombosis in a patient with aspirin resistance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Resistance; Humans; Male; Middle Aged; Myocar | 2005 |
[Myocardial infarction and subacute intrastent thrombosis in a patient with aspirin resistance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Resistance; Humans; Male; Middle Aged; Myocar | 2005 |
Low-dose aspirin: major benefits, minimal cost.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Costs; Drug Evaluation; Female; Humans; Male; Myocar | 2005 |
Low-dose aspirin: major benefits, minimal cost.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Costs; Drug Evaluation; Female; Humans; Male; Myocar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; | 2005 |
Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2005 |
Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2005 |
Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2005 |
Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Humans; Myocardial Infar | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Humans; Myocardial Infar | 2005 |
Older emergency department patients with acute myocardial infarction receive lower quality of care than younger patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; | 2005 |
Older emergency department patients with acute myocardial infarction receive lower quality of care than younger patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction; Plate | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction; Plate | 2005 |
Aspirin for everyone over 50? The buck stops in the consulting room.
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction; Patient Participation; Platelet Aggregati | 2005 |
Aspirin for everyone over 50? The buck stops in the consulting room.
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction; Patient Participation; Platelet Aggregati | 2005 |
Rebound risk: aspirin and statin withdrawal.
Topics: Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Factors | 2005 |
Rebound risk: aspirin and statin withdrawal.
Topics: Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Factors | 2005 |
Education earns high comparative AMI rankings.
Topics: Adrenergic beta-Antagonists; Aspirin; Benchmarking; Cardiology Service, Hospital; Concurrent Review; | 2005 |
Education earns high comparative AMI rankings.
Topics: Adrenergic beta-Antagonists; Aspirin; Benchmarking; Cardiology Service, Hospital; Concurrent Review; | 2005 |
Two-stage adaptive design for clinical trials with survival data.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Follow-Up Studi | 2005 |
Two-stage adaptive design for clinical trials with survival data.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Follow-Up Studi | 2005 |
Preventive aspirin for women?
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Middle Aged; Myocardial Infarction; Prevent | 2005 |
Preventive aspirin for women?
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Middle Aged; Myocardial Infarction; Prevent | 2005 |
[Aspirin for primary prevention of cardiovascular diseases].
Topics: Aspirin; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Platelet Aggregatio | 2005 |
[Aspirin for primary prevention of cardiovascular diseases].
Topics: Aspirin; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Platelet Aggregatio | 2005 |
Aspirin study refocuses prevention message for women. Aspirin therapy does less than anticipated in preventing heart attacks in women--but more than we knew in warding off strokes.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Treatment O | 2005 |
Aspirin study refocuses prevention message for women. Aspirin therapy does less than anticipated in preventing heart attacks in women--but more than we knew in warding off strokes.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Treatment O | 2005 |
A doctor talks about aspirin.
Topics: Age Factors; Aged; Aspirin; Female; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation | 2005 |
A doctor talks about aspirin.
Topics: Age Factors; Aged; Aspirin; Female; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation | 2005 |
Inflammation, atherosclerosis, and coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Coronary Disease; Humans; Infl | 2005 |
Inflammation, atherosclerosis, and coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Coronary Disease; Humans; Infl | 2005 |
Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2005 |
Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Contraindications; Drug Inte | 2005 |
Medication performance measures and mortality following acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhi | 2005 |
Medication performance measures and mortality following acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhi | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Summaries for patients. Benefits and harms of warfarin plus aspirin after acute coronary events.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
Summaries for patients. Benefits and harms of warfarin plus aspirin after acute coronary events.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal].
Topics: Adrenal Cortex Hormones; Adult; Angioplasty, Balloon, Coronary; Antiphospholipid Syndrome; Aspirin; | 2005 |
[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal].
Topics: Adrenal Cortex Hormones; Adult; Angioplasty, Balloon, Coronary; Antiphospholipid Syndrome; Aspirin; | 2005 |
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Black People; Coronary Angiography; Female; Health Servi | 2005 |
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Black People; Coronary Angiography; Female; Health Servi | 2005 |
Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Biotransformation; Cyclooxygenase Inhibitors; Electrophoreti | 2005 |
Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Biotransformation; Cyclooxygenase Inhibitors; Electrophoreti | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary | 2005 |
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary | 2005 |
Hospitals improve heart attack care. As compliance with guidelines improves, in-hospital deaths fall.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Electrocardiography; Guideline Adherence; Hospital Mo | 2005 |
Hospitals improve heart attack care. As compliance with guidelines improves, in-hospital deaths fall.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Electrocardiography; Guideline Adherence; Hospital Mo | 2005 |
Clearing up mixed messages about aspirin for women.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2005 |
Clearing up mixed messages about aspirin for women.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Case-Control Studies; Female; Humans; Male | 2005 |
Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Case-Control Studies; Female; Humans; Male | 2005 |
In-hospital care pathway delays: gender and myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Critical Pathways; Female; Fibrinolytic Agents; Hospitaliza | 2005 |
In-hospital care pathway delays: gender and myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Critical Pathways; Female; Fibrinolytic Agents; Hospitaliza | 2005 |
Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dia | 2005 |
Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dia | 2005 |
Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedul | 2005 |
Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedul | 2005 |
Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction.
Topics: Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Patient Readmission; Time Factors; Treat | 2005 |
Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction.
Topics: Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Patient Readmission; Time Factors; Treat | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
When NOT to reach for aspirin. When heart attack symptoms strike, call for help instead.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Telephone | 2005 |
When NOT to reach for aspirin. When heart attack symptoms strike, call for help instead.
Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Telephone | 2005 |
Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arter | 2005 |
Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arter | 2005 |
The lady aspirin for cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2005 |
The lady aspirin for cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2005 |
No one-size-fits-all for aspirin and elders.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Gastrointestinal Hemorrhage; Humans; Male; Myocardial In | 2005 |
No one-size-fits-all for aspirin and elders.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Gastrointestinal Hemorrhage; Humans; Male; Myocardial In | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
Aspirin prevents strokes in middle-aged and older women, heart attacks in older women.
Topics: Age Factors; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; | 2005 |
Aspirin prevents strokes in middle-aged and older women, heart attacks in older women.
Topics: Age Factors; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; | 2005 |
ST-elevation myocardial infarction: New Zealand management guidelines.
Topics: Aged; Aspirin; Biomarkers; Cardiology; Clopidogrel; Contraindications; Creatine Kinase; Drug Monitor | 2005 |
ST-elevation myocardial infarction: New Zealand management guidelines.
Topics: Aged; Aspirin; Biomarkers; Cardiology; Clopidogrel; Contraindications; Creatine Kinase; Drug Monitor | 2005 |
COX-2 chronology.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2005 |
COX-2 chronology.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2005 |
The risk for myocardial infarction with cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2005 |
Safety and efficacy of nasogastric intubation for gastrointestinal bleeding after myocardial infarction: an analysis of 125 patients at two tertiary cardiac referral hospitals.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemo | 2005 |
Safety and efficacy of nasogastric intubation for gastrointestinal bleeding after myocardial infarction: an analysis of 125 patients at two tertiary cardiac referral hospitals.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemo | 2005 |
Chew on this.
Topics: Administration, Oral; Aspirin; Dental Enamel; Dentin; Humans; Mastication; Myocardial Infarction; Pl | 2005 |
Chew on this.
Topics: Administration, Oral; Aspirin; Dental Enamel; Dentin; Humans; Mastication; Myocardial Infarction; Pl | 2005 |
Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anemia; Angina, Unstable; Angiotensin-Converting Enzyme In | 2005 |
Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anemia; Angina, Unstable; Angiotensin-Converting Enzyme In | 2005 |
Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary Angiography; Drug | 2005 |
Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary Angiography; Drug | 2005 |
Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Coronary Disease; Femal | 2005 |
Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Coronary Disease; Femal | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Coronary Angiography; Coronary Care Units; Corona | 2005 |
Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Coronary Angiography; Coronary Care Units; Corona | 2005 |
Aspirin: quitting cold turkey could be dangerous. Studies have linked aspirin withdrawal to heart attacks.
Topics: Aspirin; Brain; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorr | 2005 |
Aspirin: quitting cold turkey could be dangerous. Studies have linked aspirin withdrawal to heart attacks.
Topics: Aspirin; Brain; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorr | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia | 2005 |
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Female | 2004 |
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Female | 2004 |
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Angiography | 2006 |
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Angiography | 2006 |
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarctio | 2006 |
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarctio | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns.
Topics: Adult; Aerospace Medicine; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Milit | 2006 |
Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns.
Topics: Adult; Aerospace Medicine; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Milit | 2006 |
Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Death, Sudden, Cardi | 2006 |
Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Death, Sudden, Cardi | 2006 |
Biological basis and clinical implications of acetylsalicylic acid resistance.
Topics: Acetylation; Acetyltransferases; Arachidonic Acid; Aspirin; Drug Resistance; Fibrinolytic Agents; Hu | 2006 |
Biological basis and clinical implications of acetylsalicylic acid resistance.
Topics: Acetylation; Acetyltransferases; Arachidonic Acid; Aspirin; Drug Resistance; Fibrinolytic Agents; Hu | 2006 |
Quality of emergency care on the night shift.
Topics: After-Hours Care; Aspirin; Emergency Service, Hospital; Fibrinolytic Agents; Hospitalization; Humans | 2006 |
Quality of emergency care on the night shift.
Topics: After-Hours Care; Aspirin; Emergency Service, Hospital; Fibrinolytic Agents; Hospitalization; Humans | 2006 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibril | 2006 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibril | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Humans; | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Humans; | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; | 2006 |
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clini | 2006 |
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clini | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Creatinine; Cross-Sectional Studies; Drug Utilization; F | 2006 |
Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Creatinine; Cross-Sectional Studies; Drug Utilization; F | 2006 |
A cross-sectional study of secondary cardiac care in general practice: impact of personal and practice characteristics.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aortography; Aspirin; Coronary Angiogra | 2006 |
A cross-sectional study of secondary cardiac care in general practice: impact of personal and practice characteristics.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aortography; Aspirin; Coronary Angiogra | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Aspirin's benefits: fewer heart attacks for him, fewer strokes for her.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; | 2006 |
Aspirin's benefits: fewer heart attacks for him, fewer strokes for her.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; | 2006 |
[More modest use in secondary prevention, risky in primary prevention].
Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Bli | 2006 |
[More modest use in secondary prevention, risky in primary prevention].
Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Bli | 2006 |
Suppressing the scourge of AMI.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Suppressing the scourge of AMI.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Pla | 2006 |
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Pla | 2006 |
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method | 2006 |
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
[Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
[Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
Balancing the cyclooxygenase portfolio.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Dr | 2006 |
Balancing the cyclooxygenase portfolio.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Dr | 2006 |
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2006 |
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2006 |
What price pain relief?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cardiovascular Diseases; Cyclooxyg | 2006 |
What price pain relief?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cardiovascular Diseases; Cyclooxyg | 2006 |
A case of myocardial infarction complicating Kawasaki disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Angiography; Humans; Male; Mucocut | 2006 |
A case of myocardial infarction complicating Kawasaki disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Angiography; Humans; Male; Mucocut | 2006 |
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
[Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; D | 2006 |
[Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; D | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Use of aspirin as primary prevention of cardiovascular events.
Topics: Aspirin; Female; Humans; Male; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation I | 2006 |
Use of aspirin as primary prevention of cardiovascular events.
Topics: Aspirin; Female; Humans; Male; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation I | 2006 |
Delay in the diagnosis of acute myocardial infarction: effect on quality of care and its assessment.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; C | 2006 |
Delay in the diagnosis of acute myocardial infarction: effect on quality of care and its assessment.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; C | 2006 |
Elective surgery days after myocardial infarction: clinical and ethical considerations.
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2006 |
Elective surgery days after myocardial infarction: clinical and ethical considerations.
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2006 |
Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Hospital Administration; Hospitals; Humans; Kansas; Medicare P | 2006 |
Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Hospital Administration; Hospitals; Humans; Kansas; Medicare P | 2006 |
[Physicians and insurance may collaborate on therapy].
Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Fa | 2006 |
[Physicians and insurance may collaborate on therapy].
Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Fa | 2006 |
Letter by Kurth regarding article, "Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events".
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxyg | 2006 |
Letter by Kurth regarding article, "Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events".
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxyg | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Impact of medication therapy discontinuation on mortality after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Continuity of Patient Care; Cyclooxygenase Inhibitors; D | 2006 |
Implications of the failure to identify high-risk electrocardiogram findings for the quality of care of patients with acute myocardial infarction: results of the Emergency Department Quality in Myocardial Infarction (EDQMI) study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Cohort Studies; Colorado; Diagnostic Errors; | 2006 |
Implications of the failure to identify high-risk electrocardiogram findings for the quality of care of patients with acute myocardial infarction: results of the Emergency Department Quality in Myocardial Infarction (EDQMI) study.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Cohort Studies; Colorado; Diagnostic Errors; | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Low-molecular-weight heparin in pregnant women with prosthetic heart valves.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Aortic Valve; Aspirin; Biomarkers; Coronary Artery D | 2006 |
Low-molecular-weight heparin in pregnant women with prosthetic heart valves.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Aortic Valve; Aspirin; Biomarkers; Coronary Artery D | 2006 |
Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Stenosis; Disease- | 2006 |
Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Stenosis; Disease- | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
[Constrictive pericarditis after inferoposterior myocardial infarction].
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Aspirin; Heart Failure; Hep | 2006 |
[Constrictive pericarditis after inferoposterior myocardial infarction].
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Aspirin; Heart Failure; Hep | 2006 |
Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Depression; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 2006 |
Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes.
Topics: Aged; Angina, Unstable; Aspirin; Depression; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 2006 |
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2006 |
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial | 2006 |
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2007 |
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2007 |
Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
Hymenoptera sting-induced Kounis syndrome: effects of aspirin and beta-blocker administration.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?
Topics: Adult; Aspirin; Coronary Restenosis; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?
Topics: Adult; Aspirin; Coronary Restenosis; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2007 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2007 |
Effect of clopidogrel plus aspirin on ST segments in patients with ST-elevation acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Humans; Length of Stay; Logi | 2006 |
Effect of clopidogrel plus aspirin on ST segments in patients with ST-elevation acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Humans; Length of Stay; Logi | 2006 |
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr | 2006 |
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr | 2006 |
Introducing the primer of medical ethics.
Topics: Aspirin; Curriculum; Education, Medical; Education, Medical, Continuing; Ethics, Medical; Humans; In | 2006 |
Introducing the primer of medical ethics.
Topics: Aspirin; Curriculum; Education, Medical; Education, Medical, Continuing; Ethics, Medical; Humans; In | 2006 |
Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Hem | 2007 |
Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Hem | 2007 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Hospit | 2007 |
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Hospit | 2007 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Elec | 2007 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Elec | 2007 |
Variation and importance of aspirin resistance in patients with known cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Follow-Up Studie | 2007 |
Variation and importance of aspirin resistance in patients with known cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Follow-Up Studie | 2007 |
Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Drug Resistance; Fem | 2007 |
Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Drug Resistance; Fem | 2007 |
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Female; Genetic Markers; Humans; | 2006 |
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Female; Genetic Markers; Humans; | 2006 |
Studies show aspirin affects women differently than men.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Pre | 2006 |
Studies show aspirin affects women differently than men.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Pre | 2006 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Drug Therapy, C | 2007 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Drug Therapy, C | 2007 |
[Acute myocardial infarction after discontinuing aspirin two years after implantation of a drug-eluting coronary stent].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Contraindications; Coronary Angiography; C | 2007 |
[Acute myocardial infarction after discontinuing aspirin two years after implantation of a drug-eluting coronary stent].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Contraindications; Coronary Angiography; C | 2007 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I | 2007 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I | 2007 |
In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunos | 2007 |
In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunos | 2007 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Fe | 2007 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Fe | 2007 |
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel; | 2007 |
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel; | 2007 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2007 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2007 |
Do orders limiting aggressive treatment impact care for acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Advance Directive Adherence; Advance Directives; Aged; Aged, 80 and ove | 2007 |
Do orders limiting aggressive treatment impact care for acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Advance Directive Adherence; Advance Directives; Aged; Aged, 80 and ove | 2007 |
Take aspirin before ibuprofen, not after.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H | 2006 |
Take aspirin before ibuprofen, not after.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H | 2006 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Drug Therapy, C | 2007 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Delivery Systems; Drug Therapy, C | 2007 |
High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Collagen; Coronary Vessels; Disease Model | 2007 |
High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Collagen; Coronary Vessels; Disease Model | 2007 |
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clop | 2007 |
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clop | 2007 |
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy.
Topics: Aged; Analysis of Variance; Aspirin; Biomarkers; Controlled Clinical Trials as Topic; Coronary Angio | 2007 |
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy.
Topics: Aged; Analysis of Variance; Aspirin; Biomarkers; Controlled Clinical Trials as Topic; Coronary Angio | 2007 |
Non-ST-elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Cardiac Catheterization; Coronary Angiograph | 2007 |
Non-ST-elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Cardiac Catheterization; Coronary Angiograph | 2007 |
Gender differences in aspirin use among adults with coronary heart disease in the United States.
Topics: Age Factors; Aged; Aspirin; Coronary Disease; Female; Health Behavior; Health Care Surveys; Humans; | 2007 |
Gender differences in aspirin use among adults with coronary heart disease in the United States.
Topics: Age Factors; Aged; Aspirin; Coronary Disease; Female; Health Behavior; Health Care Surveys; Humans; | 2007 |
Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina, Unstable; Aspirin; Complementary Th | 2007 |
Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina, Unstable; Aspirin; Complementary Th | 2007 |
Dosing frequency of aspirin and prevention of heart attacks and strokes.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 2007 |
Dosing frequency of aspirin and prevention of heart attacks and strokes.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 2007 |
Enteric coated aspirin.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2007 |
Enteric coated aspirin.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Do race-specific models explain disparities in treatments after acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Corona | 2007 |
Do race-specific models explain disparities in treatments after acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Corona | 2007 |
Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction.
Topics: Aged; Aspirin; Case-Control Studies; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; | 2007 |
Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction.
Topics: Aged; Aspirin; Case-Control Studies; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; | 2007 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Education, Professiona | 2007 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Education, Professiona | 2007 |
Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, | 2007 |
Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, | 2007 |
Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Rece | 2007 |
Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Rece | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co | 2007 |
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cor | 2007 |
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cor | 2007 |
Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cyclooxygenase 1; Cycloox | 2007 |
Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cyclooxygenase 1; Cycloox | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Co | 2007 |
Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Co | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Concentration and quality of hospitals that care for elderly black patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; | 2007 |
Concentration and quality of hospitals that care for elderly black patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; | 2007 |
Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Hydroxymethy | 2007 |
Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Hydroxymethy | 2007 |
Aspirin is lifesaving for cancer patients with ACS. Benefits of aspirin treatment for patients with acute coronary syndrome are immediate.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Neoplasms; Platelet Aggregation Inhibitors | 2007 |
Aspirin is lifesaving for cancer patients with ACS. Benefits of aspirin treatment for patients with acute coronary syndrome are immediate.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Neoplasms; Platelet Aggregation Inhibitors | 2007 |
Acute myocardial infarction after consumption of aspirin in a chronic methadone user patient.
Topics: Adult; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Electrocardiography; Humans; Male; Metha | 2007 |
Acute myocardial infarction after consumption of aspirin in a chronic methadone user patient.
Topics: Adult; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Electrocardiography; Humans; Male; Metha | 2007 |
Relationship between systolic pulsed wave tissue Doppler parameters and both invasive and noninvasive reperfusion criteria in patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; E | 2008 |
Relationship between systolic pulsed wave tissue Doppler parameters and both invasive and noninvasive reperfusion criteria in patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; E | 2008 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny | 2007 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny | 2007 |
Who needs to be taking aspirin for cardiovascular protection? Studies conflict about the benefits for women.
Topics: Aspirin; Female; Guidelines as Topic; Humans; Male; Myocardial Infarction; Neoplasms; Platelet Aggre | 2007 |
Who needs to be taking aspirin for cardiovascular protection? Studies conflict about the benefits for women.
Topics: Aspirin; Female; Guidelines as Topic; Humans; Male; Myocardial Infarction; Neoplasms; Platelet Aggre | 2007 |
I recently had cardiac symptoms and high troponin levels in my blood. Prior to a coronary angiogram, I was given an intravenous dose of heparin and now take 12.5 milligrams of metoprolol, a beta-blocker, twice a day. I bleed a lot and bruise when I have a
Topics: Adrenergic beta-Antagonists; Aspirin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial I | 2007 |
I recently had cardiac symptoms and high troponin levels in my blood. Prior to a coronary angiogram, I was given an intravenous dose of heparin and now take 12.5 milligrams of metoprolol, a beta-blocker, twice a day. I bleed a lot and bruise when I have a
Topics: Adrenergic beta-Antagonists; Aspirin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial I | 2007 |
Spontaneous coronary hematoma during systemic thrombolysis for acute myocardial infarction: intracoronary ultrasound findings, percutaneous coronary intervention and complications.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Aneurysm; Drug Therapy, Combination; | 2007 |
Spontaneous coronary hematoma during systemic thrombolysis for acute myocardial infarction: intracoronary ultrasound findings, percutaneous coronary intervention and complications.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Aneurysm; Drug Therapy, Combination; | 2007 |
By the way, doctor. Must I take aspirin?
Topics: Aspirin; Attitude of Health Personnel; Colitis, Ulcerative; Diabetic Angiopathies; Female; Humans; M | 2007 |
By the way, doctor. Must I take aspirin?
Topics: Aspirin; Attitude of Health Personnel; Colitis, Ulcerative; Diabetic Angiopathies; Female; Humans; M | 2007 |
[After coronary intervention. Which platelet inhibitor for whom?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Dise | 2007 |
[After coronary intervention. Which platelet inhibitor for whom?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Dise | 2007 |
Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Atrial | 2008 |
Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Atrial | 2008 |
Aspirin: a user's guide to who needs it and how much to take. Just because you can buy aspirin without a prescription (and for pennies a tablet) doesn't mean everyone should be taking it to prevent a heart attack or stroke.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2007 |
Aspirin: a user's guide to who needs it and how much to take. Just because you can buy aspirin without a prescription (and for pennies a tablet) doesn't mean everyone should be taking it to prevent a heart attack or stroke.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2007 |
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; A | 2007 |
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; A | 2007 |
Clopidogrel: new indication. In combination with aspirin: marginal additional benefits.
Topics: Aspirin; Clinical Trials as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidi | 2007 |
Clopidogrel: new indication. In combination with aspirin: marginal additional benefits.
Topics: Aspirin; Clinical Trials as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidi | 2007 |
Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction.
Topics: Aspirin; Cardiopulmonary Resuscitation; Drug Therapy, Combination; Emergency Medical Services; Femal | 2008 |
Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction.
Topics: Aspirin; Cardiopulmonary Resuscitation; Drug Therapy, Combination; Emergency Medical Services; Femal | 2008 |
[Stable angina pectoris can be treated successfully by drugs alone--pro].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cal | 2007 |
[Stable angina pectoris can be treated successfully by drugs alone--pro].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cal | 2007 |
The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Therapy, Combinatio | 2007 |
The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Therapy, Combinatio | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum | 2007 |
National study on the quality of emergency department care in the treatment of acute myocardial infarction and pneumonia.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Anti-Bacterial Agents; Aspir | 2007 |
National study on the quality of emergency department care in the treatment of acute myocardial infarction and pneumonia.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Anti-Bacterial Agents; Aspir | 2007 |
Daily aspirin therapy. Questions and answers about benefits and risks.
Topics: Aspirin; Drug Administration Schedule; Female; Humans; Male; Myocardial Infarction; Platelet Aggrega | 2007 |
Daily aspirin therapy. Questions and answers about benefits and risks.
Topics: Aspirin; Drug Administration Schedule; Female; Humans; Male; Myocardial Infarction; Platelet Aggrega | 2007 |
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; | 2008 |
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; | 2008 |
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardia | 2007 |
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardia | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
Enoxaparin and ST elevation myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 2007 |
Enoxaparin and ST elevation myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 2007 |
Acute myocardial infarction associated with myocardial bridging: a case report.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Angiography; Coronary Thrombosi | 2007 |
Acute myocardial infarction associated with myocardial bridging: a case report.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Angiography; Coronary Thrombosi | 2007 |
Myocardial infarcts in a patient with a single right sided coronary ostium and interarterial course of the circumflex artery: the role of multi-modality imaging.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anticholesteremic Agents; Antihypertensive Agents; Asp | 2009 |
Myocardial infarcts in a patient with a single right sided coronary ostium and interarterial course of the circumflex artery: the role of multi-modality imaging.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anticholesteremic Agents; Antihypertensive Agents; Asp | 2009 |
Patient sex and quality of ED care for patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Electrocardiography; Emergency Service, Hospital; Female | 2007 |
Patient sex and quality of ED care for patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Electrocardiography; Emergency Service, Hospital; Female | 2007 |
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis; | 2008 |
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis; | 2008 |
Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.
Topics: Age Factors; Aged; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Female; Fibrinolytic Agents; Hospi | 2008 |
Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.
Topics: Age Factors; Aged; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Female; Fibrinolytic Agents; Hospi | 2008 |
Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2007 |
Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Aspirin use in the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2007 |
Aspirin use in the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2007 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
[Case report of a successful pregnancy following thrombolysis for acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Electrocardiography; Female; Fibrinolyt | 2007 |
[Case report of a successful pregnancy following thrombolysis for acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Electrocardiography; Female; Fibrinolyt | 2007 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
I've heard that taking two baby aspirins provides as much or better protection against arterial disease as taking one adult aspirin, and that two baby aspirins are more than twice as effective as one baby aspirin. This seems contradictory to other studie
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Th | 2007 |
I've heard that taking two baby aspirins provides as much or better protection against arterial disease as taking one adult aspirin, and that two baby aspirins are more than twice as effective as one baby aspirin. This seems contradictory to other studie
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Th | 2007 |
Aspirin for heart attack: chew or swallow?
Topics: Aspirin; Deglutition; Humans; Male; Mastication; Myocardial Infarction; Platelet Aggregation Inhibit | 2005 |
Aspirin for heart attack: chew or swallow?
Topics: Aspirin; Deglutition; Humans; Male; Mastication; Myocardial Infarction; Platelet Aggregation Inhibit | 2005 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; | 2008 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; | 2008 |
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Topics: Aged; Antihypertensive Agents; Aspirin; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Drug | 2008 |
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Topics: Aged; Antihypertensive Agents; Aspirin; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Drug | 2008 |
Association of early follow-up after acute myocardial infarction with higher rates of medication use.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Continuity of Patien | 2008 |
Association of early follow-up after acute myocardial infarction with higher rates of medication use.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Continuity of Patien | 2008 |
[Efficacy of intravenous aspirin use in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Aged, 80 and over; Angina, Unstable; Asp | 2007 |
[Efficacy of intravenous aspirin use in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Aged, 80 and over; Angina, Unstable; Asp | 2007 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarctio | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarctio | 2008 |
Monitoring the efficacy of antiplatelet therapy: all methods are equal, but some methods are more equal than others?
Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Humans; Myocardial Infarction; Pla | 2008 |
Monitoring the efficacy of antiplatelet therapy: all methods are equal, but some methods are more equal than others?
Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Humans; Myocardial Infarction; Pla | 2008 |
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagu | 2008 |
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagu | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Disea | 2008 |
A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Disea | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
Topics: Anticoagulants; Aspirin; Diabetes Complications; Drug Therapy, Combination; Humans; Meta-Analysis as | 2008 |
Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
Topics: Anticoagulants; Aspirin; Diabetes Complications; Drug Therapy, Combination; Humans; Meta-Analysis as | 2008 |
[Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].
Topics: Adult; Anticoagulants; Antisickling Agents; Aspirin; Coronary Angiography; Diagnosis, Differential; | 2008 |
[Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].
Topics: Adult; Anticoagulants; Antisickling Agents; Aspirin; Coronary Angiography; Diagnosis, Differential; | 2008 |
Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Electrocardiography; Female; Humans | 2008 |
Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Electrocardiography; Female; Humans | 2008 |
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin | 2008 |
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin | 2008 |
Experimental basis of platelet aggregation inhibition by acetylsalicylic acid.
Topics: Adenosine Diphosphate; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Coronary Circulation | 1984 |
Experimental basis of platelet aggregation inhibition by acetylsalicylic acid.
Topics: Adenosine Diphosphate; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Coronary Circulation | 1984 |
Treatment of the patient after myocardial infarction. The last decade and the next.
Topics: Adrenergic beta-Antagonists; Aspirin; Death, Sudden; Exercise Therapy; Humans; Myocardial Infarction | 1980 |
Treatment of the patient after myocardial infarction. The last decade and the next.
Topics: Adrenergic beta-Antagonists; Aspirin; Death, Sudden; Exercise Therapy; Humans; Myocardial Infarction | 1980 |
Placebo-controlled, double-blind clinical trials can impede medical progress.
Topics: Adrenergic beta-Antagonists; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Bl | 1980 |
Placebo-controlled, double-blind clinical trials can impede medical progress.
Topics: Adrenergic beta-Antagonists; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Bl | 1980 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
[Role of medical treatment in the rehabilitation of the coronary patient].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc | 1981 |
[Role of medical treatment in the rehabilitation of the coronary patient].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc | 1981 |
[Prevention of recurrent myocardial infarct].
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1981 |
[Prevention of recurrent myocardial infarct].
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1981 |
[Infarction prophylaxis--prevention of the sudden heart death? An alternative].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Dipyridamole; Female; Heart Arrest; Humans; Ma | 1982 |
[Infarction prophylaxis--prevention of the sudden heart death? An alternative].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Dipyridamole; Female; Heart Arrest; Humans; Ma | 1982 |
[Secondary prevention of myocardial infarct. Drug therapy].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
[Secondary prevention of myocardial infarct. Drug therapy].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
Modern drug treatment--No. 8. Drugs and the prevention of death from myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Humans; Hypolipidemic Agents; Myocar | 1982 |
Modern drug treatment--No. 8. Drugs and the prevention of death from myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Humans; Hypolipidemic Agents; Myocar | 1982 |
Clinical trials and ischaemic heart disease: can drugs reduce coronary mortality?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Femal | 1982 |
Clinical trials and ischaemic heart disease: can drugs reduce coronary mortality?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Femal | 1982 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
[Secondary prevention following a myocardial infarct].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; M | 1983 |
[Secondary prevention following a myocardial infarct].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; M | 1983 |
[Second prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; Myocardial Inf | 1984 |
[Second prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; Myocardial Inf | 1984 |
Pharmacologic management of the myocardial infarction patient after discharge from the hospital.
Topics: Adrenergic beta-Antagonists; Aftercare; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Cardiotonic A | 1984 |
Pharmacologic management of the myocardial infarction patient after discharge from the hospital.
Topics: Adrenergic beta-Antagonists; Aftercare; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Cardiotonic A | 1984 |
Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Calcium Channel Blocke | 1984 |
Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Calcium Channel Blocke | 1984 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
[Effects of medical therapy on long-term survival in ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Anticoagulants; Aspirin; Calcium Channel Blocker | 1984 |
[Effects of medical therapy on long-term survival in ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Anticoagulants; Aspirin; Calcium Channel Blocker | 1984 |
[Benefits and dangers of preventive thinking in medicine--prevention of thromboembolism].
Topics: Adult; Aspirin; Bandages; Blood Flow Velocity; Coumarins; Dextrans; Dihydroergotamine; Dipyridamole; | 1981 |
[Benefits and dangers of preventive thinking in medicine--prevention of thromboembolism].
Topics: Adult; Aspirin; Bandages; Blood Flow Velocity; Coumarins; Dextrans; Dihydroergotamine; Dipyridamole; | 1981 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
[Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders].
Topics: Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Coumarins; Dicumarol; Dipyridamole; Fibr | 1984 |
[Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders].
Topics: Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Coumarins; Dicumarol; Dipyridamole; Fibr | 1984 |
Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis.
Topics: Animals; Aspirin; Body Weight; Creatine Kinase; Cyclic AMP; Heart; Isoproterenol; Male; Myocardial I | 1981 |
Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis.
Topics: Animals; Aspirin; Body Weight; Creatine Kinase; Cyclic AMP; Heart; Isoproterenol; Male; Myocardial I | 1981 |
Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.
Topics: Animals; Aspirin; Cats; Complement C5; Coronary Vessels; Female; Granulocytes; Ibuprofen; Ligation; | 1984 |
Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.
Topics: Animals; Aspirin; Cats; Complement C5; Coronary Vessels; Female; Granulocytes; Ibuprofen; Ligation; | 1984 |
Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Coronary Vessels; El | 1983 |
Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Coronary Vessels; El | 1983 |
Brief description of the Coronary Drug Project and other studies.
Topics: Adult; Aspirin; Bibliographies as Topic; Clinical Trials as Topic; Coronary Disease; Double-Blind Me | 1983 |
Brief description of the Coronary Drug Project and other studies.
Topics: Adult; Aspirin; Bibliographies as Topic; Clinical Trials as Topic; Coronary Disease; Double-Blind Me | 1983 |
Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Aorta; Aspirin; Blood Pres | 1984 |
Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Aorta; Aspirin; Blood Pres | 1984 |
[Anticoagulants or thrombocyte aggregation inhibitors in the prevention of recurrent heart infarction?].
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence | 1983 |
[Anticoagulants or thrombocyte aggregation inhibitors in the prevention of recurrent heart infarction?].
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence | 1983 |
[Effect of various doses of aspirin after a single and long-term administration on platelet aggregation in patients with ischemic heart disease].
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fo | 1984 |
[Effect of various doses of aspirin after a single and long-term administration on platelet aggregation in patients with ischemic heart disease].
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fo | 1984 |
Acute myocardial infarction in a thirty-six year old postpartum female.
Topics: Adult; Aspirin; Digoxin; Electrocardiography; Ergonovine; Female; Heart Aneurysm; Humans; Isosorbide | 1984 |
Acute myocardial infarction in a thirty-six year old postpartum female.
Topics: Adult; Aspirin; Digoxin; Electrocardiography; Ergonovine; Female; Heart Aneurysm; Humans; Isosorbide | 1984 |
[Problems of hemostatic therapy after myocardial infarct].
Topics: Aspirin; Coumarins; Humans; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation; Thro | 1984 |
[Problems of hemostatic therapy after myocardial infarct].
Topics: Aspirin; Coumarins; Humans; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation; Thro | 1984 |
[Acetosal and the heart].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence | 1984 |
[Acetosal and the heart].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence | 1984 |
Issues in medication adherence assessment in clinical trials of the National Heart, Lung, and Blood Institute.
Topics: Aspirin; Capsules; Clinical Trials as Topic; Humans; Myocardial Infarction; National Institutes of H | 1984 |
Issues in medication adherence assessment in clinical trials of the National Heart, Lung, and Blood Institute.
Topics: Aspirin; Capsules; Clinical Trials as Topic; Humans; Myocardial Infarction; National Institutes of H | 1984 |
Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions.
Topics: Acetaminophen; Adult; Amino Acid Metabolism, Inborn Errors; Aspirin; Circadian Rhythm; Diabetes Mell | 1984 |
Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions.
Topics: Acetaminophen; Adult; Amino Acid Metabolism, Inborn Errors; Aspirin; Circadian Rhythm; Diabetes Mell | 1984 |
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?].
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazo | 1983 |
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?].
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazo | 1983 |
[Fever as the only manifestation of Dressler syndrome].
Topics: Aged; Aspirin; Fever; Humans; Male; Middle Aged; Myocardial Infarction; Postpericardiotomy Syndrome | 1983 |
[Fever as the only manifestation of Dressler syndrome].
Topics: Aged; Aspirin; Fever; Humans; Male; Middle Aged; Myocardial Infarction; Postpericardiotomy Syndrome | 1983 |
Evolution and funding of the Coronary Drug Project.
Topics: Anticholesteremic Agents; Aspirin; Budgets; Clinical Trials as Topic; Coronary Disease; Costs and Co | 1983 |
Evolution and funding of the Coronary Drug Project.
Topics: Anticholesteremic Agents; Aspirin; Budgets; Clinical Trials as Topic; Coronary Disease; Costs and Co | 1983 |
[Kawasaki disease: new and important problems in cardiology].
Topics: Aortic Aneurysm; Aspirin; Coronary Angiography; Coronary Disease; Echocardiography; Humans; Infant; | 1983 |
[Kawasaki disease: new and important problems in cardiology].
Topics: Aortic Aneurysm; Aspirin; Coronary Angiography; Coronary Disease; Echocardiography; Humans; Infant; | 1983 |
Aspirin and the risk of myocardial infarction.
Topics: Angina Pectoris; Aspirin; Humans; Male; Myocardial Infarction | 1984 |
Aspirin and the risk of myocardial infarction.
Topics: Angina Pectoris; Aspirin; Humans; Male; Myocardial Infarction | 1984 |
Aspirin in the prevention of myocardial infarction. Current status.
Topics: Angina Pectoris; Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarct | 1984 |
Aspirin in the prevention of myocardial infarction. Current status.
Topics: Angina Pectoris; Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarct | 1984 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
Randomized surgical clinical trials for treatment of coronary artery disease.
Topics: Angina Pectoris; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Europe | 1982 |
Randomized surgical clinical trials for treatment of coronary artery disease.
Topics: Angina Pectoris; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Europe | 1982 |
[Sulfinpyrazone (Anturane)--new indication: myocardial infarct?].
Topics: Arrhythmias, Cardiac; Aspirin; Death, Sudden; Humans; Myocardial Infarction; Platelet Aggregation; S | 1980 |
[Sulfinpyrazone (Anturane)--new indication: myocardial infarct?].
Topics: Arrhythmias, Cardiac; Aspirin; Death, Sudden; Humans; Myocardial Infarction; Platelet Aggregation; S | 1980 |
Non-surgical reperfusion in acute myocardial infarction.
Topics: Aspirin; Coronary Circulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Human | 1981 |
Non-surgical reperfusion in acute myocardial infarction.
Topics: Aspirin; Coronary Circulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Human | 1981 |
Effects of antiplatelet and calcium antagonist drugs on infarct size in rats.
Topics: Acute Disease; Animals; Aspirin; Blood Platelets; Calcium; Creatine Kinase; Isoproterenol; Lysine; M | 1980 |
Effects of antiplatelet and calcium antagonist drugs on infarct size in rats.
Topics: Acute Disease; Animals; Aspirin; Blood Platelets; Calcium; Creatine Kinase; Isoproterenol; Lysine; M | 1980 |
[Clinical and statistical study of 121 cases of acute myocardial infarct from 1976 to 1981 (month of April). Critical review].
Topics: Adult; Aged; Aspirin; Coronary Vessels; Erythrityl Tetranitrate; Female; Heart Failure; Humans; Lysi | 1982 |
[Clinical and statistical study of 121 cases of acute myocardial infarct from 1976 to 1981 (month of April). Critical review].
Topics: Adult; Aged; Aspirin; Coronary Vessels; Erythrityl Tetranitrate; Female; Heart Failure; Humans; Lysi | 1982 |
Scar thinning due to ibuprofen administration after experimental myocardial infarction.
Topics: Animals; Aspirin; Dogs; Female; Hydroxyproline; Ibuprofen; Male; Myocardial Infarction; Myocardium | 1983 |
Scar thinning due to ibuprofen administration after experimental myocardial infarction.
Topics: Animals; Aspirin; Dogs; Female; Hydroxyproline; Ibuprofen; Male; Myocardial Infarction; Myocardium | 1983 |
Clinical trials and statistical verdicts: probable grounds for appeal.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Humans; Jurisprudence; Lung | 1983 |
Clinical trials and statistical verdicts: probable grounds for appeal.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Humans; Jurisprudence; Lung | 1983 |
Oral anticoagulation versus aspirin after myocardial infarction.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Prothrombin Time | 1983 |
Oral anticoagulation versus aspirin after myocardial infarction.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Prothrombin Time | 1983 |
Comparative effects of acetylsalicylic acid (ASA) and sulfinpyrazone on isoproterenol-induced heart damage.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Urea Nitrogen; Creatine Kinase; Isoproterenol; | 1981 |
Comparative effects of acetylsalicylic acid (ASA) and sulfinpyrazone on isoproterenol-induced heart damage.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Urea Nitrogen; Creatine Kinase; Isoproterenol; | 1981 |
[Wrong treatment of asthma patient].
Topics: Aspirin; Asthma; Humans; Jurisprudence; Male; Medication Errors; Middle Aged; Myocardial Infarction; | 1980 |
[Wrong treatment of asthma patient].
Topics: Aspirin; Asthma; Humans; Jurisprudence; Male; Medication Errors; Middle Aged; Myocardial Infarction; | 1980 |
Myocardial infarction and aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Myocardial infarction and aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
[Present situation of therapy with platelet aggregation inhibitors].
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged; | 1982 |
[Present situation of therapy with platelet aggregation inhibitors].
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged; | 1982 |
Platelet factor 4 levels in patients with coronary artery disease.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Coagulation Factors; Coronary Artery Bypass; Coronary Dis | 1981 |
Platelet factor 4 levels in patients with coronary artery disease.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Coagulation Factors; Coronary Artery Bypass; Coronary Dis | 1981 |
Dosage of aspirin.
Topics: Adult; Aspirin; Epoprostenol; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
Dosage of aspirin.
Topics: Adult; Aspirin; Epoprostenol; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments in favor of aggregation inhibitors].
Topics: Aspirin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Plat | 1980 |
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments in favor of aggregation inhibitors].
Topics: Aspirin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Plat | 1980 |
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments against aggregation inhibitors].
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments against aggregation inhibitors].
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
[Pro and con: Anticoagulation or thrombocyte function inhibitors in the prophylaxis of myocardial infarct? Arguments in favor of thrombocyte function inhibitors].
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Agg | 1980 |
[Pro and con: Anticoagulation or thrombocyte function inhibitors in the prophylaxis of myocardial infarct? Arguments in favor of thrombocyte function inhibitors].
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Agg | 1980 |
[Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation; R | 1980 |
[Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation; R | 1980 |
Secondary prevention in myocardial infarction survivors.
Topics: Anticoagulants; Aspirin; Diabetes Mellitus; Diet, Reducing; Humans; Hypertension; Lipids; Myocardial | 1982 |
Secondary prevention in myocardial infarction survivors.
Topics: Anticoagulants; Aspirin; Diabetes Mellitus; Diet, Reducing; Humans; Hypertension; Lipids; Myocardial | 1982 |
Aspirin and myocardial infarction in young women.
Topics: Adult; Aspirin; Female; Humans; Middle Aged; Myocardial Infarction; Preventive Medicine; Risk | 1982 |
Aspirin and myocardial infarction in young women.
Topics: Adult; Aspirin; Female; Humans; Middle Aged; Myocardial Infarction; Preventive Medicine; Risk | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
How blind was the patient blind in AMIS?
Topics: Adult; Aged; Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1982 |
How blind was the patient blind in AMIS?
Topics: Adult; Aged; Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1982 |
Experience with intracoronary streptokinase in 36 patients with acute evolving myocardial infarction.
Topics: Adult; Aged; Aspirin; Coronary Circulation; Coronary Vessels; Female; Fibrinolysis; Humans; Male; Mi | 1982 |
Experience with intracoronary streptokinase in 36 patients with acute evolving myocardial infarction.
Topics: Adult; Aged; Aspirin; Coronary Circulation; Coronary Vessels; Female; Fibrinolysis; Humans; Male; Mi | 1982 |
Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Coronary Vessels; Indomethacin; Male; Myocardial Infarct | 1981 |
Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Coronary Vessels; Indomethacin; Male; Myocardial Infarct | 1981 |
Kawasaki syndrome: a new infectious disease?
Topics: Adrenal Cortex Hormones; Arterial Occlusive Diseases; Aspirin; Child; Coronary Vessels; Epidemiology | 1981 |
Kawasaki syndrome: a new infectious disease?
Topics: Adrenal Cortex Hormones; Arterial Occlusive Diseases; Aspirin; Child; Coronary Vessels; Epidemiology | 1981 |
[Myocardial infarct: present status of anticoagulant therapy].
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Streptokinase; Urokinase-Type Plasminogen Ac | 1980 |
[Myocardial infarct: present status of anticoagulant therapy].
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Streptokinase; Urokinase-Type Plasminogen Ac | 1980 |
Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Carbenicillin; Coronary Disease; Dea | 1981 |
Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Carbenicillin; Coronary Disease; Dea | 1981 |
Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte | 1981 |
Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte | 1981 |
[ST-segment trend in patients with acute myocardial infarction treated with antithrombotic drugs (author's transl)].
Topics: Aged; Aspirin; Digoxin; Diuretics; Electrocardiography; Female; Heparin; Humans; Male; Middle Aged; | 1981 |
[ST-segment trend in patients with acute myocardial infarction treated with antithrombotic drugs (author's transl)].
Topics: Aged; Aspirin; Digoxin; Diuretics; Electrocardiography; Female; Heparin; Humans; Male; Middle Aged; | 1981 |
Platelets and ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Death, Sudden; Exercise Test; Humans; M | 1980 |
Platelets and ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Death, Sudden; Exercise Test; Humans; M | 1980 |
Antiplatelet drugs after myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregati | 1980 |
Antiplatelet drugs after myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregati | 1980 |
[Acetylsalicylic acid after myocardial infarction--effective or not?].
Topics: Aspirin; Humans; Myocardial Infarction | 1980 |
[Acetylsalicylic acid after myocardial infarction--effective or not?].
Topics: Aspirin; Humans; Myocardial Infarction | 1980 |
Preventing death after myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazone | 1980 |
Preventing death after myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazone | 1980 |
Studies of myocardial infarction.
Topics: Aspirin; Dipyridamole; Drug Combinations; Gastrointestinal Diseases; Humans; Myocardial Infarction; | 1980 |
Studies of myocardial infarction.
Topics: Aspirin; Dipyridamole; Drug Combinations; Gastrointestinal Diseases; Humans; Myocardial Infarction; | 1980 |
Effect of Tromaril on platelet function and blood coagulation.
Topics: Arthritis, Rheumatoid; Aspirin; Blood Coagulation; Humans; Myocardial Infarction; ortho-Aminobenzoat | 1980 |
Effect of Tromaril on platelet function and blood coagulation.
Topics: Arthritis, Rheumatoid; Aspirin; Blood Coagulation; Humans; Myocardial Infarction; ortho-Aminobenzoat | 1980 |
Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Electrocardiography; Endocardium; Ligation; Myo | 1980 |
Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Electrocardiography; Endocardium; Ligation; Myo | 1980 |
Hyperlipidaemia advances and retreats.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence | 1980 |
Hyperlipidaemia advances and retreats.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence | 1980 |
[Sulfinpyrazone (Anturan) after myocardial infarction].
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
[Sulfinpyrazone (Anturan) after myocardial infarction].
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Management of venous thromboembolism.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrinolytic Agents; Heparin; Humans; Isometric | 1980 |
Management of venous thromboembolism.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrinolytic Agents; Heparin; Humans; Isometric | 1980 |
Antithrombotic therapy in coronary artery disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Humans; Myocardial | 1980 |
Antithrombotic therapy in coronary artery disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Humans; Myocardial | 1980 |
Prevention of cigarette smoking-induced platelet aggregate formation by aspirin.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 1981 |
Prevention of cigarette smoking-induced platelet aggregate formation by aspirin.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 1981 |
[The effect of a high-dose parenteral thrombocyte aggregation inhibitors in recent myocardial infarct. Case contribution].
Topics: Aged; Aspirin; Humans; Injections, Intravenous; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
[The effect of a high-dose parenteral thrombocyte aggregation inhibitors in recent myocardial infarct. Case contribution].
Topics: Aged; Aspirin; Humans; Injections, Intravenous; Male; Myocardial Infarction; Platelet Aggregation | 1980 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
[Platelet hyperaggregation premonitory of myocardial infarct? A clinical case report].
Topics: Anticoagulants; Aspirin; Dipyridamole; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction | 1981 |
[Platelet hyperaggregation premonitory of myocardial infarct? A clinical case report].
Topics: Anticoagulants; Aspirin; Dipyridamole; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction | 1981 |
Lack of effect of aspirin on myocardial infarct size in the dog.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Coronary Vessels; Dogs; Dose-Response Relations | 1981 |
Lack of effect of aspirin on myocardial infarct size in the dog.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Coronary Vessels; Dogs; Dose-Response Relations | 1981 |
Aspirin for prevention of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention | 1995 |
Aspirin for prevention of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention | 1995 |
Aspirin and acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1995 |
Aspirin and acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1995 |
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myoc | 1995 |
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myoc | 1995 |
Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go?
Topics: Aspirin; Contraindications; Fibrinolytic Agents; Humans; Myocardial Infarction; Streptokinase; Throm | 1995 |
Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go?
Topics: Aspirin; Contraindications; Fibrinolytic Agents; Humans; Myocardial Infarction; Streptokinase; Throm | 1995 |
Acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy | 1995 |
Acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy | 1995 |
Increasing prescription of drugs for secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Drug Prescriptions; Drug Utili | 1995 |
Increasing prescription of drugs for secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Drug Prescriptions; Drug Utili | 1995 |
Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes.
Topics: Aged; Alabama; Aspirin; Cohort Studies; Connecticut; Drug Utilization; Female; Humans; Iowa; Male; M | 1995 |
Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes.
Topics: Aged; Alabama; Aspirin; Cohort Studies; Connecticut; Drug Utilization; Female; Humans; Iowa; Male; M | 1995 |
The mechanism of action of aspirin--is there anything beyond cyclo-oxygenase?
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Membrane Lipids; Myocardial Infarction; | 1995 |
The mechanism of action of aspirin--is there anything beyond cyclo-oxygenase?
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Membrane Lipids; Myocardial Infarction; | 1995 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Acute myocardial infarction.
Topics: Aspirin; Family Practice; Humans; Male; Middle Aged; Myocardial Infarction; Time Factors | 1995 |
Acute myocardial infarction.
Topics: Aspirin; Family Practice; Humans; Male; Middle Aged; Myocardial Infarction; Time Factors | 1995 |
Acute myocardial infarction.
Topics: Anistreplase; Aspirin; Emergencies; Family Practice; Humans; Myocardial Infarction | 1995 |
Acute myocardial infarction.
Topics: Anistreplase; Aspirin; Emergencies; Family Practice; Humans; Myocardial Infarction | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
Heparin in unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenou | 1995 |
[Aspirin--yes, but 30 mg??].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Rec | 1995 |
[Aspirin--yes, but 30 mg??].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Rec | 1995 |
[Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Myocardial | 1994 |
[Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Myocardial | 1994 |
[Use of aspirin in coronary disease].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Humans | 1995 |
[Use of aspirin in coronary disease].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Humans | 1995 |
Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.
Topics: Algorithms; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Recur | 1995 |
Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.
Topics: Algorithms; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Recur | 1995 |
[Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area].
Topics: Aspirin; Coronary Disease; Drug Utilization; Female; France; Hospitalization; Humans; Male; Myocardi | 1995 |
[Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area].
Topics: Aspirin; Coronary Disease; Drug Utilization; Female; France; Hospitalization; Humans; Male; Myocardi | 1995 |
[Prevention of reinfarction with 100 mg or 30 mg aspirin daily?].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[Prevention of reinfarction with 100 mg or 30 mg aspirin daily?].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[What are the recommendations for acute therapy of myocardial infarct with acetylsalicylic acid and heparin, which analgesics should be prescribed?].
Topics: Analgesics; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Heparin; Humans | 1995 |
[What are the recommendations for acute therapy of myocardial infarct with acetylsalicylic acid and heparin, which analgesics should be prescribed?].
Topics: Analgesics; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Heparin; Humans | 1995 |
Implications of the prognostic importance of exercise-induced thromboxane formation in survivors of an acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Epoprostenol; Exerc | 1995 |
Implications of the prognostic importance of exercise-induced thromboxane formation in survivors of an acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Epoprostenol; Exerc | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anger; Aspirin; Case-Control Studies; C | 1995 |
Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes.
Topics: Angina, Unstable; Aspirin; Case-Control Studies; Chest Pain; Electrocardiography; Female; Humans; Ma | 1995 |
Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes.
Topics: Angina, Unstable; Aspirin; Case-Control Studies; Chest Pain; Electrocardiography; Female; Humans; Ma | 1995 |
Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction.
Topics: Aspirin; Coronary Care Units; Emergency Medical Services; Family Practice; Female; Humans; Male; Myo | 1994 |
Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction.
Topics: Aspirin; Coronary Care Units; Emergency Medical Services; Family Practice; Female; Humans; Male; Myo | 1994 |
Early management of myocardial infarction. Lack of knowledge is not the problem.
Topics: Aspirin; Family Practice; Humans; Myocardial Infarction; Practice Patterns, Physicians' | 1994 |
Early management of myocardial infarction. Lack of knowledge is not the problem.
Topics: Aspirin; Family Practice; Humans; Myocardial Infarction; Practice Patterns, Physicians' | 1994 |
[Survival in acute myocardial infarction in a group of 369 patients consecutively admitted between 1988 and 1992. Analysis of risk factors and medical procedure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Female; France; Humans; Male; Middle Aged; | 1994 |
[Survival in acute myocardial infarction in a group of 369 patients consecutively admitted between 1988 and 1992. Analysis of risk factors and medical procedure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Female; France; Humans; Male; Middle Aged; | 1994 |
Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Diclofenac; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggrega | 1994 |
Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Diclofenac; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggrega | 1994 |
Thrombolysis in patients with diabetes. Prophylaxis with aspirin should be considered.
Topics: Aspirin; Cardiovascular Diseases; Contraindications; Diabetic Retinopathy; Humans; Myocardial Infarc | 1995 |
Thrombolysis in patients with diabetes. Prophylaxis with aspirin should be considered.
Topics: Aspirin; Cardiovascular Diseases; Contraindications; Diabetic Retinopathy; Humans; Myocardial Infarc | 1995 |
Major depression and medication adherence in elderly patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Disease; Depressive Disorder; Dose-Response Relationship, Drug; Female; Huma | 1995 |
Major depression and medication adherence in elderly patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Disease; Depressive Disorder; Dose-Response Relationship, Drug; Female; Huma | 1995 |
Use and abuse of clinical trials. Is the timing of treatment critical?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1994 |
Use and abuse of clinical trials. Is the timing of treatment critical?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1994 |
Aspirin enhances the benefits of late reperfusion on infarct shape. A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction.
Topics: Animals; Aspirin; Coronary Vessels; Female; Myocardial Infarction; Myocardial Reperfusion; Myocardiu | 1995 |
Aspirin enhances the benefits of late reperfusion on infarct shape. A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction.
Topics: Animals; Aspirin; Coronary Vessels; Female; Myocardial Infarction; Myocardial Reperfusion; Myocardiu | 1995 |
[5-aminosalicylic acid and thrombocyte function].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Mesalamine; Myocardi | 1995 |
[5-aminosalicylic acid and thrombocyte function].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Mesalamine; Myocardi | 1995 |
Age-related differences in the utilization of therapies post acute myocardial infarction.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Angioplasty, Balloon; Aspirin; Calcium Channel Blockers | 1995 |
Age-related differences in the utilization of therapies post acute myocardial infarction.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Angioplasty, Balloon; Aspirin; Calcium Channel Blockers | 1995 |
Acute myocardial infarction. Then and now.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac Catheterization; Contraindica | 1995 |
Acute myocardial infarction. Then and now.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiac Catheterization; Contraindica | 1995 |
[Incidence and prognosis of early primary cardiogenic shock in myocardial infarction].
Topics: Aged; Aged, 80 and over; Angioplasty; Aspirin; Emergencies; Female; Heparin; Humans; Male; Middle Ag | 1994 |
[Incidence and prognosis of early primary cardiogenic shock in myocardial infarction].
Topics: Aged; Aged, 80 and over; Angioplasty; Aspirin; Emergencies; Female; Heparin; Humans; Male; Middle Ag | 1994 |
Systemic thromboembolism leading to myocardial infarction and stroke after fenestrated total cavopulmonary connection.
Topics: Aspirin; Cerebrovascular Disorders; Child, Preschool; Drug Administration Schedule; Female; Fontan P | 1995 |
Systemic thromboembolism leading to myocardial infarction and stroke after fenestrated total cavopulmonary connection.
Topics: Aspirin; Cerebrovascular Disorders; Child, Preschool; Drug Administration Schedule; Female; Fontan P | 1995 |
Does aspirin consumption affect the presentation or severity of acute myocardial infarction?
Topics: Aged; Aspirin; Creatine Kinase; Electrocardiography; Female; Humans; Logistic Models; Male; Multivar | 1995 |
Does aspirin consumption affect the presentation or severity of acute myocardial infarction?
Topics: Aged; Aspirin; Creatine Kinase; Electrocardiography; Female; Humans; Logistic Models; Male; Multivar | 1995 |
Ethical committees and noninformed consent.
Topics: Aspirin; Ethics Committees; Glycosaminoglycans; Humans; Hypolipidemic Agents; Informed Consent; Myoc | 1994 |
Ethical committees and noninformed consent.
Topics: Aspirin; Ethics Committees; Glycosaminoglycans; Humans; Hypolipidemic Agents; Informed Consent; Myoc | 1994 |
Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin.
Topics: Aged; Alprostadil; Angina, Unstable; Aspirin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female | 1994 |
Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin.
Topics: Aged; Alprostadil; Angina, Unstable; Aspirin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female | 1994 |
Aspirin for prevention of myocardial infarction.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction | 1995 |
Aspirin for prevention of myocardial infarction.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction | 1995 |
[Intracranial hemorrhage following second thrombolytic treatment of myocardial reinfarction].
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Heparin; Humans; Male; Myocardial Infarction; Recurrence | 1994 |
[Intracranial hemorrhage following second thrombolytic treatment of myocardial reinfarction].
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Heparin; Humans; Male; Myocardial Infarction; Recurrence | 1994 |
[Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne].
Topics: Adult; Analysis of Variance; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fi | 1994 |
[Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne].
Topics: Adult; Analysis of Variance; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fi | 1994 |
[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Vessels; Hu | 1994 |
[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Vessels; Hu | 1994 |
Gender differences in the presentation, treatment, and short-term mortality of acute chest pain.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Chest Pain; Coronary Angiography | 1994 |
Gender differences in the presentation, treatment, and short-term mortality of acute chest pain.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Chest Pain; Coronary Angiography | 1994 |
[Circadian changes of myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Circadian Rhythm; Humans; Myocardial | 1993 |
[Circadian changes of myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Circadian Rhythm; Humans; Myocardial | 1993 |
Oral anticoagulants or aspirin after myocardial infarction?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Humans; Middle Aged; Myocardial Infarction; Ran | 1994 |
Oral anticoagulants or aspirin after myocardial infarction?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Humans; Middle Aged; Myocardial Infarction; Ran | 1994 |
Management of myocardial infarction from the patient.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Vitamin B Complex | 1994 |
Management of myocardial infarction from the patient.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Vitamin B Complex | 1994 |
Declining hospital mortality in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Coronary Care Units; Female; Hospital Mortality; Hospita | 1994 |
Declining hospital mortality in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Coronary Care Units; Female; Hospital Mortality; Hospita | 1994 |
Effect of thrombolysis in inferior infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Urokinase-Type Plasmino | 1994 |
Effect of thrombolysis in inferior infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Streptokinase; Thrombolytic Therapy; Urokinase-Type Plasmino | 1994 |
Magnesium and myocardial infarction.
Topics: Aspirin; Captopril; Drug Therapy, Combination; Heparin; Humans; Magnesium; Myocardial Infarction; St | 1994 |
Magnesium and myocardial infarction.
Topics: Aspirin; Captopril; Drug Therapy, Combination; Heparin; Humans; Magnesium; Myocardial Infarction; St | 1994 |
Management of myocardial infarction patients with an occluded infarct-related artery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Aspirin; Calcium | 1994 |
Management of myocardial infarction patients with an occluded infarct-related artery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Aspirin; Calcium | 1994 |
Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Canada; Cohort Studies; Female; Hospital Mo | 1994 |
Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Canada; Cohort Studies; Female; Hospital Mo | 1994 |
Clinical trials versus clinical practice in the secondary prevention of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Clin | 1994 |
Clinical trials versus clinical practice in the secondary prevention of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Clin | 1994 |
[Sliding indications for balloon angioplasty].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi | 1994 |
[Sliding indications for balloon angioplasty].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi | 1994 |
Do women with acute myocardial infarction receive the same treatment as men?
Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Age Factors; Aged; Aspirin; Coronary Care Units; Fema | 1994 |
Do women with acute myocardial infarction receive the same treatment as men?
Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Age Factors; Aged; Aspirin; Coronary Care Units; Fema | 1994 |
Acute myocardial infarction in women: survival analysis in first six months.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aspirin; Coronary Care Units; Female; Follow- | 1994 |
Acute myocardial infarction in women: survival analysis in first six months.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aspirin; Coronary Care Units; Female; Follow- | 1994 |
Amaurosis fugax: prognosis and the role of acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Brain Ischemia; Cerebrovascular Disorders; Female; Foll | 1994 |
Amaurosis fugax: prognosis and the role of acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Brain Ischemia; Cerebrovascular Disorders; Female; Foll | 1994 |
Platelet activation and arterial thrombosis. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston.
Topics: Aspirin; Hemorheology; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platel | 1994 |
Platelet activation and arterial thrombosis. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston.
Topics: Aspirin; Hemorheology; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platel | 1994 |
[Drug treatment following an infarction].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Anticoagulan | 1994 |
[Drug treatment following an infarction].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Anticoagulan | 1994 |
Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin.
Topics: Administration, Oral; Anticoagulants; Antithrombin III; Aspirin; Blotting, Western; Fibrinolysin; He | 1994 |
Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin.
Topics: Administration, Oral; Anticoagulants; Antithrombin III; Aspirin; Blotting, Western; Fibrinolysin; He | 1994 |
Patterns of practice analysis for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Contraindications; Drug Utilization; Female; Humans; Mal | 1994 |
Patterns of practice analysis for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Contraindications; Drug Utilization; Female; Humans; Mal | 1994 |
Antiplatelet therapy in the treatment of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 1994 |
Antiplatelet therapy in the treatment of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 1994 |
Aspirin and suspected myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Family Practice; Humans; Myocardial Infarction; Thrombolytic Ther | 1994 |
Aspirin and suspected myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Family Practice; Humans; Myocardial Infarction; Thrombolytic Ther | 1994 |
[20,000 kg aspirin and 45 pages of the British Medical Journal].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1994 |
[20,000 kg aspirin and 45 pages of the British Medical Journal].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction | 1994 |
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Tests; Co | 1994 |
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Tests; Co | 1994 |
[Left ventricular thrombosis after acute myocardial infarction: relationship with thrombolytic therapy and the patency of the "guilty" vessel].
Topics: Adult; Aged; Aspirin; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; Male; Middle Aged; | 1994 |
[Left ventricular thrombosis after acute myocardial infarction: relationship with thrombolytic therapy and the patency of the "guilty" vessel].
Topics: Adult; Aged; Aspirin; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; Male; Middle Aged; | 1994 |
Survey of general practitioners' prehospital management of suspected acute myocardial infarction.
Topics: Aspirin; Electrocardiography; Emergency Medical Services; England; Health Knowledge, Attitudes, Prac | 1994 |
Survey of general practitioners' prehospital management of suspected acute myocardial infarction.
Topics: Aspirin; Electrocardiography; Emergency Medical Services; England; Health Knowledge, Attitudes, Prac | 1994 |
Acute coronary embolism complicating aortic valve endocarditis treated with streptokinase and aspirin. A case report.
Topics: Aortic Valve; Aspirin; Embolism; Endocarditis, Bacterial; Gastrointestinal Hemorrhage; Heart Valve D | 1994 |
Acute coronary embolism complicating aortic valve endocarditis treated with streptokinase and aspirin. A case report.
Topics: Aortic Valve; Aspirin; Embolism; Endocarditis, Bacterial; Gastrointestinal Hemorrhage; Heart Valve D | 1994 |
HCFA's Cooperative Cardiovascular Project: a nationwide quality assessment of acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Centers for Medicare and Medicaid Services, U.S.; Cor | 1994 |
HCFA's Cooperative Cardiovascular Project: a nationwide quality assessment of acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Centers for Medicare and Medicaid Services, U.S.; Cor | 1994 |
Secondary prevention after myocardial infarction. Too many choices, which ones work?
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Myocardial Infarction; Rando | 1993 |
Secondary prevention after myocardial infarction. Too many choices, which ones work?
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Myocardial Infarction; Rando | 1993 |
Suspected myocardial infarction and the GP.
Topics: Aspirin; Family Practice; Humans; Myocardial Infarction; Practice Guidelines as Topic | 1994 |
Suspected myocardial infarction and the GP.
Topics: Aspirin; Family Practice; Humans; Myocardial Infarction; Practice Guidelines as Topic | 1994 |
Use of aspirin by general practitioners in suspected acute myocardial infarction.
Topics: Aspirin; Emergency Medical Services; Family Practice; Hospitalization; Humans; Myocardial Infarction | 1994 |
Use of aspirin by general practitioners in suspected acute myocardial infarction.
Topics: Aspirin; Emergency Medical Services; Family Practice; Hospitalization; Humans; Myocardial Infarction | 1994 |
Survey of whether general practitioners carry aspirin in their doctor's bag.
Topics: Adult; Aged; Aspirin; Family Practice; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pra | 1994 |
Survey of whether general practitioners carry aspirin in their doctor's bag.
Topics: Adult; Aged; Aspirin; Family Practice; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pra | 1994 |
Antiplatelet prophylaxis. Consider the protective effect of blood loss from the gut.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction | 1994 |
Antiplatelet prophylaxis. Consider the protective effect of blood loss from the gut.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction | 1994 |
Antiplatelet therapy and risk of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1993 |
Antiplatelet therapy and risk of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1993 |
Thrombolytic therapy and intravenous heparin in acute myocardial infarction do not affect the incidence of left ventricular mural thrombus formation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; | 1994 |
Thrombolytic therapy and intravenous heparin in acute myocardial infarction do not affect the incidence of left ventricular mural thrombus formation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; | 1994 |
Early management of myocardial infarction. The challenge for the GPs is to change.
Topics: Aspirin; Chest Pain; Family Practice; Humans; Myocardial Infarction | 1994 |
Early management of myocardial infarction. The challenge for the GPs is to change.
Topics: Aspirin; Chest Pain; Family Practice; Humans; Myocardial Infarction | 1994 |
Management of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1994 |
Management of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Variable and circadian response to a fixed high-dose (12 500 IU twice daily) subcutaneous heparin regimen after thrombolytic therapy for acute myocardial infarction.
Topics: Aspirin; Blood Coagulation Tests; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administr | 1994 |
Variable and circadian response to a fixed high-dose (12 500 IU twice daily) subcutaneous heparin regimen after thrombolytic therapy for acute myocardial infarction.
Topics: Aspirin; Blood Coagulation Tests; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administr | 1994 |
Acute anuric renal failure: a complication of combined thrombolytic and antithrombotic therapy.
Topics: Acute Kidney Injury; Angioplasty, Balloon, Coronary; Anuria; Aspirin; Combined Modality Therapy; Dru | 1993 |
Acute anuric renal failure: a complication of combined thrombolytic and antithrombotic therapy.
Topics: Acute Kidney Injury; Angioplasty, Balloon, Coronary; Anuria; Aspirin; Combined Modality Therapy; Dru | 1993 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Time Factors | 1993 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Time Factors | 1993 |
[Prehospital treatment of acute myocardial infarction].
Topics: Anti-Arrhythmia Agents; Aspirin; Emergency Medical Services; Humans; Morphine; Myocardial Infarction | 1993 |
[Prehospital treatment of acute myocardial infarction].
Topics: Anti-Arrhythmia Agents; Aspirin; Emergency Medical Services; Humans; Morphine; Myocardial Infarction | 1993 |
Recent developments in secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia | 1993 |
Recent developments in secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia | 1993 |
Clinical and angiographic determinants of initial percutaneous transluminal coronary angioplasty success.
Topics: Aged; Angina Pectoris; Angiography; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; | 1993 |
Clinical and angiographic determinants of initial percutaneous transluminal coronary angioplasty success.
Topics: Aged; Angina Pectoris; Angiography; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; | 1993 |
[Acute myocardial infarct? Open the blood vessel involved].
Topics: Acute Disease; Adult; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Electrocar | 1993 |
[Acute myocardial infarct? Open the blood vessel involved].
Topics: Acute Disease; Adult; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Electrocar | 1993 |
Acute myocardial infarction: experience at a rural hospital.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Catchment Area, Health; Female; Hospitals, Rur | 1993 |
Acute myocardial infarction: experience at a rural hospital.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Catchment Area, Health; Female; Hospitals, Rur | 1993 |
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.
Topics: Age Factors; Aged; Aspirin; Female; Humans; London; Male; Middle Aged; Myocardial Infarction; Progno | 1993 |
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.
Topics: Age Factors; Aged; Aspirin; Female; Humans; London; Male; Middle Aged; Myocardial Infarction; Progno | 1993 |
[Acute myocardial infarct? Open the involved blood vessel].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Humans; Infusions, Intravenous; Myocardial Infarction | 1993 |
[Acute myocardial infarct? Open the involved blood vessel].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Humans; Infusions, Intravenous; Myocardial Infarction | 1993 |
Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats.
Topics: Administration, Oral; Animals; Aspirin; Calcium-Transporting ATPases; Cholesterol; Fatty Acids; Isop | 1993 |
Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats.
Topics: Administration, Oral; Animals; Aspirin; Calcium-Transporting ATPases; Cholesterol; Fatty Acids; Isop | 1993 |
Aspirin versus coumadin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Warfarin | 1993 |
Aspirin versus coumadin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Warfarin | 1993 |
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Dru | 1993 |
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Dru | 1993 |
Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Topics: Animals; Aspirin; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Female; Hydrazi | 1993 |
Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Topics: Animals; Aspirin; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Female; Hydrazi | 1993 |
Does magnesium prevent myocardial infarction?
Topics: Aspirin; Humans; Magnesium; Myocardial Infarction | 1993 |
Does magnesium prevent myocardial infarction?
Topics: Aspirin; Humans; Magnesium; Myocardial Infarction | 1993 |
Early heart rate variability alterations after acute myocardial infarction.
Topics: Aspirin; Autonomic Nervous System; Electrocardiography, Ambulatory; Female; Heart Rate; Heparin; Hum | 1993 |
Early heart rate variability alterations after acute myocardial infarction.
Topics: Aspirin; Autonomic Nervous System; Electrocardiography, Ambulatory; Female; Heart Rate; Heparin; Hum | 1993 |
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; | 1993 |
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; | 1993 |
Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Epoprostenol; Myocardial Inf | 1993 |
Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Epoprostenol; Myocardial Inf | 1993 |
Audit suggests that use of aspirin is rising in coronary heart disease.
Topics: Adolescent; Adult; Aged; Aspirin; England; Female; Humans; Male; Medical Audit; Middle Aged; Myocard | 1995 |
Audit suggests that use of aspirin is rising in coronary heart disease.
Topics: Adolescent; Adult; Aged; Aspirin; England; Female; Humans; Male; Medical Audit; Middle Aged; Myocard | 1995 |
The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study.
Topics: Aged; Aspirin; Calcium Channel Blockers; Female; Humans; Logistic Models; Male; Multivariate Analysi | 1996 |
The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study.
Topics: Aged; Aspirin; Calcium Channel Blockers; Female; Humans; Logistic Models; Male; Multivariate Analysi | 1996 |
Aspirin and myocardial infarction: is one positive study enough?
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Treatment Outcome; United K | 1995 |
Aspirin and myocardial infarction: is one positive study enough?
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Treatment Outcome; United K | 1995 |
[Comments on the contribution by B. Noll. Aspirin and heparin in acute myocardial infarct].
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction | 1995 |
[Comments on the contribution by B. Noll. Aspirin and heparin in acute myocardial infarct].
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction | 1995 |
[Myocardial infarction and cerebrovascular accident complicating papillary elastofibroma of the mitral valve].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Fibroma; Heart Neoplasms; He | 1995 |
[Myocardial infarction and cerebrovascular accident complicating papillary elastofibroma of the mitral valve].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Fibroma; Heart Neoplasms; He | 1995 |
Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Female; Flow Cytometry; Glutathione; Huma | 1996 |
Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Female; Flow Cytometry; Glutathione; Huma | 1996 |
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.
Topics: Aged; Aspirin; Contraindications; Female; Health Status Indicators; Humans; Male; Multivariate Analy | 1996 |
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.
Topics: Aged; Aspirin; Contraindications; Female; Health Status Indicators; Humans; Male; Multivariate Analy | 1996 |
Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life?
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1996 |
Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life?
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1996 |
Estimation of exposure prevalence in a population at risk using data from cases and an external estimate of the relative risk.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Epidemiologic Methods; Female; Humans; Male; Meta-Analysis | 1995 |
Estimation of exposure prevalence in a population at risk using data from cases and an external estimate of the relative risk.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Epidemiologic Methods; Female; Humans; Male; Meta-Analysis | 1995 |
Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Prescriptions; | 1996 |
Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Prescriptions; | 1996 |
Acute myocardial infarction treatments in 58 Italian hospitals: a drug utilization survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Drug Utilization Review; Female; Humans; Italy; Male; My | 1995 |
Acute myocardial infarction treatments in 58 Italian hospitals: a drug utilization survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Drug Utilization Review; Female; Humans; Italy; Male; My | 1995 |
The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction.
Topics: Aspirin; Drug Utilization; Family Practice; Humans; Myocardial Infarction; Narcotics; Platelet Aggre | 1995 |
The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction.
Topics: Aspirin; Drug Utilization; Family Practice; Humans; Myocardial Infarction; Narcotics; Platelet Aggre | 1995 |
[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[Response to the editorial by J. C. Frölich: Aspirin--yes, but 30 mg??].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[Response to the editorial by J. C. Frölich: Aspirin--yes, but 30 mg??].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat.
Topics: Animals; Aspirin; Collagen; Coronary Vessels; Dose-Response Relationship, Drug; Eicosanoids; Endothe | 1995 |
Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat.
Topics: Animals; Aspirin; Collagen; Coronary Vessels; Dose-Response Relationship, Drug; Eicosanoids; Endothe | 1995 |
Prevention of cardioembolic stroke with anticoagulant therapy.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascula | 1996 |
Prevention of cardioembolic stroke with anticoagulant therapy.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascula | 1996 |
Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Drug Utilization; F | 1996 |
Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Drug Utilization; F | 1996 |
Low molecular weight heparin-induced thrombocytopenia and thrombosis.
Topics: Adenocarcinoma; Aged; Arterial Occlusive Diseases; Aspirin; Dextrans; Embolism; Female; Femoral Arte | 1996 |
Low molecular weight heparin-induced thrombocytopenia and thrombosis.
Topics: Adenocarcinoma; Aged; Arterial Occlusive Diseases; Aspirin; Dextrans; Embolism; Female; Femoral Arte | 1996 |
Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Middle Aged; Myoc | 1996 |
Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Middle Aged; Myoc | 1996 |
[Drug therapy as secondary prevention following myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
[Drug therapy as secondary prevention following myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood Platelets; Female; Humans; Male | 1996 |
Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood Platelets; Female; Humans; Male | 1996 |
Follow up after spontaneous coronary artery dissection: a report of five cases.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aortic Dissection; Aspirin; Coronary Angiog | 1996 |
Follow up after spontaneous coronary artery dissection: a report of five cases.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aortic Dissection; Aspirin; Coronary Angiog | 1996 |
[What can we learn about mega-trials of drugs?].
Topics: Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Drug Therapy; Humans; Magnesium; Myocardia | 1995 |
[What can we learn about mega-trials of drugs?].
Topics: Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Drug Therapy; Humans; Magnesium; Myocardia | 1995 |
Management of acute myocardial infarction in Auckland.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 1996 |
Management of acute myocardial infarction in Auckland.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 1996 |
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Topics: Adult; Aged; Angina Pectoris; Antithrombins; Aspirin; Cholesterol; Female; Humans; Hypercholesterole | 1996 |
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Topics: Adult; Aged; Angina Pectoris; Antithrombins; Aspirin; Cholesterol; Female; Humans; Hypercholesterole | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Female; Humans; Male; Myocardial Infarction | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Female; Humans; Male; Myocardial Infarction | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Humans; Myocardial Infarction | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Humans; Myocardial Infarction | 1996 |
Aspirin in acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Practice Guidelines as Topic | 1996 |
Aspirin in acute myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Practice Guidelines as Topic | 1996 |
[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily].
Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; | 1996 |
[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily].
Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; | 1996 |
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Cor | 1996 |
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Cor | 1996 |
Aspirin, vitamin E and heart attack prevention.
Topics: Aspirin; Humans; Myocardial Infarction; Vitamin E | 1996 |
Aspirin, vitamin E and heart attack prevention.
Topics: Aspirin; Humans; Myocardial Infarction; Vitamin E | 1996 |
Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics.
Topics: Adult; Aged; Aspirin; Female; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; M | 1995 |
Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics.
Topics: Adult; Aged; Aspirin; Female; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; M | 1995 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
Intimal injury in a transiently occluded coronary artery increases myocardial necrosis. Effect of aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Blood Cell Count; Coronary | 1996 |
Intimal injury in a transiently occluded coronary artery increases myocardial necrosis. Effect of aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Blood Cell Count; Coronary | 1996 |
More uses of known drugs.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Humans; Myocardial Infarction; Thr | 1995 |
More uses of known drugs.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Humans; Myocardial Infarction; Thr | 1995 |
Effect of aspirin treatment on plasma levels of keto PGF 1 alpha and thromboxane B2.
Topics: 6-Ketoprostaglandin F1 alpha; Arrhythmias, Cardiac; Aspirin; Case-Control Studies; Coronary Artery B | 1995 |
Effect of aspirin treatment on plasma levels of keto PGF 1 alpha and thromboxane B2.
Topics: 6-Ketoprostaglandin F1 alpha; Arrhythmias, Cardiac; Aspirin; Case-Control Studies; Coronary Artery B | 1995 |
Aspirin and suspected myocardial infarction: a life-saving treatment we too often forget.
Topics: Aspirin; Drug Utilization; Emergencies; Humans; Myocardial Infarction; Practice Patterns, Physicians | 1995 |
Aspirin and suspected myocardial infarction: a life-saving treatment we too often forget.
Topics: Aspirin; Drug Utilization; Emergencies; Humans; Myocardial Infarction; Practice Patterns, Physicians | 1995 |
Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiology Service, Hospital; Electrocardiography; Female; | 1994 |
Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiology Service, Hospital; Electrocardiography; Female; | 1994 |
[Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Anticoagulants; A | 1995 |
[Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Anticoagulants; A | 1995 |
[Thrombolytic treatment for acute myocardial infarction in menstruating women].
Topics: Adult; Angioplasty; Anticoagulants; Aspirin; Contraindications; Female; Heparin; Humans; Menstruatio | 1996 |
[Thrombolytic treatment for acute myocardial infarction in menstruating women].
Topics: Adult; Angioplasty; Anticoagulants; Aspirin; Contraindications; Female; Heparin; Humans; Menstruatio | 1996 |
Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Echocardiography; Female; Follow-Up Studies; Heart Diseases | 1996 |
Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Echocardiography; Female; Follow-Up Studies; Heart Diseases | 1996 |
[Prehospital management of acute myocardial infarct in an experimental metropolitan system of medical emergencies].
Topics: Adult; Age Distribution; Aged; Aspirin; Chest Pain; Electrocardiography; Emergency Medical Services; | 1996 |
[Prehospital management of acute myocardial infarct in an experimental metropolitan system of medical emergencies].
Topics: Adult; Age Distribution; Aged; Aspirin; Chest Pain; Electrocardiography; Emergency Medical Services; | 1996 |
Acute myocardial infarction in a patient with von Willebrand disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Female; Heparin; Humans; Myocardial I | 1996 |
Acute myocardial infarction in a patient with von Willebrand disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Female; Heparin; Humans; Myocardial I | 1996 |
Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Creatine Kinase; E-Selectin; Female; Heparin; Humans; Intercellular Adhesion M | 1996 |
Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Creatine Kinase; E-Selectin; Female; Heparin; Humans; Intercellular Adhesion M | 1996 |
Low dose aspirin and secondary myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors | 1996 |
Low dose aspirin and secondary myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors | 1996 |
Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Platelets; Blood Specimen Collection; | 1996 |
Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Platelets; Blood Specimen Collection; | 1996 |
ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug; | 1996 |
ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug; | 1996 |
The cooperative cardiovascular project an AFMC special report.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Arkansas; Aspirin; Combined Modality Th | 1996 |
The cooperative cardiovascular project an AFMC special report.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Arkansas; Aspirin; Combined Modality Th | 1996 |
[Epidemiology according to the European and French scales of myocardial infarction. Data of the MONICA project].
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspir | 1996 |
[Epidemiology according to the European and French scales of myocardial infarction. Data of the MONICA project].
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspir | 1996 |
Aspirin after myocardial infarction in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Humans; Myocardial Infarc | 1996 |
Aspirin after myocardial infarction in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Humans; Myocardial Infarc | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Meta-Analysis as Topic; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Meta-Analysis as Topic; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Medical management after myocardial infarction: an evidence-based perspective.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1996 |
Medical management after myocardial infarction: an evidence-based perspective.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1996 |
Anticoagulants in acute MI.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Humans; Meta-Analysis as Topic; Myocard | 1997 |
Anticoagulants in acute MI.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Humans; Meta-Analysis as Topic; Myocard | 1997 |
Racial differences in the medical treatment of elderly Medicare patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alabama; Algorithms; Aspirin; Black or African American; Female; | 1996 |
Racial differences in the medical treatment of elderly Medicare patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alabama; Algorithms; Aspirin; Black or African American; Female; | 1996 |
Clinical effects of anticoagulants in suspected acute myocardial infarction. Use of anticoagulants in suspected acute myocardial infarction in Europe varies.
Topics: Anticoagulants; Aspirin; Heparin; Humans; Myocardial Infarction; Retrospective Studies | 1997 |
Clinical effects of anticoagulants in suspected acute myocardial infarction. Use of anticoagulants in suspected acute myocardial infarction in Europe varies.
Topics: Anticoagulants; Aspirin; Heparin; Humans; Myocardial Infarction; Retrospective Studies | 1997 |
A survey of treatment routines and educational level of health care providers in the initial phase of suspected acute myocardial infarction in Sweden in 1994. Swedish Working Group on Early Heart Attack Care.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Educational Status; Emergency Medical Ser | 1996 |
A survey of treatment routines and educational level of health care providers in the initial phase of suspected acute myocardial infarction in Sweden in 1994. Swedish Working Group on Early Heart Attack Care.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Educational Status; Emergency Medical Ser | 1996 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Body Mass Index; Cerebrovascular Disorders; Cohort | 1997 |
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Body Mass Index; Cerebrovascular Disorders; Cohort | 1997 |
Gastric safety and enteric-coated aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infa | 1997 |
Gastric safety and enteric-coated aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infa | 1997 |
The effect of comorbidity on use of thrombolysis or aspirin in patients with acute myocardial infarction eligible for treatment.
Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Confidence Intervals; Decision Making; Female; Humans; L | 1997 |
The effect of comorbidity on use of thrombolysis or aspirin in patients with acute myocardial infarction eligible for treatment.
Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Confidence Intervals; Decision Making; Female; Humans; L | 1997 |
Do comorbidities influence the treatment of myocardial infarction?
Topics: Aspirin; Comorbidity; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibit | 1997 |
Do comorbidities influence the treatment of myocardial infarction?
Topics: Aspirin; Comorbidity; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibit | 1997 |
The management of acute myocardial infarction in a patient with polycythemia rubra vera during the thrombolytic era--does it make a difference?
Topics: Adult; Anticoagulants; Aspirin; Cardiac Catheterization; Coronary Angiography; Electrocardiography; | 1997 |
The management of acute myocardial infarction in a patient with polycythemia rubra vera during the thrombolytic era--does it make a difference?
Topics: Adult; Anticoagulants; Aspirin; Cardiac Catheterization; Coronary Angiography; Electrocardiography; | 1997 |
Aspirin's role in prevention now official.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Pla | 1997 |
Aspirin's role in prevention now official.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Pla | 1997 |
Use of early aspirin in suspected acute myocardial infarction by General Practitioners in Sri Lanka.
Topics: Adult; Aspirin; Family Practice; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; | 1997 |
Use of early aspirin in suspected acute myocardial infarction by General Practitioners in Sri Lanka.
Topics: Adult; Aspirin; Family Practice; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; | 1997 |
Thrombolysis after acute myocardial infarction: are Canadian physicians up to the challenge?
Topics: Aspirin; Canada; Coronary Thrombosis; Emergencies; Humans; Myocardial Infarction; Myocardial Reperfu | 1997 |
Thrombolysis after acute myocardial infarction: are Canadian physicians up to the challenge?
Topics: Aspirin; Canada; Coronary Thrombosis; Emergencies; Humans; Myocardial Infarction; Myocardial Reperfu | 1997 |
Aspirin after thrombolysis for MI.
Topics: Anistreplase; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; My | 1997 |
Aspirin after thrombolysis for MI.
Topics: Anistreplase; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; My | 1997 |
[Anticoagulation in transitory ischemic attack after bypass surgery].
Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Bypass; Coumarins; Heparin; Humans; Ischemic Attack, | 1997 |
[Anticoagulation in transitory ischemic attack after bypass surgery].
Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Bypass; Coumarins; Heparin; Humans; Ischemic Attack, | 1997 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A | 1997 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A | 1997 |
Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; | 1997 |
Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; | 1997 |
Outcome of unstable angina in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers; | 1997 |
Outcome of unstable angina in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers; | 1997 |
Myocardial infarction caused by coronary artery myocardial bridge.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atenolol; Cardiac Catheterization; Coronary Angio | 1997 |
Myocardial infarction caused by coronary artery myocardial bridge.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atenolol; Cardiac Catheterization; Coronary Angio | 1997 |
Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Asia; Aspirin; Autonomic Nervous System; Circadian Rhythm; Female | 1997 |
Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Asia; Aspirin; Autonomic Nervous System; Circadian Rhythm; Female | 1997 |
Cooperative Cardiovascular Project.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Medicare; Myocardial Infarction; Pilot Pro | 1997 |
Cooperative Cardiovascular Project.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Medicare; Myocardial Infarction; Pilot Pro | 1997 |
Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Drug Interactions; Humans; Myocardial Infarcti | 1997 |
Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Drug Interactions; Humans; Myocardial Infarcti | 1997 |
An audit of discharge medication for secondary prophylaxis post-myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Cont | 1996 |
An audit of discharge medication for secondary prophylaxis post-myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Cont | 1996 |
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation].
Topics: Adult; Aspirin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Middle Aged; Models | 1997 |
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation].
Topics: Adult; Aspirin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Middle Aged; Models | 1997 |
Patients with suspected myocardial infarction presenting with ST segment depression.
Topics: Aspirin; Electrocardiography; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 1997 |
Patients with suspected myocardial infarction presenting with ST segment depression.
Topics: Aspirin; Electrocardiography; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitor | 1997 |
Emergency department use of aspirin in patients with possible acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization; Emergency Service, Hospita | 1997 |
Emergency department use of aspirin in patients with possible acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization; Emergency Service, Hospita | 1997 |
[Early treatment of acute myocardial infarct: implementation of therapy guidelines in routine clinical practice, MITRA pilot phase].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 1997 |
[Early treatment of acute myocardial infarct: implementation of therapy guidelines in routine clinical practice, MITRA pilot phase].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
An aspirin a day: advice that makes sense.
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation | 1997 |
An aspirin a day: advice that makes sense.
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation | 1997 |
ASHP therapeutic position statement on the use of aspirin for prophylaxis of myocardial infarction.
Topics: Aged; Angina Pectoris; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Se | 1997 |
ASHP therapeutic position statement on the use of aspirin for prophylaxis of myocardial infarction.
Topics: Aged; Angina Pectoris; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Se | 1997 |
[Aspirin. A wonder drug?].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Fibrinolyti | 1997 |
[Aspirin. A wonder drug?].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Fibrinolyti | 1997 |
Prevention of subsequent coronary events.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1997 |
Prevention of subsequent coronary events.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1997 |
Treatment after myocardial infarction: changes in the last decade--a look back.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Female; Health Services A | 1997 |
Treatment after myocardial infarction: changes in the last decade--a look back.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Female; Health Services A | 1997 |
CARS trial: warfarin and thrombin generation. Coumadin Aspirin Reinfarction Study.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Thrombin; Thrombo | 1997 |
CARS trial: warfarin and thrombin generation. Coumadin Aspirin Reinfarction Study.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Thrombin; Thrombo | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin therapy in diabetic subjects post-myocardial infarction.
Topics: Aspirin; Diabetes Complications; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1997 |
Aspirin therapy in diabetic subjects post-myocardial infarction.
Topics: Aspirin; Diabetes Complications; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1997 |
The actual therapy and in-hospital mortality of acute myocardial infarction in Flanders. Mirracle's Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Belgium; Female; Fibrinolytic | 1997 |
The actual therapy and in-hospital mortality of acute myocardial infarction in Flanders. Mirracle's Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Belgium; Female; Fibrinolytic | 1997 |
[Low-dose ASA and infarct prophylaxis. Acetylsalicylic acid (ASA): low doses with high efficiency].
Topics: Angina, Unstable; Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 1995 |
[Low-dose ASA and infarct prophylaxis. Acetylsalicylic acid (ASA): low doses with high efficiency].
Topics: Angina, Unstable; Aspirin; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 1995 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular | 1997 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular | 1997 |
Thanks, Hippocrates, for the first miracle drug.
Topics: Aspirin; History, 19th Century; History, Ancient; Humans; Myocardial Infarction; Platelet Aggregatio | 1998 |
Thanks, Hippocrates, for the first miracle drug.
Topics: Aspirin; History, 19th Century; History, Ancient; Humans; Myocardial Infarction; Platelet Aggregatio | 1998 |
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Antigens, CD; Aspirin; Blood Platelets; Cerebral Hem | 1998 |
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Antigens, CD; Aspirin; Blood Platelets; Cerebral Hem | 1998 |
Aspirin, the poor man's statin?
Topics: Anticoagulants; Aspirin; Female; Humans; Lovastatin; Male; Myocardial Infarction; Platelet Aggregati | 1998 |
Aspirin, the poor man's statin?
Topics: Anticoagulants; Aspirin; Female; Humans; Lovastatin; Male; Myocardial Infarction; Platelet Aggregati | 1998 |
High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Con | 1998 |
High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Con | 1998 |
Management of suspected myocardial infarction before admission: updated audit.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Utilization Review; Emergency Medical Services; Family | 1998 |
Management of suspected myocardial infarction before admission: updated audit.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Utilization Review; Emergency Medical Services; Family | 1998 |
Resource use and quality of care for Medicare patients with acute myocardial infarction in Maryland and the District of Columbia: analysis of data from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; District of Columbia; Drug Utilization; Female; Health S | 1998 |
Resource use and quality of care for Medicare patients with acute myocardial infarction in Maryland and the District of Columbia: analysis of data from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; District of Columbia; Drug Utilization; Female; Health S | 1998 |
Comparative knowledge and practice of emergency physicians, cardiologists, and primary care practitioners regarding drug therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Cardiology; Chi-Square Distribution; Clinical Competenc | 1998 |
Comparative knowledge and practice of emergency physicians, cardiologists, and primary care practitioners regarding drug therapy for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Cardiology; Chi-Square Distribution; Clinical Competenc | 1998 |
C-reactive protein and risks of future myocardial infarction and thrombotic stroke.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Humans; Myocardial | 1998 |
C-reactive protein and risks of future myocardial infarction and thrombotic stroke.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Humans; Myocardial | 1998 |
Beta-blockers and antithrombotics for secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1998 |
Beta-blockers and antithrombotics for secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1998 |
Blocking platelets more: are we skating on thin ice?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Immunogl | 1998 |
Blocking platelets more: are we skating on thin ice?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Immunogl | 1998 |
Early and intermediate term clinical outcome after multiple coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Coron | 1998 |
Early and intermediate term clinical outcome after multiple coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Coron | 1998 |
Not enough people taking aspirin for heart benefits.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1998 |
Not enough people taking aspirin for heart benefits.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1998 |
Heart attack rehabilitation. Helping your heart heal.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Depression; Diet; Exercise; Human | 1998 |
Heart attack rehabilitation. Helping your heart heal.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Depression; Diet; Exercise; Human | 1998 |
Aspirin therapy for cardiovascular disease.
Topics: Aspirin; Health Care Surveys; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1997 |
Aspirin therapy for cardiovascular disease.
Topics: Aspirin; Health Care Surveys; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1997 |
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fa | 1997 |
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fa | 1997 |
[Acetylsalicylic acid in ischemic insult].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P | 1998 |
[Acetylsalicylic acid in ischemic insult].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P | 1998 |
Aspirin for prevention of myocardial infarction. A double-edged sword.
Topics: Aged; Aged, 80 and over; Anemia; Angina, Unstable; Aspirin; Female; Gastrointestinal Hemorrhage; Hum | 1997 |
Aspirin for prevention of myocardial infarction. A double-edged sword.
Topics: Aged; Aged, 80 and over; Anemia; Angina, Unstable; Aspirin; Female; Gastrointestinal Hemorrhage; Hum | 1997 |
Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Drug Administration Schedule; Heart Rate; Hemodynamics; | 1998 |
Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Drug Administration Schedule; Heart Rate; Hemodynamics; | 1998 |
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A | 1998 |
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A | 1998 |
Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Utilization; Female; Humans; Male; Middle Aged; Myocardial In | 1998 |
Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Utilization; Female; Humans; Male; Middle Aged; Myocardial In | 1998 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
Aspirin after myocardial infarction: the importance of over-the-counter use.
Topics: Age Distribution; Aged; Aspirin; Drug Utilization; Family Practice; Female; Humans; London; Male; Mi | 1998 |
Aspirin after myocardial infarction: the importance of over-the-counter use.
Topics: Age Distribution; Aged; Aspirin; Drug Utilization; Family Practice; Female; Humans; London; Male; Mi | 1998 |
Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? European Secondary Prevention Study Group.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fibrinolytic Agents; Hospital Mortal | 1998 |
Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? European Secondary Prevention Study Group.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fibrinolytic Agents; Hospital Mortal | 1998 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Austral | 1998 |
Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Austral | 1998 |
Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 1998 |
Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 1998 |
Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Enzyme-Linked Immunosorbent Assay; Female; Flow Cyt | 1998 |
Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Enzyme-Linked Immunosorbent Assay; Female; Flow Cyt | 1998 |
Acute coronary disease in essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aging; Antisickling Agents; Aspirin; Female; Follow-Up Studies; Humans; Hydroxyurea; Ma | 1998 |
Acute coronary disease in essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aging; Antisickling Agents; Aspirin; Female; Follow-Up Studies; Humans; Hydroxyurea; Ma | 1998 |
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary | 1998 |
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |
Trial is needed of ACE inhibitors plus beta blockers in survivors of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1998 |
Trial is needed of ACE inhibitors plus beta blockers in survivors of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1998 |
Consultation between cardiologists and generalists in the management of acute myocardial infarction: implications for quality of care.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Confounding Factors, Epidemiologic; Family Practice; Fem | 1998 |
Consultation between cardiologists and generalists in the management of acute myocardial infarction: implications for quality of care.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Confounding Factors, Epidemiologic; Family Practice; Fem | 1998 |
After your heart attack.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1998 |
After your heart attack.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1998 |
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1998 |
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Low molecular weight heparins in acute ischaemic syndromes.
Topics: Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; | 1998 |
Low molecular weight heparins in acute ischaemic syndromes.
Topics: Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; | 1998 |
New antiplatelet agents.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 1998 |
New antiplatelet agents.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1998 |
On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1998 |
Effect of acetylsalicylic acid on nitric oxide production in infarcted heart in situ.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Heart; Injections, In | 1998 |
Effect of acetylsalicylic acid on nitric oxide production in infarcted heart in situ.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Heart; Injections, In | 1998 |
ACE inhibitors in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1998 |
ACE inhibitors in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1998 |
Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Cause of Death; Coronary Ang | 1998 |
Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Cause of Death; Coronary Ang | 1998 |
[Evaluation of drug treatment of myocardial infarction in public hospitals of Andalusia. GAUME (Andalusian Group for performance of Studies on Drug Utilization)].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Drug Utilization; Female; Fibrinolytic Agents; Heparin; | 1998 |
[Evaluation of drug treatment of myocardial infarction in public hospitals of Andalusia. GAUME (Andalusian Group for performance of Studies on Drug Utilization)].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Drug Utilization; Female; Fibrinolytic Agents; Heparin; | 1998 |
Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Bayes Theorem; Breast Neoplasms; Humans; Meta-Analysis as | 1998 |
Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Bayes Theorem; Breast Neoplasms; Humans; Meta-Analysis as | 1998 |
Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary An | 1998 |
Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary An | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Management of non-Q-wave myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Risk Factors | 1998 |
Management of non-Q-wave myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Risk Factors | 1998 |
Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Humans; Hypertension; Myocardial Infarction; Pla | 1998 |
Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Humans; Hypertension; Myocardial Infarction; Pla | 1998 |
Is prophylactic treatment after myocardial infarction evidence-based?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1998 |
Is prophylactic treatment after myocardial infarction evidence-based?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1998 |
Coronary artery stent placement with postprocedural antiplatelet therapy in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Drug Therapy, Combination; Female; Hu | 1998 |
Coronary artery stent placement with postprocedural antiplatelet therapy in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Drug Therapy, Combination; Female; Hu | 1998 |
Prevalence of aspirin use among patients calling 9-1-1 for chest pain.
Topics: Acute Disease; Adult; Aged; Aspirin; Chest Pain; Cross-Sectional Studies; Drug Utilization; Emergenc | 1998 |
Prevalence of aspirin use among patients calling 9-1-1 for chest pain.
Topics: Acute Disease; Adult; Aged; Aspirin; Chest Pain; Cross-Sectional Studies; Drug Utilization; Emergenc | 1998 |
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co | 1998 |
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co | 1998 |
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef | 1998 |
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef | 1998 |
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Inf
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 1999 |
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Inf
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 1999 |
Eptifibatide in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Eptifibatide; Heparin; Humans; Myocardial Infarction; Pep | 1999 |
Eptifibatide in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Eptifibatide; Heparin; Humans; Myocardial Infarction; Pep | 1999 |
Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Pres | 1998 |
Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Pres | 1998 |
Aspirin therapy.
Topics: Aged; Aspirin; Drug Utilization; Electrocardiography; Humans; Mass Screening; Myocardial Infarction; | 1999 |
Aspirin therapy.
Topics: Aged; Aspirin; Drug Utilization; Electrocardiography; Humans; Mass Screening; Myocardial Infarction; | 1999 |
Do "America's Best Hospitals" perform better for acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Health Care Surv | 1999 |
Do "America's Best Hospitals" perform better for acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Female; Health Care Surv | 1999 |
Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent.
Topics: Animals; Aspirin; Contrast Media; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Heparin; Ima | 1999 |
Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent.
Topics: Animals; Aspirin; Contrast Media; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Heparin; Ima | 1999 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Cohort Studies; Data Interpretation, Sta | 1999 |
Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Cohort Studies; Data Interpretation, Sta | 1999 |
Patterns of practice for acute myocardial infarction in a population from ten countries.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Canada; Data Collection; Europe; Female; Fibrinol | 1999 |
Patterns of practice for acute myocardial infarction in a population from ten countries.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Canada; Data Collection; Europe; Female; Fibrinol | 1999 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastrointestinal Hemorrhage; Humans; My | 1999 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastrointestinal Hemorrhage; Humans; My | 1999 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhoids; Humans; Male; Myocardial Infarction; Platelet Agg | 1999 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhoids; Humans; Male; Myocardial Infarction; Platelet Agg | 1999 |
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Humans; Myocardial Infarction; Platele | 1999 |
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Humans; Myocardial Infarction; Platele | 1999 |
Aspirin and the risk of hemorrhagic stroke.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Humans; Male; Meta-Analysis as Topi | 1999 |
Aspirin and the risk of hemorrhagic stroke.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Humans; Male; Meta-Analysis as Topi | 1999 |
Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hypolipidemic Agent | 1999 |
Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hypolipidemic Agent | 1999 |
Regulating information about aspirin and the prevention of heart attack.
Topics: Aspirin; Community Participation; Cyclooxygenase Inhibitors; Drug Utilization; Health Education; Hea | 1995 |
Regulating information about aspirin and the prevention of heart attack.
Topics: Aspirin; Community Participation; Cyclooxygenase Inhibitors; Drug Utilization; Health Education; Hea | 1995 |
The management of stable angina.
Topics: Angina Pectoris; Angioplasty, Balloon; Aspirin; Cardiovascular Agents; Coronary Artery Bypass; Evide | 1997 |
The management of stable angina.
Topics: Angina Pectoris; Angioplasty, Balloon; Aspirin; Cardiovascular Agents; Coronary Artery Bypass; Evide | 1997 |
Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated?
Topics: Age Factors; Aged; Aspirin; Drug Prescriptions; Drug Utilization; Female; Health Care Surveys; Healt | 1998 |
Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated?
Topics: Age Factors; Aged; Aspirin; Drug Prescriptions; Drug Utilization; Female; Health Care Surveys; Healt | 1998 |
Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Coronary Vessels; Enzyme Activation; Epoprostenol; H | 1999 |
Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Coronary Vessels; Enzyme Activation; Epoprostenol; H | 1999 |
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders | 1999 |
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders | 1999 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analy | 1999 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analy | 1999 |
Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; C | 1999 |
Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; C | 1999 |
[Improved treatment of myocardial infarction--how has the hospital mortality developed?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Fibrinolytic Agents; Hospital Mortality; Humans; Myoca | 1999 |
[Improved treatment of myocardial infarction--how has the hospital mortality developed?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Fibrinolytic Agents; Hospital Mortality; Humans; Myoca | 1999 |
Ischemic heart attacks following cessation of aspirin before coronary artery bypass surgery: A report of two cases.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 1999 |
Ischemic heart attacks following cessation of aspirin before coronary artery bypass surgery: A report of two cases.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 1999 |
Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 1999 |
Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 1999 |
Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD.
Topics: Antihypertensive Agents; Aspirin; Cost of Illness; Cost-Benefit Analysis; Humans; Hypertension; Myoc | 1998 |
Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD.
Topics: Antihypertensive Agents; Aspirin; Cost of Illness; Cost-Benefit Analysis; Humans; Hypertension; Myoc | 1998 |
Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Enzyme Tests; Confidence Intervals; | 1999 |
Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Enzyme Tests; Confidence Intervals; | 1999 |
[Role of antiplatelet in the prevention and treatment of thrombotic diseases].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1997 |
[Role of antiplatelet in the prevention and treatment of thrombotic diseases].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1997 |
Myocardial infarction.
Topics: Aspirin; Diagnosis, Differential; Electrocardiography; Emergency Treatment; Fibrinolytic Agents; Hep | 1999 |
Myocardial infarction.
Topics: Aspirin; Diagnosis, Differential; Electrocardiography; Emergency Treatment; Fibrinolytic Agents; Hep | 1999 |
Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: results from a new analytical approach. European Secondary Prevention Study Group.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Fibrinolytic Agents; Hospital Mortality; Humans; Ma | 1999 |
Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: results from a new analytical approach. European Secondary Prevention Study Group.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Fibrinolytic Agents; Hospital Mortality; Humans; Ma | 1999 |
Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients.
Topics: Adult; Aged; Aspirin; Asthma; Desensitization, Immunologic; Diagnosis, Differential; Dose-Response R | 1999 |
Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients.
Topics: Adult; Aged; Aspirin; Asthma; Desensitization, Immunologic; Diagnosis, Differential; Dose-Response R | 1999 |
Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; | 1999 |
Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; | 1999 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre | 1999 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre | 1999 |
Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority.
Topics: Aspirin; Family Practice; Female; Humans; Male; Medical Audit; Myocardial Infarction; Platelet Aggre | 1999 |
Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority.
Topics: Aspirin; Family Practice; Female; Humans; Male; Medical Audit; Myocardial Infarction; Platelet Aggre | 1999 |
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY)
Topics: Angina, Unstable; Aspirin; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Myocard | 1999 |
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY)
Topics: Angina, Unstable; Aspirin; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Myocard | 1999 |
Is intensive drug therapy appropriate for older patients?
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorder | 1999 |
Is intensive drug therapy appropriate for older patients?
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorder | 1999 |
Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.
Topics: Adult; Age Distribution; Aged; Aspirin; Blood Pressure; Coronary Disease; Female; Hospitalization; H | 1999 |
Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.
Topics: Adult; Age Distribution; Aged; Aspirin; Blood Pressure; Coronary Disease; Female; Hospitalization; H | 1999 |
Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocard | 1999 |
Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocard | 1999 |
Heart failure: a diagnostic and therapeutic dilemma in elderly patients.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Death | 1999 |
Heart failure: a diagnostic and therapeutic dilemma in elderly patients.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Death | 1999 |
Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Female; Humans; Immunoenzyme Techniques; Male; Middle A | 1999 |
Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Female; Humans; Immunoenzyme Techniques; Male; Middle A | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Low-dose versus high-dose acetylsalicylic acid in carotid endarterectomy.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet | 1999 |
Low-dose versus high-dose acetylsalicylic acid in carotid endarterectomy.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet | 1999 |
Acute myocardial infarction-failed thrombolysis followed by severe upper gastrointestinal bleeding.
Topics: Aspirin; Fibrinolytic Agents; Follow-Up Studies; Hematemesis; Heparin; Humans; Male; Middle Aged; My | 1999 |
Acute myocardial infarction-failed thrombolysis followed by severe upper gastrointestinal bleeding.
Topics: Aspirin; Fibrinolytic Agents; Follow-Up Studies; Hematemesis; Heparin; Humans; Male; Middle Aged; My | 1999 |
Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee-for-service insurance.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Electrocardiography; Emergency Treatment; Fee-for-Servic | 1999 |
Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee-for-service insurance.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Electrocardiography; Emergency Treatment; Fee-for-Servic | 1999 |
[Ticlopidine-induced cholestasis].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Chemical and Drug Induced Liver Injury; Cholestas | 1999 |
[Ticlopidine-induced cholestasis].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Chemical and Drug Induced Liver Injury; Cholestas | 1999 |
Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin.
Topics: Aged; Aspirin; Cardiotonic Agents; Confidence Intervals; Female; Fibrinolytic Agents; Humans; Likeli | 1999 |
Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin.
Topics: Aged; Aspirin; Cardiotonic Agents; Confidence Intervals; Female; Fibrinolytic Agents; Humans; Likeli | 1999 |
A 42-year-old man with recurrent myocardial infarction and normal appearing coronary arteries.
Topics: Adult; Aspirin; Coronary Thrombosis; Humans; Male; Microvascular Angina; Myocardial Infarction; Plat | 1999 |
A 42-year-old man with recurrent myocardial infarction and normal appearing coronary arteries.
Topics: Adult; Aspirin; Coronary Thrombosis; Humans; Male; Microvascular Angina; Myocardial Infarction; Plat | 1999 |
[Acute myocardial infarction in Germany between 1996 and 1998: therapy and intrahospital course. Results of the Myocardial Infarction Registry (MIR) in Germany].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Combined Modal | 1999 |
[Acute myocardial infarction in Germany between 1996 and 1998: therapy and intrahospital course. Results of the Myocardial Infarction Registry (MIR) in Germany].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Combined Modal | 1999 |
Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Tr | 1999 |
Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Tr | 1999 |
[The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis].
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Coronary Disease; Drug Resistance; Female; Hospitali | 1999 |
[The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis].
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Coronary Disease; Drug Resistance; Female; Hospitali | 1999 |
Treatment of Acute MI. Institute for Clinical Systems Improvement.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspi | 1999 |
Treatment of Acute MI. Institute for Clinical Systems Improvement.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspi | 1999 |
Dialogue with a patient with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Exercise Test; Humans; | 1999 |
Dialogue with a patient with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Exercise Test; Humans; | 1999 |
Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.
Topics: Aspirin; Coronary Disease; Disease Management; Drug Therapy, Combination; Fibrinolytic Agents; Hepar | 2000 |
Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.
Topics: Aspirin; Coronary Disease; Disease Management; Drug Therapy, Combination; Fibrinolytic Agents; Hepar | 2000 |
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Circadian Rhythm; Drug Administrat | 1999 |
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Circadian Rhythm; Drug Administrat | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.
Topics: Administration, Oral; Aspirin; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Oximes; Piperi | 2000 |
Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.
Topics: Administration, Oral; Aspirin; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Oximes; Piperi | 2000 |
Introduction: Expanding the horizons in unstable coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Disease Man | 2000 |
Introduction: Expanding the horizons in unstable coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Disease Man | 2000 |
May aspirin be replaced in the treatment of myocardial infarction?
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Salicylates | 2000 |
May aspirin be replaced in the treatment of myocardial infarction?
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Salicylates | 2000 |
Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Anticholesteremic Agents; Aspirin; Clinical Trials as | 2000 |
Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Anticholesteremic Agents; Aspirin; Clinical Trials as | 2000 |
Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States.
Topics: Aged; Aspirin; Cohort Studies; Combined Modality Therapy; Databases, Factual; Drug Therapy; Female; | 2000 |
Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States.
Topics: Aged; Aspirin; Cohort Studies; Combined Modality Therapy; Databases, Factual; Drug Therapy; Female; | 2000 |
Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Aspirin; Creatine Kinase; Dose-Response Relat | 2000 |
Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Aspirin; Creatine Kinase; Dose-Response Relat | 2000 |
Relation of plasma lipoprotein(a) with myocardial viability and left ventricular performance in survivors of myocardial infarction.
Topics: Adult; Aspirin; Coronary Angiography; Female; Heart; Humans; Lipoprotein(a); Male; Middle Aged; Myoc | 1999 |
Relation of plasma lipoprotein(a) with myocardial viability and left ventricular performance in survivors of myocardial infarction.
Topics: Adult; Aspirin; Coronary Angiography; Female; Heart; Humans; Lipoprotein(a); Male; Middle Aged; Myoc | 1999 |
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts.
Topics: Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts.
Topics: Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
The ABC's of AMI.
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Choleste | 2000 |
The ABC's of AMI.
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Choleste | 2000 |
[Check list for the use of thrombolytics and other drugs in acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Fib | 2000 |
[Check list for the use of thrombolytics and other drugs in acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Fib | 2000 |
[Acute myocardial infarction: time delay from onset of pain to hospital presentation and thrombolysis].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Chest Pain; Coronary Disease; Female; Hospital | 2000 |
[Acute myocardial infarction: time delay from onset of pain to hospital presentation and thrombolysis].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Chest Pain; Coronary Disease; Female; Hospital | 2000 |
Aspirin to prevent strokes: fact or fiction?
Topics: Aged; Aspirin; Cerebral Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 2000 |
Aspirin to prevent strokes: fact or fiction?
Topics: Aged; Aspirin; Cerebral Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 2000 |
Physicians' recommendations for patients who undergo noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Chann | 2000 |
Physicians' recommendations for patients who undergo noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Chann | 2000 |
Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Confidence Intervals; Electrocardiography; F | 2000 |
Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Confidence Intervals; Electrocardiography; F | 2000 |
Outcome in patients with symptomatic occlusion of the internal carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Outcome in patients with symptomatic occlusion of the internal carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Beyond willow bark: aspirin in the prevention of chronic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Myocardial Infarction; Pr | 2000 |
Beyond willow bark: aspirin in the prevention of chronic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Myocardial Infarction; Pr | 2000 |
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Humans; | 2000 |
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Humans; | 2000 |
Treatment of acute myocardial infarction and 30-day mortality among women and men.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2000 |
Treatment of acute myocardial infarction and 30-day mortality among women and men.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2000 |
[ASA or clopidogrel?].
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Costs; Humans; Myocardial Infarction | 2000 |
[ASA or clopidogrel?].
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Costs; Humans; Myocardial Infarction | 2000 |
[Acute myocardial infarction: management, prognosis and survival].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2000 |
[Acute myocardial infarction: management, prognosis and survival].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2000 |
Patterns of aspirin use before hospitalization for acute myocardial infarction.
Topics: Aged; Aspirin; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 2000 |
Patterns of aspirin use before hospitalization for acute myocardial infarction.
Topics: Aged; Aspirin; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 2000 |
Heparin should be administered to every patient admitted to the hospital with possible unstable angina.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myoc | 2000 |
Heparin should be administered to every patient admitted to the hospital with possible unstable angina.
Topics: Angina, Unstable; Aspirin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myoc | 2000 |
Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization.
Topics: Analysis of Variance; Animals; Aspirin; Coronary Thrombosis; Disease Models, Animal; Female; Male; M | 2000 |
Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization.
Topics: Analysis of Variance; Animals; Aspirin; Coronary Thrombosis; Disease Models, Animal; Female; Male; M | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; | 2000 |
Improving patient outcomes in heart failure: evidence and barriers.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2000 |
Improving patient outcomes in heart failure: evidence and barriers.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Hip Fractures; Humans; Male; Myocardial Infarction; P | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Hip Fractures; Humans; Male; Myocardial Infarction; P | 2000 |
The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Enzyme | 2000 |
The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Enzyme | 2000 |
[Myocardial infarction, pregnancy and anesthesia].
Topics: Adrenergic beta-Antagonists; Adult; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesic | 2000 |
[Myocardial infarction, pregnancy and anesthesia].
Topics: Adrenergic beta-Antagonists; Adult; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesic | 2000 |
The Hypertension Optimal Treatment Study: what did it give us?
Topics: Aged; Aspirin; Blood Pressure; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypertension; Mid | 1999 |
The Hypertension Optimal Treatment Study: what did it give us?
Topics: Aged; Aspirin; Blood Pressure; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypertension; Mid | 1999 |
Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cohort Studies; Coronary D | 2000 |
Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cohort Studies; Coronary D | 2000 |
Transcatheter closure of post-infarction ventricular septal defect with the Amplatzer Septal Occluder device.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Follow-Up Studies; Heart Sep | 2000 |
Transcatheter closure of post-infarction ventricular septal defect with the Amplatzer Septal Occluder device.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Follow-Up Studies; Heart Sep | 2000 |
[One-year follow-up of a population of patients with angina. Factors influencing mortality and occurrence of cardiovascular events. Results of the ELAN study].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Anti-Infl | 2000 |
[One-year follow-up of a population of patients with angina. Factors influencing mortality and occurrence of cardiovascular events. Results of the ELAN study].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Anti-Infl | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
The Bussola study. Final results, conclusions and proposals.
Topics: Anticoagulants; Aspirin; Brazil; Clinical Competence; Emergency Service, Hospital; Hospitals, Privat | 2000 |
The Bussola study. Final results, conclusions and proposals.
Topics: Anticoagulants; Aspirin; Brazil; Clinical Competence; Emergency Service, Hospital; Hospitals, Privat | 2000 |
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2000 |
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2000 |
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors | 2000 |
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors | 2000 |
Tests for homogeneity of the risk ratio in a series of 2x2 tables.
Topics: Aspirin; Binomial Distribution; Biometry; Humans; Meta-Analysis as Topic; Monte Carlo Method; Multic | 2000 |
Tests for homogeneity of the risk ratio in a series of 2x2 tables.
Topics: Aspirin; Binomial Distribution; Biometry; Humans; Meta-Analysis as Topic; Monte Carlo Method; Multic | 2000 |
Acute myocardial infarction in women: contribution of treatment variables to adverse outcome.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Disease-Free Survival; Female; Fibrinolytic Agents; Huma | 2000 |
Acute myocardial infarction in women: contribution of treatment variables to adverse outcome.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Disease-Free Survival; Female; Fibrinolytic Agents; Huma | 2000 |
[Comparison of acute myocardial infarct in the old and new lands of unified Germany, 1996-1998. Data of the Myocardial Infarct Register (MIR)].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2000 |
[Comparison of acute myocardial infarct in the old and new lands of unified Germany, 1996-1998. Data of the Myocardial Infarct Register (MIR)].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2000 |
Defining quality at Catholic Healthcare West.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Health Facilit | 2000 |
Defining quality at Catholic Healthcare West.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Health Facilit | 2000 |
Trends in acute myocardial infarction management: use of the National Registry ofMyocardial Infarction in quality improvement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benchmarking; Cardiotonic Agents; Databases, Factu | 2000 |
Trends in acute myocardial infarction management: use of the National Registry ofMyocardial Infarction in quality improvement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benchmarking; Cardiotonic Agents; Databases, Factu | 2000 |
Association of physician and hospital volume with use of aspirin and reperfusion therapy in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Drug Utilization Review; Female; Fibrinolytic Agents; Health Services Research | 2000 |
Association of physician and hospital volume with use of aspirin and reperfusion therapy in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Drug Utilization Review; Female; Fibrinolytic Agents; Health Services Research | 2000 |
Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Fema | 2000 |
Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Fema | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
Take an aspirin or have a drink: antecedent aspirin and moderate alcohol consumption similarly affect baseline platelet characteristics in patients with acute myocardial infarction.
Topics: Alcohol Drinking; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation | 2000 |
Take an aspirin or have a drink: antecedent aspirin and moderate alcohol consumption similarly affect baseline platelet characteristics in patients with acute myocardial infarction.
Topics: Alcohol Drinking; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation | 2000 |
Is optimal antithrombotic therapy after myocardial infarction well defined?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregati | 2001 |
Is optimal antithrombotic therapy after myocardial infarction well defined?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregati | 2001 |
Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Germany; Hospitalization; Hospitals, Community; Hum | 2001 |
Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Germany; Hospitalization; Hospitals, Community; Hum | 2001 |
Chest pain rule-out MI clinical pathway saves $183,000.
Topics: Aspirin; Chest Pain; Colorado; Cost Savings; Critical Pathways; Diagnosis, Differential; Exercise Te | 1999 |
Chest pain rule-out MI clinical pathway saves $183,000.
Topics: Aspirin; Chest Pain; Colorado; Cost Savings; Critical Pathways; Diagnosis, Differential; Exercise Te | 1999 |
Aspirin for primary prevention. Doctors and patients should understand potential benefits and risks of aspirin treatment.
Topics: Aspirin; Awareness; Clinical Trials as Topic; Humans; Informed Consent; Meta-Analysis as Topic; Myoc | 2000 |
Aspirin for primary prevention. Doctors and patients should understand potential benefits and risks of aspirin treatment.
Topics: Aspirin; Awareness; Clinical Trials as Topic; Humans; Informed Consent; Meta-Analysis as Topic; Myoc | 2000 |
Estimating the prevalence of aspirin use in the prevention of myocardial infarction.
Topics: Algorithms; Aspirin; Chemoprevention; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2000 |
Estimating the prevalence of aspirin use in the prevention of myocardial infarction.
Topics: Algorithms; Aspirin; Chemoprevention; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2000 |
Aspirin for healthy hearts.
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors | 2001 |
Aspirin for healthy hearts.
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors | 2001 |
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulatio | 2000 |
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulatio | 2000 |
Thrombolytic therapy impact on prognosis after twelve months of first acute myocardial infarction.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Male; Multivariate A | 2000 |
Thrombolytic therapy impact on prognosis after twelve months of first acute myocardial infarction.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Male; Multivariate A | 2000 |
Changes in the use of medications after acute myocardial infarction: possible impact on mortality after myocardial infarction and long-term outcome.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myo | 2001 |
Changes in the use of medications after acute myocardial infarction: possible impact on mortality after myocardial infarction and long-term outcome.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myo | 2001 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2001 |
Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2001 |
Management of myocardial infarction in the very elderly--impact of clinical effectiveness on practice.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electrocardiography; Fema | 2000 |
Management of myocardial infarction in the very elderly--impact of clinical effectiveness on practice.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electrocardiography; Fema | 2000 |
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2001 |
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2001 |
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty; Aspirin; Delivery of Health Care; Humans; Medicare; Myocar | 2001 |
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty; Aspirin; Delivery of Health Care; Humans; Medicare; Myocar | 2001 |
Changing face of acute myocardial infarction in east London: a prospective cohort study of trends in management and outcome in the reperfusion era.
Topics: Aged; Aspirin; Emergency Medical Services; Female; Fibrinolytic Agents; Hospital Mortality; Humans; | 2001 |
Changing face of acute myocardial infarction in east London: a prospective cohort study of trends in management and outcome in the reperfusion era.
Topics: Aged; Aspirin; Emergency Medical Services; Female; Fibrinolytic Agents; Hospital Mortality; Humans; | 2001 |
Population factors not addressed in cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Humans; Male; Myocardial I | 2001 |
Population factors not addressed in cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Humans; Male; Myocardial I | 2001 |
A comparison of statistical methods for meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Computer Simulation; Hum | 2001 |
A comparison of statistical methods for meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Computer Simulation; Hum | 2001 |
Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Drug Therapy, Combination; | 2001 |
Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Drug Therapy, Combination; | 2001 |
The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Creatine Kinase; Cyclic GMP; Fibrinolytic Agents; Hemodynami | 2001 |
The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Creatine Kinase; Cyclic GMP; Fibrinolytic Agents; Hemodynami | 2001 |
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol, L | 2001 |
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol, L | 2001 |
The effect of aspirin on C-reactive protein as a marker of risk in unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Follow-Up S | 2001 |
The effect of aspirin on C-reactive protein as a marker of risk in unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Follow-Up S | 2001 |
Benefit of aspirin plus angiotensin-converting enzyme inhibitor.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, Combination; Humans; Myocardial Inf | 2001 |
Benefit of aspirin plus angiotensin-converting enzyme inhibitor.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, Combination; Humans; Myocardial Inf | 2001 |
Treatment of patients with myocardial infarction who present with a paced rhythm.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardi | 2001 |
Treatment of patients with myocardial infarction who present with a paced rhythm.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardi | 2001 |
Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Cir | 2001 |
Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Cir | 2001 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Timing of aspirin administration in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Electrocardiography; Emergencies; Emergency Service, Hospital | 2001 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Timing of aspirin administration in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Electrocardiography; Emergencies; Emergency Service, Hospital | 2001 |
Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Comorbidity; Coronary Thrombosis; Creat | 2001 |
Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Comorbidity; Coronary Thrombosis; Creat | 2001 |
A study of the use of aspirin by general practitioners in suspected myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chest Pain; Data Collection; Drug Utilization; Family Practi | 2001 |
A study of the use of aspirin by general practitioners in suspected myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chest Pain; Data Collection; Drug Utilization; Family Practi | 2001 |
Summaries for patients. Treatment and outcomes of heart attacks in people with pacemakers.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardi | 2001 |
Summaries for patients. Treatment and outcomes of heart attacks in people with pacemakers.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardi | 2001 |
[Acute heart attacks. Prognosis can be further improved].
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combinati | 2001 |
[Acute heart attacks. Prognosis can be further improved].
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combinati | 2001 |
Is treatment with aspirin combined with dipyridamole really more cost-effective than aspirin alone?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Cost-Benefit Analysis; Dipyridamole; D | 2001 |
Is treatment with aspirin combined with dipyridamole really more cost-effective than aspirin alone?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Cost-Benefit Analysis; Dipyridamole; D | 2001 |
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic; | 2001 |
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic; | 2001 |
CURE--clopidogrel's major advance.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate | 2001 |
CURE--clopidogrel's major advance.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate | 2001 |
Interfering with healing: the benefits of intervention during acute myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cytokines; Emergen | 2001 |
Interfering with healing: the benefits of intervention during acute myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cytokines; Emergen | 2001 |
Quality of medical care and excess mortality in older patients with mental disorders.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2001 |
Quality of medical care and excess mortality in older patients with mental disorders.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2001 |
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2001 |
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2001 |
The real cost of aspirin.
Topics: Anticoagulants; Aspirin; Humans; International Normalized Ratio; Myocardial Infarction; Platelet Agg | 2001 |
The real cost of aspirin.
Topics: Anticoagulants; Aspirin; Humans; International Normalized Ratio; Myocardial Infarction; Platelet Agg | 2001 |
Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Cross- | 2001 |
Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Cross- | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anticholesteremic Agents; Aspirin; Calcium Chann | 2001 |
Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anticholesteremic Agents; Aspirin; Calcium Chann | 2001 |
[Changes in the patterns of drug prescription for acute myocardial infarct. Comparison of 2 periods].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2001 |
[Changes in the patterns of drug prescription for acute myocardial infarct. Comparison of 2 periods].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Aspirin intake and the use of serum ferritin as a measure of iron status.
Topics: Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cy | 2001 |
Aspirin intake and the use of serum ferritin as a measure of iron status.
Topics: Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cy | 2001 |
Aspirin and percutaneous coronary angioplasty are associated with a decline in mortality from cardiogenic shock. Results from a national Israeli survey, 1992--1998.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Coronary Angiography; Female; Health | 2001 |
Aspirin and percutaneous coronary angioplasty are associated with a decline in mortality from cardiogenic shock. Results from a national Israeli survey, 1992--1998.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Coronary Angiography; Female; Health | 2001 |
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
Topics: Angina Pectoris; Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Multicenter Studies as T | 2001 |
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
Topics: Angina Pectoris; Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Multicenter Studies as T | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Myocardial Infarction; Naprox | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Myocardial Infarction; Naprox | 2001 |
Clopidogrel: new preparation. An alternative to aspirin.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; S | 1999 |
Clopidogrel: new preparation. An alternative to aspirin.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; S | 1999 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Clopido | 2001 |
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Clopido | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cough; Female; Humans; Hypertension; Male; | 2001 |
The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cough; Female; Humans; Hypertension; Male; | 2001 |
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Clopidogrel; Female; Humans; Male | 2001 |
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Clopidogrel; Female; Humans; Male | 2001 |
Acute myocardial infarction 2000 treatment.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Myocardial In | 2001 |
Acute myocardial infarction 2000 treatment.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Myocardial In | 2001 |
Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: A community-wide perspective.
Topics: Acute Disease; Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibit | 2001 |
Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: A community-wide perspective.
Topics: Acute Disease; Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibit | 2001 |
Coronary stent thrombosis: insights from the porcine coronary stent model.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess | 2001 |
Coronary stent thrombosis: insights from the porcine coronary stent model.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess | 2001 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2001 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2001 |
Guidelines for the management of patients with chronic stable angina: treatment.
Topics: Adrenergic beta-Antagonists; Adult; Algorithms; Angina Pectoris; Aspirin; Calcium Channel Blockers; | 2001 |
Guidelines for the management of patients with chronic stable angina: treatment.
Topics: Adrenergic beta-Antagonists; Adult; Algorithms; Angina Pectoris; Aspirin; Calcium Channel Blockers; | 2001 |
Care of acute myocardial infarction in Oklahoma: an update from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2001 |
Care of acute myocardial infarction in Oklahoma: an update from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2001 |
Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina Pectoris; Aspirin; Case-Control Stud | 2001 |
Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina Pectoris; Aspirin; Case-Control Stud | 2001 |
Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics?
Topics: Acute Disease; Aspirin; Clinical Protocols; Emergency Medical Services; Emergency Medical Technician | 2001 |
Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics?
Topics: Acute Disease; Aspirin; Clinical Protocols; Emergency Medical Services; Emergency Medical Technician | 2001 |
Predictors of long-term outcomes following direct percutaneous coronary intervention for acute myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Disease- | 2001 |
Predictors of long-term outcomes following direct percutaneous coronary intervention for acute myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Disease- | 2001 |
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Angioplasty, | 2001 |
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Angioplasty, | 2001 |
Preoperative and immediate postoperative aspirin also reduces morbidity.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Myocardial Infarction; Postoperative C | 2001 |
Preoperative and immediate postoperative aspirin also reduces morbidity.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Myocardial Infarction; Postoperative C | 2001 |
Comparison of use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Comparison of use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Initiative raises use of interventions that prevent second heart attacks.
Topics: Adrenergic beta-Antagonists; Aspirin; Cholesterol; Humans; Hypolipidemic Agents; Myocardial Infarcti | 2000 |
Initiative raises use of interventions that prevent second heart attacks.
Topics: Adrenergic beta-Antagonists; Aspirin; Cholesterol; Humans; Hypolipidemic Agents; Myocardial Infarcti | 2000 |
Acute myocardial infarction in the young--The University of Michigan experience.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Anticoagulants; Aspirin; Coronary Artery B | 2002 |
Acute myocardial infarction in the young--The University of Michigan experience.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Anticoagulants; Aspirin; Coronary Artery B | 2002 |
beta-Thromboglobulin in patients with acute myocardial infarction according to the treatment.
Topics: Aspirin; beta-Thromboglobulin; Case-Control Studies; Female; Heparin; Humans; Male; Middle Aged; Myo | 2001 |
beta-Thromboglobulin in patients with acute myocardial infarction according to the treatment.
Topics: Aspirin; beta-Thromboglobulin; Case-Control Studies; Female; Heparin; Humans; Male; Middle Aged; Myo | 2001 |
Preventing atherosclerotic events with aspirin.
Topics: Arteriosclerosis; Aspirin; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregati | 2002 |
Preventing atherosclerotic events with aspirin.
Topics: Arteriosclerosis; Aspirin; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregati | 2002 |
[Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project].
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarct | 2001 |
[Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project].
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarct | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic A | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic A | 2001 |
[Primary prevention of coronary thrombosis by antithrombotic agents].
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Myocardial Infarction; Preventive Me | 2001 |
[Primary prevention of coronary thrombosis by antithrombotic agents].
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Myocardial Infarction; Preventive Me | 2001 |
Thrombolytic therapy after cardiac arrest and its effect on neurological outcome.
Topics: Aged; Aspirin; Cardiopulmonary Resuscitation; Case-Control Studies; Cerebrovascular Circulation; Con | 2002 |
Thrombolytic therapy after cardiac arrest and its effect on neurological outcome.
Topics: Aged; Aspirin; Cardiopulmonary Resuscitation; Case-Control Studies; Cerebrovascular Circulation; Con | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
Topics: Animals; Anticoagulants; Arteriosclerosis; Aspirin; Fibrinolytic Agents; Heparin; Humans; Lipoprotei | 2002 |
Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
Topics: Animals; Anticoagulants; Arteriosclerosis; Aspirin; Fibrinolytic Agents; Heparin; Humans; Lipoprotei | 2002 |
Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2002 |
Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2002 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; C | 2002 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; C | 2002 |
Chronic aspirin is effective--if data are massaged sufficiently.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Data Interpretation, Statistical; Humans; Myocardi | 2002 |
Chronic aspirin is effective--if data are massaged sufficiently.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Data Interpretation, Statistical; Humans; Myocardi | 2002 |
Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Middle Aged; Myocardia | 2002 |
Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Middle Aged; Myocardia | 2002 |
Mental disorders and quality of care among postacute myocardial infarction outpatients.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anticholesteremic Agents; Aspirin | 2002 |
Mental disorders and quality of care among postacute myocardial infarction outpatients.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anticholesteremic Agents; Aspirin | 2002 |
Clopidogrel--a myocardial infarction CURE?
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2001 |
Clopidogrel--a myocardial infarction CURE?
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation | 2001 |
Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hu | 2002 |
Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hu | 2002 |
Nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fibrinolytic Agents; Humans; Male; M | 2002 |
Nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fibrinolytic Agents; Humans; Male; M | 2002 |
NSAIDs and a lower risk of prostate cancer: causation or confounding?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Causality; Confounding Factors, Epidemiologi | 2002 |
NSAIDs and a lower risk of prostate cancer: causation or confounding?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Causality; Confounding Factors, Epidemiologi | 2002 |
Underuse of aspirin in a referral population with documented coronary artery disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Follow-Up Stu | 2002 |
Underuse of aspirin in a referral population with documented coronary artery disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Follow-Up Stu | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
Fallibility in estimating direct effects.
Topics: Aspirin; Bias; Causality; Confounding Factors, Epidemiologic; Epidemiologic Research Design; Humans; | 2002 |
Fallibility in estimating direct effects.
Topics: Aspirin; Bias; Causality; Confounding Factors, Epidemiologic; Epidemiologic Research Design; Humans; | 2002 |
Commentary: estimating direct and indirect effects-fallible in theory, but in the real world?
Topics: Aspirin; Bias; Epidemiologic Research Design; Humans; Myocardial Infarction; Platelet Aggregation In | 2002 |
Commentary: estimating direct and indirect effects-fallible in theory, but in the real world?
Topics: Aspirin; Bias; Epidemiologic Research Design; Humans; Myocardial Infarction; Platelet Aggregation In | 2002 |
Natural history of small and medium-sized side branches after coronary stent implantation.
Topics: Acute Disease; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary An | 2002 |
Natural history of small and medium-sized side branches after coronary stent implantation.
Topics: Acute Disease; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary An | 2002 |
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Diseases; Case-Contr | 2002 |
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Diseases; Case-Contr | 2002 |
Atherosclerosis: the new view.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Arterie | 2002 |
Atherosclerosis: the new view.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Arterie | 2002 |
Who should be taking aspirin?
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2002 |
Who should be taking aspirin?
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2002 |
NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Coronary Disease; E | 2002 |
NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Coronary Disease; E | 2002 |
Challenging the conclusions drawn in "Thrombolysis for acute myocardial infarction: drug review".
Topics: Aged; Aspirin; Clinical Trials as Topic; Contraindications; Fibrinolytic Agents; Humans; Meta-Analys | 2002 |
Challenging the conclusions drawn in "Thrombolysis for acute myocardial infarction: drug review".
Topics: Aged; Aspirin; Clinical Trials as Topic; Contraindications; Fibrinolytic Agents; Humans; Meta-Analys | 2002 |
GAP program improves patients' quality of care.
Topics: Adrenergic beta-Antagonists; Aspirin; Case Management; Critical Pathways; Humans; Myocardial Infarct | 2002 |
GAP program improves patients' quality of care.
Topics: Adrenergic beta-Antagonists; Aspirin; Case Management; Critical Pathways; Humans; Myocardial Infarct | 2002 |
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocar | 2002 |
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocar | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
An aspirin a day keeps the MI away (for some).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Antagonism; H | 2002 |
An aspirin a day keeps the MI away (for some).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Antagonism; H | 2002 |
Absolute and relative truth in clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Heparin; Hirudin Therapy; Hirudins | 2002 |
Absolute and relative truth in clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Heparin; Hirudin Therapy; Hirudins | 2002 |
Studies on the signal cascade mechanism mediating the cardioprotective actions of bradykinin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Bradykinin; Female; Heart Ventricles; Li | 2002 |
Studies on the signal cascade mechanism mediating the cardioprotective actions of bradykinin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Bradykinin; Female; Heart Ventricles; Li | 2002 |
[Risk improves effectiveness. Proper administration of platelet aggregation inhibitors].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2002 |
[Risk improves effectiveness. Proper administration of platelet aggregation inhibitors].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2002 |
[Acetylsalicylic acid for cardiovascular risk patients. Placebo or life safer?].
Topics: Aspirin; Cerebral Infarction; Humans; Myocardial Infarction; Risk; Survival Rate | 2002 |
[Acetylsalicylic acid for cardiovascular risk patients. Placebo or life safer?].
Topics: Aspirin; Cerebral Infarction; Humans; Myocardial Infarction; Risk; Survival Rate | 2002 |
Early statin initiation and outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase | 2002 |
Early statin initiation and outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase | 2002 |
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
Topics: Abciximab; Aged; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Biomarkers; Creatinine; Female; H | 2002 |
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
Topics: Abciximab; Aged; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Biomarkers; Creatinine; Female; H | 2002 |
Platelet function and myocardial injury during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Aspirin; Biomarkers; Cardiac Surgical Procedures; Female; Humans; Intraoperat | 2002 |
Platelet function and myocardial injury during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Aspirin; Biomarkers; Cardiac Surgical Procedures; Female; Humans; Intraoperat | 2002 |
[Arteriosclerosis and thrombocyte aggregation].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction; Platelet Aggr | 1977 |
[Arteriosclerosis and thrombocyte aggregation].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Aspirin; Humans; Myocardial Infarction; Platelet Aggr | 1977 |
Platelets, lipids, and myocardial infarction.
Topics: Aspirin; Chloroquine; Fatty Acids, Unsaturated; Humans; Myocardial Infarction; Prostaglandin Antagon | 1977 |
Platelets, lipids, and myocardial infarction.
Topics: Aspirin; Chloroquine; Fatty Acids, Unsaturated; Humans; Myocardial Infarction; Prostaglandin Antagon | 1977 |
Methods for detection of hypersensitive platelets. Philadelphia, June 1977.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiovascular | 1978 |
Methods for detection of hypersensitive platelets. Philadelphia, June 1977.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiovascular | 1978 |
The effect of heparin and acetysal on blood platelet functions in coronary sclerosis.
Topics: Adult; Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Heparin; Humans; Myocardial Infa | 1978 |
The effect of heparin and acetysal on blood platelet functions in coronary sclerosis.
Topics: Adult; Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Heparin; Humans; Myocardial Infa | 1978 |
Psotcardiotomy syndrome: pathogenesis and management.
Topics: Adrenal Cortex Hormones; Antibodies; Antigen-Antibody Complex; Aspirin; Heart Diseases; Hemorrhage; | 1976 |
Psotcardiotomy syndrome: pathogenesis and management.
Topics: Adrenal Cortex Hormones; Antibodies; Antigen-Antibody Complex; Aspirin; Heart Diseases; Hemorrhage; | 1976 |
[Therapeutic effectiveness of aspirin].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Recurrence; Thromboembolism | 1978 |
[Therapeutic effectiveness of aspirin].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Recurrence; Thromboembolism | 1978 |
Dietary PUFAs, lipid peroxides, atherosclerosis, aspirin.
Topics: Animals; Arteriosclerosis; Aspirin; Cats; Dietary Fats; Fatty Acids, Unsaturated; Humans; Lipid Pero | 1979 |
Dietary PUFAs, lipid peroxides, atherosclerosis, aspirin.
Topics: Animals; Arteriosclerosis; Aspirin; Cats; Dietary Fats; Fatty Acids, Unsaturated; Humans; Lipid Pero | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
[Platelet function in patients with acute myocardial infarct following administration of acetylsalicylic acid and dipyridamole].
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infarct | 1979 |
[Platelet function in patients with acute myocardial infarct following administration of acetylsalicylic acid and dipyridamole].
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infarct | 1979 |
Statistical evidence of the German-Austrian secondary prevention trial.
Topics: Actuarial Analysis; Aspirin; Austria; Germany; Humans; Myocardial Infarction; Phenprocoumon; Recurre | 1979 |
Statistical evidence of the German-Austrian secondary prevention trial.
Topics: Actuarial Analysis; Aspirin; Austria; Germany; Humans; Myocardial Infarction; Phenprocoumon; Recurre | 1979 |
Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
Topics: Adult; Arachidonic Acids; Aspirin; Blood Platelets; Coronary Disease; Dose-Response Relationship, Dr | 1979 |
Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
Topics: Adult; Arachidonic Acids; Aspirin; Blood Platelets; Coronary Disease; Dose-Response Relationship, Dr | 1979 |
Aspirin: new uses for an old drug.
Topics: Aspirin; Bartter Syndrome; Diabetic Angiopathies; Ductus Arteriosus, Patent; Humans; Myocardial Infa | 1979 |
Aspirin: new uses for an old drug.
Topics: Aspirin; Bartter Syndrome; Diabetic Angiopathies; Ductus Arteriosus, Patent; Humans; Myocardial Infa | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
[The role of the platelets in myocardial infarction induced by isoproterenol in the rat (author's transl)].
Topics: Animals; Aspirin; Calcium; Coronary Circulation; Coronary Vessels; Isoproterenol; Myocardial Infarct | 1979 |
[The role of the platelets in myocardial infarction induced by isoproterenol in the rat (author's transl)].
Topics: Animals; Aspirin; Calcium; Coronary Circulation; Coronary Vessels; Isoproterenol; Myocardial Infarct | 1979 |
[Prevention and therapy with anticoagulants. Indications, experiences, results].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; | 1979 |
[Prevention and therapy with anticoagulants. Indications, experiences, results].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; | 1979 |
Platelet suppressing drugs in arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial | 1978 |
Platelet suppressing drugs in arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial | 1978 |
[Acetylsalicylic acid and myocardial infarction].
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction | 1977 |
[Acetylsalicylic acid and myocardial infarction].
Topics: Aged; Aspirin; Humans; Middle Aged; Myocardial Infarction | 1977 |
[Lysine acetylsalicylate in the acute phase of myocardial infarct].
Topics: Acute Disease; Adult; Aged; Aspirin; Drug Evaluation; Female; Humans; Lysine; Male; Middle Aged; Myo | 1977 |
[Lysine acetylsalicylate in the acute phase of myocardial infarct].
Topics: Acute Disease; Adult; Aged; Aspirin; Drug Evaluation; Female; Humans; Lysine; Male; Middle Aged; Myo | 1977 |
[Platelet anti-aggregant and anticoagulant therapy in the secondary prevention of coronary disease. Preliminary note].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Myocardial Infarct | 1977 |
[Platelet anti-aggregant and anticoagulant therapy in the secondary prevention of coronary disease. Preliminary note].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Myocardial Infarct | 1977 |
[Secondary prevention of myocardial infarct. Evaluation of a 2-year trial comparing acetylsalicylic acid to oral anticoagulants].
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Drug Evaluation; Female; France; Humans; | 1978 |
[Secondary prevention of myocardial infarct. Evaluation of a 2-year trial comparing acetylsalicylic acid to oral anticoagulants].
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Drug Evaluation; Female; France; Humans; | 1978 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
Topics: Adult; Aged; Angina Pectoris; Arthritis, Rheumatoid; Aspirin; Cerebrovascular Disorders; Coronary Di | 1978 |
Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
Topics: Adult; Aged; Angina Pectoris; Arthritis, Rheumatoid; Aspirin; Cerebrovascular Disorders; Coronary Di | 1978 |
[1 g of acetylsalicyl acid activity upon platelet aggregation in acute myocardial infarction (author's transl)].
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1978 |
[1 g of acetylsalicyl acid activity upon platelet aggregation in acute myocardial infarction (author's transl)].
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1978 |
[Antithrombotic treatment in the acute phase of myocardial infarct].
Topics: Adult; Aged; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Thrombosis | 1978 |
[Antithrombotic treatment in the acute phase of myocardial infarct].
Topics: Adult; Aged; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Thrombosis | 1978 |
[Platelet inhibitory agents in the prevention of infarct].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
[Platelet inhibitory agents in the prevention of infarct].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Sulfinpyrazone | 1978 |
The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardi | 1978 |
The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardi | 1978 |
[Platelet aggregation before and after exertion in subjects with infarction in the rehabilitation phase].
Topics: Adult; Angina Pectoris; Arrhythmias, Cardiac; Aspirin; Exercise Therapy; Humans; Male; Middle Aged; | 1978 |
[Platelet aggregation before and after exertion in subjects with infarction in the rehabilitation phase].
Topics: Adult; Angina Pectoris; Arrhythmias, Cardiac; Aspirin; Exercise Therapy; Humans; Male; Middle Aged; | 1978 |
The jury is still out: aspirin medication for heart attack prevention.
Topics: Aspirin; Humans; Myocardial Infarction | 1979 |
The jury is still out: aspirin medication for heart attack prevention.
Topics: Aspirin; Humans; Myocardial Infarction | 1979 |
[Letter: Do antirheumatic and anti gout drugs modify the effect of Marcumar?].
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Blood Coagulation; Coumarins; Drug Inter | 1975 |
[Letter: Do antirheumatic and anti gout drugs modify the effect of Marcumar?].
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Blood Coagulation; Coumarins; Drug Inter | 1975 |
Use of newer platelet function tests ot define abnormalities of hemostasis and thrombosis.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Cell Count; Blood Platelets; Edetic Acid; Hemostasis; Hum | 1975 |
Use of newer platelet function tests ot define abnormalities of hemostasis and thrombosis.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Cell Count; Blood Platelets; Edetic Acid; Hemostasis; Hum | 1975 |
[Influence of acute exertion and physical training on platelet function of the coronary patient].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Disease; Fibrinogen; Humans; Lipids; Male; | 1976 |
[Influence of acute exertion and physical training on platelet function of the coronary patient].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Disease; Fibrinogen; Humans; Lipids; Male; | 1976 |
Peripheral venous platelet aggregates in patients with unstable angina pectoris and acute myocardial infarction.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Angina Pectoris; Aspirin; Blood Cell Count; Female; Hum | 1977 |
Peripheral venous platelet aggregates in patients with unstable angina pectoris and acute myocardial infarction.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Angina Pectoris; Aspirin; Blood Cell Count; Female; Hum | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Platelets, aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation; Thromboemboli | 1976 |
Platelets, aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation; Thromboemboli | 1976 |
Complications of percutaneous transfemoral coronary arteriography.
Topics: Angiography; Aspirin; Cardiac Catheterization; Cerebrovascular Disorders; Coronary Angiography; Femo | 1976 |
Complications of percutaneous transfemoral coronary arteriography.
Topics: Angiography; Aspirin; Cardiac Catheterization; Cerebrovascular Disorders; Coronary Angiography; Femo | 1976 |
Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
Topics: Acute Disease; Animals; Aspartate Aminotransferases; Aspirin; Calcium; Calcium Chloride; Cardiomyopa | 1976 |
Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
Topics: Acute Disease; Animals; Aspartate Aminotransferases; Aspirin; Calcium; Calcium Chloride; Cardiomyopa | 1976 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Dis | 1976 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Dis | 1976 |
The effect of a potent inhibitor of platelet aggregation, BL-3459, on adrenaline-induced myocardial necrosis in beagle dogs.
Topics: Animals; Aspirin; Blood Pressure; Disease Models, Animal; Dogs; Epinephrine; Female; Imidazoles; Mal | 1976 |
The effect of a potent inhibitor of platelet aggregation, BL-3459, on adrenaline-induced myocardial necrosis in beagle dogs.
Topics: Animals; Aspirin; Blood Pressure; Disease Models, Animal; Dogs; Epinephrine; Female; Imidazoles; Mal | 1976 |
Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Blindness; Drug Therapy, Combination; Female; Gastrointestin | 1976 |
Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Blindness; Drug Therapy, Combination; Female; Gastrointestin | 1976 |
[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
Topics: Animals; Anticoagulants; Aspirin; Dogs; Drug Hypersensitivity; Gastrointestinal Hemorrhage; Humans; | 1976 |
[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
Topics: Animals; Anticoagulants; Aspirin; Dogs; Drug Hypersensitivity; Gastrointestinal Hemorrhage; Humans; | 1976 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
Letter: Aspirin and myocardial infarction.
Topics: Aspirin; Drug Evaluation; Humans; Myocardial Infarction | 1975 |
Letter: Aspirin and myocardial infarction.
Topics: Aspirin; Drug Evaluation; Humans; Myocardial Infarction | 1975 |
Aspirin and coronary heart disease: findings of a prospective study.
Topics: Adult; Age Factors; Aged; Arthritis; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarcti | 1975 |
Aspirin and coronary heart disease: findings of a prospective study.
Topics: Adult; Age Factors; Aged; Arthritis; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarcti | 1975 |
Aspirin and myocardial infarction study.
Topics: Adult; Aged; Aspirin; Drug Evaluation; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pro | 1975 |
Aspirin and myocardial infarction study.
Topics: Adult; Aged; Aspirin; Drug Evaluation; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pro | 1975 |
[The effect of acetylsalicylic acid on the development of infarct-like myocardial necroses experimentally induced in rats by a single administration of novodrin (isopropylnoreadrenaline)].
Topics: Animals; Aspirin; Male; Myocardial Infarction; Necrosis; Norepinephrine; Rats | 1975 |
[The effect of acetylsalicylic acid on the development of infarct-like myocardial necroses experimentally induced in rats by a single administration of novodrin (isopropylnoreadrenaline)].
Topics: Animals; Aspirin; Male; Myocardial Infarction; Necrosis; Norepinephrine; Rats | 1975 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1976 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation | 1976 |
Regular aspirin use and myocardial infarction.
Topics: Acute Disease; Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction | 1976 |
Regular aspirin use and myocardial infarction.
Topics: Acute Disease; Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction | 1976 |
[Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system].
Topics: Adult; Angina, Unstable; Aspirin; Epoprostenol; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 1992 |
[Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system].
Topics: Adult; Angina, Unstable; Aspirin; Epoprostenol; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 1992 |
[Aspirin in acute myocardial infarct].
Topics: Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1992 |
[Aspirin in acute myocardial infarct].
Topics: Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1992 |
[Role of antithrombotic agents after myocardial infarction].
Topics: Anticoagulants; Aspirin; Follow-Up Studies; Humans; Myocardial Infarction; Thrombolytic Therapy; Vit | 1992 |
[Role of antithrombotic agents after myocardial infarction].
Topics: Anticoagulants; Aspirin; Follow-Up Studies; Humans; Myocardial Infarction; Thrombolytic Therapy; Vit | 1992 |
[Dynamic changes in the platelet granule membrane glycoprotein level in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Female; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Membr | 1992 |
[Dynamic changes in the platelet granule membrane glycoprotein level in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Female; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Membr | 1992 |
Demonstration of the formation of hydroxyl radicals in acute myocardial infarction in man using salicylate as probe.
Topics: Aspirin; Chromatography, High Pressure Liquid; Female; Free Radicals; Gentisates; Humans; Hydroxides | 1992 |
Demonstration of the formation of hydroxyl radicals in acute myocardial infarction in man using salicylate as probe.
Topics: Aspirin; Chromatography, High Pressure Liquid; Female; Free Radicals; Gentisates; Humans; Hydroxides | 1992 |
Clinical impact of introducing thrombolytic and aspirin therapy into the management policy of a coronary care unit.
Topics: Age Factors; Aged; Aspirin; Coronary Care Units; Diuretics; Drug Therapy, Combination; Female; Hospi | 1992 |
Clinical impact of introducing thrombolytic and aspirin therapy into the management policy of a coronary care unit.
Topics: Age Factors; Aged; Aspirin; Coronary Care Units; Diuretics; Drug Therapy, Combination; Female; Hospi | 1992 |
Streptokinase plus aspirin does the trick: ISIS-3.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Streptokinase | 1992 |
Streptokinase plus aspirin does the trick: ISIS-3.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Streptokinase | 1992 |
Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cardi | 1992 |
Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cardi | 1992 |
Changing patterns of medical treatment in acute myocardial infarction. Observations from the Perth MONICA Project 1984-1990.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Utilizat | 1992 |
Changing patterns of medical treatment in acute myocardial infarction. Observations from the Perth MONICA Project 1984-1990.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Utilizat | 1992 |
Excessive megakaryocyte migration after thrombolytic therapy and benefit of aspirin with streptokinase.
Topics: Aspirin; Cell Movement; Drug Therapy, Combination; Humans; Male; Megakaryocytes; Middle Aged; Myocar | 1992 |
Excessive megakaryocyte migration after thrombolytic therapy and benefit of aspirin with streptokinase.
Topics: Aspirin; Cell Movement; Drug Therapy, Combination; Humans; Male; Megakaryocytes; Middle Aged; Myocar | 1992 |
Secondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center.
Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Aged; Aspirin; Calcium Channel Blockers; Clinical Pro | 1992 |
Secondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center.
Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Aged; Aspirin; Calcium Channel Blockers; Clinical Pro | 1992 |
[Long-term therapy after an acute myocardial infarct].
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; | 1992 |
[Long-term therapy after an acute myocardial infarct].
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; | 1992 |
Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids.
Topics: Animals; Aspirin; Coronary Disease; Disease Models, Animal; Female; Heart; Myocardial Infarction; My | 1992 |
Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids.
Topics: Animals; Aspirin; Coronary Disease; Disease Models, Animal; Female; Heart; Myocardial Infarction; My | 1992 |
Is thrombolytic therapy striking out in unstable angina?
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy; Urokinase-T | 1992 |
Is thrombolytic therapy striking out in unstable angina?
Topics: Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy; Urokinase-T | 1992 |
Effect of aspirin on isoproterenol induced myocardial infarction--a pilot study.
Topics: Administration, Oral; Animals; Aspirin; Creatine Kinase; Isoproterenol; L-Lactate Dehydrogenase; Lip | 1992 |
Effect of aspirin on isoproterenol induced myocardial infarction--a pilot study.
Topics: Administration, Oral; Animals; Aspirin; Creatine Kinase; Isoproterenol; L-Lactate Dehydrogenase; Lip | 1992 |
[Prevention of recurrence of myocardial infarction].
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery By | 1992 |
[Prevention of recurrence of myocardial infarction].
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery By | 1992 |
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Factors; Factor VII; Humans; Male; Middle | 1992 |
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Factors; Factor VII; Humans; Male; Middle | 1992 |
Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1992 |
Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1992 |
Direct angioplasty versus initial thrombolytic therapy for acute myocardial infarction: long-term follow-up and changes in practice pattern.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Combined Modality Therapy; Female; Fo | 1992 |
Direct angioplasty versus initial thrombolytic therapy for acute myocardial infarction: long-term follow-up and changes in practice pattern.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Combined Modality Therapy; Female; Fo | 1992 |
[Aspirin in acute myocardial infarct].
Topics: Aspirin; Humans; Myocardial Infarction | 1992 |
[Aspirin in acute myocardial infarct].
Topics: Aspirin; Humans; Myocardial Infarction | 1992 |
[An aspirin and off to the hospital!].
Topics: Aspirin; First Aid; Hospitalization; Humans; Myocardial Infarction | 1992 |
[An aspirin and off to the hospital!].
Topics: Aspirin; First Aid; Hospitalization; Humans; Myocardial Infarction | 1992 |
[The era of myocardial reperfusion].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 1992 |
[The era of myocardial reperfusion].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 1992 |
ISIS 3: the last word on thrombolysis?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; | 1992 |
ISIS 3: the last word on thrombolysis?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; | 1992 |
Effect of aspirin on serum lipoprotein profile in rats subjected to myocardial stress by isoproterenol.
Topics: Animals; Aspirin; Isoproterenol; Lipoproteins; Male; Myocardial Infarction; Rats; Rats, Inbred Strai | 1992 |
Effect of aspirin on serum lipoprotein profile in rats subjected to myocardial stress by isoproterenol.
Topics: Animals; Aspirin; Isoproterenol; Lipoproteins; Male; Myocardial Infarction; Rats; Rats, Inbred Strai | 1992 |
Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning.
Topics: Analysis of Variance; Animals; Aspirin; Coronary Circulation; Disease Susceptibility; Female; Heart | 1992 |
Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning.
Topics: Analysis of Variance; Animals; Aspirin; Coronary Circulation; Disease Susceptibility; Female; Heart | 1992 |
Coronary thrombolysis, conjunctive heparin infusion, and the effect on systemic thrombin activity.
Topics: Aspirin; Coronary Thrombosis; Fibrinolytic Agents; Fibrinopeptide A; Heparin; Humans; Myocardial Inf | 1992 |
Coronary thrombolysis, conjunctive heparin infusion, and the effect on systemic thrombin activity.
Topics: Aspirin; Coronary Thrombosis; Fibrinolytic Agents; Fibrinopeptide A; Heparin; Humans; Myocardial Inf | 1992 |
Aspirin use and cardiovascular disease in women.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Risk Factors; Stress, Physiological | 1992 |
Aspirin use and cardiovascular disease in women.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Risk Factors; Stress, Physiological | 1992 |
Cholesterol, apolipoproteins, and the risk of myocardial infarction.
Topics: Aspirin; Cholesterol, HDL; Humans; Myocardial Infarction; Risk Factors | 1992 |
Cholesterol, apolipoproteins, and the risk of myocardial infarction.
Topics: Aspirin; Cholesterol, HDL; Humans; Myocardial Infarction; Risk Factors | 1992 |
[Cardiovascular risk factors and restenosis after PTCA].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1992 |
[Cardiovascular risk factors and restenosis after PTCA].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1992 |
Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspartate Aminotransferases; Aspirin; Bridged Bicyclo Compoun | 1992 |
Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspartate Aminotransferases; Aspirin; Bridged Bicyclo Compoun | 1992 |
Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.
Topics: Administration, Oral; Adult; Aspirin; Atenolol; Combined Modality Therapy; Female; Humans; Infusions | 1992 |
Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.
Topics: Administration, Oral; Adult; Aspirin; Atenolol; Combined Modality Therapy; Female; Humans; Infusions | 1992 |
Thrombosis in unstable angina.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Heparin; Humans; Myocardial Infarction; Prognosis; T | 1992 |
Thrombosis in unstable angina.
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Heparin; Humans; Myocardial Infarction; Prognosis; T | 1992 |
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction | 1992 |
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction | 1992 |
[Antiplatelet therapy in cardiac diseases].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Mitral Valve Prolapse; Myoc | 1992 |
[Antiplatelet therapy in cardiac diseases].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Mitral Valve Prolapse; Myoc | 1992 |
Ticlopidine for prevention of stroke.
Topics: Aspirin; Clinical Trials as Topic; Humans; Intracranial Embolism and Thrombosis; Myocardial Infarcti | 1992 |
Ticlopidine for prevention of stroke.
Topics: Aspirin; Clinical Trials as Topic; Humans; Intracranial Embolism and Thrombosis; Myocardial Infarcti | 1992 |
Further thoughts on the importance of models in the assessment of clinical evidence.
Topics: Aspirin; Fibrinolysis; Humans; Models, Biological; Models, Statistical; Myocardial Infarction; Proba | 1992 |
Further thoughts on the importance of models in the assessment of clinical evidence.
Topics: Aspirin; Fibrinolysis; Humans; Models, Biological; Models, Statistical; Myocardial Infarction; Proba | 1992 |
Atrial flutter in myocardial infarction.
Topics: Aspirin; Atrial Flutter; Digoxin; Electrocardiography; Furosemide; Humans; Isosorbide Dinitrate; Mal | 1992 |
Atrial flutter in myocardial infarction.
Topics: Aspirin; Atrial Flutter; Digoxin; Electrocardiography; Furosemide; Humans; Isosorbide Dinitrate; Mal | 1992 |
Changes in drug treatment and case fatality of patients with acute myocardial infarction. Observations from the Newcastle MONICA Project, 1984/1985 to 1988/1990.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Diuretics; | 1992 |
Changes in drug treatment and case fatality of patients with acute myocardial infarction. Observations from the Newcastle MONICA Project, 1984/1985 to 1988/1990.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Diuretics; | 1992 |
Adjunctive therapies in thrombolysis. Introduction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Heparin; Humans; Myocardial Infarcti | 1991 |
Adjunctive therapies in thrombolysis. Introduction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Heparin; Humans; Myocardial Infarcti | 1991 |
Use of secondary prophylaxis against myocardial infarction in the north of England.
Topics: Adrenergic beta-Antagonists; Aspirin; Contraindications; Death, Sudden; Drug Therapy, Combination; E | 1991 |
Use of secondary prophylaxis against myocardial infarction in the north of England.
Topics: Adrenergic beta-Antagonists; Aspirin; Contraindications; Death, Sudden; Drug Therapy, Combination; E | 1991 |
Secondary prophylaxis against myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction | 1991 |
Secondary prophylaxis against myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction | 1991 |
Secondary prophylaxis against myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Myocardial Infarction | 1991 |
Secondary prophylaxis against myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Humans; Myocardial Infarction | 1991 |
Myocardial infarction in patients with previous bypass surgery.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Diltiazem; Electrocard | 1991 |
Myocardial infarction in patients with previous bypass surgery.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Diltiazem; Electrocard | 1991 |
A provincial hospital C.C.U. after ISIS 2.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Coronary Care Units; Female; Fibrinolytic Agents; | 1991 |
A provincial hospital C.C.U. after ISIS 2.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Coronary Care Units; Female; Fibrinolytic Agents; | 1991 |
Early management of myocardial infraction: a report from the Waikato Hospital, New Zealand.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aspirin; Contraindications; Female; Hospitals; Hu | 1991 |
Early management of myocardial infraction: a report from the Waikato Hospital, New Zealand.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aspirin; Contraindications; Female; Hospitals; Hu | 1991 |
Effect of calcium channel blocking agents on infarct size after ischaemia-reperfusion in anaesthetised pigs: relationship between cardioprotection and cardiodepression.
Topics: Animals; Aspirin; Coronary Vessels; Depression, Chemical; Heart; Hemodynamics; Injections, Intra-Art | 1991 |
Effect of calcium channel blocking agents on infarct size after ischaemia-reperfusion in anaesthetised pigs: relationship between cardioprotection and cardiodepression.
Topics: Animals; Aspirin; Coronary Vessels; Depression, Chemical; Heart; Hemodynamics; Injections, Intra-Art | 1991 |
Thrombolytic therapy for vascular occlusions.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Intracranial Embolism and Thrombosis; Myocardia | 1992 |
Thrombolytic therapy for vascular occlusions.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Intracranial Embolism and Thrombosis; Myocardia | 1992 |
Aspirin use and cardiovascular disease in women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Male; | 1992 |
Aspirin use and cardiovascular disease in women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Male; | 1992 |
[Heparin therapy in coronary disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial | 1992 |
[Heparin therapy in coronary disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial | 1992 |
TIMI IIB follow-up. Lessons for clinicians and investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Follow-Up Studies; Humans; Myocardi | 1992 |
TIMI IIB follow-up. Lessons for clinicians and investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Follow-Up Studies; Humans; Myocardi | 1992 |
Use of acetylsalicylic acid by physicians and in the community.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Community Medicine; Dru | 1991 |
Use of acetylsalicylic acid by physicians and in the community.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Community Medicine; Dru | 1991 |
The importance of models in the assessment of synergy.
Topics: Aspirin; Drug Synergism; Drug Therapy, Combination; Humans; Models, Statistical; Myocardial Infarcti | 1991 |
The importance of models in the assessment of synergy.
Topics: Aspirin; Drug Synergism; Drug Therapy, Combination; Humans; Models, Statistical; Myocardial Infarcti | 1991 |
[Acute myocardial injury and repeated angina pectoris-like attacks in a young patient with Churg-Strauss syndrome].
Topics: Adult; Age Factors; Angina Pectoris; Aspirin; Asthma; Churg-Strauss Syndrome; Eosinophilia; Humans; | 1991 |
[Acute myocardial injury and repeated angina pectoris-like attacks in a young patient with Churg-Strauss syndrome].
Topics: Adult; Age Factors; Angina Pectoris; Aspirin; Asthma; Churg-Strauss Syndrome; Eosinophilia; Humans; | 1991 |
[A clinical trial of the secondary prevention of reinfarction with low dose aspirin].
Topics: Aged; Aspirin; China; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; R | 1991 |
[A clinical trial of the secondary prevention of reinfarction with low dose aspirin].
Topics: Aged; Aspirin; China; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; R | 1991 |
[Effect of antiplatelet therapy on prevention of thrombotic diseases].
Topics: Arachidonic Acid; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Humans; Myocardial Infa | 1991 |
[Effect of antiplatelet therapy on prevention of thrombotic diseases].
Topics: Arachidonic Acid; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Humans; Myocardial Infa | 1991 |
Principles and practice of coronary thrombolysis and conjunctive treatment.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Heparin; Humans; Infusions, Intravenous; Injections, I | 1991 |
Principles and practice of coronary thrombolysis and conjunctive treatment.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Heparin; Humans; Infusions, Intravenous; Injections, I | 1991 |
Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Myocardial Infarction; Thrombolytic Therapy | 1991 |
Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Myocardial Infarction; Thrombolytic Therapy | 1991 |
Diltiazem-induced granulomatous hepatitis.
Topics: Aged; Aspirin; Atenolol; Chemical and Drug Induced Liver Injury; Diltiazem; Female; Granuloma; Human | 1991 |
Diltiazem-induced granulomatous hepatitis.
Topics: Aged; Aspirin; Atenolol; Chemical and Drug Induced Liver Injury; Diltiazem; Female; Granuloma; Human | 1991 |
Conservative management complications after thrombolytic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; | 1991 |
Conservative management complications after thrombolytic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; | 1991 |
Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Tissue Plasminogen Activ | 1991 |
Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Tissue Plasminogen Activ | 1991 |
Coronary thrombolysis: round two and beyond.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Streptokinase; Thromboly | 1991 |
Coronary thrombolysis: round two and beyond.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Streptokinase; Thromboly | 1991 |
Management of myocardial infarction in the community: a new RCGP study.
Topics: Anistreplase; Aspirin; Family Practice; Humans; Myocardial Infarction; Prospective Studies; Streptok | 1991 |
Management of myocardial infarction in the community: a new RCGP study.
Topics: Anistreplase; Aspirin; Family Practice; Humans; Myocardial Infarction; Prospective Studies; Streptok | 1991 |
A possible acute MI: what location and type?
Topics: Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eme | 1991 |
A possible acute MI: what location and type?
Topics: Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eme | 1991 |
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Female; Heart Diseases; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 1991 |
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Female; Heart Diseases; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 1991 |
Thrombolytic therapy: then and now.
Topics: Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Myoca | 1991 |
Thrombolytic therapy: then and now.
Topics: Angioplasty, Balloon, Coronary; Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Myoca | 1991 |
Management of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1991 |
Management of myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1991 |
Clinical and angiographic characteristics and outcome of patients with rest-unstable angina occurring during regular aspirin use.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Coronary Angiography; Female; Follo | 1991 |
Clinical and angiographic characteristics and outcome of patients with rest-unstable angina occurring during regular aspirin use.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Coronary Angiography; Female; Follo | 1991 |
Thrombolysis: the need for a critical review.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Recombinant Proteins; Streptokinase; | 1991 |
Thrombolysis: the need for a critical review.
Topics: Anistreplase; Aspirin; Heparin; Humans; Myocardial Infarction; Recombinant Proteins; Streptokinase; | 1991 |
Prophylactic aspirin treatment: the merits of timing. International Womb-to-Tomb Chronome Study Group.
Topics: Aspirin; Circadian Rhythm; Female; Humans; Hypertension; Myocardial Infarction; Pilot Projects; Preg | 1991 |
Prophylactic aspirin treatment: the merits of timing. International Womb-to-Tomb Chronome Study Group.
Topics: Aspirin; Circadian Rhythm; Female; Humans; Hypertension; Myocardial Infarction; Pilot Projects; Preg | 1991 |
Early public use of aspirin in the face of probable ischaemic chest pain.
Topics: Angina Pectoris; Aspirin; Death, Sudden; Humans; Myocardial Infarction; Time Factors | 1990 |
Early public use of aspirin in the face of probable ischaemic chest pain.
Topics: Angina Pectoris; Aspirin; Death, Sudden; Humans; Myocardial Infarction; Time Factors | 1990 |
Early use of aspirin.
Topics: Aspirin; Chest Pain; Humans; Myocardial Infarction; Time Factors | 1990 |
Early use of aspirin.
Topics: Aspirin; Chest Pain; Humans; Myocardial Infarction; Time Factors | 1990 |
Early aspirin in myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Time Factors | 1990 |
Early aspirin in myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Time Factors | 1990 |
Circadian rhythms in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Diseases; Circadian R | 1990 |
Circadian rhythms in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Diseases; Circadian R | 1990 |
Aspirin and prevention of myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Blood Pressure; Humans; Male; Middle Aged; Myocardial Infarction; Sampli | 1990 |
Aspirin and prevention of myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Blood Pressure; Humans; Male; Middle Aged; Myocardial Infarction; Sampli | 1990 |
Low-dose aspirin and heparin in unstable coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Random | 1990 |
Low-dose aspirin and heparin in unstable coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Random | 1990 |
Therapeutic interventions which may improve survival in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Aspirin; Coronary Artery Bypass; Cor | 1990 |
Therapeutic interventions which may improve survival in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Aspirin; Coronary Artery Bypass; Cor | 1990 |
Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly.
Topics: Aged; Aging; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Streptokinase; Survi | 1991 |
Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly.
Topics: Aged; Aging; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Streptokinase; Survi | 1991 |
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.
Topics: Aspirin; Dose-Response Relationship, Drug; Follow-Up Studies; Germany; Humans; Middle Aged; Myocardi | 1991 |
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.
Topics: Aspirin; Dose-Response Relationship, Drug; Follow-Up Studies; Germany; Humans; Middle Aged; Myocardi | 1991 |
[Adhesive activity of blood platelets in patients with stable or unstable angina pectoris and acute myocardial infarct].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Creatine Kinase; Humans; Male; Microscopy, | 1991 |
[Adhesive activity of blood platelets in patients with stable or unstable angina pectoris and acute myocardial infarct].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Aspirin; Creatine Kinase; Humans; Male; Microscopy, | 1991 |
New guidelines for coronary thrombolysis.
Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1991 |
New guidelines for coronary thrombolysis.
Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1991 |
[The results of percutaneous transluminal coronary angioplasty in lesions with thrombi].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Combined Modality Therapy; Coronar | 1991 |
[The results of percutaneous transluminal coronary angioplasty in lesions with thrombi].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Combined Modality Therapy; Coronar | 1991 |
The role of heparin and aspirin during thrombolytic intervention in acute myocardial infarction.
Topics: Aspirin; Blood Coagulation; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1990 |
The role of heparin and aspirin during thrombolytic intervention in acute myocardial infarction.
Topics: Aspirin; Blood Coagulation; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy | 1990 |
The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Coronary Angiography; Drug Evaluat | 1990 |
The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Coronary Angiography; Drug Evaluat | 1990 |
Thrombolytic therapy for myocardial infarction.
Topics: Aged; Aspirin; Heparin; Humans; Myocardial Infarction; Risk Factors; Streptokinase; Thrombolytic The | 1990 |
Thrombolytic therapy for myocardial infarction.
Topics: Aged; Aspirin; Heparin; Humans; Myocardial Infarction; Risk Factors; Streptokinase; Thrombolytic The | 1990 |
Increased activity of circulating polymorphonuclear leukocytes in acute myocardial infarction.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adult; Aspirin; Cell Aggregation; Fema | 1990 |
Increased activity of circulating polymorphonuclear leukocytes in acute myocardial infarction.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adult; Aspirin; Cell Aggregation; Fema | 1990 |
Use of alteplase for myocardial infarction in two community hospitals.
Topics: Adult; Aged; Aspirin; Drug Therapy, Combination; Drug Utilization; Female; Hemorrhage; Heparin; Hosp | 1990 |
Use of alteplase for myocardial infarction in two community hospitals.
Topics: Adult; Aged; Aspirin; Drug Therapy, Combination; Drug Utilization; Female; Hemorrhage; Heparin; Hosp | 1990 |
Detection of silent myocardial ischemia in asymptomatic selected population and in unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Exercise | 1990 |
Detection of silent myocardial ischemia in asymptomatic selected population and in unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Exercise | 1990 |
Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin.
Topics: Adenosine Diphosphate; Anistreplase; Aspirin; Collagen; Fibrinolytic Agents; Humans; In Vitro Techni | 1990 |
Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin.
Topics: Adenosine Diphosphate; Anistreplase; Aspirin; Collagen; Fibrinolytic Agents; Humans; In Vitro Techni | 1990 |
Product licences and devious promotion.
Topics: Advertising; Angina, Unstable; Aspirin; Drug Industry; Myocardial Infarction; United Kingdom | 1990 |
Product licences and devious promotion.
Topics: Advertising; Angina, Unstable; Aspirin; Drug Industry; Myocardial Infarction; United Kingdom | 1990 |
[Aspirin in the prevention and management of coronary artery disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction | 1990 |
[Aspirin in the prevention and management of coronary artery disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction | 1990 |
Platelet hyperreactivity and prognosis in survivors of myocardial infarction.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Prognosis | 1990 |
Platelet hyperreactivity and prognosis in survivors of myocardial infarction.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Prognosis | 1990 |
[Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct].
Topics: Aged; Aspirin; Berlin; Blood Coagulation Tests; Follow-Up Studies; Humans; Middle Aged; Myocardial I | 1990 |
[Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct].
Topics: Aged; Aspirin; Berlin; Blood Coagulation Tests; Follow-Up Studies; Humans; Middle Aged; Myocardial I | 1990 |
The Physician's Health Study. A neurologist's concern.
Topics: Aspirin; Cerebrovascular Disorders; Cohort Studies; Follow-Up Studies; Humans; Male; Metoprolol; Myo | 1990 |
The Physician's Health Study. A neurologist's concern.
Topics: Aspirin; Cerebrovascular Disorders; Cohort Studies; Follow-Up Studies; Humans; Male; Metoprolol; Myo | 1990 |
Aspirin and the primary prevention of myocardial infarction and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1990 |
Aspirin and the primary prevention of myocardial infarction and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1990 |
[Thrombocyte aggregation and serum thromboxane in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Throm | 1990 |
[Thrombocyte aggregation and serum thromboxane in patients with acute myocardial infarction].
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Throm | 1990 |
The run-in period in clinical trials. The effect of misclassification on efficiency.
Topics: Aspirin; Efficiency; Humans; Myocardial Infarction; Patient Compliance; Placebos; Randomized Control | 1990 |
The run-in period in clinical trials. The effect of misclassification on efficiency.
Topics: Aspirin; Efficiency; Humans; Myocardial Infarction; Patient Compliance; Placebos; Randomized Control | 1990 |
[Expediency of long-term anti-angina therapy and physical exercises in patients with angina pectoris and a history of myocardial infarction].
Topics: Adult; Angina Pectoris; Aspirin; Exercise Therapy; Humans; Male; Middle Aged; Myocardial Infarction; | 1990 |
[Expediency of long-term anti-angina therapy and physical exercises in patients with angina pectoris and a history of myocardial infarction].
Topics: Adult; Angina Pectoris; Aspirin; Exercise Therapy; Humans; Male; Middle Aged; Myocardial Infarction; | 1990 |
Comparison of ticlopidine and aspirin for the prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Cholesterol; Humans; Myocardial Infarction; Research Design; Tic | 1990 |
Comparison of ticlopidine and aspirin for the prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Cholesterol; Humans; Myocardial Infarction; Research Design; Tic | 1990 |
Death from myocardial infarction: what are the benefits of early arrival at hospital and thrombolysis?
Topics: Adult; Aged; Aspirin; Death, Sudden; Female; Humans; Male; Middle Aged; Myocardial Infarction; New S | 1990 |
Death from myocardial infarction: what are the benefits of early arrival at hospital and thrombolysis?
Topics: Adult; Aged; Aspirin; Death, Sudden; Female; Humans; Male; Middle Aged; Myocardial Infarction; New S | 1990 |
Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Bleeding Time; Blood Platelets; Chest Pain; Epinep | 1990 |
Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Bleeding Time; Blood Platelets; Chest Pain; Epinep | 1990 |
Acute infarction during triple-vessel coronary angioplasty due to acute occlusion of a nonattempted vessel.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Combined Modality Therapy; | 1990 |
Acute infarction during triple-vessel coronary angioplasty due to acute occlusion of a nonattempted vessel.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Combined Modality Therapy; | 1990 |
Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion?
Topics: Animals; Aspirin; Dogs; Fibrinolytic Agents; Heart Diseases; Hemodynamics; Hemorrhage; Myocardial In | 1990 |
Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion?
Topics: Animals; Aspirin; Dogs; Fibrinolytic Agents; Heart Diseases; Hemodynamics; Hemorrhage; Myocardial In | 1990 |
Myocardial infarction. Primary prevention.
Topics: Adult; Aspirin; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial In | 1990 |
Myocardial infarction. Primary prevention.
Topics: Adult; Aspirin; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial In | 1990 |
Myocardial infarction. Pre-hospital care.
Topics: Aspirin; Family Practice; Hospitalization; Humans; Myocardial Infarction; Thrombolytic Therapy; Time | 1990 |
Myocardial infarction. Pre-hospital care.
Topics: Aspirin; Family Practice; Hospitalization; Humans; Myocardial Infarction; Thrombolytic Therapy; Time | 1990 |
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
Topics: Aspirin; Drug Evaluation; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Myocardial Inf | 1990 |
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
Topics: Aspirin; Drug Evaluation; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Myocardial Inf | 1990 |
Spontaneous haemarthrosis following thrombolytic therapy for myocardial infarction.
Topics: Aged; Aspirin; Emergencies; Female; Hemarthrosis; Humans; Male; Middle Aged; Myocardial Infarction; | 1990 |
Spontaneous haemarthrosis following thrombolytic therapy for myocardial infarction.
Topics: Aged; Aspirin; Emergencies; Female; Hemarthrosis; Humans; Male; Middle Aged; Myocardial Infarction; | 1990 |
Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation.
Topics: Animals; Aspirin; Isoproterenol; Lipid Peroxidation; Male; Myocardial Infarction; Rats; Rats, Inbred | 1990 |
Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation.
Topics: Animals; Aspirin; Isoproterenol; Lipid Peroxidation; Male; Myocardial Infarction; Rats; Rats, Inbred | 1990 |
[Determination of human sensitivity to the antiaggregation action of acetylsalicylic acid].
Topics: Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Methods; Myocardial Infarction; Platelet Aggre | 1986 |
[Determination of human sensitivity to the antiaggregation action of acetylsalicylic acid].
Topics: Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Methods; Myocardial Infarction; Platelet Aggre | 1986 |
No reflow and extent of infarction during maximal vasodilation in the porcine heart.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Coronary Vessels; Female; Hemodynamics; Male | 1988 |
No reflow and extent of infarction during maximal vasodilation in the porcine heart.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Coronary Vessels; Female; Hemodynamics; Male | 1988 |
Aspirin after myocardial infarction.
Topics: Aspirin; Cost-Benefit Analysis; Humans; Myocardial Infarction | 1989 |
Aspirin after myocardial infarction.
Topics: Aspirin; Cost-Benefit Analysis; Humans; Myocardial Infarction | 1989 |
Cyclo-oxygenase inhibition does not unmask leukotriene release during ischaemia-reperfusion of the rat heart in vitro.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Leukotrienes; Male; Myocardial Infarction | 1989 |
Cyclo-oxygenase inhibition does not unmask leukotriene release during ischaemia-reperfusion of the rat heart in vitro.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Leukotrienes; Male; Myocardial Infarction | 1989 |
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Coagulation; Electrocardiography; Heparin; Humans; Middle Aged; Myocardi | 1989 |
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Coagulation; Electrocardiography; Heparin; Humans; Middle Aged; Myocardi | 1989 |
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Emergencies; Fibrin Fibrinogen Degradation Products; | 1989 |
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Emergencies; Fibrin Fibrinogen Degradation Products; | 1989 |
Therapies to limit infarct size. Timing, dosage, and effectiveness.
Topics: Aspirin; Calcium Channel Blockers; Drug Administration Schedule; Fibrinolytic Agents; Humans; Myocar | 1989 |
Therapies to limit infarct size. Timing, dosage, and effectiveness.
Topics: Aspirin; Calcium Channel Blockers; Drug Administration Schedule; Fibrinolytic Agents; Humans; Myocar | 1989 |
Role of the general practitioner in managing patients with myocardial infarction: impact of thrombolytic treatment. Report of a British Heart Foundation Working Group.
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Family Practice; Fibrinolytic Agents; Huma | 1989 |
Role of the general practitioner in managing patients with myocardial infarction: impact of thrombolytic treatment. Report of a British Heart Foundation Working Group.
Topics: Aspirin; Electrocardiography; Emergency Medical Services; Family Practice; Fibrinolytic Agents; Huma | 1989 |
[Acetylsalicylic acid and myocardial infarction. Intermittent dosage means intact production of prostacyclin].
Topics: Aged; Aspirin; Epoprostenol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Thromboxanes | 1989 |
[Acetylsalicylic acid and myocardial infarction. Intermittent dosage means intact production of prostacyclin].
Topics: Aged; Aspirin; Epoprostenol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Thromboxanes | 1989 |
Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.
Topics: Adult; Aged; Aspirin; Epoprostenol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocar | 1989 |
Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.
Topics: Adult; Aged; Aspirin; Epoprostenol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocar | 1989 |
Aspirin use and chronic diseases: a cohort study of the elderly.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cataract; Chronic Disease; Cohort Studies; Coronary Di | 1989 |
Aspirin use and chronic diseases: a cohort study of the elderly.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cataract; Chronic Disease; Cohort Studies; Coronary Di | 1989 |
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Topics: Adenosine; Animals; Aspirin; Coronary Circulation; Dogs; Female; Male; Myocardial Infarction; Recept | 1989 |
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Topics: Adenosine; Animals; Aspirin; Coronary Circulation; Dogs; Female; Male; Myocardial Infarction; Recept | 1989 |
[Secondary prevention after myocardial infarction--beta blockade and acetylsalicylic acid is the basic therapy].
Topics: Adrenergic beta-Antagonists; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prog | 1989 |
[Secondary prevention after myocardial infarction--beta blockade and acetylsalicylic acid is the basic therapy].
Topics: Adrenergic beta-Antagonists; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prog | 1989 |
Aspirin and primary prophylaxis in myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Myocardia | 1989 |
Aspirin and primary prophylaxis in myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Myocardia | 1989 |
Non-Q-wave myocardial infarction.
Topics: Aspirin; Diltiazem; Electrocardiography; Humans; Myocardial Infarction; Prognosis; Thrombolytic Ther | 1989 |
Non-Q-wave myocardial infarction.
Topics: Aspirin; Diltiazem; Electrocardiography; Humans; Myocardial Infarction; Prognosis; Thrombolytic Ther | 1989 |
Platelet release in coronary heart disease: effect of antiplatelet drugs and coronary artery bypass graft.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Coronary Artery Bypass; | 1985 |
Platelet release in coronary heart disease: effect of antiplatelet drugs and coronary artery bypass graft.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Coronary Artery Bypass; | 1985 |
Aspirin, heparin, or both to treat unstable angina.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction | 1989 |
Aspirin, heparin, or both to treat unstable angina.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Heparin; Humans; Myocardial Infarction | 1989 |
[Thrombocyte function and the repair of myocardial infarct].
Topics: Aspirin; Blood Platelets; Dipyridamole; Female; Heart Function Tests; Humans; Hydroxyproline; Male; | 1989 |
[Thrombocyte function and the repair of myocardial infarct].
Topics: Aspirin; Blood Platelets; Dipyridamole; Female; Heart Function Tests; Humans; Hydroxyproline; Male; | 1989 |
Coronary thrombolysis.
Topics: Aged; Aspirin; Heart Diseases; Humans; Myocardial Infarction; Streptokinase; Thrombosis | 1989 |
Coronary thrombolysis.
Topics: Aged; Aspirin; Heart Diseases; Humans; Myocardial Infarction; Streptokinase; Thrombosis | 1989 |
[Effect of long-term anticoagulant and antithrombocytic therapy on the size of intracavitary thrombus and the incidence of thromboembolic complications in patients with acute myocardial infarction].
Topics: Aspirin; Heart Diseases; Humans; Myocardial Infarction; Phenindione; Thromboembolism; Thrombosis; Ti | 1989 |
[Effect of long-term anticoagulant and antithrombocytic therapy on the size of intracavitary thrombus and the incidence of thromboembolic complications in patients with acute myocardial infarction].
Topics: Aspirin; Heart Diseases; Humans; Myocardial Infarction; Phenindione; Thromboembolism; Thrombosis; Ti | 1989 |
[Acetylsalicylic acid in acute ischemic coronary and cerebral diseases].
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction | 1989 |
[Acetylsalicylic acid in acute ischemic coronary and cerebral diseases].
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction | 1989 |
[Streptokinase treatment and market requirements].
Topics: Aspirin; Humans; Myocardial Infarction; Quality Control; Streptokinase | 1989 |
[Streptokinase treatment and market requirements].
Topics: Aspirin; Humans; Myocardial Infarction; Quality Control; Streptokinase | 1989 |
Analysis of risk factors for myocardial infarction following carotid endarterectomy.
Topics: Arteriosclerosis; Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Humans | 1989 |
Analysis of risk factors for myocardial infarction following carotid endarterectomy.
Topics: Arteriosclerosis; Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Humans | 1989 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1989 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1989 |
Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; C | 1985 |
Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; C | 1985 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Artery Bypass; Humans; Lipids; Myocar | 1986 |
Secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Artery Bypass; Humans; Lipids; Myocar | 1986 |
[Secondary prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Death, Sudden; Humans; Myocardial Infarction; | 1986 |
[Secondary prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Death, Sudden; Humans; Myocardial Infarction; | 1986 |
Management of patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Cardiac Cat | 1987 |
Management of patients after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Cardiac Cat | 1987 |
Aspirin, expectations, and the heart.
Topics: Aspirin; Attitude to Health; Humans; Myocardial Infarction | 1988 |
Aspirin, expectations, and the heart.
Topics: Aspirin; Attitude to Health; Humans; Myocardial Infarction | 1988 |
Aspirin, infarction, and platelet/vessel-wall interactions.
Topics: Aspirin; Blood Platelets; Endothelium, Vascular; Epoprostenol; Humans; Myocardial Infarction; Thromb | 1988 |
Aspirin, infarction, and platelet/vessel-wall interactions.
Topics: Aspirin; Blood Platelets; Endothelium, Vascular; Epoprostenol; Humans; Myocardial Infarction; Thromb | 1988 |
Aspirin and fibrinolysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Time Factors; Tissue Plasminogen | 1988 |
Aspirin and fibrinolysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Time Factors; Tissue Plasminogen | 1988 |
Management of patients after thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Circulati | 1985 |
Management of patients after thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Circulati | 1985 |
Coronary angioplasty for evolving myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Coronary Vessels; Dogs; Humans; Myo | 1987 |
Coronary angioplasty for evolving myocardial infarction.
Topics: Angioplasty, Balloon; Animals; Aspirin; Cardiac Catheterization; Coronary Vessels; Dogs; Humans; Myo | 1987 |
[Advantages and shortcomings of platelet antiaggregants in the treatment of myocardial infarction].
Topics: Aged; Aspirin; Drug Eruptions; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation; Pla | 1988 |
[Advantages and shortcomings of platelet antiaggregants in the treatment of myocardial infarction].
Topics: Aged; Aspirin; Drug Eruptions; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation; Pla | 1988 |
Aspirin for unstable angina?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Pro | 1986 |
Aspirin for unstable angina?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Pro | 1986 |
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinatio | 1988 |
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinatio | 1988 |
Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Topics: Acrylates; Animals; Aspirin; Biomechanical Phenomena; Blood Platelets; Coronary Disease; Cyclooxygen | 1988 |
Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Topics: Acrylates; Animals; Aspirin; Biomechanical Phenomena; Blood Platelets; Coronary Disease; Cyclooxygen | 1988 |
A milestone for myocardial infarction.
Topics: Aspirin; Hemostasis, Surgical; Humans; Myocardial Infarction | 1988 |
A milestone for myocardial infarction.
Topics: Aspirin; Hemostasis, Surgical; Humans; Myocardial Infarction | 1988 |
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses.
Topics: Aspirin; Bleeding Time; Blood Platelets; Hemostasis; Humans; Myocardial Infarction; Thromboxane B2 | 1985 |
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses.
Topics: Aspirin; Bleeding Time; Blood Platelets; Hemostasis; Humans; Myocardial Infarction; Thromboxane B2 | 1985 |
Clinical experience of percutaneous transluminal coronary angioplasty--technique and results.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; | 1985 |
Clinical experience of percutaneous transluminal coronary angioplasty--technique and results.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; | 1985 |
[Aspirin and coronary heart disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Male; | 1988 |
[Aspirin and coronary heart disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Male; | 1988 |
[The ISIS-2 study (International Study of Infarction Survival)].
Topics: Aspirin; Drug Combinations; Humans; Myocardial Infarction; Placebos; Streptokinase | 1988 |
[The ISIS-2 study (International Study of Infarction Survival)].
Topics: Aspirin; Drug Combinations; Humans; Myocardial Infarction; Placebos; Streptokinase | 1988 |
Study suggests added benefit from combined aspirin--streptokinase therapy after myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myocardial Infarction; Streptokinase | 1988 |
Study suggests added benefit from combined aspirin--streptokinase therapy after myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myocardial Infarction; Streptokinase | 1988 |
[New benefits of aspirin].
Topics: Aspirin; Cataract; Humans; Myocardial Infarction; Reye Syndrome | 1988 |
[New benefits of aspirin].
Topics: Aspirin; Cataract; Humans; Myocardial Infarction; Reye Syndrome | 1988 |
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
Topics: Aspirin; Blood Platelets; Epoprostenol; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 1988 |
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
Topics: Aspirin; Blood Platelets; Epoprostenol; Humans; Male; Middle Aged; Myocardial Infarction; Platelet A | 1988 |
Reporting the aspirin study: the Journal and the media.
Topics: Aspirin; Humans; Information Services; Mass Media; Myocardial Infarction; Periodicals as Topic; Unit | 1988 |
Reporting the aspirin study: the Journal and the media.
Topics: Aspirin; Humans; Information Services; Mass Media; Myocardial Infarction; Periodicals as Topic; Unit | 1988 |
The aspirin-heart study and the Journal's embargo policy.
Topics: Aspirin; Humans; Information Services; Myocardial Infarction; Periodicals as Topic; United States | 1988 |
The aspirin-heart study and the Journal's embargo policy.
Topics: Aspirin; Humans; Information Services; Myocardial Infarction; Periodicals as Topic; United States | 1988 |
An overview of the British and American aspirin studies.
Topics: Aspirin; Humans; Myocardial Infarction; Research Design; United Kingdom; United States | 1988 |
An overview of the British and American aspirin studies.
Topics: Aspirin; Humans; Myocardial Infarction; Research Design; United Kingdom; United States | 1988 |
The physicians' health study: aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Male; Myocardial Infarction; Physicians; United Kingdom; United States | 1988 |
The physicians' health study: aspirin for the primary prevention of myocardial infarction.
Topics: Aspirin; Humans; Male; Myocardial Infarction; Physicians; United Kingdom; United States | 1988 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi | 1988 |
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi | 1988 |
[Aspirin and heart infarct: one proof is no proof].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; England; Humans; Male; Middle Aged; Myocardial Infar | 1988 |
[Aspirin and heart infarct: one proof is no proof].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; England; Humans; Male; Middle Aged; Myocardial Infar | 1988 |
Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Collagen; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1988 |
Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Collagen; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1988 |
Treatment or prevention?
Topics: Aspirin; Humans; Myocardial Infarction; Skin Diseases; Tretinoin | 1988 |
Treatment or prevention?
Topics: Aspirin; Humans; Myocardial Infarction; Skin Diseases; Tretinoin | 1988 |
The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Drug Labeling; Hum | 1988 |
The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Drug Labeling; Hum | 1988 |
Hennekens reconsidered.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Research Design; Risk | 1988 |
Hennekens reconsidered.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Research Design; Risk | 1988 |
[Aspirin and myocardial infarction--a gimmick from the media?].
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
[Aspirin and myocardial infarction--a gimmick from the media?].
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
[Acetylsalicylic acid in the prevention of infarct].
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
[Acetylsalicylic acid in the prevention of infarct].
Topics: Aspirin; Humans; Myocardial Infarction | 1988 |
Ameroid constriction of the proximal left circumflex coronary artery in swine. A model of limited coronary collateral circulation.
Topics: Animals; Aspirin; Collateral Circulation; Constriction; Coronary Circulation; Coronary Disease; Coro | 1987 |
Ameroid constriction of the proximal left circumflex coronary artery in swine. A model of limited coronary collateral circulation.
Topics: Animals; Aspirin; Collateral Circulation; Constriction; Coronary Circulation; Coronary Disease; Coro | 1987 |
Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Su | 1987 |
Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Su | 1987 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
Platelet aggregation and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Dipyridamole; Electrocardiography; Humans; Male; Middle Aged; Myocardial | 1986 |
Platelet aggregation and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Dipyridamole; Electrocardiography; Humans; Male; Middle Aged; Myocardial | 1986 |
Two years follow-up Cottbus reinfarction study with 30 and 60 mg acetylsalicylic acid.
Topics: Aspirin; Death, Sudden; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Ag | 1987 |
Two years follow-up Cottbus reinfarction study with 30 and 60 mg acetylsalicylic acid.
Topics: Aspirin; Death, Sudden; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Ag | 1987 |
[Prostaglandin studies in normal subjects and in post-myocardial infarct patients].
Topics: Adult; Aspirin; Child; Dinoprost; Female; Humans; Indomethacin; Male; Myocardial Infarction; Physica | 1985 |
[Prostaglandin studies in normal subjects and in post-myocardial infarct patients].
Topics: Adult; Aspirin; Child; Dinoprost; Female; Humans; Indomethacin; Male; Myocardial Infarction; Physica | 1985 |
No significant effect of chronic aspirin use on fibrinolytic response to venous occlusion in coronary patients.
Topics: Aged; Aspirin; Blood Vessels; Constriction; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infa | 1985 |
No significant effect of chronic aspirin use on fibrinolytic response to venous occlusion in coronary patients.
Topics: Aged; Aspirin; Blood Vessels; Constriction; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infa | 1985 |
Regional myocardial blood flow in experimental myocardial infarction after pretreatment with aspirin.
Topics: Animals; Aspirin; Coronary Circulation; Electrocardiography; Heart; Myocardial Infarction; Papio | 1986 |
Regional myocardial blood flow in experimental myocardial infarction after pretreatment with aspirin.
Topics: Animals; Aspirin; Coronary Circulation; Electrocardiography; Heart; Myocardial Infarction; Papio | 1986 |
Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Cardiac Pacing, Artificial; Coronary Ci | 1985 |
Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Cardiac Pacing, Artificial; Coronary Ci | 1985 |
Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infar | 1985 |
Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infar | 1985 |
Participation in a clinical trial: the patients' point of view.
Topics: Adult; Aged; Altruism; Aspirin; Attitude to Health; Clinical Trials as Topic; Double-Blind Method; F | 1985 |
Participation in a clinical trial: the patients' point of view.
Topics: Adult; Aged; Altruism; Aspirin; Attitude to Health; Clinical Trials as Topic; Double-Blind Method; F | 1985 |
High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Dipyridamole; Drug Evaluation; Female; Fibrin Fibrinogen | 1985 |
High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Dipyridamole; Drug Evaluation; Female; Fibrin Fibrinogen | 1985 |
Does dipyridamole have antithrombotic potential?
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; P | 1985 |
Does dipyridamole have antithrombotic potential?
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; P | 1985 |
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction.
Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Dipyridamole; Diuretics; Female; Hematocrit; Hu | 1985 |
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction.
Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Dipyridamole; Diuretics; Female; Hematocrit; Hu | 1985 |
Aspirin for heart patients.
Topics: Aspirin; Drug Labeling; Humans; Myocardial Infarction | 1985 |
Aspirin for heart patients.
Topics: Aspirin; Drug Labeling; Humans; Myocardial Infarction | 1985 |
Aspirin and myocardial infarction in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 1972 |
Aspirin and myocardial infarction in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 1972 |
Aspirin and myocardial infarction.
Topics: Arthritis, Rheumatoid; Aspirin; Humans; Myocardial Infarction | 1972 |
Aspirin and myocardial infarction.
Topics: Arthritis, Rheumatoid; Aspirin; Humans; Myocardial Infarction | 1972 |
[Myocardial infarct and the shoulder-hand syndrome].
Topics: Adult; Age Factors; Aged; Aspirin; Benzyl Compounds; Coumarins; Exercise Therapy; Humans; Middle Age | 1972 |
[Myocardial infarct and the shoulder-hand syndrome].
Topics: Adult; Age Factors; Aged; Aspirin; Benzyl Compounds; Coumarins; Exercise Therapy; Humans; Middle Age | 1972 |
Anticoagulants: a guide for practitioners.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Dicumarol; Disseminated Intravascular Coagulation; Electri | 1973 |
Anticoagulants: a guide for practitioners.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Dicumarol; Disseminated Intravascular Coagulation; Electri | 1973 |
Letter: Heparin thrombin clotting-time and platelet factor 4.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Te | 1974 |
Letter: Heparin thrombin clotting-time and platelet factor 4.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Te | 1974 |
Letter: Mortality and anaemia in women.
Topics: Anemia, Hypochromic; Aspirin; Cardiovascular Diseases; Contraceptives, Oral; Death, Sudden; Female; | 1974 |
Letter: Mortality and anaemia in women.
Topics: Anemia, Hypochromic; Aspirin; Cardiovascular Diseases; Contraceptives, Oral; Death, Sudden; Female; | 1974 |
[Differential treatment of coronary heart disease].
Topics: Angina Pectoris; Aspirin; Cardiac Glycosides; Coronary Disease; Dipyridamole; Furosemide; Heparin; H | 1974 |
[Differential treatment of coronary heart disease].
Topics: Angina Pectoris; Aspirin; Cardiac Glycosides; Coronary Disease; Dipyridamole; Furosemide; Heparin; H | 1974 |
[Desensitization therapy in myocardial infarct].
Topics: Adrenal Glands; Amines; Aminopyrine; Aspirin; Autoimmune Diseases; Desensitization, Immunologic; Dip | 1970 |
[Desensitization therapy in myocardial infarct].
Topics: Adrenal Glands; Amines; Aminopyrine; Aspirin; Autoimmune Diseases; Desensitization, Immunologic; Dip | 1970 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |
Editorial: Platelets.
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregation; Thrombosis | 1974 |
Editorial: Platelets.
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregation; Thrombosis | 1974 |
Protection against epinephrine-induced myocardial necrosis by drugs that inhibit platelet aggregation.
Topics: Animals; Arteriosclerosis; Aspirin; Catecholamines; Dipyridamole; Dogs; Epinephrine; Heart; Myocardi | 1972 |
Protection against epinephrine-induced myocardial necrosis by drugs that inhibit platelet aggregation.
Topics: Animals; Arteriosclerosis; Aspirin; Catecholamines; Dipyridamole; Dogs; Epinephrine; Heart; Myocardi | 1972 |
[Acetylsalicylic acid as antithrombotic agent in acute myocardial infarct without shock syndrome].
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Adhesive | 1973 |
[Acetylsalicylic acid as antithrombotic agent in acute myocardial infarct without shock syndrome].
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Adhesive | 1973 |
Lysozymuria and acute disorders of renal function.
Topics: Acetaminophen; Acute Disease; Aspirin; Electroshock; Glomerulonephritis; Heart Failure; Humans; Hypo | 1973 |
Lysozymuria and acute disorders of renal function.
Topics: Acetaminophen; Acute Disease; Aspirin; Electroshock; Glomerulonephritis; Heart Failure; Humans; Hypo | 1973 |
[Erythrocyte aggregation in nonsmokers, smokers and myocardial infarct patients].
Topics: Adrenal Cortex Hormones; Aspirin; Blood Sedimentation; Cell Aggregation; Erythrocytes; Humans; Myoca | 1973 |
[Erythrocyte aggregation in nonsmokers, smokers and myocardial infarct patients].
Topics: Adrenal Cortex Hormones; Aspirin; Blood Sedimentation; Cell Aggregation; Erythrocytes; Humans; Myoca | 1973 |
[Prophylaxis and treatment of thromboses of the deep leg veins with acetylsalicylic acid (author's transl)].
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Humans; Leg; Myocardial Infarction; Platelet | 1973 |
[Prophylaxis and treatment of thromboses of the deep leg veins with acetylsalicylic acid (author's transl)].
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Humans; Leg; Myocardial Infarction; Platelet | 1973 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrin | 1974 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrin | 1974 |
Editorial: Aspirin and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Depression, Chemical; Humans; Myocardial Infarction; Platelet Adhesivenes | 1974 |
Editorial: Aspirin and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Depression, Chemical; Humans; Myocardial Infarction; Platelet Adhesivenes | 1974 |
Regular aspirin intake and acute myocardial infarction.
Topics: Adult; Age Factors; Aged; Arthritis; Aspirin; Diabetes Mellitus; Female; Humans; Hypertension; Male; | 1974 |
Regular aspirin intake and acute myocardial infarction.
Topics: Adult; Age Factors; Aged; Arthritis; Aspirin; Diabetes Mellitus; Female; Humans; Hypertension; Male; | 1974 |
Letter: Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Male; Methods; Middle Aged; Myocardial Infarction | 1974 |
Letter: Aspirin and myocardial infarction.
Topics: Aspirin; Humans; Male; Methods; Middle Aged; Myocardial Infarction | 1974 |
[Clinical aspects and pathogenesis of the post-infarct syndrome].
Topics: Adult; Aminopyrine; Aspirin; Humans; Male; Middle Aged; Myocardial Infarction; Prednisolone; Pyrazol | 1969 |
[Clinical aspects and pathogenesis of the post-infarct syndrome].
Topics: Adult; Aminopyrine; Aspirin; Humans; Male; Middle Aged; Myocardial Infarction; Prednisolone; Pyrazol | 1969 |
[Problems in the treatment of myocardial infarct using anticoagulants or aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coumarins; Electrocardiography; Humans; Myocardial Infarction; Platelet Adh | 1972 |
[Problems in the treatment of myocardial infarct using anticoagulants or aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coumarins; Electrocardiography; Humans; Myocardial Infarction; Platelet Adh | 1972 |
[Aspirin in the treatment of myocardial infarct].
Topics: Aspirin; Bicarbonates; Blood Coagulation; Blood Sedimentation; Gastrointestinal Diseases; Hematuria; | 1971 |
[Aspirin in the treatment of myocardial infarct].
Topics: Aspirin; Bicarbonates; Blood Coagulation; Blood Sedimentation; Gastrointestinal Diseases; Hematuria; | 1971 |
[Inhibition of platelet aggregation with acetylsalicylic acid. Experimental and clinical results].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Blood Platelets; Carbon Isotopes; Drug Synergism; | 1971 |
[Inhibition of platelet aggregation with acetylsalicylic acid. Experimental and clinical results].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Blood Platelets; Carbon Isotopes; Drug Synergism; | 1971 |
[Current aspects of aspirin therapy].
Topics: Aspirin; Blood Coagulation; Embolism; Hemorrhage; Humans; Joint Diseases; Myocardial Infarction; Thr | 1970 |
[Current aspects of aspirin therapy].
Topics: Aspirin; Blood Coagulation; Embolism; Hemorrhage; Humans; Joint Diseases; Myocardial Infarction; Thr | 1970 |